
<html lang="en"     class="pb-page"  data-request-id="a1dcb977-a46d-4a79-8990-bc0ab8708ce8"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2012.55.issue-11;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/jm300065h;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks" /></meta><meta name="dc.Creator" content="Suvi T. M.  Orr" /></meta><meta name="dc.Creator" content="Sharon L.  Ripp" /></meta><meta name="dc.Creator" content="T. Eric  Ballard" /></meta><meta name="dc.Creator" content="Jaclyn L.  Henderson" /></meta><meta name="dc.Creator" content="Dennis O.  Scott" /></meta><meta name="dc.Creator" content="R. Scott  Obach" /></meta><meta name="dc.Creator" content="Hao  Sun" /></meta><meta name="dc.Creator" content="Amit S.  Kalgutkar" /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 27, 2012" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm300065h" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm300065h" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm300065h" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm300065h" /></link>
        
    
    

<title>Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm300065h" /></meta><meta property="og:title" content="Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks" /></meta><meta property="og:image" content="https://pubs.acs.org/pb-assets/images/CoverImages_2by1Scaled/jmcmar-1595795902140.png" /></meta><meta property="og:description" content="" /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm300065h"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm300065h">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm300065h&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm300065h&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm300065h&amp;href=/doi/10.1021/jm300065h" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 4896-4933</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm201136z" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm3007068" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Suvi+T.+M.++Orr">Suvi T. M. Orr</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sharon+L.++Ripp">Sharon L. Ripp</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=T.+Eric++Ballard">T. Eric Ballard</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jaclyn+L.++Henderson">Jaclyn L. Henderson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dennis+O.++Scott">Dennis O. Scott</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=R.+Scott++Obach">R. Scott Obach</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hao++Sun">Hao Sun</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Amit+S.++Kalgutkar">Amit S. Kalgutkar</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1.0"><span class="aff-text"><sup>†</sup>Worldwide Medicinal Chemistry and <sup>‡</sup>Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: (617) 551-3336. E-mail: <a href="/cdn-cgi/l/email-protection#4c2d21253862272d202b3938272d3e0c3c2a2536293e622f2321"><span class="__cf_email__" data-cfemail="e0818d8994ce8b818c8795948b8192a09086899a8592ce838f8d">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm300065h&amp;href=/doi/10.1021%2Fjm300065h" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 4896–4933</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 12, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 January 2012</li><li><span class="item_label"><b>Published</b> online</span>27 March 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 June 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm300065h" title="DOI URL">https://doi.org/10.1021/jm300065h</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4896%26pageCount%3D38%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSuvi%2BT.%2BM.%2BOrr%252C%2BSharon%2BL.%2BRipp%252C%2BT.%2BEric%2BBallard%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D11%26contentID%3Djm300065h%26title%3DMechanism-Based%2BInactivation%2B%2528MBI%2529%2Bof%2BCytochrome%2BP450%2BEnzymes%253A%2BStructure%25E2%2580%2593Activity%2BRelationships%2Band%2BDiscovery%2BStrategies%2BTo%2BMitigate%2BDrug%25E2%2580%2593Drug%2BInteraction%2BRisks%26numPages%3D38%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4933%26publicationDate%3DJune%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm300065h"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">11301</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">123</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm300065h" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Suvi&quot;,&quot;last_name&quot;:&quot;T. M. Orr&quot;},{&quot;first_name&quot;:&quot;Sharon&quot;,&quot;last_name&quot;:&quot;L. Ripp&quot;},{&quot;first_name&quot;:&quot;T.&quot;,&quot;last_name&quot;:&quot;Eric Ballard&quot;},{&quot;first_name&quot;:&quot;Jaclyn&quot;,&quot;last_name&quot;:&quot;L. Henderson&quot;},{&quot;first_name&quot;:&quot;Dennis&quot;,&quot;last_name&quot;:&quot;O. Scott&quot;},{&quot;first_name&quot;:&quot;R.&quot;,&quot;last_name&quot;:&quot;Scott Obach&quot;},{&quot;first_name&quot;:&quot;Hao&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Amit&quot;,&quot;last_name&quot;:&quot;S. Kalgutkar&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;4896-4933&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm300065h&quot;},&quot;abstract&quot;:&quot;&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300065h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300065h" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300065h&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300065h" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300065h&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300065h" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm300065h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300065h&amp;href=/doi/10.1021/jm300065h" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm300065h" /></input><a href="/doi/pdf/10.1021/jm300065h" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm300065h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm300065h%26sid%3Dliteratum%253Aachs%26pmid%3D22409598%26genre%3Darticle%26aulast%3DOrr%26date%3D2012%26atitle%3DMechanism-Based%2BInactivation%2B%2528MBI%2529%2Bof%2BCytochrome%2BP450%2BEnzymes%253A%2BStructure%25E2%2580%2593Activity%2BRelationships%2Band%2BDiscovery%2BStrategies%2BTo%2BMitigate%2BDrug%25E2%2580%2593Drug%2BInteraction%2BRisks%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D11%26spage%3D4896%26epage%3D4933%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292460" title="Bioinorganic chemistry">Bioinorganic chemistry</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jmcmar.2012.55.issue-11/production/jmcmar.2012.55.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57773" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57773" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cytochrome P450s (CYPs) constitute a superfamily of heme-containing enzymes that catalyze the oxidative metabolism of structurally diverse molecules including drugs, chemical carcinogens, steroids, and fatty acids.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> CYP1A2, 2C9, 2C19, 2D6, and 3A4/3A5 participate in the metabolism of ∼80% of marketed drugs, and more than half of these agents are metabolized by the CYP3A family. Modulation of CYP activity via induction or inhibition by xenobiotics (including drugs) can lead to clinical drug–drug interactions (DDIs) with consequences ranging from loss of efficacy to the introduction of adverse effects, respectively, for coadministered drugs. The drug that causes changes in CYP activity is referred to as the “perpetrator” or “precipitant” of DDI, whereas the coadministered drug that is affected by the change in CYP activity is referred to as the “victim” or “object” of DDI. DDIs arising from CYP inhibition are more frequent and, in some cases, have resulted in the withdrawal of the marketed perpetrator drug (e.g., the antihypertensive agent mibefradil), especially those drugs associated with potent inhibition of the major constitutively expressed human CYP enzyme CYP3A4. Removal of a drug from the marketplace due to DDI issues is usually based on (a) the nature and frequency of the pharmacokinetic (PK) interaction leading to safety concerns, (b) availability of alternative medications without DDI liability, and (c) the pharmacologic benefits of the perpetrator drug that do not significantly outweigh the risks in the population.</div><div class="NLM_p">CYP inhibitors can be categorized as reversible (competitive or noncompetitive), quasi-irreversible, or irreversible in nature. Reversible inhibition usually involves two or more agents competing for binding at the active site of a CYP isozyme, with one drug inhibiting the metabolism of the other agent. In contrast, drugs converted to electrophilic reactive metabolites (RMs) by CYP may interact with the CYP quasi-irreversibly or irreversibly leading to enzyme destruction. The inactivated CYP is catalytically incompetent and must be replenished by newly synthesized protein. The phenomenon is oftentimes referred to as time-dependent inhibition (TDI), mechanism-based inactivation (MBI), and/or suicide inactivation. Compared to reversible CYP inhibition, drug-induced MBI of CYPs presents a greater safety concern because of the increased propensity for PK interactions upon multiple dosing and the sustained duration of these interactions after discontinuation of the mechanism-based inactivator. Furthermore, depending on the fraction of the mechanism-based inactivator that is metabolized by the inactivated CYP, an additional clinical consequence could involve nonstationary increases in systemic exposure of the inactivator itself after multiple doses. Finally, covalent modification of CYP enzymes by RMs can also lead to hapten formation and, in some cases, can trigger an autoimmune response in susceptible patients.</div><div class="NLM_p last">The importance of mitigating DDI risks particularly with respect to CYP TDI has been recognized by the regulatory agencies (e.g., United States Food and Drug Administration guidance documents) and by pharmaceutical companies (position papers by member companies of the Pharmaceutical Research and Manufacturers of America (PhRMA)).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Given the concern around PK interactions through TDI of CYP isoforms, in vitro CYP TDI is routinely assessed as part of lead optimization efforts in preclinical drug discovery. Identification of an in vitro CYP TDI liability, however, can raise several questions such as the following: What is the mechanism of TDI? Does it involve the formation of RMs? Is there a 1:1 correlation between CYP TDI and RM formation (as measured from RM trapping studies using nucleophiles)? What is the likelihood that a CYP time-dependent inhibitor will also cause toxicity? What are the DDI risk mitigation options when dealing with CYP inactivators in drug discovery: compound progression or termination? Several drugs exhibit in vitro TDI of CYP enzymes, but only a fraction of them cause clinical DDIs. Hence, when do we initiate labor-intensive medicinal chemistry efforts to design compounds devoid of CYP TDI liability? What are the best methods to precisely predict the occurrence of clinical DDIs with drug candidates that inactivate CYP enzymes? What are (if any) the qualifying considerations for clinical progression of a CYP time-dependent inactivator with projected clinical DDI risks? In an effort to address these questions and hopefully provide answers to some of them, we embarked on the present venture wherein we highlight the current state-of-the-art knowledge in this field with a special emphasis on (a) available biochemical and mechanistic approaches in drug discovery to examine TDI/MBI of CYP isozymes with new chemical entities, (b) structure–activity relationship (SAR) studies with marketed drugs associated with DDIs via CYP inactivation, (c) case studies of medicinal chemistry tactics to abrogate CYP inactivation liability, (d) strategies for progression of CYP MBI-positive drug candidates, and (e) the utility of in silico methodology, including the use of physiologically based PK (PBPK) simulators, in drug discovery to predict the magnitude of clinical DDI risks anticipated with new clinical candidates.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">2 Methodology To Evaluate CYP MBI in Drug Discovery</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55465" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55465" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3">2.1 Determination of Kinetic Rate Constants for CYP Inactivation</h3><div class="NLM_p">By definition, time-dependent enzyme inhibitors are compounds that display an increasing degree of enzyme inhibition upon increased duration of preincubation with the enzyme. Mechanism-based inactivators represent a subset of time-dependent inhibitors where the inhibitory effects not only are time-dependent but also require metabolism (to a reactive intermediate) by the enzyme that is ultimately inactivated. In the case of CYP enzymes, a source of NADPH cofactor is required to generate MBI. The process leading to MBI is irreversible, and catalytic activity cannot be restored by dialysis or gel filtration. From a drug discovery standpoint, characterization of the CYP inactivation kinetics is essential for quantitative predictions of clinical DDI potential of TDI-positive drug candidates. Furthermore, quantitative comparison of inactivation kinetics can be useful for rank ordering compounds and establishing SAR for CYP TDI within a chemical series. In subsequent discussions throughout the review, we will reserve the terminology “mechanism-based inactivator” or “MBI” only in cases where the biochemical basis of time-dependent CYP inactivation (i.e., the mechanism of inactivation) has been characterized. The rest of the compounds will be simply referred to as “time-dependent inhibitors” or “TDIs”.</div><div class="NLM_p">The important kinetic constants for assessing potential severity of CYP inactivation include the maximal inactivation rate constant (<i>k</i><sub>inact</sub>), inactivator concentration that yields half of the maximum inactivation rate (<i>K</i><sub>I</sub>), and the partition coefficient. In vitro experimental protocols<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7">(3-7)</a> to measure <i>k</i><sub>inact</sub> and <i>K</i><sub>I</sub> for major human CYP enzymes are labor-intensive and are generally not amenable to high-throughput screening in early drug discovery programs. Examination of TDI of CYP activity requires two sequential incubations. The first incubation contains the enzyme source (i.e., liver microsomes, hepatocytes, recombinant expression system, or purified reconstituted system), NADPH, and the putative inactivator (i.e., “inactivation incubation”).<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7 ref8 ref9">(3-9)</a> Periodically, aliquots from the inactivation incubation mixture are added to a second incubation containing a probe substrate of the CYP isozyme at a high concentration that approaches saturation (e.g., 10 × <i>K</i><sub>M</sub>, the substrate concentration that yields half of the maximum rate of catalysis). The probe substrate concentration is kept high to minimize reversible CYP inhibition by the inactivator. The secondary reaction mixture is incubated for a set period of time after which the reaction is quenched and the product of metabolism of the probe CYP substrate is measured (i.e., the “activity incubation”). In most instances, the inactivation incubation is diluted into the activity incubation.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In other cases, the probe CYP substrate is added to the inactivation incubation mixture to start the activity incubation.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> To determine <i>k</i><sub>inact</sub> and <i>K</i><sub>I</sub>, a minimum of six inactivator concentrations and six inactivation incubation time points should be included. The percentage of activity remaining after inactivation relative to the one measured in the absence of inactivator is calculated. This percentage is plotted versus inactivation incubation time to yield a series of first order decay curves (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>A).</div><figure id="fig1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0021.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Depiction of a CYP TDI experiment to generate <i>k</i><sub>inact</sub> and <i>K</i><sub>I</sub> values: (A) measurement of loss of CYP activity over time; (B) plot of <i>k</i><sub>obs</sub> values versus inactivator concentration used in estimation of <i>k</i><sub>inact</sub> and <i>K</i><sub>I</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">These curves are then fitted to the function<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/jm-2012-00065h_m001.gif" alt="" /></img></span>The values for <i>k</i><sub>obs</sub> are the first order rate constants for loss of CYP activity (<i>A</i>) at each inactivator concentration. These are plotted versus the inactivator concentrations used in the inactivation incubation (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>B), and the data are fit to the function<span class="NLM_disp-formula" id="ueq2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/jm-2012-00065h_m002.gif" alt="" /></img></span>The term <i>k</i><sub>obs,[I]=0</sub> describes the decline in activity that is typically observed for CYP enzymes when incubated with NADPH in the absence of substrate. From this analysis, the terms <i>K</i><sub>I</sub> and <i>k</i><sub>inact</sub> can be estimated. From a drug discovery standpoint, large <i>k</i><sub>inact</sub> and small <i>K</i><sub>I</sub> values generally increase the likelihood of DDIs resulting from CYP inactivation. In preclinical drug discovery, efficiency of CYP inactivation within a given chemical series can be gauged from the <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> ratio. The partition coefficient is a measure of inactivation efficiency and also can be a useful parameter to obtain for rank-ordering CYP inactivators. Mechanism-based inactivators are substrates of the enzymes they inactivate. The partition coefficient represents the ratio of the number of inactivator molecules that get metabolized relative to the number of enzyme molecules inactivated. As an inactivator is metabolized, it can be released from the CYP enzyme (as a metabolite) or it can covalently attach to the protein causing inactivation. A highly efficient inactivator will be more prone to the latter event and thus have a low partition ratio. The partition ratio is determined by measuring (a) the inactivation rate and converting the value to moles of enzyme inactivated per unit time and (b) the consumption of the inactivator during incubation (moles of inactivator consumed per unit time). The ratio of these two values represents the partition ratio.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.2 “Abbreviated” Methodology for Examining CYP TDI in Drug Discovery</h3><div class="NLM_p">In order to satisfy compound throughput requirements in early drug discovery, methods for quantitative assessment of CYP TDI without the need for generating <i>K</i><sub>I</sub> and <i>k</i><sub>inact</sub> values have been described. The “scaled-down” methods typically are used to detect (a) time-dependent loss of CYP activity following incubation at a single compound concentration and/or (b) a shift in the IC<sub>50</sub> following preincubation at multiple concentrations of the compound of interest. The simplest approach for quantitative assessment of CYP inactivation requires four experimental measurements: (a) the effect of a single concentration of the test compound on catalytic activity of CYP upon preincubation with the enzyme source and NADPH cofactor for a set duration of time, (b) the effect of the same concentration on CYP activity as in (a) but without preincubation, (c) a control incubation involving preincubation of the enzyme with NADPH for the same set time as in (a) but lacking the test compound, and (d) a control incubation of enzyme and NADPH without preincubation and in the absence of the test compound. Typical incubation times and inactivator concentrations are 30–60 min and 10–60 μM, respectively. CYP activity in (a) is compared to those in (b) and (c), with all three normalized to CYP activity in (d). Replicates of each are necessary to provide statistical power in stating that TDI is real (not an artifact). Incubation in (b) is necessary to ensure the possibility that potent reversible inhibition is not mistaken for TDI. Incubation in (c) is necessary to ensure that the spontaneous loss of activity that is frequently observed when CYP is incubated with NADPH (possibly due to generation of reactive oxygen species) is not mistaken for TDI. There are several possible outcomes for such an abbreviated protocol, and some of these are depicted in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>.</div><figure id="fig2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0022.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Six possible outcomes when testing for CYP TDI in a simplified “one concentration” approach. Compound <b>1</b> depicts TDI with some reversible inhibition component. Compound <b>2</b> is also a time-dependent inactivator but shows no detectable reversible inhibition. Compound <b>3</b> is neither a time-dependent inactivator nor a reversible inhibitor. Compound <b>4</b> is a potent reversible inhibitor. Compound <b>5</b> is a reversible inhibitor that is consumed during the preincubation. Compound <b>6</b> is an activator (i.e., it stimulates the activity of CYP). (a) The test compound is preincubated with CYP enzyme and NADPH. (b) The test compound is not preincubated with CYP enzyme. (c) CYP preincubation is in the absence of test compound and in the presence of NADPH. (d) Results from the control (no test compound and no preincubation) are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An experimental design that resides between a complete <i>K</i><sub>I</sub> and <i>k</i><sub>inact</sub> determination and the aforementioned simple four-incubation approach is the “IC<sub>50</sub> shift” measurement. In this experiment, multiple concentrations of the test compound are preincubated with the CYP source in the presence and absence of NADPH for a preset time period (usually ∼30 min), followed by measurement of activity using a probe CYP substrate concentration at its <i>K</i><sub>M</sub> value.<a onclick="showRef(event, 'ref3 ref5 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref3 ref5 ref10 ref11 ref12">(3, 5, 10-12)</a> This is a prototypical design for estimating IC<sub>50</sub> values for reversible CYP inhibition except for the preincubation step. The two-step process can be accomplished either by diluting the inactivation incubations into a solution containing probe CYP substrate or by adding a concentrated substrate solution to the inactivation incubation.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The IC<sub>50</sub> values calculated in the presence and absence of NADPH cofactor are compared; a decrease in IC<sub>50</sub> upon preincubation is suggestive of TDI (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Because the degree of the change in IC<sub>50</sub> is dependent on the experimental design, individual laboratories must calibrate the data against well-established CYP inactivators. Among the various assays used to assess CYP TDI, the IC<sub>50</sub> shift experiment is most commonly used because of its relative ease of execution in a drug discovery setting. However, such an experimental protocol is best utilized to probe SAR for CYP inactivation in hit-to-lead optimization and not for the quantitative prediction of clinical DDIs. Additional discussion on the latter topic is provided in <a class="ref internalNav" href="#sec6" aria-label="section 6">section 6</a> of this Perspective.</div><figure id="fig3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0023.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Graphical representation of an IC<sub>50</sub> shift experiment to identify TDIs of CYP enzymes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.3 Mechanistic Investigation of Factors Leading to CYP TDI</h3><div class="NLM_p">CYP TDI usually proceeds through metabolic activation (also referred to as bioactivation) of a functional group to a RM. As seen in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, there is a common theme with respect to substituents (also referred to as structural alerts and/or toxicophores) associated with CYP inactivation as well as idiosyncratic drug toxicity.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> However, in contrast with nonspecific protein reactivity of RMs, mechanism-based inactivators of CYP enzymes are highly specific because (a) the inactivator must first bind reversibly to the enzyme and must satisfy all the constraints imposed on normal substrates of the enzyme, (b) it must be acceptable as a substrate and thus undergo bioactivation to a RM, and finally, (c) the resulting reactive species must irreversibly modify the enzyme and permanently remove it from the catalytic pool. Mechanism-based CYP inactivators can be categorized into four mechanistically distinct classes: (a) compounds that quasi-irreversibly bind to the prosthetic heme iron atom, (b) compounds that alkylate (or arylate) the apoprotein, (c) compounds that alkylate (or arylate) the porphyrin framework of the heme, and (d) compounds that degrade the prosthetic heme group to products that can, in some cases, themselves modify the apoprotein.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> This mechanistic classification is not rigid, as in the course of CYP metabolism, a compound could simultaneously partition into more than one inhibitory trajectories. Experiments that probe the mechanism underlying the time-dependence requirement for CYP inhibition usually yield critical information in designing compounds devoid of the liability, since the cause of the problem can be isolated and fixed through iterative structural modification.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Illustrations of Functional Groups Associated with Mechanism-Based Inactivation of CYP Enzymes<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0024.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0025.gif" alt="" id="GRAPHIC-d1099e562-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>Table a</sup><p class="last">(§) Hydroxyl installed through prior CYP metabolism. (‡) Forms amine cation radial, then aromatizes releasing the active alkyl radical species. In the case of verapamil, formation of the nitroso intermediate requires N-dealkylation of the parent molecule.</p></div></div><div></div></div><div id="sec2_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i7" class="anchor-spacer"></div><h4 class="article-section__title" id="_i7">2.3.1 Quasi-Irreversible Inactivation of CYP Enzymes</h4><div class="NLM_p">Quasi-irreversible inactivation occurs when the reactive species complexes with the ferrous form of heme (product of reduction of resting state ferric enzyme by NADPH-CYP reductase) in a tight, noncovalent interaction. Such metabolite-intermediate (MI) complexes exhibit a very distinctive CYP UV–visible spectrum shift in the Soret region between 448 and 460 nm when the heme iron is in the ferrous state. MI complexes are catalytically inactive; the ferrous form of the enzyme can no longer bind to carbon monoxide, which represents a diagnostic test to assess whether CYP TDI occurs via MI complex formation. Quasi-irreversible inactivation in vitro via MI complex formation is reversible after dialysis. In vivo, however, such a complex is known to be so stable that inactivated CYP enzyme is generally unavailable for drug metabolism. As a result, DDIs due to quasi-irreversible inhibitors are more prominent after multiple dosing than those of reversible inhibitors.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Primary amines and 1,3-benzodioxole (methylenedioxyphenyl) derivatives are the most common quasi-irreversible CYP inactivators. Primary amines are oxidized to nitroso metabolites (via the intermediate hydroxylamine metabolites), which can form a MI complex with the ferrous form of the heme iron atom (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Although a primary amine substituent is required, secondary and tertiary amines can serve as suitable precursors for MI complexation provided they are N-dealkylated to primary amines. Nitroso–heme complexes can be dissipated in vitro upon treating the inactivated CYP with potassium ferricyanide, which oxidizes the iron to the ferric state and liberates the active carbon monoxide-binding CYP enzyme.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The ferrous to ferric transition weakens the complex, indicating that the reactive species, like carbon monoxide, only strongly coordinates to the ferrous iron. MI complexes from aromatic amines differ from those of alkylamines in that they can be dissipated by the addition of sodium dithionite. The crystal structure of a complex between a nitroso compound and a model iron porphyrin shows, as expected, that the nitrogen rather than the oxygen atom of the nitroso group is bound to the iron. MI complex formation with 1,3-benzodioxole derivatives occurs through a carbene intermediate, formed via hydrogen atom abstraction from the methylene carbon or by elimination of water from a hydroxymethylene intermediate (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The hydroxymethylene intermediate can also undergo demethylenation, yielding a catechol intermediate and formic acid. Oxidation of the catechol metabolite to the electrophilic <i>o</i>-quinone can also result in CYP inactivation through covalent modification of an active site residue(s) in CYP.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Similar to amines, the 1,3-benzodioxole-CYP MI complex is characterized by a different absorption spectrum with maxima at 427 and 455 nm.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> It is noteworthy to point out that potassium ferricyanide does not disrupt the carbene–heme complex of 1,3-benzodioxoles. SAR studies on a series of 4-alkoxy-1,3-benzodioxole analogues reveal that the size and lipophilicity of the alkoxy group is an important determinant of the complex stability; alkyl chains of one to three carbon atoms yield unstable complexes, whereas those with longer alkyl chains are stable.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0026.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Quasi-Irreversible CYP Inactivation and Formation of MI Complex by Amines and 1,3-Benzodioxoles</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9">2.3.2 Covalent Modification of Heme Prosthetic Group and/or Apoprotein in CYP Enzymes</h4><div class="NLM_p">TDI of CYP activity can also arise through covalent adduction of the RM to the heme prosthetic group and/or to an active site amino acid residue in the apoprotein. While the pyrrole nitrogens that make up the heme porphyrin ring are not very nucleophilic (especially in comparison to many cellular components), the generation of extremely reactive species (e.g., free radicals, ketenes) in proximity to the heme prosthetic group can lead to facile alkylation of the porphyrin ring. Changes in the integrity of the porphyrin ring system can be examined by UV/visible spectroscopy, liquid chromatography tandem mass spectrometry (LC–MS/MS), and carbon monoxide binding studies. Inactivated apoprotein retains its ability to bind carbon monoxide, which provides a convenient method to distinguish protein adducts from heme modifiers. Analysis of modified heme was pioneered by Ortiz de Montellano and co-workers, and this technique has been used to map the orientation of the heme within the CYP active site.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Alkenes, alkynes, hydrazines, and cyclopropylamines are common functional groups associated with heme alkylation. The CYP-catalyzed oxidation of terminal olefins is often associated with N-alkylation of the prosthetic heme as well as apoprotein modifications leading to enzyme inactivation. Studies with 5-allyl barbiturates such as secobarbital (see Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) demonstrated that the oxidative metabolism on the olefin results in the comparable loss of CYP activity and heme content and accumulation of “green pigments” identified as abnormal loss of porphyrins.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> In the case of secobarbital, the reactive species derived from olefin oxidation is partitioned between heme N-alkylation and apoprotein modification.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> It has been speculated that a secobarbital-derived cation radical intermediate formed upon olefin oxidation by CYP covalently adducts to the heme prosthetic group or a aminoacid residue in proximity, prior to collapsing to the stable epoxide metabolite observed in the microsomal incubations and in vivo. The finding that amobarbital (a saturated analogue of secobarbital) is not a CYP inactivator is consistent with the proposed mechanism of CYP inactivation involving bioactivation of the olefinic double bond to a reactive intermediate. In contrast with the mechanistic observations on secobarbital and related sedatives, investigations into the mechanism of CYP inactivation by the allylic phenol derivative and anti-inflammatory agent alclofenac (see Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) revealed that the synthetic standard of the epoxide metabolite of alclofenac detected in human and mouse urine demonstrated TDI of CYP activity in a NADPH-independent fashion.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> This observation suggests that the electrophilic epoxide covalently modifies CYP directly and does not require further metabolic processing to a reactive species.</div><div class="NLM_p">CYP inactivation by the hydrazine derivative phenelzine (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) results in the generation of the <i>N</i>-(2-phenylethyl)protoporphyrin IX heme adduct, which presumably arises through covalent interaction of the heme with the 2-phenethyl radical species (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The chemical oxidation of 1-aminobenzotriazole (ABT), which is often used to probe the role of CYP enzymes in drug metabolism, yields benzyne, an exceedingly reactive species, and two molecules of dinitrogen (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). The observation that benzyne is bound across two of the nitrogen atoms of the prosthetic heme isolated from inactivated CYP enzymes suggests that the enzyme-catalyzed oxidation of ABT follows the same reaction pathway.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> It is unclear whether ABT oxidation to benzyne proceeds via hydroxylation of the exocyclic nitrogen or electron abstraction to afford a radical or a radical cation, but a notable similarity exists between the inactivation mechanism proposed for ABT and related 1,1-disubstituted hydrazines.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0027.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Heme Alkylation and Arylation by Hydrazine Derivatives</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Besides heme modification, the RM can also selectively react with CYP apoprotein. Apoprotein modification will result in alteration of the CYP enzymatic activity or, more likely, the complete inactivation of CYP. Inactivated CYP apoprotein can be denatured and subjected to high resolution LC–MS/MS analysis to identify the specific region of the polypeptide modification, which amino acid(s) has been specifically adducted, and the structure of the adduct.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The protein can be further subjected to partial digestion with specific enzymes, such as trypsin, to yield peptides that can be analyzed by LC–MS/MS. Comparison of the mass spectral data from control and treated CYPs can pinpoint the site of modification, the specific amino acid(s) modified, and the nature of the RM formed in the course of metabolism. Dihaloalkanes, furans, phenols, and thiophenes are common functional groups responsible for apoprotein modification.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The broad spectrum antibacterial agent chloramphenicol (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>) was among the first CYP inactivators shown to act by irreversible apoprotein modification.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Proteolytic digestion of enzyme inactivated by [<sup>14</sup>C]chloramphenicol revealed a single <sup>14</sup>C-modified amino acid. The release of lysine and chloramphenicol fragments (oxalic acid and a N-substituted oxamic acid) upon alkaline hydrolysis of the modified amino acid and the observation that the difluoromethyl derivative does not inactivate CYP suggest that chloramphenicol is oxidatively dechlorinated to the reactive acylating agent oxamyl chloride that either acylates a critical lysine residue or is hydrolyzed to the stable oxamic acid derivative depicted in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0028.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. CYP Apoprotein Acylation by the Broad-Spectrum Antibiotic Chloramphenicol</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Modified CYP apoprotein can be potentially immunogenic.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a>As with any covalently modified protein, it is postulated that an immune response to the modified CYP enzyme can generate CYP-specific antibodies. The antihypertensive drug dihydralazine (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>) is associated with immunoallergic hepatitis typically characterized by the appearance of anti-CYP1A2 autoantibodies in the sera of susceptible patients.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The finding is consistent with the in vitro observations on CYP1A2 covalent modification by a RM of dihydralazine, which leads to the formation of a neoantigen that triggers an immune response characterized by autoantibodies against CYP1A2.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Likewise, the inhaled anesthetic halothane (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>) is associated with a rare but severe form of hepatitis characterized by the presence of serum antibodies that react with CYP2E1.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The clinical observation is consistent with the major role of human CYP2E1 in the oxidative dehalogenation of halothane to a reactive trifluoroacetyl chloride species, which acylates the CYP isoform, resulting in enzyme inactivation.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0029.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Immunogenic drugs dihydralazine and halothane.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">From a mechanistic standpoint, understanding the biotransformation pathways for TDI-positives can yield critical insight into the mechanism(s) of apoprotein inactivation. The RM generated in the course of oxidative metabolism can partition between enzyme inactivation and/or release from the active site to ultimately form a stable metabolite, which can be detected in the course of metabolite identification studies. For instance, the reactive ketene generated from the metabolic activation of an alkyne can be hydrolyzed to the stable acetic acid metabolite amenable to characterization. Likewise, in incubations containing exogenous nucleophiles (e.g., reduced glutathione (GSH), semicarbazide, methoxylamine, cyanide), the characterization of stable conjugates of RMs that diffuse out of the CYP active site provides circumstantial evidence for their formation and potential involvement in the activation process. Elucidation of the structures of these stable RM conjugates provides an insight into the metabolism process that leads to CYP inactivation.</div></div><div id="sec2_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12">2.3.3 Covalent Modification of CYP by Heme Fragments</h4><div class="NLM_p last">During the catalytic oxidation of some substrates (e.g., carbon tetrachloride), some CYP enzymes are inactivated via a process in which fragments of the heme are irreversibly bound to apoprotein.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The features that predispose CYPs to cross-linking between a heme fragment(s) and the apoprotein remain unclear. Studies with carbon tetrachloride suggest that generation of free radical species is important but not sufficient, since not all CYP enzymes that form radical species undergo MBI via heme fragmentation.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">3 Representative Examples of Marketed Drugs Associated with MBI of CYP Enzymes</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02382" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02382" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">3.1 Quasi-Irreversible Inactivation by Drugs</h3><div class="NLM_p">Paroxetine and tadalafil (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>) are two noteworthy examples of drugs that inactivate CYP2D6 and CYP3A4, respectively, via MI complex formation through a carbene intermediate.<a onclick="showRef(event, 'ref12 ref35'); return false;" href="javascript:void(0);" class="ref ref12 ref35">(12, 35)</a> The major metabolic pathway of paroxetine in humans also involves CYP2D6-mediated 1,3-benzodioxole ring scission to a catechol intermediate, which is converted to the corresponding guaiacol isomers via the action of catechol-<i>O</i>-methyltransferase (COMT).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> GSH conjugates resulting from Michael addition of the thiol nucleophile to electrophilic <i>o</i>-quinone species also have been characterized in human liver microsome (HLM) incubations of paroxetine.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Because CYP2D6 is responsible for paroxetine metabolism, MBI of CYP2D6 activity by paroxetine is associated with nonstationary PK in CYP2D6 extensive metabolizers.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> In other words, paroxetine inactivates its own clearance mechanism, which results in reduced clearance and high accumulation with repeated administration. Likewise, DDIs with coadministered drugs whose clearance is mediated by CYP2D6 have been demonstrated. Examples of characterized clinical DDIs with paroxetine include interactions with desipramine,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> metoprolol,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> risperidone,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and atomoxetine,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> where the clearance of the affected drugs is impaired by 5- to 8-fold. The fold increases in the area under the plasma concentration versus time curve (AUC) of the victim drug(s) appear to be in reasonable agreement with the values obtained upon scaling of the in vitro kinetic constants for CYP2D6 MBI by paroxetine.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> In contrast with the observations on paroxetine, the clinical PK of midazolam and lovastatin, probe substrates of CYP3A4, are unaffected by up to 14 days of tadalafil administration, despite the CYP3A4 liability.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The reason(s) for the in vitro–in vivo discrepancy with tadalafil remains unclear. Besides MBI, tadalafil also induces CYP3A4 activity in vitro,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> and it is possible that simultaneous induction and inactivation of CYP3A4 could counterbalance the DDI resulting from the CYP inactivation component.</div><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0030.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Structures of Paroxetine and Tadalafil and Proposed Mechanism of CYP2D6 Inactivation by Paroxetine</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">There are several literature examples on structurally diverse aliphatic amine-based drugs that form MI complexes with CYP enzymes. The mechanism of inactivation is thought to involve metabolism of the amine substituent to a nitrosoalkane intermediate, although this has not been firmly established in some cases. In almost all instances, the amine motif is also crucial for primary pharmacology. An interesting SAR feature that emerges from mechanistic studies on CYP MBI by amines is the lack of a direct correlation between N-dealkylation by a CYP enzyme and inactivation of that same CYP enzyme via MI complex formation. For example, N-demethylation of fluoxetine to norfluoxetine is catalyzed by CYP2D6, but the process is not accompanied by MBI of the isozyme. At present, it is not known why some CYP enzymes are capable of oxidizing the parent alkylamine drug to inhibitory metabolites but are incapable of forming an MI complex.</div><div class="NLM_p">Verapamil is a calcium channel blocker that is N-dealkylated by CYP3A4 into two major metabolites <i>N</i>-desalkylverapamil D-617 (<b>1</b>) and norverpamil (Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Both parent drug and metabolites form MI complexes with CYP3A4, resulting in the MBI of the enzyme. On the basis of the <i>k</i><sub>inact</sub> to <i>K</i><sub>I</sub> ratio, the efficiency of inactivation is norverapamil > verapamil > <b>1</b>. The observations of nonstationary PK, due to autoinactivation, and clinical DDIs, due to CYP3A4 MBI, are consistent with the role of CYP3A4 in verapamil metabolism.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Thus, in healthy volunteers, the oral AUCs of drugs metabolized by CYP3A4 such as midazolam, cyclosporin A, simvastatin, and buspirone increase 2- to 6-fold after multiple doses of verapamil.</div><div class="NLM_p">Long-term treatment with the calcium channel blocker diltiazem (Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>) also leads to DDIs resulting in lowered clearance of CYP3A4 substrates.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Diltiazem is extensively metabolized in humans via multiple pathways including N-demethylation, O-demethylation, and cleavage of the ester linkage.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> N-Desmethyl diltiazem is the major metabolite of diltiazem in humans that undergoes further N-demethylation to yield a primary amine metabolite. In HLM, the products of sequential N-demethylation competitively inhibit CYP3A4 activity with <i>K</i><sub>i</sub> values of 2.0 and 0.1 μM.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> In addition, TDI of CYP3A4 activity has also been reported in HLM for both diltiazem and the N-demethylated secondary amine metabolite.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47, 48)</a> Jones et al.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> demonstrated that TDI of CYP3A4 activity by diltiazem occurs primarily via MI complex formation in a NADPH-dependent fashion. Increased TDI of CYP3A4 is also associated with loss of parent drug and simultaneous accumulation of the N-demethylated metabolites, with the secondary amine metabolite being significantly more potent as a CYP3A4 inactivator than the parent drug.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The structure of the species that is responsible for TDI via MI complex formation is not known but can be assumed to be a nitroso intermediate. It has been suggested that the N-demethylated metabolites produced via CYP3A4-catalyzed metabolism of diltiazem may accumulate during chronic therapy and lead to inhibition of the enzyme in vivo.</div><div class="NLM_p">The tertiary amine derivative amiodarone (Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>) is a class III antiarrhythmic agent, which is widely used in conjunction with other drugs. While few drugs, if any, have been shown to affect amiodarone PK, amiodarone itself has significant effects on the PK and PD of coadministered drugs that are metabolized by CYP1A2, CYP2C9, CYP2D6, and CYP3A4.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> MI complex formation with rodent CYP enzymes is consistent with the metabolism of the tertiary amine group in amiodarone to the nitrosoalkane intermediate.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> In humans, amiodarone is metabolized by CYP3A4 (with additional involvement from CYP2C8 and CYP2D6) to <i>N</i>-desethylamiodarone, which appears to inactivate CYP isozymes distinct from those inactivated by the parent drug. The in vitro inactivation profiling of CYPs in human hepatic tissue has not been fully resolved with amiodarone. In one instance, amiodarone (but not <i>N</i>-desethylamiodarone) was shown to exhibit CYP3A4 TDI, whereas in a recent report, CYP3A4 TDI was demonstrated with both the parent drug and metabolite.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51, 52)</a><i>N</i>-Desethylamiodarone, but not amiodarone, is consistently reported as a mechanism-based inactivator of CYP2D6, which highlights the importance of studying metabolites separately as inactivators of CYP enzymes.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51, 52)</a> Amiodarone also inactivates CYP2C8 and CYP2C9;<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52, 53)</a> however, spectral studies have not detected MI complex formation or heme loss with CYP2C8.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> CYP2C9 has similar time- and concentration-dependent inactivation by both amiodarone and <i>N</i>-desethylamiodarone. It is likely that <i>N</i>-desethylamiodarone formation is essential for CYP2C9 inactivation, as a correlation has been found between the warfarin dose and plasma concentrations of <i>N</i>-desethylamiodarone but not with amiodarone concentration.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div><div class="NLM_p">Similar to amiodarone, the selective serotonin reuptake inhibitor fluoxetine (Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>) is a substrate and inhibitor of multiple CYP enzymes. The principal route of fluoxetine metabolism is via N-demethylation to norfluoxetine, which is catalyzed mainly by CYP2D6 along with some contributions from other isoforms, including CYP3A4 and CYP2C9.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Both fluoxetine and norfluoxetine reversibly inhibit multiple CYP enzymes including CYP2D6, CYP2C19, and CYP3A4, with norfluoxetine displaying greater potency relative to the parent drug.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> In addition to reversible inhibition, TDI of CYP3A4 and CYP2C19 activity has also been demonstrated with fluoxetine in HLM and human hepatocytes.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Recently, Stresser et al.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> reported that norfluoxetine also exhibits TDI of CYP2C19 activity in HLM, suggesting that conversion of fluoxetine to norfluoxetine represents a metabolic pathway leading to TDI. Interestingly, CYP2D6 and CYP2C9 both form norfluoxetine efficiently but are not inactivated in the presence of fluoxetine. More so, fluoxetine demonstrates TDI of CYP2C19 activity but is a very poor substrate.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> It is possible that norfluoxetine formed by CYP2D6 and CYP2C9 is released and then inactivates other enzymes such as CYP3A4 and CYP2C19. The mechanism of TDI by fluoxetine/norfluoxetine in human hepatic tissue is unclear but most likely represents MI complex formation with a nitrosoalkane intermediate based on evidence presented using rat microsomal protein.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Overall, the case studies with tertiary amines illustrate the critical role that N-dealkylated metabolites play in CYP inactivation; therefore, from a drug discovery perspective, quantitative accounting for all N-dealkylated metabolites and individual assessment of parent drug and metabolites for MBI of all major human CYP isoforms are important for quantitative understanding and predictions of in vivo CYP inactivation. With the exception of certain macrolide drugs (e.g., erythromycin), PK profiling of most alkylamine drugs reveals the presence of N-dealkylated metabolites in circulation, often at plasma concentrations significantly higher than that of the parent drug.</div><figure id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0031.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Amine-Based Drugs That Form MI Complex with CYP Enzymes Resulting in MBI</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Several members of the macrolide class of antibacterial agents, which contain a tertiary amine group, are also known to form MI complexes with CYP3A4 following sequential metabolism to the nitrosoalkane intermediate.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> In humans, numerous PK interactions with CYP3A4 substrates upon coadministration with macrolides have been noted.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> On the basis of their affinity for CYP3A4 and their propensity to cause DDIs, macrolides may be classified into three different categories (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). The first category (e.g., troleandomycin, erythromycin, clarithromycin) comprises macrolides that are particularly prone toward MI complexation with CYP3A4 via the intermediate nitrosoalkanes.<a onclick="showRef(event, 'ref9 ref61'); return false;" href="javascript:void(0);" class="ref ref9 ref61">(9, 61)</a> The second group (e.g., josamycin, flurithromycin, roxithromycin, midecamycin, and miocamycin) forms MI complexes with CYP3A4 to a lesser extent and rarely causes DDIs.<a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62, 63)</a> The last group (e.g., spiramycin, rokitamycin, dirithromycin, and azithromycin) does not inactivate CYP3A4 and does not cause DDIs.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> SAR studies have shown that a high log <i>P</i> and a nonhindered readily accessible <i>N</i>,<i>N</i>-dimethylamino group appear to be important properties for MI complex formation with macrolides. For example, introduction of bulky functional groups in position 3 in erythromycin dramatically decreases MI complex formation with rat CYP3A enzymes, whereas introducing substituents simultaneously at the 3 and 2′ positions (adjacent to the <i>N</i>,<i>N</i>-dimethylamino group) virtually blocked CYP3A inactivation via MI complex formation.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a>An additional trend that emerges from these SAR analyses is that 14-membered macrolides (e.g., troleandomycin, erythromycin, and clarithromycin) are more prone to MI complex formation than are 15- or 16-membered macrolides (e.g., micomycin, midecamycin, spiramycin, and josamycin). The structure of CYP3A4–erythromycin cocrystal has been solved, and electron density corresponding to the macrolide ring could be identified close to the heme group in one of the molecules in the asymmetric unit.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Furthermore, the protein undergoes dramatic conformational changes upon erythromycin binding with an increase in the active site volume by >80%.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> As such, the extreme flexibility revealed upon binding of inhibitor to enzyme also challenges any prospective attempt to apply computational design tools without the support of relevant experimental data.</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0032.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. SAR analysis for MI complexation of macrolides with CYP3A4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From an SAR standpoint, the antidepressant duloxetine (Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>) provides an interesting perspective. Paris et al. reported that duloxetine causes reversible inhibition as well as TDI of multiple CYP enzymes including CYP1A2, 2B6, 2C19, and 3A4 in an IC<sub>50</sub> shift assay format in HLM.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> However, attempts to estimate kinetic constants for CYP TDI by duloxetine utilizing a sequential incubation protocol failed to detect the time–dependent component.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Certainly, clinical data support the latter findings wherein duloxetine is more prone to PK interactions as a victim drug rather than a perpetrator.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Structurally, duloxetine contains an <i>N</i>-methyl group and a thiophene ring, which can inactivate CYP enzymes via MI complex formation (amine → nitrosoalkane) and/or apoprotein covalent modification through RM (thiophene → thiophene <i>S</i>-oxide, thiophene epoxide, sulfenic acid, etc.) generation. However, both amine and the thiophene substituents are inert to oxidative metabolism by CYP enzymes in humans. Instead, duloxetine biotransformation in humans proceeds through CYP1A2-catalyzed hydroxylations of the naphthyl ring at the 4-, 5-, or 6-position, yielding reactive epoxide intermediates that have been trapped with GSH in HLM.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Despite the RM liability, duloxetine does not appear to be associated with TDI of CYP1A2 activity. The duloxetine example highlights key points to take into account when assessing CYP TDI in drug discovery: (a) not all RM-positive compounds will lead to MBI of CYP isoforms that catalyze their formation and (b) the presence of a prototypic structural alert(s) in a molecule does not necessarily translate into a CYP MBI-positive compound. The hypothesis must be tested experimentally through the conduct of a CYP TDI experiment.</div><figure id="sch6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0033.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Oxidative Bioactivation of Duloxetine by CYP1A2 Does Not Lead to MBI of the Isozyme</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As a class, HIV protease inhibitors are frequently associated with PK interactions when coadministered with other acquired immune deficiency syndrome-related therapeutic agents, such as hypolipidemics, macrolide antibiotics, calcium channel blockers, and hormones.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> All the currently available HIV protease inhibitors are metabolized mainly by CYP3A4 and are potent competitive inhibitors of the isozyme.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Protease inhibitors such as ritonavir, nelfinavir, amprenavir, lopinavir, and saquinavir (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) are also associated with potent TDI of CYP3A4 activity in HLM (ritonavir, <i>k</i><sub>inact</sub> = 0.4 min<sup>–1</sup>, <i>K</i><sub>I</sub> = 0.17 μM; nelfinavir, <i>k</i><sub>inact</sub> = 0.22 min<sup>–1</sup>, <i>K</i><sub>I</sub> = 1.0 μM; amprenavir, <i>k</i><sub>inact</sub> = 0.59 min<sup>–1</sup>, <i>K</i><sub>I</sub> = 0.37 μM; lopinavir, <i>k</i><sub>inact</sub> = 0.11 min<sup>–1</sup>, <i>K</i><sub>I</sub> = 1.0 μM; saquinavir, <i>k</i><sub>inact</sub> = 0.26 min<sup>–1</sup>, <i>K</i><sub>I</sub> = 0.65 μM).<a onclick="showRef(event, 'ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref72 ref73">(72, 73)</a> Indinavir appears to be the only protease inhibitor devoid of CYP3A4 TDI, although the drug is a potent competitive inhibitor of the isozyme.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Within the chemical class, ritonavir is the most potent (lowest <i>K</i><sub>I</sub>) and most efficient inactivator (highest <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub>). In fact, ritonavir is one of the most potent mechanism-based inactivators of CYP3A4 ever characterized among drug substances. On the basis of spectral determinations, MI complex formation with the ferrous heme iron atom in CYP3A4 has been observed for some protease inhibitors, although structural details on the metabolite(s) involved in MI complex formation remain unresolved for most compounds. With the exception of amprenavir and ritonavir, which contain structural motifs (aniline in amprenavir and thiazole rings in ritonavir) capable of metabolism-dependent CYP interactions, other protease inhibitors do not contain prototypical functional groups associated with MI complex formation.<a onclick="showRef(event, 'ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref72 ref73">(72, 73)</a> In the case of nelfinavir, the catechol metabolite generated via oxidation of the cresol moiety by CYP3A4 was considered unlikely to be responsible for CYP inactivation, as the addition of COMT cofactor <i>S</i>-adenosyl methionine did not protect against CYP3A4 inactivation in HLM.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Furthemore, separate preincubation of the catechol metabolite in NADPH-supplemented HLM did lead to MBI of CYP3A4 activity.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Lack of MI complex formation with lopinavir and saquinavir, coupled with the protective effect of GSH and reactive oxygen scavengers against inactivation, suggests an inactivation mechanism involving the formation of RMs and/or reactive oxygen species. With ritonavir, SAR studies reveal that CYP3A4 MBI requires the presence of both the 5-thiazolyl and 2-(1-methylethyl)thiazolyl groups.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Consistent with the SAR observations, Ma et al.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> recently demonstrated the CYP3A4-mediated ring scission of ritonavir’s thiazole rings, which results in the formation of the corresponding stable glyoxal derivatives as metabolites (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). On the basis of these experimental observations, it is possible that the initial oxidation step involving epoxidation of the thiazole rings in ritonavir (prerequisite for thiazole ring scission by CYP enzymes) by CYP3A4 also results in covalent modification of the heme or apoprotein. Given its potent inhibitory effects on CYP3A4, ritonavir is used as a booster of other protease inhibitors.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> The use of low-dose ritonavir with a second HIV protease inhibitor allows the achievement of a PK benefit that leads to increased systemic exposure, creating a higher genetic barrier to resistance. Boosting of protease inhibitors has become common practice and is recommended in treatment guidelines with most protease inhibitors. Like ritonavir, the thiazole analogue cobicistat (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) is a mechanism-based inactivator of CYP3A4 and is currently in phase III trials to boost systemic exposure of protease inhibitors (notably the HIV integrase inhibitor elvitegravir). In contrast with ritonavir, cobicistat has no anti-HIV activity of its own.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></div><figure id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0034.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. HIV protease inhibitors that cause TDI of CYP3A4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">3.2 Covalent Modification of Heme and/or Apoprotein by Drugs</h3><div class="NLM_p">The nontricyclic antidepressant nefazodone (Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>) is a substrate and potent inhibitor (reversible and time-dependent) of CYP3A4 in HLM (IC<sub>50</sub> values for competitive and TDI of 1.5 and 0.015 μM, respectively, estimated from the IC<sub>50</sub> shift assay format).<a onclick="showRef(event, 'ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref77 ref78">(77, 78)</a> Consistent with the in vitro observations, nefazodone is associated with nonstationary PK upon dose escalation<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> and increases maximal plasma concentrations (<i>C</i><sub>max</sub>) and AUC of diverse CYP3A4 substrates upon coadministration in humans,<a onclick="showRef(event, 'ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref79 ref80">(79, 80)</a> some of which are life-threatening (e.g., cases of rhabdomyolysis associated with simvastatin and nefazodone use).<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> In addition to the CYP3A4 TDI, nefazodone use has been associated with numerous cases of idiosyncratic hepatotoxicity, many of which required liver transplantation and/or resulted in fatalities.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Nefazodone use has been banned in many countries in the European Union and Canada, and the generic version carries a black box warning (BBW) label in the United States. Both of nefazodone’s liabilities including CYP3A4 TDI and hepatotoxicity have been linked to its metabolism to RMs capable of covalently modifying CYP3A4 and other critical proteins in hepatic tissue.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> The mechanism of RM formation involves metabolism of <i>p</i>-hydroxynefazodone, a circulating metabolite of nefazodone in humans, to reactive quinonoid species (quinoneiminium and <i>p</i>-benzoquinone derivatives), which can be trapped as GSH conjugates in HLM incubations (Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>).<a onclick="showRef(event, 'ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref77 ref78">(77, 78)</a></div><div class="NLM_p">From a SAR standpoint, structurally related antidepressants trazodone, aripiprazole, and buspirone exhibit little to no CYP3A4 TDI in vitro (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Side-by-side analysis of nefazodone and aripiprazole in the IC<sub>50</sub> shift assay indicates that aripiprazole is devoid of CYP3A4 TDI seen with nefazodone.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> The diminished and/or lack of CYP3A4 inactivation with these agents is consistent with the absence of PK interactions with CYP3A4 substrates. Like nefazodone, trazodone also contains the 3-chlorophenylpiperazine ring, which is oxidatively metabolized by CYP3A4 to <i>p</i>-hydroxytrazodone, a major urinary metabolite in humans. A reactive quinoneiminium speciesobtained from the two-electron oxidation of the <i>p</i>-hydroxytrazodone metabolite has been trapped with GSH in HLM (Scheme <a class="ref internalNav" href="#sch8" aria-label="8">8</a>).<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> In addition, the detection of a dihydrodiol metabolite of trazodone in human urine is suggestive of a second bioactivation sequence involving the formation of an electrophilic epoxide on the triazolopyridinone moiety present in the drug. Indeed, HLM and recombinant CYP3A4 incubations of trazodone in the presence of GSH have led to the detection of stable dihydrodiol and a GSH conjugate derived from epoxide ring-opening.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> While the bioactivation pattern of trazodone bears resemblance to nefazodone, the degree of CYP3A4 inactivation by trazodone is significantly weaker.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> The reason(s) for this disconnect is unclear. One possibility is that trazodone is less susceptible to CYP3A4-catalyzed metabolism/bioactivation than nefazodone because of its lower lipophilicity. With aripiprazole, CYP3A4-mediated aromatic hydroxylation on the 2,3-dichlorophenylpiperazine ring leads to the <i>p</i>-hydroxyaripiprazole circulating metabolite, which can also form a quinoneiminium species similar to nefazodone. However, failure to detect GSH adducts derived from conjugation with the <i>p</i>-hydroxyaripiprazole metabolite in HLM suggests that the secondary oxidation does not occur.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> In contrast, sequential metabolism of the pendent acetanilide motif in aripiprazole by CYP3A4 does lead to a reactive quinoneimine intermediate in HLM. Despite this liability, aripiprazole does not inactivate CYP3A4 nor is it associated with life-threatening hepatotoxicity.<a onclick="showRef(event, 'ref78 ref84'); return false;" href="javascript:void(0);" class="ref ref78 ref84">(78, 84)</a> Aripiprazole is more lipophilic than nefazodone (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>) and is more tightly bound to microsome and plasma protein, a phenomenon that may reduce the overall rate of metabolism because of a significant reduction in free fraction available for metabolism. The markedly improved safety profile of aripiprazole (versus nefazodone) can be potentially explained by the vast improvement in human PK (aripiprazole, oral bioavailability of 87%; clearance of 0.8 mL min<sup>–1</sup> kg<sup>–1</sup>, half-life of 75 h; nefazodone, oral bioavailability of 20%, clearance of 7.5 mL min<sup>–1</sup> kg<sup>–1</sup>, half-life of 1 h) via a reduction in propensity for CYP3A4-mediated metabolism/bioactivation, phenomena that ultimately translate to a significantly lower efficacious daily dose (10–15 mg) compared with nefazodone (200–600 mg). Finally, buspirone possesses a pyrimidinylpiperazine motif inlieu of the 3-chlorophenylpiperazine scaffold in nefazodone. While <i>p</i>-hydroxybuspirone represents a major circulating metabolite in human, lack of CYP3A4 TDI and/or detection of GSH conjugates in HLM incubations of buspirone suggests that <i>p</i>-hydroxybuspirone does not succumb to RM formation in a manner similar to that observed with <i>p</i>-hydroxynefazodone.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Absence of RM formation with buspirone is consistent with ab initio calculations, which suggest that a weaker resonance stabilization of the oxidation products and the greater acidity make <i>p</i>-hydroxybuspirone less favorable for the two-electron oxidation process.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><figure id="sch7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0035.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Proposed Mechanism of CYP3A4 Inactivation by the Tricyclic Antidepressant Nefazodone</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0036.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures, physicochemical properties, and CYP3A4 TDI data for nontricyclic antidepressants. Structural elements in blue represent the region susceptible to RM formation by CYP3A4. TPSA refers to topological polar surface area. Initial observed inactivation rate (<i>k</i><sub>obs</sub>) at a single inactivator concentration of 10 μM is as reported in ref <a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">84</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0037.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Metabolism of Nontricyclic Antidepressants Trazodone and Aripiprazole by CYP3A4 to RMs</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Certain multitargeted tyrosine kinase (TK) inhibitors (e.g., imatinib, dasatinib, erlotinib, lapatinib, etc.), which are frequently used in the treatment of cancer, also cause PK interactions with CYP3A4 substrates.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Because TK inhibitors are usually prescribed for prolonged periods in patients with comorbidities, the risks of DDIs tend to significantly increase with comedications in this patient population. Imatinib (Scheme <a class="ref internalNav" href="#sch9" aria-label="9">9</a>) was the first rationally designed TK inhibitor, which revolutionized the treatment of chronic myelogenous leukemia, advanced gastrointestinal stromal tumors, and other hematological diseases. Inhibitory effects of imatinib against CYP3A4 have been investigated in a clinical DDI study with simvastatin, wherein imatinib (400 mg daily) decreased simvastatin clearance by 70%, suggesting a strong CYP3A4 inhibitory effect in vivo.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Imatinib (400–600 mg daily) also reduces CYP3A4 activity in patients by 10–70%, as reflected in the erythromycin breath test.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> The clinical observations are consistent with TDI (<i>k</i><sub>inact</sub> = 0.07 min<sup>–1</sup>; <i>K</i><sub>I</sub> = 14.3 μM) of CYP3A4-catalyzed midazolam 1′-hydroxylation in vitro.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> The active <i>N</i>-desmethylimatinib metabolite (i.e., CGP74588) is not a time-dependent inactivator of CYP3A4.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> The precise mechanism of CYP3A4 inactivation by imatinib remains unclear. It is possible that RMs (e.g., imine methide) derived from the bioactivation of the alkylaniline/acetanilide motif are responsible for enzyme modification. Certainly hydroxylation of the benzylic methyl group is a known metabolic fate of imatinib in humans. From a SAR standpoint, nilotinib is structurally related to imatinib and is a second-generation TK inhibitor approved for the treatment of chronic myelogenous leukemia resistant to, or intolerant of, prior treatment that included imatinib. PK interactions with substrates of CYP3A4, CYP2C8/2C9, and CYP2D6 have been attributed to nilotinib’s competitive inhibitory effects against the respective CYP isozymes.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> The propensity of nilotinib to cause TDI of CYPs is presently unknown; the chemical structure of nilotinib preserves the aminopyrimidine and amide pharmacophores of imatinib but incorporates substituents alternative to the basic <i>N</i>-methylpiperazine ring in imatinib, thereby leading to greater lipophilicity. Like imatinib, nilotinib is cleared in humans via oxidative metabolism by CYP3A4, but information on the biotransformation pathways is not available.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Likewise, pazopanib is the newest TK inhibitor approved for the treatment of advanced or metastatic renal cell carcinoma. Pazopanib is associated with severe and fatal hepatotoxicity resulting in a BBW label. Pazopanib is primarily cleared in humans via metabolism by CYP3A4; however, details on its biotransformation pathways and/or ability to cause CYP3A4 TDI have not been published.</div><div class="NLM_p">Dasatinib (Scheme <a class="ref internalNav" href="#sch9" aria-label="9">9</a>) has been approved for the treatment of imatinib-resistant acute myeloid leukemia. Increases in simvastatin <i>C</i><sub>max</sub> and AUC upon coadministration of dasatinib suggest CYP3A4 inhibitory effects similar to those of imatinib.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Li et al.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> established TDI of CYP3A4 activity (<i>k</i><sub>inact</sub> = 0.034 min<sup>–1</sup> and <i>K</i><sub>I</sub> = 6.3 μM) by dasatinib in HLM. The mechanism is thought to involve CYP3A4-mediated <i>p</i>-hydroxylation of the 2-chloro-6-methylphenyl ring (the major metabolite of dasatinib in humans) followed by further oxidation to the reactive quinoneimine. Formation of a reactive imine methide is also detected but appears to be a minor bioactivation pathway. Characterization of stable GSH adducts of these RMs in HLM incubations of dasatinib provides evidence for the proposed bioactivation pathway. From a SAR standpoint, modifications on the piperazine or methylpyrimidine rings of dasatinib do not abolish CYP3A4 TDI, but consistent with the inactivation mechanism, simultaneously removing the methyl group and blocking the para-position of the chloromethylphenyl ring with a chlorine atom eliminate CYP3A4 inactivation.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a></div><figure id="sch9" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0038.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Pyrimidine-Based Tyrosine Kinase Inhibitors Imatinib and Dasatinib as Time- and Concentration-Dependent Inactivators of CYP3A4</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">TDI of CYP3A4 has also been reported with the TK inhibitor lapatinib (Scheme <a class="ref internalNav" href="#sch10" aria-label="10">10</a>),<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> which is used in the treatment of advanced metastatic breast cancer. Lapatinib also carries a BBW for idiosyncratic hepatotoxicity including rare cases of liver-related fatalities that can occur several days to a month after initiation of treatment. In vitro lapatinib is extensively metabolized by CYP3A4 and, to a lesser extent, CYP2C8 to yield products of O- and N-dealkylation.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> O-Dealkylation of lapatinib in humans generates a <i>p</i>-hydroxyaniline derivative that is oxidized by CYP3A4 to a reactive quinoneimine intermediate amenable to trapping by GSH (Scheme <a class="ref internalNav" href="#sch10" aria-label="10">10</a>, pathway A).<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> It has been proposed that lapatanib bioactivation to the quinoneimine metabolite could trigger downstream reactions leading to liver injury.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> In contrast, the mechanism of CYP3A4 inactivation by lapatinib (<i>k</i><sub>inact</sub> = 0.02 min<sup>–1</sup> and <i>K</i><sub>I</sub> = 1.7 μM) is thought to occur via quasi-irreversible MI complex formation (and not via adduction of the reactive quinoneimine metabolite to apoprotein or heme).<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> An increase in the signature Soret absorbance at ∼455 nm and restoration of enzymatic activity with potassium ferricyanide support this hypothesis. In addition, products of amine oxidation that include the lapatanib hydroxylamine and the oxime form of N-dealkylated lapatinib have been characterized, suggesting that a nitroso intermediate(s) derived from these metabolites is involved in MI complex formation (Scheme <a class="ref internalNav" href="#sch10" aria-label="10">10</a>, pathways B and C).<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Because lapatinib is a CYP3A4 substrate, MBI of CYP3A4 translates into nonstationary increases in systemic exposure of the drug upon repeated dosing in humans.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a></div><figure id="sch10" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0039.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Proposed Mechanism of CYP3A4 Inactivation and Idiosyncratic Hepatotoxicity Associated with the Tyrosine Kinase Inhibitor Lapatinib</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The observations on lapatinib bioactivation parallel that for other structurally related TK inhibitors such as gefitinib and erlotinib, which form reactive quinonoid intermediates (Scheme <a class="ref internalNav" href="#sch11" aria-label="11">11</a>) and where hepatotoxicity is a side effect of treatment.<a onclick="showRef(event, 'ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref94 ref95">(94, 95)</a> Gefitinib is a <i>p</i>-fluoroaniline derivative that undergoes a CYP3A4-mediated oxidative defluorination to the corresponding quinoneimine species.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> In the case of erlotinib, the <i>p</i>-hydroxyaniline metabolite generated via a CYP3A4-mediated oxidation of its 3-ethynylaniline motif is oxidized further to the quinoneimine.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Evidence for formation of reactive quinonoid intermediates has been obtained by virtue of GSH trapping studies.<a onclick="showRef(event, 'ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref94 ref95">(94, 95)</a> Interestingly, metabolism of erlotinib (but not gefitinib) is accompanied by TDI of CYP3A4 (<i>k</i><sub>inact</sub> = 0.035–0.09 min<sup>–1</sup>; <i>K</i><sub>I</sub> = 6.3–22 μM).<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Furthermore, CYP3A4 inactivation by erlotinib is consistent with a reported case of rhabdomyolysis arising from an interaction between erlotinib and the CYP3A4 substrate simvastatin.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> SAR studies suggest that CYP3A4 TDI is not dependent upon oxidation of the alkyne group to a reactive oxirene or ketene species, since replacement of the alkyne with a cyano functionality does not abolish CYP3A4 inactivation.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> However, the role of the alkyne in CYP3A4 inactivation cannot be entirely dismissed given that oxidation of this functionality to the corresponding arylacetic acid is a known metabolic fate of erlotinib in humans (see Scheme <a class="ref internalNav" href="#sch11" aria-label="11">11</a>)<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> and is catalyzed by several human CYPs (e.g., CYP2D6 and CYP1A1/1A2) in addition to CYP3A4. It is possible that oxidation of the alkyne may act as a second route of CYP3A4 inactivation.</div><figure id="sch11" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0040.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Bioactivation of the TK Inhibitors Gefitinib and Erlotinib by CYP3A4 That Leads to MBI with Erlotinib (but Not Gefitinib)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Time-dependent inactivation of CYP3A4 (in addition to competitive inhibitory effects on CYP3A4, CYP2D6, and CYP2C19) has also been demonstrated with sorafenib (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>),<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> which has been approved for the treatment of hepatocellular carcinoma. In patients, sorafenib at 400 mg twice daily alters the systemic exposures of probe CYP3A4, CYP2D6, and/or CYP2C19 substrates. However, differences in PK are sufficiently small that a clinically significant in vivo inhibition of these CYP isoenzymes is deemed unlikely.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Lack of clinical DDIs despite potent in vitro inhibitory effects on CYP3A4 can be explained on the basis of mass balance studies, which indicate that most of the sorafenib dose (∼65%) in humans is subject to fecal excretion (in the unchanged form) and phase II glucuronidation by UGT1A9, with minimal contribution (∼5%) from CYP3A4.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> The mechanism of CYP3A4 TDI by sorafenib remains unknown; sorafenib <i>N</i>-oxide, which is formed by CYP3A4, is the main circulating metabolite in humans and has in vitro potency similar to that of sorafenib.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Sunitinib (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>) is a multitargeted receptor TK inhibitor that is used in the treatment of renal cell carcinoma as well as gastrointestinal stromal tumor. Available evidence suggests that sunitinib is metabolized mainly by CYP3A4 but does not cause TDI of CYP3A4 activity, a phenomenon that is consistent with lack of DDIs with CYP3A4 substrates in the clinic.<a onclick="showRef(event, 'ref84 ref86'); return false;" href="javascript:void(0);" class="ref ref84 ref86">(84, 86)</a></div><figure id="fig8" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0041.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures of tyrosine kinase inhibitors sorafenib (CYP3A4 TDI +ve) and sunitinib (CYP3A4 TDI −ve).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Tetrahydrothienopyridines ticlopidine, clopidogrel, and prasugrel (Scheme <a class="ref internalNav" href="#sch12" aria-label="12">12</a>) are prodrugs, which require biotransformation into “active” reactive metabolites for antithrombotic activity. Metabolites of ticlopidine and clopidogrel are produced via a CYP-catalyzed oxidation (principally mediated by CYP2C19) involving initial conversion to the corresponding thiolactone metabolites followed by S-oxidation and subsequent ring scission to the free thiol derivatives, which form a covalent disulfide linkage with a cysteinyl residue on the P2Y<sub>12</sub> receptor in platelets.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Recently, Dansette et al.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> studied the pathway associated with the thiolactone ring scission in tetrahydrothienopyridines and identified the intermediate sulfenic acid species via trapping studies in HLM using dimedone as a nucleophile (Scheme <a class="ref internalNav" href="#sch12" aria-label="12">12</a>).<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Subsequent reduction of the sulfenic acid intermediate by GSH could lead to the pharmacologically active thiol derivatives (see Scheme <a class="ref internalNav" href="#sch12" aria-label="12">12</a>). In vitro metabolic processing of ticlopidine and clopidogrel into RMs also leads to TDI of CYP2C19 activity (ticlopidine, <i>k</i><sub>inact</sub> = 0.07 min<sup>–1</sup>, <i>K</i><sub>I</sub> = 3.3 μM; clopidogrel, <i>k</i><sub>inact</sub> = 0.055 min<sup>–1</sup>, <i>K</i><sub>I</sub> = 14.3 μM).<a onclick="showRef(event, 'ref102 ref103'); return false;" href="javascript:void(0);" class="ref ref102 ref103">(102, 103)</a> Since inactivation is only discerned with the parent prodrugs and not with the respective thiolactone metabolites, it is likely that thiophene ring oxidation to the thiolactone metabolites generates reactive species (e.g., thiophene <i>S</i>-oxide and/or thiophene epoxide) that inactivate CYP2C19.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Recent reports have shown that the clinical pharmacological effect of clopidogrel is affected by the polymorphically expressed CYP2C19 genotype.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Furthermore, Kurihara et al.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> reported that CYP2C19 is one of the CYP enzymes responsible for the oxidation of clopidogrel and its thiolactone in vitro. Collectively, these observations suggest that the oxidative metabolism of clopidogrel by CYP2C19 to yield the active metabolite and the inactivation of CYP2C19 occur simultaneously.</div><div class="NLM_p">From a DDI perspective, it is interesting to note that most (>70%) of the clopidogrel daily dose in humans is rapidly hydrolyzed by human carboxylesterases to the inactive carboxylic acid metabolite, which does not cause TDI of CYP2C19 activity.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Furthermore, both clopidogrel and ticlopidine cause CYP2C19 inactivation but only ticlopidine is associated with a 5.0- to 6.2-fold increase in the AUC of the probe CYP2C19 substrate omeprazole in extensive metabolizers.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Lack of DDIs via CYP2C19 inactivation by clopidogrel appears to be in reasonable agreement with the predicted fold increase in AUC of ∼1.0 with CYP2C19 substrates, presumably due to the extremely low unbound circulating concentrations.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> In contrast with the observations on ticlopidine and clopidogrel metabolism, prasugrel does not inactivate CYP2C19. The thiolactone metabolite (R-138727) of prasugrel is produced via an esterase-mediated hydrolysis (as opposed to the action of CYP enzymes) followed by CYP oxidation to afford the thiol metabolite R-95913 (Scheme <a class="ref internalNav" href="#sch13" aria-label="13">13</a>).<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> The process of ester bond cleavage is so facile that the parent drug is not detected in vivo. Consistent with this overall behavior, prasugrel does not cause TDI of CYP2C19 and is not expected to cause DDIs in vivo.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div><figure id="sch12" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0002.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Postulated Mechanism of CYP2C19 Inactivation by Tetrahydrothienopyridine Antithombotic Drugs Clopidogrel and Ticlopidine</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch13" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0001.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Metabolism of Prasugrel Leading to Its Pharmacologically Active Metabolite</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition to CYP2C19 inactivation, clopidogrel, ticlopidine,and their respective thiolactone metabolites also lead to MBI of CYP2B6 activity in vitro.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> In particular, clopidogrel is highly potent and selective for CYP2B6 inactivation in HLM, with <i>K</i><sub>I</sub> and <i>k</i><sub>inact</sub> of 0.5 μM and 0.35 min<sup>–1</sup>, respectively.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> These findings make clopidogrel the most potent mechanism-based inhibitor known for CYP2B6. Mass spectral analysis of CYP2B6 that had been inactivated by either clopidogrel or the thiolactone metabolite showed an increase in the mass of the protein by ∼350 Da, which is consistent with the addition of the thiol metabolite of clopidogrel to CYP2B6.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Peptide mapping of tryptic digests of the inactivated CYP2B6 suggests Cys475 as the site of covalent modification possibly via disulfide bond formation. Consistent with this observation, mutation of Cys475 to a serine residue eliminated the formation of the protein adduct and prevented the C475S variant from MBI by the thiolactone metabolite of clopidogrel. Interestingly, this mutation does not prevent the C475S variant from being inactivated by clopidogrel. Furthermore, inactivation of both wild-type CYP2B6 and C475S by clopidogrel, but not by the thiolactone metabolite, leads to the loss of the heme, which accounts for most of the loss of the catalytic activity. Collectively, these results suggest that clopidogrel inactivates CYP2B6 primarily through destruction of the heme, whereas the thiolactone metabolite of clopidogrel inactivates CYP2B6 through covalent modification of Cys475. Recent clinical studies have demonstrated that ticlopidine and clopidogrel are potent inhibitors of CYP2B6 in humans as judged by the increase in systemic exposure to bupropion, an antidepressant drug and specific substrate for CYP2B6, by 85 and 60%, respectively, and a decrease in the systemic exposure of the metabolite hydroxybupropion by 84 and 52%, respectively.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Against this backdrop, the thiolactone metabolite of prasugrel is 10- to 22-fold less potent, respectively, as a time–dependent inactivator of CYP2B6 than ticlopidine and clopidogrel.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Consistent with this in vitro finding, prasugrel was found to be a weak inhibitor of CYP2B6 activity in humans, with the exposure of bupropion increased by 18% and that of hydroxybupropion decreased by 23%.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></div><div class="NLM_p">The CYP inactivation mechanism of gemfibrozil (Scheme <a class="ref internalNav" href="#sch14" aria-label="14">14</a>) is perhaps one of the most interesting ones, since it involves a phase II metabolite of the parent drug. Gemfibrozil belongs to a class of drugs known as fibrates, which are used in the treatment of dyslipidemia. Although in vitro studies in HLM demonstrate that gemfibrozil is a more potent reversible inhibitor of CYP2C9 (IC<sub>50</sub> = 9.6 μM) than CYP2C8 (IC<sub>50</sub> = 95 μM) activity,<a onclick="showRef(event, 'ref113 ref114'); return false;" href="javascript:void(0);" class="ref ref113 ref114">(113, 114)</a> results from in vivo DDI studies reveal opposing trends. Gemfibrozil increases the systemic exposure of CYP2C8 substrates such as cerivastatin, repaglinide, rosiglitazone, and pioglitazone but has no effect on the PK of the CYP2C9 substrate warfarin.<a onclick="showRef(event, 'ref115 ref116 ref117'); return false;" href="javascript:void(0);" class="ref ref115 ref116 ref117">(115-117)</a> This discrepancy has been explained by demonstrating that the major metabolite of gemfibrozil, i.e., gemfibrozil-1-<i>O</i>-β-glucuronide, is a more potent inhibitor of CYP2C8 in vitro, relative to gemfibrozil (IC<sub>50</sub> of 4.1 and 28 μM, respectively, for gemfibrozil glucuronide and the parent drug).<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> In subsequent studies, Ogilvie et al.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> demonstrated that preincubation of the glucuronide metabolite with NADPH-supplemented HLM further lowered the IC<sub>50</sub> from 24 to 1.8 μM for inhibition of CYP2C8 activity, which is consistent with TDI. Associated <i>k</i><sub>inact</sub> and <i>K</i><sub>I</sub> for TDI of CYP2C8 activity in HLM by gemfibrozil glucuronide were 0.21 min<sup>–1</sup> and 20–52 μM, respectively. The TDI of CYP2C8 was not observed with gemfibrozil, and neither the substrate nor the metabolite demonstrated TDI of CYP2C9. Furthermore, the NADPH dependence ruled out the possibility that CYP2C8 was inactivated via direct covalent adduction with the acyl glucuronide metabolite, which is electrophilic in nature. Consistent with the in vitro observations on CYP2C8 TDI, Tornio et al.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> reported that volunteers who ingested 0.25 mg of repaglinide up to 12 h following a 600 mg dose of gemfibrozil demonstrated sustained (and significant) increase in repaglinide plasma concentrations compared to that observed in volunteers who ingested repaglinide and gemfibrozil simultaneously. At 12 h postadministration of gemfibrozil, plasma concentrations of gemfibrozil and its glucuronide were only 5–10% of their peak values. It was argued that the long-lasting DDI was likely due to CYP2C8 MBI by the gemfibrozil glucuronide metabolite. As such, the inhibitory effect in humans is rapid and occurs 1 h after gemfibrozil administration.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> The mechanism of CYP2C8 inactivation was initially thought to involve covalent adduction of the apoprotein by a quinone methide species generated from the aromatic hydroxylation of the 2′,5′-dimethylphenoxy group in gemfibrozil glucuronide.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> However, LC–MS/MS analysis of inactivated CYP2C8 following reaction with gemfibrozil glucuronide and NAPDH did not reveal such an adduct to the apoprotein but instead provided evidence for the direct covalent adduction of a benzylic carbon on the 2′,5′-dimethylphenoxy group to the heme prosthetic group of the CYP.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> The regiospecificity of substrate addition to the heme group was not confirmed experimentally, but computational modeling experiments indicated that the γ-meso position was the most likely site of modification. The metabolite profile, which consisted of two benzyl alcohol metabolites and a 4′-hydroxygemfibrozil glucuronide metabolite, indicated that CYP-mediated oxidation of the glucuronide metabolite was localized to the 2′,5′-dimethylphenoxy group. Overall, the results are consistent with an inactivation mechanism wherein gemfibrozil glucuronide is oxidized to a benzyl radical intermediate, which evades oxygen rebound, and adds to the γ-meso position of heme (Scheme <a class="ref internalNav" href="#sch14" aria-label="14">14</a>). The proposed mechanism is also consistent with SAR studies, wherein replacement of the aromatic methyl groups in gemfibrozil glucuronide with trifluoromethyl functionalities abolishes MBI of CYP2C8.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> An additional SAR perspective stems from the fact that commonly prescribed fibrates, in particular fenofibrate, (Scheme <a class="ref internalNav" href="#sch14" aria-label="14">14</a>), have not been associated with TDI of CYP2C8, although the drug is prone to glucuronidation following hydrolytic cleavage of its ester linkage to the active component, fenofibric acid. Likewise, acylglucuronide derivatives of structurally diverse drugs (e.g., nonsteroidal anti-inflammatory agents, statins) are devoid of CYP2C8 inactivation.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Finally, it is noteworthy to comment on the possibility that DDIs with gemfibrozil could also arise via non-CYP mechanisms, involving inhibition of (i) organic anion transporting polypeptide 2 by the parent drug and its glucuronide<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> and (ii) uridine glucuronosyltransferase (UGT) mediated glucuronidation of victim drugs.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> For instance, the most pronounced gemfibrozil interactions have been observed with repaglinide and cerivastatin, which are only partially metabolized by CYP2C8. Finally, the ability of gemfibrozil to induce CYP2C8 (in addition to inhibitory effects) may further complicate the ability to retrospectively predict the magnitude of clinical DDIs.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a></div><figure id="sch14" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0003.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. MBI of CYP2C8 by the Gemfibrozil-1-<i>O</i>-β-glucuronide Metabolite of Gemfibrozil</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Raloxifene (Scheme <a class="ref internalNav" href="#sch15" aria-label="15">15</a>) is a selective estrogen receptor modulator that is used in the treatment of osteoporosis in postmenopausal women. Raloxifene is a well-characterized mechanism-based inactivator of CYP3A4 activity (<i>k</i><sub>inact</sub> and <i>K</i><sub>I</sub> of 0.16 min<sup>–1</sup> and 9.9 μM, respectively) in HLM.<a onclick="showRef(event, 'ref126 ref127 ref128 ref129'); return false;" href="javascript:void(0);" class="ref ref126 ref127 ref128 ref129">(126-129)</a> In vitro, raloxifene is metabolized by CYP3A4 to produce several electrophilic species including a diquinone methide intermediate that can be trapped with GSH.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> The process is also accompanied by microsomal covalent binding and irreversible inactivation of CYP3A4.<a onclick="showRef(event, 'ref126 ref127 ref128 ref129'); return false;" href="javascript:void(0);" class="ref ref126 ref127 ref128 ref129">(126-129)</a> Mass spectral analyses indicate that a single equivalent of raloxifene is bound to the intact CYP apoprotein.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Furthermore, analysis of peptides following digestion with proteinase K revealed covalent binding to Cys239 presumably via the diquinone methide intermediate.<a onclick="showRef(event, 'ref127 ref128'); return false;" href="javascript:void(0);" class="ref ref127 ref128">(127, 128)</a> The findings are consistent with the observation that iodoacetamide or <i>N</i>-(1-pyrene)iodoacetamide (cysteine-specific alkylating agents) prevents CYP3A4 TDI by raloxifene. Analysis of the structure of raloxifene metabolites along with CYP3A4 active site docking studies using a computational model defined by X-ray crystal structure data suggests that the binding occurs on the pendent phenyl group.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Interestingly, CYP3A5, which lacks the Cys239 residue (corresponding residue is Ser239), is resistant to MBI by raloxifene, a finding that is associated with a significant increase in GSH conjugates of raloxifene compared with that for CYP3A4. Contrary to the findings of Baer et al.,<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> a second group of investigators identified the nucleophilic OH group of Tyr75 in CYP3A4 as the site of adduction to raloxifene diquinone methide.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Despite the in vitro observations on CYP3A4 MBI, raloxifene is not associated with significant DDIs with CYP3A4 substrates (raloxifene package insert). A probable reason for the discrepancy is that the principal clearance mechanism of raloxifene in humans is via phenolic glucuronidation that is mediated by intestinal UGT 1A enzymes (Scheme <a class="ref internalNav" href="#sch15" aria-label="15">15</a>).<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Thus, the likelihood of raloxifene bioactivation leading to CYP3A4 MBI in vivo is in question when compared with the efficiency of the glucuronidation in the small intestine.</div><figure id="sch15" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0004.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Explanation for the Lack of Clinical DDIs with Raloxifene Despite in Vitro MBI of CYP3A4</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This section cannot be complete without a final and perhaps the most important account of life-threatening DDIs arising via CYP3A4 MBI with mibefradil (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>), a nondihydropyridine calcium channel blocker approved for the treatment of hypertension. Within months of approval in the United States in 1997, there were several reports of significant PK interactions between mibefradil and drugs primarily metabolized by CYP3A4. In one instance, a single dose of the dihydropyridine nifedipine was consumed 24 h after the last dose of mibefradil. The ensuing hypotension and bradycardia were refractory to all available therapy, and the patient died within 24 h of ingesting the dihydropyridine.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Plasma concentrations of drugs such as simvastatin, tacrolimus, cyclosporine, and digoxin also exhibited a marked increase when coadministered with mibefradil.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Mibefradil was voluntarily withdrawn from the market within the first year of its release because of the heightened potential for rhabdomyolysis, renal failure, or bradycardia upon coadministration with other drugs.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> Soon after withdrawal from the market, mibefradil was characterized as a potent reversible (IC<sub>50</sub> of 0.3–2.0 μM) and time-dependent (<i>k</i><sub>inact</sub> = 0.4 min<sup>–1</sup>; <i>K</i><sub>I</sub> = 2.3 μM) inhibitor of CYP3A4 activity in vitro.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> The mechanism of TDI has been the subject of much debate; mibefradil is cleared primarily through hepatic metabolism via N-dealkylation of the tertiary amine motif, hydroxylation on the benzimidazole moiety, and hydrolytic cleavage of the ester side chain.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> MI complex formation between the N-dealkylated metabolite and the heme prosthetic group in CYP3A4 has been ruled out given the lack of a concomitant increase in Soret absorbance at 455 nm.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Likewise, failure to detect adducts in NADPH-supplemented CYP3A4 incubations of mibefradil and nucleophiles (e.g., GSH, cyanide, amines) negates the possibility of RM formation (e.g., quinoneimine generation via oxidation of the hydroxybenzimidazole metabolite).<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Foti et al.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> recently demonstrated that the NADPH- and time-dependent inactivation of CYP3A4 activity by mibefradil correlated well with the time-dependent loss of carbon monoxide binding, which, coupled with the lack of stable heme and/or apoprotein adducts, suggests heme destruction/fragmentation as the putative mechanism of inactivation in a manner similar to that of carbon tetrachloride.<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56, 57)</a> The mibefradil case illustrates the degree of complexity in probing mechanisms of CYP inactivation and also provides an important perspective in maintaining appropriate vigilance and awareness of DDIs, particularly for recently released medications.</div><figure id="fig9" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structure of nondihydropyridine calcium antagonist mibefradil, a potent mechanism-based inactivator of CYP3A4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">4 Medicinal Chemistry Tactics toward Minimizing/Eliminating CYP MBI in Drug Discovery</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43058" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43058" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Insights into the mechanism(s) underlying time-dependent CYP inhibition are a practical starting point for the rational design of compounds to circumvent CYP inactivation. However, eliminating CYP inactivation in lead chemical matter is not a trivial exercise; designing compounds to design out undesired CYP inhibitory effects could introduce a detrimental effect on primary pharmacology (e.g., changes in agonist/antagonist behavior and/or subtype selectivity for target receptor or enzyme) and otherwise attractive pharmacokinetic attributes. Chemical intervention strategies to abolish CYP inactivation liability must be an iterative process, the success of which will be heavily dependent on a close working relationship between medicinal chemists, pharmacologists, and drug metabolism scientists, as evident from the examples in this section.</div><div class="NLM_p">Several publications have demonstrated tactics to minimize and/or eliminate CYP TDI without affecting primary pharmacology and/or disposition characteristics. Solutions range from modulation of lipophilicity resulting in diminished rates of metabolism (and bioactivation to RMs) to virtually eliminating the potential for RM formation via functional group manipulations. Alterations in physicochemical properties within MBI-positive compounds will diminish rates of enzyme inactivation but may not completely eliminate the liability. An illustration of such an approach is evident in the work of Magee et al.,<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> wherein both the high metabolic turnover and CYP3A4 TDI associated with the third generation macrolide (ketolide) antibiotic telithromycin are improved by modulation of physicochemical properties (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>). As described in <a class="ref internalNav" href="#sec3" aria-label="section 3">section 3</a>, CYP3A4 inactivation by macrolides such as telithromycin results from sequential metabolism of the <i>N</i>,<i>N</i>-dimethyl group to the corresponding nitroso intermediate that forms an MI complex with the ferrous form of the heme iron atom. Because this functional group is required for the antibacterial activity, replacement or modifications thereof are not tolerated. Thus, cyclization of the tether connecting the aryl–alkyl group to the macrocylic ring system in telithromycin and strategic placement of a nitrogen into the conformationally constrained tether were utilized as a means to introduce polarity into the telithromycin scaffold as illustrated with compound <b>2</b>, which was a weak CYP3A4 inactivator relative to telithromycin.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> As such, the key analogues described in this work generally matched the in vitro potency of telithromycin against the common susceptible- and macrolide-resistant strains.</div><figure id="fig10" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Reduction in lipophilicity as a tactic to attenuate CYP MBI liability with ketolide antibiotics.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another example of the successful utilization of this tactic is evident from SAR studies on a series of proline-based antagonists of the very late antigen-4 receptor (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>).<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> The ethyl ester derivative of the lead compound <b>3</b> displayed potent CYP3A4 TDI with a <i>k</i><sub>inact</sub> and <i>K</i><sub>I</sub> of 0.05 min<sup>–1</sup> and 0.4 μM, respectively. Metabolism studies with the parent carboxylic acid <b>4</b> in HLM also revealed covalent binding to microsomal protein in a NADPH-dependent fashion, consistent with RM formation. Replacement of the 3,5-dichlorophenyl group of <b>3</b> with a 3-cyanophenyl group (compound <b>5</b>) resulted in a net reduction of the clogP from 5.5 to 3.5, a feature that appeared to be consistent with a somewhat reduced propensity for CYP3A4 inactivation (<i>k</i><sub>inact</sub> = 0.04 min<sup>–1</sup> and <i>K</i><sub>I</sub> = 1.7 μM) and covalent binding to HLM. Information pertaining to the metabolic pathways leading to CYP inactivation by <b>3</b> is unclear. As such, the picomolar whole blood activity and slow dissociation rates against the receptor displayed by <b>5</b> were shown to be sufficient to overcome the poor animal PK, and sustained activity as measured by receptor occupancy was achieved in preclinical species after oral dosing.</div><div class="NLM_p">Reduction of CYP3A4 inactivation by introducing polarity was also successfully applied by Westaway and co-workers in their work leading to the discovery of the first small molecule agonist of the motilin receptor (see Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>).<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> The lead compound <b>6</b> revealed TDI of CYP3A4 activity (∼14-fold decrease in IC<sub>50</sub> upon preincubation for 30 min; IC<sub>50</sub> at 0–5 min of 20 μM; IC<sub>50</sub> at 25–30 min of 1.4 μM) in a manner consistent with enzyme inactivation. On the basis of the hypothesis that the CYP interaction is driven by size and lipophilicity, analogues of <b>6</b> were designed with reduced molecular weight and clogP. Thus, replacement of the pyridyl and dimethylpiperazine rings of <b>6</b> with a two-carbon linker and (2<i>S</i>)-methylpiperazine ring, respectively, led to compounds with reduced agonist potency; however, these changes in combination with a terminal 3-fluoro substituent afforded <b>7</b>, which demonstrated an improved CYP3A4 inhibition profile (<3.2-fold decrease in CYP3A4 IC<sub>50</sub> in a 30 min preincubation; IC<sub>50</sub> at 0–5 min of 10 μM; IC<sub>50</sub> at 25–30 min of 3.1 μM) compared to <b>6</b> while retaining motilin potency. Further reduction in the linker size afforded <b>8</b>, which demonstrated a notable improvement in agonist potency and preclinical PK (relative to <b>6</b>) and drastically attenuated CYP inactivation (<2-fold decrease in CYP3A4 IC<sub>50</sub> in a 30 min preincubation; IC<sub>50</sub> at 0–5 min of 26 μM; IC<sub>50</sub> at 25–30 min of 18 μM).</div><div class="NLM_p">Another example of utilizing lipophilicity modulation to reduce TDI of CYP enzymes is evident with the 4,4-disubstituted piperidine series as glycine transporter 1 (GlyT1) inhibitors for potential treatment of schizophrenia.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Replacing the C-4 phenyl group in the lead piperidine derivative <b>9</b>, a time-dependent CYP inactivator, with the 2-pyridyl group and removing the metabolically labile chiral methyl and aniline NH<sub>2</sub> groups led to a net reduction in clogP by 0.6 log units and abrogated CYP inactivation potential in the resulting compound <b>10</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>). An additional 0.8 log unit reduction in lipophilicity was achieved by replacing one of the aromatic chlorine atoms with two fluorine atoms leading to <b>11</b>, which was virtually devoid of CYP TDI liabilities. Compound <b>11</b> also displayed improvements in aqueous solubility and exhibited GlyT1 potency comparable to that of <b>9</b>.</div><figure id="fig11" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Additional illustrations of physicochemical property manipulations to attenuate MBI of CYP enzymes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Elimination of CYP TDI caused by covalent modification of the heme prosthetic group and/or apoprotein by RMs can be achieved by replacing the structural motif prone to RM formation with a metabolically latent functional group or via strategic placement of a complementary substituent(s) to block the site of initial metabolism that precludes RM formation. The potassium ion channel opener <b>12</b> provides an excellent example of successful utilization of an approach to abrogate RM formation and CYP inactivation (Scheme <a class="ref internalNav" href="#sch16" aria-label="16">16</a>). Replacement of one of the hydrogen atoms ortho to the morpholine ring in <b>12</b> with a fluorine atom (compound <b>13</b>) eliminated TDI liability against CYP3A4.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> The lack of CYP3A4 inactivation by <b>13</b> appears to be consistent with a bioactivation pathway involving initial aromatic hydroxylation ortho to the morpholine ring (or para to the benzylamine methine) in <b>12</b>. Further two-electron oxidation of the hydroxylated metabolite by CYP3A4 would lead to the reactive quinoneiminium or quinone methide species capable of protein conjugation. The potential formation of either RM was prevented by introduction of the fluorine atom. Compound <b>13</b> was shown to be devoid of CYP inactivation while retaining the pharmacologic and PK attributes of the prototype compound <b>12</b>.</div><figure id="sch16" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0008.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Elimination of CYP TDI Liability in the Potassium Ion Channel Opener <b>12</b> by Blocking Putative Site(s) of Bioactivation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The second example deals with the orally active insulin-like growth factor-1 receptor kinase inhibitor BMS-536924 (<b>14</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>), whose preclinical development was suspended because of its liability involving simultaneous inactivation and induction of CYP3A4 activity.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> To reduce/eliminate CYP induction and inactivation while retaining oral pharmacology, morpholine and phenethylamine replacements of <b>14</b> were investigated. The lead optimization process was greatly facilitated by cocrystallization of the insulin-like growth factor-1 receptor with several analogues of <b>14</b>, which suggested that the morpholine group in <b>14</b> is solvent exposed and therefore could be open to SAR exploration to eliminate CYP liabilities without affecting potency. Appending various substituted morpholines did not impact CYP3A4 inactivation and/or induction. Likewise, replacing the morpholine ring with appropriate bioisosteres such as piperazines and 4-aminopiperidines and attenuating the basicity of the distal nitrogen did not yield an optimal compound that balanced CYP3A4 inactivation, CYP3A4 induction, and oral PK. However, a significant improvement in CYP3A4 profile was observed when a C-4 connected piperidine was appended on the benzimidazole core in place of morpholine (compound <b>15</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>). From a CYP inhibition standpoint, removal of the nitrogen atom that connected the heterocycle to the benzimidazole core and replacing it with a carbon appeared to have diminished the affinity for CYP3A4. Alternatively, the SAR observation suggests that the mechanism of CYP3A4 inactivation could potentially involve bioactivation of the dianiline-like motif in <b>14</b> to an electrophilic quinoneiminium intermediate. Overall, improvements in preclinical disposition properties and cellular potency were also observed by reducing the basicity of the piperidine nitrogen and installing the chloropyrazole side chain in place of the phenethylamine side chain as illustrated with compound <b>16</b>.</div><figure id="fig12" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0009.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Simultaneously abolishing CYP3A4 inactivation and induction liabilities in the insulin-like growth factor-1 receptor kinase inhibitor <b>14</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the course of SAR studies on a series of 1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid derivatives as selective agonists for the human melanocortin-4 receptor and potential antiobesity agents, the lead compound <b>17</b> (Scheme <a class="ref internalNav" href="#sch17" aria-label="17">17</a>) demonstrated potent TDI of CYP3A4 (<i>k</i><sub>inact</sub> = 0.08 min<sup>–1</sup>, unbound <i>K</i><sub>I</sub> = 23 nM).<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Upon concomitant administration with CYP3A4 substrates in the clinic, increases in the AUC for the victim drugs were expected to range from 4- to 10-fold as a result of the TDI. The projected degree of clinical DDI was considered to be unacceptable for an antiobesity indication, and as a result, compound <b>17</b> was eliminated from consideration as a development candidate. Studies were undertaken to understand the mechanism underlying <b>17</b>-mediated CYP3A4 TDI to guide medicinal chemistry efforts. Incubations of <b>17</b> with recombinant CYP3A4 revealed the formation of a UV peak at 450 nm in a NADPH-dependent fashion; the UV absorbance increased with time and was reduced to near baseline following addition of potassium ferricyanide to the incubations. These observations indicated that an MI complex was formed between the heme and a RM of <b>17</b>. The RM was proposed to be the nitroso intermediate <b>18</b>, which is obtained from a two-electron oxidation of the initially formed hydroxylamine metabolite (Scheme <a class="ref internalNav" href="#sch17" aria-label="17">17</a>). Characterization of a geminal cyanonitroso adduct <b>19</b> in incubations of <b>17</b> in NADPH-supplemented and potassium cyanide supplemented HLM was consistent with the proposed bioactivation pathway wherein the nitroso intermediate would exist in a tautomeric equilibrium with the corresponding oxime derivative, which could be oxidized to an electrophilic nitroso carbocation and trapped by a cyanide ion.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> On the basis of the insights gained from metabolism studies, it was envisioned that introducing an alkyl group α to the basic amine motif would shield this functionality from oxidation through steric hindrance, thereby reducing the probability of MI complex formation and CYP3A4 TDI. Indeed analogue <b>20</b> was synthesized and shown to be devoid of CYP3A4 TDI while retaining the potent and selective melanocortin-4 receptor agonism observed with <b>17</b>.</div><figure id="sch17" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0010.jpeg" id="gr35" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Strategy To Eliminate CYP3A4 MBI Liability in the Selective Melanocortin 4 Receptor Agonist <b>17</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">PF-562271 (<b>21</b>) (Scheme <a class="ref internalNav" href="#sch18" aria-label="18">18</a>) is a dual inhibitor of the focal adhesion kinase and proline-rich tyrosine kinase 2 with potential utility in the treatment of ovarian cancer and osteoporosis.<a onclick="showRef(event, 'ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref144 ref145">(144, 145)</a> In vitro metabolism studies in HLM revealed that <b>21</b> is a CYP3A4 substrate and a time-dependent inactivator (<i>k</i><sub>inact</sub> = 0.23 min<sup>–1</sup>; <i>K</i><sub>I</sub> = 12 μM), suggesting that <b>21</b> could inhibit its own clearance mechanism. The mechanism of CYP3A4 inactivation was shown to occur via a two-electron oxidation of the dianiline motif to a reactive diimine species, which was trapped with GSH (Scheme <a class="ref internalNav" href="#sch18" aria-label="18">18</a>).<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Furthermore, compound <b>21</b> demonstrated supraproportional increases in <i>C</i><sub>max</sub> and AUC upon repeated dosing in clinical trials, a phenomenon that was consistent with self-inactivation of its clearance mechanism. Likewise, <b>21</b> also caused >3-fold increase in the AUC of the probe CYP3A4 substrate midazolam in a clinical DDI study. Insights into the mechanism of CYP3A4 inactivation allowed a rational medicinal chemistry strategy to reduce/eliminate the MBI liability.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Thus, simply exchanging the 5-aminooxindole nitrogen and carbonyl groups in <b>21</b> afforded compounds (e.g., <b>22</b> and <b>23</b>) that were virtually devoid of CYP3A4 TDI while maintaining kinase potency. In general, disruption of the electron-rich dianiline structure present in <b>21</b> also mitigated the formation of reactive diimine metabolites in the SAR studies.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></div><figure id="sch18" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0011.jpeg" id="gr36" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Strategies To Eliminate CYP3A4 TDI by Virtue of Eliminating Reactive Diimine Formation with Oxindole-Based Focal Adhesion Kinase Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The chemoattractant receptor inhibitor <b>24</b> (Scheme <a class="ref internalNav" href="#sch19" aria-label="19">19</a>), a candidate for the treatment of asthma, also displayed potent CYP3A4 TDI.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> In HLM, <b>24</b> demonstrated time-, concentration-, and NADPH-dependent inhibition of CYP3A4 activity with <i>k</i><sub>inact</sub> and <i>K</i><sub>I</sub> of 0.16 min<sup>–1</sup> and 18 μM, respectively. Clinical DDI predictions suggested a 4.3- to 7.5-fold increase in midazolam exposure at anticipated therapeutic concentrations of <b>24</b>. While incubation of <b>24</b> with NADPH-supplemented recombinant CYP3A4 did not lead to MI complex formation, studies with [<sup>35</sup>S]<b>24</b> in HLM revealed that inactivation was accompanied by an NADPH-dependent increase in covalent binding to a 55–60 kDa microsomal protein, consistent with irreversible binding to CYP3A4 apoprotein by a RM of <b>24</b>. A GSH adduct <b>25</b> was also identified in HLM incubations and was unambiguously determined via NMR to be derived from addition of GSH to C-3 of the 2-methylindole moiety. On the basis of the structure of <b>25</b>, it was suggested that a 2,3-epoxy-2-methylindole and/or a diimine is the potential reactive species responsible for covalent adduction to CYP3A4. Replacement of the 2-methylindole motif in <b>24</b> with an oxindole group (compound <b>26</b>) prevented RM formation and abolished TDI of CYP3A4.</div><figure id="sch19" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0012.jpeg" id="gr37" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. Bioactivation of a 2-Methylindole Derivative <b>24</b> to CYP3A4-Reactive Species</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The degree of complexity associated with efforts to abrogate CYP3A4 TDI while maintaining potency and PK attributes is illustrated with a series of potent renin inhibitors (Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>).<a onclick="showRef(event, 'ref147 ref148'); return false;" href="javascript:void(0);" class="ref ref147 ref148">(147, 148)</a> Lead compounds <b>27</b> and <b>28</b> and several related analogues were identified as time-dependent inhibitors of CYP3A4 (e.g., compound <b>27</b>, 110 fold shift in CYP3A4 IC<sub>50</sub> over a 30 min incubation period, <i>k</i><sub>inact</sub> = 0.094 min<sup>–1</sup>, <i>K</i><sub>I</sub> = 3.2 μM). Trapping studies in HLM using exogenous nucleophiles (e.g., GSH, cyanide, and semicarbazide) did not prevent CYP3A4 TDI, and were not fruitful in providing insights into the RM responsible for CYP inactivation. Likewise, attempts to monitor stable metabolites derived from downstream metabolism of RM(s) were unsuccessful. O-Demethylation of <b>27</b> was observed, as well as amide hydrolysis, to reveal a cyclopropylamine metabolite that could potentially covalently bind to the heme or apoprotein after oxidation. However, replacement of the cyclopropyl group with cyclobutyl and/or cyclopropylmethyl led to loss of renin inhibitory potency and did not abolish CYP3A4 TDI. Replacement of the amide carbonyl with a methylene (compound <b>29</b>) or replacement of cyclopropylamine nitrogen with carbon (compound <b>30</b>) significantly attenuated CYP3A4 TDI (only 6-fold shift in the CYP3A4 IC<sub>50</sub> for <b>29</b> and no TDI discerned with <b>30</b>) but at the cost of renin potency. Interestingly, removal of the chlorine atom from the bottom phenyl ring and attachment of a morpholine group provided compound <b>31</b>, a potent renin inhibitor that was devoid of CYP3A4 TDI. However, the modification also led to significant HLM instability relative to lead compound <b>27</b>. CYP3A4 TDI liability also persisted in the more potent spirocyclic variants (e.g., compound <b>32</b>). On the assumption that TDI was derived from bioactivation of the right-hand aromatic region, several analogues were prepared to block metabolic soft spots but without success. Lowering the overall lipophilicity by installation of polarity to the right-hand phenyl ring provided compounds (e.g., general structure <b>33</b>) that were devoid of CYP3A4 TDI liability. Unfortunately these compounds failed to provide satisfactory bioavailability in animal PK studies, and the series was dropped from further development.</div><figure id="fig13" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Attempts to eliminate CYP3A4 TDI by removal of metabolic soft spots and/or addition of polarity as illustrated with some renin inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The final and perhaps the most intriguing example is deuteration of CYP MBI-positive drugs as a strategy to attenuate RM formation and thus diminish the enzyme inactivation process.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> In vitro metabolism studies with the doubly deuterated paroxetine analogue CTP-347 (<b>34</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>) demonstrated little to no CYP2D6 MBI, apparently because of a dramatic reduction in the formation of the reactive carbene intermediate.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Compound <b>34</b> is currently in clinical trials for the treatment of hot flashes in menopausal women, and it has also been studied in a 96-patient single- and multiple-ascending dose clinical trial. The multiple-dose subjects initially received a single dose of dextromethorphan (a probe CYP2D6 substrate), followed by 14 days of treatment with <b>34</b>, then another single dose of dextromethorphan. Subjects receiving <b>34</b> at 20–40 mg QD retained substantially greater ability to metabolize dextromethorphan compared to treatment with paroxetine administered at 20 mg QD (∼15–20% inhibition of CYP2D6-catalyzed dextromethorphan metabolism to dextrorphan vs ∼55–60% inhibition of CYP2D6 activity with paroxetine). As such, this DDI study represents the first clinical demonstration that deuteration can be utilized to ameliorate CYP MBI-mediated DDI liabilities in humans.</div><figure id="fig14" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Attenuating CYP MBI liability through deuterium incorporation at the metabolically labile site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">5 In Silico Predictors of CYP TDI Potential</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70082" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70082" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Visual examination of prototypic functional groups known to be associated with CYP MBI (e.g., structural alerts) in new chemical entities usually serves as a preliminary indicator of CYP inactivation potential. However, not all structural alert-positives will lead to mechanism-based inactivation of CYP isoforms. Depending on the physicochemical attributes (molecular weight, lipophilicity, etc.), compounds may be subject to elimination via nonmetabolic routes (e.g., biliary and/or renal excretion) and may have no interaction (substrate and/or inhibitor) with CYP enzymes. For instance, the phosphodiesterase 4 inhibitor CP-671,305 (<b>35</b>) contains the 1,3-benzodioxole functional group (Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>) but does not cause TDI of the major human CYP enzymes.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Compound <b>35</b> is resistant to metabolism in animals and humans and is primarily cleared via renal and biliary excretion (in the unchanged form) via active transport.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Likewise, functionalities capable of alkylating CYPs (e.g., aminothiazole) and/or forming an MI complex (e.g., secondary basic amine) are also present in pramipexole (Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>), a non-ergoline dopamine agonist used to treat early stage Parkinson’s disease and restless leg syndrome. However, pramipexole is subject to extensive renal excretion in humans (mediated by transport proteins) and is devoid of CYP-mediated metabolism/bioactivation leading to enzyme inactivation.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a></div><figure id="fig15" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Examples of structural alert-positive compounds that are not associated with CYP MBI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In theory, MBI can be caused by any molecule that is bioactivated to a RM by a CYP. However, in reality, not all RM-positive compounds will covalently modify CYPs (as was discussed earlier with the antidepressant duloxetine in <a class="ref internalNav" href="#sec3_2" aria-label="section 3.2">section 3.2</a>). In many such cases, the RM will escape from the active site into solution prior to the inactivation step. Upon release from the CYP active site, the RMs do, however, have the potential to react nonspecifically with other proteins and/or DNA. Such an outcome has potential toxicological implications especially for drugs with high daily doses. The RM can be detoxified (via reaction with GSH) or covalently adduct to cellular proteins, resulting in immune-mediated idiosyncratic toxicity. In extreme cases (depending on the level of RM generated), depletion of endogenous GSH pools can also lead to saturation of the detoxication pathway, resulting in toxicity. This is further exemplified with the hepatotoxin and anti-inflammatory agent acetaminophen, which is metabolized to an electrophilic quinoneimine NAPQI by CYP2E1 (Scheme <a class="ref internalNav" href="#sch20" aria-label="20">20</a>). CYP2E1, however, is not inactivated by acetaminophen during this process. Instead, NAPQI reacts with GSH and cellular proteins, causing hepatotoxicity.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> In contrast, 3-hydroxyacetanilide, the nonhepatotoxic regioisomer of acetaminophen, is metabolized by CYP2E1 to the corresponding 3,4-dihydroxy- and 3,6-dihydroxyacetanilide metabolites, which undergo further oxidation by CYP2E1 to the reactive 1,4- and 1,2-benzoquinone species (Scheme <a class="ref internalNav" href="#sch20" aria-label="20">20</a>). In this particular circumstance, the bioactivation process is accompanied by irreversible inactivation of CYP2E1.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a></div><figure id="sch20" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0016.jpeg" id="gr38" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Differences in CYP2E1 MBI by Acetaminophen and Its Regioisomer 3′-Hydroxyacetanilide</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Besides the visual identification of structural alerts previously associated with CYP MBI, in silico computational methods, including data-based statistical models and CYP crystal structure-based quantum and molecular mechanics, have also been applied to assess TDI potential. Zientek et al.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> described a CYP3A4 TDI model based on retrospective analysis of physicochemical descriptors and experimental data acquired using an automated and abbreviated TDI assay (two concentrations of test compounds at two time points). A Laplacian-corrected Bayesian classification model (a yes/no filter) categorized the compounds into two classes: positives with ≥25% change in at least one tested concentration over time (or ≥15% change when ≤70% activity is left after preincubation for at least one tested concentration) and the rest as negative. This in silico Bayesian classifier was built on a training set containing approximately 2000 compounds, which seemed to be predictive for the same training set compounds with a cross-validation receiver operator curve value of 0.85. To validate its real predictive power, the model was then applied to predict an independent external data set of 27 TDI-positive compounds from the literature. However, only 11 compounds were predicted with positive Bayesian scores and the rest with zero or negative scores. It was suggested that the poor prediction performance on the selected testing set was caused by limited structural diversity in the training set; i.e., the compounds, which failed in the prediction, are relatively dissimilar (<0.8 structural similarity) to the training set compounds. It is possible that the model can be improved in performance when more structurally diverse compounds are included in the training set. The model did clearly identify several 3-methyleneindazoles and -pyrazoles as positive TDI components, which correlates with CYP inactivation discerned with 3-methylindole analogues such as zafirlukast, a well-prescribed leukotriene receptor antagonist,<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> and SPD-304 (<b>37</b>), a small-molecule tumor necrosis factor-α inhibitor.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a></div><div class="NLM_p">Unlike data-based models, structure-based models can provide information pertaining to the molecular basis of CYP inactivation (e.g., identification of critical active site interactions leading to MBI), which can be useful in iterative design of compounds without TDI liability. Thus, by use of molecular mechanics, alkynes such as 4-<i>tert</i>-butylphenylacetylene (BPA), which are well-established as CYP inactivators, were predicted to covalently modify a threonine 302 residue in helix I of CYP2B1, 2B4, and 2B6 isoforms, resulting in enzyme inactivation. The predictions were supported by the structural identification of the covalently bound adduct and further confirmed by the direct cocrystallization of BPA with CYP2B4.<a onclick="showRef(event, 'ref157 ref158'); return false;" href="javascript:void(0);" class="ref ref157 ref158">(157, 158)</a> In general, the success of structure-based prediction using molecular and quantum mechanics approaches rests on the assumption that the reactive species generated in the course of metabolism will react with nucleophilic residues such as lysine, serine, threonine, tyrosine, or cysteine side chains within the active site, a phenomenon that is difficult to predict. Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a> illustrates the heterogeneity in the lowest energy binding poses for diverse CYP3A4 inactivators including furan derivatives L-754,394 (<b>36</b>) (an HIV protease inhibitor)<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> and bergamottin (grapefruit juice component),<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a>zafirlukast,<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> raloxifene,<a onclick="showRef(event, 'ref126 ref127 ref128'); return false;" href="javascript:void(0);" class="ref ref126 ref127 ref128">(126-128)</a> compound <b>37</b>,<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> and domperidone, a dopamine receptor antagonist.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> As such, all computational models including structure-based methods described to date are mostly retrospective in nature, since they incorporate prior mechanistic information on CYP inactivation. Without some prior information, it is virtually impossible to prospectively predict the ability of new compounds to cause CYP TDI.</div><figure id="fig16" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0017.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Postulated binding poses of CYP3A4 MBI: (A) bergamottin, (B) raloxifene, (C) zafirlukast, (D) <b>36</b>, (E) <b>37</b>, and (F) domperidone that can lead to RM formation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">6 Prediction of Clinical DDI in Drug Discovery Using in Vitro CYP TDI Data</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13764" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13764" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36">6.1 Managing CYP TDI Issues in Drug Discovery</h3><div class="NLM_p">Most pharmaceutical companies assess CYP TDI/MBI potential with abbreviated versions of CYP inactivation screens (e.g., IC<sub>50</sub> shift assay) in place to enable the assessment and/or elimination of the risk prior to candidate selection. While such an approach is useful for early detection of potent inactivators and for rank ordering compounds at the lead optimization stage, precise prediction of in vivo DDI risks from abbreviated CYP TDI assays is difficult. Several attempts have been made to establish quantitative relationships between the magnitude of the IC<sub>50</sub> shift and clinical DDI risks based on anticipated human pharmacokinetics.<a onclick="showRef(event, 'ref5 ref162'); return false;" href="javascript:void(0);" class="ref ref5 ref162">(5, 162)</a> For instance, Sekiguchi et al.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> investigated the use of IC<sub>50</sub> shift data for 46 marketed drugs as CYP3A4 inhibitors, 26 of which were determined to be TDI positive based on an IC<sub>50</sub> shift cutoff of 1.3-fold. Using the IC<sub>50</sub> data along with the observed clinical DDI data, the authors established a relationship between the magnitudes of observed IC<sub>50</sub> shift, the ratio of unbound inactivator concentration at steady state to competitive IC<sub>50</sub>, and subsequent DDI risk. A second approach that can be used in a discovery setting is to estimate DDI using the composite parameter <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub>. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a>, given the ratio of <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> and an estimate of the unbound plasma concentration of the inactivator [I], DDI risk assessments can be made relative to an expected 2-fold interaction as shown by the lines at <i>K</i><sub>I</sub> values of 1.0, 10, and 100 μM. In this example, compounds that fall below the line would have low risk for DDI. Recently Zimmerlin et al.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> reported a good correlation between CYP3A4 TDI data acquired from IC<sub>50</sub> shift and <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> assays and the one obtained from <i>k</i><sub>obs</sub> measurement at a single inactivator concentration of 10 μM using 400 marketed drugs and 4000 proprietary compounds as benchmarks. On the basis of comparison to clinical DDI data for marketed drugs, the authors established a lower limit of <i>k</i><sub>obs</sub> = 0.020 min<sup>–1</sup> for the assay, with compounds falling above this threshold flagged as TDI positive. In contrast to the IC<sub>50</sub> shift approach, this method allows for assessments of TDI risk to be obtained in early discovery such that once the risk is identified, structural modifications can be made in an attempt to mitigate the risk prior to compound selection.</div><figure id="fig17" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0018.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Relationship between the <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> ratio relative to unbound plasma concentration [I]. Lines represent parameters that would be expected to result in a 2-fold interaction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From a medicinal chemistry perspective, an optimal approach to deal with CYP TDI would be to deploy the strategies outlined in <a class="ref internalNav" href="#sec4" aria-label="section 4">section 4</a> to design compounds devoid of the liability. Such an approach serves a dual purpose of abolishing CYP inactivation liability and eliminating the potential for formation of protein-reactive metabolites that may cause idiosyncratic toxicity. It is important to note that prior to embarking on a laborious exercise to dial out CYP inactivation and/or RM formation, insights into the anticipated human PK and the daily dosing regimen for the MBI- and RM-positive compound are essential. For instance, the estrogenic contraceptive ethinyl estradiol is metabolized by CYP3A4 at the C-17α terminal alkyne motif to a reactive oxirene species, which alkylates the heme group and/or protein resulting in the MBI of the isozyme (Scheme <a class="ref internalNav" href="#sch21" aria-label="21">21</a>).<a onclick="showRef(event, 'ref163 ref164 ref165'); return false;" href="javascript:void(0);" class="ref ref163 ref164 ref165">(163-165)</a> In addition to acetylene bioactivation, Park et al.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> have demonstrated the oxidation of the phenol ring in ethinyl estradiol to an electrophilic <i>o</i>-quinone species (via the intermediate catechol metabolite) in HLM, a process that eventually leads to microsomal covalent binding.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> Lack of DDI with CYP3A4 substrates and/or idiosyncratic toxicity is most likely due to the very low dose (0.035 mg) used in birth control. Additional qualifying considerations to mitigate the risk of idiosyncratic toxicity due to RM formation have been the subject of various publications.<a onclick="showRef(event, 'ref168 ref169'); return false;" href="javascript:void(0);" class="ref ref168 ref169">(168, 169)</a></div><figure id="sch21" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0019.jpeg" id="gr39" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Metabolism of Ethinyl Estradiol into CYP3A4- and Protein-Reactive Metabolites</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38">6.2 Prediction of Clinical DDI for MBI-Positive Compounds in Drug Discovery</h3><div class="NLM_p">In the course of iterative SAR efforts, molecules may emerge with significant improvements in pharmacologic potency, PK, and diminished rates of CYP inactivation relative to a prototype (e.g., compound <b>2</b> relative to telithromycin in Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>). However, there may be instances where compound attributes needed for pharmacological activity will be inseparable from the properties that cause CYP TDI (e.g., presence of the thiophene ring in clopidogrel and the <i>N</i>,<i>N</i>-dimethyl substituents in macrolide antibiotics, which are associated with pharmacologic action and CYP inactivation). Likewise, some medicinally important functional groups that are classified as structural alerts (e.g., aniline) can be quite challenging to mimic by isosteric replacement. The aniline motif is widely used in kinase inhibitor design as evident with TK inhibitors (e.g., lapatinib, sunitinib, and erlotinib), which are associated with CYP3A4 MBI and idiosyncratic hepatotoxicity. CYP MBI via RM formation will continue to emerge in kinase programs, which rely on the aniline group.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> In such scenarios, drug discovery/development scientists might choose to go forward with a compound that has some degree of CYP TDI liability, especially if there is reason to believe that the combination of in vivo exposure needed for efficacy relative to potency of CYP inactivation will not result in a clinically relevant DDI.</div><div class="NLM_p">There have been numerous publications related to strategies for using in vitro CYP TDI data for prediction of clinical DDI, with approaches ranging from very simple (three input parameters) to more complex (four or more input parameters).<a onclick="showRef(event, 'ref2 ref9 ref43 ref170'); return false;" href="javascript:void(0);" class="ref ref2 ref9 ref43 ref170">(2, 9, 43, 170)</a> All in vitro and in vivo prediction approaches have in common three basic inputs: a measure of potency of inhibition (e.g., <i>K</i><sub>I</sub>), a measure of rate of inactivation (e.g., <i>k</i><sub>inact</sub>), and a measure of in vivo drug concentration (e.g., [I]). Approaches to predicting DDIs can be categorized into two general types, static and dynamic. Static approaches assume that the concentration of inhibitor does not change over time, while dynamic approaches incorporate changes in inhibitor concentration with time and may also incorporate other system dynamics.</div><div id="sec6_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39">6.2.1 Static Models</h4><div class="NLM_p">One of the earliest attempts at practical application of in vitro data for clinical DDI prediction was published by Mayhew et al. in 2000.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The well-stirred model was adapted for extrapolation of in vitro intrinsic clearance (CL<sub>int</sub>) to in vivo AUC, in addition to terms describing the effect of the CYP inactivator (<i>K</i><sub>I</sub> and <i>k</i><sub>inact</sub>) on the degradation rate of the enzyme. This relatively simple model requires one constant (<i>k</i><sub>deg</sub>, the degradation rate constant for the CYP isoform of interest) and three variable input parameters (in vitro <i>K</i><sub>I</sub>, <i>k</i><sub>inact</sub>, and [I]) as shown in eq <a class="ref internalNav" href="#eq1" aria-label="1">1</a> (the static model for prediction of change in AUC of a probe substrate in the presence of a time-dependent inhibitor):<span class="NLM_disp-formula" id="eq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/jm-2012-00065h_m003.gif" alt="" /></img><span class="labelSpan">(1)</span></span>where AUC and AUC′ represent the area under the curve of object drug in the absence and presence of inactivator, respectively, CL<sub>int</sub> and CL′<sub>int</sub> represent intrinsic clearance of the object drug in the absence and presence of inactivator, respectively, and [E]<sub>ss</sub> and [E]′<sub>ss</sub> represent the concentration of clearing enzyme in the absence and presence of inactivator, respectively. Mayhew et al. validated the model by precisely predicting clinical DDIs for fluoxetine, clarithromycin, and <i>N</i>-desmethyl diltiazem coadministered with CYP3A4 substrates.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The model was also applied to assess the risk of clinically relevant DDI for a series of ketolide compounds, using telithromycin (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>) as a positive control.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Using eq <a class="ref internalNav" href="#eq1" aria-label="1">1</a>, a <i>k</i><sub>inact</sub> of 0.04 min<sup>–1</sup>, a <i>K</i><sub>I</sub> of 2.4 μM, a [I] of 0.17 μM (average unbound plasma concentration for telithromycin at steady state), and <i>k</i><sub>deg</sub> of 0.0005 min<sup>–1</sup> led to a predicted 6.2-fold increase in AUC for a CYP3A substrate in the presence of telithromycin. This prediction is in good agreement with the observed ∼6.0-fold increase in midazolam AUC observed in clinical DDI study with telithromycin and midazolam and hence lends validity to the use of eq <a class="ref internalNav" href="#eq1" aria-label="1">1</a> for DDI prediction of the newer ketolides.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> The basic model described by eq <a class="ref internalNav" href="#eq1" aria-label="1">1</a> is still commonly applied to DDI predictions, although numerous refinements and adaptations have been added to improve the accuracy of the DDI predictions. For example, a term describing the fraction of the object drug that is metabolized by the inactivated CYP (<i>f</i><sub>m,CYP</sub>) is commonly incorporated in the model to account for object drugs with additional clearance pathways.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> For example, midazolam is cleared almost exclusively by CYP3A4 metabolism (<i>f</i><sub>m,CYP3A4</sub> ≈ 0.94), whereas alprazolam is cleared predominantly by CYP3A4 metabolism (<i>f</i><sub>m,CYP3A4</sub> ≈ 0.80) but has an additional renal excretion component (fraction cleared renally is ∼0.20).<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> Therefore, a CYP3A4 inactivator would be expected to produce DDI of greater magnitude with midazolam than with alprazolam, which is in agreement with clinical DDI observations.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> Incorporation of <i>f</i><sub>m,CYP</sub> was applied in the DDI risk assessment in the melanocortin 4 receptor example described previously (Scheme <a class="ref internalNav" href="#sch17" aria-label="17">17</a>). In this latter example, the predicted increase in AUC of a CYP3A4 substrate (<i>f</i><sub>m,CYP</sub> = 1) in the presence of <b>17</b> was 4- to 10-fold. This predicted interaction precluded further preclinical development of this compound.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> In addition to <i>f</i><sub>m,CYP</sub>, the static model has been further refined by incorporating a term describing potential interactions at the level of the intestine for orally administered drugs. The term <i>F</i><sub>g</sub> is used to describe the fraction of drug that escapes gut extraction in the absence of a CYP inactivator. Since CYP3A4 is expressed in the human intestine, a compound that is metabolized to a significant extent in the intestine would have a low <i>F</i><sub>g</sub>; hence, a model that takes into account the effect of intestinal CYP3A4 inhibition for an orally administered CYP3A4 inactivator and object drug would theoretically produce a more accurate prediction. Therefore, eq <a class="ref internalNav" href="#eq1" aria-label="1">1</a> can be adapted to incorporate <i>f</i><sub>m,CYP</sub> and <i>F</i><sub>g</sub>, as shown in eq <a class="ref internalNav" href="#eq2" aria-label="2">2</a> (static model for predicting effect of time-dependent inhibitor on AUC of probe substrate, with incorporation of <i>f</i><sub>m,CYP</sub> and <i>F</i><sub>g</sub> parameters),<span class="NLM_disp-formula" id="eq2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/jm-2012-00065h_m004.gif" alt="" /></img><span class="labelSpan">(2)</span></span>and described in detail in several recent publications.<a onclick="showRef(event, 'ref2 ref43 ref170'); return false;" href="javascript:void(0);" class="ref ref2 ref43 ref170">(2, 43, 170)</a> Note that for the first bracketed term in eq <a class="ref internalNav" href="#eq2" aria-label="2">2</a>, the [I] used would be the estimated hepatic concentration of inhibitor, for which the unbound maximal plasma concentration is used as a surrogate. For the second bracketed term in eq <a class="ref internalNav" href="#eq2" aria-label="2">2</a>, the [I] used would be the gut concentration of inhibitor, which can be estimated based on dose and fraction absorbed, as described previously.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">The model depicted in eq <a class="ref internalNav" href="#eq2" aria-label="2">2</a> has been applied toward DDI risk assessment for the FAK inhibitors described previously in <a class="ref internalNav" href="#sec4" aria-label="section 4">section 4</a> (compound <b>21</b>, Scheme <a class="ref internalNav" href="#sch18" aria-label="18">18</a>). The model was used to describe the increase in AUC of a coadministered CYP3A4 substrate (midazolam) and also used to describe the accumulation of <b>21</b> upon repeat dose administration, due to autoinactivation. The model predicted a 3.4- to 12-fold accumulation, if both hepatic and gut terms were included, and a 2.1- to 7.4-fold accumulation if only the hepatic term was included. The prediction using the hepatic term only was in line with the observed drug accumulation of 1.9- to 5.7-fold.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> The ability to validate the model using experimental data from the lead candidate <b>21</b> increased confidence in the use of this model for DDI risk assessment for backup FAK inhibitors. The approaches described above can be applied to predict DDI for compounds that are time-dependent inactivators of CYPs. However, it is entirely possible that a compound inhibits CYP in a reversible and irreversible fashion. For example, ritonavir is both a competitive and a time-dependent inhibitor of CYP3A4 activity. Consequently, equations used to predict DDI may be adapted to include both the time-dependent component (e.g., eqs <a class="ref internalNav" href="#eq1" aria-label="1">1</a> and <a class="ref internalNav" href="#eq2" aria-label="2">2</a>) and a reversible inhibition component, typically represented by eq <a class="ref internalNav" href="#eq3" aria-label="3">3</a> (static model for predicting effect of reversible inhibitor on AUC of probe substrate),<span class="NLM_disp-formula" id="eq3"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/jm-2012-00065h_m005.gif" alt="" /></img><span class="labelSpan">(3)</span></span>where AUC, AUC′, and [I] are as described above, and in this case <i>K</i><sub>i</sub> represents the inhibition constant for reversible inhibition.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a></div><div class="NLM_p">In addition to CYP inhibition, compounds can also cause CYP induction, which increases the amount of enzyme expressed. It is not uncommon for CYP inhibitors to simultaneously induce CYP expression. This typically occurs via compound binding to the pregnane X receptor or constitutive androstane receptor resulting in increased CYP gene transcription. Enzyme induction is thought to be a protective mechanism whereby the nuclear receptors act as “xenosensors” to detect foreign chemicals and increase the capacity of the body’s drug metabolizing enzymes. Hence, it is not surprising that there is overlap between the substrate specificity of CYPs and the ligand selectivity of xenosensing nuclear receptors. The equations used to predict DDI may also be adapted to include a term to account for enzyme induction, represented by eq <a class="ref internalNav" href="#eq4" aria-label="4">4</a> (static model for predicting effect of enzyme induction on AUC of a probe substrate),<span class="NLM_disp-formula" id="eq4"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/jm-2012-00065h_m006.gif" alt="" /></img><span class="labelSpan">(4)</span></span>where AUC, AUC′, and [I] are as described previously, <i>E</i><sub>max</sub> represents the maximum fold induction determined in an in vitro induction assay, and EC<sub>50</sub> represents the concentration of inducer producing half-maximal induction in vitro. More details regarding prediction of induction can be found in a recent review on this topic.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a></div><div class="NLM_p last">In an effort to allow for multiple CYP interaction mechanisms in the DDI prediction, a combined DDI prediction model has been proposed by Fahmi and co-workers.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> This combined or “net effect” model incorporates terms for TDI (represented by eq <a class="ref internalNav" href="#eq1" aria-label="1">1</a>), reversible inhibition (represented by eq <a class="ref internalNav" href="#eq3" aria-label="3">3</a>), and induction (represented by eq <a class="ref internalNav" href="#eq4" aria-label="4">4</a>), as well as <i>f</i><sub>m,CYP</sub> and intestinal interaction terms as shown in eq <a class="ref internalNav" href="#eq5" aria-label="5">5</a> (net effect model for DDI prediction,<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> with terms for TDI, reversible inhibition, and induction represented by eqs <a class="ref internalNav" href="#eq1" aria-label="1">1</a>, <a class="ref internalNav" href="#eq3" aria-label="3">3</a>, and <a class="ref internalNav" href="#eq4" aria-label="4">4</a>, respectively).<span class="NLM_disp-formula" id="eq5"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/jm-2012-00065h_m007.gif" alt="" /></img><span class="labelSpan">(5)</span></span>In the net effect model, the first term describes the impact of TDI, reversible inhibition, and/or induction at the level of the liver while the second multiplier is used to represent interaction at the level of the intestine. Hence for the first bracketed term in eq <a class="ref internalNav" href="#eq5" aria-label="5">5</a>, the [I] used would be the estimated hepatic concentration of inhibitor, for which the unbound maximal plasma concentration is used as a surrogate. For the second bracketed term in eq <a class="ref internalNav" href="#eq5" aria-label="5">5</a>, the [I] used would be the gut concentration of inhibitor, which can be estimated based on dose and fraction absorbed, as described previously.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a></div></div><div id="sec6_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40">6.2.2 Dynamic Models</h4><div class="NLM_p last">It is important to note that the static models described above address the extent of DDI under equilibrium, steady-state conditions, using a representative member of the human population by applying an average of the systemic blood concentrations at steady state (represented by [I] in the above equations). With the increased availability of PBPK modeling software, which may also include population based capabilities, more investigators are applying dynamic approaches to the prediction of DDI. These dynamic approaches allow one to link the time course of predicted precipitant and object liver and intestine exposure to the known CYP3A4 interaction mechanism. Several PBPK prediction software platforms are available, including but not limited to PK-Sim, GastroPlus, Cloe Predict, and Simcyp. These software platforms were developed to enable modeling and simulation of human PK and tissue distribution and, in the case of Simcyp, the capability to simulate the PK and ADME variability across a population (for a recent review on application of PBPK models in drug discovery and development, see Jones et al.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a>). Several of the software platforms also include a framework for integration of CYP metabolism and inhibition data, thereby enabling DDI prediction. For example, researchers from FDA recently published utilization of Simcyp to develop a PBPK model for telithromycin. The model incorporated parameters describing time-dependent inhibition of CYP3A4 in order to accurately describe telithromycin PK nonlinearity and DDI with midazolam.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Relative to the predictive models discussed previously, predictions with Simcyp require more comprehensive input data such as physiochemical properties, absorption, distribution, and elimination information and hence are most often applied to predictions for later stage compounds. For example, Simcyp was utilized in the planning and design of DDI trials for the recently approved anaplastic lymphoma kinase inhibitor crizotinib, which showed time-dependent inactivation of CYP3A4 in vitro (Pfizer, unpublished results).</div></div><div id="sec6_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41">6.2.3 Prediction Uncertainty</h4><div class="NLM_p">Although the more complex DDI models such as the net effect model and PBPK models should theoretically produce a more accurate prediction of DDI than simpler models, in practice this is not always the case. The impacts of reversible and time-dependent inhibition and induction on overall AUC change are multiplicative, but so are the errors associated with each of these estimates. In addition, there is error associated with each of the variables that make up the TDI, reversible inhibition, and induction terms. For example, <i>K</i><sub>i</sub>, <i>K</i><sub>I</sub>, and <i>k</i><sub>inact</sub> values can vary from laboratory to laboratory, depending on how the inhibition experiment is conducted (e.g., microsomal protein concentration, probe substrate concentration, incubation time, etc). Furthermore, the <i>k</i><sub>deg</sub> for CYP3A4 cannot be measured directly, and several different approaches toward determining this value indirectly have been applied.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> Hence, the value of <i>k</i><sub>deg</sub> used in DDI calculations can vary.</div><div class="NLM_p">The value of [I], inhibitor concentration in vivo, is another variable that cannot be directly measured, and there are several approaches for estimating the appropriate [I] for liver and for intestine. For example, the <i>C</i><sub>max</sub> concentration, corrected for plasma protein binding, is commonly used as an estimation of [I] in the liver. Intestinal [I] may be estimated based on dose, rate of absorption, and fraction absorbed. Unbound hepatic inlet concentration or total plasma concentrations are also sometimes used as estimates for [I]. There is no consensus on the correct estimate of [I] in vivo, and typically models are validated against a set of compounds with known DDI in order to assess which measures of [I] work best for a given prediction method.</div><div class="NLM_p">Another source of uncertainty in DDI prediction is the role of competing metabolic pathways for the perpetrator drug. For example, as described in <a class="ref internalNav" href="#sec3_2" aria-label="section 3.2">section 3.2</a>, raloxifene is a strong CYP3A4 inactivator in vitro and using standard prediction methods would be predicted to cause DDI with CYP3A4 substrates in vivo. However, if one factors in competing metabolic pathways, in this case intestinal glucuronidation, a more accurate prediction is achieved.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a></div><div class="NLM_p last">Finally the value for <i>F</i><sub>g</sub>, the fraction of object drug that escapes gut extraction, can have a large impact on DDI predictions for object drugs undergoing significant gut metabolism. However, <i>F</i><sub>g</sub> is determined indirectly and is difficult to estimate accurately. The impact of <i>F</i><sub>g</sub> on DDI prediction is exemplified in a recent publication focused on prediction of AUC change for simvastatin in the presence of imatinib.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a>A version of the static eq <a class="ref internalNav" href="#eq5" aria-label="5">5</a> was used for the prediction, and since simvastatin undergoes significant gut metabolism, the <i>F</i><sub>g</sub> term was incorporated. However, published estimates of <i>F</i><sub>g</sub> for simvastatin vary from 0.14 to 0.66, yielding a range of DDI predictions of approximately 5-fold, depending on whether the low or high end estimate of <i>F</i><sub>g</sub> was used. This example illustrates the difficulty in accurately estimating one of the parameters used in making prospective DDI predictions. Given the number of additional parameters that need to be measured/estimated, it is not surprising that over- or underpredictions are common.</div></div><div id="sec6_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42">6.2.4 Which TDI Prediction Approaches Work Best?</h4><div class="NLM_p">In practice, there is variable success with the predictivity of models described above, depending on the attributes of the molecules being evaluated. For example, when developing SAR for CYP TDI or for selecting among a number of compounds in early drug discovery, application of rank order of <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> or preincubation IC<sub>50</sub> may be appropriate (Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a>). However, at candidate selection stage, more quantitative estimates of DDI potential will be needed for CYP MBI positives. For late stage candidates, a number of scenarios are possible (Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a>). For example, for compounds that have measurable CYP3A4 TDI in vitro but do not show relevant reversible CYP3A4 inhibition or induction, the simpler prediction model described in eqs <a class="ref internalNav" href="#eq1" aria-label="1">1</a> or <a class="ref internalNav" href="#eq2" aria-label="2">2</a> might be as accurate as or more accurate than the models incorporating additional variables (eq <a class="ref internalNav" href="#eq5" aria-label="5">5</a> or PBPK models). The ketolide example described above is a good illustration of this phenomenon. Since most marketed macrolides and ketolides display CYP TDI but are not potent competitive inhibitors or inducers, the marketed agents can be used as reference compounds using eq <a class="ref internalNav" href="#eq1" aria-label="1">1</a>. As such, this was utilized as a tactic for predicting DDI for a series of second generation ketolides.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> For compounds and/or chemical series that exhibit CYP TDI in addition to competitive CYP inhibition and/or induction, the more complicated models will be needed. The performance of the net effect model (eq <a class="ref internalNav" href="#eq5" aria-label="5">5</a>) was compared to that of Simcyp for prediction of DDI with midazolam for 30 compounds with varying degrees of competitive and time-dependent CYP inhibition and/or CYP induction.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> For the overall data set, both approaches performed about equally well, with average geometric mean fold errors of 1.74 and 1.55 for net effect model and Simcyp, respectively. However, both models yielded several significant over- or underpredictions for some compounds. This latter fact highlights the important point that currently no single model works for all compounds. Therefore, drug development teams need to make thoughtful decisions regarding which models they will apply to their DDI risk assessment strategies, and their choice may vary depending on the chemical series in question. Another important consideration is the amount of data available at various stages in the drug development process. Most TDI prediction methods, including the methods described above, were evaluated using a set of marketed compounds, which are relatively well-understood in terms of TDI, DDI, physicochemical, and PK parameters that need to be incorporated into the models. However, for early stage compounds, many of these aspects may be unknown, and drug discovery scientists need to rely on predicted values, particularly with respect to PK parameters. In these cases, PBPK models may not be as powerful, since there is generally a higher degree of uncertainty for many of the input variables. In such scenarios, it might be more prudent to use a simpler model such as eq <a class="ref internalNav" href="#eq5" aria-label="5">5</a>, using an estimate of average unbound efficacious concentration as [I].</div><figure id="fig18" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0020.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Suggested strategies for dealing with time-dependent CYP inactivation in drug discovery.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43">7 Concluding Remarks</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33468" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33468" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Increasing use of drugs in polypharmacy settings calls for more in-depth understanding of the biochemical interactions that can lead to increased toxicity or loss of pharmacological effect. Factors such as patient population, medications that are likely to be coadministered in that population, and the elimination mechanisms of concomitantly administered medications have to be taken into account to determine the potential for a DDI. Polypharmacy especially in the aging population significantly increases the risk of CYP DDIs, leading to decreased therapeutic efficacy via enzyme induction or increased incidence of toxicity via enzyme inhibition/inactivation. With respect to time-dependent CYP inhibition caused by the formation of CYP-reactive intermediates, most drug discovery efforts exercise the appropriate caution with regard to incorporating structural alerts in drug design. However, it is likely that unanticipated oxidative metabolism yielding reactive species will emerge, as increasingly novel and proprietary functional groups are continuously sought in drug design. A pragmatic starting point to deal with CYP TDI in early discovery should involve mechanistic studies to elucidate the biochemical/molecular basis for enzyme inactivation, followed by rational structural manipulations and iterative SAR analysis for CYP TDI. Hopefully, this will result in the identification of structural types wherein the TDI liability has been eliminated or drastically reduced, relative to the prototype(s). In cases where the functional group(s) responsible for CYP inactivation is required for primary pharmacology, project teams could choose to go forward with a compound that has some degree of CYP TDI liability, especially if there is reason to believe that the combination of in vivo systemic exposure needed for efficacy relative to potency of CYP inactivation will not result in a clinically relevant DDI. In the latter case, confidence in the ability to predict clinical DDI from in vitro DDI data becomes a critical component in the decision to advance an in vitro CYP TDI positive compound into the clinic. Although much progress has been made in DDI prediction capabilities, there exists uncertainty in several of the input parameters that are used to generate the prediction, and hence, over- or underprediction of DDI is not uncommon. In order to decrease the prediction uncertainty, more work is needed to understand prediction parameters and to know which parameters are most important for a given compound or series of compounds. The combination of mechanistic understanding of TDI and confidence in a predicted lack of clinically relevant DDI will enable drug discovery and development teams to progress more safe and effective therapies to patients.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm300065h" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17622" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17622" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amit S. Kalgutkar</span> - <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics and Metabolism, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1e7f73776a30757f72796b6a757f6c5e6e7877647b6c307d7173"><span class="__cf_email__" data-cfemail="1a7b77736e34717b767d6f6e717b685a6a7c73607f6834797577">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suvi T. M. Orr</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Pharmacokinetics,
Dynamics and Metabolism, Pfizer Global Research
and Development, Eastern Point Road, Groton, Connecticut
06340, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics and Metabolism, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sharon L. Ripp</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Pharmacokinetics,
Dynamics and Metabolism, Pfizer Global Research
and Development, Eastern Point Road, Groton, Connecticut
06340, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics and Metabolism, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">T. Eric Ballard</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Pharmacokinetics,
Dynamics and Metabolism, Pfizer Global Research
and Development, Eastern Point Road, Groton, Connecticut
06340, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics and Metabolism, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jaclyn L. Henderson</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Pharmacokinetics,
Dynamics and Metabolism, Pfizer Global Research
and Development, Eastern Point Road, Groton, Connecticut
06340, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics and Metabolism, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dennis O. Scott</span> - <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics and Metabolism, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">R. Scott Obach</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Pharmacokinetics,
Dynamics and Metabolism, Pfizer Global Research
and Development, Eastern Point Road, Groton, Connecticut
06340, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics and Metabolism, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hao Sun</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Pharmacokinetics,
Dynamics and Metabolism, Pfizer Global Research
and Development, Eastern Point Road, Groton, Connecticut
06340, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics and Metabolism, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88614" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88614" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Suvi T. M. Orr</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=bio1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Suvi T. M. Orr</b> (née Simila) is Principal Scientist and Laboratory Manager in the Worldwide Medicinal Chemistry Group at Pfizer. Before joining Pfizer in 2008, she worked in the Drug Discovery Team at Transtech Pharma (2001–2003) and earned her Ph.D. in Organic Chemistry from the University of Texas at Austin under the supervision of Prof. Stephen F. Martin. Her research at Pfizer focuses on the discovery (design and synthesis) of small molecule agents for treatment of cardiovascular and metabolic diseases. She has coauthored a number of publications in organic synthesis and is a co-inventor on several patents in the area of type-2-diabetes treatments.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Sharon L. Ripp</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=bio2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Sharon L. Ripp</b> is a Senior Principal Scientist in the Drug Metabolism Group at Pfizer. Since joining Pfizer in 2002, Sharon has contributed to numerous small molecule research and development programs and most recently is focused on support of Pfizer’s late stage portfolio and marketed products. Sharon’s training included a Ph.D. in Environmental Toxicology from the University of Wisconsin—Madison and postdoctoral work in the laboratory of Professor Russell Prough at the University of Louisville, KY. Sharon has a broad range of ADME interests and expertise and has published in the area of CYP induction and methods for in vitro to in vivo extrapolation.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="41" class="article__inlineFigure"><h2 class="fig-label">T. Eric Ballard</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=bio3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>T. Eric Ballard</b> is a Postdoctoral Fellow in the Worldwide Medicinal Chemistry Group at Pfizer. He earned his Ph.D. in Organic Chemistry from North Carolina State University under Prof. Christian Melander in 2008. His research interests at Pfizer focus on the design and synthesis of clickable photoaffinity-based small molecule probes and their application to mechanism-of-action studies in neurologic and psychiatric disorders. He has coauthored numerous publications on organic synthesis, bioorganic chemistry, and chemical biology.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Jaclyn L. Henderson</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=bio4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jaclyn L. Henderson</b> is a Senior Scientist in the Worldwide Medicinal Chemistry Group at Pfizer. She earned her Ph.D. in Organic Synthesis under the supervision of Prof. Michael F. Greaney at the University of Edinburgh, U.K., and carried out postdoctoral research in the group of Prof. Stephen Buchwald at Massachusetts Institute of Technology, MA. Before joining Pfizer she worked in Drug Discovery at Organon (2001–2004) and Vertex (2007–2008). Her research interests at Pfizer are focused on the design and synthesis of small molecule drugs for neuroscience indications.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Dennis O. Scott</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=bio5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Dennis O. Scott</b> is a Senior Director in the Drug Metabolism Group at Pfizer. He received his Ph.D. (1991) in Chemistry from the University of Kansas and conducted postdoctoral research at the University of Kansas studying the in vivo disposition of camptothecin prodrugs. In 1992 he joined Marion Merrell Dow, and in 1998 he joined Pfizer in the Cardiovascular, Endocrinology and Metabolic Diseases Group, where he is currently a Senior Director, leading drug metabolism efforts at Cambridge, MA. He has coauthored more than 40 publications. Specific areas of scientific interest include semimechanistic PK/PD modeling, in silico ADME, in vivo microdialysis sampling, and active drug transport.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="44" class="article__inlineFigure"><h2 class="fig-label">R. Scott Obach</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=bio6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>R. Scott Obach</b> is a Senior Research Fellow in the Drug Metabolism Group at Pfizer. He earned his Ph.D. in Biochemistry from Brandeis University (1990), MA, and carried out postdoctoral research on cytochrome P450 enzymes at the New York State Department of Health Research Laboratories before joining Pfizer in 1992. His research interests include application of in vitro approaches to study drug metabolism, prediction of human pharmacokinetics and drug interactions, mechanisms of cytochrome P450 catalysis, and other biotransformation reactions, including generation of chemically reactive metabolites. He is currently on the editorial board of <i>Chemical Research in Toxicology</i>, <i>Drug Metabolism and Disposition</i> and <i>Xenobiotica</i>. He has coauthored more than 130 peer-reviewed publications, reviews. and book chapters.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Hao Sun</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=bio7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hao Sun</b> is a Principal Scientist in the Drug Metabolism Group at Pfizer. He earned his Ph.D. in Pharmacology from the University of Utah in 2007 under the supervision of Prof. Garold S. Yost. His research interests include application of cytochrome P450 crystal structures and various molecular and quantum mechanics-based modeling tools to study catalytic mechanisms for structure–based drug design. He is currently on the editorial board of <i>Chemico-Biological Interactions</i>.</p></figure></div><div class="bio" rid="ath8"><figure id="ath8" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Amit S. Kalgutkar</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=bio8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Amit S. Kalgutkar</b> is a Research Fellow in the Drug Metabolism Group at Pfizer. He earned his Ph.D. in Organic Chemistry from Virginia Tech, VA, and carried out postdoctoral research at Vanderbilt University, TN, before joining Pfizer. His research interest primarily focuses on medicinal chemistry and mechanistic drug metabolism. He has been a member of the editorial board of <i>Chemical Research in Toxicology</i> and is currently on the editorial board of <i>Xenobiotica</i> and <i>Drug Metabolism and Disposition</i>. Besides his current position at Pfizer, he is also an Adjunct Professor at the Department of Biomedical and Pharmaceutical Sciences, School of Pharmacy, University of Rhode Island. He has coauthored over 100 peer-reviewed papers, reviews, and book chapters and holds several patents in the area of selective COX-2 inhibition.</p></figure></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i52" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i52"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i53" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i53"> Abbreviations Used</h2><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DDI</td><td class="NLM_def"><p class="first last">drug–drug interaction</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">RM</td><td class="NLM_def"><p class="first last">reactive metabolite</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">TDI</td><td class="NLM_def"><p class="first last">time-dependent inhibition</p></td></tr><tr><td class="NLM_term">MBI</td><td class="NLM_def"><p class="first last">mechanism-based inactivation</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">PBPK</td><td class="NLM_def"><p class="first last">physiologically based pharmacokinetic</p></td></tr><tr><td class="NLM_term"><i>k</i><sub>inact</sub></td><td class="NLM_def"><p class="first last">maximal inactivation rate constant</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>I</sub></td><td class="NLM_def"><p class="first last">inactivator concentration required to achieve 50% <i>k</i><sub>inact</sub></p></td></tr><tr><td class="NLM_term"><i>K</i><sub>M</sub></td><td class="NLM_def"><p class="first last">substrate concentration that yields half of the maximum rate of catalysis</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">concentration of substrate required to achieve 50% inhibition</p></td></tr><tr><td class="NLM_term">NADPH</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate</p></td></tr><tr><td class="NLM_term">UV</td><td class="NLM_def"><p class="first last">ultraviolet</p></td></tr><tr><td class="NLM_term">MI</td><td class="NLM_def"><p class="first last">metabolite intermediate</p></td></tr><tr><td class="NLM_term">LC–MS/MS</td><td class="NLM_def"><p class="first last">liquid chromatography–tandem mass spectrometry</p></td></tr><tr><td class="NLM_term">ABT</td><td class="NLM_def"><p class="first last">1-aminobenzotriazole</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">reduced glutathione</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the plasma concentration versus time curve</p></td></tr><tr><td class="NLM_term">COMT</td><td class="NLM_def"><p class="first last">catechol-<i>O</i>-methyltransferase</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">HIV</td><td class="NLM_def"><p class="first last">human immunodeficiency virus</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximal plasma concentration</p></td></tr><tr><td class="NLM_term">BBW</td><td class="NLM_def"><p class="first last">black box warning</p></td></tr><tr><td class="NLM_term">TK</td><td class="NLM_def"><p class="first last">tyrosine kinase</p></td></tr><tr><td class="NLM_term">UGT</td><td class="NLM_def"><p class="first last">uridine glucuronosyl transferase</p></td></tr><tr><td class="NLM_term">GlyT1</td><td class="NLM_def"><p class="first last">glycine transporter 1</p></td></tr><tr><td class="NLM_term">BPA</td><td class="NLM_def"><p class="first last">4-<i>tert</i>-butylphenylacetylene</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">once-a-day</p></td></tr><tr><td class="NLM_term">NAPQI</td><td class="NLM_def"><p class="first last"><i>N</i>-acetyl-<i>p</i>-benzoquinoneimine</p></td></tr><tr><td class="NLM_term">BPA</td><td class="NLM_def"><p class="first last">4-<i>tert</i>-butylphenylacetylene</p></td></tr><tr><td class="NLM_term">[I]</td><td class="NLM_def"><p class="first last">unbound plasma concentration of a CYP inactivator in vivo</p></td></tr><tr><td class="NLM_term"><i>k</i><sub>deg</sub></td><td class="NLM_def"><p class="first last">degradation rate constant for the CYP isoform</p></td></tr><tr><td class="NLM_term"><i>f</i><sub>m,CYP</sub></td><td class="NLM_def"><p class="first last">fraction of the drug that is metabolized by CYP</p></td></tr><tr><td class="NLM_term"><i>F</i><sub>g</sub></td><td class="NLM_def"><p class="first last">fraction of object drug that escapes gut extraction</p></td></tr><tr><td class="NLM_term"><i>E</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum fold induction determined in an in vitro induction assay</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub></td><td class="NLM_def"><p class="first last">concentration of inducer producing half-maximal induction in vitro</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>i</sub></td><td class="NLM_def"><p class="first last">inhibition constant for reversible CYP inhibition</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i54">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81604" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81604" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 179 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Guengerich, F. P.</span><span> </span><span class="NLM_article-title">Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">611</span><span class="NLM_x">–</span> <span class="NLM_lpage">650</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx0002583" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjt1Wnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2001&pages=611-650&author=F.+P.+Guengerich&title=Common+and+uncommon+cytochrome+P450+reactions+related+to+metabolism+and+chemical+toxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Common and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity</span></div><div class="casAuthors">Guengerich, F. Peter</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">611-650</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 417 refs.  Cytochrome P 450 enzymes catalyze a variety of reactions and convert chems. to potentially reactive products as well as make compds. less toxic.  Most of the P 450 reactions are oxidns.  The majority of these can be rationalized in the context of an FeO3+ intermediate and odd electron abstraction/rebound mechanisms; however, other iron-oxygen complexes are possible and alternate chemistries can be considered.  Another issue regarding P 450-catalyzed reactions is the delineation of rate-limiting steps in the catalytic cycle and the contribution to reaction selectivity.  In addn. to the rather classical oxidns., P 450s also catalyze less generally discussed reactions including redn., desatn., ester cleavage, ring expansion, ring formation, aldehyde scission, dehydration, ipso attack, one-electron oxidn., coupling reactions, rearrangement of fatty acid and prostaglandin hydroperoxides, and phospholipase activity.  Most of these reactions are rationalized in the context of high-valent iron-oxygen intermediates and Fe2+ redns., but others are not and may involve acid-base catalysis.  Some of these transformations are involved in the bioactivation and detoxication of xenobiotic chems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoznx-XkuM1OrVg90H21EOLACvtfcHk0ljC2gziAzsxbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjt1Wnsbs%253D&md5=9398501ce17beed3fc0bad4840187eea</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Ftx0002583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx0002583%26sid%3Dliteratum%253Aachs%26aulast%3DGuengerich%26aufirst%3DF.%2BP.%26atitle%3DCommon%2520and%2520uncommon%2520cytochrome%2520P450%2520reactions%2520related%2520to%2520metabolism%2520and%2520chemical%2520toxicity%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2001%26volume%3D14%26spage%3D611%26epage%3D650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Grimm, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einolf, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomeir, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seibert., E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skordos, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonn, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Horn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">The conduct of in vitro studies to address time-dependent inhibition of drug metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1355</span><span class="NLM_x">–</span> <span class="NLM_lpage">1370</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1355-1370&author=S.+W.+Grimmauthor=H.+J.+Einolfauthor=S.+D.+Hallauthor=K.+Heauthor=H.+K.+Limauthor=K.+H.+Lingauthor=C.+Luauthor=A.+A.+Nomeirauthor=E.+Seibert.author=K.+W.+Skordosauthor=G.+R.+Tonnauthor=R.+Van+Hornauthor=R.+W.+Wangauthor=Y.+N.+Wongauthor=T.+J.+Yangauthor=R.+S.+Obach&title=The+conduct+of+in+vitro+studies+to+address+time-dependent+inhibition+of+drug+metabolizing+enzymes%3A+a+perspective+of+the+pharmaceutical+research+and+manufacturers+of+America"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrimm%26aufirst%3DS.%2BW.%26aulast%3DEinolf%26aufirst%3DH.%2BJ.%26aulast%3DHall%26aufirst%3DS.%2BD.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DLim%26aufirst%3DH.%2BK.%26aulast%3DLing%26aufirst%3DK.%2BH.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DNomeir%26aufirst%3DA.%2BA.%26aulast%3DSeibert.%26aufirst%3DE.%26aulast%3DSkordos%26aufirst%3DK.%2BW.%26aulast%3DTonn%26aufirst%3DG.%2BR.%26aulast%3DVan%2BHorn%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DR.%2BW.%26aulast%3DWong%26aufirst%3DY.%2BN.%26aulast%3DYang%26aufirst%3DT.%2BJ.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DThe%2520conduct%2520of%2520in%2520vitro%2520studies%2520to%2520address%2520time-dependent%2520inhibition%2520of%2520drug%2520metabolizing%2520enzymes%253A%2520a%2520perspective%2520of%2520the%2520pharmaceutical%2520research%2520and%2520manufacturers%2520of%2520America%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1355%26epage%3D1370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Parkinson, A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazmi, F</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yerino, P</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paris, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holsapple, J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otradovec, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, B. W.</span><span> </span><span class="NLM_article-title">An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1370</span><span class="NLM_x">–</span> <span class="NLM_lpage">1387</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1370-1387&author=A+Parkinsonauthor=F+Kazmiauthor=D.+B.+Buckleyauthor=P+Yerinoauthor=B.+L.+Parisauthor=J+Holsappleauthor=P.+Torenauthor=S.+M.+Otradovecauthor=B.+W.+Ogilvie&title=An+evaluation+of+the+dilution+method+for+identifying+metabolism-dependent+inhibitors+of+cytochrome+P450+enzymes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParkinson%26aufirst%3DA%26aulast%3DKazmi%26aufirst%3DF%26aulast%3DBuckley%26aufirst%3DD.%2BB.%26aulast%3DYerino%26aufirst%3DP%26aulast%3DParis%26aufirst%3DB.%2BL.%26aulast%3DHolsapple%26aufirst%3DJ%26aulast%3DToren%26aufirst%3DP.%26aulast%3DOtradovec%26aufirst%3DS.%2BM.%26aulast%3DOgilvie%26aufirst%3DB.%2BW.%26atitle%3DAn%2520evaluation%2520of%2520the%2520dilution%2520method%2520for%2520identifying%2520metabolism-dependent%2520inhibitors%2520of%2520cytochrome%2520P450%2520enzymes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1370%26epage%3D1387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Hollenberg, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, U. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bumpus, N. N.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of human cytochromes P450s: experimental characterization, reactive intermediates, and clinical implications</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">205</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx7002504" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=189-205&author=P.+F.+Hollenbergauthor=U.+M.+Kentauthor=N.+N.+Bumpus&title=Mechanism-based+inactivation+of+human+cytochromes+P450s%3A+experimental+characterization%2C+reactive+intermediates%2C+and+clinical+implications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Ftx7002504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx7002504%26sid%3Dliteratum%253Aachs%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26aulast%3DKent%26aufirst%3DU.%2BM.%26aulast%3DBumpus%26aufirst%3DN.%2BN.%26atitle%3DMechanism-based%2520inactivation%2520of%2520human%2520cytochromes%2520P450s%253A%2520experimental%2520characterization%252C%2520reactive%2520intermediates%252C%2520and%2520clinical%2520implications%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D189%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Berry, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span> </span><span class="NLM_article-title">An examination of IC<sub>50</sub> and IC<sub>50</sub>-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes</span> <span class="citation_source-journal">Drug Metab. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2174%2F187231208783478407" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=51-59&author=L.+M.+Berryauthor=Z.+Zhao&title=An+examination+of+IC50+and+IC50-shift+experiments+in+assessing+time-dependent+inhibition+of+CYP3A4%2C+CYP2D6+and+CYP2C9+in+human+liver+microsomes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2174%2F187231208783478407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231208783478407%26sid%3Dliteratum%253Aachs%26aulast%3DBerry%26aufirst%3DL.%2BM.%26aulast%3DZhao%26aufirst%3DZ.%26atitle%3DAn%2520examination%2520of%2520IC50%2520and%2520IC50-shift%2520experiments%2520in%2520assessing%2520time-dependent%2520inhibition%2520of%2520CYP3A4%252C%2520CYP2D6%2520and%2520CYP2C9%2520in%2520human%2520liver%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2008%26volume%3D21%26spage%3D51%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Venkatakrishnan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Drug–drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">–</span> <span class="NLM_lpage">462</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2174%2F138920007780866861" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=17584016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsl2jt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=449-462&author=K.+Venkatakrishnanauthor=R.+S.+Obach&title=Drug%E2%80%93drug+interactions+via+mechanism-based+cytochrome+P450+inactivation%3A+points+to+consider+for+risk+assessment+from+in+vitro+data+and+clinical+pharmacologic+evaluation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation</span></div><div class="casAuthors">Venkatakrishnan, Karthik; Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">449-462</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This commentary discusses the approaches to, and key considerations in the in vitro-in vivo extrapolation of drug-drug interactions (DDI) resulting from mechanism-based inactivation (MBI) of cytochrome P 450 (CYP) enzymes and clin. pharmacol. implications.  In vitro kinetic assessment and prediction of DDI produced via reversible inhibition and MBI rely on operationally and conceptually distinct approaches.  DDI risk assessment for inactivators requires estn. of maximal inactivation rate (kinact) and inactivator potency (KI) in vitro, that need to be considered in context of the biol. turnover rate of the enzyme (kdeg) and clin. exposures of the inactivator (I), resp., to predict interaction magnitude.  Risk assessment cannot be performed by a simple comparison of inactivator potency against in vivo exposure since inactivation is both concn. and time-dependent.  MBI contour plots tracking combinations of I:KI and kinact:kdeg resulting in identical fold-redns. in intrinsic clearance are proposed as a useful framework for DDI risk assessment.  Addnl., substrate-specific factors like fraction of the total clearance of the object drug via the enzyme being inactivated (fm(CYP)) and the bioavailability fraction across the intestine for CYP3A substrates (FG) are important determinants of interaction magnitude.  Sensitivity anal. of predicted DDI magnitude to uncertainty in input parameters is recommended to inform confidence in predictions.  The time course of reversal of DDI resulting from CYP inactivation is detd. by the half-life of the enzyme which is an important consideration in the design and interpretation of clin. DDI studies with inactivators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu6S_D7BcNBrVg90H21EOLACvtfcHk0lgDrRzhkizSAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsl2jt7c%253D&md5=d7ff970e763ca6bbae55db576d92b5e0</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2174%2F138920007780866861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920007780866861%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatakrishnan%26aufirst%3DK.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DDrug%25E2%2580%2593drug%2520interactions%2520via%2520mechanism-based%2520cytochrome%2520P450%2520inactivation%253A%2520points%2520to%2520consider%2520for%2520risk%2520assessment%2520from%2520in%2520vitro%2520data%2520and%2520clinical%2520pharmacologic%2520evaluation%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2007%26volume%3D8%26spage%3D449%26epage%3D462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Mao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohutsky, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrelson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrighton, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. D.</span><span> </span><span class="NLM_article-title">Prediction of CYP-mediated drug–drug interactions using cryopreserved human hepatocytes suspended in human plasma</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=591-602&author=J.+Maoauthor=M.+A.+Mohutskyauthor=J.+P.+Harrelsonauthor=S.+A.+Wrightonauthor=S.+D.+Hall&title=Prediction+of+CYP-mediated+drug%E2%80%93drug+interactions+using+cryopreserved+human+hepatocytes+suspended+in+human+plasma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DJ.%26aulast%3DMohutsky%26aufirst%3DM.%2BA.%26aulast%3DHarrelson%26aufirst%3DJ.%2BP.%26aulast%3DWrighton%26aufirst%3DS.%2BA.%26aulast%3DHall%26aufirst%3DS.%2BD.%26atitle%3DPrediction%2520of%2520CYP-mediated%2520drug%25E2%2580%2593drug%2520interactions%2520using%2520cryopreserved%2520human%2520hepatocytes%2520suspended%2520in%2520human%2520plasma%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D591%26epage%3D602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Grime, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bird, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, R. J.</span><span> </span><span class="NLM_article-title">Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug–drug interaction prediction methods</span> <span class="citation_source-journal">Eur. J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">191</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.ejps.2008.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=19013237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVWhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2009&pages=175-191&author=K.+H.+Grimeauthor=J.+Birdauthor=D.+Fergusonauthor=R.+J.+Riley&title=Mechanism-based+inhibition+of+cytochrome+P450+enzymes%3A+an+evaluation+of+early+decision+making+in+vitro+approaches+and+drug%E2%80%93drug+interaction+prediction+methods"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inhibition of cytochrome P450 enzymes: An evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods</span></div><div class="casAuthors">Grime, Kenneth H.; Bird, James; Ferguson, Douglas; Riley, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">175-191</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The ability to use in vitro human cytochrome P 450 (CYP) time-dependent inhibition (TDI) data for in vivo drug-drug interaction (DDI) predictions should be viewed as a prerequisite to generating the data.  Important terms in making such predictions are kinact and KI but first-line screening assays typically involve characterization of an IC50 value or a time dependent shift in IC50.  In the work presented here, two key screening methods from the scientific literature were appraised both in terms of practicality and quality of kinact/KI estn.  The utility of TDI screening data in DDI predictions was investigated and particular ref. given to a simple DDI simulation model based on a spreadsheet that calcs. the systemic exposure of unbound inhibitor drug following the input of human pharmacokinetic parameters.  Using several clin. mechanism-based CYP DDI examples, the effectiveness of the approach was assessed and compared to other widely available approaches (a simple algorithm that employs a single in vivo unbound inhibitor concn., a seven-compartment physiol. based pharmacokinetic (PBPK) model that defines the extent of interaction as a result of hepatic inhibitor concns. and the com. available software SimCYP).  All the methods gave predictions that compared favorably with the obsd. DDIs, but various advantages and disadvantages of each were also given full consideration.  The new model facilitates rapid sensitivity anal. (parameters can be easily input and altered to give a visual representation of the impact on the active enzyme concn.) and it was therefore used to derive "rules of thumb" demonstrating the relationship between extent of DDI, time-dependent IC50 and dose for typical acidic and basic drugs.  Addnl., a TDI decision tree linking into reactive metabolite investigations is proposed for use in a Drug Discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM7p75JgXkwLVg90H21EOLACvtfcHk0lhgDgbgd8RnSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVWhtQ%253D%253D&md5=1621091a7cf8f8909e2e8d0c802fdfd0</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2008.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2008.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DGrime%26aufirst%3DK.%2BH.%26aulast%3DBird%26aufirst%3DJ.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26atitle%3DMechanism-based%2520inhibition%2520of%2520cytochrome%2520P450%2520enzymes%253A%2520an%2520evaluation%2520of%2520early%2520decision%2520making%2520in%2520vitro%2520approaches%2520and%2520drug%25E2%2580%2593drug%2520interaction%2520prediction%2520methods%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2009%26volume%3D36%26spage%3D175%26epage%3D191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Mayhew, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. D.</span><span> </span><span class="NLM_article-title">An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1031</span><span class="NLM_x">–</span> <span class="NLM_lpage">1037</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=1031-1037&author=B.+S.+Mayhewauthor=D.+R.+Jonesauthor=S.+D.+Hall&title=An+in+vitro+model+for+predicting+in+vivo+inhibition+of+cytochrome+P450+3A4+by+metabolic+intermediate+complex+formation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMayhew%26aufirst%3DB.%2BS.%26aulast%3DJones%26aufirst%3DD.%2BR.%26aulast%3DHall%26aufirst%3DS.%2BD.%26atitle%3DAn%2520in%2520vitro%2520model%2520for%2520predicting%2520in%2520vivo%2520inhibition%2520of%2520cytochrome%2520P450%25203A4%2520by%2520metabolic%2520intermediate%2520complex%2520formation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2000%26volume%3D28%26spage%3D1031%26epage%3D1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Li, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balani, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, L. S.</span><span> </span><span class="NLM_article-title">A refined cytochrome P540 IC<sub>50</sub> shift assay for reliably identifying CYP3A time-dependent inhibitors</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1054</span><span class="NLM_x">–</span> <span class="NLM_lpage">1057</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1054-1057&author=P.+Liauthor=C.+Luauthor=S.+K.+Balaniauthor=L.+S.+Gan&title=A+refined+cytochrome+P540+IC50+shift+assay+for+reliably+identifying+CYP3A+time-dependent+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DP.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DBalani%26aufirst%3DS.%2BK.%26aulast%3DGan%26aufirst%3DL.%2BS.%26atitle%3DA%2520refined%2520cytochrome%2520P540%2520IC50%2520shift%2520assay%2520for%2520reliably%2520identifying%2520CYP3A%2520time-dependent%2520inhibitors%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1054%26epage%3D1057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Sekiguchi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashida, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nabuchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aso, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishigai, M.</span><span> </span><span class="NLM_article-title">Prediction of drug–drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition</span> <span class="citation_source-journal">Drug Metab. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">500</span><span class="NLM_x">–</span> <span class="NLM_lpage">510</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2133%2Fdmpk.24.500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=20045985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt12iuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2009&pages=500-510&author=N.+Sekiguchiauthor=A.+Higashidaauthor=M.+Katoauthor=Y.+Nabuchiauthor=T.+Mitsuiauthor=K.+Takanashiauthor=Y.+Asoauthor=M.+Ishigai&title=Prediction+of+drug%E2%80%93drug+interactions+based+on+time-dependent+inhibition+from+high+throughput+screening+of+cytochrome+P450+3A4+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition</span></div><div class="casAuthors">Sekiguchi, Nobuo; Higashida, Atsuko; Kato, Motohiro; Nabuchi, Yoshiaki; Mitsui, Tetsuya; Takanashi, Kenji; Aso, Yoshinori; Ishigai, Masaki</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">500-510</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society for the Study of Xenobiotics</span>)
        </div><div class="casAbstract">A method of assessing the risk of drug-drug interaction (DDI) caused by mechanism-based inhibition (MBI) was developed for early-stage drug development using cytochrome P 450 (CYP) 3A4 inhibition screening data.  CYP3A4 inhibition was evaluated using a fluorescent substrate with or without preincubation contg. an inhibitor.  The results showed that five well-known mechanism-based inhibitors, but not the competitive inhibitor ketoconazole, had lower IC50 after preincubation, suggesting the utility of the IC50 shift by preincubation to discern mechanism-based inhibitors.  A method to approx. predict the change in the area under the concn.-time curve (AUC) of a co-administered drug by MBI was found using IC50 shift data and the unbound mean plasma concn. of the inhibitor.  From our predictions of change in the AUC for 38 drugs using this method, all mechanism-based inhibitors causing change in the AUC of more than 200% were predicted to be high risk.  In conclusion, our method provides a simple assessment of the risk of DDI from mechanism-based inhibitors, esp. in the early stages of drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7M6ArbDpwt7Vg90H21EOLACvtfcHk0lhgDgbgd8RnSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt12iuro%253D&md5=c6e4c4d3dcd3b5ce125ed2f83b706110</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2133%2Fdmpk.24.500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2133%252Fdmpk.24.500%26sid%3Dliteratum%253Aachs%26aulast%3DSekiguchi%26aufirst%3DN.%26aulast%3DHigashida%26aufirst%3DA.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DNabuchi%26aufirst%3DY.%26aulast%3DMitsui%26aufirst%3DT.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DAso%26aufirst%3DY.%26aulast%3DIshigai%26aufirst%3DM.%26atitle%3DPrediction%2520of%2520drug%25E2%2580%2593drug%2520interactions%2520based%2520on%2520time-dependent%2520inhibition%2520from%2520high%2520throughput%2520screening%2520of%2520cytochrome%2520P450%25203A4%2520inhibition%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2009%26volume%3D24%26spage%3D500%26epage%3D510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Bertelsen, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatakrishnan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Moltke, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenblatt, D. J.</span><span> </span><span class="NLM_article-title">Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1124%2Fdmd.31.3.289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=12584155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsFKlt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=289-293&author=K.+M.+Bertelsenauthor=K.+Venkatakrishnanauthor=L.+L.+Von+Moltkeauthor=R.+S.+Obachauthor=D.+J.+Greenblatt&title=Apparent+mechanism-based+inhibition+of+human+CYP2D6+in+vitro+by+paroxetine%3A+comparison+with+fluoxetine+and+quinidine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine</span></div><div class="casAuthors">Bertelsen, Kirk M.; Venkatakrishnan, Karthik; Von Moltke, Lisa L.; Obach, R. Scott; Greenblatt, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">289-293</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Paroxetine, a selective serotonin reuptake inhibitor, is a potent inhibitor of cytochrome P 450 2D6 (CYP2D6) activity, but the mechanism of inhibition is not established.  To det. whether preincubation affects the inhibition of human liver microsomal dextromethorphan demethylation activity by paroxetine, we used a two-step incubation scheme in which all of the enzyme assay components, minus substrate, are preincubated with paroxetine.  The kinetic parameters of inhibition were also estd. by varying the time of preincubation as well as the concn. of inhibitor.  From these data, a Kitz-Wilson plot was constructed, allowing the estn. of both an apparent inactivator concn. required for half-maximal inactivation (KI) and the maximal rate const. of inactivation (KINACT) value for this interaction.  Preincubation of paroxetine with human liver microsomes caused an approx. 8-fold redn. in the IC50 value (0.34 vs. 2.54 μM).  Time-dependent inhibition was demonstrated with an apparent KI of 4.85 μM and an apparent KINACT value of 0.17 min-1.  Spectral scanning of CYP2D6 with paroxetine yielded an increase in absorbance at 456 nm suggesting paroxetine inactivation of CYP2D6 via the formation of a metabolite intermediate complex.  This pattern is consistent with the metab. of the methylenedioxy substituent in paroxetine; such substituents may produce mechanism-based inactivation of cytochrome P 450 enzymes.  In contrast, quinidine and fluoxetine, both of which are inhibitors of CYP2D6 activity, did not exhibit a preincubation-dependent increase in inhibitory potency.  These data are consistent with mechanism-based inhibition of CYP2D6 by paroxetine but not by quinidine or fluoxetine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj8LvS55oHs7Vg90H21EOLACvtfcHk0lhgDgbgd8RnSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsFKlt7Y%253D&md5=2336fbc058e49e7b530562809c62ba09</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1124%2Fdmd.31.3.289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.31.3.289%26sid%3Dliteratum%253Aachs%26aulast%3DBertelsen%26aufirst%3DK.%2BM.%26aulast%3DVenkatakrishnan%26aufirst%3DK.%26aulast%3DVon%2BMoltke%26aufirst%3DL.%2BL.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DGreenblatt%26aufirst%3DD.%2BJ.%26atitle%3DApparent%2520mechanism-based%2520inhibition%2520of%2520human%2520CYP2D6%2520in%2520vitro%2520by%2520paroxetine%253A%2520comparison%2520with%2520fluoxetine%2520and%2520quinidine%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2003%26volume%3D31%26spage%3D289%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, T. S.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure–activity relationships and relationship to clinical drug–drug interactions and idiosyncratic adverse drug reactions</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2174%2F138920007780866807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=17584015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsl2jt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=407-447&author=A.+S.+Kalgutkarauthor=R.+S.+Obachauthor=T.+S.+Maurer&title=Mechanism-based+inactivation+of+cytochrome+P450+enzymes%3A+chemical+mechanisms%2C+structure%E2%80%93activity+relationships+and+relationship+to+clinical+drug%E2%80%93drug+interactions+and+idiosyncratic+adverse+drug+reactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions</span></div><div class="casAuthors">Kalgutkar, Amit S.; Obach, R. Scott; Maurer, Tristan S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">407-447</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytochrome P 450 constitute a superfamily of heme-contg. enzymes that catalyze the oxidative biotransformation of structurally diverse xenobiotics including drugs.  Inhibition of P 450 enzymes is by far the most common mechanism which can lead to DDIs.  P 450 inhibition can be categorized as reversible (competitive or non-competitive) or irreversible (mechanism-based inactivation).  Mechanism-based P 450 inactivation usually involves bioactivation of the xenobiotic to a reactive intermediate, which covalently modifies an active site amino acid residue and/or coordinates to the heme prosthetic group.  Covalent modification of P 450 enzymes can also lead to hapten formation and can in some cases trigger an autoimmune response resulting in toxicol. consequences.  Compared to reversible inhibition, irreversible inhibition more frequently results in unfavorable DDIs as the inactivated P 450 enzyme has to be replaced by newly synthesized protein.  For these reasons, most drug metab. groups within pharmaceutical companies have well-established screening paradigms to assess mechanism-based inactivation of major human P 450 enzymes by new chem. entities followed by indepth mechanistic studies to elucidate the mechanism of P 450 inactivation when a pos. finding is discerned.  A deeper understanding of the process leading to enzyme inactivation by drug candidates can lead to rational chem. intervention strategies to circumvent the P 450 inactivation/bioactivation liability.  Apart from structure-activity relationship studies, methodol. to predict the magnitude of in vivo metabolic DDIs using in vitro P 450 inactivation data and predicted human pharmacokinetics of the candidate drug also exists and can be utilized to project the extent of clin. DDIs against P 450 enzyme-specific substrates.  In this review, a comprehensive anal. of the biochem. basis and known structure-activity relationships for P 450 inactivation by xenobiotics is described.  In addn., the current state-of-the-art of the methodol. used in predicting the magnitude of DDIs using in vitro P 450 inactivation data and human pharmacokinetic parameters is discussed in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV8akoVDkMzrVg90H21EOLACvtfcHk0liXu1wEldKQIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsl2jt7Y%253D&md5=f2ee4172b6165268710c10dcc32fecb4</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F138920007780866807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920007780866807%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26atitle%3DMechanism-based%2520inactivation%2520of%2520cytochrome%2520P450%2520enzymes%253A%2520chemical%2520mechanisms%252C%2520structure%25E2%2580%2593activity%2520relationships%2520and%2520relationship%2520to%2520clinical%2520drug%25E2%2580%2593drug%2520interactions%2520and%2520idiosyncratic%2520adverse%2520drug%2520reactions%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2007%26volume%3D8%26spage%3D407%26epage%3D447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Lin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, A. Y.</span><span> </span><span class="NLM_article-title">Inhibition and induction of cytochrome P450 and the clinical implications</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">390</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2165%2F00003088-199835050-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=9839089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK1cXnvVeqtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1998&pages=361-390&author=J.+H.+Linauthor=A.+Y.+Lu&title=Inhibition+and+induction+of+cytochrome+P450+and+the+clinical+implications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition and induction of cytochrome P450 and the clinical implications</span></div><div class="casAuthors">Lin, Jiunn H.; Lu, Anthony Y. H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-390</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review with 192 refs.  The cytochrome P450s (CYPs) constitute a superfamily of isoforms that play an important role in the oxidative metab. of drugs.  Each CYP isoform possesses a characteristic broad spectrum of catalytic activities of substrates.  Whenever 2 or more drugs are administered concurrently, the possibility of drug interactions exists.  The ability of a single CYP to metabolize multiple substrates is responsible for a large no. of documented drug interactions assocd. with CYP inhibition.  In addn., drug interactions can also occur as a result of the induction of several human CYPs following long term drug treatment.  The mechanisms of CYP inhibition can be divided into 3 categories: (a) reversible inhibition; (b) quasi-irreversible inhibition; and (c) irreversible inhibition.  In mechanistic terms, reversible interactions arise as a result of competition at the CYP active site and probably involve only the first step of the CYP catalytic cycle.  On the other hand, drugs that act during and subsequent to the oxygen transfer step are generally irreversible or quasi-irreversible inhibitors.  Irreversible and quasi-irreversible inhibition require at least one cycle of the CYP catalytic process.  Because human liver samples and recombinant human CYPs are now readily available, in vitro systems have been used as screening tools to predict the potential for in vivo drug interaction.  Although it is easy to det. in vitro metabolic drug interactions, the proper interpretation and extrapolation of in vitro interaction data to in vivo situations require a good understanding of pharmacokinetic principles.  From the viewpoint of drug therapy, to avoid potential drug-drug interactions, it is desirable to develop a new drug candidate that is not a potent CYP inhibitor or inducer and the metab. of which is not readily inhibited by other drugs.  In reality, drug interaction by mutual inhibition between drugs is almost inevitable, because CYP-mediated metab. represents a major route of elimination of many drugs, which can compete for the same CYP enzyme.  The clin. significance of a metabolic drug interaction depends on the magnitude of the change in the concn. of active species (parent drug and/or active metabolites) at the site of pharmacol. action and the therapeutic index of the drug.  The smaller the difference between toxic and effective concn., the greater the likelihood that a drug interaction will have serious clin. consequences.  Thus, careful evaluation of potential drug interactions of a new drug candidate during the early stage of drug development is essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxdqTupUCBbLVg90H21EOLACvtfcHk0liXu1wEldKQIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvVeqtLo%253D&md5=18993123e2cdad5517962664e986a5b4</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2165%2F00003088-199835050-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199835050-00003%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DLu%26aufirst%3DA.%2BY.%26atitle%3DInhibition%2520and%2520induction%2520of%2520cytochrome%2520P450%2520and%2520the%2520clinical%2520implications%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1998%26volume%3D35%26spage%3D361%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Franklin, M. R.</span><span> </span><span class="NLM_article-title">Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">206</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">573</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=206&publication_year=1991&pages=559-573&author=M.+R.+Franklin&title=Cytochrome+P450+metabolic+intermediate+complexes+from+macrolide+antibiotics+and+related+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFranklin%26aufirst%3DM.%2BR.%26atitle%3DCytochrome%2520P450%2520metabolic%2520intermediate%2520complexes%2520from%2520macrolide%2520antibiotics%2520and%2520related%2520compounds%26jtitle%3DMethods%2520Enzymol.%26date%3D1991%26volume%3D206%26spage%3D559%26epage%3D573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Pessayre, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konstantinova-Mitcheva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Descatoire, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobert, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wandscheer, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Level, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benhamou, J.-P.</span><span> </span><span class="NLM_article-title">Hypo activity of cytochrome P-450 after triacetyloleandomycin administration</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1981&pages=559&author=D.+Pessayreauthor=M.+Konstantinova-Mitchevaauthor=V.+Descatoireauthor=B.+Cobertauthor=J.-C.+Wandscheerauthor=R.+Levelauthor=G.+Feldmannauthor=D.+Mansuyauthor=J.-P.+Benhamou&title=Hypo+activity+of+cytochrome+P-450+after+triacetyloleandomycin+administration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPessayre%26aufirst%3DD.%26aulast%3DKonstantinova-Mitcheva%26aufirst%3DM.%26aulast%3DDescatoire%26aufirst%3DV.%26aulast%3DCobert%26aufirst%3DB.%26aulast%3DWandscheer%26aufirst%3DJ.-C.%26aulast%3DLevel%26aufirst%3DR.%26aulast%3DFeldmann%26aufirst%3DG.%26aulast%3DMansuy%26aufirst%3DD.%26aulast%3DBenhamou%26aufirst%3DJ.-P.%26atitle%3DHypo%2520activity%2520of%2520cytochrome%2520P-450%2520after%2520triacetyloleandomycin%2520administration%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1981%26volume%3D30%26spage%3D559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Murray, M.</span><span> </span><span class="NLM_article-title">Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2174%2F1389200003339270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=11467081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1Whurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2000&pages=67-84&author=M.+Murray&title=Mechanisms+of+inhibitory+and+regulatory+effects+of+methylenedioxyphenyl+compounds+on+cytochrome+P450-dependent+drug+oxidation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation</span></div><div class="casAuthors">Murray, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-84</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with 110 refs.  Cytochrome P 450 (CYP) enzymes catalyze the oxidative conversion of drugs and other lipophilic compds. to hydrophilic metabolites.  Thus, CYPs play a dominant role in the elimination of drugs from the body.  Inhibitory interactions occur when drugs compete for oxidn. by specific CYPs, whereas certain drugs increase the capacity for oxidative biotransformation by inducing the synthesis of new CYPs.  Methylenedioxyphenyl (MDP) compds. have been widely employed as com. important pesticide synergists and a no. of derivs. are found in oils and spices.  MDP compds. are of considerable toxicol. significance because of their capacity to inhibit and induce CYP enzymes in mammals; some derivs. produce neurotoxic and hepatotoxic effects.  Although there are relatively few therapeutic agents of present clin. importance that possess the MDP structural feature, the synthesis and preclin. evaluation of such agents appears to be increasing.  In the context of the existing literature surrounding MDP compds. it is noteworthy that these potential drugs also elicit significant modulatory effects on CYP activities in rat and human liver.  These developments indicate the importance of understanding the chem. mechanisms by which MDPs interact with CYPs.  Thus, the presence of the MDP structure may undermine the potential clin. value of new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYAjGf6nf5ZbVg90H21EOLACvtfcHk0lhpkHFZPVm37g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1Whurs%253D&md5=dcafc824c8bcd0080d256d6dd8c50ae7</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2174%2F1389200003339270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200003339270%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DM.%26atitle%3DMechanisms%2520of%2520inhibitory%2520and%2520regulatory%2520effects%2520of%2520methylenedioxyphenyl%2520compounds%2520on%2520cytochrome%2520P450-dependent%2520drug%2520oxidation%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2000%26volume%3D1%26spage%3D67%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Wu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otton, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inaba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalow, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, E. M.</span><span> </span><span class="NLM_article-title">Interactions of amphetamine analogs with human liver CYP2D6</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1605</span><span class="NLM_x">–</span> <span class="NLM_lpage">1612</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=1605-1612&author=D.+Wuauthor=S.+V.+Ottonauthor=T.+Inabaauthor=W.+Kalowauthor=E.+M.+Sellers&title=Interactions+of+amphetamine+analogs+with+human+liver+CYP2D6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DD.%26aulast%3DOtton%26aufirst%3DS.%2BV.%26aulast%3DInaba%26aufirst%3DT.%26aulast%3DKalow%26aufirst%3DW.%26aulast%3DSellers%26aufirst%3DE.%2BM.%26atitle%3DInteractions%2520of%2520amphetamine%2520analogs%2520with%2520human%2520liver%2520CYP2D6%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1997%26volume%3D53%26spage%3D1605%26epage%3D1612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Murray, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hetnarski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, C. F.</span><span> </span><span class="NLM_article-title">Selective inhibitory interactions of alkoxymethylenedioxybenzenes towards mono-oxygenase activity in rat-hepatic microsomes</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1985&pages=369-379&author=M.+Murrayauthor=K.+Hetnarskiauthor=C.+F.+Wilkinson&title=Selective+inhibitory+interactions+of+alkoxymethylenedioxybenzenes+towards+mono-oxygenase+activity+in+rat-hepatic+microsomes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DM.%26aulast%3DHetnarski%26aufirst%3DK.%26aulast%3DWilkinson%26aufirst%3DC.%2BF.%26atitle%3DSelective%2520inhibitory%2520interactions%2520of%2520alkoxymethylenedioxybenzenes%2520towards%2520mono-oxygenase%2520activity%2520in%2520rat-hepatic%2520microsomes%26jtitle%3DXenobiotica%26date%3D1985%26volume%3D15%26spage%3D369%26epage%3D379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Grab, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz de Montellano, P. R.</span><span> </span><span class="NLM_article-title">Cytochrome P-450 inactivation by 3-alkylsydnones. Mechanistic implications of <i>n</i>-alkyl and <i>n</i>-alkenyl heme adduct formation</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4805</span><span class="NLM_x">–</span> <span class="NLM_lpage">4814</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi00413a034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1988&pages=4805-4814&author=L.+A.+Grabauthor=B.+A.+Swansonauthor=P.+R.+Ortiz+de+Montellano&title=Cytochrome+P-450+inactivation+by+3-alkylsydnones.+Mechanistic+implications+of+n-alkyl+and+n-alkenyl+heme+adduct+formation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fbi00413a034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00413a034%26sid%3Dliteratum%253Aachs%26aulast%3DGrab%26aufirst%3DL.%2BA.%26aulast%3DSwanson%26aufirst%3DB.%2BA.%26aulast%3DOrtiz%2Bde%2BMontellano%26aufirst%3DP.%2BR.%26atitle%3DCytochrome%2520P-450%2520inactivation%2520by%25203-alkylsydnones.%2520Mechanistic%2520implications%2520of%2520n-alkyl%2520and%2520n-alkenyl%2520heme%2520adduct%2520formation%26jtitle%3DBiochemistry%26date%3D1988%26volume%3D27%26spage%3D4805%26epage%3D4814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">He, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szklarz, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halpert, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correia, M. A.</span><span> </span><span class="NLM_article-title">Secobarbital-mediated inactivation of cytochrome P450 2B1 and its active site mutants. Partitioning between heme and protein alkylation and epoxidation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">25864</span><span class="NLM_x">–</span> <span class="NLM_lpage">25872</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=25864-25872&author=K.+Heauthor=Y.+A.+Heauthor=G.+D.+Szklarzauthor=J.+R.+Halpertauthor=M.+A.+Correia&title=Secobarbital-mediated+inactivation+of+cytochrome+P450+2B1+and+its+active+site+mutants.+Partitioning+between+heme+and+protein+alkylation+and+epoxidation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DK.%26aulast%3DHe%26aufirst%3DY.%2BA.%26aulast%3DSzklarz%26aufirst%3DG.%2BD.%26aulast%3DHalpert%26aufirst%3DJ.%2BR.%26aulast%3DCorreia%26aufirst%3DM.%2BA.%26atitle%3DSecobarbital-mediated%2520inactivation%2520of%2520cytochrome%2520P450%25202B1%2520and%2520its%2520active%2520site%2520mutants.%2520Partitioning%2520between%2520heme%2520and%2520protein%2520alkylation%2520and%2520epoxidation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D25864%26epage%3D25872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Brown, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford-Hutchinson, A. W.</span><span> </span><span class="NLM_article-title">The destruction of cytochrome P-450 by alclofenac: possible involvement of an epoxide metabolite</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">199</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1982&pages=195-199&author=L.+M.+Brownauthor=A.+W.+Ford-Hutchinson&title=The+destruction+of+cytochrome+P-450+by+alclofenac%3A+possible+involvement+of+an+epoxide+metabolite"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DL.%2BM.%26aulast%3DFord-Hutchinson%26aufirst%3DA.%2BW.%26atitle%3DThe%2520destruction%2520of%2520cytochrome%2520P-450%2520by%2520alclofenac%253A%2520possible%2520involvement%2520of%2520an%2520epoxide%2520metabolite%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1982%26volume%3D31%26spage%3D195%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Ortiz de Montellano, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, M. D.</span><span> </span><span class="NLM_article-title">Free radical pathways in the in vitro hepatic metabolism of phenelzine</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1987&pages=213-219&author=P.+R.+Ortiz+de+Montellanoauthor=M.+D.+Watanabe&title=Free+radical+pathways+in+the+in+vitro+hepatic+metabolism+of+phenelzine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrtiz%2Bde%2BMontellano%26aufirst%3DP.%2BR.%26aulast%3DWatanabe%26aufirst%3DM.%2BD.%26atitle%3DFree%2520radical%2520pathways%2520in%2520the%2520in%2520vitro%2520hepatic%2520metabolism%2520of%2520phenelzine%26jtitle%3DMol.%2520Pharmacol.%26date%3D1987%26volume%3D31%26spage%3D213%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Ortiz de Montellano, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathews, J. M.</span><span> </span><span class="NLM_article-title">Autocatalytic alkylation of the cytochrome P-450 prosthetic haem group by 1-aminobenzotriazole. Isolation of an NN-bridged benzyne–protoporphyrin IX adduct</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">195</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">764</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=1981&pages=761-764&author=P.+R.+Ortiz+de+Montellanoauthor=J.+M.+Mathews&title=Autocatalytic+alkylation+of+the+cytochrome+P-450+prosthetic+haem+group+by+1-aminobenzotriazole.+Isolation+of+an+NN-bridged+benzyne%E2%80%93protoporphyrin+IX+adduct"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrtiz%2Bde%2BMontellano%26aufirst%3DP.%2BR.%26aulast%3DMathews%26aufirst%3DJ.%2BM.%26atitle%3DAutocatalytic%2520alkylation%2520of%2520the%2520cytochrome%2520P-450%2520prosthetic%2520haem%2520group%2520by%25201-aminobenzotriazole.%2520Isolation%2520of%2520an%2520NN-bridged%2520benzyne%25E2%2580%2593protoporphyrin%2520IX%2520adduct%26jtitle%3DBiochem.%2520J.%26date%3D1981%26volume%3D195%26spage%3D761%26epage%3D764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Lightning, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trager, W. F.</span><span> </span><span class="NLM_article-title">Characterization of covalent adducts to intact cytochrome P450s by mass spectrometry</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">357</span><span class="NLM_x">, </span> <span class="NLM_fpage">296</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2002&pages=296-300&author=L.+K.+Lightningauthor=W.+F.+Trager&title=Characterization+of+covalent+adducts+to+intact+cytochrome+P450s+by+mass+spectrometry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLightning%26aufirst%3DL.%2BK.%26aulast%3DTrager%26aufirst%3DW.%2BF.%26atitle%3DCharacterization%2520of%2520covalent%2520adducts%2520to%2520intact%2520cytochrome%2520P450s%2520by%2520mass%2520spectrometry%26jtitle%3DMethods%2520Enzymol.%26date%3D2002%26volume%3D357%26spage%3D296%26epage%3D300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Halpert, J.</span><span> </span><span class="NLM_article-title">Further studies of the suicide inactivation of purified rat liver cytochrome P-450 by chloramphenicol</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">166</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1982&pages=166-172&author=J.+Halpert&title=Further+studies+of+the+suicide+inactivation+of+purified+rat+liver+cytochrome+P-450+by+chloramphenicol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHalpert%26aufirst%3DJ.%26atitle%3DFurther%2520studies%2520of%2520the%2520suicide%2520inactivation%2520of%2520purified%2520rat%2520liver%2520cytochrome%2520P-450%2520by%2520chloramphenicol%26jtitle%3DMol.%2520Pharmacol.%26date%3D1982%26volume%3D21%26spage%3D166%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Halpert, J.</span><span> </span><span class="NLM_article-title">Covalent modification of lysine during the suicide inactivation of rat liver cytochrome P-450 by chloramphenicol</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">–</span> <span class="NLM_lpage">881</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1981&pages=875-881&author=J.+Halpert&title=Covalent+modification+of+lysine+during+the+suicide+inactivation+of+rat+liver+cytochrome+P-450+by+chloramphenicol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHalpert%26aufirst%3DJ.%26atitle%3DCovalent%2520modification%2520of%2520lysine%2520during%2520the%2520suicide%2520inactivation%2520of%2520rat%2520liver%2520cytochrome%2520P-450%2520by%2520chloramphenicol%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1981%26volume%3D30%26spage%3D875%26epage%3D881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Boitier, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaune, P.</span><span> </span><span class="NLM_article-title">Cytochrome P450 as targets to autoantibodies in immune mediated diseases</span> <span class="citation_source-journal">Mol. Aspects Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=10575654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252Fkt12jug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=84-137&author=E.+Boitierauthor=P.+Beaune&title=Cytochrome+P450+as+targets+to+autoantibodies+in+immune+mediated+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochromes P450 as targets to autoantibodies in immune mediated diseases</span></div><div class="casAuthors">Boitier E; Beaune P</div><div class="citationInfo"><span class="NLM_cas:title">Molecular aspects of medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">84-137</span>
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl4mJEYwjU8ekdrW1FkXG-fW6udTcc2eaEUg4Ja_Cz7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252Fkt12jug%253D%253D&md5=ff3a1c2e09b9737ff78f9d2611a7a1ee</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoitier%26aufirst%3DE.%26aulast%3DBeaune%26aufirst%3DP.%26atitle%3DCytochrome%2520P450%2520as%2520targets%2520to%2520autoantibodies%2520in%2520immune%2520mediated%2520diseases%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D1999%26volume%3D20%26spage%3D84%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Belloc, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauffre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaune, P. H.</span><span> </span><span class="NLM_article-title">Epitope mapping of human CYP1A2 in dihydralazine-induced autoimmune hepatitis</span> <span class="citation_source-journal">Pharmacogenetics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1097%2F00008571-199706000-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=9241657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK2sXkvFymtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=181-186&author=C.+Bellocauthor=A.+Gauffreauthor=C.+Andreauthor=P.+H.+Beaune&title=Epitope+mapping+of+human+CYP1A2+in+dihydralazine-induced+autoimmune+hepatitis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Epitope mapping of human CYP1A2 in dihydralazine-induced autoimmune hepatitis</span></div><div class="casAuthors">Belloc, Claire; Gauffre, Aline; Andre, Chantal; Beaune, Philippe H.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-186</span>CODEN:
                <span class="NLM_cas:coden">PHMCEE</span>;
        ISSN:<span class="NLM_cas:issn">0960-314X</span>.
    
            (<span class="NLM_cas:orgname">Chapman & Hall</span>)
        </div><div class="casAbstract">Dihydralazine-induced hepatitis is characterized by the presence of anti-liver microsomal (anti-LM) autoantibodies in the sera of patients.  Cytochrome P 450 1A2 (CYP1A2), involved in the metab. of dihydralazine, was shown to be a target for autoantibodies.  To investigate further the relation between drug metab. and the pathogenesis of this drug-induced autoimmune disease, and since the specificity of anti-LM autoantibodies towards CYP1A2 has been detd., the antigenic site was further localized.  By constructing fragments derived from CYP1A2 cDNA and probing the corresponding proteins with several anti-LM sera, the authors were able to define a region (amino acid 335-471) which was immunoreactive with 100% of sera.  An internal deletion in this region led to the loss of recognition by anti-LM autoantibodies, confirming that the epitope was conformational.  Epitope mapping studies had previously been performed for CYP2D6, CYP17, CYP21A2, and recently for CYP3A1 and CYP2C9.  Those data were compared with results obtained in the present study for CYP1A2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY5v4qEfIo57Vg90H21EOLACvtfcHk0lgipulk1JMxMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkvFymtLs%253D&md5=9c684af580ccbcd50432e8e30404659e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1097%2F00008571-199706000-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00008571-199706000-00002%26sid%3Dliteratum%253Aachs%26aulast%3DBelloc%26aufirst%3DC.%26aulast%3DGauffre%26aufirst%3DA.%26aulast%3DAndre%26aufirst%3DC.%26aulast%3DBeaune%26aufirst%3DP.%2BH.%26atitle%3DEpitope%2520mapping%2520of%2520human%2520CYP1A2%2520in%2520dihydralazine-induced%2520autoimmune%2520hepatitis%26jtitle%3DPharmacogenetics%26date%3D1997%26volume%3D7%26spage%3D181%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Masubuchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horie, T.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1028</span><span class="NLM_x">–</span> <span class="NLM_lpage">1032</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx9901276" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1999&pages=1028-1032&author=Y.+Masubuchiauthor=T.+Horie&title=Mechanism-based+inactivation+of+cytochrome+P450s+1A2+and+3A4+by+dihydralazine+in+human+liver+microsomes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Ftx9901276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx9901276%26sid%3Dliteratum%253Aachs%26aulast%3DMasubuchi%26aufirst%3DY.%26aulast%3DHorie%26aufirst%3DT.%26atitle%3DMechanism-based%2520inactivation%2520of%2520cytochrome%2520P450s%25201A2%2520and%25203A4%2520by%2520dihydralazine%2520in%2520human%2520liver%2520microsomes%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1999%26volume%3D12%26spage%3D1028%26epage%3D1032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Bourdi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peter, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buters, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pohl, L. R.</span><span> </span><span class="NLM_article-title">Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1159</span><span class="NLM_x">–</span> <span class="NLM_lpage">1166</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx960083q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK28XlslOksrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1996&pages=1159-1166&author=M.+Bourdiauthor=W.+Chenauthor=R.+M.+Peterauthor=J.+L.+Martinauthor=J.+T.+Butersauthor=S.+D.+Nelsonauthor=L.+R.+Pohl&title=Human+cytochrome+P450+2E1+is+a+major+autoantigen+associated+with+halothane+hepatitis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Human Cytochrome P450 2E1 Is a Major Autoantigen Associated with Halothane Hepatitis</span></div><div class="casAuthors">Bourdi, Mohammed; Chen, Weiqiao; Peter, Raimund M.; Martin, Jackie L.; Buters, Jeroen T. M.; Nelson, Sidney D.; Pohl, Lance R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1159-1166</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Autoantibodies against specific human cytochrome P450s have been found in the sera of patients suffering from a variety of diseases, including those caused by drugs.  In the cases of tienilic acid- and dihydralazine-induced hepatitis, patients have serum autoantibodies directed against cytochromes P 450 2C9 and P 450 1A2, resp.  In the present study, we have found that 25 of 56 (45%) patients diagnosed with halothane hepatitis have autoantibodies that react with human cytochrome P 450 2E1 that was purified from a baculovirus expression system.  The autoantibodies inhibited the activity of cytochrome P 450 2E1 and appeared to be directed against mainly conformational epitopes.  In addn., because cytochrome P 450 2E1 became trifluoroacetylated when it oxidatively metabolized halothane, it is possible that the covalently altered form of cytochrome P 450 2E1 may be able to bypass the immunol. tolerance that normally exists against cytochrome P 450 2E1.  A similar mechanism may explain the formation of autoantibodies that have been found against other cellular targets of the reactive trifluoroacetyl chloride metabolite of halothane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeJPjP9U7BhLVg90H21EOLACvtfcHk0lg6908WSMh5sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlslOksrg%253D&md5=f7e3cba9321de99ed160db4f31d00e27</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Ftx960083q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx960083q%26sid%3Dliteratum%253Aachs%26aulast%3DBourdi%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DPeter%26aufirst%3DR.%2BM.%26aulast%3DMartin%26aufirst%3DJ.%2BL.%26aulast%3DButers%26aufirst%3DJ.%2BT.%26aulast%3DNelson%26aufirst%3DS.%2BD.%26aulast%3DPohl%26aufirst%3DL.%2BR.%26atitle%3DHuman%2520cytochrome%2520P450%25202E1%2520is%2520a%2520major%2520autoantigen%2520associated%2520with%2520halothane%2520hepatitis%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1996%26volume%3D9%26spage%3D1159%26epage%3D1166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Spracklin, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hankins, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thummel, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kharasch, E. D.</span><span> </span><span class="NLM_article-title">Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">400</span><span class="NLM_x">–</span> <span class="NLM_lpage">411</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=9103523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK2sXislSkurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1997&pages=400-411&author=D.+K.+Spracklinauthor=D.+C.+Hankinsauthor=J.+M.+Fisherauthor=K.+E.+Thummelauthor=E.+D.+Kharasch&title=Cytochrome+P450+2E1+is+the+principal+catalyst+of+human+oxidative+halothane+metabolism+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro</span></div><div class="casAuthors">Spracklin, Douglas K.; Hankins, Douglas C.; Fisher, Jeannine M.; Thummel, Kenneth E.; Kharasch, Evan D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">400-411</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The volatile anesthetic halothane undergoes substantial biotransformation generating metabolites that mediate hepatotoxicity.  Aerobically, halothane undergoes cytochrome P 450-catalyzed oxidn. to trifluoroacetic acid (TFA), bromide and a reactive intermediate that can acetylate liver proteins.  These protein neo-antigens stimulate an immune reaction that mediates severe hepatic necrosis ("halothane hepatitis").  This investigation identified the human P 450 isoform(s) that catalyze oxidative halothane metab.  Halothane oxidn. by human liver microsomes was assessed by TFA and bromide formation.  Eadie-Hofstee plots of TFA and bromide formation were both nonlinear, suggesting that participation of multiple P450s.  Microsomal TFA and bromide formation were inhibited 45 to 66% and 21 to 26%, resp., by the P 450 2A6 inhibitors 8-methoxypsoralen and coumarin, 84 to 90% by the P 450 2E1 inhibitor 4-methylpyrazole and 55% by diethyldithiocarbamate, an inhibitor of both P 450 2A6 and 2E1.  Selective inhibitors of P450s 1A, 2B6, 2C9/10, 2D6 and 3A4 did not affect halothane oxidn.  At satg. halothane concns. (2.4 vol%) only cDNA-expressed P 450 2A6 and 2B6 catalyzed significant rates of TFA and bromide formation, and P 450 2E1 catalyzed comparatively minimal oxidn.  Conversely, at subsaturating halothane concns. (0.30 vol%), metab. by P 450 2E1 exceeded that by P 450 2A6.  Among a panel of human liver microsomes, there were significant linear correlations between halothane oxidn. and P 450 2A6 activity and protein content at satg. halothane concns. (2.4 vol%), and a significant correlation between metabolite formation and P 450 2E1 activity (but not P 450 2A6 activity) at subsaturating concns. (0.12 vol%).  These expts. suggested P 450 2A6 and 2E1 as the predominant catalysts at satg. and subsatn. halothane concns., resp.  Further kinetic anal. using cDNA-expressed P 450 and liver microsomes clearly demonstrated that P 450 2E1 is the high affinity/low capacity isoform (Km - 0.030-0.053 vol%) and P 450 2A6 is the low affinity/high capacity isoform (Km = 9.77-1.2 vol%).  Evidence was also obtained for substrate inhibition of P 450 2E1.  The in vitro clearance ests. (Vmax/Km) for microsomal P 450 2E1 (4.3-5.7 mL/min/g) were substantially greater than those for microsomal P 450 2A6 (0.12-0.21).  These clearances, as well as rates of apparent halothane oxidn. predicted from kinetic parameters in conjunction with plasma halothane concns. measured during clin. anesthesia in humans, demonstrated that both P 450 2E1 and P 450 2A6 participate in human halothane metab., and that P 450 2E1 is the predominant catalytic isoform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9w54zCqWUiLVg90H21EOLACvtfcHk0lg6908WSMh5sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXislSkurk%253D&md5=ec8ad431b91174da9aebbd112d3b39a4</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSpracklin%26aufirst%3DD.%2BK.%26aulast%3DHankins%26aufirst%3DD.%2BC.%26aulast%3DFisher%26aufirst%3DJ.%2BM.%26aulast%3DThummel%26aufirst%3DK.%2BE.%26aulast%3DKharasch%26aufirst%3DE.%2BD.%26atitle%3DCytochrome%2520P450%25202E1%2520is%2520the%2520principal%2520catalyst%2520of%2520human%2520oxidative%2520halothane%2520metabolism%2520in%2520vitro%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D281%26spage%3D400%26epage%3D411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Osawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pohl, L. R.</span><span> </span><span class="NLM_article-title">Covalent binding of the prostheric heme to protein: a potential mechanism for the suicide inactivation of hemoproteins</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx00009a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1989&pages=131-141&author=Y.+Osawaauthor=L.+R.+Pohl&title=Covalent+binding+of+the+prostheric+heme+to+protein%3A+a+potential+mechanism+for+the+suicide+inactivation+of+hemoproteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Ftx00009a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx00009a001%26sid%3Dliteratum%253Aachs%26aulast%3DOsawa%26aufirst%3DY.%26aulast%3DPohl%26aufirst%3DL.%2BR.%26atitle%3DCovalent%2520binding%2520of%2520the%2520prostheric%2520heme%2520to%2520protein%253A%2520a%2520potential%2520mechanism%2520for%2520the%2520suicide%2520inactivation%2520of%2520hemoproteins%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1989%26volume%3D2%26spage%3D131%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Guzelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swisher, R. W.</span><span> </span><span class="NLM_article-title">Degradation of cytochrome P-450 haem by carbon tetrachloride and 2-allyl-2-isopropylacetamide in rat liver in vivo and in vitro: involvement of non-carbon monoxide-forming mechanisms</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">481</span><span class="NLM_x">–</span> <span class="NLM_lpage">489</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=1979&pages=481-489&author=P.+S.+Guzelianauthor=R.+W.+Swisher&title=Degradation+of+cytochrome+P-450+haem+by+carbon+tetrachloride+and+2-allyl-2-isopropylacetamide+in+rat+liver+in+vivo+and+in+vitro%3A+involvement+of+non-carbon+monoxide-forming+mechanisms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuzelian%26aufirst%3DP.%2BS.%26aulast%3DSwisher%26aufirst%3DR.%2BW.%26atitle%3DDegradation%2520of%2520cytochrome%2520P-450%2520haem%2520by%2520carbon%2520tetrachloride%2520and%25202-allyl-2-isopropylacetamide%2520in%2520rat%2520liver%2520in%2520vivo%2520and%2520in%2520vitro%253A%2520involvement%2520of%2520non-carbon%2520monoxide-forming%2520mechanisms%26jtitle%3DBiochem.%2520J.%26date%3D1979%26volume%3D184%26spage%3D481%26epage%3D489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Ring, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandenbranden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillespie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedding, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forgue, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckstein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrighton, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, D. L.</span><span> </span><span class="NLM_article-title">Effect of tadalafil on cytochrome P403A4-mediated clearance: studies in vitro and in vivo</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">75</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.clpt.2004.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15637532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Wr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2005&pages=63-75&author=B.+J.+Ringauthor=B.+E.+Pattersonauthor=M.+I.+Mitchellauthor=M.+Vandenbrandenauthor=J.+Gillespieauthor=A.+W.+Beddingauthor=H.+Jewellauthor=C.+D.+Payneauthor=S.+T.+Forgueauthor=J.+Ecksteinauthor=S.+A.+Wrightonauthor=D.+L.+Phillips&title=Effect+of+tadalafil+on+cytochrome+P403A4-mediated+clearance%3A+studies+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of tadalafil on cytochrome P450 3A4-mediated clearance: Studies in vitro and in vivo</span></div><div class="casAuthors">Ring, Barbara J.; Patterson, Beverley E.; Mitchell, Malcolm I.; Vandenbranden, Mark; Gillespie, Jennifer; Bedding, Alun W.; Jewell, Hayley; Payne, Christopher D.; Forgue, S. Thomas; Eckstein, James; Wrighton, Steven A.; Phillips, Diane L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-75</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Tadalafil was examd. in vitro and in vivo for its ability to affect human cytochrome P 450 (CYP) 3A-mediated metab.  Reversible and mechanism-based inhibition of CYP3A by tadalafil was examd. in human liver microsomes.  The ability of tadalafil to influence CYP3A activity was also examd. in primary cultures of human hepatocytes.  The effect of tadalafil on the pharmacokinetics of CYP3A probe substrates was evaluated in human volunteers before and after coadministration with either a single dose or multiple doses of tadalafil (10 or 20 mg).  Negligible competitive inhibition of CYP3A was obsd. in vitro.  Mechanism-based inhibition of CYP3A was detected, albeit with a low potency.  In human hepatocytes, exposure to 1 μmol/L or greater of tadalafil resulted in increased CYP3A protein expression; however, as with a combined effect of induction and inhibition, a corresponding increase in CYP3A activity did not occur.  The clin. pharmacokinetics of midazolam and lovastatin, probe substrates of CYP3A, were unaffected by up to 14 days of tadalafil administration (90% confidence intervals for the ratio of least squares means for the pharmacokinetic parameters of tadalafil were contained within the no-effect boundaries of 0.7 to 1.43).  In vitro results suggested that tadalafil would have little effect on the pharmacokinetics of drugs metabolized by CYP3A.  Clin. studies demonstrated that the pharmacokinetics of 2 different CYP3A substrates, midazolam and lovastatin, were virtually unchanged after tadalafil coadministration.  Thus therapeutic concns. of tadalafil do not produce clin. significant changes in the clearance of drugs metabolized by CYP3A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNocgzlryAnbVg90H21EOLACvtfcHk0lgpZ2sFDfWw7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Wr&md5=0d7f3bf49e389fbc1266aeb531df1c6c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2004.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2004.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DRing%26aufirst%3DB.%2BJ.%26aulast%3DPatterson%26aufirst%3DB.%2BE.%26aulast%3DMitchell%26aufirst%3DM.%2BI.%26aulast%3DVandenbranden%26aufirst%3DM.%26aulast%3DGillespie%26aufirst%3DJ.%26aulast%3DBedding%26aufirst%3DA.%2BW.%26aulast%3DJewell%26aufirst%3DH.%26aulast%3DPayne%26aufirst%3DC.%2BD.%26aulast%3DForgue%26aufirst%3DS.%2BT.%26aulast%3DEckstein%26aufirst%3DJ.%26aulast%3DWrighton%26aufirst%3DS.%2BA.%26aulast%3DPhillips%26aufirst%3DD.%2BL.%26atitle%3DEffect%2520of%2520tadalafil%2520on%2520cytochrome%2520P403A4-mediated%2520clearance%253A%2520studies%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2005%26volume%3D77%26spage%3D63%26epage%3D75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Zhao, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soglia, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span> </span><span class="NLM_article-title">NADPH-dependent covalent binding of [<sup>3</sup>H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1649</span><span class="NLM_x">–</span> <span class="NLM_lpage">1657</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx700132x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSkurrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=1649-1657&author=S.+X.+Zhaoauthor=D.+K.+Dalvieauthor=J.+M.+Kellyauthor=J.+R.+Sogliaauthor=K.+S.+Frederickauthor=E.+B.+Smithauthor=R.+S.+Obachauthor=A.+S.+Kalgutkar&title=NADPH-dependent+covalent+binding+of+%5B3H%5Dparoxetine+to+human+liver+microsomes+and+S-9+fractions%3A+identification+of+an+electrophilic+quinone+metabolite+of+paroxetine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">NADPH-Dependent Covalent Binding of [3H]Paroxetine to Human Liver Microsomes and S-9 Fractions: Identification of an Electrophilic Quinone Metabolite of Paroxetine</span></div><div class="casAuthors">Zhao, Sabrina X.; Dalvie, Deepak K.; Kelly, Joan M.; Soglia, John R.; Frederick, Kosea S.; Smith, Evan B.; Obach, R. Scott; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1649-1657</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The primary pathway of clearance of the methylenedioxyphenyl-contg. compd. and selective serotonin reuptake inhibitor paroxetine in humans involves P 450 2D6-mediated demethylenation to a catechol intermediate.  The process of demethylenation also results in the mechanism-based inactivation of the P 450 isoenzyme.  While the link between P 450 2D6 inactivation and pharmacokinetic interactions of paroxetine with P 450 2D6 substrates has been firmly established, there is a disconnect in terms of paroxetine's excellent safety record despite the potential for bioactivation.  In the present study, the authors have systematically assessed the NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 prepns. in the absence and presence of cofactors of the various phase II drug-metabolizing enzymes involved in the downstream metab./detoxification of the putative paroxetine-catechol intermediate.  Incubation of [3H]paroxetine with human liver microsomes and S-9 prepns. resulted in irreversible binding of radioactive material to macromols. by a process that was NADPH-dependent.  The addn. of reduced glutathione (GSH) to the microsomal and S-9 incubations resulted in a dramatic redn. of covalent binding.  Following incubations with NADPH- and GSH-supplemented human liver microsomes and S-9, three sulfhydryl conjugates with MH+ ions at 623 Da (GS1), 779 Da (GS2), and 928 Da (GS3), resp., were detected by LC-MS/MS.  The collision-induced dissocn. spectra allowed an insight into the structure of the GSH conjugates, based on which, bioactivation pathways were proposed.  The formation of GS1 was consistent with Michael addn. of GSH to the quinone derived from two-electron oxidn. of paroxetine-catechol.  GS3 was formed by the addn. of a second mol. of GSH to the quinone species obtained via the two-electron oxidn. of GS1.  The mechanism of formation of GS2 can be rationalized via (i) further two-electron oxidn. of the catechol motif in GS3 to the ortho-quinone, (ii) loss of a glutamic acid residue from one of the adducted GSH mols., and (iii) condensation of a cysteine-NH2 with an adjacent carbonyl of the ortho-quinone to yield an ortho-benzoquinoneimine structure.  Inclusion of the catechol-O-methyltransferase cofactor S-adenosylmethionine (SAM) in S-9 incubations also dramatically reduced the covalent binding of [3H]paroxetine, a finding that was consistent with O-methylation of the paroxetine-catechol metabolite to the corresponding guaiacol regioisomers in S-9 incubations.  While the NADPH-dependent covalent binding was attenuated by GSH and SAM, these reagents did not alter paroxetine's ability to inactivate P 450 2D6, suggesting that the reactive intermediate responsible for P 450 inactivation did not leave the active site to react with other proteins.  The results of the studies indicate that in addn. to the low once-a-day dosing regimen (20 mg) of paroxetine, efficient scavenging of the catechol and quinone metabolites by SAM and GSH, resp., serves as an explanation for the excellent safety record of paroxetine despite the fact that it undergoes bioactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOXUHMcbZnN7Vg90H21EOLACvtfcHk0lgpZ2sFDfWw7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSkurrK&md5=e7d3aa749a419cc87340271eb9b839a0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Ftx700132x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx700132x%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DKelly%26aufirst%3DJ.%2BM.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DFrederick%26aufirst%3DK.%2BS.%26aulast%3DSmith%26aufirst%3DE.%2BB.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DNADPH-dependent%2520covalent%2520binding%2520of%2520%255B3H%255Dparoxetine%2520to%2520human%2520liver%2520microsomes%2520and%2520S-9%2520fractions%253A%2520identification%2520of%2520an%2520electrophilic%2520quinone%2520metabolite%2520of%2520paroxetine%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D1649%26epage%3D1657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Kaye, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haddock, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellows, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zussman, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greb, W. H.</span><span> </span><span class="NLM_article-title">A review of the metabolism and pharmacokinetics of paroxetine in man</span> <span class="citation_source-journal">Acta Psychiatr. Scand., Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">60</span><span class="NLM_x">–</span> <span class="NLM_lpage">75</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1111%2Fj.1600-0447.1989.tb07176.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=2530793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK3cXjtVWisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=1989&pages=60-75&author=C.+M.+Kayeauthor=R.+E.+Haddockauthor=P.+F.+Langleyauthor=G.+Mellowsauthor=T.+C.+Taskerauthor=B.+D.+Zussmanauthor=W.+H.+Greb&title=A+review+of+the+metabolism+and+pharmacokinetics+of+paroxetine+in+man"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A review of the metabolism and pharmacokinetics of paroxetine in man</span></div><div class="casAuthors">Kaye, C. M.; Haddock, R. E.; Langley, P. F.; Mellows, G.; Tasker, T. C. G.; Zussman, B. D.; Greb, W. H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Psychiatrica Scandinavica, Supplementum</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">60-75</span>CODEN:
                <span class="NLM_cas:coden">ASSUA6</span>;
        ISSN:<span class="NLM_cas:issn">0065-1591</span>.
    </div><div class="casAbstract">A review with 24 refs.  Paroxetine (I), a potent, selective 5-HT uptake inhibitor, is currently being developed as an antidepressant.  The pharmacokinetics of I exhibit extensive intersubject variability.  There is no correlation between plasma concns. of I and its clin. effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwnxjSPfqp-bVg90H21EOLACvtfcHk0lgpZ2sFDfWw7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXjtVWisw%253D%253D&md5=f3db814b92648388dad960a44f06721a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0447.1989.tb07176.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0447.1989.tb07176.x%26sid%3Dliteratum%253Aachs%26aulast%3DKaye%26aufirst%3DC.%2BM.%26aulast%3DHaddock%26aufirst%3DR.%2BE.%26aulast%3DLangley%26aufirst%3DP.%2BF.%26aulast%3DMellows%26aufirst%3DG.%26aulast%3DTasker%26aufirst%3DT.%2BC.%26aulast%3DZussman%26aufirst%3DB.%2BD.%26aulast%3DGreb%26aufirst%3DW.%2BH.%26atitle%3DA%2520review%2520of%2520the%2520metabolism%2520and%2520pharmacokinetics%2520of%2520paroxetine%2520in%2520man%26jtitle%3DActa%2520Psychiatr.%2520Scand.%252C%2520Suppl.%26date%3D1989%26volume%3D350%26spage%3D60%26epage%3D75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Alderman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preskorn, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenblatt, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penenberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allison, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, M.</span><span> </span><span class="NLM_article-title">Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers</span> <span class="citation_source-journal">J. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">284</span><span class="NLM_x">–</span> <span class="NLM_lpage">291</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1097%2F00004714-199708000-00008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=9241008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK2sXltlKnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=284-291&author=J.+Aldermanauthor=S.+H.+Preskornauthor=D.+J.+Greenblattauthor=W.+Harrisonauthor=D.+Penenbergauthor=J.+Allisonauthor=M.+Chung&title=Desipramine+pharmacokinetics+when+coadministered+with+paroxetine+or+sertraline+in+extensive+metabolizers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers</span></div><div class="casAuthors">Alderman, Jeffrey; Preskorn, Sheldon H.; Greenblatt, David J.; Harrison, Wilma; Penenberg, Darryl; Allison, Janet; Chung, Menger</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">284-291</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">In vitro studies have shown that fluoxetine and paroxetine are more potent inhibitors of cytochrome CYP2D6 than sertraline.  The pharmacokinetics of desipramine when coadministered with the selective serotonin reuptake inhibitors (SSRIs) paroxetine and sertraline were studied in 24 healthy male volunteers (CYP2D6 extensive metabolizers).  Desipramine (50 mg/day) was administered for 23 days in each phase of the crossover study with a 7-day drug-free period between phases.  In addn., subjects were randomly assigned to receive concomitant paroxetine (20 mg/day on days 8 through 17 followed by 30 mg/day on days 18 through 20) or sertraline (50 mg/day on days 8 through 17 and 100 mg/day on days 18 through 20).  SSRI treatments were switched between phases.  After 10 days of coadministration at the lower dose, mean desipramine max. concn. in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine vs. from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-h area under the concn.-time curve (AUC[24]) increased from 634 to 3,305 ng·h/mL (+421%) with paroxetine vs. from 611 to 838 ng·h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine vs. from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).  An approx. 10-fold increase in the Cmax and AUC(24) of paroxetine and an approx. 2-fold increase in these parameters for sertraline occurred simultaneously with the desipramine concn. changes.  Thus, when coadministered with 50 mg/day desipramine, sertraline had significantly less pharmacokinetic interaction than paroxetine with desipramine at the recommended starting dosages of 50 mg/day and 20 mg/day, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh6RcBgmPfO7Vg90H21EOLACvtfcHk0li7AHmYZO0KgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXltlKnu70%253D&md5=fb990d687c76c792bbd2b39f9ff140e9</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1097%2F00004714-199708000-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00004714-199708000-00008%26sid%3Dliteratum%253Aachs%26aulast%3DAlderman%26aufirst%3DJ.%26aulast%3DPreskorn%26aufirst%3DS.%2BH.%26aulast%3DGreenblatt%26aufirst%3DD.%2BJ.%26aulast%3DHarrison%26aufirst%3DW.%26aulast%3DPenenberg%26aufirst%3DD.%26aulast%3DAllison%26aufirst%3DJ.%26aulast%3DChung%26aufirst%3DM.%26atitle%3DDesipramine%2520pharmacokinetics%2520when%2520coadministered%2520with%2520paroxetine%2520or%2520sertraline%2520in%2520extensive%2520metabolizers%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D1997%26volume%3D17%26spage%3D284%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Hemeryck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebyre, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vriendt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belpaire, F. M.</span><span> </span><span class="NLM_article-title">Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">291</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1067%2Fmcp.2000.104788" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=10741632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD3cXis1Ghtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2000&pages=283-291&author=A.+Hemeryckauthor=R.+A.+Lefebyreauthor=C.+De+Vriendtauthor=F.+M.+Belpaire&title=Paroxetine+affects+metoprolol+pharmacokinetics+and+pharmacodynamics+in+healthy+volunteers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers</span></div><div class="casAuthors">Hemeryck, Alex; Lefebvre, Romain A.; De Vriendt, Cindy; Belpaire, Frans M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">283-291</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">This work investigated the effect of multiple-dose paroxetine intake on the stereoselective pharmacokinetics and the pharmacodynamics of metoprolol in healthy men.  Racemic metoprolol (100 mg, single oral dose) was administered before and after paroxetine treatment (20 mg/day for 6 days).  The pharmacokinetics of (R)- and (S)-metoprolol, metoprolol metabolic ratio (MR), exercise heart rate and blood pressure were assessed for 12 (pharmacodynamic data) or 24 (pharmacokinetic data) hours after each metoprolol intake.  Paroxetine treatment increased the mean area under the plasma concn.-time curve extrapolated to infinity (AUC) of (R)- and (S)-metoprolol (169 to 1340 ng · h/mL and 279 to 1418 ng · h/mL, resp.), with an approx. 2-fold increase in both max. plasma concn. and terminal elimination half-life.  Furthermore, the (S)/(R) AUC ratio was decreased, from 1.72 to 1.07.  The mean metoprolol MR was increased, from 0.17 to 5.69.  The AUC of the metoprolol-induced decrease in exercise-heart-rate-vs.-time curve was increased, reaching significance 6 h after metoprolol intake, illustrating a more sustained β-blockade.  Similar results were obtained for the effect on exercise systolic blood pressure.  Multiple-dose metoprolol administration combined with paroxetine can lead to an accumulation of the β-blocking (S)-enantiomer of metoprolol, possibly resulting in unacceptable bradycardia, loss of cardioselectivity, or both.  Thus, multiple-dose paroxetine intake affects both metoprolol pharmacokinetics and pharmacodynamics, suggesting that when paroxetine is added to an ongoing metoprolol therapy, caution is warranted and a redn. of the metoprolol dose may be required to prevent undesired adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU0x7IsjeKErVg90H21EOLACvtfcHk0li7AHmYZO0KgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXis1Ghtrg%253D&md5=f88ffdcdf1e4185670b19f1316b69d67</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2000.104788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2000.104788%26sid%3Dliteratum%253Aachs%26aulast%3DHemeryck%26aufirst%3DA.%26aulast%3DLefebyre%26aufirst%3DR.%2BA.%26aulast%3DDe%2BVriendt%26aufirst%3DC.%26aulast%3DBelpaire%26aufirst%3DF.%2BM.%26atitle%3DParoxetine%2520affects%2520metoprolol%2520pharmacokinetics%2520and%2520pharmacodynamics%2520in%2520healthy%2520volunteers%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2000%26volume%3D67%26spage%3D283%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Spina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avenoso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Facciola, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scordo, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ancione, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madia, A.</span><span> </span><span class="NLM_article-title">Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine</span> <span class="citation_source-journal">Ther. Drug Monit.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1097%2F00007691-200106000-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=11360029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD3MXks12jtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=223-227&author=E.+Spinaauthor=A.+Avenosoauthor=G.+Facciolaauthor=M.+G.+Scordoauthor=M.+Ancioneauthor=A.+Madia&title=Plasma+concentrations+of+risperidone+and+9-hydroxyrisperidone+during+combined+treatment+with+paroxetine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine</span></div><div class="casAuthors">Spina, Edoardo; Avenoso, Angela; Facciola, Gabriella; Scordo, Maria Gabriella; Ancione, Maria; Madia, Aldo</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Drug Monitoring</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">223-227</span>CODEN:
                <span class="NLM_cas:coden">TDMODV</span>;
        ISSN:<span class="NLM_cas:issn">0163-4356</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The effects of paroxetine on steady-state plasma concns. of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) were studied in 10 patients with schizophrenia or schizoaffective disorder.  Patients stabilized using risperidone therapy (4-8 mg/d) also received paroxetine (20 mg/d) for 4 wk.  During paroxetine administration, mean plasma concns. of risperidone increased significantly (P < 0.01), whereas levels of 9-OH-risperidone decreased slightly but not significantly.  After 4 wk of paroxetine treatment, the sum of the concns. of risperidone and 9-OH-risperidone (active moiety) increased significantly by 45% (P < 0.05) over baseline.  The mean plasma risperidone/9-OH-risperidone ratio was also significantly modified (P < 0.001) during paroxetine treatment.  The drug combination was generally well tolerated with the exception of one patient who developed Parkinsonian symptoms in the second week of adjunctive therapy.  In this patient total plasma levels of risperidone and its active metabolite increased by 62% during paroxetine co-administration.  The authors' findings indicate that paroxetine, a potent inhibitor of CYP2D6, may impair the elimination of risperidone, primarily by inhibiting CYP2D6-mediated 9-hydroxylation and to a lesser extent by simultaneously affecting the further metab. of 9-OH-risperidone or other pathways of risperidone biotransformation.  Careful clin. observation and possibly monitoring of plasma risperidone levels may be useful whenever paroxetine is co-administered with risperidone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-olVdjHGutbVg90H21EOLACvtfcHk0li7AHmYZO0KgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXks12jtbg%253D&md5=3aa6421493caa6030183cf803750e570</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1097%2F00007691-200106000-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00007691-200106000-00007%26sid%3Dliteratum%253Aachs%26aulast%3DSpina%26aufirst%3DE.%26aulast%3DAvenoso%26aufirst%3DA.%26aulast%3DFacciola%26aufirst%3DG.%26aulast%3DScordo%26aufirst%3DM.%2BG.%26aulast%3DAncione%26aufirst%3DM.%26aulast%3DMadia%26aufirst%3DA.%26atitle%3DPlasma%2520concentrations%2520of%2520risperidone%2520and%25209-hydroxyrisperidone%2520during%2520combined%2520treatment%2520with%2520paroxetine%26jtitle%3DTher.%2520Drug%2520Monit.%26date%3D2001%26volume%3D23%26spage%3D223%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Belle, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernest, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomasson, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witcher, J. W.</span><span> </span><span class="NLM_article-title">Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">–</span> <span class="NLM_lpage">1227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1177%2F009127002762491307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=12412820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVClt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2002&pages=1219-1227&author=D.+J.+Belleauthor=C.+S.+Ernestauthor=J.+M.+Sauerauthor=B.+P.+Smithauthor=H.+R.+Thomassonauthor=J.+W.+Witcher&title=Effect+of+potent+CYP2D6+inhibition+by+paroxetine+on+atomoxetine+pharmacokinetics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics</span></div><div class="casAuthors">Belle, Donna J.; Ernest, C. Steven; Sauer, John-Michael; Smith, Brian P.; Thomasson, Holly R.; Witcher, Jennifer W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1219-1227</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The purpose of this study was to characterize the effect of potent CYP2D6 inhibition by paroxetine on atomoxetine disposition in extensive metabolizers.  This was a single-blind, two-period, sequential study in 22 healthy individuals.  In period 1, 20 mg atomoxetine bid was administered to steady state.  In period 2, 20 mg paroxetine was administered qd for 17 days.  On days 12 through 17, 20 mg atomoxetine bid were coadministered.  Plasma pharmacokinetics of atomoxetine, 4-hydroxyatomoxetine, and N-desmethylatomoxetine was detd. at steady state in each treatment period.  Plasma pharmacokinetics of paroxetine were detd. after the 11th and 17th doses.  Paroxetine increased Css,max, AUC0-12, and t1/2 of atomoxetine by approx. 3.5-, 6.5-, and 2.5 fold, resp.  After coadministration with paroxetine, increases in N-desmethylatomoxetine and decreases in 4-hydroxyatomoxetine concns. were obsd.  No changes in paroxetine pharmacokinetics were obsd. after coadministration with atomoxetine.  It was concluded that inhibition of CYP2D6 by paroxetine markedly affected atomoxetine disposition, resulting in pharmacokinetics similar to poor metabolizers of CYP2D6 substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTJSWJJk3pXLVg90H21EOLACvtfcHk0li7AHmYZO0KgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVClt7w%253D&md5=612a638d304b543f58f842cfb5066e29</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1177%2F009127002762491307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F009127002762491307%26sid%3Dliteratum%253Aachs%26aulast%3DBelle%26aufirst%3DD.%2BJ.%26aulast%3DErnest%26aufirst%3DC.%2BS.%26aulast%3DSauer%26aufirst%3DJ.%2BM.%26aulast%3DSmith%26aufirst%3DB.%2BP.%26aulast%3DThomasson%26aufirst%3DH.%2BR.%26aulast%3DWitcher%26aufirst%3DJ.%2BW.%26atitle%3DEffect%2520of%2520potent%2520CYP2D6%2520inhibition%2520by%2520paroxetine%2520on%2520atomoxetine%2520pharmacokinetics%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2002%26volume%3D42%26spage%3D1219%26epage%3D1227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Venkatakrishnan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">In vitro–in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">845</span><span class="NLM_x">–</span> <span class="NLM_lpage">852</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=845-852&author=K.+Venkatakrishnanauthor=R.+S.+Obach&title=In+vitro%E2%80%93in+vivo+extrapolation+of+CYP2D6+inactivation+by+paroxetine%3A+prediction+of+nonstationary+pharmacokinetics+and+drug+interaction+magnitude"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatakrishnan%26aufirst%3DK.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DIn%2520vitro%25E2%2580%2593in%2520vivo%2520extrapolation%2520of%2520CYP2D6%2520inactivation%2520by%2520paroxetine%253A%2520prediction%2520of%2520nonstationary%2520pharmacokinetics%2520and%2520drug%2520interaction%2520magnitude%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D845%26epage%3D852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Wang, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. D.</span><span> </span><span class="NLM_article-title">Prediction of cytochrome P4503A inhibition by verapamil enantiomers and their metabolites</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">266</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=259-266&author=Y.+H.+Wangauthor=D.+R.+Jonesauthor=S.+D.+Hall&title=Prediction+of+cytochrome+P4503A+inhibition+by+verapamil+enantiomers+and+their+metabolites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BH.%26aulast%3DJones%26aufirst%3DD.%2BR.%26aulast%3DHall%26aufirst%3DS.%2BD.%26atitle%3DPrediction%2520of%2520cytochrome%2520P4503A%2520inhibition%2520by%2520verapamil%2520enantiomers%2520and%2520their%2520metabolites%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2004%26volume%3D32%26spage%3D259%26epage%3D266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Lemma, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaheer, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorski, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. D.</span><span> </span><span class="NLM_article-title">The effect of short and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">218</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.clpt.2005.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=16513446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVKhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2006&pages=218-230&author=G.+L.+Lemmaauthor=Z.+Wangauthor=M.+A.+Hammanauthor=N.+A.+Zaheerauthor=J.+C.+Gorskiauthor=S.+D.+Hall&title=The+effect+of+short+and+long-term+administration+of+verapamil+on+the+disposition+of+cytochrome+P450+3A+and+P-glycoprotein+substrates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates</span></div><div class="casAuthors">Lemma, Girum L.; Wang, Zaiqi; Hamman, Mitchell A.; Zaheer, Narjis A.; Gorski, J. Christopher; Hall, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">218-230</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background: Verapamil has the capability to inhibit and induce cytochrome P 450 (CYP) 3A and P-glycoprotein (P-gp), but the relative extent and time course of these events in vivo are unclear.  The effect of verapamil on CYP3A and P-gp activity was detd. by examg. its effect on its own disposition and on the disposition of fexofenadine, resp.  Methods: Twelve healthy volunteers received 60 mg fexofenadine alone or after administration of 240 mg verapamil for 1, 10, and 38 days.  The concns. of verapamil and norverapamil, as well as their enantiomers, were quantified in serum by chiral HPLC.  The concns. of fexofenadine and its metabolite, azacyclonol, were quantified in serum and urine by liq. chromatog.-mass spectrometry.  Results: The mean ± SD max. serum concn. (Cmax) and the area under the serum concn.-time curve of S-verapamil increased significantly on days 10 (40 ± 21 ng/mL [P = .00044] and 433 ± 316 ng · h · mL-1 [P = .00047], resp.) and 38 (42 ± 27 ng/mL [P = .019] and 433 ± 256 ng · h · mL-1 [P = .0081], resp.) compared with day 1 (21 ± 12 ng/mL and 222 ± 156 ng · h · mL-1, resp.).  The oral clearance (CLoral) of S-verapamil decreased significantly from 702 ± 304 L/h on day 1 to 377 ± 210 L/h on day 10 (P = .0029) and 449 ± 419 L/h on day 38 (P = .05).  Similar trends were obsd. for the Cmax and area under the serum concn.-time curve of R-verapamil and R- and S-norverapamil.  All subjects showed a significant decrease in the CLoral of fexofenadine after a single dose (98 ± 54 L/h, P = .00105) and 10-day dosing (102 ± 40 L/h, P = .0011) of verapamil compared with the control value (156 ± 69 L/h).  The Cmax of fexofenadine was significantly increased by a single dose (165 ± 42 ng/mL, P = .0005) and 10-day dosing (148 ± 39 ng/mL, P = .0008) of verapamil compared with the control value (114 ± 45 ng/mL).  No significant difference in fexofenadine Cmax (P = .37) and CLoral (P = .43) was obsd. between the control values and values at 38 days of verapamil treatment.  Conclusion: Verapamil inhibited CYP3A activity, with a max. effect occurring within 10 days.  Short-term administration of verapamil caused net inhibition of intestinal P-gp, whereas long-term administration of verapamil induced P-gp activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtd0_Zupd77LVg90H21EOLACvtfcHk0lg_7yqVX0IVXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVKhuro%253D&md5=83116ec48e249000698eb5628237932b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2005.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2005.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DLemma%26aufirst%3DG.%2BL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DHamman%26aufirst%3DM.%2BA.%26aulast%3DZaheer%26aufirst%3DN.%2BA.%26aulast%3DGorski%26aufirst%3DJ.%2BC.%26aulast%3DHall%26aufirst%3DS.%2BD.%26atitle%3DThe%2520effect%2520of%2520short%2520and%2520long-term%2520administration%2520of%2520verapamil%2520on%2520the%2520disposition%2520of%2520cytochrome%2520P450%25203A%2520and%2520P-glycoprotein%2520substrates%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2006%26volume%3D79%26spage%3D218%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Jerling, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huan, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdallah, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussein, Z.</span><span> </span><span class="NLM_article-title">Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">422</span><span class="NLM_x">–</span> <span class="NLM_lpage">433</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1177%2F0091270004273992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15778423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFyhtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=422-433&author=M.+Jerlingauthor=B.+L.+Huanauthor=K.+Leungauthor=N.+Chuauthor=H.+Abdallahauthor=Z.+Hussein&title=Studies+to+investigate+the+pharmacokinetic+interactions+between+ranolazine+and+ketoconazole%2C+diltiazem%2C+or+simvastatin+during+combined+administration+in+healthy+subjects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects</span></div><div class="casAuthors">Jerling, Markus; Huan, Bee-Lian; Leung, Kwan; Chu, Nancy; Abdallah, Hisham; Hussein, Ziad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">422-433</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The interactions of ranolazine, a new antianginal compd., with inhibitors and substrates of the CYP3A isoenzyme family were studied in 1 open-label and 4 double-blind, randomized, multiple-dose studies.  In healthy adult volunteers, the authors sought (1) to det. the steady-state pharmacokinetics, safety, and tolerability of immediate- and sustained-release ranolazine with and without ketoconazole, diltiazem, or simvastatin and (2) to evaluate the effect of ranolazine on the pharmacokinetics of diltiazem, simvastatin, simvastatin metabolites, and HMG-CoA reductase activity.  Ketoconazole increased ranolazine plasma concns. and reduced the CYP3A4-mediated metabolic transformation of ranolazine, confirming that CYP3A4 is the primary metabolic pathway for ranolazine.  Diltiazem reduced oral clearance of ranolazine in a dose-dependent manner.  Simvastatin did not affect ranolazine pharmacokinetics, although ranolazine increased the AUC and Cmax of simvastatin, simvastatin acid, 2 simvastatin metabolites, and HMG-CoA reductase activity by <2-fold.  Administration of ranolazine in combination with diltiazem or simvastatin was safe and well tolerated during the interval studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVS4QJjh97BLVg90H21EOLACvtfcHk0lg_7yqVX0IVXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFyhtLo%253D&md5=1f64fb883ea8a3308f7f06d22d2e780d</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1177%2F0091270004273992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270004273992%26sid%3Dliteratum%253Aachs%26aulast%3DJerling%26aufirst%3DM.%26aulast%3DHuan%26aufirst%3DB.%2BL.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DChu%26aufirst%3DN.%26aulast%3DAbdallah%26aufirst%3DH.%26aulast%3DHussein%26aufirst%3DZ.%26atitle%3DStudies%2520to%2520investigate%2520the%2520pharmacokinetic%2520interactions%2520between%2520ranolazine%2520and%2520ketoconazole%252C%2520diltiazem%252C%2520or%2520simvastatin%2520during%2520combined%2520administration%2520in%2520healthy%2520subjects%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D45%26spage%3D422%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Sutton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, M.</span><span> </span><span class="NLM_article-title">Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">294</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=9223567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK2sXksFyitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=1997&pages=294-300&author=D.+Suttonauthor=A.+M.+Butlerauthor=L.+Nadinauthor=M.+Murray&title=Role+of+CYP3A4+in+human+hepatic+diltiazem+N-demethylation%3A+inhibition+of+CYP3A4+activity+by+oxidized+diltiazem+metabolites"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites</span></div><div class="casAuthors">Sutton, Dylan; Butler, Alison M.; Nadin, Louise; Murray, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">294-300</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The antihypertensive agent diltiazem (DTZ) impairs hepatic drug metab. by inhibition of cytochrome P 450 (CYP).  The accumulation of DTZ metabolites in serum occurs during prolonged therapy and leads to decreased DTZ elimination.  Thus, DTZ metabolites may contribute to CYP inhibition.  This study assessed the role of human CYPs in microsomal DTZ oxidn. and the capacity of DTZ metabolites to inhibit specific CYP activities.  DTZ N-demethylation varied 10-fold in microsomal fractions from 17 livers (0.33-3.31 nmol/mg of protein/min).  DTZ oxidn. was correlated with testosterone 6β-hydroxylation (r = 0.82) and, to a lesser extent, tolbutamide hydroxylation (r = 0.59) but not with activities mediated by CYP1A2 or CYP2E1.  CYP3A4 in lymphoblastoid cell microsomes catalyzed DTZ N-demethylation but CYP2C8 and CYP2C9 were also active (∼20% and 10% of the activity supported by CYP3A4); seven other CYPs produced little or no N-desmethyl DTZ from DTZ.  The CYP3A4 inhibitors ketoconazole and troleandomycin decreased microsomal DTZ oxidn., but inhibitors or substrates of CYP2C, CYP2D and CYP2E1 produced no inhibition.  Some inhibition was produced by α-naphthoflavone, a chem. that inhibits CYP1As and also interacts with CYP3A4.  In further expts., the capacities of DTZ and three metabolites to modulate human CYP 1A2, 1A2, 2E1, 2C9 and 3A4 activities were evaluated in vitro.  DTZ and its N-desmethyl and N,N-didesmethyl metabolites selectively inhibited CYP3A4 activity, whereas O-desmethyl DTZ was not inhibitory.  The IC50 value of DTZ against CYP3A4-mediated testosterone 6β-hydroxylation (substrate concn., 50 μM) was 120 μM.  The N-desmethyl (IC50 = 11 μM) and N,N-didesmethyl (IC50 = 0.6 μM) metabolites were 11 and 200 times, resp., more potent.  From kinetic studies, N-desmethyl DTZ and N,N-didesmethyl DTZ were potent competitive inhibitors of CYP3A4 (Ki = ∼2 and 0.1 μM, resp.).  CYP3A4 inhibition was enhanced when DTZ and N-desmethyl DTZ underwent biotransformation in NADPH-supplemented hepatic microsomes in vitro, supporting the contention that inhibitory metabolites may be generated in situ.  These findings suggest that N-demethylation metabolites of DTZ may contribute to CYP3A4 inhibition in vivo, esp. under conditions in which N-desmethyl DTZ accumulates, such as during prolonged DTZ therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIL8o2n_0Da7Vg90H21EOLACvtfcHk0li6mEmJ-7gv6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksFyitb0%253D&md5=1b1cb145c6246ca57f1455963adc721c</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSutton%26aufirst%3DD.%26aulast%3DButler%26aufirst%3DA.%2BM.%26aulast%3DNadin%26aufirst%3DL.%26aulast%3DMurray%26aufirst%3DM.%26atitle%3DRole%2520of%2520CYP3A4%2520in%2520human%2520hepatic%2520diltiazem%2520N-demethylation%253A%2520inhibition%2520of%2520CYP3A4%2520activity%2520by%2520oxidized%2520diltiazem%2520metabolites%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D282%26spage%3D294%26epage%3D300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Jones, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorski, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayhew, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rider, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. D.</span><span> </span><span class="NLM_article-title">Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">290</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1125</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=10454485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK1MXlsVOqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=1999&pages=1116-1125&author=D.+R.+Jonesauthor=J.+C.+Gorskiauthor=M.+A.+Hammanauthor=B.+S.+Mayhewauthor=S.+Riderauthor=S.+D.+Hall&title=Diltiazem+inhibition+of+cytochrome+P-450+3A+activity+is+due+to+metabolite+intermediate+complex+formation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation</span></div><div class="casAuthors">Jones, David R.; Gorski, J. Christopher; Hamman, Mitchell A.; Mayhew, Bradley S.; Rider, Steven; Hall, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1116-1125</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Diltiazem (DTZ) N-demethylation occurs by cytochrome P 450 (CYP) 3A based on the following observations: 1) a single enzyme Michaelis-Menten model of metabolite formation, 2) high correlations of DTZ N-demethylation activity to other CYP3A activities, 3) inhibition of DTZ N-demethylation activity by triacetyloleandomycin, and 4) DTZ N-demethylation activity by expressed CYP3A enzymes only.  The mean Kms for DTZ N-demethylation in human liver microsomes and expressed CYP3A4(+b5) were 53 and 16 μM, resp.  A 30-min preincubation of DTZ in expressed CYPs inhibited CYP3A4(+b5) by 100%, of which 55% was due to formation of a metabolite intermediate complex (MIC), which is an inactive form of CYP.  MIC was obsd. in human liver microsomes and cDNA-expressed CYP3A only.  In expts. to assess simultaneous MIC formation and loss of CYP3A activity, DTZ caused greater than 80% inhibition of midazolam hydroxylation after a 60-min preincubation in human liver microsomes.  The rate consts. for MIC formation and loss of midazolam hydroxylation activity were equiv. for the line of best fit for both data sets, which illustrates that MIC formation causes the inhibition of CYP3A activity.  The mechanistic inhibition was characterized in expressed CYP3A4(+b5), which exhibited a concn.-dependent formation of MIC by DTZ (1-100 μM) with an estd. kinact of 0.17 min-1 and Ki of 2.2 μM.  The partition ratio for expressed CYP3A4(+b5) was substrate concn. dependent and varied from 13 to 86.  This study showed that DTZ inhibition of CYP3A substrate metab. occurs primarily by MIC formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCuYDxmIk1jrVg90H21EOLACvtfcHk0li6mEmJ-7gv6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlsVOqsb8%253D&md5=199c2d20dc3e9770f9495d8f46f98e5e</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DD.%2BR.%26aulast%3DGorski%26aufirst%3DJ.%2BC.%26aulast%3DHamman%26aufirst%3DM.%2BA.%26aulast%3DMayhew%26aufirst%3DB.%2BS.%26aulast%3DRider%26aufirst%3DS.%26aulast%3DHall%26aufirst%3DS.%2BD.%26atitle%3DDiltiazem%2520inhibition%2520of%2520cytochrome%2520P-450%25203A%2520activity%2520is%2520due%2520to%2520metabolite%2520intermediate%2520complex%2520formation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D290%26spage%3D1116%26epage%3D1125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Zhao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunze, K. L.</span><span> </span><span class="NLM_article-title">Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">704</span><span class="NLM_x">–</span> <span class="NLM_lpage">712</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=704-712&author=P.+Zhaoauthor=C.+A.+Leeauthor=K.+L.+Kunze&title=Sequential+metabolism+is+responsible+for+diltiazem-induced+time-dependent+loss+of+CYP3A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DC.%2BA.%26aulast%3DKunze%26aufirst%3DK.%2BL.%26atitle%3DSequential%2520metabolism%2520is%2520responsible%2520for%2520diltiazem-induced%2520time-dependent%2520loss%2520of%2520CYP3A%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26spage%3D704%26epage%3D712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Lesko, L. J.</span><span> </span><span class="NLM_article-title">Pharmacokinetic drug interactions with amiodarone</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">140</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2165%2F00003088-198917020-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=2673606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaL1MXlsVKisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1989&pages=130-140&author=L.+J.+Lesko&title=Pharmacokinetic+drug+interactions+with+amiodarone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic drug interactions with amiodarone</span></div><div class="casAuthors">Lesko, Lawrence J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-40</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    </div><div class="casAbstract">A review with ∼55 refs.  Amiodarone alters the pharmacokinetics, and in some cases the pharmacodynamics, of several clin. important drugs.  The major mechanism of its drug interactions is inhibition of hepatic metab., but it can also affect the bioavailability, protein binding and renal excretion of coadministered drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBxe0QuUq5SrVg90H21EOLACvtfcHk0li6mEmJ-7gv6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXlsVKisLw%253D&md5=cea9a9a3e88185f454ee966f7ed5b58b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.2165%2F00003088-198917020-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-198917020-00005%26sid%3Dliteratum%253Aachs%26aulast%3DLesko%26aufirst%3DL.%2BJ.%26atitle%3DPharmacokinetic%2520drug%2520interactions%2520with%2520amiodarone%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1989%26volume%3D17%26spage%3D130%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Larrey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tinel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letteron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geneve, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Descatoire, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pessayre, D.</span><span> </span><span class="NLM_article-title">Formation of an inactive cytochrome P-450Fe(II)-metabolite complex after administration of amiodarone in rats, mice and hamsters</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">2213</span><span class="NLM_x">–</span> <span class="NLM_lpage">2220</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1986&pages=2213-2220&author=D.+Larreyauthor=M.+Tinelauthor=P.+Letteronauthor=J.+Geneveauthor=V.+Descatoireauthor=D.+Pessayre&title=Formation+of+an+inactive+cytochrome+P-450Fe%28II%29-metabolite+complex+after+administration+of+amiodarone+in+rats%2C+mice+and+hamsters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLarrey%26aufirst%3DD.%26aulast%3DTinel%26aufirst%3DM.%26aulast%3DLetteron%26aufirst%3DP.%26aulast%3DGeneve%26aufirst%3DJ.%26aulast%3DDescatoire%26aufirst%3DV.%26aulast%3DPessayre%26aufirst%3DD.%26atitle%3DFormation%2520of%2520an%2520inactive%2520cytochrome%2520P-450Fe%2528II%2529-metabolite%2520complex%2520after%2520administration%2520of%2520amiodarone%2520in%2520rats%252C%2520mice%2520and%2520hamsters%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1986%26volume%3D35%26spage%3D2213%26epage%3D2220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Ohyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoi, T.</span><span> </span><span class="NLM_article-title">Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">244</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1046%2Fj.1365-2125.2000.00134.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=10718780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD3cXis1ehu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2000&pages=244-253&author=K.+Ohyamaauthor=M.+Nakajimaauthor=M.+Suzukiauthor=N.+Shimadaauthor=H.+Yamazakiauthor=T.+Yokoi&title=Inhibitory+effects+of+amiodarone+and+its+N-deethylated+metabolite+on+human+cytochrome+P450+activities%3A+prediction+of+in+vivo+drug+interactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions</span></div><div class="casAuthors">Ohyama, K.; Nakajima, M.; Suzuki, M.; Shimada, N.; Yamazaki, H.; Yokoi, T.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">244-253</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">To predict the drug interactions of amiodarone and other drugs, the inhibitory effects and inactivation potential for human cytochrome P 450 (CYP) enzymes by amiodarone and its N-dealkylated metabolite, desethylamiodarone were examd.  The inhibition or inactivation potency of amiodarone and desethylamiodarone for human CYP activities were investigated using microsomes from B-lymphoblastoid cell lines expressing CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4.  The in vivo drug interactions of amiodarone and desethylamiodarone were predicted in vitro using the 1+Iu/Ki values.  Amiodarone weakly inhibited CYP2C9, CYP2D6, and CYP3A4-mediated activities with Ki values of 45.1-271.6 μM.  Desethylamiodarone competitively inhibited the catalytic activities of CYP2D6 (Ki=4.5 μM) and noncompetitively inhibited CYP2A6 (Ki=13.5 μM), CYP2B6 (Ki=5.4 μM), and CYP3A4 (Ki=12.1 μM).  The catalytic activities of CYP1A1 (Ki=1.5 μM, α=5.7), CYP1A2 (Ki=18.8 μM, α=2.6), CYP2C9 (Ki=2.3 μM, α=5.9), and CYP2C19 (Ki=15.7 μM, α=4.5) were inhibited by desethylamiodarone with mixed type.  The 1+Iu/Ki values of desethylamiodarone were higher than those of amiodarone.  Amiodarone inactivated CYP3A4, while desethylamiodarone inactivated CYP1A1, CYP1A2, CYP2B6, and CYP2D6.  The interactions between amiodarone and other drugs might occur via the inhibition of CYP activities by its N-dealkylated metabolite, desethylamiodarone, rather than by amiodarone itself.  In addn., the inactivation of CYPs by desethylamiodarone as well as by amiodarone would also contribute to the drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0_Eep6RxC5LVg90H21EOLACvtfcHk0lgKDCFfzY7QMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXis1ehu7o%253D&md5=0d2004ab911e28d059469f2da781c45b</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2125.2000.00134.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2125.2000.00134.x%26sid%3Dliteratum%253Aachs%26aulast%3DOhyama%26aufirst%3DK.%26aulast%3DNakajima%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DShimada%26aufirst%3DN.%26aulast%3DYamazaki%26aufirst%3DH.%26aulast%3DYokoi%26aufirst%3DT.%26atitle%3DInhibitory%2520effects%2520of%2520amiodarone%2520and%2520its%2520N-deethylated%2520metabolite%2520on%2520human%2520cytochrome%2520P450%2520activities%253A%2520prediction%2520of%2520in%2520vivo%2520drug%2520interactions%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2000%26volume%3D49%26spage%3D244%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Mori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takatsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuda-Tsukimoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kume, T.</span><span> </span><span class="NLM_article-title">Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">415</span><span class="NLM_x">–</span> <span class="NLM_lpage">422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=415-422&author=K.+Moriauthor=H.+Hashimotoauthor=H.+Takatsuauthor=M.+Tsuda-Tsukimotoauthor=T.+Kume&title=Cocktail-substrate+assay+system+for+mechanism-based+inhibition+of+CYP2C9%2C+CYP2D6%2C+and+CYP3A+using+human+liver+microsomes+at+an+early+stage+of+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DK.%26aulast%3DHashimoto%26aufirst%3DH.%26aulast%3DTakatsu%26aufirst%3DH.%26aulast%3DTsuda-Tsukimoto%26aufirst%3DM.%26aulast%3DKume%26aufirst%3DT.%26atitle%3DCocktail-substrate%2520assay%2520system%2520for%2520mechanism-based%2520inhibition%2520of%2520CYP2C9%252C%2520CYP2D6%252C%2520and%2520CYP3A%2520using%2520human%2520liver%2520microsomes%2520at%2520an%2520early%2520stage%2520of%2520drug%2520development%26jtitle%3DXenobiotica%26date%3D2009%26volume%3D39%26spage%3D415%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Polasek, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliot, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minors, J. O.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">311</span><span class="NLM_x">, </span> <span class="NLM_fpage">996</span><span class="NLM_x">–</span> <span class="NLM_lpage">1007</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1124%2Fjpet.104.071803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15304522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKmtLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2004&pages=996-1007&author=T.+M.+Polasekauthor=D.+J.+Elliotauthor=B.+C.+Lewisauthor=J.+O.+Minors&title=Mechanism-based+inactivation+of+human+cytochrome+P4502C8+by+drugs+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro</span></div><div class="casAuthors">Polasek, Thomas M.; Elliot, David J.; Lewis, Benjamin C.; Miners, John O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">996-1007</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Studies were conducted to evaluate the potential mechanism-based inactivation of recombinant and human liver microsomal CYP2C8 by clin. used drugs.  Several tricyclic antidepressants, calcium channel blockers, monoamine oxidase inhibitors, and various other known CYP3A4 inhibitors exhibited greater inhibition of CYP2C8 (paclitaxel 6α-hydroxylation) following preincubation, consistent with mechanism-based inactivation.  Inactivation of recombinant CYP2C8 by phenelzine, amiodarone, verapamil, nortriptyline, fluoxetine, and isoniazid was of the pseudo-first order type and was characterized by resp. inactivation kinetic consts. (K1 and kinact) of 1.2 μM and 0.243 min-1, 1.5 μM and 0.079 min-1, 17.5 μM and 0.065 min-1, 49.9 μM and 0.036 min-1, 294 μM and 0.083 min-1, and 374 μM and 0.042 min-1.  Spectral scanning of recombinant CYP2C8 demonstrated the formation of metabolite-intermediate complexes with verapamil, nortriptyline, fluoxetine, and isoniazid, but not amiodarone.  In contrast, inactivation by phenelzine resulted from heme destruction by free radicals.  Studies with human liver microsomes (HLMs) revealed that nortriptyline, verapamil, and fluoxetine were not mechanism-based inactivators (MBIs) of CYP2C8.  Simultaneous inactivation of CYP2C8 and CYP3A4 (paclitaxel 3'-phenyl-hydroxylation) was obsd. using amiodarone, isoniazid, and phenelzine with the efficiency of inactivation greater for the CYP3A4 pathway.  With the exception of phenelzine, glutathione and superoxide dismutase failed to protect CYP2C8 (recombinant and HLMs) or CYP3A4 from inactivation by MBIs.  However, the alternate CYP2C8 substrate, torsemide, prevented CYP2C8 inactivation in all cases.  These data are consistent with mechanism-based inactivation of CYP2C8 by a range of commonly prescribed drugs, several of which have been implicated in clin. important drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriCb9GyIpU57Vg90H21EOLACvtfcHk0lgKDCFfzY7QMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKmtLzL&md5=ba8b39957d6b8f82d42921e70c686796</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.071803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.071803%26sid%3Dliteratum%253Aachs%26aulast%3DPolasek%26aufirst%3DT.%2BM.%26aulast%3DElliot%26aufirst%3DD.%2BJ.%26aulast%3DLewis%26aufirst%3DB.%2BC.%26aulast%3DMinors%26aufirst%3DJ.%2BO.%26atitle%3DMechanism-based%2520inactivation%2520of%2520human%2520cytochrome%2520P4502C8%2520by%2520drugs%2520in%2520vitro%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D311%26spage%3D996%26epage%3D1007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Nagauma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishikata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuchiya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasanuki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, E.</span><span> </span><span class="NLM_article-title">Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">363</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1177%2F107424840100600405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=11907638" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2001&pages=363-367&author=M.+Nagaumaauthor=T.+Shigaauthor=K.+Nishikataauthor=T.+Tsuchiyaauthor=H.+Kasanukiauthor=E.+Fujii&title=Role+of+desethylamiodarone+in+the+anticoagulant+effect+of+concurrent+amiodarone+and+warfarin+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1177%2F107424840100600405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F107424840100600405%26sid%3Dliteratum%253Aachs%26aulast%3DNagauma%26aufirst%3DM.%26aulast%3DShiga%26aufirst%3DT.%26aulast%3DNishikata%26aufirst%3DK.%26aulast%3DTsuchiya%26aufirst%3DT.%26aulast%3DKasanuki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DE.%26atitle%3DRole%2520of%2520desethylamiodarone%2520in%2520the%2520anticoagulant%2520effect%2520of%2520concurrent%2520amiodarone%2520and%2520warfarin%2520therapy%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%2520Ther.%26date%3D2001%26volume%3D6%26spage%3D363%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Mandrioli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forti, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raggi, M. A.</span><span> </span><span class="NLM_article-title">Fluoxetine metabolism and pharmacological interactions: the role of cytochrome P450</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">133</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2174%2F138920006775541561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=16472103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Oms74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=127-133&author=R.+Mandrioliauthor=G.+C.+Fortiauthor=M.+A.+Raggi&title=Fluoxetine+metabolism+and+pharmacological+interactions%3A+the+role+of+cytochrome+P450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Fluoxetine metabolism and pharmacological interactions: the role of cytochrome P450</span></div><div class="casAuthors">Mandrioli, R.; Cantelli Forti, G.; Raggi, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-133</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with 103 refs.  Fluoxetine is the parent drug of the SSRI (selective serotonin reuptake inhibitor) antidepressant class, and is still one of the most highly used drugs of this class world-wide.  Fluoxetine now has largely (albeit not completely) substituted older and less safe drugs such as tricyclic antidepressants.  Different cytochrome P 450 isoforms are involved in the metab. of fluoxetine, however, the main active metabolite, norfluoxetine, is produced by the CYP2D6 action in the human liver.  In this paper, the main metabolic characteristics of fluoxetine will be reviewed, with particular attention paid to the role of cytochrome isoenzymes.  The pharmacol. interactions of the drug will be overviewed, esp. those concerning other drugs used in psychiatric clinics, such as antipsychotics and antidepressants and the relationships between pharmacol. interactions and cytochrome activity will be discussed.  Recently, much attention has been drawn to the therapeutic drug monitoring (TDM) of fluoxetine, and in particular to the anal. of fluoxetine enantiomers for which enantiomeric sepns. and enantioselective metab. will also briefly be mentioned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzhEc2P671LrVg90H21EOLACvtfcHk0lguZtCqfbH8Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Oms74%253D&md5=9fcf86af57228deac12810dc28a69321</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2174%2F138920006775541561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920006775541561%26sid%3Dliteratum%253Aachs%26aulast%3DMandrioli%26aufirst%3DR.%26aulast%3DForti%26aufirst%3DG.%2BC.%26aulast%3DRaggi%26aufirst%3DM.%2BA.%26atitle%3DFluoxetine%2520metabolism%2520and%2520pharmacological%2520interactions%253A%2520the%2520role%2520of%2520cytochrome%2520P450%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2006%26volume%3D7%26spage%3D127%26epage%3D133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Stevens, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrighton, S. A.</span><span> </span><span class="NLM_article-title">Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">266</span><span class="NLM_x">, </span> <span class="NLM_fpage">964</span><span class="NLM_x">–</span> <span class="NLM_lpage">971</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=8355218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK3sXmtFKksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=1993&pages=964-971&author=J.+C.+Stevensauthor=S.+A.+Wrighton&title=Interaction+of+the+enantiomers+of+fluoxetine+and+norfluoxetine+with+human+liver+cytochromes+P450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450</span></div><div class="casAuthors">Stevens, Jeffrey C.; Wrighton, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">266</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">964-71</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">(R)- and (S)-fluoxetine are competitive inhibitors of P 450 2D6-mediated bufuralol 1'-hydroxylation in vitro, yielding Ki values of 1.38 and 0.22 μM, resp.  Their N-demethylated metabolites also are potent inhibitors (Ki, (R)-norfluoxetine, 1.48 μM; (S)-norfluoxetine 0.31 μM).  The microsomal (R)- and (S)-fluoxetine N-demethylase activities for 14 human liver samples were on av. 29.6 and 19.4 pmol of product/min/mg of protein, resp.  The individual rates of N-demethylation correlated with microsomal immunodetectable P 450 2D6 levels; (R)-fluoxetine, r = 0.64, P < .05; (S) fluoxetine, r = 0.63, P < .05.  However, this correlation was weaker than the excellent correlation obtained for P 450 2D6-marker bufuralol 1'-hydroxylase activity and P 450 2D6 levels (r = 0.92, P ≤ .01).  Quinidine, a potent inhibitor of P 450 2D6, inhibited the demethylation of each enantiomer by only ∼20% at a concn. 300 times greater than the Ki detd. for the quinidine inhibition of bufuralol 1'-hydroxylase.  Furthermore, antiserum recognizing P 450 2D6 inhibited 82% of microsomal bufuralol 1'-hydroxylase activity but only 27% of the (R)-fluoxetine N-demethylase activity in the same human liver sample.  In summary, these data indicate that the enantiomers of fluoxetine and norfluoxetine are potent inhibitors of P 450 2D6 and that P 450 forms other than P 450 2D6 appear to be responsible for the majority of microsomal fluoxetine N-demethylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBhmcK4Ci5g7Vg90H21EOLACvtfcHk0lguZtCqfbH8Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmtFKksbo%253D&md5=28d1e7b5bb081ec01069afbb236d2848</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStevens%26aufirst%3DJ.%2BC.%26aulast%3DWrighton%26aufirst%3DS.%2BA.%26atitle%3DInteraction%2520of%2520the%2520enantiomers%2520of%2520fluoxetine%2520and%2520norfluoxetine%2520with%2520human%2520liver%2520cytochromes%2520P450%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1993%26volume%3D266%26spage%3D964%26epage%3D971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Stresser, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perloff, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crespi, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandeneau, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehal, S. S.</span><span> </span><span class="NLM_article-title">Differential time- and NADPH-dependent inhibition of CYP2C19 by enantiomers of fluoxetine</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">698</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=695-698&author=D.+M.+Stresserauthor=A.+K.+Masonauthor=E.+S.+Perloffauthor=T.+Hoauthor=C.+L.+Crespiauthor=A.+A.+Dandeneauauthor=L.+Morganauthor=S.+S.+Dehal&title=Differential+time-+and+NADPH-dependent+inhibition+of+CYP2C19+by+enantiomers+of+fluoxetine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStresser%26aufirst%3DD.%2BM.%26aulast%3DMason%26aufirst%3DA.%2BK.%26aulast%3DPerloff%26aufirst%3DE.%2BS.%26aulast%3DHo%26aufirst%3DT.%26aulast%3DCrespi%26aufirst%3DC.%2BL.%26aulast%3DDandeneau%26aufirst%3DA.%2BA.%26aulast%3DMorgan%26aufirst%3DL.%26aulast%3DDehal%26aufirst%3DS.%2BS.%26atitle%3DDifferential%2520time-%2520and%2520NADPH-dependent%2520inhibition%2520of%2520CYP2C19%2520by%2520enantiomers%2520of%2520fluoxetine%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D695%26epage%3D698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Bensoussan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaforge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuy, D.</span><span> </span><span class="NLM_article-title">Particular ability of cytochrome P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1995&pages=591-602&author=C.+Bensoussanauthor=M.+Delaforgeauthor=D.+Mansuy&title=Particular+ability+of+cytochrome+P450+3A+to+form+inhibitory+P450-iron-metabolite+complexes+upon+metabolic+oxidation+of+aminodrugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBensoussan%26aufirst%3DC.%26aulast%3DDelaforge%26aufirst%3DM.%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DParticular%2520ability%2520of%2520cytochrome%2520P450%25203A%2520to%2520form%2520inhibitory%2520P450-iron-metabolite%2520complexes%2520upon%2520metabolic%2520oxidation%2520of%2520aminodrugs%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1995%26volume%3D49%26spage%3D591%26epage%3D602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Mansuy, D.</span><span> </span><span class="NLM_article-title">Formation of reactive intermediates and metabolites: effects of macrolide antibiotics on cytochrome P-450</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2F0163-7258%2887%2990026-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=3628477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaL2sXltVyltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1987&pages=41-45&author=D.+Mansuy&title=Formation+of+reactive+intermediates+and+metabolites%3A+effects+of+macrolide+antibiotics+on+cytochrome+P-450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Formation of reactive intermediates and metabolites:  effects of macrolide antibiotics on cytochrome P-450</span></div><div class="casAuthors">Mansuy, D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-5</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    </div><div class="casAbstract">A review with 8 refs.  Xenobiotics have multiple effects on cytochrome P-450 in vivo and, thus, can change the metab. of other drugs.  The effects of macrolide antibiotics (including erythromycin and oleandomycin triacetate) on cytochrome P-450 are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonWtzH1Zbf-bVg90H21EOLACvtfcHk0li41auAJuPc2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXltVyltL4%253D&md5=40652d9d77251aefe23d35796a07fbfe</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2F0163-7258%2887%2990026-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0163-7258%252887%252990026-X%26sid%3Dliteratum%253Aachs%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DFormation%2520of%2520reactive%2520intermediates%2520and%2520metabolites%253A%2520effects%2520of%2520macrolide%2520antibiotics%2520on%2520cytochrome%2520P-450%26jtitle%3DPharmacol.%2520Ther.%26date%3D1987%26volume%3D33%26spage%3D41%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Piacentini, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trifiro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tari, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moretti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcoraci, V.</span><span> </span><span class="NLM_article-title">UVEC group. Statin–macrolide interaction risk: a population-based study throughout a general practice database</span> <span class="citation_source-journal">Eur. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">615</span><span class="NLM_x">–</span> <span class="NLM_lpage">620</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2005&pages=615-620&author=N.+Piacentiniauthor=G.+Trifiroauthor=M.+Tariauthor=S.+Morettiauthor=V.+Arcoraci&title=UVEC+group.+Statin%E2%80%93macrolide+interaction+risk%3A+a+population-based+study+throughout+a+general+practice+database"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPiacentini%26aufirst%3DN.%26aulast%3DTrifiro%26aufirst%3DG.%26aulast%3DTari%26aufirst%3DM.%26aulast%3DMoretti%26aufirst%3DS.%26aulast%3DArcoraci%26aufirst%3DV.%26atitle%3DUVEC%2520group.%2520Statin%25E2%2580%2593macrolide%2520interaction%2520risk%253A%2520a%2520population-based%2520study%2520throughout%2520a%2520general%2520practice%2520database%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D61%26spage%3D615%26epage%3D620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Larrey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funck-Bretano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitaux, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theodore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babany, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pessayre, D.</span><span> </span><span class="NLM_article-title">Effects of erythromycin on hepatic drug-metabolizing enzymes in humans</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1063</span><span class="NLM_x">–</span> <span class="NLM_lpage">1068</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1983&pages=1063-1068&author=D.+Larreyauthor=C.+Funck-Bretanoauthor=P.+Breilauthor=J.+Vitauxauthor=C.+Theodoreauthor=G.+Babanyauthor=D.+Pessayre&title=Effects+of+erythromycin+on+hepatic+drug-metabolizing+enzymes+in+humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLarrey%26aufirst%3DD.%26aulast%3DFunck-Bretano%26aufirst%3DC.%26aulast%3DBreil%26aufirst%3DP.%26aulast%3DVitaux%26aufirst%3DJ.%26aulast%3DTheodore%26aufirst%3DC.%26aulast%3DBabany%26aufirst%3DG.%26aulast%3DPessayre%26aufirst%3DD.%26atitle%3DEffects%2520of%2520erythromycin%2520on%2520hepatic%2520drug-metabolizing%2520enzymes%2520in%2520humans%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1983%26volume%3D32%26spage%3D1063%26epage%3D1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Larrey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tinel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pessayre, D.</span><span> </span><span class="NLM_article-title">Formation of inactive cytochrome P-450 Fe(II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1487</span><span class="NLM_x">–</span> <span class="NLM_lpage">1493</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1983&pages=1487-1493&author=D.+Larreyauthor=M.+Tinelauthor=D.+Pessayre&title=Formation+of+inactive+cytochrome+P-450+Fe%28II%29-metabolite+complexes+with+several+erythromycin+derivatives+but+not+with+josamycin+and+midecamycin+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLarrey%26aufirst%3DD.%26aulast%3DTinel%26aufirst%3DM.%26aulast%3DPessayre%26aufirst%3DD.%26atitle%3DFormation%2520of%2520inactive%2520cytochrome%2520P-450%2520Fe%2528II%2529-metabolite%2520complexes%2520with%2520several%2520erythromycin%2520derivatives%2520but%2520not%2520with%2520josamycin%2520and%2520midecamycin%2520in%2520rats%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1983%26volume%3D32%26spage%3D1487%26epage%3D1493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Yamazaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, T.</span><span> </span><span class="NLM_article-title">Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1053</span><span class="NLM_x">–</span> <span class="NLM_lpage">1057</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1998&pages=1053-1057&author=H.+Yamazakiauthor=T.+Shimada&title=Comparative+studies+of+in+vitro+inhibition+of+cytochrome+P450+3A4-dependent+testosterone+6beta-hydroxylation+by+roxithromycin+and+its+metabolites%2C+troleandomycin%2C+and+erythromycin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DH.%26aulast%3DShimada%26aufirst%3DT.%26atitle%3DComparative%2520studies%2520of%2520in%2520vitro%2520inhibition%2520of%2520cytochrome%2520P450%25203A4-dependent%2520testosterone%25206beta-hydroxylation%2520by%2520roxithromycin%2520and%2520its%2520metabolites%252C%2520troleandomycin%252C%2520and%2520erythromycin%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1998%26volume%3D26%26spage%3D1053%26epage%3D1057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Amacher, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schomaker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Retsema, J. A.</span><span> </span><span class="NLM_article-title">Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1186</span><span class="NLM_x">–</span> <span class="NLM_lpage">1190</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1991&pages=1186-1190&author=D.+E.+Amacherauthor=S.+J.+Schomakerauthor=J.+A.+Retsema&title=Comparison+of+the+effects+of+the+new+azalide+antibiotic%2C+azithromycin%2C+and+erythromycin+estolate+on+rat+liver+cytochrome+P-450"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAmacher%26aufirst%3DD.%2BE.%26aulast%3DSchomaker%26aufirst%3DS.%2BJ.%26aulast%3DRetsema%26aufirst%3DJ.%2BA.%26atitle%3DComparison%2520of%2520the%2520effects%2520of%2520the%2520new%2520azalide%2520antibiotic%252C%2520azithromycin%252C%2520and%2520erythromycin%2520estolate%2520on%2520rat%2520liver%2520cytochrome%2520P-450%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1991%26volume%3D35%26spage%3D1186%26epage%3D1190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Sartori, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaforge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuy, D.</span><span> </span><span class="NLM_article-title">In vivo interaction of rat liver cytochrome P-450 with erythromycin, oleandomycin and erythralosamine derivatives. Importance of structural factor</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">2061</span><span class="NLM_x">–</span> <span class="NLM_lpage">2068</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1989&pages=2061-2068&author=E.+Sartoriauthor=M.+Delaforgeauthor=D.+Mansuy&title=In+vivo+interaction+of+rat+liver+cytochrome+P-450+with+erythromycin%2C+oleandomycin+and+erythralosamine+derivatives.+Importance+of+structural+factor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSartori%26aufirst%3DE.%26aulast%3DDelaforge%26aufirst%3DM.%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DIn%2520vivo%2520interaction%2520of%2520rat%2520liver%2520cytochrome%2520P-450%2520with%2520erythromycin%252C%2520oleandomycin%2520and%2520erythralosamine%2520derivatives.%2520Importance%2520of%2520structural%2520factor%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1989%26volume%3D38%26spage%3D2061%26epage%3D2068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Ekroos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjogren, T.</span><span> </span><span class="NLM_article-title">Structural basis for ligand promiscuity in cytochrome P450 3A4</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">13682</span><span class="NLM_x">–</span> <span class="NLM_lpage">13687</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1073%2Fpnas.0603236103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=16954191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFerurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=13682-13687&author=M.+Ekroosauthor=T.+Sjogren&title=Structural+basis+for+ligand+promiscuity+in+cytochrome+P450+3A4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for ligand promiscuity in cytochrome P 450 3A4</span></div><div class="casAuthors">Ekroos, Marika; Sjoegren, Tove</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">13682-13687</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Cytochrome P 450 (CYP) 3A4 is the most promiscuous of the human CYP isoforms and contributes to the metab. of ∼50% of marketed drugs.  It is also the isoform most often involved in unwanted drug-drug interactions.  A better understanding of the mol. mechanisms governing CYP3A4-ligand interactions therefore would be of great importance to any drug discovery effort.  Here, the authors present crystal structures of human CYP3A4 in complex with 2 well-characterized drugs, ketoconazole and erythromycin.  In contrast to previous reports, the protein undergoes dramatic conformational changes upon ligand binding with an increase in the active site vol. by >80%.  The structures represent 2 distinct open conformations of CYP3A4 because ketoconazole and erythromycin induce different types of coordinate shifts.  The binding of 2 mols. of ketoconazole to the CYP3A4 active site and the clear indication of multiple binding modes for erythromycin has implications for the interpretation of the atypical kinetic data often displayed by CYP3A4.  The extreme flexibility revealed by the present structures also challenges any attempt to apply computational design tools without the support of relevant exptl. data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnDKVSe72voLVg90H21EOLACvtfcHk0lgBTA6QI7QB4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFerurs%253D&md5=d343043ae054f93d9de31148c09bb987</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0603236103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0603236103%26sid%3Dliteratum%253Aachs%26aulast%3DEkroos%26aufirst%3DM.%26aulast%3DSjogren%26aufirst%3DT.%26atitle%3DStructural%2520basis%2520for%2520ligand%2520promiscuity%2520in%2520cytochrome%2520P450%25203A4%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D13682%26epage%3D13687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Paris, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheinkoenig, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ndikum-Moffor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, A.</span><span> </span><span class="NLM_article-title">In vitro inhibition and induction of human liver cytochrome P450 enzymes by milnacipran</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">2045</span><span class="NLM_x">–</span> <span class="NLM_lpage">2054</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=2045-2054&author=B.+L.+Parisauthor=B.+W.+Ogilvieauthor=J.+A.+Scheinkoenigauthor=F.+Ndikum-Mofforauthor=R.+Gibsonauthor=A.+Parkinson&title=In+vitro+inhibition+and+induction+of+human+liver+cytochrome+P450+enzymes+by+milnacipran"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParis%26aufirst%3DB.%2BL.%26aulast%3DOgilvie%26aufirst%3DB.%2BW.%26aulast%3DScheinkoenig%26aufirst%3DJ.%2BA.%26aulast%3DNdikum-Moffor%26aufirst%3DF.%26aulast%3DGibson%26aufirst%3DR.%26aulast%3DParkinson%26aufirst%3DA.%26atitle%3DIn%2520vitro%2520inhibition%2520and%2520induction%2520of%2520human%2520liver%2520cytochrome%2520P450%2520enzymes%2520by%2520milnacipran%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D2045%26epage%3D2054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Chan, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">New, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. C.</span><span> </span><span class="NLM_article-title">Reversible time-dependent inhibition of cytochrome P450 enzymes by duloxetine and inertness of its thiophene ring towards bioactivation</span> <span class="citation_source-journal">Toxicol. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">206</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.toxlet.2011.07.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=21839818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1agurfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=206&publication_year=2011&pages=314-324&author=C.+Y.+Chanauthor=L.+S.+Newauthor=H.+K.+Hoauthor=E.+C.+Chan&title=Reversible+time-dependent+inhibition+of+cytochrome+P450+enzymes+by+duloxetine+and+inertness+of+its+thiophene+ring+towards+bioactivation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible time-dependent inhibition of cytochrome P450 enzymes by duloxetine and inertness of its thiophene ring towards bioactivation</span></div><div class="casAuthors">Chan, Chun Yip; New, Lee Sun; Ho, Han Kiat; Chan, Eric Chun Yong</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">206</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">314-324</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Duloxetine is a selective serotonin-norepinephrine reuptake inhibitor (SNRI) approved to treat major depressive disorder and diabetic peripheral neuropathic pain.  It is known to cause hepatotoxicity, in some cases leading to death.  It has been reported that duloxetine causes time-dependent inhibition (TDI) of CYP1A2, CYP2B6, CYP2C19 and CYP3A4/5; but the nature of these TDI (whether reversible or irreversible) is not known.  Irreversible TDI can cause clin. significant drug-drug interactions and also immune-mediated hepatotoxicity.  Structurally, duloxetine possesses several toxicophores, i.e. the naphthyl and thiophene rings.  It has been reported that the naphthyl ring undergoes epoxidn. and was subsequently adducted to glutathione, but bioactivation related to the thiophene ring has not been completely elucidated.  In this paper, the potential of duloxetine in causing irreversible TDI and generating reactive metabolites was investigated.  Human liver microsomal assays demonstrated that duloxetine did not cause irreversible TDI of CYP1A2, CYP2B6, CYP2D6, CYP2C19 and CYP3A4/5.  Subsequently, reactive metabolite trapping assays using soft nucleophiles (glutathione and glutathione Et ester) revealed a previously reported adduct at the naphthyl ring of duloxetine but not at the thiophene ring.  Trapping assays utilizing a hard nucleophile (semicarbazide) did not demonstrate adducts with the thiophene ring, indicating an absence of thiophene ring opening.  The hepatotoxicity of duloxetine is possibly not related to the irreversible TDI of CYP450 or the bioactivation of its thiophene moiety, but might be due to the epoxidn. of its naphthyl ring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2Ze6sQYk6W7Vg90H21EOLACvtfcHk0lgBTA6QI7QB4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1agurfL&md5=7e61dd91445d7427fe939e5cd0a2642b</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.toxlet.2011.07.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.toxlet.2011.07.019%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DC.%2BY.%26aulast%3DNew%26aufirst%3DL.%2BS.%26aulast%3DHo%26aufirst%3DH.%2BK.%26aulast%3DChan%26aufirst%3DE.%2BC.%26atitle%3DReversible%2520time-dependent%2520inhibition%2520of%2520cytochrome%2520P450%2520enzymes%2520by%2520duloxetine%2520and%2520inertness%2520of%2520its%2520thiophene%2520ring%2520towards%2520bioactivation%26jtitle%3DToxicol.%2520Lett.%26date%3D2011%26volume%3D206%26spage%3D314%26epage%3D324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Knadler, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chappell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, R.</span><span> </span><span class="NLM_article-title">Duloxetine: clinical pharmacokinetics and drug interactions</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">281</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2165%2F11539240-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=21366359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntlKlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=281-294&author=M.+P.+Knadlerauthor=E.+Loboauthor=J.+Chappellauthor=R.+Bergstrom&title=Duloxetine%3A+clinical+pharmacokinetics+and+drug+interactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Duloxetine: clinical pharmacokinetics and drug interactions</span></div><div class="casAuthors">Knadler, Mary Pat; Lobo, Evelyn; Chappell, Jill; Bergstrom, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">281-294</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  Duloxetine, a potent reuptake inhibitor of serotonin (5-HT) and norepinephrine, is effective for the treatment of major depressive disorder, diabetic neuropathic pain, stress urinary incontinence, generalized anxiety disorder and fibromyalgia.  Duloxetine achieves a max. plasma concn. (Cmax) of approx. 47 ng/mL (40 mg twice-daily dosing) to 110 ng/mL (80 mg twice-daily dosing) approx. 6 h after dosing.  The elimination half-life of duloxetine is approx. 10-12 h and the vol. of distribution is approx. 1640 L.  The goal of this paper is to provide a review of the literature on intrinsic and extrinsic factors that may impact the pharmacokinetics of duloxetine with a focus on concomitant medications and their clin. implications.  Patient demog. characteristics found to influence the pharmacokinetics of duloxetine include sex, smoking status, age, ethnicity, cytochrome P 450 (CYP) 2D6 genotype, hepatic function and renal function.  Of these, only impaired hepatic function or severely impaired renal function warrant specific warnings or dose recommendations.  Pharmacokinetic results from drug interaction studies show that activated charcoal decreases duloxetine exposure, and that CYP1A2 inhibition increases duloxetine exposure to a clin. significant degree.  Specifically, following oral administration in the presence of fluvoxamine, the area under the plasma concn.-time curve and Cmax of duloxetine significantly increased by 460% (90% CI 359, 584) and 141% (90% CI 93, 200), resp.  In addn., smoking is assocd. with a 30% decrease in duloxetine concn.  The exposure of duloxetine with CYP2D6 inhibitors or in CYP2D6 poor metabolizers is increased to a lesser extent than that obsd. with CYP1A2 inhibition and does not require a dose adjustment.  In addn., duloxetine increases the exposure of drugs that are metabolized by CYP2D6, but not CYP1A2.  Pharmacodynamic study results indicate that duloxetine may enhance the effects of benzodiazepines, but not alc. or warfarin.  An increase in gastric pH produced by histamine H2-receptor antagonists or antacids did not impact the absorption of duloxetine.  While duloxetine is generally well tolerated, it is important to be knowledgeable about the potential for pharmacokinetic interactions between duloxetine and drugs that inhibit CYP1A2 or drugs that are metabolized by CYP2D6 enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6yAIBWsbwCrVg90H21EOLACvtfcHk0lgBTA6QI7QB4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntlKlsbg%253D&md5=5e453b083889f9c03e87e4b3aa7ad19a</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.2165%2F11539240-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11539240-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DKnadler%26aufirst%3DM.%2BP.%26aulast%3DLobo%26aufirst%3DE.%26aulast%3DChappell%26aufirst%3DJ.%26aulast%3DBergstrom%26aufirst%3DR.%26atitle%3DDuloxetine%253A%2520clinical%2520pharmacokinetics%2520and%2520drug%2520interactions%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2011%26volume%3D50%26spage%3D281%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vashishtha, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erve, J. C.</span><span> </span><span class="NLM_article-title">Characterization of glutathione conjugates of duloxetine by mass spectrometry and evaluation of in silico approaches to rationalize the site of conjugation for thiophene containing rings</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1393</span><span class="NLM_x">–</span> <span class="NLM_lpage">1404</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx100141d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=1393-1404&author=G.+Wuauthor=S.+C.+Vashishthaauthor=J.+C.+Erve&title=Characterization+of+glutathione+conjugates+of+duloxetine+by+mass+spectrometry+and+evaluation+of+in+silico+approaches+to+rationalize+the+site+of+conjugation+for+thiophene+containing+rings"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Ftx100141d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx100141d%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DVashishtha%26aufirst%3DS.%2BC.%26aulast%3DErve%26aufirst%3DJ.%2BC.%26atitle%3DCharacterization%2520of%2520glutathione%2520conjugates%2520of%2520duloxetine%2520by%2520mass%2520spectrometry%2520and%2520evaluation%2520of%2520in%2520silico%2520approaches%2520to%2520rationalize%2520the%2520site%2520of%2520conjugation%2520for%2520thiophene%2520containing%2520rings%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2010%26volume%3D23%26spage%3D1393%26epage%3D1404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Winston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boffito, M.</span><span> </span><span class="NLM_article-title">The management of HIV-1 protease inhibitor pharmacokinetic interactions</span> <span class="citation_source-journal">J. Antimicrob. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1093%2Fjac%2Fdki184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15941777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmsV2iur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2005&pages=1-5&author=A.+Winstonauthor=M.+Boffito&title=The+management+of+HIV-1+protease+inhibitor+pharmacokinetic+interactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">The management of HIV-1 protease inhibitor pharmacokinetic interactions</span></div><div class="casAuthors">Winston, Alan; Boffito, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-5</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  The HIV-1 protease inhibitors (PIs) are widely used in combination antiretroviral therapy for the management of HIV-1 infection.  Certain characteristics of the PIs, in particular their metab. being mainly via the cytochrome P 450 isoenzyme group and their gastric absorption being pH dependent, make them prone to clin. significant drug interactions with other antiretrovirals, concomitant medication and complementary treatments.  Owing to the nature of the disease, individuals with HIV are frequently prescribed complex treatment regimens (both for the management of intolerance, toxicity and viral resistance to antiretroviral therapy, and in the management of co-morbid states) that may interact with PI therapy.  For many of these potential interactions, few data are available.  This review will focus on the current use of PIs, highlighting some important management issues encountered with common pharmacokinetic interactions seen in clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_nyqEZk_mlLVg90H21EOLACvtfcHk0lg15zWdiDE2eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmsV2iur8%253D&md5=6364cefc26a387dd411167586a216d4d</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdki184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdki184%26sid%3Dliteratum%253Aachs%26aulast%3DWinston%26aufirst%3DA.%26aulast%3DBoffito%26aufirst%3DM.%26atitle%3DThe%2520management%2520of%2520HIV-1%2520protease%2520inhibitor%2520pharmacokinetic%2520interactions%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2005%26volume%3D56%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Ernest, C. S.,  2nd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. R.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of CYP3A by HIV protease inhibitors</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x">, </span> <span class="NLM_fpage">583</span><span class="NLM_x">–</span> <span class="NLM_lpage">591</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1124%2Fjpet.104.075416" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15523003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsVCnsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2005&pages=583-591&author=C.+S.+Ernestauthor=S.+D.+Hallauthor=D.+R.+Jones&title=Mechanism-based+inactivation+of+CYP3A+by+HIV+protease+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inactivation of CYP3A by HIV protease inhibitors</span></div><div class="casAuthors">Ernest, C. Steven, II; Hall, Stephen D.; Jones, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">583-591</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Human immunodeficiency virus (HIV) protease inhibitors (PIs) are inhibitors of CYP3A enzymes, but the mechanism is poorly defined.  In this study, time- and concn.-dependent decreases in activity as defined by max. rate of inactivation (kinact) and inhibitor concn. that gives 50% maximal inactivation (K1) of CYP3A by amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir were quantified using testosterone 6β-hydroxylation as a marker for CYP3A activity with recombinant CYP3A4(+b5), recombinant CYP3A5, and pooled human liver microsomes (HLMs).  All the PIs, except indinavir, displayed inactivation with CYP3A4(+b5) and HLMs.  Ritonavir was the most potent (K1 = 0.10 and 0.17 μM) and demonstrated high kinact values (0.32 and 0.40 min-1) with both CYP3A4(+b5) and HLMs.  Ritonavir was not significantly depleted by high-affinity binding with CYP3A4(+b5) and confirmed that estn. of reversible inhibition was confounded with irreversible inhibition.  For CYP3A5, nelfinavir exhibited the highest kinact (0.47 min-1), but ritonavir was the most potent (K1 = 0.12 μM).  Saquinavir and indinavir did not show time- and concn.-dependent decreases in activity with CYP3A5.  Spectrophotometrically detd. metabolic intermediate complex formation was obsd. for all of the PIs with CYP3A4(+b5), except for lopinavir and saquinavir.  The addn. of nucleophilic and free aldehyde trapping agents and free iron and reactive oxygen species scavengers did not prevent inactivation of CYP3A4(+b5) by ritonavir, amprenavir, or nelfinavir, but glutathione decreased the inactivation by saquinavir (17%) and catalase decreased the inactivation by lopinavir (39%).  In conclusion, all the PIs exhibited mechanism-based inactivation, and predictions of the extent and time course of drug interactions with PIs could be underestimated if based solely on reversible inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjaqMRAR0CXbVg90H21EOLACvtfcHk0lg15zWdiDE2eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsVCnsb0%253D&md5=514ecebccd37156c9ef12621d7e98c82</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.075416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.075416%26sid%3Dliteratum%253Aachs%26aulast%3DErnest%26aufirst%3DC.%2BS.%26aulast%3DHall%26aufirst%3DS.%2BD.%26aulast%3DJones%26aufirst%3DD.%2BR.%26atitle%3DMechanism-based%2520inactivation%2520of%2520CYP3A%2520by%2520HIV%2520protease%2520inhibitors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D312%26spage%3D583%26epage%3D591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Lillibridge, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quart, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shetty, B. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. A.</span><span> </span><span class="NLM_article-title">Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus protease inhibitor nelfinavir mesylate</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">–</span> <span class="NLM_lpage">616</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1998&pages=609-616&author=J.+H.+Lillibridgeauthor=B.+H.+Liangauthor=B.+M.+Kerrauthor=S.+Webberauthor=B.+Quartauthor=B.+V.+Shettyauthor=C.+A.+Lee&title=Characterization+of+the+selectivity+and+mechanism+of+human+cytochrome+P450+inhibition+by+the+human+immunodeficiency+virus+protease+inhibitor+nelfinavir+mesylate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLillibridge%26aufirst%3DJ.%2BH.%26aulast%3DLiang%26aufirst%3DB.%2BH.%26aulast%3DKerr%26aufirst%3DB.%2BM.%26aulast%3DWebber%26aufirst%3DS.%26aulast%3DQuart%26aufirst%3DB.%26aulast%3DShetty%26aufirst%3DB.%2BV.%26aulast%3DLee%26aufirst%3DC.%2BA.%26atitle%3DCharacterization%2520of%2520the%2520selectivity%2520and%2520mechanism%2520of%2520human%2520cytochrome%2520P450%2520inhibition%2520by%2520the%2520human%2520immunodeficiency%2520virus%2520protease%2520inhibitor%2520nelfinavir%2520mesylate%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1998%26volume%3D26%26spage%3D609%26epage%3D616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Kempf, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denissen, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukulka, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granneman, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baroldi, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pizzuti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plattner, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norbeck, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, J. M.</span><span> </span><span class="NLM_article-title">Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">654</span><span class="NLM_x">–</span> <span class="NLM_lpage">660</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1997&pages=654-660&author=D.+J.+Kempfauthor=K.+C.+Marshauthor=G.+Kumarauthor=A.+D.+Rodriguesauthor=J.+F.+Denissenauthor=E.+McDonaldauthor=M.+J.+Kukulkaauthor=A.+Hsuauthor=G.+R.+Grannemanauthor=P.+A.+Baroldiauthor=E.+Sunauthor=D.+Pizzutiauthor=J.+J.+Plattnerauthor=D.+W.+Norbeckauthor=J.+M.+Leonard&title=Pharmacokinetic+enhancement+of+inhibitors+of+the+human+immunodeficiency+virus+protease+by+coadministration+with+ritonavir"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKempf%26aufirst%3DD.%2BJ.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DKumar%26aufirst%3DG.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26aulast%3DDenissen%26aufirst%3DJ.%2BF.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DKukulka%26aufirst%3DM.%2BJ.%26aulast%3DHsu%26aufirst%3DA.%26aulast%3DGranneman%26aufirst%3DG.%2BR.%26aulast%3DBaroldi%26aufirst%3DP.%2BA.%26aulast%3DSun%26aufirst%3DE.%26aulast%3DPizzuti%26aufirst%3DD.%26aulast%3DPlattner%26aufirst%3DJ.%2BJ.%26aulast%3DNorbeck%26aufirst%3DD.%2BW.%26aulast%3DLeonard%26aufirst%3DJ.%2BM.%26atitle%3DPharmacokinetic%2520enhancement%2520of%2520inhibitors%2520of%2520the%2520human%2520immunodeficiency%2520virus%2520protease%2520by%2520coadministration%2520with%2520ritonavir%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1997%26volume%3D41%26spage%3D654%26epage%3D660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J.</span><span> </span><span class="NLM_article-title">Metabolomic screening and identification of bioactivation pathways of ritonavir</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2109</span><span class="NLM_x">–</span> <span class="NLM_lpage">2114</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=2109-2114&author=X.+Maauthor=F.+Liauthor=J.+Lu&title=Metabolomic+screening+and+identification+of+bioactivation+pathways+of+ritonavir"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DJ.%26atitle%3DMetabolomic%2520screening%2520and%2520identification%2520of%2520bioactivation%2520pathways%2520of%2520ritonavir%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D2109%26epage%3D2114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Mathias, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">German, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kearney, B. P.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity</span> <span class="citation_source-journal">Clin. Pharmacol. Ther</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">322</span><span class="NLM_x">–</span> <span class="NLM_lpage">329</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1038%2Fclpt.2009.228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=20043009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitVSqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2010&pages=322-329&author=A.+A.+Mathiasauthor=P.+Germanauthor=B.+P.+Murrayauthor=L.+Weiauthor=A.+Jainauthor=S.+Westauthor=D.+Warrenauthor=J.+Huiauthor=B.+P.+Kearney&title=Pharmacokinetics+and+pharmacodynamics+of+GS-9350%3A+a+novel+pharmacokinetic+enhancer+without+anti-HIV+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer without Anti-HIV Activity</span></div><div class="casAuthors">Mathias, A. A.; German, P.; Murray, B. P.; Wei, L.; Jain, A.; West, S.; Warren, D.; Hui, J.; Kearney, B. P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">322-329</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">GS-9350 is a new chem. entity under development as a potent, mechanism-based inhibitor of human cytochrome P 450 3A (CYP3A) isoforms.  Its intended use is to increase the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes.  Unlike ritonavir, which is in current clin. use for this purpose, GS-9350 is devoid of anti-HIV activity.  The pharmacokinetics of GS-9350 and its efficacy in increasing systemic exposure of the probe CYP3A substrate midazolam were examd. in a study involving single- and multiple-dose escalations of GS-9350 from 50 to 400 mg.  Single-dose escalation from 50 to 400 mg resulted in a 164-fold increase in GS-9350 exposure, whereas multiple-dose escalation in the dosage range of 50-300 mg resulted in a 47-fold increase in exposure.  GS-9350 potently inhibited midazolam apparent clearance (95% redn.), similar in effect to ritonavir 100 mg.  GS-9350 was generally well tolerated at all doses, and there was no evidence of dose-limiting toxicity.  Establishing proof-of-concept, GS-9350 is currently under phase II development as a potential alternative to ritonavir for use with antiretroviral agents (including the HIV integrase inhibitor elvitegravir) that are often prescribed along with a "booster" drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIdpdocXWNQbVg90H21EOLACvtfcHk0lhoLWKfuPa9Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitVSqtbw%253D&md5=1cc99e46f1178edb9507664fc19406b7</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2009.228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2009.228%26sid%3Dliteratum%253Aachs%26aulast%3DMathias%26aufirst%3DA.%2BA.%26aulast%3DGerman%26aufirst%3DP.%26aulast%3DMurray%26aufirst%3DB.%2BP.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DJain%26aufirst%3DA.%26aulast%3DWest%26aufirst%3DS.%26aulast%3DWarren%26aufirst%3DD.%26aulast%3DHui%26aufirst%3DJ.%26aulast%3DKearney%26aufirst%3DB.%2BP.%26atitle%3DPharmacokinetics%2520and%2520pharmacodynamics%2520of%2520GS-9350%253A%2520a%2520novel%2520pharmacokinetic%2520enhancer%2520without%2520anti-HIV%2520activity%26jtitle%3DClin.%2520Pharmacol.%2520Ther%26date%3D2010%26volume%3D87%26spage%3D322%26epage%3D329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaz, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lame, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soglia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abramov, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendsch, Z. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hop, C. E.</span><span> </span><span class="NLM_article-title">Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P4503A4</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=243-253&author=A.+S.+Kalgutkarauthor=A.+D.+Vazauthor=M.+E.+Lameauthor=K.+R.+Henneauthor=J.+Sogliaauthor=S.+X.+Zhaoauthor=Y.+A.+Abramovauthor=F.+Lombardoauthor=C.+Collinauthor=Z.+S.+Hendschauthor=C.+E.+Hop&title=Bioactivation+of+the+nontricyclic+antidepressant+nefazodone+to+a+reactive+quinone-imine+species+in+human+liver+microsomes+and+recombinant+cytochrome+P4503A4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DVaz%26aufirst%3DA.%2BD.%26aulast%3DLame%26aufirst%3DM.%2BE.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DSoglia%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DAbramov%26aufirst%3DY.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DCollin%26aufirst%3DC.%26aulast%3DHendsch%26aufirst%3DZ.%2BS.%26aulast%3DHop%26aufirst%3DC.%2BE.%26atitle%3DBioactivation%2520of%2520the%2520nontricyclic%2520antidepressant%2520nefazodone%2520to%2520a%2520reactive%2520quinone-imine%2520species%2520in%2520human%2520liver%2520microsomes%2520and%2520recombinant%2520cytochrome%2520P4503A4%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D243%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Bauman, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawant, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsky, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span> </span><span class="NLM_article-title">Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1016</span><span class="NLM_x">–</span> <span class="NLM_lpage">1029</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1124%2Fdmd.108.020545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=18332080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVOmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1016-1029&author=J.+N.+Baumanauthor=K.+S.+Frederickauthor=A.+Sawantauthor=R.+L.+Walskyauthor=L.+M.+Coxauthor=R.+S.+Obachauthor=A.+S.+Kalgutkar&title=Comparison+of+the+bioactivation+potential+of+the+antidepressant+and+hepatotoxin+nefazodone+with+aripiprazole%2C+a+structural+analog+and+marketed+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug</span></div><div class="casAuthors">Bauman, Jonathan N.; Frederick, Kosea S.; Sawant, Aarti; Walsky, Robert L.; Cox, Loretta M.; Obach, Ronald S.; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1016-1029</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In vitro metab./bioactivation of structurally related central nervous system agents nefazodone (hepatotoxin) and aripiprazole (nonhepatotoxin) were undertaken in human liver microsomes in an attempt to understand the differences in toxicol. profile.  NADPH-supplemented microsomal incubations of nefazodone and glutathione generated conjugates derived from addn. of thiol to quinonoid intermediates.  Inclusion of cyanide afforded cyano conjugates to iminium ions derived from α-carbon oxidn. of the piperazine ring in nefazodone and downstream metabolites.  Although the arylpiperazine motif in aripiprazole did not succumb to bioactivation, the dihydroquinolinone group was bioactivated via an intermediate monohydroxy metabolite to a reactive species, which was trapped by glutathione.  Studies with synthetic dehydroaripiprazole metabolite revealed an analogous glutathione conjugate with mol. wt. 2 Da lower.  Based on the proposed structure of the glutathione conjugate(s), a bioactivation sequence involving arom. ortho- or para-hydroxylation on the quinolinone followed by oxidn. to a quinone-imine was proposed.  P 4503A4 inactivation studies in microsomes indicated that, unlike nefazodone, aripiprazole was not a time- and concn.-dependent inactivator of the enzyme.  Overall, these studies reinforce the notion that not all drugs that are bioactivated in vitro elicit a toxicol. response in vivo.  A likely explanation for the markedly improved safety profile of aripiprazole (vs. nefazodone) despite the accompanying bioactivation liability is the vastly improved pharmacokinetics (enhanced oral bioavailability, longer elimination half-life) due to reduced P 4503A4-mediated metab./bioactivation, which result in a lower daily dose (5-20 mg/day) compared with nefazodone (200-400 mg/day).  This attribute probably reduces the total body burden to reactive metabolite exposure and may not exceed a threshold needed for toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVpVGcV7pKb7Vg90H21EOLACvtfcHk0lg1CKTF6XdhaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVOmtbo%253D&md5=fbc3413e2855e61631687d253971a08c</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.020545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.020545%26sid%3Dliteratum%253Aachs%26aulast%3DBauman%26aufirst%3DJ.%2BN.%26aulast%3DFrederick%26aufirst%3DK.%2BS.%26aulast%3DSawant%26aufirst%3DA.%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DCox%26aufirst%3DL.%2BM.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DComparison%2520of%2520the%2520bioactivation%2520potential%2520of%2520the%2520antidepressant%2520and%2520hepatotoxin%2520nefazodone%2520with%2520aripiprazole%252C%2520a%2520structural%2520analog%2520and%2520marketed%2520drug%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D1016%26epage%3D1029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Greene, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbhaiya, R. H.</span><span> </span><span class="NLM_article-title">Clinical pharmacokinetics of nefazodone</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2165%2F00003088-199733040-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=9342502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK2sXntVGgtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1997&pages=260-275&author=D.+S.+Greeneauthor=R.+H.+Barbhaiya&title=Clinical+pharmacokinetics+of+nefazodone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of nefazodone</span></div><div class="casAuthors">Greene, Douglas S.; Barbhaiya, Rashmi H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">260-275</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">A review with 51 refs.  Nefazodone is a new antidepressant drug, chem. unrelated to the tricyclic, tetracyclic or selective serotonin uptake inhibitors.  Nefazodone blocks the serotonin 5-HT2 receptors and reversibly inhibits serotonin reuptake in vivo.  Nefazodone is completely and rapidly absorbed after oral administration with a peak plasma concn. obsd. within 2 h of administration.  Nefazodone undergoes significant first-pass metab. resulting in an oral bioavailability of approx. 20%.  Although there is an 18% increase in nefazodone bioavailability with food, this increase is not clin. significant and nefazodone can be administered without regard to meals.  Three pharmacol. active nefazodone metabolites have been identified: hydroxy-nefazodone, triazoledione and m-chlorophenylpiperazine (mCPP).  The pharmacokinetics of nefazodone are nonlinear.  The increase in plasma concns. of nefazodone are greater than would be expected if they were proportional to increases in dose.  Steady-state plasma concns. of nefazodone are attained within 4 days of the commencement of administration.  The pharmacokinetics of nefazodone are not appreciably altered in patients with renal or mild-to-moderate hepatic impairment.  However, nefazodone plasma concns. are increased in severe hepatic impairment and in the elderly, esp. in elderly females.  Lower doses of nefazodone may be necessary in these groups.  Nefazodone is a weak inhibitor of cytochrome P 450 (CYP) 2D6 and does not inhibit CYP1A2.  It is not anticipated that nefazodone will interact with drugs cleared by these isoenzymes.  Indeed, nefazodone did not affect the pharmacokinetics of theophylline, a compd. cleared by CYP1A2.  Nefazodone is metabolized by and inhibits CYP3A4.  Clin. significant interactions have been obsd. between nefazodone and the benzodiazepines triazolam and alprazolam, cyclosporin and carbamazepine.  The potential for a clin. significant interaction between nefazodone and other drugs cleared by CYP3A4 (e.g. terfenadine) should be considered before the coadministration of these compds.  There was an increase in haloperidol plasma concns. when coadministered with nefazodone; nefazodone pharmacokinetics were not affected after coadministration.  No clin. significant interaction was obsd. when nefazodone was administered with lorazepam, lithium, alc., cimetidine, warfarin, theophylline or propranolol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowyKhx9mQWVrVg90H21EOLACvtfcHk0lg1CKTF6XdhaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXntVGgtrk%253D&md5=a5606549e2a64ad8d479197334bc3b65</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.2165%2F00003088-199733040-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199733040-00002%26sid%3Dliteratum%253Aachs%26aulast%3DGreene%26aufirst%3DD.%2BS.%26aulast%3DBarbhaiya%26aufirst%3DR.%2BH.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520nefazodone%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1997%26volume%3D33%26spage%3D260%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">DeVane, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donovan, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liston, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markowitz, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risch, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willard, L.</span><span> </span><span class="NLM_article-title">Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers</span> <span class="citation_source-journal">J. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1097%2F01.jcp.0000104908.75206.26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=14709940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtlCmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=4-10&author=C.+L.+DeVaneauthor=J.+L.+Donovanauthor=H.+L.+Listonauthor=J.+S.+Markowitzauthor=K.+T.+Chengauthor=S.+C.+Rischauthor=L.+Willard&title=Comparative+CYP3A4+inhibitory+effects+of+venlafaxine%2C+fluoxetine%2C+sertraline%2C+and+nefazodone+in+healthy+volunteers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative CYP3A4 Inhibitory Effects of Venlafaxine, Fluoxetine, Sertraline, and Nefazodone in Healthy Volunteers</span></div><div class="casAuthors">DeVane, C. Lindsay; Donovan, Jennifer L.; Liston, Heidi L.; Markowitz, John S.; Cheng, Kenneth T.; Risch, S. Craig; Willard, Lauren</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-10</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">An antidepressant for use in the patient receiving concomitant drug treatment, over-the-counter medications, or herbal products should lack cytochrome P 450 (CYP) 3A4 inductive or inhibitory activity to provide the least likelihood of a drug-drug interaction.  This study addresses the potential of 4 diverse antidepressants (venlafaxine, nefazodone, sertraline, and fluoxetine) to inhibit or induce CYP3A4.  In a 4-way crossover design, 16 subjects received clin. relevant doses of venlafaxine, nefazodone, or sertraline for 8 days or fluoxetine for 11 days.  Treatments were sepd. by a 7- to 14-day washout period and fluoxetine was always the last antidepressant taken.  CYP3A4 activity was evaluated for each subject at baseline and following each antidepressant using the erythromycin breath test (EBT) and by the pharmacokinetics of alprazolam (ALPZ) after 2-mg dose of oral ALPZ.  Compared to baseline, venlafaxine, sertraline, and fluoxetine caused no apparent inhibition or induction of erythromycin metab. (P > 0.05).  For nefazodone, a statistically significant inhibition was obsd. (P < 0.0005).  Nefazodone was also the only antidepressant that caused a significant change in ALPZ disposition, decreasing its area under the concn.-vs.-time curve (AUC; P < 0.01), and increasing its elimination half-life (16.4 vs. 12.3 h; P < 0.05) compared with values at baseline.  No significant differences were found in the pharmacokinetics of ALPZ with any of the other antidepressants tested.  These results demonstrate in vivo that, unlike nefazodone, venlafaxine, sertraline, and fluoxetine do not possess significant metabolic inductive or inhibitory effects on CYP3A4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQJt9i-5P-L7Vg90H21EOLACvtfcHk0lg1CKTF6XdhaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtlCmsw%253D%253D&md5=a445f0a02a02c9e17710a691b5e1ffab</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1097%2F01.jcp.0000104908.75206.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.jcp.0000104908.75206.26%26sid%3Dliteratum%253Aachs%26aulast%3DDeVane%26aufirst%3DC.%2BL.%26aulast%3DDonovan%26aufirst%3DJ.%2BL.%26aulast%3DListon%26aufirst%3DH.%2BL.%26aulast%3DMarkowitz%26aufirst%3DJ.%2BS.%26aulast%3DCheng%26aufirst%3DK.%2BT.%26aulast%3DRisch%26aufirst%3DS.%2BC.%26aulast%3DWillard%26aufirst%3DL.%26atitle%3DComparative%2520CYP3A4%2520inhibitory%2520effects%2520of%2520venlafaxine%252C%2520fluoxetine%252C%2520sertraline%252C%2520and%2520nefazodone%2520in%2520healthy%2520volunteers%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2004%26volume%3D24%26spage%3D4%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Thompson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuels, S.</span><span> </span><span class="NLM_article-title">Rhabdomyolysis with simvastatin and nefazodone</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x">, </span> <span class="NLM_fpage">1607</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1176%2Fappi.ajp.159.9.1607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=12202291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A280%3ADC%252BD38vmtFSmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2002&pages=1607&author=M.+Thompsonauthor=S.+Samuels&title=Rhabdomyolysis+with+simvastatin+and+nefazodone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Rhabdomyolysis with simvastatin and nefazodone</span></div><div class="casAuthors">Thompson Matthew; Samuels Steven</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1607</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSy_jgJgoceo2gRQsDqrjW_fW6udTcc2eYpJz20sGdwbLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vmtFSmsQ%253D%253D&md5=c278a93efbdc46c4b662bab559713dc4</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.159.9.1607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.159.9.1607%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DM.%26aulast%3DSamuels%26aufirst%3DS.%26atitle%3DRhabdomyolysis%2520with%2520simvastatin%2520and%2520nefazodone%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2002%26volume%3D159%26spage%3D1607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Choi, S.</span><span> </span><span class="NLM_article-title">Nefazodone (Serzone) withdrawn because of hepatotoxicity</span> <span class="citation_source-journal">Can. Med. Assoc. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">169</span><span class="NLM_x">, </span> <span class="NLM_fpage">1187</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=14638657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A280%3ADC%252BD3srls1yqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2003&pages=1187&author=S.+Choi&title=Nefazodone+%28Serzone%29+withdrawn+because+of+hepatotoxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Nefazodone (Serzone) withdrawn because of hepatotoxicity</span></div><div class="casAuthors">Choi Stephen</div><div class="citationInfo"><span class="NLM_cas:title">CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1187</span>
        ISSN:<span class="NLM_cas:issn">0820-3946</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkxphSHq9grg5nADWVYHg1fW6udTcc2eYpJz20sGdwbLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3srls1yqtw%253D%253D&md5=5d755f54ddfc2569e2ce16aabd6e4371</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DS.%26atitle%3DNefazodone%2520%2528Serzone%2529%2520withdrawn%2520because%2520of%2520hepatotoxicity%26jtitle%3DCan.%2520Med.%2520Assoc.%2520J.%26date%3D2003%26volume%3D169%26spage%3D1187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soglia, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S. X.</span><span> </span><span class="NLM_article-title">Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1814</span><span class="NLM_x">–</span> <span class="NLM_lpage">1822</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx800161s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Knurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=1814-1822&author=R.+S.+Obachauthor=A.+S.+Kalgutkarauthor=J.+R.+Sogliaauthor=S.+X.+Zhao&title=Can+in+vitro+metabolism-dependent+covalent+binding+data+in+liver+microsomes+distinguish+hepatotoxic+from+nonhepatotoxic+drugs%3F+An+analysis+of+18+drugs+with+consideration+of+intrinsic+clearance+and+daily+dose"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Can In Vitro Metabolism-Dependent Covalent Binding Data in Liver Microsomes Distinguish Hepatotoxic from Nonhepatotoxic Drugs? An Analysis of 18 Drugs with Consideration of Intrinsic Clearance and Daily Dose</span></div><div class="casAuthors">Obach, R. Scott; Kalgutkar, Amit S.; Soglia, John R.; Zhao, Sabrina X.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1814-1822</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In vitro covalent binding assessments of drugs have been useful in providing retrospective insights into the assocn. between drug metab. and a resulting toxicol. response.  On the basis of these studies, it has been advocated that in vitro covalent binding to liver microsomal proteins in the presence and the absence of NADPH be used routinely to screen drug candidates.  However, the utility of this approach in predicting toxicities of drug candidates accurately remains an unanswered question.  Importantly, the years of research that have been invested in understanding metabolic bioactivation and covalent binding and its potential role in toxicity have focused only on those compds. that demonstrate toxicity.  Investigations have not frequently queried whether in vitro covalent binding could be obsd. with drugs with good safety records.  Eighteen drugs (nine hepatotoxins and nine nonhepatotoxins in humans) were assessed for in vitro covalent binding in NADPH-supplemented human liver microsomes.  Of the two sets of nine drugs, seven in each set were shown to undergo some degree of covalent binding.  Among hepatotoxic drugs, acetaminophen, carbamazepine, diclofenac, indomethacin, nefazodone, sudoxicam, and tienilic acid demonstrated covalent binding, while benoxaprofen and felbamate did not.  Of the nonhepatotoxic drugs evaluated, buspirone, diphenhydramine, meloxicam, paroxetine, propranolol, raloxifene, and simvastatin demonstrated covalent binding, while ibuprofen and theophylline did not.  A quant. comparison of covalent binding in vitro intrinsic clearance did not sep. the two groups of compds., and in fact, paroxetine, a nonhepatotoxin, showed the greatest amt. of covalent binding in microsomes.  Including factors such as the fraction of total metab. comprised by covalent binding and the total daily dose of each drug improved the discrimination between hepatotoxic and nontoxic drugs based on in vitro covalent binding data; however, the approach still would falsely identify some agents as potentially hepatotoxic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9_hVRAC3RD7Vg90H21EOLACvtfcHk0lj2qAP82kdPSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Knurw%253D&md5=67c82883825ef529c84d03f462b1f669</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Ftx800161s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx800161s%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26atitle%3DCan%2520in%2520vitro%2520metabolism-dependent%2520covalent%2520binding%2520data%2520in%2520liver%2520microsomes%2520distinguish%2520hepatotoxic%2520from%2520nonhepatotoxic%2520drugs%253F%2520An%2520analysis%2520of%252018%2520drugs%2520with%2520consideration%2520of%2520intrinsic%2520clearance%2520and%2520daily%2520dose%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D1814%26epage%3D1822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Zimmerlin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trunzer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faller, B.</span><span> </span><span class="NLM_article-title">CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1046</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1039-1046&author=A.+Zimmerlinauthor=M.+Trunzerauthor=B.+Faller&title=CYP3A+time-dependent+inhibition+risk+assessment+validated+with+400+reference+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DTrunzer%26aufirst%3DM.%26aulast%3DFaller%26aufirst%3DB.%26atitle%3DCYP3A%2520time-dependent%2520inhibition%2520risk%2520assessment%2520validated%2520with%2520400%2520reference%2520drugs%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1039%26epage%3D1046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lame, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaz, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soglia, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hop, C. E.</span><span> </span><span class="NLM_article-title">Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4</span> <span class="citation_source-journal">Chem.-Biol. Interact.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">155</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.cbi.2005.03.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15978881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFGisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2005&pages=10-20&author=A.+S.+Kalgutkarauthor=K.+R.+Henneauthor=M.+E.+Lameauthor=A.+D.+Vazauthor=C.+Collinauthor=J.+R.+Sogliaauthor=S.+X.+Zhaoauthor=C.+E.+Hop&title=Metabolic+activation+of+the+nontricyclic+antidepressant+trazodone+to+electrophilic+quinone-imine+and+epoxide+intermediates+in+human+liver+microsomes+and+recombinant+P4503A4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P450 3A4</span></div><div class="casAuthors">Kalgutkar, Amit S.; Henne, Kirk R.; Lame, Mary E.; Vaz, Alfin D. N.; Collin, Claire; Soglia, John R.; Zhao, Sabrina X.; Hop, Cornelis E. C. A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">10-20</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Therapy with the antidepressant trazodone has been assocd. with several cases of idiosyncratic hepatotoxicity.  While the mechanism of hepatotoxicity remains unknown, it is possible that reactive metabolites of trazodone play a causative role.  Studies were initiated to det. whether trazodone undergoes bioactivation in human liver microsomes to electrophilic intermediates.  LC/MS/MS anal. of incubations contg. trazodone and NADPH-supplemented microsomes or recombinant P 4503A4 in the presence of glutathione revealed the formation of conjugates derived from the addn. of the sulfydryl nucleophile to mono-hydroxylated- and hydrated-trazodone metabolites.  Product ion spectra suggested that mono-hydroxylation and sulfydryl conjugation occurred on the 3-chlorophenyl-ring, whereas hydration and subsequent sulfydryl conjugation had occurred on the triazolopyridinone ring system.  These findings are consistent with bioactivation sequences involving: (1) arom. hydroxylation of the 3-chlorophenyl-ring in trazodone followed by the two-electron oxidn. of this metabolite to a reactive quinone-imine intermediate, which reacts with glutathione in a 1,4-Michael fashion and (2) oxidn. of the pyridinone ring to an electrophilic epoxide, ring opening of which, by glutathione or water generates the corresponding hydrated-trazodone-thiol conjugate or the stable diol metabolite, resp.  The pathway involving trazodone bioactivation to the quinone-imine has also been obsd. with many para-hydroxyanilines including the structurally related antidepressant nefazodone.  It is proposed that the quinone-imine and/or the epoxide intermediate(s) may represent a rate-limiting step in the initiation of trazodone-mediated hepatotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolswLWloW_gbVg90H21EOLACvtfcHk0liMyzd4D_JVMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFGisLk%253D&md5=eac3b8b1c4e8710f6f4fc653a15e6e7d</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2005.03.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2005.03.036%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DLame%26aufirst%3DM.%2BE.%26aulast%3DVaz%26aufirst%3DA.%2BD.%26aulast%3DCollin%26aufirst%3DC.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DHop%26aufirst%3DC.%2BE.%26atitle%3DMetabolic%2520activation%2520of%2520the%2520nontricyclic%2520antidepressant%2520trazodone%2520to%2520electrophilic%2520quinone-imine%2520and%2520epoxide%2520intermediates%2520in%2520human%2520liver%2520microsomes%2520and%2520recombinant%2520P4503A4%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2005%26volume%3D155%26spage%3D10%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Di Gion, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanefendt, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheffler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshyenko, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuhr, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaehde, U.</span><span> </span><span class="NLM_article-title">Clinical pharmacokinetics of tyrosine kinase inhibitors</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">551</span><span class="NLM_x">–</span> <span class="NLM_lpage">603</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2165%2F11593320-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=21827214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1KrsLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=551-603&author=P.+Di+Gionauthor=F.+Kanefendtauthor=A.+Lindauerauthor=M.+Schefflerauthor=O.+Doroshyenkoauthor=U.+Fuhrauthor=J.+Wolfauthor=U.+Jaehde&title=Clinical+pharmacokinetics+of+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles</span></div><div class="casAuthors">Di Gion, Paola; Kanefendt, Friederike; Lindauer, Andreas; Scheffler, Matthias; Doroshyenko, Oxana; Fuhr, Uwe; Wolf, Juergen; Jaehde, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">551-603</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  Pyrimidine (imatinib, dasatinib, nilotinib and pazopanib), pyridine (sorafenib) and pyrrole (sunitinib) tyrosine kinase inhibitors (TKIs) are multi-targeted TKIs with high activity towards several families of receptor and non-receptor tyrosine kinases involved in angiogenesis, tumor growth and metastatic progression of cancer.  These orally administered TKIs have quite diverse characteristics with regard to absorption from the gastrointestinal tract.  Abs. bioavailability in humans has been investigated only for imatinib (almost 100%) and pazopanib (14-39%; n = 3).  On the basis of human radioactivity data, dasatinib is considered to be well absorbed after oral administration (19% and 0.1% of the total radioactivity were excreted as unchanged dasatinib in the faeces and urine, resp.).  Quite low abs. bioavailability under fasted conditions is assumed for nilotinib (31%), sorafenib (50%) and sunitinib (50%).  Imatinib, dasatinib and sunitinib exhibit dose-proportional increases in their area under the plasma concn.-time curve values over their therapeutic dose ranges.  Less than dose-proportional increases were obsd. for nilotinib at doses ≥400 mg/day and for sorafenib and pazopanib at doses ≥800 mg/day.  At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).  Concomitant intake of a high-fat meal does not alter exposure to imatinib, dasatinib and sunitinib but leads to considerably increased bioavailability of nilotinib and pazopanib and decreased bioavailability of sorafenib.  With the exception of pazopanib, the TKIs described here have large apparent vols. of distribution, exceeding the vol. of body water by at least 4-fold.  Very low penetration into the central nervous system in humans has been reported for imatinib and dasatinib, but there are currently no published human data for nilotinib, pazopanib, sorafenib or sunitinib.  All TKIs that have been described are more than 90% bound to the plasma proteins: α1-acid glycoprotein and/or albumin.  They are metabolized primarily via cytochrome P 450 (CYP) 3A4, the only exception being sorafenib, for which uridine diphosphate glucuronosyltransferase 1A9 is the other main enzyme involved.  Active metabolites of imatinib and sunitinib contribute to their antitumor activity.  Although some patient demographics have been identified as significant co-factors that partly explain interindividual variability in exposure to TKIs, these findings have not been regarded as sufficient to recommend age-, sex-, bodyweight- or ethnicity-specific dose adjustment.  Systemic exposure to imatinib, sorafenib and pazopanib increases in patients with hepatic impairment, and redn. of the initial therapeutic dose is recommended in this subpopulation.  The starting dose of imatinib should also be reduced in renally impaired subjects.  Because the soly. of dasatinib is pH dependent, co-administration of histamine H2-receptor antagonists and proton pump inhibitors with dasatinib should be avoided.  With the exception of sorafenib, systemic exposure to TKIs is significantly decreased/increased by co-administration of potent CYP3A4 inducers/inhibitors, and so it is strongly recommended that the TKI dose is adjusted or that such co-administration is avoided.  Caution is also recommended for co-administration of CYP3A4 substrates with TKIs, esp. for those with a narrow therapeutic index.  However, current recommendations with regard to dose adjustment of TKIs need to be validated in clin. studies.  Further investigations are needed to explain the large interindividual variability in the pharmacokinetics of these drugs and to assess the clin. relevance of their interaction potential and inhibitory effects on metabolizing enzymes and transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowEdzHq6mAsbVg90H21EOLACvtfcHk0liMyzd4D_JVMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1KrsLrF&md5=4a49fcb300a03c49a9ac58bc31d1edbe</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.2165%2F11593320-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11593320-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BGion%26aufirst%3DP.%26aulast%3DKanefendt%26aufirst%3DF.%26aulast%3DLindauer%26aufirst%3DA.%26aulast%3DScheffler%26aufirst%3DM.%26aulast%3DDoroshyenko%26aufirst%3DO.%26aulast%3DFuhr%26aufirst%3DU.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DJaehde%26aufirst%3DU.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2011%26volume%3D50%26spage%3D551%26epage%3D603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">O’Brien, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinhardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bond, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutreix, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehring, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milosavljev, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, T.</span><span> </span><span class="NLM_article-title">Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">1855</span><span class="NLM_x">–</span> <span class="NLM_lpage">1859</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1038%2Fsj.bjc.6601152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=14612892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVersrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2003&pages=1855-1859&author=S.+G.+O%E2%80%99Brienauthor=P.+Meinhardtauthor=E.+Bondauthor=J.+Beckauthor=B.+Pengauthor=C.+Dutreixauthor=G.+Mehringauthor=S.+Milosavljevauthor=C.+Huberauthor=R.+Capdevilleauthor=T.+Fischer&title=Effects+of+imatinib+mesylate+%28STI571%2C+Glivec%29+on+the+pharmacokinetics+of+simvastatin%2C+a+cytochrome+P450+3A4+substrate%2C+in+patients+with+chronic+myeloid+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia</span></div><div class="casAuthors">O'Brien, S. G.; Meinhardt, P.; Bond, E.; Beck, J.; Peng, B.; Dutreix, C.; Mehring, G.; Milosavljev, S.; Huber, C.; Capdeville, R.; Fischer, T.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1855-1859</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The inhibition by imatinib of the cytochrome P 450 3A4 isoenzyme may reduce the CYP3A4-mediated metabolic clearance of clin. important coadministered drugs.  The main purpose of this study was to evaluate the effect of the coadministration of imatinib on the pharmacokinetics of simvastatin, a probe CYP3A4 substrate.  In total, 20 patients with chronic myeloid leukemia received an oral dose of 40 mg of simvastatin on study day 1.  On study days 2-7, each patient received 400 mg of imatinib once daily orally and on study day 8, 400 mg imatinib together with 40 mg of simvastatin was given.  Blood levels of simvastatin were measured predose and for 24 h postdose on study days 1 and 8.  Two addnl. blood samples were taken for imatinib pharmacokinetic (PK) assessment on day 8 before, and 24 h after, imatinib administration.  Imatinib increased the mean max. concn. (Cmax) value of simvastatin two-fold and the area under concn.-time curve (AUC (0-inf)) value 3.5-fold (P<0.001) compared with simvastatin alone.  There was a statistically significant decrease in total-body clearance of drug from the plasma (CL/F) with a mean redn. of 70% for simvastatin (P<0.001): the mean half-life of simvastatin was prolonged from 1.4-2.7 h when given together with imatinib.  No changes in imatinib PK parameters were found when given concomitantly with simvastatin.  In conclusion, the coadministration of imatinib at steady state with 40 mg simvastatin increases the exposure (Cmax and AUCs) of simvastatin significantly (P<0.001) by two-three-fold.  Caution is therefore required when administering imatinib with CYP3A4 substrates with a narrow therapeutic window.  The coadministration of simvastatin with imatinib (400 mg) was well tolerated and no major safety findings were reported in this study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6n6TNNlDup7Vg90H21EOLACvtfcHk0liMyzd4D_JVMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVersrs%253D&md5=3d0fcc73b4d5609907bb22c8c3aab2c4</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6601152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6601152%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BG.%26aulast%3DMeinhardt%26aufirst%3DP.%26aulast%3DBond%26aufirst%3DE.%26aulast%3DBeck%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DDutreix%26aufirst%3DC.%26aulast%3DMehring%26aufirst%3DG.%26aulast%3DMilosavljev%26aufirst%3DS.%26aulast%3DHuber%26aufirst%3DC.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DFischer%26aufirst%3DT.%26atitle%3DEffects%2520of%2520imatinib%2520mesylate%2520%2528STI571%252C%2520Glivec%2529%2520on%2520the%2520pharmacokinetics%2520of%2520simvastatin%252C%2520a%2520cytochrome%2520P450%25203A4%2520substrate%252C%2520in%2520patients%2520with%2520chronic%2520myeloid%2520leukaemia%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2003%26volume%3D89%26spage%3D1855%26epage%3D1859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Connolly, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett-Mayer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeter, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donehower, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fetting, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emens, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stearns, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolff, A. C.</span><span> </span><span class="NLM_article-title">Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1007%2Fs10549-011-1413-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=21350820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksFegt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2011&pages=153-162&author=R.+M.+Connollyauthor=M.+A.+Rudekauthor=E.+Garrett-Mayerauthor=S.+C.+Jeterauthor=M.+G.+Donehowerauthor=L.+A.+Wrightauthor=M.+Zhaoauthor=J.+H.+Fettingauthor=L.+A.+Emensauthor=V.+Stearnsauthor=N.+E.+Davidsonauthor=S.+D.+Bakerauthor=A.+C.+Wolff&title=Docetaxel+metabolism+is+not+altered+by+imatinib%3A+findings+from+an+early+phase+study+in+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer</span></div><div class="casAuthors">Connolly, Roisin M.; Rudek, Michelle A.; Garrett-Mayer, Elizabeth; Jeter, Stacie C.; Donehower, Michele G.; Wright, Laurie A.; Zhao, Ming; Fetting, John H.; Emens, Leisha A.; Stearns, Vered; Davidson, Nancy E.; Baker, Sharyn D.; Wolff, Antonio C.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">153-162</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Docetaxel is primarily metabolized by CYP3A4 and susceptible to alterations in clearance by CYP3A4 inhibition and induction.  Imatinib is a CYP3A4 inhibitor.  A phase I study of docetaxel and imatinib in metastatic breast cancer (MBC) was conducted to test the hypothesis that imatinib decreased docetaxel clearance.  Docetaxel was administered weekly × 3 with daily imatinib, repeated every 28 days; during cycle 1, imatinib was started on day 8.  Docetaxel and imatinib pharmacokinetics, and hepatic CYP3A4 activity (erythromycin breath test) were evaluated during cycles 1 and 2.  Toxicity and efficacy were assessed.  Twelve patients were enrolled to three docetaxel/imatinib dose levels: 20 mg/m2/600 mg (DL1), 25 mg/m2/600 mg (DL2), and 25 mg/m2/400 mg (DL2a).  Median no. of prior chemotherapy regimens was 2 (range, 0-8).  Toxicities were primarily obsd. at DL2; dose-limiting toxicities were Grade 3 transaminase elevations and diarrhea, and 5 patients had grade 2 nausea.  Two patients had partial responses (7 mo); two stable disease (2 and 4 mo); five had progressive disease.  Despite a 42% decrease in CYP3A4 activity after 3 wk of imatinib co-administration, docetaxel clearance was unchanged.  Mean ± std. deviation steady-state imatinib trough concn. (2.6 ± 1.2 μg/mL) was approx. 2.6-fold higher than previously obsd. in other cancer populations, and likely contributed to the poor tolerability of the combination in MBC.  In conclusion, imatinib inhibited CYP3A4 but did not affect docetaxel clearance.  Clin., further investigation of this combination in MBC is not warranted due to excessive toxicities.  However, these unexpected pharmacokinetic findings support further investigation of mechanisms underlying docetaxel elimination pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTISM9lNnY77Vg90H21EOLACvtfcHk0lieC_W1oQWXkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksFegt7o%253D&md5=3f2f258f49e34eaad76f54b024d84192</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1007%2Fs10549-011-1413-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-011-1413-6%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DR.%2BM.%26aulast%3DRudek%26aufirst%3DM.%2BA.%26aulast%3DGarrett-Mayer%26aufirst%3DE.%26aulast%3DJeter%26aufirst%3DS.%2BC.%26aulast%3DDonehower%26aufirst%3DM.%2BG.%26aulast%3DWright%26aufirst%3DL.%2BA.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DFetting%26aufirst%3DJ.%2BH.%26aulast%3DEmens%26aufirst%3DL.%2BA.%26aulast%3DStearns%26aufirst%3DV.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26aulast%3DBaker%26aufirst%3DS.%2BD.%26aulast%3DWolff%26aufirst%3DA.%2BC.%26atitle%3DDocetaxel%2520metabolism%2520is%2520not%2520altered%2520by%2520imatinib%253A%2520findings%2520from%2520an%2520early%2520phase%2520study%2520in%2520metastatic%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2011%26volume%3D127%26spage%3D153%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Filppula, A. M.; Laitila, J.; Neuvonen, P. J.; Backman, J. T.</span><span> </span><span class="NLM_article-title">Potent mechanism-based inhibition of CYP3A4 by imatinib explains its interaction liability with CYP3A4 substrates</span>.  <span class="citation_source-journal">Br. J. Pharmacol.</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01732.x</span> . Published Online: Oct 20,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1111%2Fj.1476-5381.2011.01732.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+M.+Filppula&author=J.+Laitila&author=P.+J.+Neuvonen&author=J.+T.+Backman&title=Potent+mechanism-based+inhibition+of+CYP3A4+by+imatinib+explains+its+interaction+liability+with+CYP3A4+substrates&doi=10.1111%2Fj.1476-5381.2011.01732.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01732.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01732.x%26sid%3Dliteratum%253Aachs%26aulast%3DFilppula%26aufirst%3DA.%2BM.%26atitle%3DPotent%2520mechanism-based%2520inhibition%2520of%2520CYP3A4%2520by%2520imatinib%2520explains%2520its%2520interaction%2520liability%2520with%2520CYP3A4%2520substrates%26jtitle%3DBr.%2520J.%2520Pharmacol.%26doi%3D10.1111%2Fj.1476-5381.2011.01732.x%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Haouala, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widmer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duchosal, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montemurro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buclin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decosterd, L A.</span><span> </span><span class="NLM_article-title">Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">e75</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=e75-87&author=A.+Haoualaauthor=N.+Widmerauthor=M.+A.+Duchosalauthor=M.+Montemurroauthor=T.+Buclinauthor=L+A.+Decosterd&title=Drug+interactions+with+the+tyrosine+kinase+inhibitors+imatinib%2C+dasatinib%2C+and+nilotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHaouala%26aufirst%3DA.%26aulast%3DWidmer%26aufirst%3DN.%26aulast%3DDuchosal%26aufirst%3DM.%2BA.%26aulast%3DMontemurro%26aufirst%3DM.%26aulast%3DBuclin%26aufirst%3DT.%26aulast%3DDecosterd%26aufirst%3DL%2BA.%26atitle%3DDrug%2520interactions%2520with%2520the%2520tyrosine%2520kinase%2520inhibitors%2520imatinib%252C%2520dasatinib%252C%2520and%2520nilotinib%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3De75%26epage%3D87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koenig, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, M. D.</span><span> </span><span class="NLM_article-title">Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1242</span><span class="NLM_x">–</span> <span class="NLM_lpage">1250</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1242-1250&author=X.+Liauthor=Y.+Heauthor=C.+H.+Ruizauthor=M.+Koenigauthor=M.+D.+Cameron&title=Characterization+of+dasatinib+and+its+structural+analogs+as+CYP3A4+mechanism-based+inactivators+and+the+proposed+bioactivation+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DRuiz%26aufirst%3DC.%2BH.%26aulast%3DKoenig%26aufirst%3DM.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26atitle%3DCharacterization%2520of%2520dasatinib%2520and%2520its%2520structural%2520analogs%2520as%2520CYP3A4%2520mechanism-based%2520inactivators%2520and%2520the%2520proposed%2520bioactivation%2520pathways%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1242%26epage%3D1250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Teng, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">New, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahlin, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. C.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of cytochrome P4503A4 by lapatinib</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">703</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2010&pages=693-703&author=W.+C.+Tengauthor=J.+W.+Ohauthor=L.+S.+Newauthor=M.+D.+Wahlinauthor=S.+D.+Nelsonauthor=H.+K.+Hoauthor=E.+C.+Chan&title=Mechanism-based+inactivation+of+cytochrome+P4503A4+by+lapatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTeng%26aufirst%3DW.%2BC.%26aulast%3DOh%26aufirst%3DJ.%2BW.%26aulast%3DNew%26aufirst%3DL.%2BS.%26aulast%3DWahlin%26aufirst%3DM.%2BD.%26aulast%3DNelson%26aufirst%3DS.%2BD.%26aulast%3DHo%26aufirst%3DH.%2BK.%26aulast%3DChan%26aufirst%3DE.%2BC.%26atitle%3DMechanism-based%2520inactivation%2520of%2520cytochrome%2520P4503A4%2520by%2520lapatinib%26jtitle%3DMol.%2520Pharmacol.%26date%3D2010%26volume%3D78%26spage%3D693%26epage%3D703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Takakusa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahlin, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">New, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S. D.</span><span> </span><span class="NLM_article-title">Metabolic intermediate complex formation of human cytochrome P4503A4 by lapatinib</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1022</span><span class="NLM_x">–</span> <span class="NLM_lpage">1030</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1022-1030&author=H.+Takakusaauthor=M.+D.+Wahlinauthor=C.+Zhaoauthor=K.+L.+Hansonauthor=L.+S.+Newauthor=E.+C.+Chanauthor=S.+D.+Nelson&title=Metabolic+intermediate+complex+formation+of+human+cytochrome+P4503A4+by+lapatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakakusa%26aufirst%3DH.%26aulast%3DWahlin%26aufirst%3DM.%2BD.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DHanson%26aufirst%3DK.%2BL.%26aulast%3DNew%26aufirst%3DL.%2BS.%26aulast%3DChan%26aufirst%3DE.%2BC.%26aulast%3DNelson%26aufirst%3DS.%2BD.%26atitle%3DMetabolic%2520intermediate%2520complex%2520formation%2520of%2520human%2520cytochrome%2520P4503A4%2520by%2520lapatinib%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1022%26epage%3D1030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamenecka, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, M. D.</span><span> </span><span class="NLM_article-title">Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1736</span><span class="NLM_x">–</span> <span class="NLM_lpage">1742</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx900256y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=1736-1742&author=X.+Liauthor=T.+M.+Kameneckaauthor=M.+D.+Cameron&title=Bioactivation+of+the+epidermal+growth+factor+receptor+inhibitor+gefitinib%3A+implications+for+pulmonary+and+hepatic+toxicities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Ftx900256y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx900256y%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DKamenecka%26aufirst%3DT.%2BM.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26atitle%3DBioactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%2520gefitinib%253A%2520implications%2520for%2520pulmonary%2520and%2520hepatic%2520toxicities%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D1736%26epage%3D1742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamenecka, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, M. D.</span><span> </span><span class="NLM_article-title">Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1238</span><span class="NLM_x">–</span> <span class="NLM_lpage">1245</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1238-1245&author=X.+Liauthor=T.+M.+Kameneckaauthor=M.+D.+Cameron&title=Cytochrome+P450-mediated+bioactivation+of+the+epidermal+growth+factor+receptor+inhibitor+erlotinib+to+a+reactive+electrophile"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DKamenecka%26aufirst%3DT.%2BM.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26atitle%3DCytochrome%2520P450-mediated%2520bioactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%2520erlotinib%2520to%2520a%2520reactive%2520electrophile%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1238%26epage%3D1245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Veeraputhiran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundermeyer, M.</span><span> </span><span class="NLM_article-title">Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin</span> <span class="citation_source-journal">Clin. Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">232</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.3816%2FCLC.2008.n.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=18650173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVWntb%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=232-234&author=M.+Veeraputhiranauthor=M.+Sundermeyer&title=Rhabdomyolysis+resulting+from+pharmacologic+interaction+between+erlotinib+and+simvastatin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin</span></div><div class="casAuthors">Veeraputhiran, Muthu; Sundermeyer, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lung Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">232-234</span>CODEN:
                <span class="NLM_cas:coden">CLCLCA</span>;
        ISSN:<span class="NLM_cas:issn">1525-7304</span>.
    
            (<span class="NLM_cas:orgname">CIG Media Group, LP</span>)
        </div><div class="casAbstract">Erlotinib is an epidermal growth factor receptor inhibitor indicated as a second line of therapy for locally advanced and metastatic non-small-cell lung cancer after the failure of 1 previous chemotherapy.  Simvastatin belongs to the statin family used to lower blood cholesterol.  Drug interaction between erlotinib and statin has not been reported before.  Both drugs are major substrates of the CYP3A4 enzyme in the liver.  Thus, co-administration of these drugs can increase their serum levels, potentially leading to adverse effects.  We report the interaction between erlotinib and simvastatin leading to rhabdomyolysis.  Thus, caution is required with increasing usage of both of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5pBd7vbbexbVg90H21EOLACvtfcHk0lgwS-WjpWUQbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVWntb%252FF&md5=85f7cead100accac93464078c353d6fe</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.3816%2FCLC.2008.n.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3816%252FCLC.2008.n.036%26sid%3Dliteratum%253Aachs%26aulast%3DVeeraputhiran%26aufirst%3DM.%26aulast%3DSundermeyer%26aufirst%3DM.%26atitle%3DRhabdomyolysis%2520resulting%2520from%2520pharmacologic%2520interaction%2520between%2520erlotinib%2520and%2520simvastatin%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2008%26volume%3D9%26spage%3D232%26epage%3D234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lathia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchter, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redlinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span> </span><span class="NLM_article-title">Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advance melanoma: a phase I/II pharmacokinetic interaction study</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">1111</span><span class="NLM_x">–</span> <span class="NLM_lpage">1118</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1007%2Fs00280-011-1585-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=21350850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsV2iu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2011&pages=1111-1118&author=K.+T.+Flahertyauthor=C.+Lathiaauthor=R.+F.+Fryeauthor=L.+Schuchterauthor=M.+Redlingerauthor=M.+Rosenauthor=P.+J.+O%E2%80%99Dwyer&title=Interaction+of+sorafenib+and+cytochrome+P450+isoenzymes+in+patients+with+advance+melanoma%3A+a+phase+I%2FII+pharmacokinetic+interaction+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study</span></div><div class="casAuthors">Flaherty, Keith T.; Lathia, Chetan; Frye, Reginald F.; Schuchter, Lynn; Redlinger, Maryann; Rosen, Mark; O'Dwyer, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1111-1118</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background In vitro data indicate that the sorafenib is a moderate inhibitor of cytochrome P 450 (CYP) enzymes, including CYP3A4, CYP2C19, and CYP2D6.  This phase I/II study in patients with advanced melanoma evaluated the potential effect of sorafenib on the pharmacokinetics of midazolam, omeprazole, and dextromethorphan, specific substrates of CYP3A4, CYP2C19, and CYP2D6, resp.  Methods Twenty-one patients received sorafenib 400 mg twice daily for 28 consecutive days.  On days 1 and 28, a cocktail contg. midazolam 2 mg, omeprazole 20 mg, and dextromethorphan 30 mg was administered.  Pharmacokinetic analyses were performed on day 1 without sorafenib and day 28 after steady-state sorafenib exposure; sorafenib pharmacokinetics were evaluated on day 28.  We defined an interaction to be excluded if the 90% confidence interval of the ratio of all day 28:day 1 analyses fell within a range from 0.80 to 1.25.  Results In all, 18 patients were evaluable.  On day 28, area under the plasma concn.-time curve from time 0 to 12 h (AUC0-12) and max. plasma concn. (Cmax) for sorafenib were 38.1 mg h/l and 4.9 mg/l, resp.  Day 28:day 1 ratios for AUC from time 0 extrapolated to infinity (AUC0-inf) and Cmax for midazolam were 0.85 and 0.98, resp.  Day 28:day 1 ratio for 5-OH-omeprazole:omeprazole plasma concn. at 3 h postdose was 1.26, slightly outside of the 0.80-1.25 range.  Thus, an interaction could not be excluded, but is considered unlikely to be clin. significant.  Day 28:day 1 ratio for dextromethorphan:dextrorphan concn. in urine was 0.94.  Sorafenib had an acceptable safety profile.  The most frequently obsd. grade 3-4 toxicities in cycle 1 included elevated lipase (19%) and hypertension (10%).  Conclusions In this patient population, our results demonstrate that exposures of probes of CYP3A4, CYP2D6, or CYP2C19 activity are potentially altered by administration of sorafenib at 400 mg twice daily.  However, these differences are sufficiently small that a clin. significant inhibition or induction of these important drug metabolizing P 450 isoenzymes is unlikely.  Clin. and, where possible, drug level monitoring may still be appropriate for drugs of narrow therapeutic range co-administered with sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9HELt_N8Op7Vg90H21EOLACvtfcHk0lgwS-WjpWUQbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsV2iu7fN&md5=f181d46594e09645235d89e15c8d7b37</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1585-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1585-0%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DLathia%26aufirst%3DC.%26aulast%3DFrye%26aufirst%3DR.%2BF.%26aulast%3DSchuchter%26aufirst%3DL.%26aulast%3DRedlinger%26aufirst%3DM.%26aulast%3DRosen%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26atitle%3DInteraction%2520of%2520sorafenib%2520and%2520cytochrome%2520P450%2520isoenzymes%2520in%2520patients%2520with%2520advance%2520melanoma%253A%2520a%2520phase%2520I%252FII%2520pharmacokinetic%2520interaction%2520study%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2011%26volume%3D68%26spage%3D1111%26epage%3D1118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Lathia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lettieri, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cihon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallentine, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radtke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaresan, P.</span><span> </span><span class="NLM_article-title">Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">–</span> <span class="NLM_lpage">692</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1007%2Fs00280-005-0068-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=16133532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjs1KktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2006&pages=685-692&author=C.+Lathiaauthor=J.+Lettieriauthor=F.+Cihonauthor=M.+Gallentineauthor=M.+Radtkeauthor=P.+Sundaresan&title=Lack+of+effect+of+ketoconazole-mediated+CYP3A+inhibition+on+sorafenib+clinical+pharmacokinetics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics</span></div><div class="casAuthors">Lathia, Chetan; Lettieri, John; Cihon, Frank; Gallentine, Martha; Radtke, Martin; Sundaresan, Pavur</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">685-692</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Sorafenib is a novel, small-mol. anticancer compd. that inhibits tumor cell proliferation by targeting Raf in the Raf/MEK/ERK signaling pathway, and inhibits angiogenesis by targeting tyrosine kinases such as vascular-endothelial growth factor receptor (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor (PDGFR).  In vitro microsomal data indicate that sorafenib is metabolized by two pathways: phase I oxidn. mediated by cytochrome P 450 (CYP) 3A4; and phase II conjugation mediated by UGT1A9.  Approx. 50% of an orally administered dose is recovered as unchanged drug in the feces, due to either biliary excretion or lack of absorption.  The aim of this study was to evaluate the effect of CYP3A inhibition by ketoconazole on sorafenib pharmacokinetics.  This was an open-label, non-randomized, 2-period, one-way crossover study in sixteen healthy male subjects.  A single 50 mg dose of sorafenib was administered alone (period 1) and in combination with ketoconazole 400 mg once daily (period 2) (ketoconazole was given for 7 days, and a single 50 mg sorafenib dose was administered concomitantly on day 4).  No clin. relevant change in pharmacokinetics of sorafenib and no clin. relevant adverse events or lab. abnormalities were obsd. in this study upon co-administration of the two drugs.  Plasma concns. of the main CYP3A4 generated metabolite, sorafenib N-oxide, decreased considerably upon ketoconazole co-administration.  This effect is in accordance with the in vitro finding that CYP3A4 is the primary enzyme for sorafenib N-oxide formation.  Further, these data indicate that blocking sorafenib metab. by the CYP3A4 pathway will not lead to an increase in sorafenib exposure.  This is consistent with data from a clin. mass-balance study that showed 15% of the administered dose was eliminated by glucuronidation, compared to less than 5% eliminated as oxidative metabolites.  Since there was no increase in sorafenib exposure following concomitant administration of the highly potent CYP3A4 inhibitor ketoconazole with low dose sorafenib, it is postulated that higher therapeutic doses of sorafenib may be safely co-administered with ketoconazole, as well as with other inhibitors of CYP3A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV-01_MtXZH7Vg90H21EOLACvtfcHk0liH_13wtfJV8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjs1KktLk%253D&md5=7d13ee0c45f5280fcdaf9d6982339dec</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1007%2Fs00280-005-0068-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-005-0068-6%26sid%3Dliteratum%253Aachs%26aulast%3DLathia%26aufirst%3DC.%26aulast%3DLettieri%26aufirst%3DJ.%26aulast%3DCihon%26aufirst%3DF.%26aulast%3DGallentine%26aufirst%3DM.%26aulast%3DRadtke%26aufirst%3DM.%26aulast%3DSundaresan%26aufirst%3DP.%26atitle%3DLack%2520of%2520effect%2520of%2520ketoconazole-mediated%2520CYP3A%2520inhibition%2520on%2520sorafenib%2520clinical%2520pharmacokinetics%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2006%26volume%3D57%26spage%3D685%26epage%3D692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navid, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. D.</span><span> </span><span class="NLM_article-title">Quantitation of sorafenib and its active metabolite sorafenib <i>N</i>-oxide in human plasma by liquid chromatography–tandem mass spectrometry</span> <span class="citation_source-journal">J. Chromatogr., B: Anal. Technol. Biomed. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">878</span><span class="NLM_x">, </span> <span class="NLM_fpage">3033</span><span class="NLM_x">–</span> <span class="NLM_lpage">3038</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.jchromb.2010.08.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=20870468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlSnu7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=878&publication_year=2010&pages=3033-3038&author=L.+Liauthor=M.+Zhaoauthor=F.+Navidauthor=K.+Pratzauthor=B.+D.+Smithauthor=M.+A.+Rudekauthor=S.+D.+Baker&title=Quantitation+of+sorafenib+and+its+active+metabolite+sorafenib+N-oxide+in+human+plasma+by+liquid+chromatography%E2%80%93tandem+mass+spectrometry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry</span></div><div class="casAuthors">Li, Lie; Zhao, Ming; Navid, Fariba; Pratz, Keith; Smith, B. Doug; Rudek, Michelle A.; Baker, Sharyn D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">878</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3033-3038</span>CODEN:
                <span class="NLM_cas:coden">JCBAAI</span>;
        ISSN:<span class="NLM_cas:issn">1570-0232</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A simple and rapid method with high performance liq. chromatog./tandem mass spectrometry is described for the quantitation of the kinase inhibitor sorafenib and its active metabolite sorafenib N-oxide in human plasma.  A protein pptn. extn. procedure was applied to 50 μL of plasma.  Chromatog. sepn. of the two analytes, and the internal std. [2H3 13C]-sorafenib, was achieved on a C18 anal. column and isocratic flow at 0.3 mL/min for 4 min.  Mean within-run and between-run precision for all analytes were <6.9% and accuracy was <5.3%.  Calibration curves were linear over the concn. range of 50-10,000 ng/mL for sorafenib and 10-2500 ng/mL for sorafenib N-oxide.  This method allows a specific, sensitive, and reliable detn. of the kinase inhibitor sorafenib and its active metabolite sorafenib N-oxide in human plasma in a single anal. run.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJxMkbb0kf67Vg90H21EOLACvtfcHk0liH_13wtfJV8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlSnu7zI&md5=724e2c8ebd5cd7b9470157961fbea54c</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.jchromb.2010.08.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jchromb.2010.08.049%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DNavid%26aufirst%3DF.%26aulast%3DPratz%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DRudek%26aufirst%3DM.%2BA.%26aulast%3DBaker%26aufirst%3DS.%2BD.%26atitle%3DQuantitation%2520of%2520sorafenib%2520and%2520its%2520active%2520metabolite%2520sorafenib%2520N-oxide%2520in%2520human%2520plasma%2520by%2520liquid%2520chromatography%25E2%2580%2593tandem%2520mass%2520spectrometry%26jtitle%3DJ.%2520Chromatogr.%252C%2520B%253A%2520Anal.%2520Technol.%2520Biomed.%2520Life%2520Sci.%26date%3D2010%26volume%3D878%26spage%3D3033%26epage%3D3038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Pereillo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maftouh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrieu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uzabiaga, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedili, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maffrand, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picard, C.</span><span> </span><span class="NLM_article-title">Structure and stereochemistry of the active metabolite of clopidogrel</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1288</span><span class="NLM_x">–</span> <span class="NLM_lpage">1295</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=1288-1295&author=J.+M.+Pereilloauthor=M.+Maftouhauthor=A.+Andrieuauthor=M.+F.+Uzabiagaauthor=O.+Fediliauthor=P.+Saviauthor=M.+Pascalauthor=J.+M.+Herbertauthor=J.+P.+Maffrandauthor=C.+Picard&title=Structure+and+stereochemistry+of+the+active+metabolite+of+clopidogrel"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPereillo%26aufirst%3DJ.%2BM.%26aulast%3DMaftouh%26aufirst%3DM.%26aulast%3DAndrieu%26aufirst%3DA.%26aulast%3DUzabiaga%26aufirst%3DM.%2BF.%26aulast%3DFedili%26aufirst%3DO.%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DPascal%26aufirst%3DM.%26aulast%3DHerbert%26aufirst%3DJ.%2BM.%26aulast%3DMaffrand%26aufirst%3DJ.%2BP.%26aulast%3DPicard%26aufirst%3DC.%26atitle%3DStructure%2520and%2520stereochemistry%2520of%2520the%2520active%2520metabolite%2520of%2520clopidogrel%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D1288%26epage%3D1295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Dansette, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Libraire, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertho, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuy, D.</span><span> </span><span class="NLM_article-title">Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">373</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx8004828" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtV2ksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=369-373&author=P.+M.+Dansetteauthor=J.+Libraireauthor=G.+Berthoauthor=D.+Mansuy&title=Metabolic+oxidative+cleavage+of+thioesters%3A+evidence+for+the+formation+of+sulfenic+acid+intermediates+in+the+bioactivation+of+the+antithrombotic+prodrugs+ticlopidine+and+clopidogrel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic Oxidative Cleavage of Thioesters: Evidence for the Formation of Sulfenic Acid Intermediates in the Bioactivation of the Antithrombotic Prodrugs Ticlopidine and Clopidogrel</span></div><div class="casAuthors">Dansette, Patrick M.; Libraire, Julie; Bertho, Gildas; Mansuy, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">369-373</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Metabolic cleavage of the CO-S bond of some thioesters RCOSR' with the formation of RCOOH requires a monooxygenase-dependent oxidative activation of this bond.  The nature of the S-contg. product(s) resulting from this cleavage remains unclear in most cases.  This communication provides the first evidence for the formation of sulfenic acid intermediates 4a and 4b during the oxidative cleavage of the CO-S bond of thiolactone metabolites 2a and 2b of antithrombotic prodrugs, ticlopidine and clopidogrel, by rat and human liver microsomes.  These intermediates have been trapped by dimedone, and the corresponding adducts 5a and 5b have been characterized by mass spectrometry (MS) and 1H and 13C NMR spectroscopy.  Their formation is monooxygenase-dependent and almost completely inhibited by microsomal cytochrome P 450 inhibitors.  Moreover, they were also formed upon incubation with microsomes contg. recombinant human P 450 3A4, 3A5, 2C8, 2C9, 2C19, 2D6, or 1A2.  In the presence of thiols such as mercaptoethanol, N-acetylcysteine, or glutathione, microsomal incubations of 2a led to mixed disulfides that have been characterized by MS and should result from reaction of 4a with these thiols.  At high thiol concns., one obsd. in HPLC-MS the formation of a product exhibiting the MS expected for the previously described thiol metabolite 3a, a redn. product of 4a that has been reported as the pharmacol. active metabolite of ticlopidine.  These data provide the first evidence for the formation of sulfenic acid reactive metabolites upon P 450-catalyzed oxidative cleavage of thioesters.  They also provide a first detailed mechanism for the previously described formation of pharmacol. active thiols such as 3a upon oxidative metab. of ticlopidine and clopidogrel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT08wJDRg6g7Vg90H21EOLACvtfcHk0li8ZmgvW0XUOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtV2ksrc%253D&md5=5b7783f3cfabd4dff3de96558bf9a63a</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Ftx8004828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx8004828%26sid%3Dliteratum%253Aachs%26aulast%3DDansette%26aufirst%3DP.%2BM.%26aulast%3DLibraire%26aufirst%3DJ.%26aulast%3DBertho%26aufirst%3DG.%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DMetabolic%2520oxidative%2520cleavage%2520of%2520thioesters%253A%2520evidence%2520for%2520the%2520formation%2520of%2520sulfenic%2520acid%2520intermediates%2520in%2520the%2520bioactivation%2520of%2520the%2520antithrombotic%2520prodrugs%2520ticlopidine%2520and%2520clopidogrel%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D369%26epage%3D373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Ha-Duong, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dijols, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macherey, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansette, P. M</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuy, D.</span><span> </span><span class="NLM_article-title">Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P4502C19</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">12112</span><span class="NLM_x">–</span> <span class="NLM_lpage">12122</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi010254c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=12112-12122&author=N.+T.+Ha-Duongauthor=S.+Dijolsauthor=A.+C.+Machereyauthor=J.+A.+Goldsteinauthor=P.+M+Dansetteauthor=D.+Mansuy&title=Ticlopidine+as+a+selective+mechanism-based+inhibitor+of+human+cytochrome+P4502C19"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Fbi010254c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi010254c%26sid%3Dliteratum%253Aachs%26aulast%3DHa-Duong%26aufirst%3DN.%2BT.%26aulast%3DDijols%26aufirst%3DS.%26aulast%3DMacherey%26aufirst%3DA.%2BC.%26aulast%3DGoldstein%26aufirst%3DJ.%2BA.%26aulast%3DDansette%26aufirst%3DP.%2BM%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DTiclopidine%2520as%2520a%2520selective%2520mechanism-based%2520inhibitor%2520of%2520human%2520cytochrome%2520P4502C19%26jtitle%3DBiochemistry%26date%3D2001%26volume%3D40%26spage%3D12112%26epage%3D12122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Nishiya, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okudaira, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okazaki, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, T.</span><span> </span><span class="NLM_article-title">Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">836</span><span class="NLM_x">–</span> <span class="NLM_lpage">843</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=836-843&author=Y.+Nishiyaauthor=K.+Hagiharaauthor=A.+Kuriharaauthor=N.+Okudairaauthor=N.+A.+Faridauthor=O.+Okazakiauthor=T.+Ikeda&title=Comparison+of+mechanism-based+inhibition+of+human+cytochrome+P450+2C19+by+ticlopidine%2C+clopidogrel%2C+and+prasugrel"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNishiya%26aufirst%3DY.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DOkudaira%26aufirst%3DN.%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DOkazaki%26aufirst%3DO.%26aulast%3DIkeda%26aufirst%3DT.%26atitle%3DComparison%2520of%2520mechanism-based%2520inhibition%2520of%2520human%2520cytochrome%2520P450%25202C19%2520by%2520ticlopidine%252C%2520clopidogrel%252C%2520and%2520prasugrel%26jtitle%3DXenobiotica%26date%3D2009%26volume%3D39%26spage%3D836%26epage%3D843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Mega, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Close, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiviott, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hockett, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antman, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macias, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braunwald, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatine, M. S.</span><span> </span><span class="NLM_article-title">Cytochrome P-450 polymorphisms and response to clopidogrel</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">360</span><span class="NLM_x">, </span> <span class="NLM_fpage">354</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1056%2FNEJMoa0809171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=19106084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVSlsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=354-362&author=J.+L.+Megaauthor=S.+L.+Closeauthor=S.+D.+Wiviottauthor=L.+Shenauthor=R.+D.+Hockettauthor=J.+T.+Brandtauthor=J.+R.+Walkerauthor=E.+M.+Antmanauthor=W.+Maciasauthor=E.+Braunwaldauthor=M.+S.+Sabatine&title=Cytochrome+P-450+polymorphisms+and+response+to+clopidogrel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P-450 polymorphisms and response to clopidogrel</span></div><div class="casAuthors">Mega, Jessica L.; Close, Sandra L.; Wiviott, Stephen D.; Shen, Lei; Hockett, Richard D.; Brandt, John T.; Walker, Joseph R.; Antman, Elliott M.; Macias, William; Braunwald, Eugene; Sabatine, Marc S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">354-362</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Clopidogrel requires transformation into an active metabolite by cytochrome P 450 (CYP) enzymes for its antiplatelet effect.  The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function.  METHODS: We tested the assocn. between functional genetic variants in CYP genes, plasma concns. of active drug metabolite, and platelet inhibition in response to clopidogrel in 162 healthy subjects.  We then examd. the assocn. between these genetic variants and cardiovascular outcomes in a sep. cohort of 1477 subjects with acute coronary syndromes who were treated with clopidogrel in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38.  RESULTS: In healthy subjects who were treated with clopidogrel, carriers of at least one CYP2C19 reduced-function allele (approx. 30% of the study population) had a relative redn. of 32.4% in plasma exposure to the active metabolite of clopidogrel, as compared with noncarriers (P < 0.001).  Carriers also had an abs. redn. in maximal platelet aggregation in response to clopidogrel that was 9 percentage points less than that seen in noncarriers (P < 0.001).  Among clopidogrel-treated subjects in TRITON-TIMI 38, carriers had a relative increase of 53% in the composite primary efficacy outcome of the risk of death from cardiovascular causes, myocardial infarction, or stroke, as compared with noncarriers (12.1% vs. 8.0%; hazard ratio for carriers, 1.53; 95% confidence interval [CI], 1.07 to 2.19; P = 0.01) and an increase by a factor of 3 in the risk of stent thrombosis (2.60/% vs. 0.8%; hazard ratio, 3.09; 95% CI, 1.19 to 8.00; P = 0.02).  CONCLUSIONS: Among persons treated with clopidogrel, carriers of a reduced-function CYP2C19 allele had significantly lower levels of the active metabolite of clopidogrel, diminished platelet inhibition, and a higher rate of major adverse cardiovascular events, including stent thrombosis, than did noncarriers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPuhhoYObiQrVg90H21EOLACvtfcHk0li8ZmgvW0XUOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVSlsbs%253D&md5=3afb94927199d94890771d7e2ce26253</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0809171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0809171%26sid%3Dliteratum%253Aachs%26aulast%3DMega%26aufirst%3DJ.%2BL.%26aulast%3DClose%26aufirst%3DS.%2BL.%26aulast%3DWiviott%26aufirst%3DS.%2BD.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DHockett%26aufirst%3DR.%2BD.%26aulast%3DBrandt%26aufirst%3DJ.%2BT.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DAntman%26aufirst%3DE.%2BM.%26aulast%3DMacias%26aufirst%3DW.%26aulast%3DBraunwald%26aufirst%3DE.%26aulast%3DSabatine%26aufirst%3DM.%2BS.%26atitle%3DCytochrome%2520P-450%2520polymorphisms%2520and%2520response%2520to%2520clopidogrel%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D354%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Kurihara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazui, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozeki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, T.</span><span> </span><span class="NLM_article-title">In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in the active metabolite formation</span> <span class="citation_source-journal">Drug Metab. Rev., Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=99&author=A.+Kuriharaauthor=K.+Hagiharaauthor=M.+Kazuiauthor=T.+Ozekiauthor=N.+A.+Faridauthor=T.+Ikeda&title=In+vitro+metabolism+of+antiplatelet+agent+clopidogrel%3A+cytochrome+P450+isoforms+responsible+for+two+oxidation+steps+involved+in+the+active+metabolite+formation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DKazui%26aufirst%3DM.%26aulast%3DOzeki%26aufirst%3DT.%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DIkeda%26aufirst%3DT.%26atitle%3DIn%2520vitro%2520metabolism%2520of%2520antiplatelet%2520agent%2520clopidogrel%253A%2520cytochrome%2520P450%2520isoforms%2520responsible%2520for%2520two%2520oxidation%2520steps%2520involved%2520in%2520the%2520active%2520metabolite%2520formation%26jtitle%3DDrug%2520Metab.%2520Rev.%252C%2520Suppl.%26date%3D2005%26volume%3D2%26spage%3D99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Hagihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiya, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazui, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, T.</span><span> </span><span class="NLM_article-title">Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel and ticlopidine</span> <span class="citation_source-journal">Drug Metab. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">412</span><span class="NLM_x">–</span> <span class="NLM_lpage">420</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2133%2Fdmpk.23.412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=19122335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1ags7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2008&pages=412-420&author=K.+Hagiharaauthor=Y.+Nishiyaauthor=A.+Kuriharaauthor=M.+Kazuiauthor=N.+A.+Faridauthor=T.+Ikeda&title=Comparison+of+human+cytochrome+P450+inhibition+by+the+thienopyridines+prasugrel%2C+clopidogrel+and+ticlopidine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine</span></div><div class="casAuthors">Hagihara, Katsunobu; Nishiya, Yumi; Kurihara, Atsushi; Kazui, Miho; Farid, Nagy A.; Ikeda, Toshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">412-420</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society for the Study of Xenobiotics</span>)
        </div><div class="casAbstract">Differences in the inhibition of cytochrome P 450 activities among thienopyridine antiplatelet agents, ticlopidine, clopidogrel, prasugrel, and the metabolites, 2-oxo-clopidogrel, clopidogrel acid metabolite, deacetylated metabolite of prasugrel (R-95913) and the pharmacol. active metabolites of clopidogrel and prasugrel, were examd. using recombinant cytochromes P 450 and fluorescent probe substrates.  Ticlopidine and clopidogrel inhibited CYP2B6 with IC50 values of 0.0517 ± 0.0323 μM and 0.0182 ± 0.0069 μM, resp., and inhibited CYP2C19 with IC50 values of 0.203 ± 0.124 μM and 0.524 ± 0.160 μM, resp.  Ticlopidine also inhibited CYP2D6 (IC50 of 0.354 ± 0.158 μM).  In contrast, 2-oxo-clopidogrel, prasugrel and R-95913 were much weaker inhibitors of CYP2B6, CYP2C19 and CYP2D6.  The inhibitory effects of all the compds. tested were much weaker on the isoforms other than those indicated above.  The active metabolites of clopidogrel and prasugrel and clopidogrel acid metabolite also did not affect the activities of the P450s examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxq55ig_qqtbVg90H21EOLACvtfcHk0lhUYMvD9EEYhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1ags7o%253D&md5=e8c0d0d2edfe2c4ebd12d21aab12de05</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.2133%2Fdmpk.23.412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2133%252Fdmpk.23.412%26sid%3Dliteratum%253Aachs%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DNishiya%26aufirst%3DY.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DKazui%26aufirst%3DM.%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DIkeda%26aufirst%3DT.%26atitle%3DComparison%2520of%2520human%2520cytochrome%2520P450%2520inhibition%2520by%2520the%2520thienopyridines%2520prasugrel%252C%2520clopidogrel%2520and%2520ticlopidine%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2008%26volume%3D23%26spage%3D412%26epage%3D420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Rehmel, J. L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckstein, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasper, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrighton, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ring, B. J.</span><span> </span><span class="NLM_article-title">Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">600</span><span class="NLM_x">–</span> <span class="NLM_lpage">607</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=600-607&author=J.+L.+F.+Rehmelauthor=J.+A.+Ecksteinauthor=N.+A.+Faridauthor=J.+B.+Heimauthor=S.+C.+Kasperauthor=A.+Kuriharaauthor=S.+A.+Wrightonauthor=B.+J.+Ring&title=Interactions+of+two+major+metabolites+of+prasugrel%2C+a+thienopyridine+antiplatelet+agent%2C+with+the+cytochromes+P450"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRehmel%26aufirst%3DJ.%2BL.%2BF.%26aulast%3DEckstein%26aufirst%3DJ.%2BA.%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DHeim%26aufirst%3DJ.%2BB.%26aulast%3DKasper%26aufirst%3DS.%2BC.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DWrighton%26aufirst%3DS.%2BA.%26aulast%3DRing%26aufirst%3DB.%2BJ.%26atitle%3DInteractions%2520of%2520two%2520major%2520metabolites%2520of%2520prasugrel%252C%2520a%2520thienopyridine%2520antiplatelet%2520agent%252C%2520with%2520the%2520cytochromes%2520P450%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D600%26epage%3D607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Nishiya, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tajima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, T.</span><span> </span><span class="NLM_article-title">Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">589</span><span class="NLM_x">–</span> <span class="NLM_lpage">593</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=589-593&author=Y.+Nishiyaauthor=K.+Hagiharaauthor=T.+Itoauthor=M.+Tajimaauthor=S.+Miuraauthor=A.+Kuriharaauthor=N.+A.+Faridauthor=T.+Ikeda&title=Mechanism-based+inhibition+of+human+cytochrome+P450+2B6+by+ticlopidine%2C+clopidogrel%2C+and+the+thiolactone+metabolite+of+prasugrel"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNishiya%26aufirst%3DY.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DTajima%26aufirst%3DM.%26aulast%3DMiura%26aufirst%3DS.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DIkeda%26aufirst%3DT.%26atitle%3DMechanism-based%2520inhibition%2520of%2520human%2520cytochrome%2520P450%25202B6%2520by%2520ticlopidine%252C%2520clopidogrel%252C%2520and%2520the%2520thiolactone%2520metabolite%2520of%2520prasugrel%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D589%26epage%3D593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Richter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murdter, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinkele, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pleiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatzel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwab, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichelbaum, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanger, U. M.</span><span> </span><span class="NLM_article-title">Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1124%2Fjpet.103.056127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=14563790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsFegsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2004&pages=189-197&author=T.+Richterauthor=T.+E.+Murdterauthor=G.+Heinkeleauthor=J.+Pleissauthor=S.+Tatzelauthor=M.+Schwabauthor=M.+Eichelbaumauthor=U.+M.+Zanger&title=Potent+mechanism-based+inhibition+of+human+CYP2B6+by+clopidogrel+and+ticlopidine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine</span></div><div class="casAuthors">Richter, Tanja; Muerdter, Thomas E.; Heinkele, Georg; Pleiss, Juergen; Tatzel, Stephan; Schwab, Matthias; Eichelbaum, Michel; Zanger, Ulrich M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">189-197</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The thienopyridine derivs. ticlopidine and clopidogrel are inhibitors of ADP-induced platelet aggregation.  Pharmacol. activity of these prodrugs depends on cytochrome P 450 (P 450)-dependent oxidn. to the active antithrombotic agent.  In this study, we investigated the interaction potential of clopidogrel and ticlopidine by using human liver microsomes and recombinantly expressed P 450 isoforms.  Both clopidogrel and ticlopidine inhibited CYP2B6 with highest potency and CYP2C19 with lower potency.  Clopidogrel also inhibited CYP2C9, and ticlopidine also inhibited CYP1A2, with lower potency.  Inhibition of CYP2B6 was time- and concn.-dependent, and as shown by dialysis expts., it was irreversible and dependent on NADPH, suggesting a mechanism-based mode of action.  Inactivation was of nonpseudo-first-order type with maximal rates of inactivation (Kinact) for clopidogrel and ticlopidine in microsomes (recombinant CYP2B6) of 0.35 (1.5 min-1) and 0.5 min-1 (0.8 min-1), resp., and half-maximal inactivator concns. (KI) were 0.5 μM (1.1 μM) for clopidogrel and 0.2 μM (0.8 μM) for ticlopidine.  Inhibition was attenuated by the presence of alternative active site ligands but not by nucleophilic trapping agents or reactive oxygen scavengers, further supporting mechanism-based action.  A chem. mechanism is discussed based on the known metabolic activation of clopidogrel and on the finding that hemoprotein integrity of recombinant CYP2B6 was not affected by irreversible inhibition.  These results suggest the possibility of drug interactions between thienopyridine derivs. and drug substrates of CYP2B6 and CYP2C19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriG4-lqQezJLVg90H21EOLACvtfcHk0lj7kjQE21V0SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsFegsg%253D%253D&md5=aa9debeee9b3eac31888f6a843de6518</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.056127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.056127%26sid%3Dliteratum%253Aachs%26aulast%3DRichter%26aufirst%3DT.%26aulast%3DMurdter%26aufirst%3DT.%2BE.%26aulast%3DHeinkele%26aufirst%3DG.%26aulast%3DPleiss%26aufirst%3DJ.%26aulast%3DTatzel%26aufirst%3DS.%26aulast%3DSchwab%26aufirst%3DM.%26aulast%3DEichelbaum%26aufirst%3DM.%26aulast%3DZanger%26aufirst%3DU.%2BM.%26atitle%3DPotent%2520mechanism-based%2520inhibition%2520of%2520human%2520CYP2B6%2520by%2520clopidogrel%2520and%2520ticlopidine%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D308%26spage%3D189%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amunugama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ney, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenberg, P. F.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">839</span><span class="NLM_x">–</span> <span class="NLM_lpage">847</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=839-847&author=H.+Zhangauthor=H.+Amunugamaauthor=S.+Neyauthor=N.+Cooperauthor=P.+F.+Hollenberg&title=Mechanism-based+inactivation+of+human+cytochrome+P450+2B6+by+clopidogrel%3A+involvement+of+both+covalent+modification+of+cysteinyl+residue+475+and+loss+of+heme"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DAmunugama%26aufirst%3DH.%26aulast%3DNey%26aufirst%3DS.%26aulast%3DCooper%26aufirst%3DN.%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26atitle%3DMechanism-based%2520inactivation%2520of%2520human%2520cytochrome%2520P450%25202B6%2520by%2520clopidogrel%253A%2520involvement%2520of%2520both%2520covalent%2520modification%2520of%2520cysteinyl%2520residue%2520475%2520and%2520loss%2520of%2520heme%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26spage%3D839%26epage%3D847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Turpeinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolonen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uusitalo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalonen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelkonen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laine, K.</span><span> </span><span class="NLM_article-title">Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">553</span><span class="NLM_x">–</span> <span class="NLM_lpage">559</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.clpt.2005.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15961986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt1Gqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2005&pages=553-559&author=M.+Turpeinenauthor=A.+Tolonenauthor=J.+Uusitaloauthor=J.+Jalonenauthor=O.+Pelkonenauthor=K.+Laine&title=Effect+of+clopidogrel+and+ticlopidine+on+cytochrome+P450+2B6+activity+as+measured+by+bupropion+hydroxylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation</span></div><div class="casAuthors">Turpeinen, Miia; Tolonen, Ari; Uusitalo, Jouko; Jalonen, Jorma; Pelkonen, Olavi; Laine, Kari</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">553-559</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Our objective was to study the effect of the antiplatelet agents clopidogrel and ticlopidine on bupropion (INN, amfebutamone) hydroxylation, a probe reaction for cytochrome P 450 (CYP) 2B6 activity.  Twelve healthy male volunteers took a single 150-mg oral dose of bupropion either alone or after pretreatment with 75 mg clopidogrel once daily or 250 mg ticlopidine twice daily for 4 days.  On day 4, a single 150-mg oral dose of bupropion was administered.  Plasma concns. of bupropion and its CYP2B6-catalyzed metabolite, hydroxybupropion, were measured for up to 72 h.  The mean area under the plasma concn.-time curve (AUC) of hydroxybupropion calcd. from time 0 to infinity was reduced by 52% (P = .001; 95% confidence interval [CI], 39% to 66%) by clopidogrel and by 84% (P < .0001; 95% CI, 73% to 94%) by ticlopidine.  Clopidogrel reduced the AUC ratio of hydroxybupropion over bupropion by 68% (P = .002; 95% CI, 58% to 77%) and ticlopidine by 90% (P = .001; 95% CI, 85% to 96%).  The AUC of bupropion was increased by 60% (P = .02; 95% CI, 21% to 98%) and by 85% (P < .0001; 95% CI, 48% to 85%) with clopidogrel and ticlopidine, resp.  Both clopidogrel and ticlopidine significantly inhibited the CYP2B6-catalyzed bupropion hydroxylation.  Patients receiving either clopidogrel or ticlopidine are likely to require dose adjustments when treated with drugs primarily metabolized by CYP2B6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY2fUuI14JnLVg90H21EOLACvtfcHk0lj7kjQE21V0SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt1Gqt7k%253D&md5=0c2c6314543eb7cee27c29b7dbe6ff40</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2005.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2005.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DTurpeinen%26aufirst%3DM.%26aulast%3DTolonen%26aufirst%3DA.%26aulast%3DUusitalo%26aufirst%3DJ.%26aulast%3DJalonen%26aufirst%3DJ.%26aulast%3DPelkonen%26aufirst%3DO.%26aulast%3DLaine%26aufirst%3DK.%26atitle%3DEffect%2520of%2520clopidogrel%2520and%2520ticlopidine%2520on%2520cytochrome%2520P450%25202B6%2520activity%2520as%2520measured%2520by%2520bupropion%2520hydroxylation%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2005%26volume%3D77%26spage%3D553%26epage%3D559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Farid, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernest, C. S.,  2nd.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salazar, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D. S.</span><span> </span><span class="NLM_article-title">Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1177%2F0091270007309709" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=18094219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVGqt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=53-59&author=N.+A.+Faridauthor=C.+D.+Payneauthor=C.+S.+Ernestauthor=Y.+G.+Liauthor=K.+J.+Wintersauthor=D.+E.+Salazarauthor=D.+S.+Small&title=Prasugrel%2C+a+new+thienopyridine+antiplatelet+drug%2C+weakly+inhibits+cytochrome+P450+2B6+in+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans</span></div><div class="casAuthors">Farid, Nagy A.; Payne, Christopher D.; Ernest, C. Steven, II; Li, Y. Grace; Winters, Kenneth J.; Salazar, Daniel E.; Small, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-59</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Prasugrel, a thienopyridine prodrug, is hydrolyzed in vivo by esterases to a thiolactone followed by a single cytochrome P 450 (CYP)-dependent step to an active metabolite that is a potent inhibitor of ADP-induced platelet aggregation.  This open-label, multiple-dose, 2-period, fixed-sequence study assessed CYP2B6 inhibition by prasugrel using bupropion as a probe substrate, where its active metabolite, hydroxybupropion, is almost exclusively formed by CYP2B6.  Thirty healthy subjects received a single 150-mg oral dose of sustained-release bupropion.  After a 7-day washout, a 60-mg prasugrel loading dose, followed by a 10-mg daily maintenance dose for 10 days, was administered.  Bupropion (150 mg) was given with prasugrel on day 7 of this phase.  Prasugrel weakly inhibited CYP2B6 activity as it increased bupropion Cmax and AUC0-∞ by 14% and 18%, resp., and decreased hydroxybupropion Cmax and AUC0-∞ by 32% and 23%.  These results are consistent with patients receiving prasugrel not requiring dose adjustments when treated with drugs primarily metabolized by CYP2B6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3NGiEGDmKJbVg90H21EOLACvtfcHk0lj7kjQE21V0SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVGqt78%253D&md5=940e4dd7b49069ab2747f83c8ac371a4</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1177%2F0091270007309709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270007309709%26sid%3Dliteratum%253Aachs%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DPayne%26aufirst%3DC.%2BD.%26aulast%3DErnest%26aufirst%3DC.%2BS.%26aulast%3DLi%26aufirst%3DY.%2BG.%26aulast%3DWinters%26aufirst%3DK.%2BJ.%26aulast%3DSalazar%26aufirst%3DD.%2BE.%26aulast%3DSmall%26aufirst%3DD.%2BS.%26atitle%3DPrasugrel%252C%2520a%2520new%2520thienopyridine%2520antiplatelet%2520drug%252C%2520weakly%2520inhibits%2520cytochrome%2520P450%25202B6%2520in%2520humans%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D48%26spage%3D53%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kivisto, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Gemfibrozil is a potent inhibitor of human cytochrome P4502C9</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1359</span><span class="NLM_x">–</span> <span class="NLM_lpage">1361</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2001&pages=1359-1361&author=X.+Wenauthor=J.+S.+Wangauthor=J.+T.+Backmanauthor=K.+T.+Kivistoauthor=P.+J.+Neuvonen&title=Gemfibrozil+is+a+potent+inhibitor+of+human+cytochrome+P4502C9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%2BS.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DKivisto%26aufirst%3DK.%2BT.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DGemfibrozil%2520is%2520a%2520potent%2520inhibitor%2520of%2520human%2520cytochrome%2520P4502C9%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2001%26volume%3D29%26spage%3D1359%26epage%3D1361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Wang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1352</span><span class="NLM_x">–</span> <span class="NLM_lpage">1356</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=1352-1356&author=J.+S.+Wangauthor=M.+Neuvonenauthor=X.+Wenauthor=J.+T.+Backmanauthor=P.+J.+Neuvonen&title=Gemfibrozil+inhibits+CYP2C8-mediated+cerivastatin+metabolism+in+human+liver+microsomes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BS.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DGemfibrozil%2520inhibits%2520CYP2C8-mediated%2520cerivastatin%2520metabolism%2520in%2520human%2520liver%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D1352%26epage%3D1356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyrklund, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Gemfibrozil greatly increases plasma concentrations of cerivastatin</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">–</span> <span class="NLM_lpage">691</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1067%2Fmcp.2002.128469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=12496749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlt1SjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2002&pages=685-691&author=J.+T.+Backmanauthor=C.+Kyrklundauthor=M.+Neuvonenauthor=P.+J.+Neuvonen&title=Gemfibrozil+greatly+increases+plasma+concentrations+of+cerivastatin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Gemfibrozil greatly increases plasma concentrations of cerivastatin</span></div><div class="casAuthors">Backman, Janne T.; Kyrklund, Carl; Neuvonen, Mikko; Neuvonen, Pertti J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">685-691</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Concomitant use of gemfibrozil with statins, particularly with cerivastatin, increases the risk of rhabdomyolysis, but the mechanism of this potentially fatal drug interaction remains unclear.  Our aim was to study the effect of gemfibrozil on cerivastatin pharmacokinetics.  In a randomized, double-blind crossover study, 10 healthy volunteers took 600 mg gemfibrozil or placebo twice daily for 3 days.  On day 3, each subject ingested a single 0.3-mg dose of cerivastatin.  Plasma concns. of cerivastatin, its metabolites, and gemfibrozil were measured up to 24 h.  During gemfibrozil treatment, the area under the plasma concn.-time curve [AUC(0-∞)] of parent cerivastatin was on av. 559% (range, 138% to 995%; P =.0002) and the peak concn. in plasma was 307% (138% to 809%; P =.0019) of the corresponding values in the placebo phase.  Gemfibrozil increased the AUC(0-∞) of cerivastatin lactone, on av., to 440% (94% to 594%; P =.0024) and that of metabolite M-1 to 435% (216% to 802%; P =.0002) of the control (placebo) values, whereas the AUC(0-24) of metabolite M-23 was decreased to 22% (11% to 74%; P=.0017).  Gemfibrozil greatly increases plasma concns. of cerivastatin, cerivastatin lactone, and metabolite M-1, whereas the level of metabolite M-23 is markedly reduced by gemfibrozil.  Gemfibrozil therefore inhibits the formation of M-23, which is thought to be dependent on CYP2C8.  The increased exposure to cerivastatin in the presence of gemfibrozil may explain the high incidence of myopathy obsd. with this combination, although the role of pharmacodynamic interactions between these 2 agents cannot be excluded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyOpdQOdq0kLVg90H21EOLACvtfcHk0lgo8RqeywjmTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlt1SjsQ%253D%253D&md5=2dce3480b6cea92874faf468c81b834c</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2002.128469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2002.128469%26sid%3Dliteratum%253Aachs%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DKyrklund%26aufirst%3DC.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DGemfibrozil%2520greatly%2520increases%2520plasma%2520concentrations%2520of%2520cerivastatin%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2002%26volume%3D72%26spage%3D685%26epage%3D691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Jaakkola, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">404</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.clpt.2004.12.266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15900286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFCrtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2005&pages=404-414&author=T.+Jaakkolaauthor=J.+T.+Backmanauthor=M.+Neuvonenauthor=P.+J.+Neuvonen&title=Effects+of+gemfibrozil%2C+itraconazole%2C+and+their+combination+on+the+pharmacokinetics+of+pioglitazone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone</span></div><div class="casAuthors">Jaakkola, Tiina; Backman, Janne T.; Neuvonen, Mikko; Neuvonen, Pertti J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">404-414</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background and objective: The thiazolidinedione antidiabetic drug pioglitazone is metabolized mainly by cytochrome P 450 (CYP) 2C8 and CYP3A4 in vitro.  Our objective was to study the effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone to det. the role of these enzymes in the fate of pioglitazone in humans.  Methods: In a randomized, double-blind, 4-phase crossover study, 12 healthy volunteers took either 600 mg gemfibrozil or 100 mg itraconazole (first dose, 200 mg), both gemfibrozil and itraconazole, or placebo twice daily for 4 days.  On day 3, they received a single dose of 15 mg pioglitazone.  Plasma drug concns. and the cumulative excretion of pioglitazone and its metabolites into urine were measured for up to 48 h.  Results: Gemfibrozil alone raised the mean total area under the plasma concn.-time curve from time 0 to infinity [AUC(0-∞)] of pioglitazone 3.2-fold (range, 2.3-fold to 6.5-fold; P <.001) and prolonged its elimination half-life (t1/2) from 8.3 to 22.7 h (P <.001) but had no significant effect on its peak concn. (Cmax) compared with placebo (control).  Gemfibrozil increased the 48-h excretion of pioglitazone into urine by 2.5-fold (P <.001) and reduced the ratios of the active metabolites M-III and M-IV to pioglitazone in plasma and urine.  Gemfibrozil decreased the area under the plasma concn.-time curve from time 0 to 48 h [AUC(0-48)] of the metabolites M-III and M-IV by 42% (P <.05) and 45% (P <.001), resp., but their total AUC(0-∞) values were reduced by less or not at all.  Itraconazole had no significant effect on the pharmacokinetics of pioglitazone and did not alter the effect of gemfibrozil on pioglitazone pharmacokinetics.  The mean area under the concn. vs. time curve to 49 h [AUC(0-49)] of itraconazole was 46% lower (P <.001) during the gemfibrozil-itraconazole phase than during the itraconazole phase.  Conclusions: Gemfibrozil elevates the plasma concns. of pioglitazone, probably by inhibition of its CYP2C8-mediated metab.  CYP2C8 appears to be of major importance and CYP3A4 of minor importance in pioglitazone metab. in vivo in humans.  Concomitant use of gemfibrozil with pioglitazone may increase the effects and risk of dose-related adverse effects of pioglitazone.  However, studies in diabetic patients are needed to det. the clin. significance of the gemfibrozil-pioglitazone interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjiP-NzZlXnrVg90H21EOLACvtfcHk0ljIUqaTtlA39A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFCrtLg%253D&md5=44f68ebede1b1bf43cd353ac13007899</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2004.12.266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2004.12.266%26sid%3Dliteratum%253Aachs%26aulast%3DJaakkola%26aufirst%3DT.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DEffects%2520of%2520gemfibrozil%252C%2520itraconazole%252C%2520and%2520their%2520combination%2520on%2520the%2520pharmacokinetics%2520of%2520pioglitazone%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2005%26volume%3D77%26spage%3D404%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Lilja, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1111%2Fj.1365-2125.2004.02323.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15801938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFals7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2005&pages=433-439&author=J.+J.+Liljaauthor=J.+T.+Backmanauthor=P.+J.+Neuvonen&title=Effect+of+gemfibrozil+on+the+pharmacokinetics+and+pharmacodynamics+of+racemic+warfarin+in+healthy+subjects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects</span></div><div class="casAuthors">Lilja, Jari J.; Backman, Janne T.; Neuvonen, Pertti J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">433-439</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Case reports suggest that gemfobrozil can increase the anticoagulant effect of warfarin.  Because gemfibrozil inhibits CYP2C9 in vitro, we studied its effects on the pharmacokinetics and pharmacodynamics of racemic warfarin.  In a randomized cross-over study, 10 healthy subjects ingested 600 mg gemfibrozil or placebo twice daily for 8 days.  On day 3, they were administered a single dose of 10 mg racemic R-S-warfarin orally.  The concns. of R- and S-warfarin in plasma and thromboplastin time were monitored up to 168 h.  Gemfibrozil decreased the mean (±SD) area under the plasma concn.-time curve [AUC(0-∞)] of S-warfarin by 11%, from 19.9 ± 5.2 mg l-1 h to 17.6 ± 4.7 mg l-1 h (95% Cl on the difference -3.7, -0.78; P < 0.01) and that of R-warfarin by 6% from 31.3 ± 7.5 mg l-1 h during the gemfibrozil phase to 29.5 ± 6.9 mg l-1 h during the placebo phase (95% Cl -3.3, -0.33; P < 0.05).  There were no significant differences in the elimination half-lives of S- or R-warfarin between the phases.  Gemfibrozil did not alter the anticoagulant effect of warfarin.  Unexpectedly, gemfibrozil slightly decreased the plasma concns. of R- and S-warfarin.  Displacement of warfarin from plasma albumin by gemfibrozil or its interference with the absorption of warfarin could explain the present findings.  Usual therapeutic doses of gemfibrozil seem to have limited effects on the pharmacokinetics and pharmacodynamics of single dose warfarin in healthy subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI1IjWgq_Ub7Vg90H21EOLACvtfcHk0ljIUqaTtlA39A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFals7o%253D&md5=930bbdaf7f9814d486875d423b7981e5</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2004.02323.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2004.02323.x%26sid%3Dliteratum%253Aachs%26aulast%3DLilja%26aufirst%3DJ.%2BJ.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DEffect%2520of%2520gemfibrozil%2520on%2520the%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520racemic%2520warfarin%2520in%2520healthy%2520subjects%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D59%26spage%3D433%26epage%3D439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Shitara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span> </span><span class="NLM_article-title">Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug–drug interaction between cerivastatin and gemfibrozil</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">311</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">–</span> <span class="NLM_lpage">236</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1124%2Fjpet.104.068536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15194707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXosVKrt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2004&pages=228-236&author=Y.+Shitaraauthor=M.+Hiranoauthor=H.+Satoauthor=Y.+Sugiyama&title=Gemfibrozil+and+its+glucuronide+inhibit+the+organic+anion+transporting+polypeptide+2+%28OATP2%2FOATP1B1%3ASLC21A6%29-mediated+hepatic+uptake+and+CYP2C8-mediated+metabolism+of+cerivastatin%3A+analysis+of+the+mechanism+of+the+clinically+relevant+drug%E2%80%93drug+interaction+between+cerivastatin+and+gemfibrozil"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil</span></div><div class="casAuthors">Shitara, Yoshihisa; Hirano, Masaru; Sato, Hitoshi; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">228-236</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A serious pharmacokinetic interaction between cerivastatin (CER) and gemfibrozil (GEM) has been reported.  In the present study, we examd. the inhibitory effects of GEM and its metabolites, M3 and gemfibrozil 1-O-β-glucuronide (GEM-1-O-glu), on the uptake of CER by human org. anion transporting polypeptide 2 (OATP2)-expressing cells and its metab. in cytochrome P 450 expression systems.  Uptake studies showed that GEM and GEM-1-O-glu significantly inhibited the OATP2-mediated uptake of CER with IC50 values of 72 and 24 μM, resp.  They also inhibited the CYP2C8-mediated metab. of CER with IC50 values of 28 and 4 μM, resp., whereas M3 had no effects.  GEM and GEM-1-O-glu minimally inhibited the CYP3A4-mediated metab. of CER.  The IC50 values of GEM and GEM-1-O-glu for the uptake and the metab. of CER obtained in the present study were lower than their total, and not unbound, plasma concns.  However, considering the possibly concd. high unbound concns. of GEM-1-O-glu in the liver and its relatively larger plasma unbound fraction compared with GEM itself, the glucuronide inhibition of the CYP2C8-mediated metab. of CER appears to be the main mechanism for the clin. relevant drug-drug interaction.  Previously reported clin. drug interaction studies showing that coadministration of GEM with pravastatin or pitavastatin, both of which are known to be cleared from the plasma by the uptake transporters in the liver, only minimally (less than 2-fold) increased the area under the plasma concn.-time curve of these statins, also supported our present conclusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplgMf8fP3WyrVg90H21EOLACvtfcHk0ljIUqaTtlA39A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXosVKrt7g%253D&md5=47713127a0aa0747c2e9520811193a22</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.068536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.068536%26sid%3Dliteratum%253Aachs%26aulast%3DShitara%26aufirst%3DY.%26aulast%3DHirano%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DGemfibrozil%2520and%2520its%2520glucuronide%2520inhibit%2520the%2520organic%2520anion%2520transporting%2520polypeptide%25202%2520%2528OATP2%252FOATP1B1%253ASLC21A6%2529-mediated%2520hepatic%2520uptake%2520and%2520CYP2C8-mediated%2520metabolism%2520of%2520cerivastatin%253A%2520analysis%2520of%2520the%2520mechanism%2520of%2520the%2520clinically%2520relevant%2520drug%25E2%2580%2593drug%2520interaction%2520between%2520cerivastatin%2520and%2520gemfibrozil%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D311%26spage%3D228%26epage%3D236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Ogilvie, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gipson, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holsapple, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, A.</span><span> </span><span class="NLM_article-title">Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug–drug interactions</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=191-197&author=B.+W.+Ogilvieauthor=D.+Zhangauthor=W.+Liauthor=A.+D.+Rodriguesauthor=A.+E.+Gipsonauthor=J.+Holsappleauthor=P.+Torenauthor=A.+Parkinson&title=Glucuronidation+converts+gemfibrozil+to+a+potent%2C+metabolism-dependent+inhibitor+of+CYP2C8%3A+implications+for+drug%E2%80%93drug+interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOgilvie%26aufirst%3DB.%2BW.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26aulast%3DGipson%26aufirst%3DA.%2BE.%26aulast%3DHolsapple%26aufirst%3DJ.%26aulast%3DToren%26aufirst%3DP.%26aulast%3DParkinson%26aufirst%3DA.%26atitle%3DGlucuronidation%2520converts%2520gemfibrozil%2520to%2520a%2520potent%252C%2520metabolism-dependent%2520inhibitor%2520of%2520CYP2C8%253A%2520implications%2520for%2520drug%25E2%2580%2593drug%2520interactions%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D191%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Tornio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laitila, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalliokoski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span> </span><span class="NLM_article-title">The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">403</span><span class="NLM_x">–</span> <span class="NLM_lpage">411</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1038%2Fclpt.2008.34" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=18388877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVShtr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2008&pages=403-411&author=A.+Tornioauthor=M.+Niemiauthor=M.+Neuvonenauthor=J.+Laitilaauthor=A.+Kalliokoskiauthor=P.+J.+Neuvonenauthor=J.+T.+Backman&title=The+effect+of+gemfibrozil+on+repaglinide+pharmacokinetics+persists+for+at+least+12+h+after+the+dose%3A+evidence+for+mechanism-based+inhibition+of+CYP2C8+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo</span></div><div class="casAuthors">Tornio, A.; Niemi, M.; Neuvonen, M.; Laitila, J.; Kalliokoski, A.; Neuvonen, P. J.; Backman, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">403-411</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Repaglinide is metabolized by cytochrome P 450 (CYP) 2C8 and 3A4.  Gemfibrozil has the effect of increasing the area under the concn.-time curve (AUC) of repaglinide eightfold.  We studied the effect of dosing interval on the extent of the gemfibrozil-repaglinide interaction.  In a randomized five-phase crossover study, 10 healthy volunteers ingested 0.25 mg repaglinide, with or without gemfibrozil pretreatment.  Plasma repaglinide, gemfibrozil, their metabolites, and blood glucose were measured.  When the last dose of 600 mg gemfibrozil was ingested simultaneously with repaglinide, or 3, 6, or 12 h before, it increased the AUC0-∞ of repaglinide 7.0-, 6.5-, 6.2- and 5.0-fold, resp. (P < 0.001).  The peak repaglinide concn. increased approx. twofold (P < 0.001), and the half-life was prolonged from 1.2 h to 2-3 h (P < 0.001) during all the gemfibrozil phases.  The drug interaction effects persisted at least 12 h after gemfibrozil was administered, although plasma gemfibrozil and gemfibrozil 1-O-β-glucuronide concns. were only 5 and 10% of their peak values, resp.  The long-lasting interaction is likely caused by mechanism-based inhibition of CYP2C8 by gemfibrozil glucuronide.  Clin. Pharmacol. & Therapeutics (2008); 84, 3, 403-411 doi:10.1038/clpt.2008.34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrcii5pN3YQLVg90H21EOLACvtfcHk0lgvigso2yKv8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVShtr7K&md5=bb45f6f89c9f504af39116de52b5b825</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2008.34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2008.34%26sid%3Dliteratum%253Aachs%26aulast%3DTornio%26aufirst%3DA.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DLaitila%26aufirst%3DJ.%26aulast%3DKalliokoski%26aufirst%3DA.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520effect%2520of%2520gemfibrozil%2520on%2520repaglinide%2520pharmacokinetics%2520persists%2520for%2520at%2520least%252012%2520h%2520after%2520the%2520dose%253A%2520evidence%2520for%2520mechanism-based%2520inhibition%2520of%2520CYP2C8%2520in%2520vivo%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2008%26volume%3D84%26spage%3D403%26epage%3D411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Honkalammi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1038%2Fclpt.2010.358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=21368757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjs1Cls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=579-586&author=J.+Honkalammiauthor=M.+Niemiauthor=P.+J.+Neuvonenauthor=J.+T.+Backman&title=Mechanism-based+inactivation+of+CYP2C8+by+gemfibrozil+occurs+rapidly+in+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans</span></div><div class="casAuthors">Honkalammi, J.; Niemi, M.; Neuvonen, P. J.; Backman, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">579-586</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To study the time to onset of mechanism-based inactivation of cytochrome P 450 (CYP) 2C8 by gemfibrozil in vivo, we conducted a randomized five-phase crossover study in 10 healthy volunteers.  In one phase the volunteers ingested 0.25 mg of repaglinide alone (control), and in the other phases they received 600 mg of gemfibrozil 0-6 h prior to the repaglinide dose.  When gemfibrozil was taken 0, 1, 3, or 6 h before repaglinide, the geometric mean ratio relative to control (90% confidence interval (CI)) of repaglinide area under the plasma concn.-time curve (AUC0-∞) was 5.0-fold (4.3-5.7-fold), 6.3-fold (5.4-7.5-fold), 6.6-fold (5.6-7.7-fold), and 5.4-fold (4.8-6.1-fold), resp. (P < 0.001 vs. control).  The geometric mean ratio relative to control (90% CI) of the max. plasma concn. (Cmax) of the CYP2C8-mediated metabolite M4 was 1.0-fold (0.8-1.3-fold), 0.10-fold (0.06-0.17-fold, P < 0.001), 0.06-fold (0.04-0.10-fold, P < 0.001), and 0.09-fold (0.05-0.14-fold, P < 0.001), resp.  The strong inactivation of CYP2C8, evident as soon as 1 h after gemfibrozil dosing, has implications in clin. practice and in studies with gemfibrozil as a CYP2C8 model inhibitor.  Clin. Pharmacol. & Therapeutics (2011) 89 4, 579-586. doi:10.1038/clpt.2010.358.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0t7uqdCQkRLVg90H21EOLACvtfcHk0lgvigso2yKv8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjs1Cls70%253D&md5=6aaf0c8576c45142bb428bad130cae77</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2010.358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2010.358%26sid%3Dliteratum%253Aachs%26aulast%3DHonkalammi%26aufirst%3DJ.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26atitle%3DMechanism-based%2520inactivation%2520of%2520CYP2C8%2520by%2520gemfibrozil%2520occurs%2520rapidly%2520in%2520humans%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D89%26spage%3D579%26epage%3D586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Baer, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeLisle, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Benzylic oxidation of gemfibrozil-1-<i>O</i>-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1298</span><span class="NLM_x">–</span> <span class="NLM_lpage">1309</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx900105n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=1298-1309&author=B.+R.+Baerauthor=R.+K.+DeLisleauthor=A.+Allen&title=Benzylic+oxidation+of+gemfibrozil-1-O-beta-glucuronide+by+P450+2C8+leads+to+heme+alkylation+and+irreversible+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Ftx900105n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx900105n%26sid%3Dliteratum%253Aachs%26aulast%3DBaer%26aufirst%3DB.%2BR.%26aulast%3DDeLisle%26aufirst%3DR.%2BK.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DBenzylic%2520oxidation%2520of%2520gemfibrozil-1-O-beta-glucuronide%2520by%2520P450%25202C8%2520leads%2520to%2520heme%2520alkylation%2520and%2520irreversible%2520inhibition%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D1298%26epage%3D1309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Jenkins, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, A. D.</span><span> </span><span class="NLM_article-title">Studies to further investigate the inhibition of human liver microsomal cytochrome P4502C8 (CYP2C8) by the acyl-β-glucuronide of gemfibrozil</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">2421</span><span class="NLM_x">–</span> <span class="NLM_lpage">2430</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=2421-2430&author=S.+M.+Jenkinsauthor=T.+Zvyagaauthor=S.+R.+Johnsonauthor=J.+Hurleyauthor=A.+Wagnerauthor=R.+Burrellauthor=W.+Turleyauthor=J.+E.+Leetauthor=T.+Philipauthor=A.+D.+Rodrigues&title=Studies+to+further+investigate+the+inhibition+of+human+liver+microsomal+cytochrome+P4502C8+%28CYP2C8%29+by+the+acyl-%CE%B2-glucuronide+of+gemfibrozil"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJenkins%26aufirst%3DS.%2BM.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DHurley%26aufirst%3DJ.%26aulast%3DWagner%26aufirst%3DA.%26aulast%3DBurrell%26aufirst%3DR.%26aulast%3DTurley%26aufirst%3DW.%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DPhilip%26aufirst%3DT.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26atitle%3DStudies%2520to%2520further%2520investigate%2520the%2520inhibition%2520of%2520human%2520liver%2520microsomal%2520cytochrome%2520P4502C8%2520%2528CYP2C8%2529%2520by%2520the%2520acyl-%25CE%25B2-glucuronide%2520of%2520gemfibrozil%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D2421%26epage%3D2430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roadcap, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Mechanistic studies on metabolic interactions between gemfibrozil and statins</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">301</span><span class="NLM_x">, </span> <span class="NLM_fpage">1042</span><span class="NLM_x">–</span> <span class="NLM_lpage">1051</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1124%2Fjpet.301.3.1042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=12023536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlGjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=2002&pages=1042-1051&author=T.+Prueksaritanontauthor=J.+J.+Zhaoauthor=B.+Maauthor=B.+A.+Roadcapauthor=C.+Tangauthor=Y.+Qiuauthor=L.+Liuauthor=J.+H.+Linauthor=P.+G.+Pearsonauthor=T.+A.+Baillie&title=Mechanistic+studies+on+metabolic+interactions+between+gemfibrozil+and+statins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic studies on metabolic interactions between gemfibrozil and statins</span></div><div class="casAuthors">Prueksaritanont, Thomayant; Zhao, Jamie J.; Ma, Bennett; Roadcap, Brad A.; Tang, Cuyue; Qiu, Yue; Liu, Lida; Lin, Jiunn H.; Pearson, Paul G.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1042-1051</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A series of studies were conducted to explore the mechanism of the pharmacokinetic interaction between simvastatin (SV) and gemfibrozil (GFZ) reported recently in human subjects.  After administration of a single dose of SV (4 mg/kg p.o.) to dogs pretreated with GFZ (75 mg/kg p.o., twice daily for 5 days), there was an increase (∼4-fold) in systemic exposure to simvastatin hydroxy acid (SVA), but not to SV, similar to the observation in humans.  GFZ pretreatment did not increase the ex vivo hydrolysis of SV to SVA in dog plasma.  In dog and human liver microsomes, GFZ exerted a minimal inhibitory effect on CYP3A-mediated SVA oxidn., but did inhibit SVA glucuronidation.  After i.v. administration of [14C]SVA to dogs, GFZ treatment significantly reduced (2-3-fold) the plasma clearance of SVA and the biliary excretion of SVA glucuronide (together with its cyclization product SV), but not the excretion of a major oxidative metabolite of SVA, consistent with the in vitro findings in dogs.  Among six human UGT isoenzymes tested, UGT1A1 and 1A3 were capable of catalyzing the glucuronidation of both GFZ and SVA.  Further studies conducted in human liver microsomes with atorvastatin (AVA) showed that, as with SVA, GFZ was a less potent inhibitor of the CYP3A4-mediated oxidn. of this drug than its glucuronidation.  However, with cerivastatin (CVA), the glucuronidation as well as the CYP2C8- and CYP3A4-mediated oxidn. pathways were much more susceptible to inhibition by GFZ than was obsd. with SVA or AVA.  Collectively, the results of these studies provide metabolic insight into the nature of drug-drug interaction between GFZ and statins, and a possible explanation for the enhanced susceptibility of CVA to interactions with GFZ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqflGfEYfS4MbVg90H21EOLACvtfcHk0lifczRQJpxQRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlGjsbw%253D&md5=f265ac0589d946766de5206f4fb41de7</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1124%2Fjpet.301.3.1042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.301.3.1042%26sid%3Dliteratum%253Aachs%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DRoadcap%26aufirst%3DB.%2BA.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DMechanistic%2520studies%2520on%2520metabolic%2520interactions%2520between%2520gemfibrozil%2520and%2520statins%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D301%26spage%3D1042%26epage%3D1051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strong-Basalyga, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenhandler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlini, E. J.</span><span> </span><span class="NLM_article-title">Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">71</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2005&pages=71-78&author=T.+Prueksaritanontauthor=K.+M.+Richardsauthor=Y.+Qiuauthor=K.+Strong-Basalygaauthor=A.+Millerauthor=C.+Liauthor=R.+Eisenhandlerauthor=E.+J.+Carlini&title=Comparative+effects+of+fibrates+on+drug+metabolizing+enzymes+in+human+hepatocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DRichards%26aufirst%3DK.%2BM.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DStrong-Basalyga%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DEisenhandler%26aufirst%3DR.%26aulast%3DCarlini%26aufirst%3DE.%2BJ.%26atitle%3DComparative%2520effects%2520of%2520fibrates%2520on%2520drug%2520metabolizing%2520enzymes%2520in%2520human%2520hepatocytes%26jtitle%3DPharm.%2520Res.%26date%3D2005%26volume%3D22%26spage%3D71%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngui, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doss, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNinno, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blizzard, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stearns, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">907</span><span class="NLM_x">–</span> <span class="NLM_lpage">914</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx0200109" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD38Xkt1KrurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2002&pages=907-914&author=Q.+Chenauthor=J.+S.+Nguiauthor=G.+A.+Dossauthor=R.+W.+Wangauthor=X.+Caiauthor=F.+P.+DiNinnoauthor=T.+A.+Blizzardauthor=M.+L.+Hammondauthor=R.+A.+Stearnsauthor=D.+C.+Evansauthor=T.+A.+Baillie&title=Cytochrome+P450+3A4-mediated+bioactivation+of+raloxifene%3A+irreversible+enzyme+inhibition+and+thiol+adduct+formation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation</span></div><div class="casAuthors">Chen, Qing; Ngui, Jason S.; Doss, George A.; Wang, Regina W.; Cai, Xiaoxin; DiNinno, Frank P.; Blizzard, Timothy A.; Hammond, Milton L.; Stearns, Ralph A.; Evans, David C.; Baillie, Thomas A.; Tang, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">907-914</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Raloxifene is a selective estrogen receptor modulator which is effective in the treatment of osteoporosis in postmenopausal women.  We report herein that cytochrome P 450 3A4 is inhibited by raloxifene in human liver microsomal incubations.  The nature of the inhibition was irreversible and was NADPH- and preincubation time-dependent, with KI and kinact values estd. at 9.9 μM and 0.16 min-1, resp.  The obsd. loss of P 450 3A4 activity was attenuated partially by glutathione (GSH), implying the involvement of a reactive metabolite(s) in the inactivation process.  Subsequently, GSH adducts of raloxifene were identified in incubations with human liver microsomes; substitution with GSH occurred at the 5- or 7-position of the benzothiophene moiety or at the 3'-position of the phenol ring, with the 7-glutathionyl deriv. being most abundant based on LC/MS and NMR analyses.  These adducts are postulated to derive from addn. of GSH to raloxifene arene oxides followed by dehydration and aromatization.  Alternatively, raloxifene may be oxidized to an extended quinone intermediate, which then is trapped by GSH conjugation.  The bioactivation of raloxifene most likely is catalyzed by P 450 3A4, since the formation of GSH adducts was almost abolished when liver microsomes were pretreated with ketoconazole or with an inhibitory anti-P 450 3A4 IgG.  The GSH adducts also were detected in incubations of raloxifene with rat or human hepatocytes, while the corresponding N-acetylcysteine adducts were identified in the bile and urine from rats treated orally with the drug at 5 mg/kg.  Taken together, these data indicate that P 450 3A4-mediated bioactivation of raloxifene in vitro is accompanied by loss of enzyme activity.  The significance of these findings with respect to the clin. use of raloxifene remains to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvQ7INUtJwIbVg90H21EOLACvtfcHk0lifczRQJpxQRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xkt1KrurY%253D&md5=cec21bf3d8ce150474291a5e48206744</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Ftx0200109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx0200109%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DNgui%26aufirst%3DJ.%2BS.%26aulast%3DDoss%26aufirst%3DG.%2BA.%26aulast%3DWang%26aufirst%3DR.%2BW.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DDiNinno%26aufirst%3DF.%2BP.%26aulast%3DBlizzard%26aufirst%3DT.%2BA.%26aulast%3DHammond%26aufirst%3DM.%2BL.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DCytochrome%2520P450%25203A4-mediated%2520bioactivation%2520of%2520raloxifene%253A%2520irreversible%2520enzyme%2520inhibition%2520and%2520thiol%2520adduct%2520formation%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2002%26volume%3D15%26spage%3D907%26epage%3D914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Baer, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wienkers, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rock, D. A.</span><span> </span><span class="NLM_article-title">Time-dependent inactivation of P4503A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">954</span><span class="NLM_x">–</span> <span class="NLM_lpage">964</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx700037e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=954-964&author=B.+R.+Baerauthor=L.+C.+Wienkersauthor=D.+A.+Rock&title=Time-dependent+inactivation+of+P4503A4+by+raloxifene%3A+identification+of+Cys239+as+the+site+of+apoprotein+alkylation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Ftx700037e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx700037e%26sid%3Dliteratum%253Aachs%26aulast%3DBaer%26aufirst%3DB.%2BR.%26aulast%3DWienkers%26aufirst%3DL.%2BC.%26aulast%3DRock%26aufirst%3DD.%2BA.%26atitle%3DTime-dependent%2520inactivation%2520of%2520P4503A4%2520by%2520raloxifene%253A%2520identification%2520of%2520Cys239%2520as%2520the%2520site%2520of%2520apoprotein%2520alkylation%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D954%26epage%3D964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Pearson, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahlstrom, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickman, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halpert, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wienkers, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foti, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rock, D. A.</span><span> </span><span class="NLM_article-title">Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1778</span><span class="NLM_x">–</span> <span class="NLM_lpage">1786</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx700207u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=1778-1786&author=J.+T.+Pearsonauthor=J.+L.+Wahlstromauthor=L.+J.+Dickmanauthor=S.+Kumarauthor=J.+R.+Halpertauthor=L.+C.+Wienkersauthor=R.+S.+Fotiauthor=D.+A.+Rock&title=Differential+time-dependent+inactivation+of+P450+3A4+and+P450+3A5+by+raloxifene%3A+a+key+role+for+C239+in+quenching+reactive+intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Ftx700207u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx700207u%26sid%3Dliteratum%253Aachs%26aulast%3DPearson%26aufirst%3DJ.%2BT.%26aulast%3DWahlstrom%26aufirst%3DJ.%2BL.%26aulast%3DDickman%26aufirst%3DL.%2BJ.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DHalpert%26aufirst%3DJ.%2BR.%26aulast%3DWienkers%26aufirst%3DL.%2BC.%26aulast%3DFoti%26aufirst%3DR.%2BS.%26aulast%3DRock%26aufirst%3DD.%2BA.%26atitle%3DDifferential%2520time-dependent%2520inactivation%2520of%2520P450%25203A4%2520and%2520P450%25203A5%2520by%2520raloxifene%253A%2520a%2520key%2520role%2520for%2520C239%2520in%2520quenching%2520reactive%2520intermediates%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D1778%26epage%3D1786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Yukinaga, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takami, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shioyama, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozuka, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masumoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okazaki, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudo, K.</span><span> </span><span class="NLM_article-title">Identification of cytochrome P450 3A4 modification site with reactive metabolite using linear ion trap-Fourier transform mass spectrometry</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1373</span><span class="NLM_x">–</span> <span class="NLM_lpage">1378</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx700165q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=1373-1378&author=H.+Yukinagaauthor=T.+Takamiauthor=S.+H.+Shioyamaauthor=Z.+Tozukaauthor=H.+Masumotoauthor=O.+Okazakiauthor=K.+Sudo&title=Identification+of+cytochrome+P450+3A4+modification+site+with+reactive+metabolite+using+linear+ion+trap-Fourier+transform+mass+spectrometry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Ftx700165q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx700165q%26sid%3Dliteratum%253Aachs%26aulast%3DYukinaga%26aufirst%3DH.%26aulast%3DTakami%26aufirst%3DT.%26aulast%3DShioyama%26aufirst%3DS.%2BH.%26aulast%3DTozuka%26aufirst%3DZ.%26aulast%3DMasumoto%26aufirst%3DH.%26aulast%3DOkazaki%26aufirst%3DO.%26aulast%3DSudo%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520cytochrome%2520P450%25203A4%2520modification%2520site%2520with%2520reactive%2520metabolite%2520using%2520linear%2520ion%2520trap-Fourier%2520transform%2520mass%2520spectrometry%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D1373%26epage%3D1378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">Mizuma, T.</span><span> </span><span class="NLM_article-title">Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10</span> <span class="citation_source-journal">Int. J. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">378</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.ijpharm.2009.05.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=19486934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovFKqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2009&pages=140-141&author=T.+Mizuma&title=Intestinal+glucuronidation+metabolism+may+have+a+greater+impact+on+oral+bioavailability+than+hepatic+glucuronidation+metabolism+in+humans%3A+a+study+with+raloxifene%2C+substrate+for+UGT1A1%2C+1A8%2C+1A9%2C+and+1A10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10</span></div><div class="casAuthors">Mizuma, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">140-141</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The kinetic impact of intestinal glucuronidation metab. on oral bioavailability (F) was assessed using reported human data of raloxifene, of which oral bioavailability was only 2%.  Kinetic anal. showed that presystemic intestinal availability (Fpg) was 5.4%, whereas fraction absorbed (Ff) and hepatic availability (Fh) were 63% and 59.3%, resp.  Thus, Fpg was the lowest among factors, which affect oral bioavailability.  In addn., Fpg was much lower than Fh, suggesting that intestinal glucuronidation metab. has a greater impact on oral bioavailability than hepatic glucuronidation metab.  It has been reported that UDP-glucuronosyltransferase (UGT) 1A1, UGT1A8, UGT1A9, and UGT1A10 are enzymes for raloxifene glucuronidation, and UGT1A8 and UGT1A10 are absent in the human liver, whereas UGT1A1, UGT1A8, UGT1A9, and UGT1A10 are present in the human intestine.  Therefore, it is also suggested that intestinal glucuronidation catalyzed by UGTs, particularly UGT1A8 and UGT1A10, may play important roles in the first-pass metab., causing low oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFWR7hNsC17rVg90H21EOLACvtfcHk0lhCgGGGInjjSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovFKqtbs%253D&md5=293c4c269d54a0e92e32c9aa473d50d6</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2009.05.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2009.05.044%26sid%3Dliteratum%253Aachs%26aulast%3DMizuma%26aufirst%3DT.%26atitle%3DIntestinal%2520glucuronidation%2520metabolism%2520may%2520have%2520a%2520greater%2520impact%2520on%2520oral%2520bioavailability%2520than%2520hepatic%2520glucuronidation%2520metabolism%2520in%2520humans%253A%2520a%2520study%2520with%2520raloxifene%252C%2520substrate%2520for%2520UGT1A1%252C%25201A8%252C%25201A9%252C%2520and%25201A10%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2009%26volume%3D378%26spage%3D140%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Mullins, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horowitz, B. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linden, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stump, J.</span><span> </span><span class="NLM_article-title">Life-threatening interaction between mibefradil and beta-blockers with dihydropyridine calcium channel blockers</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">158</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=1998&pages=157-158&author=M.+E.+Mullinsauthor=B.+Z.+Horowitzauthor=D.+H.+Lindenauthor=G.+W.+Smithauthor=R.+L.+Nortonauthor=J.+Stump&title=Life-threatening+interaction+between+mibefradil+and+beta-blockers+with+dihydropyridine+calcium+channel+blockers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMullins%26aufirst%3DM.%2BE.%26aulast%3DHorowitz%26aufirst%3DB.%2BZ.%26aulast%3DLinden%26aufirst%3DD.%2BH.%26aulast%3DSmith%26aufirst%3DG.%2BW.%26aulast%3DNorton%26aufirst%3DR.%2BL.%26aulast%3DStump%26aufirst%3DJ.%26atitle%3DLife-threatening%2520interaction%2520between%2520mibefradil%2520and%2520beta-blockers%2520with%2520dihydropyridine%2520calcium%2520channel%2520blockers%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D1998%26volume%3D280%26spage%3D157%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Schmassmann-Suhijar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullingham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmutz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haefeli, W. E.</span><span> </span><span class="NLM_article-title">Rhabdomyolysis due to interaction of simvastatin with mibefradil</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">351</span><span class="NLM_x">, </span> <span class="NLM_fpage">1929</span><span class="NLM_x">–</span> <span class="NLM_lpage">1930</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=1998&pages=1929-1930&author=D.+Schmassmann-Suhijarauthor=R.+Bullinghamauthor=R.+Gasserauthor=J.+Schmutzauthor=W.+E.+Haefeli&title=Rhabdomyolysis+due+to+interaction+of+simvastatin+with+mibefradil"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchmassmann-Suhijar%26aufirst%3DD.%26aulast%3DBullingham%26aufirst%3DR.%26aulast%3DGasser%26aufirst%3DR.%26aulast%3DSchmutz%26aufirst%3DJ.%26aulast%3DHaefeli%26aufirst%3DW.%2BE.%26atitle%3DRhabdomyolysis%2520due%2520to%2520interaction%2520of%2520simvastatin%2520with%2520mibefradil%26jtitle%3DLancet%26date%3D1998%26volume%3D351%26spage%3D1929%26epage%3D1930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Billups, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, B. L.</span><span> </span><span class="NLM_article-title">Mibefradil withdrawn from the market</span> <span class="citation_source-journal">Ann. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">841</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1998&pages=841&author=S.+J.+Billupsauthor=B.+L.+Carter&title=Mibefradil+withdrawn+from+the+market"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBillups%26aufirst%3DS.%2BJ.%26aulast%3DCarter%26aufirst%3DB.%2BL.%26atitle%3DMibefradil%2520withdrawn%2520from%2520the%2520market%26jtitle%3DAnn.%2520Pharmacother.%26date%3D1998%26volume%3D32%26spage%3D841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reider, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver microsomes</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1046%2Fj.1365-2125.1999.00903.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=10215754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK1MXisVKiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1999&pages=291-298&author=T.+Prueksaritanontauthor=B.+Maauthor=C.+Tangauthor=Y.+Mengauthor=C.+Assangauthor=P.+Luauthor=P.+J.+Reiderauthor=J.+H.+Linauthor=T.+A.+Baillie&title=Metabolic+interactions+between+mibefradil+and+HMG-CoA+reductase+inhibitors%3A+an+in+vitro+investigation+with+human+liver+microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations</span></div><div class="casAuthors">Prueksaritanont, Thomayant; Ma, Bennett; Tang, Cuyue; Meng, Yuan; Assang, Carol; Lu, Ping; Reider, Paul J.; Lin, Jiunn H.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-298</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Aims: To det. the effects of mibefradil on the metab. in human liver microsomal prepns. of the HMG-CoA reductase inhibitors simvastatin, lovastatin, atorvastatin, cerivastatin and fluvastatin.  Metab. of the above five statins (0.5, 5 or 10 μM), as well as of specific CYP3A4/5 and CYP2C8/9 marker substrates, was examd. in human liver microsomal prepns. in the presence and absence of mibefradil (0.1-50 μM).  Mibefradil inhibited, in a concn.-dependent fashion, the metab. of the four statins (simvastatin, lovastatin, atorvastatin and cerivastatin) known to be substrates for CYP3A.  The potency of inhibition was such that the IC50 values (< 1μM) for inhibition of all of the CYP3A substrates fell within the therapeutic plasma concns. of mibefradil, and was comparable with that of ketoconazole.  However, the inhibition by mibefradil, unlike that of ketoconazole, was at least in part mechanism-based.  Based on the kinetics of its inhibition of hepatic testosterone 6β-hydroxylase activity, mibefradil was judged to be a powerful mechanism-based inhibitor of CYP3A4/5, with values for Kinactivation, Ki and partition ratio (moles of mibefradil metabolized per mol. of enzyme inactivated) of 0.4 min-1, 2.3 μM and 1.7, resp.  In contrast to the results with substrates of CYP3A, metab. of fluvastatin, a substrate of CYP2C8/9, and the hydroxylation of tolbutamide, a functional probe for CYP2C8/9, were not inhibited by mibefradil.  Mibefradil, at therapeutically relevant concns., strongly suppressed the metab. in human liver microsomes of simvastatin, lovastatin, atorvastatin and cerivastatin through its inhibitory effects on CYP3A4/5, while the effects of mibefradil on fluvastatin, a substrate for CYP2C8/9, were minimal in this system.  Since mibefradil is a potent mechanism-based inhibitor of CYP3A4/5, it is anticipated that clin. significant drug-drug interactions will likely ensue when mibefradil is coadministered with agents which are cleared primarily by CYP3A-mediated pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2qEUHS8dzULVg90H21EOLACvtfcHk0ljZxUDie-zz5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXisVKiu7c%253D&md5=b919d4f3a0312ad030c4b9b80c9ef4f9</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2125.1999.00903.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2125.1999.00903.x%26sid%3Dliteratum%253Aachs%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DMeng%26aufirst%3DY.%26aulast%3DAssang%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DReider%26aufirst%3DP.%2BJ.%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DMetabolic%2520interactions%2520between%2520mibefradil%2520and%2520HMG-CoA%2520reductase%2520inhibitors%253A%2520an%2520in%2520vitro%2520investigation%2520with%2520human%2520liver%2520microsomes%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1999%26volume%3D47%26spage%3D291%26epage%3D298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Wiltshire, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heeps, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betty, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angus, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madigan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, S. R.</span><span> </span><span class="NLM_article-title">Metabolism of the calcium antagonist, mibefradil (POSICOR, Ro 40-5967). Part II. Metabolism in hepatic microsomes from rat, marmoset, cynomolgus monkey, rabbit and man</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">556</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1997&pages=539-556&author=H.+R.+Wiltshireauthor=B.+M.+Suttonauthor=G.+Heepsauthor=A.+M.+Bettyauthor=D.+W.+Angusauthor=M.+J.+Madiganauthor=S.+R.+Sharp&title=Metabolism+of+the+calcium+antagonist%2C+mibefradil+%28POSICOR%2C+Ro+40-5967%29.+Part+II.+Metabolism+in+hepatic+microsomes+from+rat%2C+marmoset%2C+cynomolgus+monkey%2C+rabbit+and+man"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWiltshire%26aufirst%3DH.%2BR.%26aulast%3DSutton%26aufirst%3DB.%2BM.%26aulast%3DHeeps%26aufirst%3DG.%26aulast%3DBetty%26aufirst%3DA.%2BM.%26aulast%3DAngus%26aufirst%3DD.%2BW.%26aulast%3DMadigan%26aufirst%3DM.%2BJ.%26aulast%3DSharp%26aufirst%3DS.%2BR.%26atitle%3DMetabolism%2520of%2520the%2520calcium%2520antagonist%252C%2520mibefradil%2520%2528POSICOR%252C%2520Ro%252040-5967%2529.%2520Part%2520II.%2520Metabolism%2520in%2520hepatic%2520microsomes%2520from%2520rat%252C%2520marmoset%252C%2520cynomolgus%2520monkey%252C%2520rabbit%2520and%2520man%26jtitle%3DXenobiotica%26date%3D1997%26volume%3D27%26spage%3D539%26epage%3D556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">Foti, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rock, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahlstrom, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wienkers, L. C.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of cytochrome P4503A4 by mibefradil through heme destruction</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1188</span><span class="NLM_x">–</span> <span class="NLM_lpage">1195</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1188-1195&author=R.+S.+Fotiauthor=D.+A.+Rockauthor=J.+T.+Pearsonauthor=J.+L.+Wahlstromauthor=L.+C.+Wienkers&title=Mechanism-based+inactivation+of+cytochrome+P4503A4+by+mibefradil+through+heme+destruction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFoti%26aufirst%3DR.%2BS.%26aulast%3DRock%26aufirst%3DD.%2BA.%26aulast%3DPearson%26aufirst%3DJ.%2BT.%26aulast%3DWahlstrom%26aufirst%3DJ.%2BL.%26aulast%3DWienkers%26aufirst%3DL.%2BC.%26atitle%3DMechanism-based%2520inactivation%2520of%2520cytochrome%2520P4503A4%2520by%2520mibefradil%2520through%2520heme%2520destruction%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1188%26epage%3D1195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Magee, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripp, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buzon, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chupak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougherty, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finegan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagen, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcone, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granskog, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardnik, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huband, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamicker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knickerbocker, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noe, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penzien, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, U. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schafer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tait-Kamradt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaz, A. D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widlicka, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishka, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolkowski, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span> </span><span class="NLM_article-title">Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7446</span><span class="NLM_x">–</span> <span class="NLM_lpage">7457</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900729s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7446-7457&author=T.+V.+Mageeauthor=S.+L.+Rippauthor=B.+Liauthor=R.+A.+Buzonauthor=L.+Chupakauthor=T.+J.+Doughertyauthor=S.+M.+Fineganauthor=D.+Girardauthor=A.+E.+Hagenauthor=M.+J.+Falconeauthor=K.+A.+Farleyauthor=K.+Granskogauthor=J.+R.+Hardnikauthor=M.+D.+Hubandauthor=B.+J.+Kamickerauthor=T.+Kanekoauthor=M.+J.+Knickerbockerauthor=J.+L.+Lirasauthor=A.+Marraauthor=I.+Medinaauthor=T.-T.+Nguyenauthor=M.+C.+Noeauthor=R.+S.+Obachauthor=J.+P.+O%E2%80%99Donnellauthor=J.+B.+Penzienauthor=U.+D.+Reillyauthor=J.+R.+Schaferauthor=Y.+Shenauthor=G.+G.+Stoneauthor=T.+J.+Strelevitzauthor=J.+Sunauthor=A.+Tait-Kamradtauthor=A.+D.+N.+Vazauthor=D.+A.+Whippleauthor=D.+W.+Widlickaauthor=D.+G.+Wishkaauthor=J.+P.+Wolkowskiauthor=M.+E.+Flanagan&title=Discovery+of+azetidinyl+ketolides+for+the+treatment+of+susceptible+and+multidrug+resistant+community-acquired+respiratory+tract+infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Fjm900729s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900729s%26sid%3Dliteratum%253Aachs%26aulast%3DMagee%26aufirst%3DT.%2BV.%26aulast%3DRipp%26aufirst%3DS.%2BL.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DBuzon%26aufirst%3DR.%2BA.%26aulast%3DChupak%26aufirst%3DL.%26aulast%3DDougherty%26aufirst%3DT.%2BJ.%26aulast%3DFinegan%26aufirst%3DS.%2BM.%26aulast%3DGirard%26aufirst%3DD.%26aulast%3DHagen%26aufirst%3DA.%2BE.%26aulast%3DFalcone%26aufirst%3DM.%2BJ.%26aulast%3DFarley%26aufirst%3DK.%2BA.%26aulast%3DGranskog%26aufirst%3DK.%26aulast%3DHardnik%26aufirst%3DJ.%2BR.%26aulast%3DHuband%26aufirst%3DM.%2BD.%26aulast%3DKamicker%26aufirst%3DB.%2BJ.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DKnickerbocker%26aufirst%3DM.%2BJ.%26aulast%3DLiras%26aufirst%3DJ.%2BL.%26aulast%3DMarra%26aufirst%3DA.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DNguyen%26aufirst%3DT.-T.%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BP.%26aulast%3DPenzien%26aufirst%3DJ.%2BB.%26aulast%3DReilly%26aufirst%3DU.%2BD.%26aulast%3DSchafer%26aufirst%3DJ.%2BR.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DStone%26aufirst%3DG.%2BG.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DTait-Kamradt%26aufirst%3DA.%26aulast%3DVaz%26aufirst%3DA.%2BD.%2BN.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DWidlicka%26aufirst%3DD.%2BW.%26aulast%3DWishka%26aufirst%3DD.%2BG.%26aulast%3DWolkowski%26aufirst%3DJ.%2BP.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26atitle%3DDiscovery%2520of%2520azetidinyl%2520ketolides%2520for%2520the%2520treatment%2520of%2520susceptible%2520and%2520multidrug%2520resistant%2520community-acquired%2520respiratory%2520tract%2520infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7446%26epage%3D7457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Linus, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanza, T.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieczykowski, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treonze, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Si, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manior, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuelke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pivnichny, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacCoss, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mumford, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagmann, W. K.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-{<i>N</i>-[(3-cyanophenyl)sulfonyl]-4(<i>R</i>)-cyclobutylamino-(<span class="smallcaps smallerCapital">l</span>)-prolyl}-4-[(3′,5′-dichloroisonicotinoyl)amino]-(<span class="smallcaps smallerCapital">l</span>)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3449</span><span class="NLM_x">–</span> <span class="NLM_lpage">3452</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3449-3452&author=L.+S.+Linusauthor=T.+Lanzaauthor=J.+P.+Jewellauthor=P.+Liuauthor=C.+Jonesauthor=G.+R.+Kieczykowskiauthor=K.+Treonzeauthor=Q.+Siauthor=S.+Maniorauthor=G.+Kooauthor=X.+Tongauthor=J.+Wangauthor=A.+Schuelkeauthor=J.+Pivnichnyauthor=R.+Wangauthor=C.+Raabauthor=S.+Vincentauthor=P.+Daviesauthor=M.+MacCossauthor=R.+A.+Mumfordauthor=W.+K.+Hagmann&title=Discovery+of+N-%7BN-%5B%283-cyanophenyl%29sulfonyl%5D-4%28R%29-cyclobutylamino-%28l%29-prolyl%7D-4-%5B%283%E2%80%B2%2C5%E2%80%B2-dichloroisonicotinoyl%29amino%5D-%28l%29-phenylalanine+%28MK-0668%29%2C+an+extremely+potent+and+orally+active+antagonist+of+very+late+antigen-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLinus%26aufirst%3DL.%2BS.%26aulast%3DLanza%26aufirst%3DT.%26aulast%3DJewell%26aufirst%3DJ.%2BP.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DKieczykowski%26aufirst%3DG.%2BR.%26aulast%3DTreonze%26aufirst%3DK.%26aulast%3DSi%26aufirst%3DQ.%26aulast%3DManior%26aufirst%3DS.%26aulast%3DKoo%26aufirst%3DG.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSchuelke%26aufirst%3DA.%26aulast%3DPivnichny%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DRaab%26aufirst%3DC.%26aulast%3DVincent%26aufirst%3DS.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DMacCoss%26aufirst%3DM.%26aulast%3DMumford%26aufirst%3DR.%2BA.%26aulast%3DHagmann%26aufirst%3DW.%2BK.%26atitle%3DDiscovery%2520of%2520N-%257BN-%255B%25283-cyanophenyl%2529sulfonyl%255D-4%2528R%2529-cyclobutylamino-%2528l%2529-prolyl%257D-4-%255B%25283%25E2%2580%25B2%252C5%25E2%2580%25B2-dichloroisonicotinoyl%2529amino%255D-%2528l%2529-phenylalanine%2520%2528MK-0668%2529%252C%2520an%2520extremely%2520potent%2520and%2520orally%2520active%2520antagonist%2520of%2520very%2520late%2520antigen-4%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3449%26epage%3D3452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Westaway, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fell, S. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacPherson, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myatt, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanway, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seal, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stemp, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawless, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKay, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cluff, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahmood, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohamed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolton, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvie, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanger, G. J.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(3-fluorophenyl)-1-[(4-([(3<i>S</i>)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1180</span><span class="NLM_x">–</span> <span class="NLM_lpage">1189</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801332q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1180-1189&author=S.+M.+Westawayauthor=S.+L.+Brownauthor=S.+C.+M.+Fellauthor=C.+N.+Johnsonauthor=D.+T.+MacPhersonauthor=D.+J.+Mitchellauthor=J.+W.+Myattauthor=S.+J.+Stanwayauthor=J.+T.+Sealauthor=G.+Stempauthor=M.+Thompsonauthor=K.+Lawlessauthor=F.+McKayauthor=A.+I.+Muirauthor=J.+M.+Barfordauthor=C.+Cluffauthor=S.+R.+Mahmoodauthor=K.+L.+Matthewsauthor=S.+Mohamedauthor=B.+Smithauthor=A.+J.+Stevensauthor=V.+J.+Boltonauthor=E.+M.+Jarvieauthor=G.+J.+Sanger&title=Discovery+of+N-%283-fluorophenyl%29-1-%5B%284-%28%5B%283S%29-3-methyl-1-piperazinyl%5Dmethyl%29phenyl%29acetyl%5D-4-piperidinamine+%28GSK962040%29%2C+the+first+small+molecule+motilin+receptor+agonist+clinical+candidate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(3-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the First Small Molecule Motilin Receptor Agonist Clinical Candidate</span></div><div class="casAuthors">Westaway, Susan M.; Brown, Samantha L.; Fell, Stephen C. M.; Johnson, Christopher N.; MacPherson, David T.; Mitchell, Darren J.; Myatt, James W.; Stanway, Steven J.; Seal, Jon T.; Stemp, Geoffrey; Thompson, Mervyn; Lawless, Kirk; McKay, Fiona; Muir, Alison I.; Barford, Jonathan M.; Cluff, Chermaine; Mahmood, Sadhia R.; Matthews, Kim L.; Mohamed, Shiyam; Smith, Beverley; Stevens, Alexander J.; Bolton, Victoria J.; Jarvie, Emma M.; Sanger, Gareth J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1180-1189</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-(3-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine 12 (GSK962040) is a novel small mol. motilin receptor agonist.  It possesses excellent activity at the recombinant human motilin receptor and also at the native rabbit motilin receptor where its agonist activity results in potentiation of the amplitude of neuronal-mediated contractions of isolated gastric antrum tissue.  Compd. 12 also possesses highly promising pharmacokinetic profiles in both rat and dog, and these results, in combination with further profiling in human native tissue and an in vivo model of gastrointestinal transit in the rabbit, have led to its selection as a candidate for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQHUqCK5ybBrVg90H21EOLACvtfcHk0lglInQFZJAhfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSltbg%253D&md5=908680cc14aa8542d05cb128a2cea49b</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Fjm801332q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801332q%26sid%3Dliteratum%253Aachs%26aulast%3DWestaway%26aufirst%3DS.%2BM.%26aulast%3DBrown%26aufirst%3DS.%2BL.%26aulast%3DFell%26aufirst%3DS.%2BC.%2BM.%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26aulast%3DMacPherson%26aufirst%3DD.%2BT.%26aulast%3DMitchell%26aufirst%3DD.%2BJ.%26aulast%3DMyatt%26aufirst%3DJ.%2BW.%26aulast%3DStanway%26aufirst%3DS.%2BJ.%26aulast%3DSeal%26aufirst%3DJ.%2BT.%26aulast%3DStemp%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DM.%26aulast%3DLawless%26aufirst%3DK.%26aulast%3DMcKay%26aufirst%3DF.%26aulast%3DMuir%26aufirst%3DA.%2BI.%26aulast%3DBarford%26aufirst%3DJ.%2BM.%26aulast%3DCluff%26aufirst%3DC.%26aulast%3DMahmood%26aufirst%3DS.%2BR.%26aulast%3DMatthews%26aufirst%3DK.%2BL.%26aulast%3DMohamed%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DStevens%26aufirst%3DA.%2BJ.%26aulast%3DBolton%26aufirst%3DV.%2BJ.%26aulast%3DJarvie%26aufirst%3DE.%2BM.%26aulast%3DSanger%26aufirst%3DG.%2BJ.%26atitle%3DDiscovery%2520of%2520N-%25283-fluorophenyl%2529-1-%255B%25284-%2528%255B%25283S%2529-3-methyl-1-piperazinyl%255Dmethyl%2529phenyl%2529acetyl%255D-4-piperidinamine%2520%2528GSK962040%2529%252C%2520the%2520first%2520small%2520molecule%2520motilin%2520receptor%2520agonist%2520clinical%2520candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1180%26epage%3D1189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leister, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. L.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinney, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiller, P.; R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolkenberg, S. C.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamides as novel, selective and potent GlyT1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1488</span><span class="NLM_x">–</span> <span class="NLM_lpage">1491</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1488-1491&author=Z.+Zhaoauthor=W.+H.+Leisterauthor=J.+A.+O%E2%80%99Brienauthor=W.+Lemaireauthor=D.+L.+Williamsauthor=M.+A.+Jacobsonauthor=C.+Surauthor=G.+G.+Kinneyauthor=D.+J.+Pettiboneauthor=P.%3B+R.+Tillerauthor=S.+Smithauthor=G.+D.+Hartmanauthor=C.+W.+Lindsleyauthor=S.+C.+Wolkenberg&title=Discovery+of+N-%7B%5B1-%28propylsulfonyl%29-4-pyridin-2-ylpiperidin-4-yl%5Dmethyl%7Dbenzamides+as+novel%2C+selective+and+potent+GlyT1+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLeister%26aufirst%3DW.%2BH.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%2BA.%26aulast%3DLemaire%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DD.%2BL.%26aulast%3DJacobson%26aufirst%3DM.%2BA.%26aulast%3DSur%26aufirst%3DC.%26aulast%3DKinney%26aufirst%3DG.%2BG.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DTiller%26aufirst%3DP.%253B%2BR.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DWolkenberg%26aufirst%3DS.%2BC.%26atitle%3DDiscovery%2520of%2520N-%257B%255B1-%2528propylsulfonyl%2529-4-pyridin-2-ylpiperidin-4-yl%255Dmethyl%257Dbenzamides%2520as%2520novel%252C%2520selective%2520and%2520potent%2520GlyT1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1488%26epage%3D1491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Wu, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dworetzky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzpatrick, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harden, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knox, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sivarao, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tertyshnikova, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeola, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoeckler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span> </span><span class="NLM_article-title">Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (<i>S</i>)-<i>N</i>-[1-(4-fluoro-3-morpholin-4-ylphenyl)ethyl]-3-(4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3778</span><span class="NLM_x">–</span> <span class="NLM_lpage">3781</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm034111v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3778-3781&author=Y.-J.+Wuauthor=C.+D.+Davisauthor=S.+Dworetzkyauthor=W.+C.+Fitzpatrickauthor=D.+Hardenauthor=H.+Heauthor=R.+J.+Knoxauthor=A.+E.+Newtonauthor=T.+Philipauthor=C.+Polsonauthor=D.+V.+Sivaraoauthor=L.-Q.+Sunauthor=S.+Tertyshnikovaauthor=D.+Weaverauthor=S.+Yeolaauthor=M.+Zoecklerauthor=M.+W.+Sinz&title=Fluorine+substitution+can+block+CYP3A4+metabolism-dependent+inhibition%3A+identification+of+%28S%29-N-%5B1-%284-fluoro-3-morpholin-4-ylphenyl%29ethyl%5D-3-%284-fluorophenyl%29acrylamide+as+an+orally+bioavailable+KCNQ2+opener+devoid+of+CYP3A4+metabolism-dependent+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Fjm034111v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034111v%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-J.%26aulast%3DDavis%26aufirst%3DC.%2BD.%26aulast%3DDworetzky%26aufirst%3DS.%26aulast%3DFitzpatrick%26aufirst%3DW.%2BC.%26aulast%3DHarden%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DKnox%26aufirst%3DR.%2BJ.%26aulast%3DNewton%26aufirst%3DA.%2BE.%26aulast%3DPhilip%26aufirst%3DT.%26aulast%3DPolson%26aufirst%3DC.%26aulast%3DSivarao%26aufirst%3DD.%2BV.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DTertyshnikova%26aufirst%3DS.%26aulast%3DWeaver%26aufirst%3DD.%26aulast%3DYeola%26aufirst%3DS.%26aulast%3DZoeckler%26aufirst%3DM.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26atitle%3DFluorine%2520substitution%2520can%2520block%2520CYP3A4%2520metabolism-dependent%2520inhibition%253A%2520identification%2520of%2520%2528S%2529-N-%255B1-%25284-fluoro-3-morpholin-4-ylphenyl%2529ethyl%255D-3-%25284-fluorophenyl%2529acrylamide%2520as%2520an%2520orally%2520bioavailable%2520KCNQ2%2520opener%2520devoid%2520of%2520CYP3A4%2520metabolism-dependent%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D3778%26epage%3D3781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Velaparthi, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carboni, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balimane, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurlburt, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discenza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saulnier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D.</span><span> </span><span class="NLM_article-title">Discovery and evaluation of 4-(2-(4-chloro-1<i>H</i>-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)pyridin-2(1<i>H</i>)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5897</span><span class="NLM_x">–</span> <span class="NLM_lpage">5900</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800832q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5897-5900&author=U.+Velaparthiauthor=M.+Wittmanauthor=P.+Liuauthor=J.+M.+Carboniauthor=F.+Y.+Leeauthor=R.+Attarauthor=P.+Balimaneauthor=W.+Clarkeauthor=M.+W.+Sinzauthor=W.+Hurlburtauthor=K.+Patelauthor=L.+Discenzaauthor=S.+Kimauthor=M.+Gottardisauthor=A.+Greerauthor=A.+Liauthor=M.+Saulnierauthor=Z.+Yangauthor=K.+Zimmermannauthor=G.+Trainorauthor=D.+Vyas&title=Discovery+and+evaluation+of+4-%282-%284-chloro-1H-pyrazol-1-yl%29ethylamino%29-3-%286-%281-%283-fluoropropyl%29piperidin-4-yl%29-4-methyl-1H-benzo%5Bd%5Dimidazol-2-yl%29pyridin-2%281H%29-one+%28BMS-695735%29%2C+an+orally+efficacious+inhibitor+of+insulin-like+growth+factor-1+receptor+kinase+with+broad+spectrum+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Fjm800832q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800832q%26sid%3Dliteratum%253Aachs%26aulast%3DVelaparthi%26aufirst%3DU.%26aulast%3DWittman%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCarboni%26aufirst%3DJ.%2BM.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DAttar%26aufirst%3DR.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DW.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DHurlburt%26aufirst%3DW.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DGreer%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DSaulnier%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZimmermann%26aufirst%3DK.%26aulast%3DTrainor%26aufirst%3DG.%26aulast%3DVyas%26aufirst%3DD.%26atitle%3DDiscovery%2520and%2520evaluation%2520of%25204-%25282-%25284-chloro-1H-pyrazol-1-yl%2529ethylamino%2529-3-%25286-%25281-%25283-fluoropropyl%2529piperidin-4-yl%2529-4-methyl-1H-benzo%255Bd%255Dimidazol-2-yl%2529pyridin-2%25281H%2529-one%2520%2528BMS-695735%2529%252C%2520an%2520orally%2520efficacious%2520inhibitor%2520of%2520insulin-like%2520growth%2520factor-1%2520receptor%2520kinase%2520with%2520broad%2520spectrum%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5897%26epage%3D5900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stearns, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakshi, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nargund, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: a case study with melanocortin-4 receptor agonists</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1437</span><span class="NLM_x">–</span> <span class="NLM_lpage">1451</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2008&pages=1437-1451&author=W.+Tangauthor=R.+A.+Stearnsauthor=R.+W.+Wangauthor=R.+R.+Millerauthor=Q.+Chenauthor=J.+Nguiauthor=R.+K.+Bakshiauthor=R.+P.+Nargundauthor=D.+C.+Deanauthor=T.+A.+Baillie&title=Assessing+and+minimizing+time-dependent+inhibition+of+cytochrome+P450+3A+in+drug+discovery%3A+a+case+study+with+melanocortin-4+receptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DW.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DWang%26aufirst%3DR.%2BW.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DNgui%26aufirst%3DJ.%26aulast%3DBakshi%26aufirst%3DR.%2BK.%26aulast%3DNargund%26aufirst%3DR.%2BP.%26aulast%3DDean%26aufirst%3DD.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DAssessing%2520and%2520minimizing%2520time-dependent%2520inhibition%2520of%2520cytochrome%2520P450%25203A%2520in%2520drug%2520discovery%253A%2520a%2520case%2520study%2520with%2520melanocortin-4%2520receptor%2520agonists%26jtitle%3DXenobiotica%26date%3D2008%26volume%3D38%26spage%3D1437%26epage%3D1451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Roberts, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whalen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulford, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Autry, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emerson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Alsina, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorenzen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berliner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luzzio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaGreca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jani, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wessel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marr, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vajdos, F.</span><span> </span><span class="NLM_article-title">Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">1935</span><span class="NLM_x">–</span> <span class="NLM_lpage">1944</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=1935-1944&author=W.+G.+Robertsauthor=E.+Ungauthor=P.+Whalenauthor=B.+Cooperauthor=C.+Hulfordauthor=C.+Autryauthor=D.+Richterauthor=E.+Emersonauthor=J.+Linauthor=J.+Kathauthor=K.+Colemanauthor=L.+Yaoauthor=L.+Martinez-Alsinaauthor=M.+Lorenzenauthor=M.+Berlinerauthor=M.+Luzzioauthor=N.+Patelauthor=E.+Schmittauthor=S.+LaGrecaauthor=J.+Janiauthor=M.+Wesselauthor=E.+Marrauthor=M.+Grifforauthor=F.+Vajdos&title=Antitumor+activity+and+pharmacology+of+a+selective+focal+adhesion+kinase+inhibitor%2C+PF-562%2C271"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26aulast%3DUng%26aufirst%3DE.%26aulast%3DWhalen%26aufirst%3DP.%26aulast%3DCooper%26aufirst%3DB.%26aulast%3DHulford%26aufirst%3DC.%26aulast%3DAutry%26aufirst%3DC.%26aulast%3DRichter%26aufirst%3DD.%26aulast%3DEmerson%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DKath%26aufirst%3DJ.%26aulast%3DColeman%26aufirst%3DK.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMartinez-Alsina%26aufirst%3DL.%26aulast%3DLorenzen%26aufirst%3DM.%26aulast%3DBerliner%26aufirst%3DM.%26aulast%3DLuzzio%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DSchmitt%26aufirst%3DE.%26aulast%3DLaGreca%26aufirst%3DS.%26aulast%3DJani%26aufirst%3DJ.%26aulast%3DWessel%26aufirst%3DM.%26aulast%3DMarr%26aufirst%3DE.%26aulast%3DGriffor%26aufirst%3DM.%26aulast%3DVajdos%26aufirst%3DF.%26atitle%3DAntitumor%2520activity%2520and%2520pharmacology%2520of%2520a%2520selective%2520focal%2520adhesion%2520kinase%2520inhibitor%252C%2520PF-562%252C271%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D1935%26epage%3D1944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Walker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bi, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soglia, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aspnes, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klug-McLeod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawistoski, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGlynn, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulford, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Autry, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luzzio, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ung, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnette, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckbinder, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffor, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman-Perez, A.</span><span> </span><span class="NLM_article-title">Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure–activity relationships and strategies for the elimination of reactive metabolite formation</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">6071</span><span class="NLM_x">–</span> <span class="NLM_lpage">6077</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6071-6077&author=D.+P.+Walkerauthor=F.+C.+Biauthor=A.+S.+Kalgutkarauthor=J.+N.+Baumanauthor=S.+X.+Zhaoauthor=J.+R.+Sogliaauthor=G.+E.+Aspnesauthor=D.+W.+Kungauthor=J.+Klug-McLeodauthor=M.+P.+Zawistoskiauthor=M.+A.+McGlynnauthor=R.+Oliverauthor=M.+Dunnauthor=J.+C.+Liauthor=D.+T.+Richterauthor=B.+A.+Cooperauthor=J.+C.+Kathauthor=C.+A.+Hulfordauthor=C.+L.+Autryauthor=M.+J.+Luzzioauthor=E.+J.+Ungauthor=W.+G.+Robertsauthor=P.+C.+Bonnetteauthor=L.+Buckbinderauthor=A.+Mistryauthor=M.+C.+Grifforauthor=S.+Hanauthor=A.+Guzman-Perez&title=Trifluoromethylpyrimidine-based+inhibitors+of+proline-rich+tyrosine+kinase+2+%28PYK2%29%3A+structure%E2%80%93activity+relationships+and+strategies+for+the+elimination+of+reactive+metabolite+formation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBi%26aufirst%3DF.%2BC.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DBauman%26aufirst%3DJ.%2BN.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DAspnes%26aufirst%3DG.%2BE.%26aulast%3DKung%26aufirst%3DD.%2BW.%26aulast%3DKlug-McLeod%26aufirst%3DJ.%26aulast%3DZawistoski%26aufirst%3DM.%2BP.%26aulast%3DMcGlynn%26aufirst%3DM.%2BA.%26aulast%3DOliver%26aufirst%3DR.%26aulast%3DDunn%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%2BC.%26aulast%3DRichter%26aufirst%3DD.%2BT.%26aulast%3DCooper%26aufirst%3DB.%2BA.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DHulford%26aufirst%3DC.%2BA.%26aulast%3DAutry%26aufirst%3DC.%2BL.%26aulast%3DLuzzio%26aufirst%3DM.%2BJ.%26aulast%3DUng%26aufirst%3DE.%2BJ.%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26aulast%3DBonnette%26aufirst%3DP.%2BC.%26aulast%3DBuckbinder%26aufirst%3DL.%26aulast%3DMistry%26aufirst%3DA.%26aulast%3DGriffor%26aufirst%3DM.%2BC.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26atitle%3DTrifluoromethylpyrimidine-based%2520inhibitors%2520of%2520proline-rich%2520tyrosine%2520kinase%25202%2520%2528PYK2%2529%253A%2520structure%25E2%2580%2593activity%2520relationships%2520and%2520strategies%2520for%2520the%2520elimination%2520of%2520reactive%2520metabolite%2520formation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D6071%26epage%3D6077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Wong, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonn, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadano Lohr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B. K.</span><span> </span><span class="NLM_article-title">Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug–drug interaction</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">841</span><span class="NLM_x">–</span> <span class="NLM_lpage">850</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=841-850&author=S.+G.+Wongauthor=P.+W.+Fanauthor=R.+Subramanianauthor=G.+R.+Tonnauthor=K.+R.+Henneauthor=M.+G.+Johnsonauthor=M.+Tadano+Lohrauthor=B.+K.+Wong&title=Bioactivation+of+a+novel+2-methylindole-containing+dual+chemoattractant+receptor-homologous+molecule+expressed+on+T-helper+type-2+cells%2FD-prostanoid+receptor+antagonist+leads+to+mechanism-based+CYP3A+inactivation%3A+glutathione+adduct+characterization+and+prediction+of+in+vivo+drug%E2%80%93drug+interaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DS.%2BG.%26aulast%3DFan%26aufirst%3DP.%2BW.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DTonn%26aufirst%3DG.%2BR.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DTadano%2BLohr%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DB.%2BK.%26atitle%3DBioactivation%2520of%2520a%2520novel%25202-methylindole-containing%2520dual%2520chemoattractant%2520receptor-homologous%2520molecule%2520expressed%2520on%2520T-helper%2520type-2%2520cells%252FD-prostanoid%2520receptor%2520antagonist%2520leads%2520to%2520mechanism-based%2520CYP3A%2520inactivation%253A%2520glutathione%2520adduct%2520characterization%2520and%2520prediction%2520of%2520in%2520vivo%2520drug%25E2%2580%2593drug%2520interaction%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D841%26epage%3D850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dube, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dube, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagne, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">gallant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudreault, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimm, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacombe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laliberte, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, J.-F.</span><span> </span><span class="NLM_article-title">Addressing time-dependent CYP3A4 inhibition in a novel series substituted amino propanamide renin inhibitors, a case study</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5074</span><span class="NLM_x">–</span> <span class="NLM_lpage">5079</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5074-5079&author=A.+Chenauthor=D.+Dubeauthor=L.+Dubeauthor=S.+Gagneauthor=M.+gallantauthor=M.+Gaudreaultauthor=E.+Grimmauthor=R.+Houleauthor=P.+Lacombeauthor=S.+Laliberteauthor=S.+Liuauthor=D.+MacDonaldauthor=B.+Mackayauthor=D.+Martinauthor=D.+McKayauthor=D.+Powellauthor=J.-F.+Levesque&title=Addressing+time-dependent+CYP3A4+inhibition+in+a+novel+series+substituted+amino+propanamide+renin+inhibitors%2C+a+case+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DA.%26aulast%3DDube%26aufirst%3DD.%26aulast%3DDube%26aufirst%3DL.%26aulast%3DGagne%26aufirst%3DS.%26aulast%3Dgallant%26aufirst%3DM.%26aulast%3DGaudreault%26aufirst%3DM.%26aulast%3DGrimm%26aufirst%3DE.%26aulast%3DHoule%26aufirst%3DR.%26aulast%3DLacombe%26aufirst%3DP.%26aulast%3DLaliberte%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMacDonald%26aufirst%3DD.%26aulast%3DMackay%26aufirst%3DB.%26aulast%3DMartin%26aufirst%3DD.%26aulast%3DMcKay%26aufirst%3DD.%26aulast%3DPowell%26aufirst%3DD.%26aulast%3DLevesque%26aufirst%3DJ.-F.%26atitle%3DAddressing%2520time-dependent%2520CYP3A4%2520inhibition%2520in%2520a%2520novel%2520series%2520substituted%2520amino%2520propanamide%2520renin%2520inhibitors%252C%2520a%2520case%2520study%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5074%26epage%3D5079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aspiotis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campeau, L.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cauchon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chefson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ducharme, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falgueyret, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagné, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laliberté, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larouche, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lévesque, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Percival, D.</span><span> </span><span class="NLM_article-title">Renin inhibitors for treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">7399</span><span class="NLM_x">–</span> <span class="NLM_lpage">7404</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=7399-7404&author=A.+Chenauthor=R.+Aspiotisauthor=L.-C.+Campeauauthor=E.+Cauchonauthor=A.+Chefsonauthor=Y.+Ducharmeauthor=J.-P.+Falgueyretauthor=S.+Gagn%C3%A9author=Y.+Hanauthor=R.+Houleauthor=S.+Lalibert%C3%A9author=G.+Laroucheauthor=J.-F.+L%C3%A9vesqueauthor=D.+McKayauthor=D.+Percival&title=Renin+inhibitors+for+treatment+of+hypertension%3A+design+and+optimization+of+a+novel+series+of+spirocyclic+piperidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DA.%26aulast%3DAspiotis%26aufirst%3DR.%26aulast%3DCampeau%26aufirst%3DL.-C.%26aulast%3DCauchon%26aufirst%3DE.%26aulast%3DChefson%26aufirst%3DA.%26aulast%3DDucharme%26aufirst%3DY.%26aulast%3DFalgueyret%26aufirst%3DJ.-P.%26aulast%3DGagn%25C3%25A9%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DHoule%26aufirst%3DR.%26aulast%3DLalibert%25C3%25A9%26aufirst%3DS.%26aulast%3DLarouche%26aufirst%3DG.%26aulast%3DL%25C3%25A9vesque%26aufirst%3DJ.-F.%26aulast%3DMcKay%26aufirst%3DD.%26aulast%3DPercival%26aufirst%3DD.%26atitle%3DRenin%2520inhibitors%2520for%2520treatment%2520of%2520hypertension%253A%2520design%2520and%2520optimization%2520of%2520a%2520novel%2520series%2520of%2520spirocyclic%2520piperidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D7399%26epage%3D7404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">Yarnell, A. T.</span><span> </span><span class="NLM_article-title">Heavy-hydrogen drugs turn heads, again</span> <span class="citation_source-journal">Chem. Eng. News</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">36</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><div class="note"><p class="first last">; <a href="http://pubs.acs.org/cen/science/87/8725sci1.html" class="extLink">http://pubs.acs.org/cen/science/87/8725sci1.html</a></p></div></span><div class="citationLinks">[<a href="/doi/10.1021/cen-v087n025.p036" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2009&pages=36-39&author=A.+T.+Yarnell&title=Heavy-hydrogen+drugs+turn+heads%2C+again"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Fcen-v087n025.p036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcen-v087n025.p036%26sid%3Dliteratum%253Aachs%26aulast%3DYarnell%26aufirst%3DA.%2BT.%26atitle%3DHeavy-hydrogen%2520drugs%2520turn%2520heads%252C%2520again%26jtitle%3DChem.%2520Eng.%2520News%26date%3D2009%26volume%3D87%26spage%3D36%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marfat, A.</span><span> </span><span class="NLM_article-title">Disposition of CP-671,305, a selective phosphodiesterase 4 inhibitor in preclinical species</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">755</span><span class="NLM_x">–</span> <span class="NLM_lpage">770</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2004&pages=755-770&author=A.+S.+Kalgutkarauthor=E.+Chooauthor=T.+J.+Taylorauthor=A.+Marfat&title=Disposition+of+CP-671%2C305%2C+a+selective+phosphodiesterase+4+inhibitor+in+preclinical+species"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DChoo%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DT.%2BJ.%26aulast%3DMarfat%26aufirst%3DA.%26atitle%3DDisposition%2520of%2520CP-671%252C305%252C%2520a%2520selective%2520phosphodiesterase%25204%2520inhibitor%2520in%2520preclinical%2520species%26jtitle%3DXenobiotica%26date%3D2004%26volume%3D34%26spage%3D755%26epage%3D770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group">Ishiguro, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igarashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamai, I.</span><span> </span><span class="NLM_article-title">Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">499</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=495-499&author=N.+Ishiguroauthor=A.+Saitoauthor=K.+Yokoyamaauthor=M.+Morikawaauthor=T.+Igarashiauthor=I.+Tamai&title=Transport+of+the+dopamine+D2+agonist+pramipexole+by+rat+organic+cation+transporters+OCT1+and+OCT2+in+kidney"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIshiguro%26aufirst%3DN.%26aulast%3DSaito%26aufirst%3DA.%26aulast%3DYokoyama%26aufirst%3DK.%26aulast%3DMorikawa%26aufirst%3DM.%26aulast%3DIgarashi%26aufirst%3DT.%26aulast%3DTamai%26aufirst%3DI.%26atitle%3DTransport%2520of%2520the%2520dopamine%2520D2%2520agonist%2520pramipexole%2520by%2520rat%2520organic%2520cation%2520transporters%2520OCT1%2520and%2520OCT2%2520in%2520kidney%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D495%26epage%3D499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">James, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayeux, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinson, J. A.</span><span> </span><span class="NLM_article-title">Acetaminophen-induced hepatotoxicity</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1499</span><span class="NLM_x">–</span> <span class="NLM_lpage">1506</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=1499-1506&author=L.+P.+Jamesauthor=P.+R.+Mayeuxauthor=J.+A.+Hinson&title=Acetaminophen-induced+hepatotoxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DL.%2BP.%26aulast%3DMayeux%26aufirst%3DP.%2BR.%26aulast%3DHinson%26aufirst%3DJ.%2BA.%26atitle%3DAcetaminophen-induced%2520hepatotoxicity%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2003%26volume%3D31%26spage%3D1499%26epage%3D1506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Halmes, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samokyszyn, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinton, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pumford, N. R.</span><span> </span><span class="NLM_article-title">The acetaminophen regioisomer 3′-hydroxyacetanilide inhibits and covalently binds to cytochrome P4502E1</span> <span class="citation_source-journal">Toxicol. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2FS0378-4274%2897%2900100-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=9544700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK1cXhtVWkt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1998&pages=65-71&author=N.+C.+Halmesauthor=V.+M.+Samokyszynauthor=T.+W.+Hintonauthor=J.+A.+Hinsonauthor=N.+R.+Pumford&title=The+acetaminophen+regioisomer+3%E2%80%B2-hydroxyacetanilide+inhibits+and+covalently+binds+to+cytochrome+P4502E1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">The acetaminophen regioisomer 3'-hydroxyacetanilide inhibits and covalently binds to cytochrome P450 2E1</span></div><div class="casAuthors">Halmes, N. Christine; Samokyszyn, Victor M.; Hinton, Thomas W.; Hinson, Jack A.; Pumford, Neil R.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-71</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">3'-Hydroxyacetanilide has been previously studied as a nontoxic regioisomer of the analgesic acetaminophen (4'-hydroxyacetanilide).  The radiolabeled deriv. has been shown to covalently bind to liver proteins at levels similar to that obsd. with hepatotoxic doses of radiolabeled acetaminophen with no evidence of hepatic damage.  Using an anti-arylacetamide antiserum the primary protein adduct detected following administration of 3'-hydroxyacetanilide (300 and 600 mg/kg) to mice was a 50 kDa microsomal protein that co-migrated with cytochrome P 450 2E1.  Cytochrome P 450 2E1 enzyme activity (p-nitrophenol hydroxylase) was decreased by 79 in the mice treated with 3'-hydroxyacetanilide (600 mg/kg).  Incubation of 3'-hydroxyacetanilide with hepatic microsomes resulted in a time dependent 47 decrease in cytochrome P 450 2E1 activity.  Pre-incubation of acetaminophen with microsomes did not result in covalent binding to the cytochrome P 450 nor was there a decrease in p-nitrophenol hydroxylase activity.  These data suggest that 3'-hydroxyacetanilide covalently binds to cytochrome P 450 2E1 with preferential loss of activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmncuZqNcypbVg90H21EOLACvtfcHk0lh22jbZ29er1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtVWkt7s%253D&md5=102c168d3d3827021f55791cd658dcab</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2FS0378-4274%2897%2900100-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-4274%252897%252900100-8%26sid%3Dliteratum%253Aachs%26aulast%3DHalmes%26aufirst%3DN.%2BC.%26aulast%3DSamokyszyn%26aufirst%3DV.%2BM.%26aulast%3DHinton%26aufirst%3DT.%2BW.%26aulast%3DHinson%26aufirst%3DJ.%2BA.%26aulast%3DPumford%26aufirst%3DN.%2BR.%26atitle%3DThe%2520acetaminophen%2520regioisomer%25203%25E2%2580%25B2-hydroxyacetanilide%2520inhibits%2520and%2520covalently%2520binds%2520to%2520cytochrome%2520P4502E1%26jtitle%3DToxicol.%2520Lett.%26date%3D1998%26volume%3D94%26spage%3D65%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group">Zientek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayscue, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klug-McLeod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekins, S.</span><span> </span><span class="NLM_article-title">Integrated in silico–in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">664</span><span class="NLM_x">–</span> <span class="NLM_lpage">676</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx900417f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=664-676&author=M.+Zientekauthor=C.+Stonerauthor=R.+Ayscueauthor=J.+Klug-McLeodauthor=Y.+Jiangauthor=M.+Westauthor=C.+Collinsauthor=S.+Ekins&title=Integrated+in+silico%E2%80%93in+vitro+strategy+for+addressing+cytochrome+P450+3A4+time-dependent+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Ftx900417f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx900417f%26sid%3Dliteratum%253Aachs%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DStoner%26aufirst%3DC.%26aulast%3DAyscue%26aufirst%3DR.%26aulast%3DKlug-McLeod%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DIntegrated%2520in%2520silico%25E2%2580%2593in%2520vitro%2520strategy%2520for%2520addressing%2520cytochrome%2520P450%25203A4%2520time-dependent%2520inhibition%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2010%26volume%3D23%26spage%3D664%26epage%3D676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Kassahun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skordos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntosh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slaughter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doss, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yost, G. S.</span><span> </span><span class="NLM_article-title">Zafirlukast metabolism by cytochrome P450 3A4 produces an electrophilic alpha,beta-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1427</span><span class="NLM_x">–</span> <span class="NLM_lpage">1437</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx050092b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=1427-1437&author=K.+Kassahunauthor=K.+Skordosauthor=I.+McIntoshauthor=D.+Slaughterauthor=G.+A.+Dossauthor=T.+A.+Baillieauthor=G.+S.+Yost&title=Zafirlukast+metabolism+by+cytochrome+P450+3A4+produces+an+electrophilic+alpha%2Cbeta-unsaturated+iminium+species+that+results+in+the+selective+mechanism-based+inactivation+of+the+enzyme"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Ftx050092b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx050092b%26sid%3Dliteratum%253Aachs%26aulast%3DKassahun%26aufirst%3DK.%26aulast%3DSkordos%26aufirst%3DK.%26aulast%3DMcIntosh%26aufirst%3DI.%26aulast%3DSlaughter%26aufirst%3DD.%26aulast%3DDoss%26aufirst%3DG.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DYost%26aufirst%3DG.%2BS.%26atitle%3DZafirlukast%2520metabolism%2520by%2520cytochrome%2520P450%25203A4%2520produces%2520an%2520electrophilic%2520alpha%252Cbeta-unsaturated%2520iminium%2520species%2520that%2520results%2520in%2520the%2520selective%2520mechanism-based%2520inactivation%2520of%2520the%2520enzyme%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2005%26volume%3D18%26spage%3D1427%26epage%3D1437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yost, G. S.</span><span> </span><span class="NLM_article-title">Metabolic activation of a novel 3-substituted indole-containing TNF-alpha inhibitor: dehydrogenation and inactivation of CYP3A4</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">374</span><span class="NLM_x">–</span> <span class="NLM_lpage">385</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx700294g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=374-385&author=H.+Sunauthor=G.+S.+Yost&title=Metabolic+activation+of+a+novel+3-substituted+indole-containing+TNF-alpha+inhibitor%3A+dehydrogenation+and+inactivation+of+CYP3A4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Ftx700294g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx700294g%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DYost%26aufirst%3DG.%2BS.%26atitle%3DMetabolic%2520activation%2520of%2520a%2520novel%25203-substituted%2520indole-containing%2520TNF-alpha%2520inhibitor%253A%2520dehydrogenation%2520and%2520inactivation%2520of%2520CYP3A4%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D374%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">Gay, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilderman, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, V. L.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenberg, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halpert, J. R.</span><span> </span><span class="NLM_article-title">Structural analysis of mammalian cytochrome P450 2B4 covalently bound to the mechanism-based inactivator <i>tert</i>-butylphenylacetylene: insight into partial enzymatic activity</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">4903</span><span class="NLM_x">–</span> <span class="NLM_lpage">4911</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi200482g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVCntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=4903-4911&author=S.+C.+Gayauthor=H.+Zhangauthor=P.+R.+Wildermanauthor=A.+G.+Robertsauthor=T.+Liuauthor=S.+Liauthor=H.+L.+Linauthor=Q.+Zhangauthor=V.+L.+Woodsauthor=C.+D.+Stoutauthor=P.+F.+Hollenbergauthor=J.+R.+Halpert&title=Structural+analysis+of+mammalian+cytochrome+P450+2B4+covalently+bound+to+the+mechanism-based+inactivator+tert-butylphenylacetylene%3A+insight+into+partial+enzymatic+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Structural analysis of mammalian cytochrome P 450 2B4 covalently bound to the mechanism-based inactivator tert-butylphenylacetylene: Insight into partial enzymatic activity</span></div><div class="casAuthors">Gay, Sean C.; Zhang, Haoming; Wilderman, P. Ross; Roberts, Arthur G.; Liu, Tong; Li, Sheng; Lin, Hsia-lien; Zhang, Qinghai; Woods, Virgil L.; Stout, C. David; Hollenberg, Paul F.; Halpert, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4903-4911</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A combined crystal structure and computational anal. of rabbit cytochrome P 450 2B4 (CYP2B4)covalently bound to the mechanism-based inactivator, tert-butylphenylacetylene (tBPA), yielded insight into how the enzyme retains partial activity.  Since conjugation to tBPA modified a highly conserved active site residue, the residual activity of tBPA-labeled CYP2B4 obsd. in previous studies was puzzling.  Here, the authors describe the 1st crystal structures of a modified mammalian P 450, which show an oxygenated metabolite of tBPA conjugated to Thr-302 of helix I.  These results were consistent with previous studies that identified Thr-302 as the site of conjugation.  In each structure, the core of CYP2B4 remained unchanged, but the arrangement of plastic regions differs.  This resulted in one structure that was compact and closed.  In this conformation, tBPA pointed toward helix B', making a 31° angle with the heme plane.  This conformation was in agreement with previously performed in silico expts.  However, dimerization of CYP2B4 in the other structure, which was caused by movement of the B/C loop and helixes F through G, altered the position of tBPA.  In this case, tBPA was found to lie almost parallel to the heme plane due to the presence of helix F' of the opposite monomer entering the active site to stabilize the dimer.  However, docking expts. using this open form showed that tBPA was able to rotate upward to give testosterone and 7-ethoxy-4-trifluoromethylcoumarin access to the heme, which could explain the previously obsd. partial activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojn823UJa1s7Vg90H21EOLACvtfcHk0ljfZ2ceUX-nzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVCntbw%253D&md5=93172e85e5683fa426975dbd221ffcc4</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Fbi200482g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi200482g%26sid%3Dliteratum%253Aachs%26aulast%3DGay%26aufirst%3DS.%2BC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWilderman%26aufirst%3DP.%2BR.%26aulast%3DRoberts%26aufirst%3DA.%2BG.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DH.%2BL.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DWoods%26aufirst%3DV.%2BL.%26aulast%3DStout%26aufirst%3DC.%2BD.%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26aulast%3DHalpert%26aufirst%3DJ.%2BR.%26atitle%3DStructural%2520analysis%2520of%2520mammalian%2520cytochrome%2520P450%25202B4%2520covalently%2520bound%2520to%2520the%2520mechanism-based%2520inactivator%2520tert-butylphenylacetylene%253A%2520insight%2520into%2520partial%2520enzymatic%2520activity%26jtitle%3DBiochemistry%26date%3D2011%26volume%3D50%26spage%3D4903%26epage%3D4911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">Lin, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratt-Hyatt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenberg, P. F.</span><span> </span><span class="NLM_article-title">Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by <i>tert</i>-butylphenylacetylene</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">2431</span><span class="NLM_x">–</span> <span class="NLM_lpage">2439</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=2431-2439&author=H.+L.+Linauthor=H.+Zhangauthor=M.+Pratt-Hyattauthor=P.+F.+Hollenberg&title=Thr302+is+the+site+for+the+covalent+modification+of+human+cytochrome+P450+2B6+leading+to+mechanism-based+inactivation+by+tert-butylphenylacetylene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%2BL.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPratt-Hyatt%26aufirst%3DM.%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26atitle%3DThr302%2520is%2520the%2520site%2520for%2520the%2520covalent%2520modification%2520of%2520human%2520cytochrome%2520P450%25202B6%2520leading%2520to%2520mechanism-based%2520inactivation%2520by%2520tert-butylphenylacetylene%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D2431%26epage%3D2439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">Lightning, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rushmore, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trager, W. F.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">4276</span><span class="NLM_x">–</span> <span class="NLM_lpage">4287</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi992412u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=4276-4287&author=L.+K.+Lightningauthor=J.+P.+Jonesauthor=T.+Friedbergauthor=M.+P.+Pritchardauthor=M.+Shouauthor=T.+H.+Rushmoreauthor=W.+F.+Trager&title=Mechanism-based+inactivation+of+cytochrome+P450+3A4+by+L-754%2C394"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Fbi992412u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi992412u%26sid%3Dliteratum%253Aachs%26aulast%3DLightning%26aufirst%3DL.%2BK.%26aulast%3DJones%26aufirst%3DJ.%2BP.%26aulast%3DFriedberg%26aufirst%3DT.%26aulast%3DPritchard%26aufirst%3DM.%2BP.%26aulast%3DShou%26aufirst%3DM.%26aulast%3DRushmore%26aufirst%3DT.%2BH.%26aulast%3DTrager%26aufirst%3DW.%2BF.%26atitle%3DMechanism-based%2520inactivation%2520of%2520cytochrome%2520P450%25203A4%2520by%2520L-754%252C394%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D4276%26epage%3D4287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">He, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolf, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenberg, P. F.</span><span> </span><span class="NLM_article-title">Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">252</span><span class="NLM_x">–</span> <span class="NLM_lpage">259</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx970192k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1998&pages=252-259&author=K.+Heauthor=K.+R.+Iyerauthor=R.+N.+Hayesauthor=M.+W.+Sinzauthor=T.+F.+Woolfauthor=P.+F.+Hollenberg&title=Inactivation+of+cytochrome+P450+3A4+by+bergamottin%2C+a+component+of+grapefruit+juice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Ftx970192k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx970192k%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DK.%26aulast%3DIyer%26aufirst%3DK.%2BR.%26aulast%3DHayes%26aufirst%3DR.%2BN.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DWoolf%26aufirst%3DT.%2BF.%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26atitle%3DInactivation%2520of%2520cytochrome%2520P450%25203A4%2520by%2520bergamottin%252C%2520a%2520component%2520of%2520grapefruit%2520juice%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1998%26volume%3D11%26spage%3D252%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group">Chang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fancher, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, J.</span><span> </span><span class="NLM_article-title">Mechanism-based inhibition of human cytochrome P4503A4 by domperidone</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">138</span><span class="NLM_x">–</span> <span class="NLM_lpage">145</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2010&pages=138-145&author=S.+Y.+Changauthor=R.+M.+Fancherauthor=H.+Zhangauthor=J.+Gan&title=Mechanism-based+inhibition+of+human+cytochrome+P4503A4+by+domperidone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%2BY.%26aulast%3DFancher%26aufirst%3DR.%2BM.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGan%26aufirst%3DJ.%26atitle%3DMechanism-based%2520inhibition%2520of%2520human%2520cytochrome%2520P4503A4%2520by%2520domperidone%26jtitle%3DXenobiotica%26date%3D2010%26volume%3D40%26spage%3D138%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group">Kajbaf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longhi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, S.</span><span> </span><span class="NLM_article-title">Evaluation of different approaches to identifying a higher throughput assay for time-dependent inhibition (TDI)</span> <span class="citation_source-journal">Drug Metab. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">113</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2174%2F187231211795305230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=21457139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltF2mt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=104-113&author=M.+Kajbafauthor=R.+Longhiauthor=S.+Fontana&title=Evaluation+of+different+approaches+to+identifying+a+higher+throughput+assay+for+time-dependent+inhibition+%28TDI%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of different approaches to identifying a higher throughput assay for time-dependent inhibition (TDI)</span></div><div class="casAuthors">Kajbaf, M.; Longhi, R.; Fontana, S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">104-113</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The availability of a reliable in vitro assay to evaluate time-dependent inhibition (TDI) of cytochrome P 450 enzymes by novel compds. is essential for the identification of candidate medicines.  We have evaluated three assay methods, making use of 59 marketed compds. and 28 novel GSK compds.  Recombinant bactosomes expressing the CYP3A4 isoenzyme were used with two fluorescence-based methods: a "Re-addn." assay and a "30 min" assay.  The third method evaluated used pooled human liver microsomes (PHLM) with LC-MS/MS detection (the data for GSK compds. were evaluated in this study, whereas data for marketed drugs were reported recently).  Our evaluation showed that the Re-addn. method is comparable to the LC-MS/MS method in terms of predictivity and reproducibility.  In conclusion, Re-addn. method is inexpensive, and provides a simple assessment of the risk of TDI for novel compds.  This assay is particularly appropriate for use during the early stages of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmyXN8bHdYPLVg90H21EOLACvtfcHk0ljqGHbRaVl29w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltF2mt7o%253D&md5=1a863e49da22633485ef524ad8ddfbf1</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.2174%2F187231211795305230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231211795305230%26sid%3Dliteratum%253Aachs%26aulast%3DKajbaf%26aufirst%3DM.%26aulast%3DLonghi%26aufirst%3DR.%26aulast%3DFontana%26aufirst%3DS.%26atitle%3DEvaluation%2520of%2520different%2520approaches%2520to%2520identifying%2520a%2520higher%2520throughput%2520assay%2520for%2520time-dependent%2520inhibition%2520%2528TDI%2529%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2011%26volume%3D5%26spage%3D104%26epage%3D113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group">Ortiz de Montellano, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunze, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yost, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mico, B. A.</span><span> </span><span class="NLM_article-title">Self-catalyzed destruction of cytochrome P450: covalent binding of ethynyl sterols to prosthetic heme</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">746</span><span class="NLM_x">–</span> <span class="NLM_lpage">749</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1979&pages=746-749&author=P.+R.+Ortiz+de+Montellanoauthor=K.+L.+Kunzeauthor=G.+S.+Yostauthor=B.+A.+Mico&title=Self-catalyzed+destruction+of+cytochrome+P450%3A+covalent+binding+of+ethynyl+sterols+to+prosthetic+heme"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrtiz%2Bde%2BMontellano%26aufirst%3DP.%2BR.%26aulast%3DKunze%26aufirst%3DK.%2BL.%26aulast%3DYost%26aufirst%3DG.%2BS.%26aulast%3DMico%26aufirst%3DB.%2BA.%26atitle%3DSelf-catalyzed%2520destruction%2520of%2520cytochrome%2520P450%253A%2520covalent%2520binding%2520of%2520ethynyl%2520sterols%2520to%2520prosthetic%2520heme%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1979%26volume%3D76%26spage%3D746%26epage%3D749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group">Guengerich, F. P.</span><span> </span><span class="NLM_article-title">Metabolism of 17a-ethynylestradiol in humans</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1981</span><span class="NLM_x">–</span> <span class="NLM_lpage">1988</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1990&pages=1981-1988&author=F.+P.+Guengerich&title=Metabolism+of+17a-ethynylestradiol+in+humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuengerich%26aufirst%3DF.%2BP.%26atitle%3DMetabolism%2520of%252017a-ethynylestradiol%2520in%2520humans%26jtitle%3DLife%2520Sci.%26date%3D1990%26volume%3D47%26spage%3D1981%26epage%3D1988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group">Lin, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, U. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenberg, P. F.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of cytochrome P4503A4 by 17α-ethynylestradiol: evidence for heme destruction and covalent binding to protein</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">301</span><span class="NLM_x">, </span> <span class="NLM_fpage">160</span><span class="NLM_x">–</span> <span class="NLM_lpage">167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1124%2Fjpet.301.1.160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=11907170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=2002&pages=160-167&author=H.-L.+Linauthor=U.+M.+Kentauthor=P.+F.+Hollenberg&title=Mechanism-based+inactivation+of+cytochrome+P4503A4+by+17%CE%B1-ethynylestradiol%3A+evidence+for+heme+destruction+and+covalent+binding+to+protein"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inactivation of cytochrome P450 3A4 by 17α-ethynylestradiol: Evidence for heme destruction and covalent binding to protein</span></div><div class="casAuthors">Lin, Hsia-Lien; Kent, Ute M.; Hollenberg, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">160-167</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">17α-Ethynylestradiol (EE), a major constituent of many oral contraceptives, inactivated the testosterone 6β-hydroxylation activity of purified P 450 3A4 reconstituted with phospholipid and NADPH-cytochrome P 450 reductase in a mechanism-based manner.  The inactivation of P 450 3A4 followed pseudo first order kinetics and was dependent on NADPH.  The values for the K1 and kinact were 18 μM and 0.04 min-1, resp., and the t1/2 was 16 min.  Incubation of 50 μM EE with P 450 3A4 at 37° for 30 min resulted in a 67% loss of testosterone 6β-hydroxylation activity accompanied by a 35% loss of the spectral absorbance of the native protein at 415 nm and a 70% loss of the spectrally detectable P 450-CO complex.  The inactivation of P 450 3A4 by EE was irreversible.  Testosterone, an alternate substrate, was able to protect P 450 3A4 from EE-dependent inactivation.  The partition ratio was ∼50.  The stoichiometry of binding was approx. 1.3 nmol of an EE metabolite bound per nmol of P 450 3A4 inactivated.  SDS-polyacrylamide gel electrophoresis anal. demonstrated that [3H]EE was irreversibly bound to the P 450 3A4 apoprotein.  After extensive dialysis of the [3H]EE inactivated samples, high-pressure liq. chromatog. (HPLC) anal. demonstrated that the inactivation resulting from EE metab. led to the destruction of approx. half the heme with the concomitant generation of modified heme and EE-labeled heme fragments and produced covalently radiolabeled P 450 3A4 apoprotein.  Electrospray mass spectrometry demonstrated that the fraction corresponding to the major radiolabeled product of EE metab. has a mass (M - H)- of 479 Da.  HPLC and gas chromatog.-mass spectrometry analyses revealed that EE metab. by P 450 3A4 generated one major metabolite, 2-hydroxyethynylestradiol, and at least three addnl. metabolites.  In conclusion, our results demonstrate that EE is an effective mechanism-based inactivator of P 450 3A4 and that the mechanism of inactivation involves not only heme destruction, but also the irreversible modification of the apoprotein at the active site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7_op9UJz9HrVg90H21EOLACvtfcHk0liyad8Ak7Mnug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kru7Y%253D&md5=0e1f037095f387682c995f4c8ca85038</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1124%2Fjpet.301.1.160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.301.1.160%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.-L.%26aulast%3DKent%26aufirst%3DU.%2BM.%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26atitle%3DMechanism-based%2520inactivation%2520of%2520cytochrome%2520P4503A4%2520by%252017%25CE%25B1-ethynylestradiol%253A%2520evidence%2520for%2520heme%2520destruction%2520and%2520covalent%2520binding%2520to%2520protein%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D301%26spage%3D160%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group">Purba, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggs, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Back, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, B. K.</span><span> </span><span class="NLM_article-title">The metabolism of 17α-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">447</span><span class="NLM_x">–</span> <span class="NLM_lpage">453</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1111%2Fj.1365-2125.1987.tb03074.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=3555579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaL2sXktVWjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1987&pages=447-453&author=H.+S.+Purbaauthor=J.+L.+Maggsauthor=M.+L.+Ormeauthor=D.+J.+Backauthor=B.+K.+Park&title=The+metabolism+of+17%CE%B1-ethinyloestradiol+by+human+liver+microsomes%3A+formation+of+catechol+and+chemically+reactive+metabolites"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolism of 17α-ethinylestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites</span></div><div class="casAuthors">Purba, H. S.; Maggs, J. L.; Orme, M. L. E.; Back, D. J.; Park, B. K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">447-53</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    </div><div class="casAbstract">The metab. of 17α-ethynylestradiol (EE2) to catechol and reactive metabolites by human liver microsomes was investigated.  2-Hydroxyethynylestradiol (2-OHEE2) was either the sole or principal metabolite and small amts. of 6-hydroxyethynylestradiol and 16-hydroxyethynylestradiol were produced by some of the livers.  EE2 (10 μm) underwent substantial (5-20% of incubated drug), though highly variable, NADPH-dependent metab. to material irreversibly bound to microsomal protein.  2-OHEE2 appeared to be the proreactive metabolite.  The max. EE2 2-hydroxylase activity was 0.67 nmol/min/mg microsomal protein, with a Km value of 8.6 mM.  Estradiol, which is mainly hydroxylated to 2-hydroxyestradiol, was the most potent inhibitor of hydroxylase activity and exhibited competitive inhibition.  Progesterone, which undergoes 2-hydroxylation to a minor extent was also a competitive inhibitor, whereas cholesterol and cortisol did not have any appreciable inhibitory effect.  Primaquine was the most potent nonsteroidal inhibitor but was noncompetitive.  Other nonsteroidal compds. investigated, e.g., antipyrine, had no effect on EE2 2-hydroxylation.  Evidently, EE2 2-hydroxylation is metabolized by a form(s) of cytochrome P 450 which has affinity for endogenous steroids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKoA2Y7m5eObVg90H21EOLACvtfcHk0liyad8Ak7Mnug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXktVWjsr8%253D&md5=2661a4e945f907a58ca94acfa4031f4d</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.1987.tb03074.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.1987.tb03074.x%26sid%3Dliteratum%253Aachs%26aulast%3DPurba%26aufirst%3DH.%2BS.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DOrme%26aufirst%3DM.%2BL.%26aulast%3DBack%26aufirst%3DD.%2BJ.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DThe%2520metabolism%2520of%252017%25CE%25B1-ethinyloestradiol%2520by%2520human%2520liver%2520microsomes%253A%2520formation%2520of%2520catechol%2520and%2520chemically%2520reactive%2520metabolites%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1987%26volume%3D23%26spage%3D447%26epage%3D453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group">Nakayama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atsumi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takakusa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okazaki, O.</span><span> </span><span class="NLM_article-title">A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1970</span><span class="NLM_x">–</span> <span class="NLM_lpage">1977</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1124%2Fdmd.109.027797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=19487250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1970-1977&author=S.+Nakayamaauthor=R.+Atsumiauthor=H.+Takakusaauthor=Y.+Kobayashiauthor=A.+Kuriharaauthor=Y.+Nagaiauthor=D.+Nakaiauthor=O.+Okazaki&title=A+zone+classification+system+for+risk+assessment+of+idiosyncratic+drug+toxicity+using+daily+dose+and+covalent+binding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding</span></div><div class="casAuthors">Nakayama, Shintaro; Atsumi, Ryo; Takakusa, Hideo; Kobayashi, Yoshimasa; Kurihara, Atsushi; Nagai, Yoko; Nakai, Daisuke; Okazaki, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1970-1977</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The risk of idiosyncratic drug toxicity (IDT) is of great concern to the pharmaceutical industry.  Current hypotheses based on retrospective studies suggest that the occurrence of IDT is related to covalent binding and daily dose.  The authors detd. the covalent binding of 42 radiolabeled drugs in three test systems (human liver microsomes and hepatocytes in vitro and rat liver in vivo) to assess the risk of IDT.  On the basis of safety profiles given in official documentation, tested drugs were classified into the safety categories of safe, warning, black box warning, and withdrawn.  The covalent binding in each of the three test systems did not distinguish the safety categories clearly.  However, when the log-normalized covalent binding was plotted against the log-normalized daily dose, the distribution of the plot in the safety categories became clear.  An ordinal logistic regression anal. indicated that both covalent binding and daily dose were significantly correlated with safety category and that covalent binding in hepatocytes was the best predictor among the three systems.  When two sepn. lines were drawn on the correlation graph between covalent binding in human hepatocytes and daily dose by a regression anal. to create three zones, 30 of 37 tested drugs were located in zones corresponding to their resp. classified safety categories.  In conclusion, the authors established a zone classification system using covalent binding in human hepatocytes and daily dose for the risk assessment of IDTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtahZPkNJ3JbVg90H21EOLACvtfcHk0liyad8Ak7Mnug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO&md5=425119e0451fc50ec6ca95d5e3fe5fd3</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.027797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.027797%26sid%3Dliteratum%253Aachs%26aulast%3DNakayama%26aufirst%3DS.%26aulast%3DAtsumi%26aufirst%3DR.%26aulast%3DTakakusa%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DNakai%26aufirst%3DD.%26aulast%3DOkazaki%26aufirst%3DO.%26atitle%3DA%2520zone%2520classification%2520system%2520for%2520risk%2520assessment%2520of%2520idiosyncratic%2520drug%2520toxicity%2520using%2520daily%2520dose%2520and%2520covalent%2520binding%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1970%26epage%3D1977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group">Park, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boobis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldring, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenna, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laverty, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naisbitt, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll-Griffith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Routledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tweedie, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeulen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Managing the challenge of chemically reactive metabolites in drug development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">292</span><span class="NLM_x">–</span> <span class="NLM_lpage">306</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1038%2Fnrd3408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=21455238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=292-306&author=B.+K.+Parkauthor=A.+Boobisauthor=S.+Clarkeauthor=C.+E.+Goldringauthor=D.+Jonesauthor=J.+G.+Kennaauthor=C.+Lambertauthor=H.+G.+Lavertyauthor=D.+J.+Naisbittauthor=S.+Nelsonauthor=D.+A.+Nicoll-Griffithauthor=R.+S.+Obachauthor=P.+Routledgeauthor=D.+A.+Smithauthor=D.+J.+Tweedieauthor=N.+Vermeulenauthor=D.+P.+Williamsauthor=I.+D.+Wilsonauthor=T.+A.+Baillie&title=Managing+the+challenge+of+chemically+reactive+metabolites+in+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Managing the challenge of chemically reactive metabolites in drug development</span></div><div class="casAuthors">Park, B. Kevin; Boobis, Alan; Clarke, Stephen; Goldring, Chris E. P.; Jones, David; Kenna, J. Gerry; Lambert, Craig; Laverty, Hugh G.; Naisbitt, Dean J.; Nelson, Sidney; Nicoll-Griffith, Deborah A.; Obach, R. Scott; Routledge, Philip; Smith, Dennis A.; Tweedie, Donald J.; Vermeulen, Nico; Williams, Dominic P.; Wilson, Ian D.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">292-306</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The normal metab. of drugs can generate metabolites that have intrinsic chem. reactivity towards cellular mols., and therefore have the potential to alter biol. function and initiate serious adverse drug reactions.  Here, we present an assessment of the current approaches used for the evaluation of chem. reactive metabolites.  We also describe how these approaches are being used within the pharmaceutical industry to assess and minimize the potential of drug candidates to cause toxicity.  At early stages of drug discovery, iteration between medicinal chem. and drug metab. can eliminate perceived reactive metabolite-mediated chem. liabilities without compromising pharmacol. activity or the need for extensive safety evaluation beyond std. practices.  In the future, reactive metabolite evaluation may also be useful during clin. development for improving clin. risk assessment and risk management.  Currently, there remains a huge gap in our understanding of the basic mechanisms that underlie chem. stress-mediated adverse reactions in humans.  This Review summarizes our views on this complex topic, and includes insights into practices considered by the pharmaceutical industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBv41vr7ZlNLVg90H21EOLACvtfcHk0lhypmBz-YvG0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGnu78%253D&md5=8f6865f17bbe50b51aa4282379e82a08</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1038%2Fnrd3408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3408%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DBoobis%26aufirst%3DA.%26aulast%3DClarke%26aufirst%3DS.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DLambert%26aufirst%3DC.%26aulast%3DLaverty%26aufirst%3DH.%2BG.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DS.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DRoutledge%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DTweedie%26aufirst%3DD.%2BJ.%26aulast%3DVermeulen%26aufirst%3DN.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3DWilson%26aufirst%3DI.%2BD.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DManaging%2520the%2520challenge%2520of%2520chemically%2520reactive%2520metabolites%2520in%2520drug%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D292%26epage%3D306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group">Stepan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aleo, M. D.</span><span> </span><span class="NLM_article-title">Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1345</span><span class="NLM_x">–</span> <span class="NLM_lpage">1410</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx200168d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1345-1410&author=A.+F.+Stepanauthor=D.+P.+Walkerauthor=J.+Baumanauthor=D.+A.+Priceauthor=T.+A.+Baillieauthor=A.+S.+Kalgutkarauthor=M.+D.+Aleo&title=Structural+alert%2Freactive+metabolite+concept+as+applied+in+medicinal+chemistry+to+mitigate+the+risk+of+idiosyncratic+drug+toxicity%3A+a+perspective+based+on+the+critical+examination+of+trends+in+the+top+200+drugs+marketed+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States</span></div><div class="casAuthors">Stepan, Antonia F.; Walker, Daniel P.; Bauman, Jonathan; Price, David A.; Baillie, Thomas A.; Kalgutkar, Amit S.; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1345-1410</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Because of a preconceived notion that eliminating reactive metabolite (RM) formation with new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM formation is routinely examd. as part of lead optimization efforts in drug discovery.  Likewise, avoidance of "structural alerts" is almost a norm in drug design.  However, there is a growing concern that the perceived safety hazards assocd. with structural alerts and/or RM screening tools as standalone predictors of toxicity risks may be over exaggerated.  In addn., the multifactorial nature of idiosyncratic toxicity is now well recognized based upon observations that mechanisms other than RM formation (e.g., mitochondrial toxicity and inhibition of bile salt export pump (BSEP)) also can account for certain target organ toxicities.  Hence, fundamental questions arise such as: When is a mol. that contains a structural alert (RM pos. or neg.) a cause for concern.  Could the mol. in its parent form exert toxicity.  Can a low dose drug candidate truly mitigate metab.-dependent and -independent idiosyncratic toxicity risks.  In an effort to address these questions, we have retrospectively examd. 68 drugs (recalled or assocd. with a black box warning due to idiosyncratic toxicity) and the top 200 drugs (prescription and sales) in the United States in 2009 for trends in physiochem. characteristics, daily doses, presence of structural alerts, evidence for RM formation as well as toxicity mechanism(s) potentially mediated by parent drugs.  Collectively, our anal. revealed that a significant proportion (∼78-86%) of drugs assocd. with toxicity contained structural alerts and evidence indicating that RM formation as a causative factor for toxicity has been presented in 62-69% of these mols.  In several cases, mitochondrial toxicity and BSEP inhibition mediated by parent drugs were also noted as potential causative factors.  Most drugs were administered at daily doses exceeding several hundred milligrams.  There was no obvious link between idiosyncratic toxicity and physicochem. properties such as mol. wt., lipophilicity, etc.  Approx. half of the top 200 drugs for 2009 (prescription and sales) also contained one or more alerts in their chem. architecture, and many were found to be RM-pos.  Several instances of BSEP and mitochondrial liabilities were also noted with agents in the top 200 category.  However, with relatively few exceptions, the vast majority of these drugs are rarely assocd. with idiosyncratic toxicity, despite years of patient use.  The major differentiating factor appeared to be the daily dose; most of the drugs in the top 200 list are administered at low daily doses.  In addn., competing detoxication pathways and/or alternate nonmetabolic clearance routes provided suitable justifications for the safety records of RM-pos. drugs in the top 200 category.  Thus, while RM elimination may be a useful and pragmatic starting point in mitigating idiosyncratic toxicity risks, our anal. suggests a need for a more integrated screening paradigm for chem. hazard identification in drug discovery.  Thus, in addn. to a detailed assessment of RM formation potential (in relationship to the overall elimination mechanisms of the compd.(s)) for lead compds., effects on cellular health (e.g., cytotoxicity assays), BSEP inhibition, and mitochondrial toxicity are the recommended suite of assays to characterize compd. liabilities.  However, the prospective use of such data in compd. selection will require further validation of the cellular assays using marketed agents.  Until we gain a better understanding of the pathophysiol. mechanisms assocd. with idiosyncratic toxicities, improving pharmacokinetics and intrinsic potency as means of decreasing the dose size and the assocd. "body burden" of the parent drug and its metabolites will remain an overarching goal in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IhczIcvVDLVg90H21EOLACvtfcHk0lhypmBz-YvG0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D&md5=632b73f755738e49eb233bc8dca1fbcc</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Ftx200168d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200168d%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DStructural%2520alert%252Freactive%2520metabolite%2520concept%2520as%2520applied%2520in%2520medicinal%2520chemistry%2520to%2520mitigate%2520the%2520risk%2520of%2520idiosyncratic%2520drug%2520toxicity%253A%2520a%2520perspective%2520based%2520on%2520the%2520critical%2520examination%2520of%2520trends%2520in%2520the%2520top%2520200%2520drugs%2520marketed%2520in%2520the%2520United%2520States%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1345%26epage%3D1410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group">Brown, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galetin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houston, J. B.</span><span> </span><span class="NLM_article-title">Prediction of in vivo drug–drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">508</span><span class="NLM_x">–</span> <span class="NLM_lpage">518</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1111%2Fj.1365-2125.2005.02483.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=16236041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Ojt7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2005&pages=508-518&author=H.+S.+Brownauthor=K.+Itoauthor=A.+Galetinauthor=J.+B.+Houston&title=Prediction+of+in+vivo+drug%E2%80%93drug+interactions+from+in+vitro+data%3A+impact+of+incorporating+parallel+pathways+of+drug+elimination+and+inhibitor+absorption+rate+constant"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant</span></div><div class="casAuthors">Brown, Hayley S.; Ito, Kiyomi; Galetin, Aleksandra; Houston, J. Brian</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">508-518</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Aims: Success of the quant. prediction of drug-drug interactions via inhibition of CYP-mediated metab. from the inhibitor concn. at the enzyme active site ([I]) and the in vitro inhibition const. (Ki) is variable.  The aim of this study was to examine the impact of the fraction of victim drug metabolized by a particular CYP (fmCYP) and the inhibitor absorption rate const. (ka) on prediction accuracy.  Methods: Drug-drug interaction studies involving inhibition of CYP2C9, CYP2D6 and CYP3A4 (n = 115) were investigated.  Data on fmCYP for the probe substrates of each enzyme and ka values for the inhibitors were incorporated into in vivo predictions, alone or in combination, using either the max. hepatic input or the av. systemic plasma concn. as a surrogate for [I].  The success of prediction (AUC ratio predicted within twofold of in vivo value) was compared using nominal values of fmCYP = 1 and ka = 0.1 min-1.  Results: The incorporation of fmCYP values into in vivo predictions using the hepatic input plasma concn. resulted in 84% of studies within twofold of in vivo value.  The effect of ka values alone significantly reduced the no. of over-predictions for CYP2D6 and CYP3A4; however, less precision was obsd. compared with the fmCYP.  The incorporation of both fmCYP and ka values resulted in 81% of studies within twofold of in vivo value.  Conclusions: The incorporation of substrate and inhibitor-related information, namely fmCYP and ka, markedly improved prediction of 115 interaction studies with CYP2C9, CYP2D6 and CYP3A4 in comparison with [I]/Ki ratio alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovEiyVGwCJZ7Vg90H21EOLACvtfcHk0lhypmBz-YvG0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Ojt7bJ&md5=57ba994039c26e7d21d0ee0e159aa4ac</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2005.02483.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2005.02483.x%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DH.%2BS.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DGaletin%26aufirst%3DA.%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26atitle%3DPrediction%2520of%2520in%2520vivo%2520drug%25E2%2580%2593drug%2520interactions%2520from%2520in%2520vitro%2520data%253A%2520impact%2520of%2520incorporating%2520parallel%2520pathways%2520of%2520drug%2520elimination%2520and%2520inhibitor%2520absorption%2520rate%2520constant%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D60%26spage%3D508%26epage%3D518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maclin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span> </span><span class="NLM_article-title">Mechanism-based inhibition of human liver microsomal cytochrome P450 3A by a focal adhesion kinase (FAK) inhibitor PF-562,271</span> <span class="citation_source-journal">Drug Metab. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">86</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=86&issue=Suppl.+2&author=H.+Rongauthor=D.+Maclinauthor=L.+Yaoauthor=J.+Linauthor=D.+Yinauthor=H.+Xu&title=Mechanism-based+inhibition+of+human+liver+microsomal+cytochrome+P450+3A+by+a+focal+adhesion+kinase+%28FAK%29+inhibitor+PF-562%2C271"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRong%26aufirst%3DH.%26aulast%3DMaclin%26aufirst%3DD.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DH.%26atitle%3DMechanism-based%2520inhibition%2520of%2520human%2520liver%2520microsomal%2520cytochrome%2520P450%25203A%2520by%2520a%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%2520inhibitor%2520PF-562%252C271%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2008%26volume%3D40%26issue%3DSuppl.%25202%26spage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group">Tucker, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houston, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. M.</span><span> </span><span class="NLM_article-title">Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential—towards a consensus</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">117</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1046%2Fj.0306-5251.2001.temp.1441.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=11453898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A280%3ADC%252BD3Mvhs1WqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2001&pages=107-117&author=G.+T.+Tuckerauthor=J.+B.+Houstonauthor=S.+M.+Huang&title=Optimizing+drug+development%3A+strategies+to+assess+drug+metabolism%2Ftransporter+interaction+potential%E2%80%94towards+a+consensus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus</span></div><div class="casAuthors">Tucker G T; Houston J B; Huang S M</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-17</span>
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8P0AfNxMICYIRAdBLKY41fW6udTcc2ebZlVnEv7ioebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3Mvhs1WqsQ%253D%253D&md5=a6edcbdd0b2ba6f88784f2b30673c808</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1046%2Fj.0306-5251.2001.temp.1441.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.0306-5251.2001.temp.1441.x%26sid%3Dliteratum%253Aachs%26aulast%3DTucker%26aufirst%3DG.%2BT.%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26aulast%3DHuang%26aufirst%3DS.%2BM.%26atitle%3DOptimizing%2520drug%2520development%253A%2520strategies%2520to%2520assess%2520drug%2520metabolism%252Ftransporter%2520interaction%2520potential%25E2%2580%2594towards%2520a%2520consensus%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2001%26volume%3D52%26spage%3D107%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group">Fahmi, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripp, S. L.</span><span> </span><span class="NLM_article-title">Evaluation of models for predicting drug–drug interactions due to induction</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1399</span><span class="NLM_x">–</span> <span class="NLM_lpage">1416</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1517%2F17425255.2010.516251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=20955108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=1399-1416&author=O.+A.+Fahmiauthor=S.+L.+Ripp&title=Evaluation+of+models+for+predicting+drug%E2%80%93drug+interactions+due+to+induction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of models for predicting drug-drug interactions due to induction</span></div><div class="casAuthors">Fahmi, Odette A.; Ripp, Sharon L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1399-1416</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Drug-drug interactions caused by induction of metabolizing enzymes, particularly CYP3A, can impact the efficacy and safety of co-administered drugs.  It is, therefore, important to understand a new compd.'s potential for enzyme induction and to understand how to use the induction data generated in vitro to predict potential for drug-drug interactions in vivo.  Areas covered in this review: Recent advances in methods for using in vitro data to predict potential for CYP3A induction in vivo are reviewed.  What the reader will gain: The reader will gain a comprehensive understanding of the advantages and disadvantages of various prediction methods for induction and be able to directly compare different methods using a common in vitro data set.  Take home message: The various methods for predicting clin. CYP3A induction from in vitro induction data all have demonstrated utility; it is the authors' opinion that the correlation-based approaches offer as good or better predictivity and have simpler input requirements than more complex approaches.  Of the different correlation approaches, the relatively simple unbound Cmax/EC50 or AUC/EC50 approaches are the simplest and yet show the best correlation to the obsd. clin. data.  While the approaches discussed herein represent an improvement in our understanding of the predictive value of in vitro induction data, it is important to recognize that there is still room for improvement in quant. prediction of magnitude of drug interactions due to induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBLyowSf3OMrVg90H21EOLACvtfcHk0lhx14N7tiOi3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtbzN&md5=1b95f24bb423f019f8d2b349cc4af592</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1517%2F17425255.2010.516251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2010.516251%26sid%3Dliteratum%253Aachs%26aulast%3DFahmi%26aufirst%3DO.%2BA.%26aulast%3DRipp%26aufirst%3DS.%2BL.%26atitle%3DEvaluation%2520of%2520models%2520for%2520predicting%2520drug%25E2%2580%2593drug%2520interactions%2520due%2520to%2520induction%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2010%26volume%3D6%26spage%3D1399%26epage%3D1416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group">Fahmi, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardenas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boldt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettleton, D.</span><span> </span><span class="NLM_article-title">A combined model for predicting CYP3A4 clinical net drug–drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1698</span><span class="NLM_x">–</span> <span class="NLM_lpage">1708</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1698-1708&author=O.+A.+Fahmiauthor=T.+S.+Maurerauthor=M.+Kishauthor=E.+Cardenasauthor=S.+Boldtauthor=D.+Nettleton&title=A+combined+model+for+predicting+CYP3A4+clinical+net+drug%E2%80%93drug+interaction+based+on+CYP3A4+inhibition%2C+inactivation%2C+and+induction+determined+in+vitro"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFahmi%26aufirst%3DO.%2BA.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DKish%26aufirst%3DM.%26aulast%3DCardenas%26aufirst%3DE.%26aulast%3DBoldt%26aufirst%3DS.%26aulast%3DNettleton%26aufirst%3DD.%26atitle%3DA%2520combined%2520model%2520for%2520predicting%2520CYP3A4%2520clinical%2520net%2520drug%25E2%2580%2593drug%2520interaction%2520based%2520on%2520CYP3A4%2520inhibition%252C%2520inactivation%252C%2520and%2520induction%2520determined%2520in%2520vitro%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D1698%26epage%3D1708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group">Jones, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youdim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosset, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attkins, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurrell, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bungay, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, I. B.</span><span> </span><span class="NLM_article-title">Application of PBPK modelling in drug discovery and development at Pfizer</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2011&pages=94-106&author=H.+M.+Jonesauthor=M.+Dickinsauthor=K.+Youdimauthor=J.+R.+Gossetauthor=N.+J.+Attkinsauthor=T.+L.+Hayauthor=I.+K.+Gurrellauthor=Y.+R.+Loganauthor=P.+J.+Bungayauthor=B.+C.+Jonesauthor=I.+B.+Gardner&title=Application+of+PBPK+modelling+in+drug+discovery+and+development+at+Pfizer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DH.%2BM.%26aulast%3DDickins%26aufirst%3DM.%26aulast%3DYoudim%26aufirst%3DK.%26aulast%3DGosset%26aufirst%3DJ.%2BR.%26aulast%3DAttkins%26aufirst%3DN.%2BJ.%26aulast%3DHay%26aufirst%3DT.%2BL.%26aulast%3DGurrell%26aufirst%3DI.%2BK.%26aulast%3DLogan%26aufirst%3DY.%2BR.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DGardner%26aufirst%3DI.%2BB.%26atitle%3DApplication%2520of%2520PBPK%2520modelling%2520in%2520drug%2520discovery%2520and%2520development%2520at%2520Pfizer%26jtitle%3DXenobiotica%26date%3D2011%26volume%3D42%26spage%3D94%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group">de LT Vieira, M.; Zhao, P.; Huang, S.-M.</span><span> </span><span class="NLM_article-title">Predicting Drug Interaction Potential of Telithromycin Using a Physiologically-Based Pharmacokinetic (PBPK) Model That Incorporates Time-Dependent Enzyme Inhibition Mechanism Derived from Nonlinear Pharmacokinetics</span>. Presented at the AAPS Annual Meeting, Washington, DC, October 23–27,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>Poster.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+de+LT+Vieira&author=P.+Zhao&author=S.-M.+Huang&title=Predicting+Drug+Interaction+Potential+of+Telithromycin+Using+a+Physiologically-Based+Pharmacokinetic+%28PBPK%29+Model+That+Incorporates+Time-Dependent+Enzyme+Inhibition+Mechanism+Derived+from+Nonlinear+Pharmacokinetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLT%2BVieira%26aufirst%3DM.%26atitle%3DPredicting%2520Drug%2520Interaction%2520Potential%2520of%2520Telithromycin%2520Using%2520a%2520Physiologically-Based%2520Pharmacokinetic%2520%2528PBPK%2529%2520Model%2520That%2520Incorporates%2520Time-Dependent%2520Enzyme%2520Inhibition%2520Mechanism%2520Derived%2520from%2520Nonlinear%2520Pharmacokinetics%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group">Rowland Yeo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsky, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rostami-Hodjegan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, G. T.</span><span> </span><span class="NLM_article-title">Prediction of time-dependent CYP3A4 drug–drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover</span> <span class="citation_source-journal">Eur. J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">160</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.ejps.2011.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=21540107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFSkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2011&pages=160-173&author=K.+Rowland+Yeoauthor=R.+L.+Walskyauthor=M.+Jameiauthor=A.+Rostami-Hodjeganauthor=G.+T.+Tucker&title=Prediction+of+time-dependent+CYP3A4+drug%E2%80%93drug+interactions+by+physiologically+based+pharmacokinetic+modelling%3A+impact+of+inactivation+parameters+and+enzyme+turnover"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: Impact of inactivation parameters and enzyme turnover</span></div><div class="casAuthors">Rowland Yeo, K.; Walsky, R. L.; Jamei, M.; Rostami-Hodjegan, A.; Tucker, G. T.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">160-173</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Predicting the magnitude of time-dependent metabolic drug-drug (mDDIs) interactions involving cytochrome P 450 3A4 (CYP3A4) from in vitro data requires accurate knowledge of the inactivation parameters of the inhibitor (K I, k inact) and of the turnover of the enzyme (k deg) in both the gut and the liver.  We have predicted the magnitude of mDDIs obsd. in 29 in vivo studies involving six CYP3A4 probe substrates and five mechanism based inhibitors of CYP3A4 of variable potency (azithromycin, clarithromycin, diltiazem, erythromycin and verapamil).  Inactivation parameters detd. anew in a single lab. under standardised conditions together with data from substrate and inhibitor files within the Simcyp Simulator (Version 9.3) were used to det. a value of the hepatic k deg (0.0193 or 0.0077 h-1) most appropriate for the prediction of mDDIs involving time-dependent inhibition of CYP3A4.  The higher value resulted in decreased bias (geometric mean fold error - 1.05 vs. 1.30) and increased precision (root mean squared error - 1.29 vs. 2.30) of predictions of mean ratios of AUC in the absence and presence of inhibitor.  Depending on the k deg value used (0.0193 vs. 0.0077 h-1), predicted mean ratios of AUC were within 2-fold of the obsd. values for all (100%) and 27 (93%) of the 29 studies, resp. and within 1.5-fold for 24 (83%) and 17 (59%) of the 29 studies, resp.  Comprehensive PBPK models were applied for accurate assessment of the potential for mDDIs involving time-dependent inhibition of CYP3A4 using a hepatic k deg value of 0.0193 h-1 in conjunction with inactivation parameters detd. by the conventional exptl. approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3Smu_gOTvVbVg90H21EOLACvtfcHk0liHZ2NqF3J2Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFSkt7Y%253D&md5=ab242e3e6c530c220ca3d73340d6ac00</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2011.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2011.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DRowland%2BYeo%26aufirst%3DK.%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DJamei%26aufirst%3DM.%26aulast%3DRostami-Hodjegan%26aufirst%3DA.%26aulast%3DTucker%26aufirst%3DG.%2BT.%26atitle%3DPrediction%2520of%2520time-dependent%2520CYP3A4%2520drug%25E2%2580%2593drug%2520interactions%2520by%2520physiologically%2520based%2520pharmacokinetic%2520modelling%253A%2520impact%2520of%2520inactivation%2520parameters%2520and%2520enzyme%2520turnover%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D43%26spage%3D160%26epage%3D173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group">Zientek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span> </span><span class="NLM_article-title">Utilization of a multi-staged time-dependent inhibition assay to assess the impact of intestinal metabolism on drug–drug interaction potential</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">467</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=467-473&author=M.+Zientekauthor=D.+Dalvie&title=Utilization+of+a+multi-staged+time-dependent+inhibition+assay+to+assess+the+impact+of+intestinal+metabolism+on+drug%E2%80%93drug+interaction+potential"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DDalvie%26aufirst%3DD.%26atitle%3DUtilization%2520of%2520a%2520multi-staged%2520time-dependent%2520inhibition%2520assay%2520to%2520assess%2520the%2520impact%2520of%2520intestinal%2520metabolism%2520on%2520drug%25E2%2580%2593drug%2520interaction%2520potential%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D467%26epage%3D473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group">Fahmi, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plowchalk, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youdim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phipps, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darekar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Comparison of different algorithms for predicting clinical drug–drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1658</span><span class="NLM_x">–</span> <span class="NLM_lpage">1666</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1658-1666&author=O.+A.+Fahmiauthor=S.+Hurstauthor=D.+Plowchalkauthor=J.+Cookauthor=F.+Guoauthor=K.+Youdimauthor=M.+Dickinsauthor=A.+Phippsauthor=A.+Darekarauthor=R.+Hylandauthor=R.+S.+Obach&title=Comparison+of+different+algorithms+for+predicting+clinical+drug%E2%80%93drug+interactions%2C+based+on+the+use+of+CYP3A4+in+vitro+data%3A+predictions+of+compounds+as+precipitants+of+interaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFahmi%26aufirst%3DO.%2BA.%26aulast%3DHurst%26aufirst%3DS.%26aulast%3DPlowchalk%26aufirst%3DD.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DF.%26aulast%3DYoudim%26aufirst%3DK.%26aulast%3DDickins%26aufirst%3DM.%26aulast%3DPhipps%26aufirst%3DA.%26aulast%3DDarekar%26aufirst%3DA.%26aulast%3DHyland%26aufirst%3DR.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DComparison%2520of%2520different%2520algorithms%2520for%2520predicting%2520clinical%2520drug%25E2%2580%2593drug%2520interactions%252C%2520based%2520on%2520the%2520use%2520of%2520CYP3A4%2520in%2520vitro%2520data%253A%2520predictions%2520of%2520compounds%2520as%2520precipitants%2520of%2520interaction%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1658%26epage%3D1666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 123 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Lloyd Wei Tat Tang, Jian Wei Teng, Siew Kwan Koh, Lei Zhou, Mei Lin Go, <span class="NLM_string-name hlFld-ContribAuthor">Eric Chun Yong Chan</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2021,</strong> <em>34 </em>
                                    (7)
                                     , 1800-1813. <a href="https://doi.org/10.1021/acs.chemrestox.1c00178" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.1c00178</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.1c00178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.1c00178%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DMechanism-Based%252BInactivation%252Bof%252BCytochrome%252BP450%252B3A4%252Band%252B3A5%252Bby%252Bthe%252BFibroblast%252BGrowth%252BFactor%252BReceptor%252BInhibitor%252BErdafitinib%26aulast%3DTang%26aufirst%3DLloyd%2BWei%2BTat%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D10052021%26date%3D30062021%26volume%3D34%26issue%3D7%26spage%3D1800%26epage%3D1813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chaitanya K. Jaladanki, Samima Khatun, Holger Gohlke, <span class="NLM_string-name hlFld-ContribAuthor">Prasad V. Bharatam</span>. </span><span class="cited-content_cbyCitation_article-title">Reactive Metabolites from Thiazole-Containing Drugs: Quantum Chemical Insights into Biotransformation and Toxicity. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2021,</strong> <em>34 </em>
                                    (6)
                                     , 1503-1517. <a href="https://doi.org/10.1021/acs.chemrestox.0c00450" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.0c00450</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.0c00450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.0c00450%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DReactive%252BMetabolites%252Bfrom%252BThiazole-Containing%252BDrugs%25253A%252BQuantum%252BChemical%252BInsights%252Binto%252BBiotransformation%252Band%252BToxicity%26aulast%3DJaladanki%26aufirst%3DChaitanya%2BK.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D13102020%26date%3D26042021%26volume%3D34%26issue%3D6%26spage%3D1503%26epage%3D1517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">M. Saeed Mirzaei, Maxim V. Ivanov, Avat Arman Taherpour, <span class="NLM_string-name hlFld-ContribAuthor">Saber Mirzaei</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Computational Insights. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2021,</strong> <em>34 </em>
                                    (4)
                                     , 959-987. <a href="https://doi.org/10.1021/acs.chemrestox.0c00483" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.0c00483</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.0c00483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.0c00483%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DMechanism-Based%252BInactivation%252Bof%252BCytochrome%252BP450%252BEnzymes%25253A%252BComputational%252BInsights%26aulast%3DMirzaei%26aufirst%3DM.%2BSaeed%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D10112020%26date%3D26032021%26volume%3D34%26issue%3D4%26spage%3D959%26epage%3D987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yuji Koriyama, Akihiro Hori, Hisanori Ito, Shuji Yonezawa, Yoshiyasu Baba, Norihiko Tanimoto, Tatsuhiko Ueno, Shiho Yamamoto, Takahiko Yamamoto, Naoya Asada, Kenji Morimoto, Shunsuke Einaru, Katsunori Sakai, Takushi Kanazu, Akihiro Matsuda, Yoshitaka Yamaguchi, Takuya Oguma, Maarten Timmers, Luc Tritsmans, Ken-ichi Kusakabe, Akira Kato, <span class="NLM_string-name hlFld-ContribAuthor">Gaku Sakaguchi</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (4)
                                     , 1873-1888. <a href="https://doi.org/10.1021/acs.jmedchem.0c01917" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01917</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01917%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BAtabecestat%252B%252528JNJ-54861911%252529%25253A%252BA%252BThiazine-Based%252B%2525CE%2525B2-Amyloid%252BPrecursor%252BProtein%252BCleaving%252BEnzyme%252B1%252BInhibitor%252BAdvanced%252Bto%252Bthe%252BPhase%252B2b%25252F3%252BEARLY%252BClinical%252BTrial%26aulast%3DKoriyama%26aufirst%3DYuji%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D05112020%26date%3D15022021%26volume%3D64%26issue%3D4%26spage%3D1873%26epage%3D1888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kim Huard, Aaron C. Smith, Gregg Cappon, Robert L. Dow, David J. Edmonds, Ayman El-Kattan, William P. Esler, Dilinie P. Fernando, David A. Griffith, Amit S. Kalgutkar, Trenton T. Ross, Scott W. Bagley, David Beebe, Yi-An Bi, Shawn Cabral, Collin Crowley, Shawn D. Doran, Matthew S. Dowling, Spiros Liras, Vincent Mascitti, Mark Niosi, Jeffrey A. Pfefferkorn, Jana Polivkova, Cathy Préville, David A. Price, Andre Shavnya, Norimitsu Shirai, Andrew H. Smith, James R. Southers, David A. Tess, Benjamin A. Thuma, Manthena V. Varma, <span class="NLM_string-name hlFld-ContribAuthor">Xiaojing Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10879-10896. <a href="https://doi.org/10.1021/acs.jmedchem.0c00640" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00640%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOptimizing%252Bthe%252BBenefit%25252FRisk%252Bof%252BAcetyl-CoA%252BCarboxylase%252BInhibitors%252Bthrough%252BLiver%252BTargeting%26aulast%3DHuard%26aufirst%3DKim%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17042020%26date%3D18092020%26date%3D18082020%26volume%3D63%26issue%3D19%26spage%3D10879%26epage%3D10896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Taylor M. Sodano, Logan A. Combee, <span class="NLM_string-name hlFld-ContribAuthor">Corey R. J. Stephenson</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances and Outlook for the Isosteric Replacement of Anilines. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (10)
                                     , 1785-1788. <a href="https://doi.org/10.1021/acsmedchemlett.9b00687" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00687</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00687%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRecent%252BAdvances%252Band%252BOutlook%252Bfor%252Bthe%252BIsosteric%252BReplacement%252Bof%252BAnilines%26aulast%3DSodano%26aufirst%3DTaylor%2BM.%26date%3D2020%26date%3D2020%26date%3D21022020%26volume%3D11%26issue%3D10%26spage%3D1785%26epage%3D1788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chenghong Zhang, James J. Crawford, Matthew L. Landry, Huifen Chen, Jane R. Kenny, S. Cyrus Khojasteh, Wendy Lee, Shuguang Ma, <span class="NLM_string-name hlFld-ContribAuthor">Wendy B. Young</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies to Mitigate the Bioactivation of Aryl Amines. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2020,</strong> <em>33 </em>
                                    (7)
                                     , 1950-1959. <a href="https://doi.org/10.1021/acs.chemrestox.0c00138" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.0c00138</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.0c00138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.0c00138%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DStrategies%252Bto%252BMitigate%252Bthe%252BBioactivation%252Bof%252BAryl%252BAmines%26aulast%3DZhang%26aufirst%3DChenghong%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09042020%26date%3D23062020%26date%3D08062020%26volume%3D33%26issue%3D7%26spage%3D1950%26epage%3D1959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Matthew A. Cerny, Amit S. Kalgutkar, R. Scott Obach, Raman Sharma, Douglas K. Spracklin, <span class="NLM_string-name hlFld-ContribAuthor">Gregory S. Walker</span>. </span><span class="cited-content_cbyCitation_article-title">Effective Application of Metabolite Profiling in Drug Design and Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (12)
                                     , 6387-6406. <a href="https://doi.org/10.1021/acs.jmedchem.9b01840" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01840%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEffective%252BApplication%252Bof%252BMetabolite%252BProfiling%252Bin%252BDrug%252BDesign%252Band%252BDiscovery%26aulast%3DCerny%26aufirst%3DMatthew%2BA.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D06112019%26date%3D06032020%26date%3D25022020%26volume%3D63%26issue%3D12%26spage%3D6387%26epage%3D6406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zi-Yi Yang, Jun-Hong He, Ai-Ping Lu, Ting-Jun Hou, <span class="NLM_string-name hlFld-ContribAuthor">Dong-Sheng Cao</span>. </span><span class="cited-content_cbyCitation_article-title">Application of Negative Design To Design a More Desirable Virtual Screening Library. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (9)
                                     , 4411-4429. <a href="https://doi.org/10.1021/acs.jmedchem.9b01476" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01476</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01476%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DApplication%252Bof%252BNegative%252BDesign%252BTo%252BDesign%252Ba%252BMore%252BDesirable%252BVirtual%252BScreening%252BLibrary%26aulast%3DYang%26aufirst%3DZi-Yi%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D05092019%26date%3D27012020%26date%3D13012020%26volume%3D63%26issue%3D9%26spage%3D4411%26epage%3D4429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Angela S. Carlson, En-Chih Liu, <span class="NLM_string-name hlFld-ContribAuthor">Joseph J. Topczewski</span>. </span><span class="cited-content_cbyCitation_article-title">A Cascade Reaction of Cinnamyl Azides with Acrylates Directly Generates Tetrahydro-Pyrrolo-Pyrazole Heterocycles. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (9)
                                     , 6044-6059. <a href="https://doi.org/10.1021/acs.joc.0c00535" title="DOI URL">https://doi.org/10.1021/acs.joc.0c00535</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c00535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c00535%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DA%252BCascade%252BReaction%252Bof%252BCinnamyl%252BAzides%252Bwith%252BAcrylates%252BDirectly%252BGenerates%252BTetrahydro-Pyrrolo-Pyrazole%252BHeterocycles%26aulast%3DCarlson%26aufirst%3DAngela%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28022020%26date%3D20042020%26date%3D13042020%26volume%3D85%26issue%3D9%26spage%3D6044%26epage%3D6059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Te-Chun Chu, Zachary J. Buras, Brook Eyob, Mica C. Smith, Mengjie Liu, <span class="NLM_string-name hlFld-ContribAuthor">William H. Green</span>. </span><span class="cited-content_cbyCitation_article-title">Direct Kinetics and Product Measurement of Phenyl Radical + Ethylene. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Physical Chemistry A</span><span> <strong>2020,</strong> <em>124 </em>
                                    (12)
                                     , 2352-2365. <a href="https://doi.org/10.1021/acs.jpca.9b11543" title="DOI URL">https://doi.org/10.1021/acs.jpca.9b11543</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jpca.9b11543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jpca.9b11543%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Physical%2520Chemistry%2520A%26atitle%3DDirect%252BKinetics%252Band%252BProduct%252BMeasurement%252Bof%252BPhenyl%252BRadical%252B%25252B%252BEthylene%26aulast%3DChu%26aufirst%3DTe-Chun%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D2020%26date%3D13122019%26date%3D27022020%26date%3D17032020%26date%3D02032020%26volume%3D124%26issue%3D12%26spage%3D2352%26epage%3D2365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marie-Noëlle Paludetto, Jean-Luc Stigliani, Anne Robert, Vania Bernardes-Génisson, Etienne Chatelut, Florent Puisset, <span class="NLM_string-name hlFld-ContribAuthor">Cécile Arellano</span>. </span><span class="cited-content_cbyCitation_article-title">Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug–Drug Interactions in Vitro and in Patient Samples. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2020,</strong> <em>33 </em>
                                    (1)
                                     , 181-190. <a href="https://doi.org/10.1021/acs.chemrestox.9b00205" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.9b00205</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.9b00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.9b00205%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DInvolvement%252Bof%252BPazopanib%252Band%252BSunitinib%252BAldehyde%252BReactive%252BMetabolites%252Bin%252BToxicity%252Band%252BDrug%2525E2%252580%252593Drug%252BInteractions%252Bin%252BVitro%252Band%252Bin%252BPatient%252BSamples%26aulast%3DPaludetto%26aufirst%3DMarie-No%25C3%25ABlle%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D16052019%26date%3D26092019%26date%3D19092019%26volume%3D33%26issue%3D1%26spage%3D181%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Justin H. Wilde, Jacob A. Smith, Diane A. Dickie, <span class="NLM_string-name hlFld-ContribAuthor">W. Dean Harman</span>. </span><span class="cited-content_cbyCitation_article-title">Molybdenum-Promoted Synthesis of Isoquinuclidines with Bridgehead CF3 Groups. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (47)
                                     , 18890-18899. <a href="https://doi.org/10.1021/jacs.9b10781" title="DOI URL">https://doi.org/10.1021/jacs.9b10781</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b10781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b10781%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DMolybdenum-Promoted%252BSynthesis%252Bof%252BIsoquinuclidines%252Bwith%252BBridgehead%252BCF3%252BGroups%26aulast%3DWilde%26aufirst%3DJustin%2BH.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D07102019%26date%3D14112019%26date%3D04112019%26volume%3D141%26issue%3D47%26spage%3D18890%26epage%3D18899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Rasmus Leth, Bogac Ercig, Lars Olsen, <span class="NLM_string-name hlFld-ContribAuthor">Flemming Steen Jørgensen</span>. </span><span class="cited-content_cbyCitation_article-title">Both Reactivity and Accessibility Are Important in Cytochrome P450 Metabolism: A Combined DFT and MD Study of Fenamic Acids in BM3 Mutants. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (2)
                                     , 743-753. <a href="https://doi.org/10.1021/acs.jcim.8b00750" title="DOI URL">https://doi.org/10.1021/acs.jcim.8b00750</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.8b00750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.8b00750%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DBoth%252BReactivity%252Band%252BAccessibility%252BAre%252BImportant%252Bin%252BCytochrome%252BP450%252BMetabolism%25253A%252BA%252BCombined%252BDFT%252Band%252BMD%252BStudy%252Bof%252BFenamic%252BAcids%252Bin%252BBM3%252BMutants%26aulast%3DLeth%26aufirst%3DRasmus%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D26102018%26date%3D13022019%26volume%3D59%26issue%3D2%26spage%3D743%26epage%3D753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mihirbaran Mandal, Kaushik Mitra, Diane Grotz, Xinjie Lin, Jairam Palamanda, Pramila Kumari, Alexei Buevich, John P. Caldwell, Xia Chen, Kathleen Cox, Leonard Favreau, Lynn Hyde, Matthew E. Kennedy, Reshma Kuvelkar, Xiaoxiang Liu, Robert D. Mazzola, Eric Parker, Diane Rindgen, Edward Sherer, Hongwu Wang, Zhaoning Zhu, Andrew W. Stamford, <span class="NLM_string-name hlFld-ContribAuthor">Jared N. Cumming</span>. </span><span class="cited-content_cbyCitation_article-title">Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (23)
                                     , 10700-10708. <a href="https://doi.org/10.1021/acs.jmedchem.8b01326" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01326</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01326%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOvercoming%252BTime-Dependent%252BInhibition%252B%252528TDI%252529%252Bof%252BCytochrome%252BP450%252B3A4%252B%252528CYP3A4%252529%252BResulting%252Bfrom%252BBioactivation%252Bof%252Ba%252BFluoropyrimidine%252BMoiety%26aulast%3DMandal%26aufirst%3DMihirbaran%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D22082018%26date%3D15112018%26date%3D02112018%26volume%3D61%26issue%3D23%26spage%3D10700%26epage%3D10708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lauren
N. Carnevale, Andres S. Arango, William R. Arnold, Emad Tajkhorshid, <span class="NLM_string-name hlFld-ContribAuthor">Aditi Das</span>. </span><span class="cited-content_cbyCitation_article-title">Endocannabinoid Virodhamine Is an Endogenous Inhibitor of Human Cardiovascular CYP2J2 Epoxygenase. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2018,</strong> <em>57 </em>
                                    (46)
                                     , 6489-6499. <a href="https://doi.org/10.1021/acs.biochem.8b00691" title="DOI URL">https://doi.org/10.1021/acs.biochem.8b00691</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.8b00691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.8b00691%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DEndocannabinoid%252BVirodhamine%252BIs%252Ban%252BEndogenous%252BInhibitor%252Bof%252BHuman%252BCardiovascular%252BCYP2J2%252BEpoxygenase%26aulast%3DCarnevale%26aufirst%3DLauren%2BN.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D25062018%26date%3D21092018%26date%3D06112018%26date%3D04102018%26volume%3D57%26issue%3D46%26spage%3D6489%26epage%3D6499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Nicholas A. Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (14)
                                     , 5822-5880. <a href="https://doi.org/10.1021/acs.jmedchem.7b01788" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01788</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFluorine%252Band%252BFluorinated%252BMotifs%252Bin%252Bthe%252BDesign%252Band%252BApplication%252Bof%252BBioisosteres%252Bfor%252BDrug%252BDesign%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D05122017%26date%3D05022018%26volume%3D61%26issue%3D14%26spage%3D5822%26epage%3D5880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Alf Claesson, <span class="NLM_string-name hlFld-ContribAuthor">Alexander Minidis</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic Approach to Organizing Structural Alerts for Reactive Metabolite Formation from Potential Drugs. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2018,</strong> <em>31 </em>
                                    (6)
                                     , 389-411. <a href="https://doi.org/10.1021/acs.chemrestox.8b00046" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.8b00046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.8b00046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.8b00046%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DSystematic%252BApproach%252Bto%252BOrganizing%252BStructural%252BAlerts%252Bfor%252BReactive%252BMetabolite%252BFormation%252Bfrom%252BPotential%252BDrugs%26aulast%3DClaesson%26aufirst%3DAlf%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D21022018%26date%3D21052018%26date%3D10052018%26volume%3D31%26issue%3D6%26spage%3D389%26epage%3D411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robert L. Dow, Mark Ammirati, Scott W. Bagley, Samit K. Bhattacharya, Leonard Buckbinder, Christian Cortes, Ayman F. El-Kattan, Kristen Ford, Gary B. Freeman, Cristiano R. W. Guimarães, Shenping Liu, Mark Niosi, Athanasia Skoura, <span class="NLM_string-name hlFld-ContribAuthor">David Tess</span>. </span><span class="cited-content_cbyCitation_article-title">2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (7)
                                     , 3114-3125. <a href="https://doi.org/10.1021/acs.jmedchem.8b00152" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00152</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00152%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D2-Aminopyridine-Based%252BMitogen-Activated%252BProtein%252BKinase%252BKinase%252BKinase%252BKinase%252B4%252B%252528MAP4K4%252529%252BInhibitors%25253A%252BAssessment%252Bof%252BMechanism-Based%252BSafety%26aulast%3DDow%26aufirst%3DRobert%2BL.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D29012018%26date%3D03042018%26date%3D23032018%26volume%3D61%26issue%3D7%26spage%3D3114%26epage%3D3125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chaitanya K.  Jaladanki</span>, <span class="hlFld-ContribAuthor ">Akbar  Shaikh</span>, and <span class="hlFld-ContribAuthor ">Prasad V.  Bharatam</span>  . </span><span class="cited-content_cbyCitation_article-title">Biotransformation of Isoniazid by Cytochromes P450: Analyzing the Molecular Mechanism using Density Functional Theory. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2017,</strong> <em>30 </em>
                                    (11)
                                     , 2060-2073. <a href="https://doi.org/10.1021/acs.chemrestox.7b00129" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.7b00129</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.7b00129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.7b00129%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DBiotransformation%252Bof%252BIsoniazid%252Bby%252BCytochromes%252BP450%25253A%252BAnalyzing%252Bthe%252BMolecular%252BMechanism%252Busing%252BDensity%252BFunctional%252BTheory%26aulast%3DJaladanki%26aufirst%3DChaitanya%2BK.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D15052017%26date%3D16102017%26date%3D20112017%26date%3D26092017%26volume%3D30%26issue%3D11%26spage%3D2060%26epage%3D2073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong  Ma</span>, <span class="hlFld-ContribAuthor ">Yue  Fu</span>, <span class="hlFld-ContribAuthor ">S. Cyrus  Khojasteh</span>, <span class="hlFld-ContribAuthor ">Deepak  Dalvie</span>, and <span class="hlFld-ContribAuthor ">Donglu  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (21)
                                     , 8691-8705. <a href="https://doi.org/10.1021/acs.jmedchem.7b00510" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00510</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00510%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DGlucuronides%252Bas%252BPotential%252BAnionic%252BSubstrates%252Bof%252BHuman%252BCytochrome%252BP450%252B2C8%252B%252528CYP2C8%252529%26aulast%3DMa%26aufirst%3DYong%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D01042017%26date%3D27062017%26date%3D09112017%26volume%3D60%26issue%3D21%26spage%3D8691%26epage%3D8705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Howard  Bregman</span>, <span class="hlFld-ContribAuthor ">Jeffrey R.  Simard</span>, <span class="hlFld-ContribAuthor ">Kristin L.  Andrews</span>, <span class="hlFld-ContribAuthor ">Shawn  Ayube</span>, <span class="hlFld-ContribAuthor ">Hao  Chen</span>, <span class="hlFld-ContribAuthor ">Hakan  Gunaydin</span>, <span class="hlFld-ContribAuthor ">Angel  Guzman-Perez</span>, <span class="hlFld-ContribAuthor ">Jiali  Hu</span>, <span class="hlFld-ContribAuthor ">Liyue  Huang</span>, <span class="hlFld-ContribAuthor ">Xin  Huang</span>, <span class="hlFld-ContribAuthor ">Paul H.  Krolikowski</span>, <span class="hlFld-ContribAuthor ">Sonya G.  Lehto</span>, <span class="hlFld-ContribAuthor ">Richard T.  Lewis</span>, <span class="hlFld-ContribAuthor ">Klaus  Michelsen</span>, <span class="hlFld-ContribAuthor ">Pamela  Pegman</span>, <span class="hlFld-ContribAuthor ">Matthew H.  Plant</span>, <span class="hlFld-ContribAuthor ">Paul L.  Shaffer</span>, <span class="hlFld-ContribAuthor ">Yohannes  Teffera</span>, <span class="hlFld-ContribAuthor ">Shuyan  Yi</span>, <span class="hlFld-ContribAuthor ">Maosheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Jacinthe  Gingras</span>, and <span class="hlFld-ContribAuthor ">Erin F.  DiMauro</span>  . </span><span class="cited-content_cbyCitation_article-title">The Discovery and Hit-to-Lead Optimization of Tricyclic Sulfonamides as Potent and Efficacious Potentiators of Glycine Receptors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (3)
                                     , 1105-1125. <a href="https://doi.org/10.1021/acs.jmedchem.6b01496" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01496</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01496%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BDiscovery%252Band%252BHit-to-Lead%252BOptimization%252Bof%252BTricyclic%252BSulfonamides%252Bas%252BPotent%252Band%252BEfficacious%252BPotentiators%252Bof%252BGlycine%252BReceptors%26aulast%3DBregman%26aufirst%3DHoward%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D12102016%26date%3D21122016%26date%3D09022017%26volume%3D60%26issue%3D3%26spage%3D1105%26epage%3D1125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amit S.  Kalgutkar</span>  . </span><span class="cited-content_cbyCitation_article-title">Liabilities Associated with the Formation of “Hard” Electrophiles in Reactive Metabolite Trapping Screens. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2017,</strong> <em>30 </em>
                                    (1)
                                     , 220-238. <a href="https://doi.org/10.1021/acs.chemrestox.6b00332" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.6b00332</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.6b00332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.6b00332%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DLiabilities%252BAssociated%252Bwith%252Bthe%252BFormation%252Bof%252B%2525E2%252580%25259CHard%2525E2%252580%25259D%252BElectrophiles%252Bin%252BReactive%252BMetabolite%252BTrapping%252BScreens%26aulast%3DKalgutkar%26aufirst%3DAmit%2BS.%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D20092016%26date%3D10112016%26date%3D17012017%26date%3D02112016%26volume%3D30%26issue%3D1%26spage%3D220%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carlo  Barnaba</span>, <span class="hlFld-ContribAuthor ">Jaydeep  Yadav</span>, <span class="hlFld-ContribAuthor ">Swati  Nagar</span>, <span class="hlFld-ContribAuthor ">Ken  Korzekwa</span>, and <span class="hlFld-ContribAuthor ">Jeffrey P.  Jones</span>  . </span><span class="cited-content_cbyCitation_article-title">Mechanism-Based Inhibition of CYP3A4 by Podophyllotoxin: Aging of an Intermediate Is Important for in Vitro/in Vivo Correlations. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2016,</strong> <em>13 </em>
                                    (8)
                                     , 2833-2843. <a href="https://doi.org/10.1021/acs.molpharmaceut.6b00436" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.6b00436</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.6b00436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.6b00436%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DMechanism-Based%252BInhibition%252Bof%252BCYP3A4%252Bby%252BPodophyllotoxin%25253A%252BAging%252Bof%252Ban%252BIntermediate%252BIs%252BImportant%252Bfor%252Bin%252BVitro%25252Fin%252BVivo%252BCorrelations%26aulast%3DBarnaba%26aufirst%3DCarlo%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D16052016%26date%3D23062016%26date%3D16062016%26date%3D01072016%26date%3D01082016%26date%3D23062016%26volume%3D13%26issue%3D8%26spage%3D2833%26epage%3D2843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin  Pouliot</span> and <span class="hlFld-ContribAuthor ">Stephane  Jeanmart</span>  . </span><span class="cited-content_cbyCitation_article-title">Pan Assay Interference Compounds (PAINS) and Other Promiscuous Compounds in Antifungal Research. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (2)
                                     , 497-503. <a href="https://doi.org/10.1021/acs.jmedchem.5b00361" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00361</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00361%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPan%252BAssay%252BInterference%252BCompounds%252B%252528PAINS%252529%252Band%252BOther%252BPromiscuous%252BCompounds%252Bin%252BAntifungal%252BResearch%26aulast%3DPouliot%26aufirst%3DMartin%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D04032015%26date%3D08092015%26date%3D28012016%26date%3D27082015%26volume%3D59%26issue%3D2%26spage%3D497%26epage%3D503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chaitanya K.  Jaladanki</span>, <span class="hlFld-ContribAuthor ">Nikhil  Taxak</span>, <span class="hlFld-ContribAuthor ">Rohith A.  Varikoti</span>, and <span class="hlFld-ContribAuthor ">Prasad V.  Bharatam</span>  . </span><span class="cited-content_cbyCitation_article-title">Toxicity Originating from Thiophene Containing Drugs: Exploring the Mechanism using Quantum Chemical Methods. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2015,</strong> <em>28 </em>
                                    (12)
                                     , 2364-2376. <a href="https://doi.org/10.1021/acs.chemrestox.5b00364" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.5b00364</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.5b00364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.5b00364%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DToxicity%252BOriginating%252Bfrom%252BThiophene%252BContaining%252BDrugs%25253A%252BExploring%252Bthe%252BMechanism%252Busing%252BQuantum%252BChemical%252BMethods%26aulast%3DJaladanki%26aufirst%3DChaitanya%2BK.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D01092015%26date%3D10122015%26date%3D21122015%26date%3D17112015%26volume%3D28%26issue%3D12%26spage%3D2364%26epage%3D2376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roger B.  Ruggeri</span>, <span class="hlFld-ContribAuthor ">Leonard  Buckbinder</span>, <span class="hlFld-ContribAuthor ">Scott W.  Bagley</span>, <span class="hlFld-ContribAuthor ">Philip A.  Carpino</span>, <span class="hlFld-ContribAuthor ">Edward L.  Conn</span>, <span class="hlFld-ContribAuthor ">Matthew S.  Dowling</span>, <span class="hlFld-ContribAuthor ">Dilinie P.  Fernando</span>, <span class="hlFld-ContribAuthor ">Wenhua  Jiao</span>, <span class="hlFld-ContribAuthor ">Daniel W.  Kung</span>, <span class="hlFld-ContribAuthor ">Suvi T. M.  Orr</span>, <span class="hlFld-ContribAuthor ">Yingmei  Qi</span>, <span class="hlFld-ContribAuthor ">Benjamin N.  Rocke</span>, <span class="hlFld-ContribAuthor ">Aaron  Smith</span>, <span class="hlFld-ContribAuthor ">Joseph S.  Warmus</span>, <span class="hlFld-ContribAuthor ">Yan  Zhang</span>, <span class="hlFld-ContribAuthor ">Daniel  Bowles</span>, <span class="hlFld-ContribAuthor ">Daniel W.  Widlicka</span>, <span class="hlFld-ContribAuthor ">Heather  Eng</span>, <span class="hlFld-ContribAuthor ">Tim  Ryder</span>, <span class="hlFld-ContribAuthor ">Raman  Sharma</span>, <span class="hlFld-ContribAuthor ">Angela  Wolford</span>, <span class="hlFld-ContribAuthor ">Carlin  Okerberg</span>, <span class="hlFld-ContribAuthor ">Karen  Walters</span>, <span class="hlFld-ContribAuthor ">Tristan S.  Maurer</span>, <span class="hlFld-ContribAuthor ">Yanwei  Zhang</span>, <span class="hlFld-ContribAuthor ">Paul D.  Bonin</span>, <span class="hlFld-ContribAuthor ">Samantha N.  Spath</span>, <span class="hlFld-ContribAuthor ">Gang  Xing</span>, <span class="hlFld-ContribAuthor ">David  Hepworth</span>, <span class="hlFld-ContribAuthor ">Kay  Ahn</span>, and <span class="hlFld-ContribAuthor ">Amit S.  Kalgutkar</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (21)
                                     , 8513-8528. <a href="https://doi.org/10.1021/acs.jmedchem.5b00963" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00963</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00963%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-%2525286-%2525285-Chloro-2-methoxyphenyl%252529-4-oxo-2-thioxo-3%25252C4-dihydropyrimidin-1%2525282H%252529-yl%252529acetamide%252B%252528PF-06282999%252529%25253A%252BA%252BHighly%252BSelective%252BMechanism-Based%252BMyeloperoxidase%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BCardiovascular%252BDiseases%26aulast%3DRuggeri%26aufirst%3DRoger%2BB.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D22062015%26date%3D28102015%26date%3D12112015%26volume%3D58%26issue%3D21%26spage%3D8513%26epage%3D8528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark  Ammirati</span>, <span class="hlFld-ContribAuthor ">Scott W.  Bagley</span>, <span class="hlFld-ContribAuthor ">Samit K.  Bhattacharya</span>, <span class="hlFld-ContribAuthor ">Leonard  Buckbinder</span>, <span class="hlFld-ContribAuthor ">Anthony A.  Carlo</span>, <span class="hlFld-ContribAuthor ">Rebecca  Conrad</span>, <span class="hlFld-ContribAuthor ">Christian  Cortes</span>, <span class="hlFld-ContribAuthor ">Robert L.  Dow</span>, <span class="hlFld-ContribAuthor ">Matthew S.  Dowling</span>, <span class="hlFld-ContribAuthor ">Ayman  El-Kattan</span>, <span class="hlFld-ContribAuthor ">Kristen  Ford</span>, <span class="hlFld-ContribAuthor ">Cristiano R. W.  Guimarães</span>, <span class="hlFld-ContribAuthor ">David  Hepworth</span>, <span class="hlFld-ContribAuthor ">Wenhua  Jiao</span>, <span class="hlFld-ContribAuthor ">Jennifer  LaPerle</span>, <span class="hlFld-ContribAuthor ">Shenping  Liu</span>, <span class="hlFld-ContribAuthor ">Allyn  Londregan</span>, <span class="hlFld-ContribAuthor ">Paula M.  Loria</span>, <span class="hlFld-ContribAuthor ">Alan M.  Mathiowetz</span>, <span class="hlFld-ContribAuthor ">Michael  Munchhof</span>, <span class="hlFld-ContribAuthor ">Suvi T. M.  Orr</span>, <span class="hlFld-ContribAuthor ">Donna N.  Petersen</span>, <span class="hlFld-ContribAuthor ">David A.  Price</span>, <span class="hlFld-ContribAuthor ">Athanasia  Skoura</span>, <span class="hlFld-ContribAuthor ">Aaron C.  Smith</span>, and <span class="hlFld-ContribAuthor ">Jian  Wang</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (11)
                                     , 1128-1133. <a href="https://doi.org/10.1021/acsmedchemlett.5b00215" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00215</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00215%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ban%252Bin%252BVivo%252BTool%252Bto%252BEstablish%252BProof-of-Concept%252Bfor%252BMAP4K4-Based%252BAntidiabetic%252BTreatment%26aulast%3DAmmirati%26aufirst%3DMark%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D29052015%26date%3D28092015%26date%3D06102015%26date%3D12112015%26volume%3D6%26issue%3D11%26spage%3D1128%26epage%3D1133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaojing  Wang</span>, <span class="hlFld-ContribAuthor ">Minghua  Sun</span>, <span class="hlFld-ContribAuthor ">Connie  New</span>, <span class="hlFld-ContribAuthor ">Spencer  Nam</span>, <span class="hlFld-ContribAuthor ">Wesley P.  Blackaby</span>, <span class="hlFld-ContribAuthor ">Alastair J.  Hodges</span>, <span class="hlFld-ContribAuthor ">David  Nash</span>, <span class="hlFld-ContribAuthor ">Mizio  Matteucci</span>, <span class="hlFld-ContribAuthor ">Joseph P.  Lyssikatos</span>, <span class="hlFld-ContribAuthor ">Peter W.  Fan</span>, <span class="hlFld-ContribAuthor ">Suzanne  Tay</span>, and <span class="hlFld-ContribAuthor ">Jae H.  Chang</span>  . </span><span class="cited-content_cbyCitation_article-title">Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (8)
                                     , 925-929. <a href="https://doi.org/10.1021/acsmedchemlett.5b00191" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00191</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00191%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DProbing%252BMechanisms%252Bof%252BCYP3A%252BTime-Dependent%252BInhibition%252BUsing%252Ba%252BTruncated%252BModel%252BSystem%26aulast%3DWang%26aufirst%3DXiaojing%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D07052015%26date%3D12072015%26date%3D15072015%26date%3D13082015%26date%3D12072015%26volume%3D6%26issue%3D8%26spage%3D925%26epage%3D929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pratanphorn  Chuanprasit</span>, <span class="hlFld-ContribAuthor ">Shu Hui  Goh</span>, and <span class="hlFld-ContribAuthor ">Hajime  Hirao</span>  . </span><span class="cited-content_cbyCitation_article-title">Benzyne Formation in the Mechanism-Based Inactivation of Cytochrome P450 by 1-Aminobenzotriazole and N-Benzyl-1-Aminobenzotriazole: Computational Insights. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2015,</strong> <em>5 </em>
                                    (5)
                                     , 2952-2960. <a href="https://doi.org/10.1021/acscatal.5b00423" title="DOI URL">https://doi.org/10.1021/acscatal.5b00423</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.5b00423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.5b00423%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DBenzyne%252BFormation%252Bin%252Bthe%252BMechanism-Based%252BInactivation%252Bof%252BCytochrome%252BP450%252Bby%252B1-Aminobenzotriazole%252Band%252BN-Benzyl-1-Aminobenzotriazole%25253A%252BComputational%252BInsights%26aulast%3DChuanprasit%26aufirst%3DPratanphorn%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D26022015%26date%3D30032015%26date%3D13042015%26date%3D01052015%26date%3D31032015%26volume%3D5%26issue%3D5%26spage%3D2952%26epage%3D2960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rasmus  Leth</span>, <span class="hlFld-ContribAuthor ">Patrik  Rydberg</span>, <span class="hlFld-ContribAuthor ">Flemming Steen  Jørgensen</span>, and <span class="hlFld-ContribAuthor ">Lars  Olsen</span>  . </span><span class="cited-content_cbyCitation_article-title">Density Functional Theory Study on the Formation of Reactive Benzoquinone Imines by Hydrogen Abstraction. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2015,</strong> <em>55 </em>
                                    (3)
                                     , 660-666. <a href="https://doi.org/10.1021/ci500653b" title="DOI URL">https://doi.org/10.1021/ci500653b</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci500653b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci500653b%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDensity%252BFunctional%252BTheory%252BStudy%252Bon%252Bthe%252BFormation%252Bof%252BReactive%252BBenzoquinone%252BImines%252Bby%252BHydrogen%252BAbstraction%26aulast%3DLeth%26aufirst%3DRasmus%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D29102014%26date%3D20022015%26date%3D23032015%26date%3D06022015%26volume%3D55%26issue%3D3%26spage%3D660%26epage%3D666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suvi T. M.  Orr</span>, <span class="hlFld-ContribAuthor ">Ramsay  Beveridge</span>, <span class="hlFld-ContribAuthor ">Samit K.  Bhattacharya</span>, <span class="hlFld-ContribAuthor ">Kimberly O.  Cameron</span>, <span class="hlFld-ContribAuthor ">Steven  Coffey</span>, <span class="hlFld-ContribAuthor ">Dilinie  Fernando</span>, <span class="hlFld-ContribAuthor ">David  Hepworth</span>, <span class="hlFld-ContribAuthor ">Margaret V.  Jackson</span>, <span class="hlFld-ContribAuthor ">Vishal  Khot</span>, <span class="hlFld-ContribAuthor ">Rachel  Kosa</span>, <span class="hlFld-ContribAuthor ">Kimberly  Lapham</span>, <span class="hlFld-ContribAuthor ">Paula M.  Loria</span>, <span class="hlFld-ContribAuthor ">Kim F.  McClure</span>, <span class="hlFld-ContribAuthor ">Jigna  Patel</span>, <span class="hlFld-ContribAuthor ">Colin  Rose</span>, <span class="hlFld-ContribAuthor ">James  Saenz</span>, <span class="hlFld-ContribAuthor ">Ingrid A.  Stock</span>, <span class="hlFld-ContribAuthor ">Gregory  Storer</span>, <span class="hlFld-ContribAuthor ">Maria  von Volkenburg</span>, <span class="hlFld-ContribAuthor ">Derek  Vrieze</span>, <span class="hlFld-ContribAuthor ">Guoqiang  Wang</span>, <span class="hlFld-ContribAuthor ">Jun  Xiao</span>, and <span class="hlFld-ContribAuthor ">Yingxin  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Evaluation and Synthesis of Polar Aryl- and Heteroaryl Spiroazetidine-Piperidine Acetamides as Ghrelin Inverse Agonists. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (2)
                                     , 156-161. <a href="https://doi.org/10.1021/ml500414n" title="DOI URL">https://doi.org/10.1021/ml500414n</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml500414n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml500414n%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DEvaluation%252Band%252BSynthesis%252Bof%252BPolar%252BAryl-%252Band%252BHeteroaryl%252BSpiroazetidine-Piperidine%252BAcetamides%252Bas%252BGhrelin%252BInverse%252BAgonists%26aulast%3DOrr%26aufirst%3DSuvi%2BT.%2BM.%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D09102014%26date%3D14122014%26date%3D19122014%26date%3D12022015%26date%3D14122014%26volume%3D6%26issue%3D2%26spage%3D156%26epage%3D161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanou  Yang</span>, <span class="hlFld-ContribAuthor ">Qing  Xiao</span>, <span class="hlFld-ContribAuthor ">W. Griffith  Humphreys</span>, <span class="hlFld-ContribAuthor ">Ashok  Dongre</span>, and <span class="hlFld-ContribAuthor ">Yue-Zhong  Shu</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of Human Liver Microsomal Proteins Adducted by a Reactive Metabolite Using Shotgun Proteomics. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2014,</strong> <em>27 </em>
                                    (9)
                                     , 1537-1546. <a href="https://doi.org/10.1021/tx500181p" title="DOI URL">https://doi.org/10.1021/tx500181p</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/tx500181p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Ftx500181p%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DIdentification%252Bof%252BHuman%252BLiver%252BMicrosomal%252BProteins%252BAdducted%252Bby%252Ba%252BReactive%252BMetabolite%252BUsing%252BShotgun%252BProteomics%26aulast%3DYang%26aufirst%3DYanou%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D11052014%26date%3D19082014%26date%3D15092014%26date%3D08082014%26volume%3D27%26issue%3D9%26spage%3D1537%26epage%3D1546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikhil  Taxak</span>, <span class="hlFld-ContribAuthor ">Sourav  Kalra</span>, and <span class="hlFld-ContribAuthor ">Prasad V.  Bharatam</span>  . </span><span class="cited-content_cbyCitation_article-title">Mechanism-Based Inactivation of Cytochromes by Furan Epoxide: Unraveling the Molecular Mechanism. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry</span><span> <strong>2013,</strong> <em>52 </em>
                                    (23)
                                     , 13496-13508. <a href="https://doi.org/10.1021/ic401907k" title="DOI URL">https://doi.org/10.1021/ic401907k</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ic401907k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fic401907k%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%26atitle%3DMechanism-Based%252BInactivation%252Bof%252BCytochromes%252Bby%252BFuran%252BEpoxide%25253A%252BUnraveling%252Bthe%252BMolecular%252BMechanism%26aulast%3DTaxak%26aufirst%3DNikhil%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D23072013%26date%3D15112013%26date%3D02122013%26volume%3D52%26issue%3D23%26spage%3D13496%26epage%3D13508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John C. L.  Erve</span>, <span class="hlFld-ContribAuthor ">Shawn  Gauby</span>, <span class="hlFld-ContribAuthor ">John W.  Maynard, Jr.</span>, <span class="hlFld-ContribAuthor ">Mats A.  Svensson</span>, <span class="hlFld-ContribAuthor ">George  Tonn</span>, and <span class="hlFld-ContribAuthor ">Kevin P.  Quinn</span>  . </span><span class="cited-content_cbyCitation_article-title">Bioactivation of Sitaxentan in Liver Microsomes, Hepatocytes, and Expressed Human P450s with Characterization of the Glutathione Conjugate by Liquid Chromatography Tandem Mass Spectrometry. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2013,</strong> <em>26 </em>
                                    (6)
                                     , 926-936. <a href="https://doi.org/10.1021/tx4001144" title="DOI URL">https://doi.org/10.1021/tx4001144</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/tx4001144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Ftx4001144%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DBioactivation%252Bof%252BSitaxentan%252Bin%252BLiver%252BMicrosomes%25252C%252BHepatocytes%25252C%252Band%252BExpressed%252BHuman%252BP450s%252Bwith%252BCharacterization%252Bof%252Bthe%252BGlutathione%252BConjugate%252Bby%252BLiquid%252BChromatography%252BTandem%252BMass%252BSpectrometry%26aulast%3DErve%26aufirst%3DJohn%2BC.%2BL.%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D18032013%26date%3D30052013%26date%3D17062013%26volume%3D26%26issue%3D6%26spage%3D926%26epage%3D936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikhil  Taxak</span>, <span class="hlFld-ContribAuthor ">Bhargav  Patel</span>, and <span class="hlFld-ContribAuthor ">Prasad V.  Bharatam</span>  . </span><span class="cited-content_cbyCitation_article-title">Carbene Generation by Cytochromes and Electronic Structure of Heme-Iron-Porphyrin-Carbene Complex: A Quantum Chemical Study. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry</span><span> <strong>2013,</strong> <em>52 </em>
                                    (9)
                                     , 5097-5109. <a href="https://doi.org/10.1021/ic400010d" title="DOI URL">https://doi.org/10.1021/ic400010d</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ic400010d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fic400010d%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%26atitle%3DCarbene%252BGeneration%252Bby%252BCytochromes%252Band%252BElectronic%252BStructure%252Bof%252BHeme-Iron-Porphyrin-Carbene%252BComplex%25253A%252BA%252BQuantum%252BChemical%252BStudy%26aulast%3DTaxak%26aufirst%3DNikhil%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D02012013%26date%3D05042013%26date%3D06052013%26volume%3D52%26issue%3D9%26spage%3D5097%26epage%3D5109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony A.  Estrada</span>, <span class="hlFld-ContribAuthor ">Daniel G.  Shore</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Blackwood</span>, <span class="hlFld-ContribAuthor ">Yung-Hsiang  Chen</span>, <span class="hlFld-ContribAuthor ">Gauri  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Antonio G.  DiPasquale</span>, <span class="hlFld-ContribAuthor ">Jennifer A.  Epler</span>, <span class="hlFld-ContribAuthor ">Lori S.  Friedman</span>, <span class="hlFld-ContribAuthor ">Michael F. T.  Koehler</span>, <span class="hlFld-ContribAuthor ">Lichuan  Liu</span>, <span class="hlFld-ContribAuthor ">Shiva  Malek</span>, <span class="hlFld-ContribAuthor ">Jim  Nonomiya</span>, <span class="hlFld-ContribAuthor ">Daniel F.  Ortwine</span>, <span class="hlFld-ContribAuthor ">Zhonghua  Pei</span>, <span class="hlFld-ContribAuthor ">Steve  Sideris</span>, <span class="hlFld-ContribAuthor ">Frederic  St-Jean</span>, <span class="hlFld-ContribAuthor ">Lan  Trinh</span>, <span class="hlFld-ContribAuthor ">Tom  Truong</span>, and <span class="hlFld-ContribAuthor ">Joseph P.  Lyssikatos</span>  . </span><span class="cited-content_cbyCitation_article-title">Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (7)
                                     , 3090-3101. <a href="https://doi.org/10.1021/jm400194n" title="DOI URL">https://doi.org/10.1021/jm400194n</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400194n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400194n%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrimidoaminotropanes%252Bas%252BPotent%25252C%252BSelective%25252C%252Band%252BEfficacious%252BSmall%252BMolecule%252BKinase%252BInhibitors%252Bof%252Bthe%252BMammalian%252BTarget%252Bof%252BRapamycin%252B%252528mTOR%252529%26aulast%3DEstrada%26aufirst%3DAnthony%2BA.%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D06022013%26date%3D29032013%26date%3D11042013%26date%3D08032013%26volume%3D56%26issue%3D7%26spage%3D3090%26epage%3D3101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhonghua  Pei</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Blackwood</span>, <span class="hlFld-ContribAuthor ">Lichuan  Liu</span>, <span class="hlFld-ContribAuthor ">Shiva  Malek</span>, <span class="hlFld-ContribAuthor ">Marcia  Belvin</span>, <span class="hlFld-ContribAuthor ">Michael F. T.  Koehler</span>, <span class="hlFld-ContribAuthor ">Daniel F.  Ortwine</span>, <span class="hlFld-ContribAuthor ">Huifen  Chen</span>, <span class="hlFld-ContribAuthor ">Frederick  Cohen</span>, <span class="hlFld-ContribAuthor ">Jane R.  Kenny</span>, <span class="hlFld-ContribAuthor ">Philippe  Bergeron</span>, <span class="hlFld-ContribAuthor ">Kevin  Lau</span>, <span class="hlFld-ContribAuthor ">Cuong  Ly</span>, <span class="hlFld-ContribAuthor ">Xianrui  Zhao</span>, <span class="hlFld-ContribAuthor ">Anthony A.  Estrada</span>, <span class="hlFld-ContribAuthor ">Tom  Truong</span>, <span class="hlFld-ContribAuthor ">Jennifer A.  Epler</span>, <span class="hlFld-ContribAuthor ">Jim  Nonomiya</span>, <span class="hlFld-ContribAuthor ">Lan  Trinh</span>, <span class="hlFld-ContribAuthor ">Steve  Sideris</span>, <span class="hlFld-ContribAuthor ">John  Lesnick</span>, <span class="hlFld-ContribAuthor ">Linda  Bao</span>, <span class="hlFld-ContribAuthor ">Ulka  Vijapurkar</span>, <span class="hlFld-ContribAuthor ">Sophie  Mukadam</span>, <span class="hlFld-ContribAuthor ">Suzanne  Tay</span>, <span class="hlFld-ContribAuthor ">Gauri  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Yung-Hsiang  Chen</span>, <span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Lori S.  Friedman</span>, and <span class="hlFld-ContribAuthor ">Joseph P.  Lyssikatos</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>4 </em>
                                    (1)
                                     , 103-107. <a href="https://doi.org/10.1021/ml3003132" title="DOI URL">https://doi.org/10.1021/ml3003132</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml3003132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml3003132%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Band%252BBiological%252BProfiling%252Bof%252BPotent%252Band%252BSelective%252BmTOR%252BInhibitor%252BGDC-0349%26aulast%3DPei%26aufirst%3DZhonghua%26date%3D2013%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D04102012%26date%3D29112012%26date%3D06122012%26date%3D10012013%26date%3D29112012%26volume%3D4%26issue%3D1%26spage%3D103%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heather  Eng</span>, <span class="hlFld-ContribAuthor ">Elaine  Tseng</span>, <span class="hlFld-ContribAuthor ">Matthew A.  Cerny</span>, <span class="hlFld-ContribAuthor ">Theunis C.  Goosen</span>, <span class="hlFld-ContribAuthor ">R. Scott  Obach</span>. </span><span class="cited-content_cbyCitation_article-title">Cytochrome P450 3A Time-Dependent Inhibition Assays Are Too Sensitive for Identification of Drugs Causing Clinically Significant Drug-Drug Interactions: A Comparison of Human Liver Microsomes and Hepatocytes and Definition of Boundaries for Inactivation Rate Constants. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2021,</strong> <em>49 </em>
                                    (6)
                                     , 442-450. <a href="https://doi.org/10.1124/dmd.121.000356" title="DOI URL">https://doi.org/10.1124/dmd.121.000356</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.121.000356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.121.000356%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DCytochrome%252BP450%252B3A%252BTime-Dependent%252BInhibition%252BAssays%252BAre%252BToo%252BSensitive%252Bfor%252BIdentification%252Bof%252BDrugs%252BCausing%252BClinically%252BSignificant%252BDrug-Drug%252BInteractions%25253A%252BA%252BComparison%252Bof%252BHuman%252BLiver%252BMicrosomes%252Band%252BHepatocytes%252Band%252BDefinition%252Bof%252BBoundaries%252Bfor%252BInactivation%252BRate%252BConstants%26aulast%3DEng%26aufirst%3DHeather%26date%3D2021%26date%3D2021%26volume%3D49%26issue%3D6%26spage%3D442%26epage%3D450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohamed M.Y.  Kaddah</span>, <span class="hlFld-ContribAuthor ">Susan  Billig</span>, <span class="hlFld-ContribAuthor ">Ramona  Oehme</span>, <span class="hlFld-ContribAuthor ">Claudia  Birkemeyer</span>. </span><span class="cited-content_cbyCitation_article-title">Bio-activation of simeprevir in liver microsomes and characterization of its glutathione conjugates by liquid chromatography coupled to ultrahigh-resolution quadrupole time-of-flight mass spectrometry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chromatography A</span><span> <strong>2021,</strong> <em>1645 </em>, 462095. <a href="https://doi.org/10.1016/j.chroma.2021.462095" title="DOI URL">https://doi.org/10.1016/j.chroma.2021.462095</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chroma.2021.462095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chroma.2021.462095%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chromatography%2520A%26atitle%3DBio-activation%252Bof%252Bsimeprevir%252Bin%252Bliver%252Bmicrosomes%252Band%252Bcharacterization%252Bof%252Bits%252Bglutathione%252Bconjugates%252Bby%252Bliquid%252Bchromatography%252Bcoupled%252Bto%252Bultrahigh-resolution%252Bquadrupole%252Btime-of-flight%252Bmass%252Bspectrometry%26aulast%3DKaddah%26aufirst%3DMohamed%2BM.Y.%26date%3D2021%26volume%3D1645%26spage%3D462095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deepak K.  Dalvie</span>, <span class="hlFld-ContribAuthor ">Bernard  Testa</span>. </span><span class="cited-content_cbyCitation_article-title">Principles of Drug Metabolism. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-139. <a href="https://doi.org/10.1002/0471266949.bmc033.pub3" title="DOI URL">https://doi.org/10.1002/0471266949.bmc033.pub3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc033.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc033.pub3%26sid%3Dliteratum%253Aachs%26atitle%3DPrinciples%252Bof%252BDrug%252BMetabolism%26aulast%3DDalvie%26aufirst%3DDeepak%2BK.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D139%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Clinton G. L.  Veale</span>. </span><span class="cited-content_cbyCitation_article-title">Into the Fray! A Beginner's Guide to Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (8)
                                     , 1199-1225. <a href="https://doi.org/10.1002/cmdc.202000929" title="DOI URL">https://doi.org/10.1002/cmdc.202000929</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000929%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DInto%252Bthe%252BFray%252521%252BA%252BBeginner%252527s%252BGuide%252Bto%252BMedicinal%252BChemistry%26aulast%3DVeale%26aufirst%3DClinton%2BG.%2BL.%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D8%26spage%3D1199%26epage%3D1225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yurie  Katsube</span>, <span class="hlFld-ContribAuthor ">Masayuki  Tsujimoto</span>, <span class="hlFld-ContribAuthor ">Hiroyoshi  Koide</span>, <span class="hlFld-ContribAuthor ">Daiki  Hira</span>, <span class="hlFld-ContribAuthor ">Yoshito  Ikeda</span>, <span class="hlFld-ContribAuthor ">Tetsuya  Minegaki</span>, <span class="hlFld-ContribAuthor ">Shin-ya  Morita</span>, <span class="hlFld-ContribAuthor ">Tomohiro  Terada</span>, <span class="hlFld-ContribAuthor ">Kohshi  Nishiguchi</span>. </span><span class="cited-content_cbyCitation_article-title">In Vitro Evidence of Potential Interactions between CYP2C8 and Candesartan Acyl-
              β
              -D-glucuronide in the Liver. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2021,</strong> <em>49 </em>
                                    (4)
                                     , 289-297. <a href="https://doi.org/10.1124/dmd.120.000126" title="DOI URL">https://doi.org/10.1124/dmd.120.000126</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.120.000126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.120.000126%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DIn%252BVitro%252BEvidence%252Bof%252BPotential%252BInteractions%252Bbetween%252BCYP2C8%252Band%252BCandesartan%252BAcyl-%252B%2525CE%2525B2%252B-D-glucuronide%252Bin%252Bthe%252BLiver%26aulast%3DKatsube%26aufirst%3DYurie%26date%3D2021%26date%3D2021%26volume%3D49%26issue%3D4%26spage%3D289%26epage%3D297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Safiulla Basha  Syed</span>, <span class="hlFld-ContribAuthor ">Shu‐Yu  Lin</span>, <span class="hlFld-ContribAuthor ">Hemant  Arya</span>, <span class="hlFld-ContribAuthor ">I‐Hsuan  Fu</span>, <span class="hlFld-ContribAuthor ">Teng‐Kuang  Yeh</span>, <span class="hlFld-ContribAuthor ">Mariasoosai Ramya Chandar  Charles</span>, <span class="hlFld-ContribAuthor ">Latha  Periyasamy</span>, <span class="hlFld-ContribAuthor ">Hsing‐Pang  Hsieh</span>, <span class="hlFld-ContribAuthor ">Mohane Selvaraj  Coumar</span>. </span><span class="cited-content_cbyCitation_article-title">Overcoming vincristine resistance in cancer: Computational design and discovery of piperine‐inspired P‐glycoprotein inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2021,</strong> <em>97 </em>
                                    (1)
                                     , 51-66. <a href="https://doi.org/10.1111/cbdd.13758" title="DOI URL">https://doi.org/10.1111/cbdd.13758</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13758%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DOvercoming%252Bvincristine%252Bresistance%252Bin%252Bcancer%25253A%252BComputational%252Bdesign%252Band%252Bdiscovery%252Bof%252Bpiperine%2525E2%252580%252590inspired%252BP%2525E2%252580%252590glycoprotein%252Binhibitors%26aulast%3DSyed%26aufirst%3DSafiulla%2BBasha%26date%3D2021%26date%3D2020%26volume%3D97%26issue%3D1%26spage%3D51%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Wang</span>, <span class="hlFld-ContribAuthor ">Lili  Xie</span>, <span class="hlFld-ContribAuthor ">Jing  Ni</span>. </span><span class="cited-content_cbyCitation_article-title">Assessing Cytochrome P450 Time-Dependent Inhibition (IC50 Shift Assay) Using Both Diluted and Non-Diluted Methods. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 121-139. <a href="https://doi.org/10.1007/978-1-0716-1542-3_8" title="DOI URL">https://doi.org/10.1007/978-1-0716-1542-3_8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-0716-1542-3_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-0716-1542-3_8%26sid%3Dliteratum%253Aachs%26atitle%3DAssessing%252BCytochrome%252BP450%252BTime-Dependent%252BInhibition%252B%252528IC50%252BShift%252BAssay%252529%252BUsing%252BBoth%252BDiluted%252Band%252BNon-Diluted%252BMethods%26aulast%3DWang%26aufirst%3DYu%26date%3D2021%26date%3D2021%26spage%3D121%26epage%3D139%26pub%3DSpringer%2520US%26atitle%3DCytochrome%252BP450%26aulast%3DYan%26aufirst%3DZhengyin%26date%3D2021%26volume%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ha Gyeong  Kim</span>, <span class="hlFld-ContribAuthor ">Han Sol  Lee</span>, <span class="hlFld-ContribAuthor ">Jang Su  Jeon</span>, <span class="hlFld-ContribAuthor ">Young Jae  Choi</span>, <span class="hlFld-ContribAuthor ">Yeon Jung  Choi</span>, <span class="hlFld-ContribAuthor ">So-Yeol  Yoo</span>, <span class="hlFld-ContribAuthor ">Eun-yeong  Kim</span>, <span class="hlFld-ContribAuthor ">Kiho  Lee</span>, <span class="hlFld-ContribAuthor ">InWha  Park</span>, <span class="hlFld-ContribAuthor ">MinKyun  Na</span>, <span class="hlFld-ContribAuthor ">Han-Jin  Park</span>, <span class="hlFld-ContribAuthor ">Seung-Woo  Cho</span>, <span class="hlFld-ContribAuthor ">Jong-Hoon  Kim</span>, <span class="hlFld-ContribAuthor ">Jae-Young  Lee</span>, <span class="hlFld-ContribAuthor ">Sang Kyum  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Quasi-Irreversible Inhibition of CYP2D6 by Berberine. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutics</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 916. <a href="https://doi.org/10.3390/pharmaceutics12100916" title="DOI URL">https://doi.org/10.3390/pharmaceutics12100916</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pharmaceutics12100916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpharmaceutics12100916%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutics%26atitle%3DQuasi-Irreversible%252BInhibition%252Bof%252BCYP2D6%252Bby%252BBerberine%26aulast%3DKim%26aufirst%3DHa%2BGyeong%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tingting  Zhang</span>, <span class="hlFld-ContribAuthor ">Jinqiu  Rao</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Kai  Wang</span>, <span class="hlFld-ContribAuthor ">Feng  Qiu</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanism-based inactivation of cytochrome P450 enzymes by natural products based on metabolic activation. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism Reviews</span><span> <strong>2020,</strong> <em>52 </em>
                                    (4)
                                     , 501-530. <a href="https://doi.org/10.1080/03602532.2020.1828910" title="DOI URL">https://doi.org/10.1080/03602532.2020.1828910</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/03602532.2020.1828910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F03602532.2020.1828910%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520Reviews%26atitle%3DMechanism-based%252Binactivation%252Bof%252Bcytochrome%252BP450%252Benzymes%252Bby%252Bnatural%252Bproducts%252Bbased%252Bon%252Bmetabolic%252Bactivation%26aulast%3DZhang%26aufirst%3DTingting%26date%3D2020%26date%3D2020%26volume%3D52%26issue%3D4%26spage%3D501%26epage%3D530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanqing  Wang</span>, <span class="hlFld-ContribAuthor ">Qianqian  Han</span>, <span class="hlFld-ContribAuthor ">Hongmei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of the binding interactions of p-acetylaminophenol, aspirin, ibuprofen and aminopyrine with norfloxacin from the view of antipyretic and anti-inflammatory. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Liquids</span><span> <strong>2020,</strong> <em>312 </em>, 113397. <a href="https://doi.org/10.1016/j.molliq.2020.113397" title="DOI URL">https://doi.org/10.1016/j.molliq.2020.113397</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molliq.2020.113397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molliq.2020.113397%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Liquids%26atitle%3DEvaluation%252Bof%252Bthe%252Bbinding%252Binteractions%252Bof%252Bp-acetylaminophenol%25252C%252Baspirin%25252C%252Bibuprofen%252Band%252Baminopyrine%252Bwith%252Bnorfloxacin%252Bfrom%252Bthe%252Bview%252Bof%252Bantipyretic%252Band%252Banti-inflammatory%26aulast%3DWang%26aufirst%3DYanqing%26date%3D2020%26volume%3D312%26spage%3D113397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chaitanya K.  Jaladanki</span>, <span class="hlFld-ContribAuthor ">Anuj  Gahlawat</span>, <span class="hlFld-ContribAuthor ">Gajanan  Rathod</span>, <span class="hlFld-ContribAuthor ">Hardeep  Sandhu</span>, <span class="hlFld-ContribAuthor ">Kousar  Jahan</span>, <span class="hlFld-ContribAuthor ">Prasad V.  Bharatam</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanistic studies on the drug metabolism and toxicity originating from cytochromes P450. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism Reviews</span><span> <strong>2020,</strong> <em>52 </em>
                                    (3)
                                     , 366-394. <a href="https://doi.org/10.1080/03602532.2020.1765792" title="DOI URL">https://doi.org/10.1080/03602532.2020.1765792</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/03602532.2020.1765792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F03602532.2020.1765792%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520Reviews%26atitle%3DMechanistic%252Bstudies%252Bon%252Bthe%252Bdrug%252Bmetabolism%252Band%252Btoxicity%252Boriginating%252Bfrom%252Bcytochromes%252BP450%26aulast%3DJaladanki%26aufirst%3DChaitanya%2BK.%26date%3D2020%26date%3D2020%26volume%3D52%26issue%3D3%26spage%3D366%26epage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas A.  Baillie</span>. </span><span class="cited-content_cbyCitation_article-title">Drug–protein adducts: past, present, and future. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2020,</strong> <em>29 </em>
                                    (7)
                                     , 1093-1104. <a href="https://doi.org/10.1007/s00044-020-02567-8" title="DOI URL">https://doi.org/10.1007/s00044-020-02567-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-020-02567-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-020-02567-8%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DDrug%2525E2%252580%252593protein%252Badducts%25253A%252Bpast%25252C%252Bpresent%25252C%252Band%252Bfuture%26aulast%3DBaillie%26aufirst%3DThomas%2BA.%26date%3D2020%26date%3D2020%26volume%3D29%26issue%3D7%26spage%3D1093%26epage%3D1104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Structural Alerts for Toxicity. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 305-379. <a href="https://doi.org/10.1002/9781119607311.ch5" title="DOI URL">https://doi.org/10.1002/9781119607311.ch5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119607311.ch5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119607311.ch5%26sid%3Dliteratum%253Aachs%26atitle%3DStructural%252BAlerts%252Bfor%252BToxicity%26date%3D2020%26date%3D2020%26spage%3D305%26epage%3D379%26pub%3DWiley%26atitle%3DMedicinal%252BChemistry%252Bfor%252BPractitioners%26aulast%3DLi%26aufirst%3DJie%2BJack%26date%3D2020%26date%3D2020%26volume%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harika Topal  Önal</span>, <span class="hlFld-ContribAuthor ">Abdulcelil  Yuzer</span>, <span class="hlFld-ContribAuthor ">Mine  Ince</span>, <span class="hlFld-ContribAuthor ">Furkan  Ayaz</span>. </span><span class="cited-content_cbyCitation_article-title">Photo induced anti-inflammatory activities of a Thiophene substituted subphthalocyanine derivative. </span><span class="cited-content_cbyCitation_journal-name">Photodiagnosis and Photodynamic Therapy</span><span> <strong>2020,</strong> <em>30 </em>, 101701. <a href="https://doi.org/10.1016/j.pdpdt.2020.101701" title="DOI URL">https://doi.org/10.1016/j.pdpdt.2020.101701</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pdpdt.2020.101701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pdpdt.2020.101701%26sid%3Dliteratum%253Aachs%26jtitle%3DPhotodiagnosis%2520and%2520Photodynamic%2520Therapy%26atitle%3DPhoto%252Binduced%252Banti-inflammatory%252Bactivities%252Bof%252Ba%252BThiophene%252Bsubstituted%252Bsubphthalocyanine%252Bderivative%26aulast%3D%25C3%2596nal%26aufirst%3DHarika%2BTopal%26date%3D2020%26volume%3D30%26spage%3D101701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John T.  Barr</span>, <span class="hlFld-ContribAuthor ">Zhican  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoshan  Min</span>, <span class="hlFld-ContribAuthor ">Henry J.  Wienkers</span>, <span class="hlFld-ContribAuthor ">Brooke M.  Rock</span>, <span class="hlFld-ContribAuthor ">Dan A.  Rock</span>, <span class="hlFld-ContribAuthor ">Larry C.  Wienkers</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanistic Studies of Cytochrome P450 3A4 Time-Dependent Inhibition Using Two Cysteine-Targeting Electrophiles. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2020,</strong> <em>48 </em>
                                    (6)
                                     , 508-514. <a href="https://doi.org/10.1124/dmd.119.089813" title="DOI URL">https://doi.org/10.1124/dmd.119.089813</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.119.089813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.119.089813%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DMechanistic%252BStudies%252Bof%252BCytochrome%252BP450%252B3A4%252BTime-Dependent%252BInhibition%252BUsing%252BTwo%252BCysteine-Targeting%252BElectrophiles%26aulast%3DBarr%26aufirst%3DJohn%2BT.%26date%3D2020%26date%3D2020%26volume%3D48%26issue%3D6%26spage%3D508%26epage%3D514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mette Marie  Hougaard Christensen</span>, <span class="hlFld-ContribAuthor ">Maija  Bruun Haastrup</span>, <span class="hlFld-ContribAuthor ">Thomas  Øhlenschlæger</span>, <span class="hlFld-ContribAuthor ">Peter  Esbech</span>, <span class="hlFld-ContribAuthor ">Sidsel  Arnspang Pedersen</span>, <span class="hlFld-ContribAuthor ">Ann‐Cathrine  Bach Dunvald</span>, <span class="hlFld-ContribAuthor ">Tore  Bjerregaard Stage</span>, <span class="hlFld-ContribAuthor ">Daniel  Pilsgaard Henriksen</span>, <span class="hlFld-ContribAuthor ">Andreas James  Thestrup Pedersen</span>. </span><span class="cited-content_cbyCitation_article-title">Interaction potential between clarithromycin and individual statins—A systematic review. </span><span class="cited-content_cbyCitation_journal-name">Basic & Clinical Pharmacology & Toxicology</span><span> <strong>2020,</strong> <em>126 </em>
                                    (4)
                                     , 307-317. <a href="https://doi.org/10.1111/bcpt.13343" title="DOI URL">https://doi.org/10.1111/bcpt.13343</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bcpt.13343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbcpt.13343%26sid%3Dliteratum%253Aachs%26jtitle%3DBasic%2520%2526%2520Clinical%2520Pharmacology%2520%2526%2520Toxicology%26atitle%3DInteraction%252Bpotential%252Bbetween%252Bclarithromycin%252Band%252Bindividual%252Bstatins%2525E2%252580%252594A%252Bsystematic%252Breview%26aulast%3DHougaard%2BChristensen%26aufirst%3DMette%2BMarie%26date%3D2020%26date%3D2019%26volume%3D126%26issue%3D4%26spage%3D307%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Basu Dev  Banerjee</span>, <span class="hlFld-ContribAuthor ">Ranjeet  Kumar</span>, <span class="hlFld-ContribAuthor ">Krishna Latha  Thamineni</span>, <span class="hlFld-ContribAuthor ">Harendra  Shah</span>, <span class="hlFld-ContribAuthor ">Gaurav Kumar  Thakur</span>, <span class="hlFld-ContribAuthor ">Tusha  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">Effect of Environmental Exposure and Pharmacogenomics on Drug Metabolism. </span><span class="cited-content_cbyCitation_journal-name">Current Drug Metabolism</span><span> <strong>2020,</strong> <em>20 </em>
                                    (14)
                                     , 1103-1113. <a href="https://doi.org/10.2174/1389200221666200110153304" title="DOI URL">https://doi.org/10.2174/1389200221666200110153304</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1389200221666200110153304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1389200221666200110153304%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Drug%2520Metabolism%26atitle%3DEffect%252Bof%252BEnvironmental%252BExposure%252Band%252BPharmacogenomics%252Bon%252BDrug%252BMetabolism%26aulast%3DBanerjee%26aufirst%3DBasu%2BDev%26date%3D2020%26volume%3D20%26issue%3D14%26spage%3D1103%26epage%3D1113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Cytochrome P450 Inhibition. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 183-261. <a href="https://doi.org/10.1002/9781119658016.ch5" title="DOI URL">https://doi.org/10.1002/9781119658016.ch5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119658016.ch5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119658016.ch5%26sid%3Dliteratum%253Aachs%26atitle%3DCytochrome%252BP450%252BInhibition%26date%3D2020%26date%3D2020%26spage%3D183%26epage%3D261%26pub%3DWiley%26atitle%3DHuman%252BDrug%252BMetabolism%26aulast%3DColeman%26aufirst%3DMichael%2BD.%26date%3D2020%26date%3D2020%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chuang  Lu</span>, <span class="hlFld-ContribAuthor ">Li  Di</span>. </span><span class="cited-content_cbyCitation_article-title">In vitro
              and
              in vivo
              methods to assess pharmacokinetic drug– drug interactions in drug discovery and development. </span><span class="cited-content_cbyCitation_journal-name">Biopharmaceutics & Drug Disposition</span><span> <strong>2020,</strong> <em>41 </em>
                                    (1-2)
                                     , 3-31. <a href="https://doi.org/10.1002/bdd.2212" title="DOI URL">https://doi.org/10.1002/bdd.2212</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bdd.2212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbdd.2212%26sid%3Dliteratum%253Aachs%26jtitle%3DBiopharmaceutics%2520%2526%2520Drug%2520Disposition%26atitle%3DIn%252Bvitro%252Band%252Bin%252Bvivo%252Bmethods%252Bto%252Bassess%252Bpharmacokinetic%252Bdrug%2525E2%252580%252593%252Bdrug%252Binteractions%252Bin%252Bdrug%252Bdiscovery%252Band%252Bdevelopment%26aulast%3DLu%26aufirst%3DChuang%26date%3D2020%26date%3D2020%26volume%3D41%26issue%3D1-2%26spage%3D3%26epage%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jaydeep  Yadav</span>, <span class="hlFld-ContribAuthor ">Erickson  Paragas</span>, <span class="hlFld-ContribAuthor ">Ken  Korzekwa</span>, <span class="hlFld-ContribAuthor ">Swati  Nagar</span>. </span><span class="cited-content_cbyCitation_article-title">Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2020,</strong> <em>206 </em>, 107449. <a href="https://doi.org/10.1016/j.pharmthera.2019.107449" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2019.107449</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2019.107449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2019.107449%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DTime-dependent%252Benzyme%252Binactivation%25253A%252BNumerical%252Banalyses%252Bof%252Bin%252Bvitro%252Bdata%252Band%252Bprediction%252Bof%252Bdrug-drug%252Binteractions%26aulast%3DYadav%26aufirst%3DJaydeep%26date%3D2020%26volume%3D206%26spage%3D107449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Sun</span>, <span class="hlFld-ContribAuthor ">Dennis  Scott</span>. </span><span class="cited-content_cbyCitation_article-title">Using Crystal Structures of Drug‐Metabolizing Enzymes in Mechanism‐Based Modeling for Drug Design. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 567-585. <a href="https://doi.org/10.1002/9781118681121.ch24" title="DOI URL">https://doi.org/10.1002/9781118681121.ch24</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118681121.ch24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118681121.ch24%26sid%3Dliteratum%253Aachs%26atitle%3DUsing%252BCrystal%252BStructures%252Bof%252BDrug%2525E2%252580%252590Metabolizing%252BEnzymes%252Bin%252BMechanism%2525E2%252580%252590Based%252BModeling%252Bfor%252BDrug%252BDesign%26aulast%3DSun%26aufirst%3DHao%26date%3D2020%26date%3D2020%26spage%3D567%26epage%3D585%26pub%3DWiley%26atitle%3DStructural%252BBiology%252Bin%252BDrug%252BDiscovery%26aulast%3DRenaud%26aufirst%3DJean%25E2%2580%2590Paul%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John T.  Rodgers</span>, <span class="hlFld-ContribAuthor ">Jeffrey P.  Jones</span>. </span><span class="cited-content_cbyCitation_article-title">Numerical Analysis of Time-Dependent Inhibition by MDMA. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2020,</strong> <em>48 </em>
                                    (1)
                                     , 1-7. <a href="https://doi.org/10.1124/dmd.119.089268" title="DOI URL">https://doi.org/10.1124/dmd.119.089268</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.119.089268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.119.089268%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DNumerical%252BAnalysis%252Bof%252BTime-Dependent%252BInhibition%252Bby%252BMDMA%26aulast%3DRodgers%26aufirst%3DJohn%2BT.%26date%3D2020%26date%3D2019%26volume%3D48%26issue%3D1%26spage%3D1%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marie‐Noëlle  Paludetto</span>, <span class="hlFld-ContribAuthor ">Florent  Puisset</span>, <span class="hlFld-ContribAuthor ">Etienne  Chatelut</span>, <span class="hlFld-ContribAuthor ">Cécile  Arellano</span>. </span><span class="cited-content_cbyCitation_article-title">Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2105-2152. <a href="https://doi.org/10.1002/med.21577" title="DOI URL">https://doi.org/10.1002/med.21577</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21577%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DIdentifying%252Bthe%252Breactive%252Bmetabolites%252Bof%252Btyrosine%252Bkinase%252Binhibitors%252Bin%252Ba%252Bcomprehensive%252Bapproach%25253A%252BImplications%252Bfor%252Bdrug%2525E2%252580%252590drug%252Binteractions%252Band%252Bhepatotoxicity%26aulast%3DPaludetto%26aufirst%3DMarie%25E2%2580%2590No%25C3%25ABlle%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2105%26epage%3D2152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eleanor Jing Yi  Cheong</span>, <span class="hlFld-ContribAuthor ">Denise Wun Xi  Teo</span>, <span class="hlFld-ContribAuthor ">Denise Xin Yi  Chua</span>, <span class="hlFld-ContribAuthor ">Eric Chun Yong  Chan</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2019,</strong> <em>47 </em>
                                    (11)
                                     , 1291-1306. <a href="https://doi.org/10.1124/dmd.119.086918" title="DOI URL">https://doi.org/10.1124/dmd.119.086918</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.119.086918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.119.086918%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DSystematic%252BDevelopment%252Band%252BVerification%252Bof%252Ba%252BPhysiologically%252BBased%252BPharmacokinetic%252BModel%252Bof%252BRivaroxaban%26aulast%3DCheong%26aufirst%3DEleanor%2BJing%2BYi%26date%3D2019%26date%3D2019%26volume%3D47%26issue%3D11%26spage%3D1291%26epage%3D1306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hiroki  Sakai</span>, <span class="hlFld-ContribAuthor ">Hidekazu  Inoue</span>, <span class="hlFld-ContribAuthor ">Tetsuya  Toba</span>, <span class="hlFld-ContribAuthor ">Kenji  Murata</span>, <span class="hlFld-ContribAuthor ">Nobuhiro  Narii</span>, <span class="hlFld-ContribAuthor ">Yoshiari  Shimmyo</span>, <span class="hlFld-ContribAuthor ">Yoshiyuki  Igawa</span>, <span class="hlFld-ContribAuthor ">Takahiro  Matsumoto</span>, <span class="hlFld-ContribAuthor ">Naohiro  Takemoto</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 1,2,3-triazole-based fibroblast growth factor receptor modulators. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (16)
                                     , 2332-2337. <a href="https://doi.org/10.1016/j.bmcl.2019.06.016" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.06.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.06.016%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B1%25252C2%25252C3-triazole-based%252Bfibroblast%252Bgrowth%252Bfactor%252Breceptor%252Bmodulators%26aulast%3DSakai%26aufirst%3DHiroki%26date%3D2019%26volume%3D29%26issue%3D16%26spage%3D2332%26epage%3D2337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haruka  Nishimuta</span>, <span class="hlFld-ContribAuthor ">Kimihiko  Sato</span>, <span class="hlFld-ContribAuthor ">Takao  Watanabe</span>, <span class="hlFld-ContribAuthor ">Masashi  Yabuki</span>. </span><span class="cited-content_cbyCitation_article-title">Time-dependent inhibition (TDI) of CYP1A2 by a CYP3A4-mediated reactive metabolite: proposal for a novel mechanism of irreversible TDI by a non-suicide substrate. </span><span class="cited-content_cbyCitation_journal-name">Xenobiotica</span><span> <strong>2019,</strong> <em>49 </em>
                                    (6)
                                     , 636-645. <a href="https://doi.org/10.1080/00498254.2018.1488011" title="DOI URL">https://doi.org/10.1080/00498254.2018.1488011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00498254.2018.1488011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00498254.2018.1488011%26sid%3Dliteratum%253Aachs%26jtitle%3DXenobiotica%26atitle%3DTime-dependent%252Binhibition%252B%252528TDI%252529%252Bof%252BCYP1A2%252Bby%252Ba%252BCYP3A4-mediated%252Breactive%252Bmetabolite%25253A%252Bproposal%252Bfor%252Ba%252Bnovel%252Bmechanism%252Bof%252Birreversible%252BTDI%252Bby%252Ba%252Bnon-suicide%252Bsubstrate%26aulast%3DNishimuta%26aufirst%3DHaruka%26date%3D2019%26date%3D2018%26volume%3D49%26issue%3D6%26spage%3D636%26epage%3D645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Agnieszka  Potęga</span>, <span class="hlFld-ContribAuthor ">Dorota  Żelaszczyk</span>, <span class="hlFld-ContribAuthor ">Zofia  Mazerska</span>. </span><span class="cited-content_cbyCitation_article-title">Electrochemical simulation of metabolism for antitumor-active imidazoacridinone C-1311 and in silico prediction of drug metabolic reactions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical and Biomedical Analysis</span><span> <strong>2019,</strong> <em>169 </em>, 269-278. <a href="https://doi.org/10.1016/j.jpba.2019.03.017" title="DOI URL">https://doi.org/10.1016/j.jpba.2019.03.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpba.2019.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpba.2019.03.017%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520and%2520Biomedical%2520Analysis%26atitle%3DElectrochemical%252Bsimulation%252Bof%252Bmetabolism%252Bfor%252Bantitumor-active%252Bimidazoacridinone%252BC-1311%252Band%252Bin%252Bsilico%252Bprediction%252Bof%252Bdrug%252Bmetabolic%252Breactions%26aulast%3DPot%25C4%2599ga%26aufirst%3DAgnieszka%26date%3D2019%26volume%3D169%26spage%3D269%26epage%3D278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S. Cyrus  Khojasteh</span>, <span class="hlFld-ContribAuthor ">Namandjé N.  Bumpus</span>, <span class="hlFld-ContribAuthor ">James P.  Driscoll</span>, <span class="hlFld-ContribAuthor ">Grover P.  Miller</span>, <span class="hlFld-ContribAuthor ">Kaushik  Mitra</span>, <span class="hlFld-ContribAuthor ">Ivonne M. C. M.  Rietjens</span>, <span class="hlFld-ContribAuthor ">Donglu  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Biotransformation and bioactivation reactions – 2018 literature highlights. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism Reviews</span><span> <strong>2019,</strong> <em>51 </em>
                                    (2)
                                     , 121-161. <a href="https://doi.org/10.1080/03602532.2019.1615937" title="DOI URL">https://doi.org/10.1080/03602532.2019.1615937</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/03602532.2019.1615937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F03602532.2019.1615937%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520Reviews%26atitle%3DBiotransformation%252Band%252Bbioactivation%252Breactions%252B%2525E2%252580%252593%252B2018%252Bliterature%252Bhighlights%26aulast%3DKhojasteh%26aufirst%3DS.%2BCyrus%26date%3D2019%26date%3D2019%26volume%3D51%26issue%3D2%26spage%3D121%26epage%3D161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kerri J.  Grove</span>, <span class="hlFld-ContribAuthor ">Shaila  Hoque</span>, <span class="hlFld-ContribAuthor ">Patrick J.  Rudewicz</span>. </span><span class="cited-content_cbyCitation_article-title">Investigation of amodiaquine localization in liver lobules using matrix-assisted laser desorption/ionization imaging mass spectrometry. </span><span class="cited-content_cbyCitation_journal-name">Rapid Communications in Mass Spectrometry</span><span> <strong>2019,</strong> <em>33 </em>
                                    (3)
                                     , 252-258. <a href="https://doi.org/10.1002/rcm.8339" title="DOI URL">https://doi.org/10.1002/rcm.8339</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/rcm.8339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Frcm.8339%26sid%3Dliteratum%253Aachs%26jtitle%3DRapid%2520Communications%2520in%2520Mass%2520Spectrometry%26atitle%3DInvestigation%252Bof%252Bamodiaquine%252Blocalization%252Bin%252Bliver%252Blobules%252Busing%252Bmatrix-assisted%252Blaser%252Bdesorption%25252Fionization%252Bimaging%252Bmass%252Bspectrometry%26aulast%3DGrove%26aufirst%3DKerri%2BJ.%26date%3D2019%26date%3D2019%26volume%3D33%26issue%3D3%26spage%3D252%26epage%3D258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daryl  Staveness</span>, <span class="hlFld-ContribAuthor ">Taylor M.  Sodano</span>, <span class="hlFld-ContribAuthor ">Kangjun  Li</span>, <span class="hlFld-ContribAuthor ">Elizabeth A.  Burnham</span>, <span class="hlFld-ContribAuthor ">Klarissa D.  Jackson</span>, <span class="hlFld-ContribAuthor ">Corey R.J.  Stephenson</span>. </span><span class="cited-content_cbyCitation_article-title">Providing a New Aniline Bioisostere through the Photochemical Production of 1-Aminonorbornanes. </span><span class="cited-content_cbyCitation_journal-name">Chem</span><span> <strong>2019,</strong> <em>5 </em>
                                    (1)
                                     , 215-226. <a href="https://doi.org/10.1016/j.chempr.2018.10.017" title="DOI URL">https://doi.org/10.1016/j.chempr.2018.10.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chempr.2018.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chempr.2018.10.017%26sid%3Dliteratum%253Aachs%26jtitle%3DChem%26atitle%3DProviding%252Ba%252BNew%252BAniline%252BBioisostere%252Bthrough%252Bthe%252BPhotochemical%252BProduction%252Bof%252B1-Aminonorbornanes%26aulast%3DStaveness%26aufirst%3DDaryl%26date%3D2019%26volume%3D5%26issue%3D1%26spage%3D215%26epage%3D226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roy J  Vaz</span>, <span class="hlFld-ContribAuthor ">Yi  Li</span>, <span class="hlFld-ContribAuthor ">Mark  Munson</span>, <span class="hlFld-ContribAuthor ">Michael  Elliot</span>, <span class="hlFld-ContribAuthor ">Sukanthini  Thurairatnam</span>. </span><span class="cited-content_cbyCitation_article-title">Amelioration of mechanism-based inactivation of CYP3A4 by a H-PGDS inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (18)
                                     , 3046-3049. <a href="https://doi.org/10.1016/j.bmcl.2018.07.049" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.07.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.07.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.07.049%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAmelioration%252Bof%252Bmechanism-based%252Binactivation%252Bof%252BCYP3A4%252Bby%252Ba%252BH-PGDS%252Binhibitor%26aulast%3DVaz%26aufirst%3DRoy%2BJ%26date%3D2018%26volume%3D28%26issue%3D18%26spage%3D3046%26epage%3D3049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John T.  Rodgers</span>, <span class="hlFld-ContribAuthor ">Nadezhda Y.  Davydova</span>, <span class="hlFld-ContribAuthor ">Erickson M.  Paragas</span>, <span class="hlFld-ContribAuthor ">Jeffrey P.  Jones</span>, <span class="hlFld-ContribAuthor ">Dmitri R.  Davydov</span>. </span><span class="cited-content_cbyCitation_article-title">Kinetic mechanism of time-dependent inhibition of CYP2D6 by 3,4-methylenedioxymethamphetamine (MDMA): Functional heterogeneity of the enzyme and the reversibility of its inactivation. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2018,</strong> <em>156 </em>, 86-98. <a href="https://doi.org/10.1016/j.bcp.2018.08.010" title="DOI URL">https://doi.org/10.1016/j.bcp.2018.08.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2018.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2018.08.010%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DKinetic%252Bmechanism%252Bof%252Btime-dependent%252Binhibition%252Bof%252BCYP2D6%252Bby%252B3%25252C4-methylenedioxymethamphetamine%252B%252528MDMA%252529%25253A%252BFunctional%252Bheterogeneity%252Bof%252Bthe%252Benzyme%252Band%252Bthe%252Breversibility%252Bof%252Bits%252Binactivation%26aulast%3DRodgers%26aufirst%3DJohn%2BT.%26date%3D2018%26volume%3D156%26spage%3D86%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ji Woong  Lim</span>, <span class="hlFld-ContribAuthor ">Seok Kyu  Kim</span>, <span class="hlFld-ContribAuthor ">Seo Yun  Choi</span>, <span class="hlFld-ContribAuthor ">Dong Hoi  Kim</span>, <span class="hlFld-ContribAuthor ">Changdev G.  Gadhe</span>, <span class="hlFld-ContribAuthor ">Hae Nim  Lee</span>, <span class="hlFld-ContribAuthor ">Hyo-Ji  Kim</span>, <span class="hlFld-ContribAuthor ">Jina  Kim</span>, <span class="hlFld-ContribAuthor ">Sung Jin  Cho</span>, <span class="hlFld-ContribAuthor ">Hayoung  Hwang</span>, <span class="hlFld-ContribAuthor ">Jihye  Seong</span>, <span class="hlFld-ContribAuthor ">Kyu-Sung  Jeong</span>, <span class="hlFld-ContribAuthor ">Jae Yeol  Lee</span>, <span class="hlFld-ContribAuthor ">Sang Min  Lim</span>, <span class="hlFld-ContribAuthor ">Jae Wook  Lee</span>, <span class="hlFld-ContribAuthor ">Ae Nim  Pae</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>157 </em>, 405-422. <a href="https://doi.org/10.1016/j.ejmech.2018.07.071" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.07.071</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.07.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.07.071%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bcrizotinib%252Bderivatives%252Bas%252Bpotent%252BSHIP2%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252BAlzheimer%252527s%252Bdisease%26aulast%3DLim%26aufirst%3DJi%2BWoong%26date%3D2018%26volume%3D157%26spage%3D405%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emily J.  Johnson</span>, <span class="hlFld-ContribAuthor ">Vanessa  González-Peréz</span>, <span class="hlFld-ContribAuthor ">Dan-Dan  Tian</span>, <span class="hlFld-ContribAuthor ">Yvonne S.  Lin</span>, <span class="hlFld-ContribAuthor ">Jashvant D.  Unadkat</span>, <span class="hlFld-ContribAuthor ">Allan E.  Rettie</span>, <span class="hlFld-ContribAuthor ">Danny D.  Shen</span>, <span class="hlFld-ContribAuthor ">Jeannine S.  McCune</span>, <span class="hlFld-ContribAuthor ">Mary F.  Paine</span>. </span><span class="cited-content_cbyCitation_article-title">Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product–Drug Interactions: A NaPDI Center Recommended Approach. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2018,</strong> <em>46 </em>
                                    (7)
                                     , 1046-1052. <a href="https://doi.org/10.1124/dmd.118.081273" title="DOI URL">https://doi.org/10.1124/dmd.118.081273</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.118.081273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.118.081273%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DSelection%252Bof%252BPriority%252BNatural%252BProducts%252Bfor%252BEvaluation%252Bas%252BPotential%252BPrecipitants%252Bof%252BNatural%252BProduct%2525E2%252580%252593Drug%252BInteractions%25253A%252BA%252BNaPDI%252BCenter%252BRecommended%252BApproach%26aulast%3DJohnson%26aufirst%3DEmily%2BJ.%26date%3D2018%26date%3D2018%26volume%3D46%26issue%3D7%26spage%3D1046%26epage%3D1052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huimin  Zhao</span>, <span class="hlFld-ContribAuthor ">Siyuan  Li</span>, <span class="hlFld-ContribAuthor ">Zixin  Yang</span>, <span class="hlFld-ContribAuthor ">Ying  Peng</span>, <span class="hlFld-ContribAuthor ">Xiaohui  Chen</span>, <span class="hlFld-ContribAuthor ">Jiang  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Ketene-Reactive Intermediate of Erlotinib Possibly Responsible for Inactivation of P450 Enzymes. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2018,</strong> <em>46 </em>
                                    (4)
                                     , 442-450. <a href="https://doi.org/10.1124/dmd.117.079327" title="DOI URL">https://doi.org/10.1124/dmd.117.079327</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.117.079327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.117.079327%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DIdentification%252Bof%252BKetene-Reactive%252BIntermediate%252Bof%252BErlotinib%252BPossibly%252BResponsible%252Bfor%252BInactivation%252Bof%252BP450%252BEnzymes%26aulast%3DZhao%26aufirst%3DHuimin%26date%3D2018%26date%3D2018%26volume%3D46%26issue%3D4%26spage%3D442%26epage%3D450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Axel  Pähler</span>. </span><span class="cited-content_cbyCitation_article-title">Reactive Metabolite Assessment in Drug Discovery and Development in Support of Safe Drug Design. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 263-281. <a href="https://doi.org/10.1007/978-1-4939-7677-5_13" title="DOI URL">https://doi.org/10.1007/978-1-4939-7677-5_13</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4939-7677-5_13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4939-7677-5_13%26sid%3Dliteratum%253Aachs%26atitle%3DReactive%252BMetabolite%252BAssessment%252Bin%252BDrug%252BDiscovery%252Band%252BDevelopment%252Bin%252BSupport%252Bof%252BSafe%252BDrug%252BDesign%26aulast%3DP%25C3%25A4hler%26aufirst%3DAxel%26date%3D2018%26date%3D2018%26spage%3D263%26epage%3D281%26pub%3DSpringer%2520New%2520York%26atitle%3DDrug-Induced%252BLiver%252BToxicity%26aulast%3DChen%26aufirst%3DMinjun%26date%3D2018%26volume%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Julie  Ducharme</span>, <span class="hlFld-ContribAuthor ">Karine  Auclair</span>. </span><span class="cited-content_cbyCitation_article-title">Use of bioconjugation with cytochrome P450 enzymes. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics</span><span> <strong>2018,</strong> <em>1866 </em>
                                    (1)
                                     , 32-51. <a href="https://doi.org/10.1016/j.bbapap.2017.06.007" title="DOI URL">https://doi.org/10.1016/j.bbapap.2017.06.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbapap.2017.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbapap.2017.06.007%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Proteins%2520and%2520Proteomics%26atitle%3DUse%252Bof%252Bbioconjugation%252Bwith%252Bcytochrome%252BP450%252Benzymes%26aulast%3DDucharme%26aufirst%3DJulie%26date%3D2018%26volume%3D1866%26issue%3D1%26spage%3D32%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Momir  Mikov</span>, <span class="hlFld-ContribAuthor ">Maja  Đanić</span>, <span class="hlFld-ContribAuthor ">Nebojša  Pavlović</span>, <span class="hlFld-ContribAuthor ">Bojan  Stanimirov</span>, <span class="hlFld-ContribAuthor ">Svetlana  Goločorbin-Kon</span>, <span class="hlFld-ContribAuthor ">Karmen  Stankov</span>, <span class="hlFld-ContribAuthor ">Hani  Al-Salami</span>. </span><span class="cited-content_cbyCitation_article-title">The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Drug Metabolism and Pharmacokinetics</span><span> <strong>2017,</strong> <em>42 </em>
                                    (6)
                                     , 881-890. <a href="https://doi.org/10.1007/s13318-017-0417-y" title="DOI URL">https://doi.org/10.1007/s13318-017-0417-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13318-017-0417-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13318-017-0417-y%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Drug%2520Metabolism%2520and%2520Pharmacokinetics%26atitle%3DThe%252BRole%252Bof%252BDrug%252BMetabolites%252Bin%252Bthe%252BInhibition%252Bof%252BCytochrome%252BP450%252BEnzymes%26aulast%3DMikov%26aufirst%3DMomir%26date%3D2017%26date%3D2017%26volume%3D42%26issue%3D6%26spage%3D881%26epage%3D890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaheed  Rehman</span>, <span class="hlFld-ContribAuthor ">In  Kim</span>, <span class="hlFld-ContribAuthor ">Min  Choi</span>, <span class="hlFld-ContribAuthor ">Seung  Kim</span>, <span class="hlFld-ContribAuthor ">Yonghui  Zhang</span>, <span class="hlFld-ContribAuthor ">Hye  Yoo</span>. </span><span class="cited-content_cbyCitation_article-title">Time-dependent Inhibition of CYP2C8 and CYP2C19 by Hedera helix Extracts, A Traditional Respiratory Herbal Medicine. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2017,</strong> <em>22 </em>
                                    (7)
                                     , 1241. <a href="https://doi.org/10.3390/molecules22071241" title="DOI URL">https://doi.org/10.3390/molecules22071241</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules22071241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules22071241%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DTime-dependent%252BInhibition%252Bof%252BCYP2C8%252Band%252BCYP2C19%252Bby%252BHedera%252Bhelix%252BExtracts%25252C%252BA%252BTraditional%252BRespiratory%252BHerbal%252BMedicine%26aulast%3DRehman%26aufirst%3DShaheed%26date%3D2017%26date%3D2017%26volume%3D22%26issue%3D7%26spage%3D1241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eleanor Jing Yi  Cheong</span>, <span class="hlFld-ContribAuthor ">Janice Jia Ni  Goh</span>, <span class="hlFld-ContribAuthor ">Yanjun  Hong</span>, <span class="hlFld-ContribAuthor ">Gopalakrishnan  Venkatesan</span>, <span class="hlFld-ContribAuthor ">Yuanjie  Liu</span>, <span class="hlFld-ContribAuthor ">Gigi Ngar Chee  Chiu</span>, <span class="hlFld-ContribAuthor ">Pipin  Kojodjojo</span>, <span class="hlFld-ContribAuthor ">Eric Chun Yong  Chan</span>. </span><span class="cited-content_cbyCitation_article-title">Application of Static Modeling ­­in the Prediction of In Vivo Drug–Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2017,</strong> <em>45 </em>
                                    (3)
                                     , 260-268. <a href="https://doi.org/10.1124/dmd.116.073890" title="DOI URL">https://doi.org/10.1124/dmd.116.073890</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.116.073890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.116.073890%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DApplication%252Bof%252BStatic%252BModeling%252B%2525C2%2525AD%2525C2%2525ADin%252Bthe%252BPrediction%252Bof%252BIn%252BVivo%252BDrug%2525E2%252580%252593Drug%252BInteractions%252Bbetween%252BRivaroxaban%252Band%252BAntiarrhythmic%252BAgents%252BBased%252Bon%252BIn%252BVitro%252BInhibition%252BStudies%26aulast%3DCheong%26aufirst%3DEleanor%2BJing%2BYi%26date%3D2017%26date%3D2017%26volume%3D45%26issue%3D3%26spage%3D260%26epage%3D268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephen  Fowler</span>, <span class="hlFld-ContribAuthor ">Peter N.  Morcos</span>, <span class="hlFld-ContribAuthor ">Yumi  Cleary</span>, <span class="hlFld-ContribAuthor ">Meret  Martin-Facklam</span>, <span class="hlFld-ContribAuthor ">Neil  Parrott</span>, <span class="hlFld-ContribAuthor ">Michael  Gertz</span>, <span class="hlFld-ContribAuthor ">Li  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities. </span><span class="cited-content_cbyCitation_journal-name">Current Pharmacology Reports</span><span> <strong>2017,</strong> <em>3 </em>
                                    (1)
                                     , 36-49. <a href="https://doi.org/10.1007/s40495-017-0082-5" title="DOI URL">https://doi.org/10.1007/s40495-017-0082-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40495-017-0082-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40495-017-0082-5%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Pharmacology%2520Reports%26atitle%3DProgress%252Bin%252BPrediction%252Band%252BInterpretation%252Bof%252BClinically%252BRelevant%252BMetabolic%252BDrug-Drug%252BInteractions%25253A%252Ba%252BMinireview%252BIllustrating%252BRecent%252BDevelopments%252Band%252BCurrent%252BOpportunities%26aulast%3DFowler%26aufirst%3DStephen%26date%3D2017%26date%3D2017%26volume%3D3%26issue%3D1%26spage%3D36%26epage%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoqian  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiao-Xi  Li</span>, <span class="hlFld-ContribAuthor ">Yufang  Liu</span>, <span class="hlFld-ContribAuthor ">Yong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Suicide Inhibition of Cytochrome P450 Enzymes by Cyclopropylamines via a Ring-Opening Mechanism: Proton-Coupled Electron Transfer Makes a Difference. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2017,</strong> <em>5 </em><a href="https://doi.org/10.3389/fchem.2017.00003" title="DOI URL">https://doi.org/10.3389/fchem.2017.00003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2017.00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2017.00003%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DSuicide%252BInhibition%252Bof%252BCytochrome%252BP450%252BEnzymes%252Bby%252BCyclopropylamines%252Bvia%252Ba%252BRing-Opening%252BMechanism%25253A%252BProton-Coupled%252BElectron%252BTransfer%252BMakes%252Ba%252BDifference%26aulast%3DZhang%26aufirst%3DXiaoqian%26date%3D2017%26date%3D2017%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bianca M.  Liederer</span>, <span class="hlFld-ContribAuthor ">Xingrong  Liu</span>, <span class="hlFld-ContribAuthor ">Simon  Wong</span>, <span class="hlFld-ContribAuthor ">Daniel R.  Mudra</span>. </span><span class="cited-content_cbyCitation_article-title">Integrated Lead Optimization: Translational Models as We Advance Toward the Clinic. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 165-230. <a href="https://doi.org/10.1007/978-3-319-50042-3_6" title="DOI URL">https://doi.org/10.1007/978-3-319-50042-3_6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-50042-3_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-50042-3_6%26sid%3Dliteratum%253Aachs%26atitle%3DIntegrated%252BLead%252BOptimization%25253A%252BTranslational%252BModels%252Bas%252BWe%252BAdvance%252BToward%252Bthe%252BClinic%26aulast%3DLiederer%26aufirst%3DBianca%2BM.%26date%3D2017%26date%3D2017%26spage%3D165%26epage%3D230%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DTranslating%252BMolecules%252Binto%252BMedicines%26aulast%3DBhattachar%26aufirst%3DShobha%2BN.%26date%3D2017%26volume%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">N.A.  Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">A Synopsis of the Properties and Applications of Heteroaromatic Rings in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 245-361. <a href="https://doi.org/10.1016/bs.aihch.2016.11.002" title="DOI URL">https://doi.org/10.1016/bs.aihch.2016.11.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2016.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2016.11.002%26sid%3Dliteratum%253Aachs%26atitle%3DA%252BSynopsis%252Bof%252Bthe%252BProperties%252Band%252BApplications%252Bof%252BHeteroaromatic%252BRings%252Bin%252BMedicinal%252BChemistry%26aulast%3DMeanwell%26aufirst%3DN.A.%26date%3D2017%26spage%3D245%26epage%3D361%26pub%3DElsevier%26date%3D2017%26volume%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fei  Gao</span>, <span class="hlFld-ContribAuthor ">Jiu-Tao  Wang</span>, <span class="hlFld-ContribAuthor ">Lin-Lin  Liu</span>, <span class="hlFld-ContribAuthor ">Na  Ma</span>, <span class="hlFld-ContribAuthor ">Chao  Yang</span>, <span class="hlFld-ContribAuthor ">Yuan  Gao</span>, <span class="hlFld-ContribAuthor ">Wujiong  Xia</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of carbonylated heteroaromatic compounds via visible-light-driven intramolecular decarboxylative cyclization of o-alkynylated carboxylic acids. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2017,</strong> <em>53 </em>
                                    (61)
                                     , 8533-8536. <a href="https://doi.org/10.1039/C7CC04813K" title="DOI URL">https://doi.org/10.1039/C7CC04813K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7CC04813K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7CC04813K%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DSynthesis%252Bof%252Bcarbonylated%252Bheteroaromatic%252Bcompounds%252Bvia%252Bvisible-light-driven%252Bintramolecular%252Bdecarboxylative%252Bcyclization%252Bof%252Bo-alkynylated%252Bcarboxylic%252Bacids%26aulast%3DGao%26aufirst%3DFei%26date%3D2017%26date%3D2017%26volume%3D53%26issue%3D61%26spage%3D8533%26epage%3D8536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Hoemann</span>, <span class="hlFld-ContribAuthor ">Noel  Wilson</span>, <span class="hlFld-ContribAuthor ">Maria  Argiriadi</span>, <span class="hlFld-ContribAuthor ">David  Banach</span>, <span class="hlFld-ContribAuthor ">Andrew  Burchat</span>, <span class="hlFld-ContribAuthor ">David  Calderwood</span>, <span class="hlFld-ContribAuthor ">Bruce  Clapham</span>, <span class="hlFld-ContribAuthor ">Phil  Cox</span>, <span class="hlFld-ContribAuthor ">David B.  Duignan</span>, <span class="hlFld-ContribAuthor ">Don  Konopacki</span>, <span class="hlFld-ContribAuthor ">Gagandeep  Somal</span>, <span class="hlFld-ContribAuthor ">Anil  Vasudevan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and optimization of furano[3,2- d ]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (22)
                                     , 5562-5567. <a href="https://doi.org/10.1016/j.bmcl.2016.09.077" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.09.077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.09.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.09.077%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Boptimization%252Bof%252Bfurano%25255B3%25252C2-%252Bd%252B%25255Dpyrimidines%252Bas%252Bselective%252Bspleen%252Btyrosine%252Bkinase%252B%252528Syk%252529%252Binhibitors%26aulast%3DHoemann%26aufirst%3DMichael%26date%3D2016%26volume%3D26%26issue%3D22%26spage%3D5562%26epage%3D5567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shabbir  Ahmed</span>, <span class="hlFld-ContribAuthor ">Zhan  Zhou</span>, <span class="hlFld-ContribAuthor ">Jie  Zhou</span>, <span class="hlFld-ContribAuthor ">Shu-Qing  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine. </span><span class="cited-content_cbyCitation_journal-name">Genomics, Proteomics & Bioinformatics</span><span> <strong>2016,</strong> <em>14 </em>
                                    (5)
                                     , 298-313. <a href="https://doi.org/10.1016/j.gpb.2016.03.008" title="DOI URL">https://doi.org/10.1016/j.gpb.2016.03.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.gpb.2016.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.gpb.2016.03.008%26sid%3Dliteratum%253Aachs%26jtitle%3DGenomics%252C%2520Proteomics%2520%2526%2520Bioinformatics%26atitle%3DPharmacogenomics%252Bof%252BDrug%252BMetabolizing%252BEnzymes%252Band%252BTransporters%25253A%252BRelevance%252Bto%252BPrecision%252BMedicine%26aulast%3DAhmed%26aufirst%3DShabbir%26date%3D2016%26volume%3D14%26issue%3D5%26spage%3D298%26epage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Volker  Lauschke</span>, <span class="hlFld-ContribAuthor ">Magnus  Ingelman-Sundberg</span>. </span><span class="cited-content_cbyCitation_article-title">The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2016,</strong> <em>17 </em>
                                    (10)
                                     , 1714. <a href="https://doi.org/10.3390/ijms17101714" title="DOI URL">https://doi.org/10.3390/ijms17101714</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms17101714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms17101714%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DThe%252BImportance%252Bof%252BPatient-Specific%252BFactors%252Bfor%252BHepatic%252BDrug%252BResponse%252Band%252BToxicity%26aulast%3DLauschke%26aufirst%3DVolker%26date%3D2016%26date%3D2016%26volume%3D17%26issue%3D10%26spage%3D1714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Watanabe</span>, <span class="hlFld-ContribAuthor ">H.  Takakusa</span>, <span class="hlFld-ContribAuthor ">T.  Kimura</span>, <span class="hlFld-ContribAuthor ">S.-i.  Inoue</span>, <span class="hlFld-ContribAuthor ">H.  Kusuhara</span>, <span class="hlFld-ContribAuthor ">O.  Ando</span>. </span><span class="cited-content_cbyCitation_article-title">Analysis of Mechanism-Based Inhibition of CYP 3A4 by a Series of Fluoroquinolone Antibacterial Agents. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2016,</strong> <em>44 </em>
                                    (10)
                                     , 1608-1616. <a href="https://doi.org/10.1124/dmd.116.071654" title="DOI URL">https://doi.org/10.1124/dmd.116.071654</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.116.071654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.116.071654%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DAnalysis%252Bof%252BMechanism-Based%252BInhibition%252Bof%252BCYP%252B3A4%252Bby%252Ba%252BSeries%252Bof%252BFluoroquinolone%252BAntibacterial%252BAgents%26aulast%3DWatanabe%26aufirst%3DA.%26date%3D2016%26date%3D2016%26volume%3D44%26issue%3D10%26spage%3D1608%26epage%3D1616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M. José  Gómez-Lechón</span>, <span class="hlFld-ContribAuthor ">Laia  Tolosa</span>, <span class="hlFld-ContribAuthor ">M. Teresa  Donato</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolic activation and drug-induced liver injury:
              in vitro
              approaches for the safety risk assessment of new drugs. </span><span class="cited-content_cbyCitation_journal-name">Journal of Applied Toxicology</span><span> <strong>2016,</strong> <em>36 </em>
                                    (6)
                                     , 752-768. <a href="https://doi.org/10.1002/jat.3277" title="DOI URL">https://doi.org/10.1002/jat.3277</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jat.3277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjat.3277%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Applied%2520Toxicology%26atitle%3DMetabolic%252Bactivation%252Band%252Bdrug-induced%252Bliver%252Binjury%25253A%252Bin%252Bvitro%252Bapproaches%252Bfor%252Bthe%252Bsafety%252Brisk%252Bassessment%252Bof%252Bnew%252Bdrugs%26aulast%3DG%25C3%25B3mez-Lech%25C3%25B3n%26aufirst%3DM.%2BJos%25C3%25A9%26date%3D2016%26date%3D2015%26volume%3D36%26issue%3D6%26spage%3D752%26epage%3D768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vamshi K.  Manda</span>, <span class="hlFld-ContribAuthor ">Bharathi  Avula</span>, <span class="hlFld-ContribAuthor ">Amar G.  Chittiboyina</span>, <span class="hlFld-ContribAuthor ">Ikhlas A.  Khan</span>, <span class="hlFld-ContribAuthor ">Larry A.  Walker</span>, <span class="hlFld-ContribAuthor ">Shabana I.  Khan</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of CYP3A4 and CYP1A2 by
              Aegle marmelos
              and its constituents. </span><span class="cited-content_cbyCitation_journal-name">Xenobiotica</span><span> <strong>2016,</strong> <em>46 </em>
                                    (2)
                                     , 117-125. <a href="https://doi.org/10.3109/00498254.2015.1053006" title="DOI URL">https://doi.org/10.3109/00498254.2015.1053006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3109/00498254.2015.1053006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3109%2F00498254.2015.1053006%26sid%3Dliteratum%253Aachs%26jtitle%3DXenobiotica%26atitle%3DInhibition%252Bof%252BCYP3A4%252Band%252BCYP1A2%252Bby%252BAegle%252Bmarmelos%252Band%252Bits%252Bconstituents%26aulast%3DManda%26aufirst%3DVamshi%2BK.%26date%3D2016%26date%3D2015%26volume%3D46%26issue%3D2%26spage%3D117%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H.  Li</span>, <span class="hlFld-ContribAuthor ">Y.  Peng</span>, <span class="hlFld-ContribAuthor ">J.  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolic Activation and Toxicities of Furanoterpenoids. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 55-97. <a href="https://doi.org/10.1016/B978-0-12-804700-2.00002-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-804700-2.00002-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-804700-2.00002-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-804700-2.00002-7%26sid%3Dliteratum%253Aachs%26atitle%3DMetabolic%252BActivation%252Band%252BToxicities%252Bof%252BFuranoterpenoids%26aulast%3DLi%26aufirst%3DH.%26date%3D2016%26spage%3D55%26epage%3D97%26pub%3DElsevier%26date%3D2016%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jay R.  Winkler</span>, <span class="hlFld-ContribAuthor ">Harry B.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Electron flow through biological molecules: does hole hopping protect proteins from oxidative damage?. </span><span class="cited-content_cbyCitation_journal-name">Quarterly Reviews of Biophysics</span><span> <strong>2015,</strong> <em>48 </em>
                                    (4)
                                     , 411-420. <a href="https://doi.org/10.1017/S0033583515000062" title="DOI URL">https://doi.org/10.1017/S0033583515000062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1017/S0033583515000062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1017%2FS0033583515000062%26sid%3Dliteratum%253Aachs%26jtitle%3DQuarterly%2520Reviews%2520of%2520Biophysics%26atitle%3DElectron%252Bflow%252Bthrough%252Bbiological%252Bmolecules%25253A%252Bdoes%252Bhole%252Bhopping%252Bprotect%252Bproteins%252Bfrom%252Boxidative%252Bdamage%25253F%26aulast%3DWinkler%26aufirst%3DJay%2BR.%26date%3D2015%26date%3D2015%26volume%3D48%26issue%3D4%26spage%3D411%26epage%3D420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A. S.  Youssef</span>, <span class="hlFld-ContribAuthor ">H. P.  Parkman</span>, <span class="hlFld-ContribAuthor ">S.  Nagar</span>. </span><span class="cited-content_cbyCitation_article-title">Drug-drug interactions in pharmacologic management of gastroparesis. </span><span class="cited-content_cbyCitation_journal-name">Neurogastroenterology & Motility</span><span> <strong>2015,</strong> <em>27 </em>
                                    (11)
                                     , 1528-1541. <a href="https://doi.org/10.1111/nmo.12614" title="DOI URL">https://doi.org/10.1111/nmo.12614</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/nmo.12614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fnmo.12614%26sid%3Dliteratum%253Aachs%26jtitle%3DNeurogastroenterology%2520%2526%2520Motility%26atitle%3DDrug-drug%252Binteractions%252Bin%252Bpharmacologic%252Bmanagement%252Bof%252Bgastroparesis%26aulast%3DYoussef%26aufirst%3DA.%2BS.%26date%3D2015%26date%3D2015%26volume%3D27%26issue%3D11%26spage%3D1528%26epage%3D1541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Drug-Drug Interaction: From Bench to Drug Label. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 139-178. <a href="https://doi.org/10.1002/9781118838440.ch5" title="DOI URL">https://doi.org/10.1002/9781118838440.ch5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118838440.ch5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118838440.ch5%26sid%3Dliteratum%253Aachs%26atitle%3DDrug-Drug%252BInteraction%25253A%252BFrom%252BBench%252Bto%252BDrug%252BLabel%26date%3D2015%26date%3D2015%26spage%3D139%26epage%3D178%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DTranslational%252BADMET%252Bfor%252BDrug%252BTherapy%26aulast%3DYanni%26aufirst%3DSouzan%2BB.%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kenjiro  Sato</span>, <span class="hlFld-ContribAuthor ">Hiroki  Takahagi</span>, <span class="hlFld-ContribAuthor ">Osamu  Kubo</span>, <span class="hlFld-ContribAuthor ">Kousuke  Hidaka</span>, <span class="hlFld-ContribAuthor ">Takeshi  Yoshikawa</span>, <span class="hlFld-ContribAuthor ">Masahiro  Kamaura</span>, <span class="hlFld-ContribAuthor ">Masanori  Nakakariya</span>, <span class="hlFld-ContribAuthor ">Nobuyuki  Amano</span>, <span class="hlFld-ContribAuthor ">Ryutaro  Adachi</span>, <span class="hlFld-ContribAuthor ">Toshiyuki  Maki</span>, <span class="hlFld-ContribAuthor ">Kazumi  Take</span>, <span class="hlFld-ContribAuthor ">Shiro  Takekawa</span>, <span class="hlFld-ContribAuthor ">Tomoyuki  Kitazaki</span>, <span class="hlFld-ContribAuthor ">Tsuyoshi  Maekawa</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of a novel series of N-phenylindoline-5-sulfonamide-based acyl CoA:monoacylglycerol acyltransferase-2 inhibitors: Mitigation of CYP3A4 time-dependent inhibition and phototoxic liabilities. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (15)
                                     , 4544-4560. <a href="https://doi.org/10.1016/j.bmc.2015.06.003" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.06.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.06.003%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DOptimization%252Bof%252Ba%252Bnovel%252Bseries%252Bof%252BN-phenylindoline-5-sulfonamide-based%252Bacyl%252BCoA%25253Amonoacylglycerol%252Bacyltransferase-2%252Binhibitors%25253A%252BMitigation%252Bof%252BCYP3A4%252Btime-dependent%252Binhibition%252Band%252Bphototoxic%252Bliabilities%26aulast%3DSato%26aufirst%3DKenjiro%26date%3D2015%26volume%3D23%26issue%3D15%26spage%3D4544%26epage%3D4560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vinita  Uttamsingh</span>, <span class="hlFld-ContribAuthor ">Richard  Gallegos</span>, <span class="hlFld-ContribAuthor ">Julie F.  Liu</span>, <span class="hlFld-ContribAuthor ">Scott L.  Harbeson</span>, <span class="hlFld-ContribAuthor ">Gary W.  Bridson</span>, <span class="hlFld-ContribAuthor ">Changfu  Cheng</span>, <span class="hlFld-ContribAuthor ">David S.  Wells</span>, <span class="hlFld-ContribAuthor ">Philip B.  Graham</span>, <span class="hlFld-ContribAuthor ">Robert  Zelle</span>, <span class="hlFld-ContribAuthor ">Roger  Tung</span>. </span><span class="cited-content_cbyCitation_article-title">Altering Metabolic Profiles of Drugs by Precision Deuteration: Reducing Mechanism-Based Inhibition of CYP2D6 by Paroxetine. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2015,</strong> <em>354 </em>
                                    (1)
                                     , 43-54. <a href="https://doi.org/10.1124/jpet.115.223768" title="DOI URL">https://doi.org/10.1124/jpet.115.223768</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.115.223768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.115.223768%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DAltering%252BMetabolic%252BProfiles%252Bof%252BDrugs%252Bby%252BPrecision%252BDeuteration%25253A%252BReducing%252BMechanism-Based%252BInhibition%252Bof%252BCYP2D6%252Bby%252BParoxetine%26aulast%3DUttamsingh%26aufirst%3DVinita%26date%3D2015%26date%3D2015%26volume%3D354%26issue%3D1%26spage%3D43%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hannu  Raunio</span>, <span class="hlFld-ContribAuthor ">Mira  Kuusisto</span>, <span class="hlFld-ContribAuthor ">Risto O.  Juvonen</span>, <span class="hlFld-ContribAuthor ">Olli T.  PentikÃ¤inen</span>. </span><span class="cited-content_cbyCitation_article-title">Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2015,</strong> <em>6 </em><a href="https://doi.org/10.3389/fphar.2015.00123" title="DOI URL">https://doi.org/10.3389/fphar.2015.00123</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2015.00123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2015.00123%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DModeling%252Bof%252Binteractions%252Bbetween%252Bxenobiotics%252Band%252Bcytochrome%252BP450%252B%252528CYP%252529%252Benzymes%26aulast%3DRaunio%26aufirst%3DHannu%26date%3D2015%26date%3D2015%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongbin  Yu</span>, <span class="hlFld-ContribAuthor ">Suresh K.  Balani</span>, <span class="hlFld-ContribAuthor ">Weichao  Chen</span>, <span class="hlFld-ContribAuthor ">Donghui  Cui</span>, <span class="hlFld-ContribAuthor ">Ling  He</span>, <span class="hlFld-ContribAuthor ">W. Griffith  Humphreys</span>, <span class="hlFld-ContribAuthor ">Jialin  Mao</span>, <span class="hlFld-ContribAuthor ">W. George  Lai</span>, <span class="hlFld-ContribAuthor ">Anthony J.  Lee</span>, <span class="hlFld-ContribAuthor ">Heng-Keang  Lim</span>, <span class="hlFld-ContribAuthor ">Christopher  MacLauchlin</span>, <span class="hlFld-ContribAuthor ">Chandra  Prakash</span>, <span class="hlFld-ContribAuthor ">Sekhar  Surapaneni</span>, <span class="hlFld-ContribAuthor ">Susanna  Tse</span>, <span class="hlFld-ContribAuthor ">Alana  Upthagrove</span>, <span class="hlFld-ContribAuthor ">Robert L.  Walsky</span>, <span class="hlFld-ContribAuthor ">Bo  Wen</span>, <span class="hlFld-ContribAuthor ">Zhaopie  Zeng</span>. </span><span class="cited-content_cbyCitation_article-title">Contribution of Metabolites to P450 Inhibition–Based Drug–Drug Interactions: Scholarship from the Drug Metabolism Leadership Group of the Innovation and Quality Consortium Metabolite Group. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2015,</strong> <em>43 </em>
                                    (4)
                                     , 620-630. <a href="https://doi.org/10.1124/dmd.114.059345" title="DOI URL">https://doi.org/10.1124/dmd.114.059345</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.114.059345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.114.059345%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DContribution%252Bof%252BMetabolites%252Bto%252BP450%252BInhibition%2525E2%252580%252593Based%252BDrug%2525E2%252580%252593Drug%252BInteractions%25253A%252BScholarship%252Bfrom%252Bthe%252BDrug%252BMetabolism%252BLeadership%252BGroup%252Bof%252Bthe%252BInnovation%252Band%252BQuality%252BConsortium%252BMetabolite%252BGroup%26aulast%3DYu%26aufirst%3DHongbin%26date%3D2015%26date%3D2015%26volume%3D43%26issue%3D4%26spage%3D620%26epage%3D630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amit S.  Kalgutkar</span>, <span class="hlFld-ContribAuthor ">Deepak  Dalvie</span>. </span><span class="cited-content_cbyCitation_article-title">Predicting Toxicities of Reactive Metabolite–Positive Drug Candidates. </span><span class="cited-content_cbyCitation_journal-name">Annual Review of Pharmacology and Toxicology</span><span> <strong>2015,</strong> <em>55 </em>
                                    (1)
                                     , 35-54. <a href="https://doi.org/10.1146/annurev-pharmtox-010814-124720" title="DOI URL">https://doi.org/10.1146/annurev-pharmtox-010814-124720</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1146/annurev-pharmtox-010814-124720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1146%2Fannurev-pharmtox-010814-124720%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnual%2520Review%2520of%2520Pharmacology%2520and%2520Toxicology%26atitle%3DPredicting%252BToxicities%252Bof%252BReactive%252BMetabolite%2525E2%252580%252593Positive%252BDrug%252BCandidates%26aulast%3DKalgutkar%26aufirst%3DAmit%2BS.%26date%3D2015%26volume%3D55%26issue%3D1%26spage%3D35%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonid I.  Belen'kii</span>, <span class="hlFld-ContribAuthor ">Yu B.  Evdokimenkova</span>. </span><span class="cited-content_cbyCitation_article-title">The Literature of Heterocyclic Chemistry, Part XIII, 2012–2013. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 193-363. <a href="https://doi.org/10.1016/bs.aihch.2015.04.002" title="DOI URL">https://doi.org/10.1016/bs.aihch.2015.04.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2015.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2015.04.002%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BLiterature%252Bof%252BHeterocyclic%252BChemistry%25252C%252BPart%252BXIII%25252C%252B2012%2525E2%252580%2525932013%26aulast%3DBelen%2527kii%26aufirst%3DLeonid%2BI.%26date%3D2015%26spage%3D193%26epage%3D363%26pub%3DElsevier%26date%3D2015%26volume%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bitoku  Takahashi</span>, <span class="hlFld-ContribAuthor ">Hideaki  Funami</span>, <span class="hlFld-ContribAuthor ">Makoto  Shibata</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Maruoka</span>, <span class="hlFld-ContribAuthor ">Makoto  Koyama</span>, <span class="hlFld-ContribAuthor ">Satomi  Kanki</span>, <span class="hlFld-ContribAuthor ">Tsuyoshi  Muto</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Optimization of Ghrelin Receptor Inverse Agonists to Improve Lipophilicity and Avoid Mechanism-Based CYP3A4 Inactivation. </span><span class="cited-content_cbyCitation_journal-name">CHEMICAL & PHARMACEUTICAL BULLETIN</span><span> <strong>2015,</strong> <em>63 </em>
                                    (10)
                                     , 825-832. <a href="https://doi.org/10.1248/cpb.c15-00285" title="DOI URL">https://doi.org/10.1248/cpb.c15-00285</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c15-00285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c15-00285%26sid%3Dliteratum%253Aachs%26jtitle%3DCHEMICAL%2520%2526%2520PHARMACEUTICAL%2520BULLETIN%26atitle%3DStructural%252BOptimization%252Bof%252BGhrelin%252BReceptor%252BInverse%252BAgonists%252Bto%252BImprove%252BLipophilicity%252Band%252BAvoid%252BMechanism-Based%252BCYP3A4%252BInactivation%26aulast%3DTakahashi%26aufirst%3DBitoku%26date%3D2015%26volume%3D63%26issue%3D10%26spage%3D825%26epage%3D832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm300065h&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-11%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Fjm300065h%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text&amp;citedByCount=123&amp;pagesCount=2&amp;pageNumber=-1" title="Load all citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load all citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="fig1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0021.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Depiction of a CYP TDI experiment to generate <i>k</i><sub>inact</sub> and <i>K</i><sub>I</sub> values: (A) measurement of loss of CYP activity over time; (B) plot of <i>k</i><sub>obs</sub> values versus inactivator concentration used in estimation of <i>k</i><sub>inact</sub> and <i>K</i><sub>I</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0022.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Six possible outcomes when testing for CYP TDI in a simplified “one concentration” approach. Compound <b>1</b> depicts TDI with some reversible inhibition component. Compound <b>2</b> is also a time-dependent inactivator but shows no detectable reversible inhibition. Compound <b>3</b> is neither a time-dependent inactivator nor a reversible inhibitor. Compound <b>4</b> is a potent reversible inhibitor. Compound <b>5</b> is a reversible inhibitor that is consumed during the preincubation. Compound <b>6</b> is an activator (i.e., it stimulates the activity of CYP). (a) The test compound is preincubated with CYP enzyme and NADPH. (b) The test compound is not preincubated with CYP enzyme. (c) CYP preincubation is in the absence of test compound and in the presence of NADPH. (d) Results from the control (no test compound and no preincubation) are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0023.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Graphical representation of an IC<sub>50</sub> shift experiment to identify TDIs of CYP enzymes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0026.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Quasi-Irreversible CYP Inactivation and Formation of MI Complex by Amines and 1,3-Benzodioxoles</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0027.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Heme Alkylation and Arylation by Hydrazine Derivatives</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0028.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. CYP Apoprotein Acylation by the Broad-Spectrum Antibiotic Chloramphenicol</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0029.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Immunogenic drugs dihydralazine and halothane.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0030.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Structures of Paroxetine and Tadalafil and Proposed Mechanism of CYP2D6 Inactivation by Paroxetine</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0031.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Amine-Based Drugs That Form MI Complex with CYP Enzymes Resulting in MBI</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0032.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. SAR analysis for MI complexation of macrolides with CYP3A4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0033.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Oxidative Bioactivation of Duloxetine by CYP1A2 Does Not Lead to MBI of the Isozyme</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0034.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. HIV protease inhibitors that cause TDI of CYP3A4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0035.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Proposed Mechanism of CYP3A4 Inactivation by the Tricyclic Antidepressant Nefazodone</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0036.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures, physicochemical properties, and CYP3A4 TDI data for nontricyclic antidepressants. Structural elements in blue represent the region susceptible to RM formation by CYP3A4. TPSA refers to topological polar surface area. Initial observed inactivation rate (<i>k</i><sub>obs</sub>) at a single inactivator concentration of 10 μM is as reported in ref <a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">84</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0037.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Metabolism of Nontricyclic Antidepressants Trazodone and Aripiprazole by CYP3A4 to RMs</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch9" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0038.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Pyrimidine-Based Tyrosine Kinase Inhibitors Imatinib and Dasatinib as Time- and Concentration-Dependent Inactivators of CYP3A4</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch10" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0039.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Proposed Mechanism of CYP3A4 Inactivation and Idiosyncratic Hepatotoxicity Associated with the Tyrosine Kinase Inhibitor Lapatinib</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch11" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0040.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Bioactivation of the TK Inhibitors Gefitinib and Erlotinib by CYP3A4 That Leads to MBI with Erlotinib (but Not Gefitinib)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0041.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures of tyrosine kinase inhibitors sorafenib (CYP3A4 TDI +ve) and sunitinib (CYP3A4 TDI −ve).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch12" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0002.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Postulated Mechanism of CYP2C19 Inactivation by Tetrahydrothienopyridine Antithombotic Drugs Clopidogrel and Ticlopidine</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch13" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0001.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Metabolism of Prasugrel Leading to Its Pharmacologically Active Metabolite</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch14" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0003.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. MBI of CYP2C8 by the Gemfibrozil-1-<i>O</i>-β-glucuronide Metabolite of Gemfibrozil</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch15" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0004.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Explanation for the Lack of Clinical DDIs with Raloxifene Despite in Vitro MBI of CYP3A4</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structure of nondihydropyridine calcium antagonist mibefradil, a potent mechanism-based inactivator of CYP3A4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Reduction in lipophilicity as a tactic to attenuate CYP MBI liability with ketolide antibiotics.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Additional illustrations of physicochemical property manipulations to attenuate MBI of CYP enzymes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch16" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0008.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Elimination of CYP TDI Liability in the Potassium Ion Channel Opener <b>12</b> by Blocking Putative Site(s) of Bioactivation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0009.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Simultaneously abolishing CYP3A4 inactivation and induction liabilities in the insulin-like growth factor-1 receptor kinase inhibitor <b>14</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch17" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0010.jpeg" id="rightTab-gr35" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Strategy To Eliminate CYP3A4 MBI Liability in the Selective Melanocortin 4 Receptor Agonist <b>17</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch18" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0011.jpeg" id="rightTab-gr36" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Strategies To Eliminate CYP3A4 TDI by Virtue of Eliminating Reactive Diimine Formation with Oxindole-Based Focal Adhesion Kinase Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch19" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0012.jpeg" id="rightTab-gr37" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. Bioactivation of a 2-Methylindole Derivative <b>24</b> to CYP3A4-Reactive Species</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Attempts to eliminate CYP3A4 TDI by removal of metabolic soft spots and/or addition of polarity as illustrated with some renin inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Attenuating CYP MBI liability through deuterium incorporation at the metabolically labile site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Examples of structural alert-positive compounds that are not associated with CYP MBI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch20" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0016.jpeg" id="rightTab-gr38" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Differences in CYP2E1 MBI by Acetaminophen and Its Regioisomer 3′-Hydroxyacetanilide</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0017.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Postulated binding poses of CYP3A4 MBI: (A) bergamottin, (B) raloxifene, (C) zafirlukast, (D) <b>36</b>, (E) <b>37</b>, and (F) domperidone that can lead to RM formation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0018.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Relationship between the <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> ratio relative to unbound plasma concentration [I]. Lines represent parameters that would be expected to result in a 2-fold interaction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch21" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0019.jpeg" id="rightTab-gr39" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Metabolism of Ethinyl Estradiol into CYP3A4- and Protein-Reactive Metabolites</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/medium/jm-2012-00065h_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0020.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Suggested strategies for dealing with time-dependent CYP inactivation in drug discovery.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-11/jm300065h/production/images/large/jm-2012-00065h_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300065h&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i54">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28175" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28175" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 179 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Guengerich, F. P.</span><span> </span><span class="NLM_article-title">Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">611</span><span class="NLM_x">–</span> <span class="NLM_lpage">650</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx0002583" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjt1Wnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2001&pages=611-650&author=F.+P.+Guengerich&title=Common+and+uncommon+cytochrome+P450+reactions+related+to+metabolism+and+chemical+toxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Common and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity</span></div><div class="casAuthors">Guengerich, F. Peter</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">611-650</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 417 refs.  Cytochrome P 450 enzymes catalyze a variety of reactions and convert chems. to potentially reactive products as well as make compds. less toxic.  Most of the P 450 reactions are oxidns.  The majority of these can be rationalized in the context of an FeO3+ intermediate and odd electron abstraction/rebound mechanisms; however, other iron-oxygen complexes are possible and alternate chemistries can be considered.  Another issue regarding P 450-catalyzed reactions is the delineation of rate-limiting steps in the catalytic cycle and the contribution to reaction selectivity.  In addn. to the rather classical oxidns., P 450s also catalyze less generally discussed reactions including redn., desatn., ester cleavage, ring expansion, ring formation, aldehyde scission, dehydration, ipso attack, one-electron oxidn., coupling reactions, rearrangement of fatty acid and prostaglandin hydroperoxides, and phospholipase activity.  Most of these reactions are rationalized in the context of high-valent iron-oxygen intermediates and Fe2+ redns., but others are not and may involve acid-base catalysis.  Some of these transformations are involved in the bioactivation and detoxication of xenobiotic chems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoznx-XkuM1OrVg90H21EOLACvtfcHk0liF7iL_j2oEWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjt1Wnsbs%253D&md5=9398501ce17beed3fc0bad4840187eea</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Ftx0002583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx0002583%26sid%3Dliteratum%253Aachs%26aulast%3DGuengerich%26aufirst%3DF.%2BP.%26atitle%3DCommon%2520and%2520uncommon%2520cytochrome%2520P450%2520reactions%2520related%2520to%2520metabolism%2520and%2520chemical%2520toxicity%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2001%26volume%3D14%26spage%3D611%26epage%3D650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Grimm, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einolf, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomeir, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seibert., E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skordos, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonn, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Horn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">The conduct of in vitro studies to address time-dependent inhibition of drug metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1355</span><span class="NLM_x">–</span> <span class="NLM_lpage">1370</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1355-1370&author=S.+W.+Grimmauthor=H.+J.+Einolfauthor=S.+D.+Hallauthor=K.+Heauthor=H.+K.+Limauthor=K.+H.+Lingauthor=C.+Luauthor=A.+A.+Nomeirauthor=E.+Seibert.author=K.+W.+Skordosauthor=G.+R.+Tonnauthor=R.+Van+Hornauthor=R.+W.+Wangauthor=Y.+N.+Wongauthor=T.+J.+Yangauthor=R.+S.+Obach&title=The+conduct+of+in+vitro+studies+to+address+time-dependent+inhibition+of+drug+metabolizing+enzymes%3A+a+perspective+of+the+pharmaceutical+research+and+manufacturers+of+America"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrimm%26aufirst%3DS.%2BW.%26aulast%3DEinolf%26aufirst%3DH.%2BJ.%26aulast%3DHall%26aufirst%3DS.%2BD.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DLim%26aufirst%3DH.%2BK.%26aulast%3DLing%26aufirst%3DK.%2BH.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DNomeir%26aufirst%3DA.%2BA.%26aulast%3DSeibert.%26aufirst%3DE.%26aulast%3DSkordos%26aufirst%3DK.%2BW.%26aulast%3DTonn%26aufirst%3DG.%2BR.%26aulast%3DVan%2BHorn%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DR.%2BW.%26aulast%3DWong%26aufirst%3DY.%2BN.%26aulast%3DYang%26aufirst%3DT.%2BJ.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DThe%2520conduct%2520of%2520in%2520vitro%2520studies%2520to%2520address%2520time-dependent%2520inhibition%2520of%2520drug%2520metabolizing%2520enzymes%253A%2520a%2520perspective%2520of%2520the%2520pharmaceutical%2520research%2520and%2520manufacturers%2520of%2520America%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1355%26epage%3D1370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Parkinson, A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazmi, F</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yerino, P</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paris, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holsapple, J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otradovec, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, B. W.</span><span> </span><span class="NLM_article-title">An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1370</span><span class="NLM_x">–</span> <span class="NLM_lpage">1387</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1370-1387&author=A+Parkinsonauthor=F+Kazmiauthor=D.+B.+Buckleyauthor=P+Yerinoauthor=B.+L.+Parisauthor=J+Holsappleauthor=P.+Torenauthor=S.+M.+Otradovecauthor=B.+W.+Ogilvie&title=An+evaluation+of+the+dilution+method+for+identifying+metabolism-dependent+inhibitors+of+cytochrome+P450+enzymes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParkinson%26aufirst%3DA%26aulast%3DKazmi%26aufirst%3DF%26aulast%3DBuckley%26aufirst%3DD.%2BB.%26aulast%3DYerino%26aufirst%3DP%26aulast%3DParis%26aufirst%3DB.%2BL.%26aulast%3DHolsapple%26aufirst%3DJ%26aulast%3DToren%26aufirst%3DP.%26aulast%3DOtradovec%26aufirst%3DS.%2BM.%26aulast%3DOgilvie%26aufirst%3DB.%2BW.%26atitle%3DAn%2520evaluation%2520of%2520the%2520dilution%2520method%2520for%2520identifying%2520metabolism-dependent%2520inhibitors%2520of%2520cytochrome%2520P450%2520enzymes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1370%26epage%3D1387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Hollenberg, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, U. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bumpus, N. N.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of human cytochromes P450s: experimental characterization, reactive intermediates, and clinical implications</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">205</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx7002504" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=189-205&author=P.+F.+Hollenbergauthor=U.+M.+Kentauthor=N.+N.+Bumpus&title=Mechanism-based+inactivation+of+human+cytochromes+P450s%3A+experimental+characterization%2C+reactive+intermediates%2C+and+clinical+implications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Ftx7002504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx7002504%26sid%3Dliteratum%253Aachs%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26aulast%3DKent%26aufirst%3DU.%2BM.%26aulast%3DBumpus%26aufirst%3DN.%2BN.%26atitle%3DMechanism-based%2520inactivation%2520of%2520human%2520cytochromes%2520P450s%253A%2520experimental%2520characterization%252C%2520reactive%2520intermediates%252C%2520and%2520clinical%2520implications%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D189%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Berry, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span> </span><span class="NLM_article-title">An examination of IC<sub>50</sub> and IC<sub>50</sub>-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes</span> <span class="citation_source-journal">Drug Metab. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2174%2F187231208783478407" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=51-59&author=L.+M.+Berryauthor=Z.+Zhao&title=An+examination+of+IC50+and+IC50-shift+experiments+in+assessing+time-dependent+inhibition+of+CYP3A4%2C+CYP2D6+and+CYP2C9+in+human+liver+microsomes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2174%2F187231208783478407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231208783478407%26sid%3Dliteratum%253Aachs%26aulast%3DBerry%26aufirst%3DL.%2BM.%26aulast%3DZhao%26aufirst%3DZ.%26atitle%3DAn%2520examination%2520of%2520IC50%2520and%2520IC50-shift%2520experiments%2520in%2520assessing%2520time-dependent%2520inhibition%2520of%2520CYP3A4%252C%2520CYP2D6%2520and%2520CYP2C9%2520in%2520human%2520liver%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2008%26volume%3D21%26spage%3D51%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Venkatakrishnan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Drug–drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">–</span> <span class="NLM_lpage">462</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2174%2F138920007780866861" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=17584016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsl2jt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=449-462&author=K.+Venkatakrishnanauthor=R.+S.+Obach&title=Drug%E2%80%93drug+interactions+via+mechanism-based+cytochrome+P450+inactivation%3A+points+to+consider+for+risk+assessment+from+in+vitro+data+and+clinical+pharmacologic+evaluation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation</span></div><div class="casAuthors">Venkatakrishnan, Karthik; Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">449-462</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This commentary discusses the approaches to, and key considerations in the in vitro-in vivo extrapolation of drug-drug interactions (DDI) resulting from mechanism-based inactivation (MBI) of cytochrome P 450 (CYP) enzymes and clin. pharmacol. implications.  In vitro kinetic assessment and prediction of DDI produced via reversible inhibition and MBI rely on operationally and conceptually distinct approaches.  DDI risk assessment for inactivators requires estn. of maximal inactivation rate (kinact) and inactivator potency (KI) in vitro, that need to be considered in context of the biol. turnover rate of the enzyme (kdeg) and clin. exposures of the inactivator (I), resp., to predict interaction magnitude.  Risk assessment cannot be performed by a simple comparison of inactivator potency against in vivo exposure since inactivation is both concn. and time-dependent.  MBI contour plots tracking combinations of I:KI and kinact:kdeg resulting in identical fold-redns. in intrinsic clearance are proposed as a useful framework for DDI risk assessment.  Addnl., substrate-specific factors like fraction of the total clearance of the object drug via the enzyme being inactivated (fm(CYP)) and the bioavailability fraction across the intestine for CYP3A substrates (FG) are important determinants of interaction magnitude.  Sensitivity anal. of predicted DDI magnitude to uncertainty in input parameters is recommended to inform confidence in predictions.  The time course of reversal of DDI resulting from CYP inactivation is detd. by the half-life of the enzyme which is an important consideration in the design and interpretation of clin. DDI studies with inactivators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu6S_D7BcNBrVg90H21EOLACvtfcHk0lhPtEYS-tuTSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsl2jt7c%253D&md5=d7ff970e763ca6bbae55db576d92b5e0</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2174%2F138920007780866861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920007780866861%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatakrishnan%26aufirst%3DK.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DDrug%25E2%2580%2593drug%2520interactions%2520via%2520mechanism-based%2520cytochrome%2520P450%2520inactivation%253A%2520points%2520to%2520consider%2520for%2520risk%2520assessment%2520from%2520in%2520vitro%2520data%2520and%2520clinical%2520pharmacologic%2520evaluation%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2007%26volume%3D8%26spage%3D449%26epage%3D462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Mao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohutsky, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrelson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrighton, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. D.</span><span> </span><span class="NLM_article-title">Prediction of CYP-mediated drug–drug interactions using cryopreserved human hepatocytes suspended in human plasma</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=591-602&author=J.+Maoauthor=M.+A.+Mohutskyauthor=J.+P.+Harrelsonauthor=S.+A.+Wrightonauthor=S.+D.+Hall&title=Prediction+of+CYP-mediated+drug%E2%80%93drug+interactions+using+cryopreserved+human+hepatocytes+suspended+in+human+plasma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DJ.%26aulast%3DMohutsky%26aufirst%3DM.%2BA.%26aulast%3DHarrelson%26aufirst%3DJ.%2BP.%26aulast%3DWrighton%26aufirst%3DS.%2BA.%26aulast%3DHall%26aufirst%3DS.%2BD.%26atitle%3DPrediction%2520of%2520CYP-mediated%2520drug%25E2%2580%2593drug%2520interactions%2520using%2520cryopreserved%2520human%2520hepatocytes%2520suspended%2520in%2520human%2520plasma%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D591%26epage%3D602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Grime, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bird, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, R. J.</span><span> </span><span class="NLM_article-title">Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug–drug interaction prediction methods</span> <span class="citation_source-journal">Eur. J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">191</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.ejps.2008.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=19013237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVWhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2009&pages=175-191&author=K.+H.+Grimeauthor=J.+Birdauthor=D.+Fergusonauthor=R.+J.+Riley&title=Mechanism-based+inhibition+of+cytochrome+P450+enzymes%3A+an+evaluation+of+early+decision+making+in+vitro+approaches+and+drug%E2%80%93drug+interaction+prediction+methods"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inhibition of cytochrome P450 enzymes: An evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods</span></div><div class="casAuthors">Grime, Kenneth H.; Bird, James; Ferguson, Douglas; Riley, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">175-191</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The ability to use in vitro human cytochrome P 450 (CYP) time-dependent inhibition (TDI) data for in vivo drug-drug interaction (DDI) predictions should be viewed as a prerequisite to generating the data.  Important terms in making such predictions are kinact and KI but first-line screening assays typically involve characterization of an IC50 value or a time dependent shift in IC50.  In the work presented here, two key screening methods from the scientific literature were appraised both in terms of practicality and quality of kinact/KI estn.  The utility of TDI screening data in DDI predictions was investigated and particular ref. given to a simple DDI simulation model based on a spreadsheet that calcs. the systemic exposure of unbound inhibitor drug following the input of human pharmacokinetic parameters.  Using several clin. mechanism-based CYP DDI examples, the effectiveness of the approach was assessed and compared to other widely available approaches (a simple algorithm that employs a single in vivo unbound inhibitor concn., a seven-compartment physiol. based pharmacokinetic (PBPK) model that defines the extent of interaction as a result of hepatic inhibitor concns. and the com. available software SimCYP).  All the methods gave predictions that compared favorably with the obsd. DDIs, but various advantages and disadvantages of each were also given full consideration.  The new model facilitates rapid sensitivity anal. (parameters can be easily input and altered to give a visual representation of the impact on the active enzyme concn.) and it was therefore used to derive "rules of thumb" demonstrating the relationship between extent of DDI, time-dependent IC50 and dose for typical acidic and basic drugs.  Addnl., a TDI decision tree linking into reactive metabolite investigations is proposed for use in a Drug Discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM7p75JgXkwLVg90H21EOLACvtfcHk0lhPtEYS-tuTSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVWhtQ%253D%253D&md5=1621091a7cf8f8909e2e8d0c802fdfd0</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2008.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2008.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DGrime%26aufirst%3DK.%2BH.%26aulast%3DBird%26aufirst%3DJ.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26atitle%3DMechanism-based%2520inhibition%2520of%2520cytochrome%2520P450%2520enzymes%253A%2520an%2520evaluation%2520of%2520early%2520decision%2520making%2520in%2520vitro%2520approaches%2520and%2520drug%25E2%2580%2593drug%2520interaction%2520prediction%2520methods%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2009%26volume%3D36%26spage%3D175%26epage%3D191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Mayhew, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. D.</span><span> </span><span class="NLM_article-title">An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1031</span><span class="NLM_x">–</span> <span class="NLM_lpage">1037</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=1031-1037&author=B.+S.+Mayhewauthor=D.+R.+Jonesauthor=S.+D.+Hall&title=An+in+vitro+model+for+predicting+in+vivo+inhibition+of+cytochrome+P450+3A4+by+metabolic+intermediate+complex+formation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMayhew%26aufirst%3DB.%2BS.%26aulast%3DJones%26aufirst%3DD.%2BR.%26aulast%3DHall%26aufirst%3DS.%2BD.%26atitle%3DAn%2520in%2520vitro%2520model%2520for%2520predicting%2520in%2520vivo%2520inhibition%2520of%2520cytochrome%2520P450%25203A4%2520by%2520metabolic%2520intermediate%2520complex%2520formation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2000%26volume%3D28%26spage%3D1031%26epage%3D1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Li, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balani, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, L. S.</span><span> </span><span class="NLM_article-title">A refined cytochrome P540 IC<sub>50</sub> shift assay for reliably identifying CYP3A time-dependent inhibitors</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1054</span><span class="NLM_x">–</span> <span class="NLM_lpage">1057</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1054-1057&author=P.+Liauthor=C.+Luauthor=S.+K.+Balaniauthor=L.+S.+Gan&title=A+refined+cytochrome+P540+IC50+shift+assay+for+reliably+identifying+CYP3A+time-dependent+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DP.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DBalani%26aufirst%3DS.%2BK.%26aulast%3DGan%26aufirst%3DL.%2BS.%26atitle%3DA%2520refined%2520cytochrome%2520P540%2520IC50%2520shift%2520assay%2520for%2520reliably%2520identifying%2520CYP3A%2520time-dependent%2520inhibitors%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1054%26epage%3D1057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Sekiguchi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashida, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nabuchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aso, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishigai, M.</span><span> </span><span class="NLM_article-title">Prediction of drug–drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition</span> <span class="citation_source-journal">Drug Metab. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">500</span><span class="NLM_x">–</span> <span class="NLM_lpage">510</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2133%2Fdmpk.24.500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=20045985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt12iuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2009&pages=500-510&author=N.+Sekiguchiauthor=A.+Higashidaauthor=M.+Katoauthor=Y.+Nabuchiauthor=T.+Mitsuiauthor=K.+Takanashiauthor=Y.+Asoauthor=M.+Ishigai&title=Prediction+of+drug%E2%80%93drug+interactions+based+on+time-dependent+inhibition+from+high+throughput+screening+of+cytochrome+P450+3A4+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition</span></div><div class="casAuthors">Sekiguchi, Nobuo; Higashida, Atsuko; Kato, Motohiro; Nabuchi, Yoshiaki; Mitsui, Tetsuya; Takanashi, Kenji; Aso, Yoshinori; Ishigai, Masaki</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">500-510</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society for the Study of Xenobiotics</span>)
        </div><div class="casAbstract">A method of assessing the risk of drug-drug interaction (DDI) caused by mechanism-based inhibition (MBI) was developed for early-stage drug development using cytochrome P 450 (CYP) 3A4 inhibition screening data.  CYP3A4 inhibition was evaluated using a fluorescent substrate with or without preincubation contg. an inhibitor.  The results showed that five well-known mechanism-based inhibitors, but not the competitive inhibitor ketoconazole, had lower IC50 after preincubation, suggesting the utility of the IC50 shift by preincubation to discern mechanism-based inhibitors.  A method to approx. predict the change in the area under the concn.-time curve (AUC) of a co-administered drug by MBI was found using IC50 shift data and the unbound mean plasma concn. of the inhibitor.  From our predictions of change in the AUC for 38 drugs using this method, all mechanism-based inhibitors causing change in the AUC of more than 200% were predicted to be high risk.  In conclusion, our method provides a simple assessment of the risk of DDI from mechanism-based inhibitors, esp. in the early stages of drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7M6ArbDpwt7Vg90H21EOLACvtfcHk0ljoEtg3AKEAjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt12iuro%253D&md5=c6e4c4d3dcd3b5ce125ed2f83b706110</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2133%2Fdmpk.24.500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2133%252Fdmpk.24.500%26sid%3Dliteratum%253Aachs%26aulast%3DSekiguchi%26aufirst%3DN.%26aulast%3DHigashida%26aufirst%3DA.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DNabuchi%26aufirst%3DY.%26aulast%3DMitsui%26aufirst%3DT.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DAso%26aufirst%3DY.%26aulast%3DIshigai%26aufirst%3DM.%26atitle%3DPrediction%2520of%2520drug%25E2%2580%2593drug%2520interactions%2520based%2520on%2520time-dependent%2520inhibition%2520from%2520high%2520throughput%2520screening%2520of%2520cytochrome%2520P450%25203A4%2520inhibition%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2009%26volume%3D24%26spage%3D500%26epage%3D510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Bertelsen, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatakrishnan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Moltke, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenblatt, D. J.</span><span> </span><span class="NLM_article-title">Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1124%2Fdmd.31.3.289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=12584155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsFKlt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=289-293&author=K.+M.+Bertelsenauthor=K.+Venkatakrishnanauthor=L.+L.+Von+Moltkeauthor=R.+S.+Obachauthor=D.+J.+Greenblatt&title=Apparent+mechanism-based+inhibition+of+human+CYP2D6+in+vitro+by+paroxetine%3A+comparison+with+fluoxetine+and+quinidine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine</span></div><div class="casAuthors">Bertelsen, Kirk M.; Venkatakrishnan, Karthik; Von Moltke, Lisa L.; Obach, R. Scott; Greenblatt, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">289-293</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Paroxetine, a selective serotonin reuptake inhibitor, is a potent inhibitor of cytochrome P 450 2D6 (CYP2D6) activity, but the mechanism of inhibition is not established.  To det. whether preincubation affects the inhibition of human liver microsomal dextromethorphan demethylation activity by paroxetine, we used a two-step incubation scheme in which all of the enzyme assay components, minus substrate, are preincubated with paroxetine.  The kinetic parameters of inhibition were also estd. by varying the time of preincubation as well as the concn. of inhibitor.  From these data, a Kitz-Wilson plot was constructed, allowing the estn. of both an apparent inactivator concn. required for half-maximal inactivation (KI) and the maximal rate const. of inactivation (KINACT) value for this interaction.  Preincubation of paroxetine with human liver microsomes caused an approx. 8-fold redn. in the IC50 value (0.34 vs. 2.54 μM).  Time-dependent inhibition was demonstrated with an apparent KI of 4.85 μM and an apparent KINACT value of 0.17 min-1.  Spectral scanning of CYP2D6 with paroxetine yielded an increase in absorbance at 456 nm suggesting paroxetine inactivation of CYP2D6 via the formation of a metabolite intermediate complex.  This pattern is consistent with the metab. of the methylenedioxy substituent in paroxetine; such substituents may produce mechanism-based inactivation of cytochrome P 450 enzymes.  In contrast, quinidine and fluoxetine, both of which are inhibitors of CYP2D6 activity, did not exhibit a preincubation-dependent increase in inhibitory potency.  These data are consistent with mechanism-based inhibition of CYP2D6 by paroxetine but not by quinidine or fluoxetine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj8LvS55oHs7Vg90H21EOLACvtfcHk0ljoEtg3AKEAjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsFKlt7Y%253D&md5=2336fbc058e49e7b530562809c62ba09</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1124%2Fdmd.31.3.289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.31.3.289%26sid%3Dliteratum%253Aachs%26aulast%3DBertelsen%26aufirst%3DK.%2BM.%26aulast%3DVenkatakrishnan%26aufirst%3DK.%26aulast%3DVon%2BMoltke%26aufirst%3DL.%2BL.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DGreenblatt%26aufirst%3DD.%2BJ.%26atitle%3DApparent%2520mechanism-based%2520inhibition%2520of%2520human%2520CYP2D6%2520in%2520vitro%2520by%2520paroxetine%253A%2520comparison%2520with%2520fluoxetine%2520and%2520quinidine%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2003%26volume%3D31%26spage%3D289%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, T. S.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure–activity relationships and relationship to clinical drug–drug interactions and idiosyncratic adverse drug reactions</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2174%2F138920007780866807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=17584015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsl2jt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=407-447&author=A.+S.+Kalgutkarauthor=R.+S.+Obachauthor=T.+S.+Maurer&title=Mechanism-based+inactivation+of+cytochrome+P450+enzymes%3A+chemical+mechanisms%2C+structure%E2%80%93activity+relationships+and+relationship+to+clinical+drug%E2%80%93drug+interactions+and+idiosyncratic+adverse+drug+reactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions</span></div><div class="casAuthors">Kalgutkar, Amit S.; Obach, R. Scott; Maurer, Tristan S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">407-447</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytochrome P 450 constitute a superfamily of heme-contg. enzymes that catalyze the oxidative biotransformation of structurally diverse xenobiotics including drugs.  Inhibition of P 450 enzymes is by far the most common mechanism which can lead to DDIs.  P 450 inhibition can be categorized as reversible (competitive or non-competitive) or irreversible (mechanism-based inactivation).  Mechanism-based P 450 inactivation usually involves bioactivation of the xenobiotic to a reactive intermediate, which covalently modifies an active site amino acid residue and/or coordinates to the heme prosthetic group.  Covalent modification of P 450 enzymes can also lead to hapten formation and can in some cases trigger an autoimmune response resulting in toxicol. consequences.  Compared to reversible inhibition, irreversible inhibition more frequently results in unfavorable DDIs as the inactivated P 450 enzyme has to be replaced by newly synthesized protein.  For these reasons, most drug metab. groups within pharmaceutical companies have well-established screening paradigms to assess mechanism-based inactivation of major human P 450 enzymes by new chem. entities followed by indepth mechanistic studies to elucidate the mechanism of P 450 inactivation when a pos. finding is discerned.  A deeper understanding of the process leading to enzyme inactivation by drug candidates can lead to rational chem. intervention strategies to circumvent the P 450 inactivation/bioactivation liability.  Apart from structure-activity relationship studies, methodol. to predict the magnitude of in vivo metabolic DDIs using in vitro P 450 inactivation data and predicted human pharmacokinetics of the candidate drug also exists and can be utilized to project the extent of clin. DDIs against P 450 enzyme-specific substrates.  In this review, a comprehensive anal. of the biochem. basis and known structure-activity relationships for P 450 inactivation by xenobiotics is described.  In addn., the current state-of-the-art of the methodol. used in predicting the magnitude of DDIs using in vitro P 450 inactivation data and human pharmacokinetic parameters is discussed in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV8akoVDkMzrVg90H21EOLACvtfcHk0ljoEtg3AKEAjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsl2jt7Y%253D&md5=f2ee4172b6165268710c10dcc32fecb4</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F138920007780866807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920007780866807%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26atitle%3DMechanism-based%2520inactivation%2520of%2520cytochrome%2520P450%2520enzymes%253A%2520chemical%2520mechanisms%252C%2520structure%25E2%2580%2593activity%2520relationships%2520and%2520relationship%2520to%2520clinical%2520drug%25E2%2580%2593drug%2520interactions%2520and%2520idiosyncratic%2520adverse%2520drug%2520reactions%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2007%26volume%3D8%26spage%3D407%26epage%3D447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Lin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, A. Y.</span><span> </span><span class="NLM_article-title">Inhibition and induction of cytochrome P450 and the clinical implications</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">390</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2165%2F00003088-199835050-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=9839089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK1cXnvVeqtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1998&pages=361-390&author=J.+H.+Linauthor=A.+Y.+Lu&title=Inhibition+and+induction+of+cytochrome+P450+and+the+clinical+implications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition and induction of cytochrome P450 and the clinical implications</span></div><div class="casAuthors">Lin, Jiunn H.; Lu, Anthony Y. H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-390</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review with 192 refs.  The cytochrome P450s (CYPs) constitute a superfamily of isoforms that play an important role in the oxidative metab. of drugs.  Each CYP isoform possesses a characteristic broad spectrum of catalytic activities of substrates.  Whenever 2 or more drugs are administered concurrently, the possibility of drug interactions exists.  The ability of a single CYP to metabolize multiple substrates is responsible for a large no. of documented drug interactions assocd. with CYP inhibition.  In addn., drug interactions can also occur as a result of the induction of several human CYPs following long term drug treatment.  The mechanisms of CYP inhibition can be divided into 3 categories: (a) reversible inhibition; (b) quasi-irreversible inhibition; and (c) irreversible inhibition.  In mechanistic terms, reversible interactions arise as a result of competition at the CYP active site and probably involve only the first step of the CYP catalytic cycle.  On the other hand, drugs that act during and subsequent to the oxygen transfer step are generally irreversible or quasi-irreversible inhibitors.  Irreversible and quasi-irreversible inhibition require at least one cycle of the CYP catalytic process.  Because human liver samples and recombinant human CYPs are now readily available, in vitro systems have been used as screening tools to predict the potential for in vivo drug interaction.  Although it is easy to det. in vitro metabolic drug interactions, the proper interpretation and extrapolation of in vitro interaction data to in vivo situations require a good understanding of pharmacokinetic principles.  From the viewpoint of drug therapy, to avoid potential drug-drug interactions, it is desirable to develop a new drug candidate that is not a potent CYP inhibitor or inducer and the metab. of which is not readily inhibited by other drugs.  In reality, drug interaction by mutual inhibition between drugs is almost inevitable, because CYP-mediated metab. represents a major route of elimination of many drugs, which can compete for the same CYP enzyme.  The clin. significance of a metabolic drug interaction depends on the magnitude of the change in the concn. of active species (parent drug and/or active metabolites) at the site of pharmacol. action and the therapeutic index of the drug.  The smaller the difference between toxic and effective concn., the greater the likelihood that a drug interaction will have serious clin. consequences.  Thus, careful evaluation of potential drug interactions of a new drug candidate during the early stage of drug development is essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxdqTupUCBbLVg90H21EOLACvtfcHk0ljZKBKqmTcfsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvVeqtLo%253D&md5=18993123e2cdad5517962664e986a5b4</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2165%2F00003088-199835050-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199835050-00003%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DLu%26aufirst%3DA.%2BY.%26atitle%3DInhibition%2520and%2520induction%2520of%2520cytochrome%2520P450%2520and%2520the%2520clinical%2520implications%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1998%26volume%3D35%26spage%3D361%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Franklin, M. R.</span><span> </span><span class="NLM_article-title">Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">206</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">573</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=206&publication_year=1991&pages=559-573&author=M.+R.+Franklin&title=Cytochrome+P450+metabolic+intermediate+complexes+from+macrolide+antibiotics+and+related+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFranklin%26aufirst%3DM.%2BR.%26atitle%3DCytochrome%2520P450%2520metabolic%2520intermediate%2520complexes%2520from%2520macrolide%2520antibiotics%2520and%2520related%2520compounds%26jtitle%3DMethods%2520Enzymol.%26date%3D1991%26volume%3D206%26spage%3D559%26epage%3D573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Pessayre, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konstantinova-Mitcheva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Descatoire, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobert, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wandscheer, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Level, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benhamou, J.-P.</span><span> </span><span class="NLM_article-title">Hypo activity of cytochrome P-450 after triacetyloleandomycin administration</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1981&pages=559&author=D.+Pessayreauthor=M.+Konstantinova-Mitchevaauthor=V.+Descatoireauthor=B.+Cobertauthor=J.-C.+Wandscheerauthor=R.+Levelauthor=G.+Feldmannauthor=D.+Mansuyauthor=J.-P.+Benhamou&title=Hypo+activity+of+cytochrome+P-450+after+triacetyloleandomycin+administration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPessayre%26aufirst%3DD.%26aulast%3DKonstantinova-Mitcheva%26aufirst%3DM.%26aulast%3DDescatoire%26aufirst%3DV.%26aulast%3DCobert%26aufirst%3DB.%26aulast%3DWandscheer%26aufirst%3DJ.-C.%26aulast%3DLevel%26aufirst%3DR.%26aulast%3DFeldmann%26aufirst%3DG.%26aulast%3DMansuy%26aufirst%3DD.%26aulast%3DBenhamou%26aufirst%3DJ.-P.%26atitle%3DHypo%2520activity%2520of%2520cytochrome%2520P-450%2520after%2520triacetyloleandomycin%2520administration%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1981%26volume%3D30%26spage%3D559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Murray, M.</span><span> </span><span class="NLM_article-title">Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2174%2F1389200003339270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=11467081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1Whurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2000&pages=67-84&author=M.+Murray&title=Mechanisms+of+inhibitory+and+regulatory+effects+of+methylenedioxyphenyl+compounds+on+cytochrome+P450-dependent+drug+oxidation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation</span></div><div class="casAuthors">Murray, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-84</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with 110 refs.  Cytochrome P 450 (CYP) enzymes catalyze the oxidative conversion of drugs and other lipophilic compds. to hydrophilic metabolites.  Thus, CYPs play a dominant role in the elimination of drugs from the body.  Inhibitory interactions occur when drugs compete for oxidn. by specific CYPs, whereas certain drugs increase the capacity for oxidative biotransformation by inducing the synthesis of new CYPs.  Methylenedioxyphenyl (MDP) compds. have been widely employed as com. important pesticide synergists and a no. of derivs. are found in oils and spices.  MDP compds. are of considerable toxicol. significance because of their capacity to inhibit and induce CYP enzymes in mammals; some derivs. produce neurotoxic and hepatotoxic effects.  Although there are relatively few therapeutic agents of present clin. importance that possess the MDP structural feature, the synthesis and preclin. evaluation of such agents appears to be increasing.  In the context of the existing literature surrounding MDP compds. it is noteworthy that these potential drugs also elicit significant modulatory effects on CYP activities in rat and human liver.  These developments indicate the importance of understanding the chem. mechanisms by which MDPs interact with CYPs.  Thus, the presence of the MDP structure may undermine the potential clin. value of new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYAjGf6nf5ZbVg90H21EOLACvtfcHk0ljZKBKqmTcfsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1Whurs%253D&md5=dcafc824c8bcd0080d256d6dd8c50ae7</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2174%2F1389200003339270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200003339270%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DM.%26atitle%3DMechanisms%2520of%2520inhibitory%2520and%2520regulatory%2520effects%2520of%2520methylenedioxyphenyl%2520compounds%2520on%2520cytochrome%2520P450-dependent%2520drug%2520oxidation%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2000%26volume%3D1%26spage%3D67%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Wu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otton, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inaba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalow, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, E. M.</span><span> </span><span class="NLM_article-title">Interactions of amphetamine analogs with human liver CYP2D6</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1605</span><span class="NLM_x">–</span> <span class="NLM_lpage">1612</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=1605-1612&author=D.+Wuauthor=S.+V.+Ottonauthor=T.+Inabaauthor=W.+Kalowauthor=E.+M.+Sellers&title=Interactions+of+amphetamine+analogs+with+human+liver+CYP2D6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DD.%26aulast%3DOtton%26aufirst%3DS.%2BV.%26aulast%3DInaba%26aufirst%3DT.%26aulast%3DKalow%26aufirst%3DW.%26aulast%3DSellers%26aufirst%3DE.%2BM.%26atitle%3DInteractions%2520of%2520amphetamine%2520analogs%2520with%2520human%2520liver%2520CYP2D6%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1997%26volume%3D53%26spage%3D1605%26epage%3D1612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Murray, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hetnarski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, C. F.</span><span> </span><span class="NLM_article-title">Selective inhibitory interactions of alkoxymethylenedioxybenzenes towards mono-oxygenase activity in rat-hepatic microsomes</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1985&pages=369-379&author=M.+Murrayauthor=K.+Hetnarskiauthor=C.+F.+Wilkinson&title=Selective+inhibitory+interactions+of+alkoxymethylenedioxybenzenes+towards+mono-oxygenase+activity+in+rat-hepatic+microsomes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DM.%26aulast%3DHetnarski%26aufirst%3DK.%26aulast%3DWilkinson%26aufirst%3DC.%2BF.%26atitle%3DSelective%2520inhibitory%2520interactions%2520of%2520alkoxymethylenedioxybenzenes%2520towards%2520mono-oxygenase%2520activity%2520in%2520rat-hepatic%2520microsomes%26jtitle%3DXenobiotica%26date%3D1985%26volume%3D15%26spage%3D369%26epage%3D379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Grab, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz de Montellano, P. R.</span><span> </span><span class="NLM_article-title">Cytochrome P-450 inactivation by 3-alkylsydnones. Mechanistic implications of <i>n</i>-alkyl and <i>n</i>-alkenyl heme adduct formation</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4805</span><span class="NLM_x">–</span> <span class="NLM_lpage">4814</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi00413a034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1988&pages=4805-4814&author=L.+A.+Grabauthor=B.+A.+Swansonauthor=P.+R.+Ortiz+de+Montellano&title=Cytochrome+P-450+inactivation+by+3-alkylsydnones.+Mechanistic+implications+of+n-alkyl+and+n-alkenyl+heme+adduct+formation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fbi00413a034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00413a034%26sid%3Dliteratum%253Aachs%26aulast%3DGrab%26aufirst%3DL.%2BA.%26aulast%3DSwanson%26aufirst%3DB.%2BA.%26aulast%3DOrtiz%2Bde%2BMontellano%26aufirst%3DP.%2BR.%26atitle%3DCytochrome%2520P-450%2520inactivation%2520by%25203-alkylsydnones.%2520Mechanistic%2520implications%2520of%2520n-alkyl%2520and%2520n-alkenyl%2520heme%2520adduct%2520formation%26jtitle%3DBiochemistry%26date%3D1988%26volume%3D27%26spage%3D4805%26epage%3D4814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">He, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szklarz, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halpert, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correia, M. A.</span><span> </span><span class="NLM_article-title">Secobarbital-mediated inactivation of cytochrome P450 2B1 and its active site mutants. Partitioning between heme and protein alkylation and epoxidation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">25864</span><span class="NLM_x">–</span> <span class="NLM_lpage">25872</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=25864-25872&author=K.+Heauthor=Y.+A.+Heauthor=G.+D.+Szklarzauthor=J.+R.+Halpertauthor=M.+A.+Correia&title=Secobarbital-mediated+inactivation+of+cytochrome+P450+2B1+and+its+active+site+mutants.+Partitioning+between+heme+and+protein+alkylation+and+epoxidation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DK.%26aulast%3DHe%26aufirst%3DY.%2BA.%26aulast%3DSzklarz%26aufirst%3DG.%2BD.%26aulast%3DHalpert%26aufirst%3DJ.%2BR.%26aulast%3DCorreia%26aufirst%3DM.%2BA.%26atitle%3DSecobarbital-mediated%2520inactivation%2520of%2520cytochrome%2520P450%25202B1%2520and%2520its%2520active%2520site%2520mutants.%2520Partitioning%2520between%2520heme%2520and%2520protein%2520alkylation%2520and%2520epoxidation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D25864%26epage%3D25872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Brown, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford-Hutchinson, A. W.</span><span> </span><span class="NLM_article-title">The destruction of cytochrome P-450 by alclofenac: possible involvement of an epoxide metabolite</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">199</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1982&pages=195-199&author=L.+M.+Brownauthor=A.+W.+Ford-Hutchinson&title=The+destruction+of+cytochrome+P-450+by+alclofenac%3A+possible+involvement+of+an+epoxide+metabolite"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DL.%2BM.%26aulast%3DFord-Hutchinson%26aufirst%3DA.%2BW.%26atitle%3DThe%2520destruction%2520of%2520cytochrome%2520P-450%2520by%2520alclofenac%253A%2520possible%2520involvement%2520of%2520an%2520epoxide%2520metabolite%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1982%26volume%3D31%26spage%3D195%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Ortiz de Montellano, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, M. D.</span><span> </span><span class="NLM_article-title">Free radical pathways in the in vitro hepatic metabolism of phenelzine</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1987&pages=213-219&author=P.+R.+Ortiz+de+Montellanoauthor=M.+D.+Watanabe&title=Free+radical+pathways+in+the+in+vitro+hepatic+metabolism+of+phenelzine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrtiz%2Bde%2BMontellano%26aufirst%3DP.%2BR.%26aulast%3DWatanabe%26aufirst%3DM.%2BD.%26atitle%3DFree%2520radical%2520pathways%2520in%2520the%2520in%2520vitro%2520hepatic%2520metabolism%2520of%2520phenelzine%26jtitle%3DMol.%2520Pharmacol.%26date%3D1987%26volume%3D31%26spage%3D213%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Ortiz de Montellano, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathews, J. M.</span><span> </span><span class="NLM_article-title">Autocatalytic alkylation of the cytochrome P-450 prosthetic haem group by 1-aminobenzotriazole. Isolation of an NN-bridged benzyne–protoporphyrin IX adduct</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">195</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">764</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=1981&pages=761-764&author=P.+R.+Ortiz+de+Montellanoauthor=J.+M.+Mathews&title=Autocatalytic+alkylation+of+the+cytochrome+P-450+prosthetic+haem+group+by+1-aminobenzotriazole.+Isolation+of+an+NN-bridged+benzyne%E2%80%93protoporphyrin+IX+adduct"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrtiz%2Bde%2BMontellano%26aufirst%3DP.%2BR.%26aulast%3DMathews%26aufirst%3DJ.%2BM.%26atitle%3DAutocatalytic%2520alkylation%2520of%2520the%2520cytochrome%2520P-450%2520prosthetic%2520haem%2520group%2520by%25201-aminobenzotriazole.%2520Isolation%2520of%2520an%2520NN-bridged%2520benzyne%25E2%2580%2593protoporphyrin%2520IX%2520adduct%26jtitle%3DBiochem.%2520J.%26date%3D1981%26volume%3D195%26spage%3D761%26epage%3D764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Lightning, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trager, W. F.</span><span> </span><span class="NLM_article-title">Characterization of covalent adducts to intact cytochrome P450s by mass spectrometry</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">357</span><span class="NLM_x">, </span> <span class="NLM_fpage">296</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2002&pages=296-300&author=L.+K.+Lightningauthor=W.+F.+Trager&title=Characterization+of+covalent+adducts+to+intact+cytochrome+P450s+by+mass+spectrometry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLightning%26aufirst%3DL.%2BK.%26aulast%3DTrager%26aufirst%3DW.%2BF.%26atitle%3DCharacterization%2520of%2520covalent%2520adducts%2520to%2520intact%2520cytochrome%2520P450s%2520by%2520mass%2520spectrometry%26jtitle%3DMethods%2520Enzymol.%26date%3D2002%26volume%3D357%26spage%3D296%26epage%3D300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Halpert, J.</span><span> </span><span class="NLM_article-title">Further studies of the suicide inactivation of purified rat liver cytochrome P-450 by chloramphenicol</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">166</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1982&pages=166-172&author=J.+Halpert&title=Further+studies+of+the+suicide+inactivation+of+purified+rat+liver+cytochrome+P-450+by+chloramphenicol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHalpert%26aufirst%3DJ.%26atitle%3DFurther%2520studies%2520of%2520the%2520suicide%2520inactivation%2520of%2520purified%2520rat%2520liver%2520cytochrome%2520P-450%2520by%2520chloramphenicol%26jtitle%3DMol.%2520Pharmacol.%26date%3D1982%26volume%3D21%26spage%3D166%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Halpert, J.</span><span> </span><span class="NLM_article-title">Covalent modification of lysine during the suicide inactivation of rat liver cytochrome P-450 by chloramphenicol</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">–</span> <span class="NLM_lpage">881</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1981&pages=875-881&author=J.+Halpert&title=Covalent+modification+of+lysine+during+the+suicide+inactivation+of+rat+liver+cytochrome+P-450+by+chloramphenicol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHalpert%26aufirst%3DJ.%26atitle%3DCovalent%2520modification%2520of%2520lysine%2520during%2520the%2520suicide%2520inactivation%2520of%2520rat%2520liver%2520cytochrome%2520P-450%2520by%2520chloramphenicol%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1981%26volume%3D30%26spage%3D875%26epage%3D881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Boitier, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaune, P.</span><span> </span><span class="NLM_article-title">Cytochrome P450 as targets to autoantibodies in immune mediated diseases</span> <span class="citation_source-journal">Mol. Aspects Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=10575654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252Fkt12jug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=84-137&author=E.+Boitierauthor=P.+Beaune&title=Cytochrome+P450+as+targets+to+autoantibodies+in+immune+mediated+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochromes P450 as targets to autoantibodies in immune mediated diseases</span></div><div class="casAuthors">Boitier E; Beaune P</div><div class="citationInfo"><span class="NLM_cas:title">Molecular aspects of medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">84-137</span>
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl4mJEYwjU8ekdrW1FkXG-fW6udTcc2eZoH4G19bMvU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252Fkt12jug%253D%253D&md5=ff3a1c2e09b9737ff78f9d2611a7a1ee</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoitier%26aufirst%3DE.%26aulast%3DBeaune%26aufirst%3DP.%26atitle%3DCytochrome%2520P450%2520as%2520targets%2520to%2520autoantibodies%2520in%2520immune%2520mediated%2520diseases%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D1999%26volume%3D20%26spage%3D84%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Belloc, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauffre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaune, P. H.</span><span> </span><span class="NLM_article-title">Epitope mapping of human CYP1A2 in dihydralazine-induced autoimmune hepatitis</span> <span class="citation_source-journal">Pharmacogenetics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1097%2F00008571-199706000-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=9241657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK2sXkvFymtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=181-186&author=C.+Bellocauthor=A.+Gauffreauthor=C.+Andreauthor=P.+H.+Beaune&title=Epitope+mapping+of+human+CYP1A2+in+dihydralazine-induced+autoimmune+hepatitis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Epitope mapping of human CYP1A2 in dihydralazine-induced autoimmune hepatitis</span></div><div class="casAuthors">Belloc, Claire; Gauffre, Aline; Andre, Chantal; Beaune, Philippe H.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-186</span>CODEN:
                <span class="NLM_cas:coden">PHMCEE</span>;
        ISSN:<span class="NLM_cas:issn">0960-314X</span>.
    
            (<span class="NLM_cas:orgname">Chapman & Hall</span>)
        </div><div class="casAbstract">Dihydralazine-induced hepatitis is characterized by the presence of anti-liver microsomal (anti-LM) autoantibodies in the sera of patients.  Cytochrome P 450 1A2 (CYP1A2), involved in the metab. of dihydralazine, was shown to be a target for autoantibodies.  To investigate further the relation between drug metab. and the pathogenesis of this drug-induced autoimmune disease, and since the specificity of anti-LM autoantibodies towards CYP1A2 has been detd., the antigenic site was further localized.  By constructing fragments derived from CYP1A2 cDNA and probing the corresponding proteins with several anti-LM sera, the authors were able to define a region (amino acid 335-471) which was immunoreactive with 100% of sera.  An internal deletion in this region led to the loss of recognition by anti-LM autoantibodies, confirming that the epitope was conformational.  Epitope mapping studies had previously been performed for CYP2D6, CYP17, CYP21A2, and recently for CYP3A1 and CYP2C9.  Those data were compared with results obtained in the present study for CYP1A2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY5v4qEfIo57Vg90H21EOLACvtfcHk0ljyieW7eZgAsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkvFymtLs%253D&md5=9c684af580ccbcd50432e8e30404659e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1097%2F00008571-199706000-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00008571-199706000-00002%26sid%3Dliteratum%253Aachs%26aulast%3DBelloc%26aufirst%3DC.%26aulast%3DGauffre%26aufirst%3DA.%26aulast%3DAndre%26aufirst%3DC.%26aulast%3DBeaune%26aufirst%3DP.%2BH.%26atitle%3DEpitope%2520mapping%2520of%2520human%2520CYP1A2%2520in%2520dihydralazine-induced%2520autoimmune%2520hepatitis%26jtitle%3DPharmacogenetics%26date%3D1997%26volume%3D7%26spage%3D181%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Masubuchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horie, T.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1028</span><span class="NLM_x">–</span> <span class="NLM_lpage">1032</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx9901276" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1999&pages=1028-1032&author=Y.+Masubuchiauthor=T.+Horie&title=Mechanism-based+inactivation+of+cytochrome+P450s+1A2+and+3A4+by+dihydralazine+in+human+liver+microsomes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Ftx9901276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx9901276%26sid%3Dliteratum%253Aachs%26aulast%3DMasubuchi%26aufirst%3DY.%26aulast%3DHorie%26aufirst%3DT.%26atitle%3DMechanism-based%2520inactivation%2520of%2520cytochrome%2520P450s%25201A2%2520and%25203A4%2520by%2520dihydralazine%2520in%2520human%2520liver%2520microsomes%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1999%26volume%3D12%26spage%3D1028%26epage%3D1032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Bourdi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peter, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buters, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pohl, L. R.</span><span> </span><span class="NLM_article-title">Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1159</span><span class="NLM_x">–</span> <span class="NLM_lpage">1166</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx960083q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK28XlslOksrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1996&pages=1159-1166&author=M.+Bourdiauthor=W.+Chenauthor=R.+M.+Peterauthor=J.+L.+Martinauthor=J.+T.+Butersauthor=S.+D.+Nelsonauthor=L.+R.+Pohl&title=Human+cytochrome+P450+2E1+is+a+major+autoantigen+associated+with+halothane+hepatitis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Human Cytochrome P450 2E1 Is a Major Autoantigen Associated with Halothane Hepatitis</span></div><div class="casAuthors">Bourdi, Mohammed; Chen, Weiqiao; Peter, Raimund M.; Martin, Jackie L.; Buters, Jeroen T. M.; Nelson, Sidney D.; Pohl, Lance R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1159-1166</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Autoantibodies against specific human cytochrome P450s have been found in the sera of patients suffering from a variety of diseases, including those caused by drugs.  In the cases of tienilic acid- and dihydralazine-induced hepatitis, patients have serum autoantibodies directed against cytochromes P 450 2C9 and P 450 1A2, resp.  In the present study, we have found that 25 of 56 (45%) patients diagnosed with halothane hepatitis have autoantibodies that react with human cytochrome P 450 2E1 that was purified from a baculovirus expression system.  The autoantibodies inhibited the activity of cytochrome P 450 2E1 and appeared to be directed against mainly conformational epitopes.  In addn., because cytochrome P 450 2E1 became trifluoroacetylated when it oxidatively metabolized halothane, it is possible that the covalently altered form of cytochrome P 450 2E1 may be able to bypass the immunol. tolerance that normally exists against cytochrome P 450 2E1.  A similar mechanism may explain the formation of autoantibodies that have been found against other cellular targets of the reactive trifluoroacetyl chloride metabolite of halothane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeJPjP9U7BhLVg90H21EOLACvtfcHk0lizApUQLxmQrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlslOksrg%253D&md5=f7e3cba9321de99ed160db4f31d00e27</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Ftx960083q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx960083q%26sid%3Dliteratum%253Aachs%26aulast%3DBourdi%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DPeter%26aufirst%3DR.%2BM.%26aulast%3DMartin%26aufirst%3DJ.%2BL.%26aulast%3DButers%26aufirst%3DJ.%2BT.%26aulast%3DNelson%26aufirst%3DS.%2BD.%26aulast%3DPohl%26aufirst%3DL.%2BR.%26atitle%3DHuman%2520cytochrome%2520P450%25202E1%2520is%2520a%2520major%2520autoantigen%2520associated%2520with%2520halothane%2520hepatitis%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1996%26volume%3D9%26spage%3D1159%26epage%3D1166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Spracklin, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hankins, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thummel, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kharasch, E. D.</span><span> </span><span class="NLM_article-title">Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">400</span><span class="NLM_x">–</span> <span class="NLM_lpage">411</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=9103523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK2sXislSkurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1997&pages=400-411&author=D.+K.+Spracklinauthor=D.+C.+Hankinsauthor=J.+M.+Fisherauthor=K.+E.+Thummelauthor=E.+D.+Kharasch&title=Cytochrome+P450+2E1+is+the+principal+catalyst+of+human+oxidative+halothane+metabolism+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro</span></div><div class="casAuthors">Spracklin, Douglas K.; Hankins, Douglas C.; Fisher, Jeannine M.; Thummel, Kenneth E.; Kharasch, Evan D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">400-411</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The volatile anesthetic halothane undergoes substantial biotransformation generating metabolites that mediate hepatotoxicity.  Aerobically, halothane undergoes cytochrome P 450-catalyzed oxidn. to trifluoroacetic acid (TFA), bromide and a reactive intermediate that can acetylate liver proteins.  These protein neo-antigens stimulate an immune reaction that mediates severe hepatic necrosis ("halothane hepatitis").  This investigation identified the human P 450 isoform(s) that catalyze oxidative halothane metab.  Halothane oxidn. by human liver microsomes was assessed by TFA and bromide formation.  Eadie-Hofstee plots of TFA and bromide formation were both nonlinear, suggesting that participation of multiple P450s.  Microsomal TFA and bromide formation were inhibited 45 to 66% and 21 to 26%, resp., by the P 450 2A6 inhibitors 8-methoxypsoralen and coumarin, 84 to 90% by the P 450 2E1 inhibitor 4-methylpyrazole and 55% by diethyldithiocarbamate, an inhibitor of both P 450 2A6 and 2E1.  Selective inhibitors of P450s 1A, 2B6, 2C9/10, 2D6 and 3A4 did not affect halothane oxidn.  At satg. halothane concns. (2.4 vol%) only cDNA-expressed P 450 2A6 and 2B6 catalyzed significant rates of TFA and bromide formation, and P 450 2E1 catalyzed comparatively minimal oxidn.  Conversely, at subsaturating halothane concns. (0.30 vol%), metab. by P 450 2E1 exceeded that by P 450 2A6.  Among a panel of human liver microsomes, there were significant linear correlations between halothane oxidn. and P 450 2A6 activity and protein content at satg. halothane concns. (2.4 vol%), and a significant correlation between metabolite formation and P 450 2E1 activity (but not P 450 2A6 activity) at subsaturating concns. (0.12 vol%).  These expts. suggested P 450 2A6 and 2E1 as the predominant catalysts at satg. and subsatn. halothane concns., resp.  Further kinetic anal. using cDNA-expressed P 450 and liver microsomes clearly demonstrated that P 450 2E1 is the high affinity/low capacity isoform (Km - 0.030-0.053 vol%) and P 450 2A6 is the low affinity/high capacity isoform (Km = 9.77-1.2 vol%).  Evidence was also obtained for substrate inhibition of P 450 2E1.  The in vitro clearance ests. (Vmax/Km) for microsomal P 450 2E1 (4.3-5.7 mL/min/g) were substantially greater than those for microsomal P 450 2A6 (0.12-0.21).  These clearances, as well as rates of apparent halothane oxidn. predicted from kinetic parameters in conjunction with plasma halothane concns. measured during clin. anesthesia in humans, demonstrated that both P 450 2E1 and P 450 2A6 participate in human halothane metab., and that P 450 2E1 is the predominant catalytic isoform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9w54zCqWUiLVg90H21EOLACvtfcHk0lizApUQLxmQrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXislSkurk%253D&md5=ec8ad431b91174da9aebbd112d3b39a4</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSpracklin%26aufirst%3DD.%2BK.%26aulast%3DHankins%26aufirst%3DD.%2BC.%26aulast%3DFisher%26aufirst%3DJ.%2BM.%26aulast%3DThummel%26aufirst%3DK.%2BE.%26aulast%3DKharasch%26aufirst%3DE.%2BD.%26atitle%3DCytochrome%2520P450%25202E1%2520is%2520the%2520principal%2520catalyst%2520of%2520human%2520oxidative%2520halothane%2520metabolism%2520in%2520vitro%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D281%26spage%3D400%26epage%3D411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Osawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pohl, L. R.</span><span> </span><span class="NLM_article-title">Covalent binding of the prostheric heme to protein: a potential mechanism for the suicide inactivation of hemoproteins</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx00009a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1989&pages=131-141&author=Y.+Osawaauthor=L.+R.+Pohl&title=Covalent+binding+of+the+prostheric+heme+to+protein%3A+a+potential+mechanism+for+the+suicide+inactivation+of+hemoproteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Ftx00009a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx00009a001%26sid%3Dliteratum%253Aachs%26aulast%3DOsawa%26aufirst%3DY.%26aulast%3DPohl%26aufirst%3DL.%2BR.%26atitle%3DCovalent%2520binding%2520of%2520the%2520prostheric%2520heme%2520to%2520protein%253A%2520a%2520potential%2520mechanism%2520for%2520the%2520suicide%2520inactivation%2520of%2520hemoproteins%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1989%26volume%3D2%26spage%3D131%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Guzelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swisher, R. W.</span><span> </span><span class="NLM_article-title">Degradation of cytochrome P-450 haem by carbon tetrachloride and 2-allyl-2-isopropylacetamide in rat liver in vivo and in vitro: involvement of non-carbon monoxide-forming mechanisms</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">481</span><span class="NLM_x">–</span> <span class="NLM_lpage">489</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=1979&pages=481-489&author=P.+S.+Guzelianauthor=R.+W.+Swisher&title=Degradation+of+cytochrome+P-450+haem+by+carbon+tetrachloride+and+2-allyl-2-isopropylacetamide+in+rat+liver+in+vivo+and+in+vitro%3A+involvement+of+non-carbon+monoxide-forming+mechanisms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuzelian%26aufirst%3DP.%2BS.%26aulast%3DSwisher%26aufirst%3DR.%2BW.%26atitle%3DDegradation%2520of%2520cytochrome%2520P-450%2520haem%2520by%2520carbon%2520tetrachloride%2520and%25202-allyl-2-isopropylacetamide%2520in%2520rat%2520liver%2520in%2520vivo%2520and%2520in%2520vitro%253A%2520involvement%2520of%2520non-carbon%2520monoxide-forming%2520mechanisms%26jtitle%3DBiochem.%2520J.%26date%3D1979%26volume%3D184%26spage%3D481%26epage%3D489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Ring, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandenbranden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillespie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedding, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forgue, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckstein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrighton, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, D. L.</span><span> </span><span class="NLM_article-title">Effect of tadalafil on cytochrome P403A4-mediated clearance: studies in vitro and in vivo</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">75</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.clpt.2004.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15637532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Wr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2005&pages=63-75&author=B.+J.+Ringauthor=B.+E.+Pattersonauthor=M.+I.+Mitchellauthor=M.+Vandenbrandenauthor=J.+Gillespieauthor=A.+W.+Beddingauthor=H.+Jewellauthor=C.+D.+Payneauthor=S.+T.+Forgueauthor=J.+Ecksteinauthor=S.+A.+Wrightonauthor=D.+L.+Phillips&title=Effect+of+tadalafil+on+cytochrome+P403A4-mediated+clearance%3A+studies+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of tadalafil on cytochrome P450 3A4-mediated clearance: Studies in vitro and in vivo</span></div><div class="casAuthors">Ring, Barbara J.; Patterson, Beverley E.; Mitchell, Malcolm I.; Vandenbranden, Mark; Gillespie, Jennifer; Bedding, Alun W.; Jewell, Hayley; Payne, Christopher D.; Forgue, S. Thomas; Eckstein, James; Wrighton, Steven A.; Phillips, Diane L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-75</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Tadalafil was examd. in vitro and in vivo for its ability to affect human cytochrome P 450 (CYP) 3A-mediated metab.  Reversible and mechanism-based inhibition of CYP3A by tadalafil was examd. in human liver microsomes.  The ability of tadalafil to influence CYP3A activity was also examd. in primary cultures of human hepatocytes.  The effect of tadalafil on the pharmacokinetics of CYP3A probe substrates was evaluated in human volunteers before and after coadministration with either a single dose or multiple doses of tadalafil (10 or 20 mg).  Negligible competitive inhibition of CYP3A was obsd. in vitro.  Mechanism-based inhibition of CYP3A was detected, albeit with a low potency.  In human hepatocytes, exposure to 1 μmol/L or greater of tadalafil resulted in increased CYP3A protein expression; however, as with a combined effect of induction and inhibition, a corresponding increase in CYP3A activity did not occur.  The clin. pharmacokinetics of midazolam and lovastatin, probe substrates of CYP3A, were unaffected by up to 14 days of tadalafil administration (90% confidence intervals for the ratio of least squares means for the pharmacokinetic parameters of tadalafil were contained within the no-effect boundaries of 0.7 to 1.43).  In vitro results suggested that tadalafil would have little effect on the pharmacokinetics of drugs metabolized by CYP3A.  Clin. studies demonstrated that the pharmacokinetics of 2 different CYP3A substrates, midazolam and lovastatin, were virtually unchanged after tadalafil coadministration.  Thus therapeutic concns. of tadalafil do not produce clin. significant changes in the clearance of drugs metabolized by CYP3A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNocgzlryAnbVg90H21EOLACvtfcHk0lgSVjedlF3Dfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Wr&md5=0d7f3bf49e389fbc1266aeb531df1c6c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2004.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2004.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DRing%26aufirst%3DB.%2BJ.%26aulast%3DPatterson%26aufirst%3DB.%2BE.%26aulast%3DMitchell%26aufirst%3DM.%2BI.%26aulast%3DVandenbranden%26aufirst%3DM.%26aulast%3DGillespie%26aufirst%3DJ.%26aulast%3DBedding%26aufirst%3DA.%2BW.%26aulast%3DJewell%26aufirst%3DH.%26aulast%3DPayne%26aufirst%3DC.%2BD.%26aulast%3DForgue%26aufirst%3DS.%2BT.%26aulast%3DEckstein%26aufirst%3DJ.%26aulast%3DWrighton%26aufirst%3DS.%2BA.%26aulast%3DPhillips%26aufirst%3DD.%2BL.%26atitle%3DEffect%2520of%2520tadalafil%2520on%2520cytochrome%2520P403A4-mediated%2520clearance%253A%2520studies%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2005%26volume%3D77%26spage%3D63%26epage%3D75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Zhao, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soglia, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span> </span><span class="NLM_article-title">NADPH-dependent covalent binding of [<sup>3</sup>H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1649</span><span class="NLM_x">–</span> <span class="NLM_lpage">1657</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx700132x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSkurrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=1649-1657&author=S.+X.+Zhaoauthor=D.+K.+Dalvieauthor=J.+M.+Kellyauthor=J.+R.+Sogliaauthor=K.+S.+Frederickauthor=E.+B.+Smithauthor=R.+S.+Obachauthor=A.+S.+Kalgutkar&title=NADPH-dependent+covalent+binding+of+%5B3H%5Dparoxetine+to+human+liver+microsomes+and+S-9+fractions%3A+identification+of+an+electrophilic+quinone+metabolite+of+paroxetine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">NADPH-Dependent Covalent Binding of [3H]Paroxetine to Human Liver Microsomes and S-9 Fractions: Identification of an Electrophilic Quinone Metabolite of Paroxetine</span></div><div class="casAuthors">Zhao, Sabrina X.; Dalvie, Deepak K.; Kelly, Joan M.; Soglia, John R.; Frederick, Kosea S.; Smith, Evan B.; Obach, R. Scott; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1649-1657</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The primary pathway of clearance of the methylenedioxyphenyl-contg. compd. and selective serotonin reuptake inhibitor paroxetine in humans involves P 450 2D6-mediated demethylenation to a catechol intermediate.  The process of demethylenation also results in the mechanism-based inactivation of the P 450 isoenzyme.  While the link between P 450 2D6 inactivation and pharmacokinetic interactions of paroxetine with P 450 2D6 substrates has been firmly established, there is a disconnect in terms of paroxetine's excellent safety record despite the potential for bioactivation.  In the present study, the authors have systematically assessed the NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 prepns. in the absence and presence of cofactors of the various phase II drug-metabolizing enzymes involved in the downstream metab./detoxification of the putative paroxetine-catechol intermediate.  Incubation of [3H]paroxetine with human liver microsomes and S-9 prepns. resulted in irreversible binding of radioactive material to macromols. by a process that was NADPH-dependent.  The addn. of reduced glutathione (GSH) to the microsomal and S-9 incubations resulted in a dramatic redn. of covalent binding.  Following incubations with NADPH- and GSH-supplemented human liver microsomes and S-9, three sulfhydryl conjugates with MH+ ions at 623 Da (GS1), 779 Da (GS2), and 928 Da (GS3), resp., were detected by LC-MS/MS.  The collision-induced dissocn. spectra allowed an insight into the structure of the GSH conjugates, based on which, bioactivation pathways were proposed.  The formation of GS1 was consistent with Michael addn. of GSH to the quinone derived from two-electron oxidn. of paroxetine-catechol.  GS3 was formed by the addn. of a second mol. of GSH to the quinone species obtained via the two-electron oxidn. of GS1.  The mechanism of formation of GS2 can be rationalized via (i) further two-electron oxidn. of the catechol motif in GS3 to the ortho-quinone, (ii) loss of a glutamic acid residue from one of the adducted GSH mols., and (iii) condensation of a cysteine-NH2 with an adjacent carbonyl of the ortho-quinone to yield an ortho-benzoquinoneimine structure.  Inclusion of the catechol-O-methyltransferase cofactor S-adenosylmethionine (SAM) in S-9 incubations also dramatically reduced the covalent binding of [3H]paroxetine, a finding that was consistent with O-methylation of the paroxetine-catechol metabolite to the corresponding guaiacol regioisomers in S-9 incubations.  While the NADPH-dependent covalent binding was attenuated by GSH and SAM, these reagents did not alter paroxetine's ability to inactivate P 450 2D6, suggesting that the reactive intermediate responsible for P 450 inactivation did not leave the active site to react with other proteins.  The results of the studies indicate that in addn. to the low once-a-day dosing regimen (20 mg) of paroxetine, efficient scavenging of the catechol and quinone metabolites by SAM and GSH, resp., serves as an explanation for the excellent safety record of paroxetine despite the fact that it undergoes bioactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOXUHMcbZnN7Vg90H21EOLACvtfcHk0ljd1Cy_zOzaKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSkurrK&md5=e7d3aa749a419cc87340271eb9b839a0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Ftx700132x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx700132x%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DKelly%26aufirst%3DJ.%2BM.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DFrederick%26aufirst%3DK.%2BS.%26aulast%3DSmith%26aufirst%3DE.%2BB.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DNADPH-dependent%2520covalent%2520binding%2520of%2520%255B3H%255Dparoxetine%2520to%2520human%2520liver%2520microsomes%2520and%2520S-9%2520fractions%253A%2520identification%2520of%2520an%2520electrophilic%2520quinone%2520metabolite%2520of%2520paroxetine%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D1649%26epage%3D1657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Kaye, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haddock, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellows, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zussman, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greb, W. H.</span><span> </span><span class="NLM_article-title">A review of the metabolism and pharmacokinetics of paroxetine in man</span> <span class="citation_source-journal">Acta Psychiatr. Scand., Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">60</span><span class="NLM_x">–</span> <span class="NLM_lpage">75</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1111%2Fj.1600-0447.1989.tb07176.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=2530793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK3cXjtVWisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=1989&pages=60-75&author=C.+M.+Kayeauthor=R.+E.+Haddockauthor=P.+F.+Langleyauthor=G.+Mellowsauthor=T.+C.+Taskerauthor=B.+D.+Zussmanauthor=W.+H.+Greb&title=A+review+of+the+metabolism+and+pharmacokinetics+of+paroxetine+in+man"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A review of the metabolism and pharmacokinetics of paroxetine in man</span></div><div class="casAuthors">Kaye, C. M.; Haddock, R. E.; Langley, P. F.; Mellows, G.; Tasker, T. C. G.; Zussman, B. D.; Greb, W. H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Psychiatrica Scandinavica, Supplementum</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">60-75</span>CODEN:
                <span class="NLM_cas:coden">ASSUA6</span>;
        ISSN:<span class="NLM_cas:issn">0065-1591</span>.
    </div><div class="casAbstract">A review with 24 refs.  Paroxetine (I), a potent, selective 5-HT uptake inhibitor, is currently being developed as an antidepressant.  The pharmacokinetics of I exhibit extensive intersubject variability.  There is no correlation between plasma concns. of I and its clin. effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwnxjSPfqp-bVg90H21EOLACvtfcHk0ljd1Cy_zOzaKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXjtVWisw%253D%253D&md5=f3db814b92648388dad960a44f06721a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0447.1989.tb07176.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0447.1989.tb07176.x%26sid%3Dliteratum%253Aachs%26aulast%3DKaye%26aufirst%3DC.%2BM.%26aulast%3DHaddock%26aufirst%3DR.%2BE.%26aulast%3DLangley%26aufirst%3DP.%2BF.%26aulast%3DMellows%26aufirst%3DG.%26aulast%3DTasker%26aufirst%3DT.%2BC.%26aulast%3DZussman%26aufirst%3DB.%2BD.%26aulast%3DGreb%26aufirst%3DW.%2BH.%26atitle%3DA%2520review%2520of%2520the%2520metabolism%2520and%2520pharmacokinetics%2520of%2520paroxetine%2520in%2520man%26jtitle%3DActa%2520Psychiatr.%2520Scand.%252C%2520Suppl.%26date%3D1989%26volume%3D350%26spage%3D60%26epage%3D75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Alderman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preskorn, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenblatt, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penenberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allison, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, M.</span><span> </span><span class="NLM_article-title">Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers</span> <span class="citation_source-journal">J. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">284</span><span class="NLM_x">–</span> <span class="NLM_lpage">291</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1097%2F00004714-199708000-00008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=9241008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK2sXltlKnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=284-291&author=J.+Aldermanauthor=S.+H.+Preskornauthor=D.+J.+Greenblattauthor=W.+Harrisonauthor=D.+Penenbergauthor=J.+Allisonauthor=M.+Chung&title=Desipramine+pharmacokinetics+when+coadministered+with+paroxetine+or+sertraline+in+extensive+metabolizers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers</span></div><div class="casAuthors">Alderman, Jeffrey; Preskorn, Sheldon H.; Greenblatt, David J.; Harrison, Wilma; Penenberg, Darryl; Allison, Janet; Chung, Menger</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">284-291</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">In vitro studies have shown that fluoxetine and paroxetine are more potent inhibitors of cytochrome CYP2D6 than sertraline.  The pharmacokinetics of desipramine when coadministered with the selective serotonin reuptake inhibitors (SSRIs) paroxetine and sertraline were studied in 24 healthy male volunteers (CYP2D6 extensive metabolizers).  Desipramine (50 mg/day) was administered for 23 days in each phase of the crossover study with a 7-day drug-free period between phases.  In addn., subjects were randomly assigned to receive concomitant paroxetine (20 mg/day on days 8 through 17 followed by 30 mg/day on days 18 through 20) or sertraline (50 mg/day on days 8 through 17 and 100 mg/day on days 18 through 20).  SSRI treatments were switched between phases.  After 10 days of coadministration at the lower dose, mean desipramine max. concn. in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine vs. from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-h area under the concn.-time curve (AUC[24]) increased from 634 to 3,305 ng·h/mL (+421%) with paroxetine vs. from 611 to 838 ng·h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine vs. from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).  An approx. 10-fold increase in the Cmax and AUC(24) of paroxetine and an approx. 2-fold increase in these parameters for sertraline occurred simultaneously with the desipramine concn. changes.  Thus, when coadministered with 50 mg/day desipramine, sertraline had significantly less pharmacokinetic interaction than paroxetine with desipramine at the recommended starting dosages of 50 mg/day and 20 mg/day, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh6RcBgmPfO7Vg90H21EOLACvtfcHk0lhHlTq76bExHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXltlKnu70%253D&md5=fb990d687c76c792bbd2b39f9ff140e9</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1097%2F00004714-199708000-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00004714-199708000-00008%26sid%3Dliteratum%253Aachs%26aulast%3DAlderman%26aufirst%3DJ.%26aulast%3DPreskorn%26aufirst%3DS.%2BH.%26aulast%3DGreenblatt%26aufirst%3DD.%2BJ.%26aulast%3DHarrison%26aufirst%3DW.%26aulast%3DPenenberg%26aufirst%3DD.%26aulast%3DAllison%26aufirst%3DJ.%26aulast%3DChung%26aufirst%3DM.%26atitle%3DDesipramine%2520pharmacokinetics%2520when%2520coadministered%2520with%2520paroxetine%2520or%2520sertraline%2520in%2520extensive%2520metabolizers%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D1997%26volume%3D17%26spage%3D284%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Hemeryck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebyre, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vriendt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belpaire, F. M.</span><span> </span><span class="NLM_article-title">Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">291</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1067%2Fmcp.2000.104788" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=10741632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD3cXis1Ghtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2000&pages=283-291&author=A.+Hemeryckauthor=R.+A.+Lefebyreauthor=C.+De+Vriendtauthor=F.+M.+Belpaire&title=Paroxetine+affects+metoprolol+pharmacokinetics+and+pharmacodynamics+in+healthy+volunteers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers</span></div><div class="casAuthors">Hemeryck, Alex; Lefebvre, Romain A.; De Vriendt, Cindy; Belpaire, Frans M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">283-291</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">This work investigated the effect of multiple-dose paroxetine intake on the stereoselective pharmacokinetics and the pharmacodynamics of metoprolol in healthy men.  Racemic metoprolol (100 mg, single oral dose) was administered before and after paroxetine treatment (20 mg/day for 6 days).  The pharmacokinetics of (R)- and (S)-metoprolol, metoprolol metabolic ratio (MR), exercise heart rate and blood pressure were assessed for 12 (pharmacodynamic data) or 24 (pharmacokinetic data) hours after each metoprolol intake.  Paroxetine treatment increased the mean area under the plasma concn.-time curve extrapolated to infinity (AUC) of (R)- and (S)-metoprolol (169 to 1340 ng · h/mL and 279 to 1418 ng · h/mL, resp.), with an approx. 2-fold increase in both max. plasma concn. and terminal elimination half-life.  Furthermore, the (S)/(R) AUC ratio was decreased, from 1.72 to 1.07.  The mean metoprolol MR was increased, from 0.17 to 5.69.  The AUC of the metoprolol-induced decrease in exercise-heart-rate-vs.-time curve was increased, reaching significance 6 h after metoprolol intake, illustrating a more sustained β-blockade.  Similar results were obtained for the effect on exercise systolic blood pressure.  Multiple-dose metoprolol administration combined with paroxetine can lead to an accumulation of the β-blocking (S)-enantiomer of metoprolol, possibly resulting in unacceptable bradycardia, loss of cardioselectivity, or both.  Thus, multiple-dose paroxetine intake affects both metoprolol pharmacokinetics and pharmacodynamics, suggesting that when paroxetine is added to an ongoing metoprolol therapy, caution is warranted and a redn. of the metoprolol dose may be required to prevent undesired adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU0x7IsjeKErVg90H21EOLACvtfcHk0lhHlTq76bExHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXis1Ghtrg%253D&md5=f88ffdcdf1e4185670b19f1316b69d67</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2000.104788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2000.104788%26sid%3Dliteratum%253Aachs%26aulast%3DHemeryck%26aufirst%3DA.%26aulast%3DLefebyre%26aufirst%3DR.%2BA.%26aulast%3DDe%2BVriendt%26aufirst%3DC.%26aulast%3DBelpaire%26aufirst%3DF.%2BM.%26atitle%3DParoxetine%2520affects%2520metoprolol%2520pharmacokinetics%2520and%2520pharmacodynamics%2520in%2520healthy%2520volunteers%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2000%26volume%3D67%26spage%3D283%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Spina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avenoso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Facciola, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scordo, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ancione, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madia, A.</span><span> </span><span class="NLM_article-title">Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine</span> <span class="citation_source-journal">Ther. Drug Monit.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1097%2F00007691-200106000-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=11360029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD3MXks12jtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=223-227&author=E.+Spinaauthor=A.+Avenosoauthor=G.+Facciolaauthor=M.+G.+Scordoauthor=M.+Ancioneauthor=A.+Madia&title=Plasma+concentrations+of+risperidone+and+9-hydroxyrisperidone+during+combined+treatment+with+paroxetine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine</span></div><div class="casAuthors">Spina, Edoardo; Avenoso, Angela; Facciola, Gabriella; Scordo, Maria Gabriella; Ancione, Maria; Madia, Aldo</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Drug Monitoring</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">223-227</span>CODEN:
                <span class="NLM_cas:coden">TDMODV</span>;
        ISSN:<span class="NLM_cas:issn">0163-4356</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The effects of paroxetine on steady-state plasma concns. of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) were studied in 10 patients with schizophrenia or schizoaffective disorder.  Patients stabilized using risperidone therapy (4-8 mg/d) also received paroxetine (20 mg/d) for 4 wk.  During paroxetine administration, mean plasma concns. of risperidone increased significantly (P < 0.01), whereas levels of 9-OH-risperidone decreased slightly but not significantly.  After 4 wk of paroxetine treatment, the sum of the concns. of risperidone and 9-OH-risperidone (active moiety) increased significantly by 45% (P < 0.05) over baseline.  The mean plasma risperidone/9-OH-risperidone ratio was also significantly modified (P < 0.001) during paroxetine treatment.  The drug combination was generally well tolerated with the exception of one patient who developed Parkinsonian symptoms in the second week of adjunctive therapy.  In this patient total plasma levels of risperidone and its active metabolite increased by 62% during paroxetine co-administration.  The authors' findings indicate that paroxetine, a potent inhibitor of CYP2D6, may impair the elimination of risperidone, primarily by inhibiting CYP2D6-mediated 9-hydroxylation and to a lesser extent by simultaneously affecting the further metab. of 9-OH-risperidone or other pathways of risperidone biotransformation.  Careful clin. observation and possibly monitoring of plasma risperidone levels may be useful whenever paroxetine is co-administered with risperidone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-olVdjHGutbVg90H21EOLACvtfcHk0ljNY5klTo5PrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXks12jtbg%253D&md5=3aa6421493caa6030183cf803750e570</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1097%2F00007691-200106000-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00007691-200106000-00007%26sid%3Dliteratum%253Aachs%26aulast%3DSpina%26aufirst%3DE.%26aulast%3DAvenoso%26aufirst%3DA.%26aulast%3DFacciola%26aufirst%3DG.%26aulast%3DScordo%26aufirst%3DM.%2BG.%26aulast%3DAncione%26aufirst%3DM.%26aulast%3DMadia%26aufirst%3DA.%26atitle%3DPlasma%2520concentrations%2520of%2520risperidone%2520and%25209-hydroxyrisperidone%2520during%2520combined%2520treatment%2520with%2520paroxetine%26jtitle%3DTher.%2520Drug%2520Monit.%26date%3D2001%26volume%3D23%26spage%3D223%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Belle, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernest, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomasson, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witcher, J. W.</span><span> </span><span class="NLM_article-title">Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">–</span> <span class="NLM_lpage">1227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1177%2F009127002762491307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=12412820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVClt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2002&pages=1219-1227&author=D.+J.+Belleauthor=C.+S.+Ernestauthor=J.+M.+Sauerauthor=B.+P.+Smithauthor=H.+R.+Thomassonauthor=J.+W.+Witcher&title=Effect+of+potent+CYP2D6+inhibition+by+paroxetine+on+atomoxetine+pharmacokinetics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics</span></div><div class="casAuthors">Belle, Donna J.; Ernest, C. Steven; Sauer, John-Michael; Smith, Brian P.; Thomasson, Holly R.; Witcher, Jennifer W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1219-1227</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The purpose of this study was to characterize the effect of potent CYP2D6 inhibition by paroxetine on atomoxetine disposition in extensive metabolizers.  This was a single-blind, two-period, sequential study in 22 healthy individuals.  In period 1, 20 mg atomoxetine bid was administered to steady state.  In period 2, 20 mg paroxetine was administered qd for 17 days.  On days 12 through 17, 20 mg atomoxetine bid were coadministered.  Plasma pharmacokinetics of atomoxetine, 4-hydroxyatomoxetine, and N-desmethylatomoxetine was detd. at steady state in each treatment period.  Plasma pharmacokinetics of paroxetine were detd. after the 11th and 17th doses.  Paroxetine increased Css,max, AUC0-12, and t1/2 of atomoxetine by approx. 3.5-, 6.5-, and 2.5 fold, resp.  After coadministration with paroxetine, increases in N-desmethylatomoxetine and decreases in 4-hydroxyatomoxetine concns. were obsd.  No changes in paroxetine pharmacokinetics were obsd. after coadministration with atomoxetine.  It was concluded that inhibition of CYP2D6 by paroxetine markedly affected atomoxetine disposition, resulting in pharmacokinetics similar to poor metabolizers of CYP2D6 substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTJSWJJk3pXLVg90H21EOLACvtfcHk0ljNY5klTo5PrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVClt7w%253D&md5=612a638d304b543f58f842cfb5066e29</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1177%2F009127002762491307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F009127002762491307%26sid%3Dliteratum%253Aachs%26aulast%3DBelle%26aufirst%3DD.%2BJ.%26aulast%3DErnest%26aufirst%3DC.%2BS.%26aulast%3DSauer%26aufirst%3DJ.%2BM.%26aulast%3DSmith%26aufirst%3DB.%2BP.%26aulast%3DThomasson%26aufirst%3DH.%2BR.%26aulast%3DWitcher%26aufirst%3DJ.%2BW.%26atitle%3DEffect%2520of%2520potent%2520CYP2D6%2520inhibition%2520by%2520paroxetine%2520on%2520atomoxetine%2520pharmacokinetics%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2002%26volume%3D42%26spage%3D1219%26epage%3D1227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Venkatakrishnan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">In vitro–in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">845</span><span class="NLM_x">–</span> <span class="NLM_lpage">852</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=845-852&author=K.+Venkatakrishnanauthor=R.+S.+Obach&title=In+vitro%E2%80%93in+vivo+extrapolation+of+CYP2D6+inactivation+by+paroxetine%3A+prediction+of+nonstationary+pharmacokinetics+and+drug+interaction+magnitude"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatakrishnan%26aufirst%3DK.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DIn%2520vitro%25E2%2580%2593in%2520vivo%2520extrapolation%2520of%2520CYP2D6%2520inactivation%2520by%2520paroxetine%253A%2520prediction%2520of%2520nonstationary%2520pharmacokinetics%2520and%2520drug%2520interaction%2520magnitude%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D845%26epage%3D852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Wang, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. D.</span><span> </span><span class="NLM_article-title">Prediction of cytochrome P4503A inhibition by verapamil enantiomers and their metabolites</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">266</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=259-266&author=Y.+H.+Wangauthor=D.+R.+Jonesauthor=S.+D.+Hall&title=Prediction+of+cytochrome+P4503A+inhibition+by+verapamil+enantiomers+and+their+metabolites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BH.%26aulast%3DJones%26aufirst%3DD.%2BR.%26aulast%3DHall%26aufirst%3DS.%2BD.%26atitle%3DPrediction%2520of%2520cytochrome%2520P4503A%2520inhibition%2520by%2520verapamil%2520enantiomers%2520and%2520their%2520metabolites%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2004%26volume%3D32%26spage%3D259%26epage%3D266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Lemma, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaheer, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorski, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. D.</span><span> </span><span class="NLM_article-title">The effect of short and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">218</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.clpt.2005.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=16513446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVKhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2006&pages=218-230&author=G.+L.+Lemmaauthor=Z.+Wangauthor=M.+A.+Hammanauthor=N.+A.+Zaheerauthor=J.+C.+Gorskiauthor=S.+D.+Hall&title=The+effect+of+short+and+long-term+administration+of+verapamil+on+the+disposition+of+cytochrome+P450+3A+and+P-glycoprotein+substrates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates</span></div><div class="casAuthors">Lemma, Girum L.; Wang, Zaiqi; Hamman, Mitchell A.; Zaheer, Narjis A.; Gorski, J. Christopher; Hall, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">218-230</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background: Verapamil has the capability to inhibit and induce cytochrome P 450 (CYP) 3A and P-glycoprotein (P-gp), but the relative extent and time course of these events in vivo are unclear.  The effect of verapamil on CYP3A and P-gp activity was detd. by examg. its effect on its own disposition and on the disposition of fexofenadine, resp.  Methods: Twelve healthy volunteers received 60 mg fexofenadine alone or after administration of 240 mg verapamil for 1, 10, and 38 days.  The concns. of verapamil and norverapamil, as well as their enantiomers, were quantified in serum by chiral HPLC.  The concns. of fexofenadine and its metabolite, azacyclonol, were quantified in serum and urine by liq. chromatog.-mass spectrometry.  Results: The mean ± SD max. serum concn. (Cmax) and the area under the serum concn.-time curve of S-verapamil increased significantly on days 10 (40 ± 21 ng/mL [P = .00044] and 433 ± 316 ng · h · mL-1 [P = .00047], resp.) and 38 (42 ± 27 ng/mL [P = .019] and 433 ± 256 ng · h · mL-1 [P = .0081], resp.) compared with day 1 (21 ± 12 ng/mL and 222 ± 156 ng · h · mL-1, resp.).  The oral clearance (CLoral) of S-verapamil decreased significantly from 702 ± 304 L/h on day 1 to 377 ± 210 L/h on day 10 (P = .0029) and 449 ± 419 L/h on day 38 (P = .05).  Similar trends were obsd. for the Cmax and area under the serum concn.-time curve of R-verapamil and R- and S-norverapamil.  All subjects showed a significant decrease in the CLoral of fexofenadine after a single dose (98 ± 54 L/h, P = .00105) and 10-day dosing (102 ± 40 L/h, P = .0011) of verapamil compared with the control value (156 ± 69 L/h).  The Cmax of fexofenadine was significantly increased by a single dose (165 ± 42 ng/mL, P = .0005) and 10-day dosing (148 ± 39 ng/mL, P = .0008) of verapamil compared with the control value (114 ± 45 ng/mL).  No significant difference in fexofenadine Cmax (P = .37) and CLoral (P = .43) was obsd. between the control values and values at 38 days of verapamil treatment.  Conclusion: Verapamil inhibited CYP3A activity, with a max. effect occurring within 10 days.  Short-term administration of verapamil caused net inhibition of intestinal P-gp, whereas long-term administration of verapamil induced P-gp activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtd0_Zupd77LVg90H21EOLACvtfcHk0lhIBq-m_34hoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVKhuro%253D&md5=83116ec48e249000698eb5628237932b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2005.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2005.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DLemma%26aufirst%3DG.%2BL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DHamman%26aufirst%3DM.%2BA.%26aulast%3DZaheer%26aufirst%3DN.%2BA.%26aulast%3DGorski%26aufirst%3DJ.%2BC.%26aulast%3DHall%26aufirst%3DS.%2BD.%26atitle%3DThe%2520effect%2520of%2520short%2520and%2520long-term%2520administration%2520of%2520verapamil%2520on%2520the%2520disposition%2520of%2520cytochrome%2520P450%25203A%2520and%2520P-glycoprotein%2520substrates%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2006%26volume%3D79%26spage%3D218%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Jerling, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huan, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdallah, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussein, Z.</span><span> </span><span class="NLM_article-title">Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">422</span><span class="NLM_x">–</span> <span class="NLM_lpage">433</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1177%2F0091270004273992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15778423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFyhtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=422-433&author=M.+Jerlingauthor=B.+L.+Huanauthor=K.+Leungauthor=N.+Chuauthor=H.+Abdallahauthor=Z.+Hussein&title=Studies+to+investigate+the+pharmacokinetic+interactions+between+ranolazine+and+ketoconazole%2C+diltiazem%2C+or+simvastatin+during+combined+administration+in+healthy+subjects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects</span></div><div class="casAuthors">Jerling, Markus; Huan, Bee-Lian; Leung, Kwan; Chu, Nancy; Abdallah, Hisham; Hussein, Ziad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">422-433</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The interactions of ranolazine, a new antianginal compd., with inhibitors and substrates of the CYP3A isoenzyme family were studied in 1 open-label and 4 double-blind, randomized, multiple-dose studies.  In healthy adult volunteers, the authors sought (1) to det. the steady-state pharmacokinetics, safety, and tolerability of immediate- and sustained-release ranolazine with and without ketoconazole, diltiazem, or simvastatin and (2) to evaluate the effect of ranolazine on the pharmacokinetics of diltiazem, simvastatin, simvastatin metabolites, and HMG-CoA reductase activity.  Ketoconazole increased ranolazine plasma concns. and reduced the CYP3A4-mediated metabolic transformation of ranolazine, confirming that CYP3A4 is the primary metabolic pathway for ranolazine.  Diltiazem reduced oral clearance of ranolazine in a dose-dependent manner.  Simvastatin did not affect ranolazine pharmacokinetics, although ranolazine increased the AUC and Cmax of simvastatin, simvastatin acid, 2 simvastatin metabolites, and HMG-CoA reductase activity by <2-fold.  Administration of ranolazine in combination with diltiazem or simvastatin was safe and well tolerated during the interval studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVS4QJjh97BLVg90H21EOLACvtfcHk0lhIBq-m_34hoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFyhtLo%253D&md5=1f64fb883ea8a3308f7f06d22d2e780d</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1177%2F0091270004273992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270004273992%26sid%3Dliteratum%253Aachs%26aulast%3DJerling%26aufirst%3DM.%26aulast%3DHuan%26aufirst%3DB.%2BL.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DChu%26aufirst%3DN.%26aulast%3DAbdallah%26aufirst%3DH.%26aulast%3DHussein%26aufirst%3DZ.%26atitle%3DStudies%2520to%2520investigate%2520the%2520pharmacokinetic%2520interactions%2520between%2520ranolazine%2520and%2520ketoconazole%252C%2520diltiazem%252C%2520or%2520simvastatin%2520during%2520combined%2520administration%2520in%2520healthy%2520subjects%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D45%26spage%3D422%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Sutton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, M.</span><span> </span><span class="NLM_article-title">Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">294</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=9223567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK2sXksFyitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=1997&pages=294-300&author=D.+Suttonauthor=A.+M.+Butlerauthor=L.+Nadinauthor=M.+Murray&title=Role+of+CYP3A4+in+human+hepatic+diltiazem+N-demethylation%3A+inhibition+of+CYP3A4+activity+by+oxidized+diltiazem+metabolites"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites</span></div><div class="casAuthors">Sutton, Dylan; Butler, Alison M.; Nadin, Louise; Murray, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">294-300</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The antihypertensive agent diltiazem (DTZ) impairs hepatic drug metab. by inhibition of cytochrome P 450 (CYP).  The accumulation of DTZ metabolites in serum occurs during prolonged therapy and leads to decreased DTZ elimination.  Thus, DTZ metabolites may contribute to CYP inhibition.  This study assessed the role of human CYPs in microsomal DTZ oxidn. and the capacity of DTZ metabolites to inhibit specific CYP activities.  DTZ N-demethylation varied 10-fold in microsomal fractions from 17 livers (0.33-3.31 nmol/mg of protein/min).  DTZ oxidn. was correlated with testosterone 6β-hydroxylation (r = 0.82) and, to a lesser extent, tolbutamide hydroxylation (r = 0.59) but not with activities mediated by CYP1A2 or CYP2E1.  CYP3A4 in lymphoblastoid cell microsomes catalyzed DTZ N-demethylation but CYP2C8 and CYP2C9 were also active (∼20% and 10% of the activity supported by CYP3A4); seven other CYPs produced little or no N-desmethyl DTZ from DTZ.  The CYP3A4 inhibitors ketoconazole and troleandomycin decreased microsomal DTZ oxidn., but inhibitors or substrates of CYP2C, CYP2D and CYP2E1 produced no inhibition.  Some inhibition was produced by α-naphthoflavone, a chem. that inhibits CYP1As and also interacts with CYP3A4.  In further expts., the capacities of DTZ and three metabolites to modulate human CYP 1A2, 1A2, 2E1, 2C9 and 3A4 activities were evaluated in vitro.  DTZ and its N-desmethyl and N,N-didesmethyl metabolites selectively inhibited CYP3A4 activity, whereas O-desmethyl DTZ was not inhibitory.  The IC50 value of DTZ against CYP3A4-mediated testosterone 6β-hydroxylation (substrate concn., 50 μM) was 120 μM.  The N-desmethyl (IC50 = 11 μM) and N,N-didesmethyl (IC50 = 0.6 μM) metabolites were 11 and 200 times, resp., more potent.  From kinetic studies, N-desmethyl DTZ and N,N-didesmethyl DTZ were potent competitive inhibitors of CYP3A4 (Ki = ∼2 and 0.1 μM, resp.).  CYP3A4 inhibition was enhanced when DTZ and N-desmethyl DTZ underwent biotransformation in NADPH-supplemented hepatic microsomes in vitro, supporting the contention that inhibitory metabolites may be generated in situ.  These findings suggest that N-demethylation metabolites of DTZ may contribute to CYP3A4 inhibition in vivo, esp. under conditions in which N-desmethyl DTZ accumulates, such as during prolonged DTZ therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIL8o2n_0Da7Vg90H21EOLACvtfcHk0lgERNf4k8Fa-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksFyitb0%253D&md5=1b1cb145c6246ca57f1455963adc721c</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSutton%26aufirst%3DD.%26aulast%3DButler%26aufirst%3DA.%2BM.%26aulast%3DNadin%26aufirst%3DL.%26aulast%3DMurray%26aufirst%3DM.%26atitle%3DRole%2520of%2520CYP3A4%2520in%2520human%2520hepatic%2520diltiazem%2520N-demethylation%253A%2520inhibition%2520of%2520CYP3A4%2520activity%2520by%2520oxidized%2520diltiazem%2520metabolites%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D282%26spage%3D294%26epage%3D300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Jones, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorski, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayhew, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rider, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. D.</span><span> </span><span class="NLM_article-title">Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">290</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1125</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=10454485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK1MXlsVOqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=1999&pages=1116-1125&author=D.+R.+Jonesauthor=J.+C.+Gorskiauthor=M.+A.+Hammanauthor=B.+S.+Mayhewauthor=S.+Riderauthor=S.+D.+Hall&title=Diltiazem+inhibition+of+cytochrome+P-450+3A+activity+is+due+to+metabolite+intermediate+complex+formation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation</span></div><div class="casAuthors">Jones, David R.; Gorski, J. Christopher; Hamman, Mitchell A.; Mayhew, Bradley S.; Rider, Steven; Hall, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1116-1125</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Diltiazem (DTZ) N-demethylation occurs by cytochrome P 450 (CYP) 3A based on the following observations: 1) a single enzyme Michaelis-Menten model of metabolite formation, 2) high correlations of DTZ N-demethylation activity to other CYP3A activities, 3) inhibition of DTZ N-demethylation activity by triacetyloleandomycin, and 4) DTZ N-demethylation activity by expressed CYP3A enzymes only.  The mean Kms for DTZ N-demethylation in human liver microsomes and expressed CYP3A4(+b5) were 53 and 16 μM, resp.  A 30-min preincubation of DTZ in expressed CYPs inhibited CYP3A4(+b5) by 100%, of which 55% was due to formation of a metabolite intermediate complex (MIC), which is an inactive form of CYP.  MIC was obsd. in human liver microsomes and cDNA-expressed CYP3A only.  In expts. to assess simultaneous MIC formation and loss of CYP3A activity, DTZ caused greater than 80% inhibition of midazolam hydroxylation after a 60-min preincubation in human liver microsomes.  The rate consts. for MIC formation and loss of midazolam hydroxylation activity were equiv. for the line of best fit for both data sets, which illustrates that MIC formation causes the inhibition of CYP3A activity.  The mechanistic inhibition was characterized in expressed CYP3A4(+b5), which exhibited a concn.-dependent formation of MIC by DTZ (1-100 μM) with an estd. kinact of 0.17 min-1 and Ki of 2.2 μM.  The partition ratio for expressed CYP3A4(+b5) was substrate concn. dependent and varied from 13 to 86.  This study showed that DTZ inhibition of CYP3A substrate metab. occurs primarily by MIC formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCuYDxmIk1jrVg90H21EOLACvtfcHk0lgERNf4k8Fa-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlsVOqsb8%253D&md5=199c2d20dc3e9770f9495d8f46f98e5e</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DD.%2BR.%26aulast%3DGorski%26aufirst%3DJ.%2BC.%26aulast%3DHamman%26aufirst%3DM.%2BA.%26aulast%3DMayhew%26aufirst%3DB.%2BS.%26aulast%3DRider%26aufirst%3DS.%26aulast%3DHall%26aufirst%3DS.%2BD.%26atitle%3DDiltiazem%2520inhibition%2520of%2520cytochrome%2520P-450%25203A%2520activity%2520is%2520due%2520to%2520metabolite%2520intermediate%2520complex%2520formation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D290%26spage%3D1116%26epage%3D1125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Zhao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunze, K. L.</span><span> </span><span class="NLM_article-title">Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">704</span><span class="NLM_x">–</span> <span class="NLM_lpage">712</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=704-712&author=P.+Zhaoauthor=C.+A.+Leeauthor=K.+L.+Kunze&title=Sequential+metabolism+is+responsible+for+diltiazem-induced+time-dependent+loss+of+CYP3A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DC.%2BA.%26aulast%3DKunze%26aufirst%3DK.%2BL.%26atitle%3DSequential%2520metabolism%2520is%2520responsible%2520for%2520diltiazem-induced%2520time-dependent%2520loss%2520of%2520CYP3A%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26spage%3D704%26epage%3D712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Lesko, L. J.</span><span> </span><span class="NLM_article-title">Pharmacokinetic drug interactions with amiodarone</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">140</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2165%2F00003088-198917020-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=2673606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaL1MXlsVKisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1989&pages=130-140&author=L.+J.+Lesko&title=Pharmacokinetic+drug+interactions+with+amiodarone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic drug interactions with amiodarone</span></div><div class="casAuthors">Lesko, Lawrence J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-40</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    </div><div class="casAbstract">A review with ∼55 refs.  Amiodarone alters the pharmacokinetics, and in some cases the pharmacodynamics, of several clin. important drugs.  The major mechanism of its drug interactions is inhibition of hepatic metab., but it can also affect the bioavailability, protein binding and renal excretion of coadministered drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBxe0QuUq5SrVg90H21EOLACvtfcHk0lh4lM_2A8r--A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXlsVKisLw%253D&md5=cea9a9a3e88185f454ee966f7ed5b58b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.2165%2F00003088-198917020-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-198917020-00005%26sid%3Dliteratum%253Aachs%26aulast%3DLesko%26aufirst%3DL.%2BJ.%26atitle%3DPharmacokinetic%2520drug%2520interactions%2520with%2520amiodarone%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1989%26volume%3D17%26spage%3D130%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Larrey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tinel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letteron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geneve, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Descatoire, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pessayre, D.</span><span> </span><span class="NLM_article-title">Formation of an inactive cytochrome P-450Fe(II)-metabolite complex after administration of amiodarone in rats, mice and hamsters</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">2213</span><span class="NLM_x">–</span> <span class="NLM_lpage">2220</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1986&pages=2213-2220&author=D.+Larreyauthor=M.+Tinelauthor=P.+Letteronauthor=J.+Geneveauthor=V.+Descatoireauthor=D.+Pessayre&title=Formation+of+an+inactive+cytochrome+P-450Fe%28II%29-metabolite+complex+after+administration+of+amiodarone+in+rats%2C+mice+and+hamsters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLarrey%26aufirst%3DD.%26aulast%3DTinel%26aufirst%3DM.%26aulast%3DLetteron%26aufirst%3DP.%26aulast%3DGeneve%26aufirst%3DJ.%26aulast%3DDescatoire%26aufirst%3DV.%26aulast%3DPessayre%26aufirst%3DD.%26atitle%3DFormation%2520of%2520an%2520inactive%2520cytochrome%2520P-450Fe%2528II%2529-metabolite%2520complex%2520after%2520administration%2520of%2520amiodarone%2520in%2520rats%252C%2520mice%2520and%2520hamsters%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1986%26volume%3D35%26spage%3D2213%26epage%3D2220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Ohyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoi, T.</span><span> </span><span class="NLM_article-title">Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">244</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1046%2Fj.1365-2125.2000.00134.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=10718780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD3cXis1ehu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2000&pages=244-253&author=K.+Ohyamaauthor=M.+Nakajimaauthor=M.+Suzukiauthor=N.+Shimadaauthor=H.+Yamazakiauthor=T.+Yokoi&title=Inhibitory+effects+of+amiodarone+and+its+N-deethylated+metabolite+on+human+cytochrome+P450+activities%3A+prediction+of+in+vivo+drug+interactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions</span></div><div class="casAuthors">Ohyama, K.; Nakajima, M.; Suzuki, M.; Shimada, N.; Yamazaki, H.; Yokoi, T.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">244-253</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">To predict the drug interactions of amiodarone and other drugs, the inhibitory effects and inactivation potential for human cytochrome P 450 (CYP) enzymes by amiodarone and its N-dealkylated metabolite, desethylamiodarone were examd.  The inhibition or inactivation potency of amiodarone and desethylamiodarone for human CYP activities were investigated using microsomes from B-lymphoblastoid cell lines expressing CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4.  The in vivo drug interactions of amiodarone and desethylamiodarone were predicted in vitro using the 1+Iu/Ki values.  Amiodarone weakly inhibited CYP2C9, CYP2D6, and CYP3A4-mediated activities with Ki values of 45.1-271.6 μM.  Desethylamiodarone competitively inhibited the catalytic activities of CYP2D6 (Ki=4.5 μM) and noncompetitively inhibited CYP2A6 (Ki=13.5 μM), CYP2B6 (Ki=5.4 μM), and CYP3A4 (Ki=12.1 μM).  The catalytic activities of CYP1A1 (Ki=1.5 μM, α=5.7), CYP1A2 (Ki=18.8 μM, α=2.6), CYP2C9 (Ki=2.3 μM, α=5.9), and CYP2C19 (Ki=15.7 μM, α=4.5) were inhibited by desethylamiodarone with mixed type.  The 1+Iu/Ki values of desethylamiodarone were higher than those of amiodarone.  Amiodarone inactivated CYP3A4, while desethylamiodarone inactivated CYP1A1, CYP1A2, CYP2B6, and CYP2D6.  The interactions between amiodarone and other drugs might occur via the inhibition of CYP activities by its N-dealkylated metabolite, desethylamiodarone, rather than by amiodarone itself.  In addn., the inactivation of CYPs by desethylamiodarone as well as by amiodarone would also contribute to the drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0_Eep6RxC5LVg90H21EOLACvtfcHk0lh4lM_2A8r--A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXis1ehu7o%253D&md5=0d2004ab911e28d059469f2da781c45b</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2125.2000.00134.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2125.2000.00134.x%26sid%3Dliteratum%253Aachs%26aulast%3DOhyama%26aufirst%3DK.%26aulast%3DNakajima%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DShimada%26aufirst%3DN.%26aulast%3DYamazaki%26aufirst%3DH.%26aulast%3DYokoi%26aufirst%3DT.%26atitle%3DInhibitory%2520effects%2520of%2520amiodarone%2520and%2520its%2520N-deethylated%2520metabolite%2520on%2520human%2520cytochrome%2520P450%2520activities%253A%2520prediction%2520of%2520in%2520vivo%2520drug%2520interactions%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2000%26volume%3D49%26spage%3D244%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Mori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takatsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuda-Tsukimoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kume, T.</span><span> </span><span class="NLM_article-title">Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">415</span><span class="NLM_x">–</span> <span class="NLM_lpage">422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=415-422&author=K.+Moriauthor=H.+Hashimotoauthor=H.+Takatsuauthor=M.+Tsuda-Tsukimotoauthor=T.+Kume&title=Cocktail-substrate+assay+system+for+mechanism-based+inhibition+of+CYP2C9%2C+CYP2D6%2C+and+CYP3A+using+human+liver+microsomes+at+an+early+stage+of+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DK.%26aulast%3DHashimoto%26aufirst%3DH.%26aulast%3DTakatsu%26aufirst%3DH.%26aulast%3DTsuda-Tsukimoto%26aufirst%3DM.%26aulast%3DKume%26aufirst%3DT.%26atitle%3DCocktail-substrate%2520assay%2520system%2520for%2520mechanism-based%2520inhibition%2520of%2520CYP2C9%252C%2520CYP2D6%252C%2520and%2520CYP3A%2520using%2520human%2520liver%2520microsomes%2520at%2520an%2520early%2520stage%2520of%2520drug%2520development%26jtitle%3DXenobiotica%26date%3D2009%26volume%3D39%26spage%3D415%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Polasek, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliot, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minors, J. O.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">311</span><span class="NLM_x">, </span> <span class="NLM_fpage">996</span><span class="NLM_x">–</span> <span class="NLM_lpage">1007</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1124%2Fjpet.104.071803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15304522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKmtLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2004&pages=996-1007&author=T.+M.+Polasekauthor=D.+J.+Elliotauthor=B.+C.+Lewisauthor=J.+O.+Minors&title=Mechanism-based+inactivation+of+human+cytochrome+P4502C8+by+drugs+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro</span></div><div class="casAuthors">Polasek, Thomas M.; Elliot, David J.; Lewis, Benjamin C.; Miners, John O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">996-1007</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Studies were conducted to evaluate the potential mechanism-based inactivation of recombinant and human liver microsomal CYP2C8 by clin. used drugs.  Several tricyclic antidepressants, calcium channel blockers, monoamine oxidase inhibitors, and various other known CYP3A4 inhibitors exhibited greater inhibition of CYP2C8 (paclitaxel 6α-hydroxylation) following preincubation, consistent with mechanism-based inactivation.  Inactivation of recombinant CYP2C8 by phenelzine, amiodarone, verapamil, nortriptyline, fluoxetine, and isoniazid was of the pseudo-first order type and was characterized by resp. inactivation kinetic consts. (K1 and kinact) of 1.2 μM and 0.243 min-1, 1.5 μM and 0.079 min-1, 17.5 μM and 0.065 min-1, 49.9 μM and 0.036 min-1, 294 μM and 0.083 min-1, and 374 μM and 0.042 min-1.  Spectral scanning of recombinant CYP2C8 demonstrated the formation of metabolite-intermediate complexes with verapamil, nortriptyline, fluoxetine, and isoniazid, but not amiodarone.  In contrast, inactivation by phenelzine resulted from heme destruction by free radicals.  Studies with human liver microsomes (HLMs) revealed that nortriptyline, verapamil, and fluoxetine were not mechanism-based inactivators (MBIs) of CYP2C8.  Simultaneous inactivation of CYP2C8 and CYP3A4 (paclitaxel 3'-phenyl-hydroxylation) was obsd. using amiodarone, isoniazid, and phenelzine with the efficiency of inactivation greater for the CYP3A4 pathway.  With the exception of phenelzine, glutathione and superoxide dismutase failed to protect CYP2C8 (recombinant and HLMs) or CYP3A4 from inactivation by MBIs.  However, the alternate CYP2C8 substrate, torsemide, prevented CYP2C8 inactivation in all cases.  These data are consistent with mechanism-based inactivation of CYP2C8 by a range of commonly prescribed drugs, several of which have been implicated in clin. important drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriCb9GyIpU57Vg90H21EOLACvtfcHk0liOVVdTl0l2Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKmtLzL&md5=ba8b39957d6b8f82d42921e70c686796</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.071803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.071803%26sid%3Dliteratum%253Aachs%26aulast%3DPolasek%26aufirst%3DT.%2BM.%26aulast%3DElliot%26aufirst%3DD.%2BJ.%26aulast%3DLewis%26aufirst%3DB.%2BC.%26aulast%3DMinors%26aufirst%3DJ.%2BO.%26atitle%3DMechanism-based%2520inactivation%2520of%2520human%2520cytochrome%2520P4502C8%2520by%2520drugs%2520in%2520vitro%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D311%26spage%3D996%26epage%3D1007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Nagauma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishikata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuchiya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasanuki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, E.</span><span> </span><span class="NLM_article-title">Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">363</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1177%2F107424840100600405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=11907638" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2001&pages=363-367&author=M.+Nagaumaauthor=T.+Shigaauthor=K.+Nishikataauthor=T.+Tsuchiyaauthor=H.+Kasanukiauthor=E.+Fujii&title=Role+of+desethylamiodarone+in+the+anticoagulant+effect+of+concurrent+amiodarone+and+warfarin+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1177%2F107424840100600405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F107424840100600405%26sid%3Dliteratum%253Aachs%26aulast%3DNagauma%26aufirst%3DM.%26aulast%3DShiga%26aufirst%3DT.%26aulast%3DNishikata%26aufirst%3DK.%26aulast%3DTsuchiya%26aufirst%3DT.%26aulast%3DKasanuki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DE.%26atitle%3DRole%2520of%2520desethylamiodarone%2520in%2520the%2520anticoagulant%2520effect%2520of%2520concurrent%2520amiodarone%2520and%2520warfarin%2520therapy%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%2520Ther.%26date%3D2001%26volume%3D6%26spage%3D363%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Mandrioli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forti, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raggi, M. A.</span><span> </span><span class="NLM_article-title">Fluoxetine metabolism and pharmacological interactions: the role of cytochrome P450</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">133</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2174%2F138920006775541561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=16472103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Oms74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=127-133&author=R.+Mandrioliauthor=G.+C.+Fortiauthor=M.+A.+Raggi&title=Fluoxetine+metabolism+and+pharmacological+interactions%3A+the+role+of+cytochrome+P450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Fluoxetine metabolism and pharmacological interactions: the role of cytochrome P450</span></div><div class="casAuthors">Mandrioli, R.; Cantelli Forti, G.; Raggi, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-133</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with 103 refs.  Fluoxetine is the parent drug of the SSRI (selective serotonin reuptake inhibitor) antidepressant class, and is still one of the most highly used drugs of this class world-wide.  Fluoxetine now has largely (albeit not completely) substituted older and less safe drugs such as tricyclic antidepressants.  Different cytochrome P 450 isoforms are involved in the metab. of fluoxetine, however, the main active metabolite, norfluoxetine, is produced by the CYP2D6 action in the human liver.  In this paper, the main metabolic characteristics of fluoxetine will be reviewed, with particular attention paid to the role of cytochrome isoenzymes.  The pharmacol. interactions of the drug will be overviewed, esp. those concerning other drugs used in psychiatric clinics, such as antipsychotics and antidepressants and the relationships between pharmacol. interactions and cytochrome activity will be discussed.  Recently, much attention has been drawn to the therapeutic drug monitoring (TDM) of fluoxetine, and in particular to the anal. of fluoxetine enantiomers for which enantiomeric sepns. and enantioselective metab. will also briefly be mentioned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzhEc2P671LrVg90H21EOLACvtfcHk0liOVVdTl0l2Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Oms74%253D&md5=9fcf86af57228deac12810dc28a69321</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2174%2F138920006775541561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920006775541561%26sid%3Dliteratum%253Aachs%26aulast%3DMandrioli%26aufirst%3DR.%26aulast%3DForti%26aufirst%3DG.%2BC.%26aulast%3DRaggi%26aufirst%3DM.%2BA.%26atitle%3DFluoxetine%2520metabolism%2520and%2520pharmacological%2520interactions%253A%2520the%2520role%2520of%2520cytochrome%2520P450%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2006%26volume%3D7%26spage%3D127%26epage%3D133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Stevens, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrighton, S. A.</span><span> </span><span class="NLM_article-title">Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">266</span><span class="NLM_x">, </span> <span class="NLM_fpage">964</span><span class="NLM_x">–</span> <span class="NLM_lpage">971</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=8355218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK3sXmtFKksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=1993&pages=964-971&author=J.+C.+Stevensauthor=S.+A.+Wrighton&title=Interaction+of+the+enantiomers+of+fluoxetine+and+norfluoxetine+with+human+liver+cytochromes+P450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450</span></div><div class="casAuthors">Stevens, Jeffrey C.; Wrighton, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">266</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">964-71</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">(R)- and (S)-fluoxetine are competitive inhibitors of P 450 2D6-mediated bufuralol 1'-hydroxylation in vitro, yielding Ki values of 1.38 and 0.22 μM, resp.  Their N-demethylated metabolites also are potent inhibitors (Ki, (R)-norfluoxetine, 1.48 μM; (S)-norfluoxetine 0.31 μM).  The microsomal (R)- and (S)-fluoxetine N-demethylase activities for 14 human liver samples were on av. 29.6 and 19.4 pmol of product/min/mg of protein, resp.  The individual rates of N-demethylation correlated with microsomal immunodetectable P 450 2D6 levels; (R)-fluoxetine, r = 0.64, P < .05; (S) fluoxetine, r = 0.63, P < .05.  However, this correlation was weaker than the excellent correlation obtained for P 450 2D6-marker bufuralol 1'-hydroxylase activity and P 450 2D6 levels (r = 0.92, P ≤ .01).  Quinidine, a potent inhibitor of P 450 2D6, inhibited the demethylation of each enantiomer by only ∼20% at a concn. 300 times greater than the Ki detd. for the quinidine inhibition of bufuralol 1'-hydroxylase.  Furthermore, antiserum recognizing P 450 2D6 inhibited 82% of microsomal bufuralol 1'-hydroxylase activity but only 27% of the (R)-fluoxetine N-demethylase activity in the same human liver sample.  In summary, these data indicate that the enantiomers of fluoxetine and norfluoxetine are potent inhibitors of P 450 2D6 and that P 450 forms other than P 450 2D6 appear to be responsible for the majority of microsomal fluoxetine N-demethylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBhmcK4Ci5g7Vg90H21EOLACvtfcHk0lhk9vTKnG0WKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmtFKksbo%253D&md5=28d1e7b5bb081ec01069afbb236d2848</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStevens%26aufirst%3DJ.%2BC.%26aulast%3DWrighton%26aufirst%3DS.%2BA.%26atitle%3DInteraction%2520of%2520the%2520enantiomers%2520of%2520fluoxetine%2520and%2520norfluoxetine%2520with%2520human%2520liver%2520cytochromes%2520P450%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1993%26volume%3D266%26spage%3D964%26epage%3D971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Stresser, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perloff, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crespi, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandeneau, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehal, S. S.</span><span> </span><span class="NLM_article-title">Differential time- and NADPH-dependent inhibition of CYP2C19 by enantiomers of fluoxetine</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">698</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=695-698&author=D.+M.+Stresserauthor=A.+K.+Masonauthor=E.+S.+Perloffauthor=T.+Hoauthor=C.+L.+Crespiauthor=A.+A.+Dandeneauauthor=L.+Morganauthor=S.+S.+Dehal&title=Differential+time-+and+NADPH-dependent+inhibition+of+CYP2C19+by+enantiomers+of+fluoxetine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStresser%26aufirst%3DD.%2BM.%26aulast%3DMason%26aufirst%3DA.%2BK.%26aulast%3DPerloff%26aufirst%3DE.%2BS.%26aulast%3DHo%26aufirst%3DT.%26aulast%3DCrespi%26aufirst%3DC.%2BL.%26aulast%3DDandeneau%26aufirst%3DA.%2BA.%26aulast%3DMorgan%26aufirst%3DL.%26aulast%3DDehal%26aufirst%3DS.%2BS.%26atitle%3DDifferential%2520time-%2520and%2520NADPH-dependent%2520inhibition%2520of%2520CYP2C19%2520by%2520enantiomers%2520of%2520fluoxetine%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D695%26epage%3D698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Bensoussan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaforge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuy, D.</span><span> </span><span class="NLM_article-title">Particular ability of cytochrome P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1995&pages=591-602&author=C.+Bensoussanauthor=M.+Delaforgeauthor=D.+Mansuy&title=Particular+ability+of+cytochrome+P450+3A+to+form+inhibitory+P450-iron-metabolite+complexes+upon+metabolic+oxidation+of+aminodrugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBensoussan%26aufirst%3DC.%26aulast%3DDelaforge%26aufirst%3DM.%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DParticular%2520ability%2520of%2520cytochrome%2520P450%25203A%2520to%2520form%2520inhibitory%2520P450-iron-metabolite%2520complexes%2520upon%2520metabolic%2520oxidation%2520of%2520aminodrugs%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1995%26volume%3D49%26spage%3D591%26epage%3D602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Mansuy, D.</span><span> </span><span class="NLM_article-title">Formation of reactive intermediates and metabolites: effects of macrolide antibiotics on cytochrome P-450</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2F0163-7258%2887%2990026-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=3628477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaL2sXltVyltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1987&pages=41-45&author=D.+Mansuy&title=Formation+of+reactive+intermediates+and+metabolites%3A+effects+of+macrolide+antibiotics+on+cytochrome+P-450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Formation of reactive intermediates and metabolites:  effects of macrolide antibiotics on cytochrome P-450</span></div><div class="casAuthors">Mansuy, D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-5</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    </div><div class="casAbstract">A review with 8 refs.  Xenobiotics have multiple effects on cytochrome P-450 in vivo and, thus, can change the metab. of other drugs.  The effects of macrolide antibiotics (including erythromycin and oleandomycin triacetate) on cytochrome P-450 are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonWtzH1Zbf-bVg90H21EOLACvtfcHk0ljXloF30TKKtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXltVyltL4%253D&md5=40652d9d77251aefe23d35796a07fbfe</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2F0163-7258%2887%2990026-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0163-7258%252887%252990026-X%26sid%3Dliteratum%253Aachs%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DFormation%2520of%2520reactive%2520intermediates%2520and%2520metabolites%253A%2520effects%2520of%2520macrolide%2520antibiotics%2520on%2520cytochrome%2520P-450%26jtitle%3DPharmacol.%2520Ther.%26date%3D1987%26volume%3D33%26spage%3D41%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Piacentini, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trifiro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tari, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moretti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcoraci, V.</span><span> </span><span class="NLM_article-title">UVEC group. Statin–macrolide interaction risk: a population-based study throughout a general practice database</span> <span class="citation_source-journal">Eur. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">615</span><span class="NLM_x">–</span> <span class="NLM_lpage">620</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2005&pages=615-620&author=N.+Piacentiniauthor=G.+Trifiroauthor=M.+Tariauthor=S.+Morettiauthor=V.+Arcoraci&title=UVEC+group.+Statin%E2%80%93macrolide+interaction+risk%3A+a+population-based+study+throughout+a+general+practice+database"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPiacentini%26aufirst%3DN.%26aulast%3DTrifiro%26aufirst%3DG.%26aulast%3DTari%26aufirst%3DM.%26aulast%3DMoretti%26aufirst%3DS.%26aulast%3DArcoraci%26aufirst%3DV.%26atitle%3DUVEC%2520group.%2520Statin%25E2%2580%2593macrolide%2520interaction%2520risk%253A%2520a%2520population-based%2520study%2520throughout%2520a%2520general%2520practice%2520database%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D61%26spage%3D615%26epage%3D620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Larrey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funck-Bretano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitaux, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theodore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babany, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pessayre, D.</span><span> </span><span class="NLM_article-title">Effects of erythromycin on hepatic drug-metabolizing enzymes in humans</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1063</span><span class="NLM_x">–</span> <span class="NLM_lpage">1068</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1983&pages=1063-1068&author=D.+Larreyauthor=C.+Funck-Bretanoauthor=P.+Breilauthor=J.+Vitauxauthor=C.+Theodoreauthor=G.+Babanyauthor=D.+Pessayre&title=Effects+of+erythromycin+on+hepatic+drug-metabolizing+enzymes+in+humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLarrey%26aufirst%3DD.%26aulast%3DFunck-Bretano%26aufirst%3DC.%26aulast%3DBreil%26aufirst%3DP.%26aulast%3DVitaux%26aufirst%3DJ.%26aulast%3DTheodore%26aufirst%3DC.%26aulast%3DBabany%26aufirst%3DG.%26aulast%3DPessayre%26aufirst%3DD.%26atitle%3DEffects%2520of%2520erythromycin%2520on%2520hepatic%2520drug-metabolizing%2520enzymes%2520in%2520humans%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1983%26volume%3D32%26spage%3D1063%26epage%3D1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Larrey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tinel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pessayre, D.</span><span> </span><span class="NLM_article-title">Formation of inactive cytochrome P-450 Fe(II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1487</span><span class="NLM_x">–</span> <span class="NLM_lpage">1493</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1983&pages=1487-1493&author=D.+Larreyauthor=M.+Tinelauthor=D.+Pessayre&title=Formation+of+inactive+cytochrome+P-450+Fe%28II%29-metabolite+complexes+with+several+erythromycin+derivatives+but+not+with+josamycin+and+midecamycin+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLarrey%26aufirst%3DD.%26aulast%3DTinel%26aufirst%3DM.%26aulast%3DPessayre%26aufirst%3DD.%26atitle%3DFormation%2520of%2520inactive%2520cytochrome%2520P-450%2520Fe%2528II%2529-metabolite%2520complexes%2520with%2520several%2520erythromycin%2520derivatives%2520but%2520not%2520with%2520josamycin%2520and%2520midecamycin%2520in%2520rats%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1983%26volume%3D32%26spage%3D1487%26epage%3D1493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Yamazaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, T.</span><span> </span><span class="NLM_article-title">Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1053</span><span class="NLM_x">–</span> <span class="NLM_lpage">1057</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1998&pages=1053-1057&author=H.+Yamazakiauthor=T.+Shimada&title=Comparative+studies+of+in+vitro+inhibition+of+cytochrome+P450+3A4-dependent+testosterone+6beta-hydroxylation+by+roxithromycin+and+its+metabolites%2C+troleandomycin%2C+and+erythromycin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DH.%26aulast%3DShimada%26aufirst%3DT.%26atitle%3DComparative%2520studies%2520of%2520in%2520vitro%2520inhibition%2520of%2520cytochrome%2520P450%25203A4-dependent%2520testosterone%25206beta-hydroxylation%2520by%2520roxithromycin%2520and%2520its%2520metabolites%252C%2520troleandomycin%252C%2520and%2520erythromycin%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1998%26volume%3D26%26spage%3D1053%26epage%3D1057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Amacher, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schomaker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Retsema, J. A.</span><span> </span><span class="NLM_article-title">Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1186</span><span class="NLM_x">–</span> <span class="NLM_lpage">1190</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1991&pages=1186-1190&author=D.+E.+Amacherauthor=S.+J.+Schomakerauthor=J.+A.+Retsema&title=Comparison+of+the+effects+of+the+new+azalide+antibiotic%2C+azithromycin%2C+and+erythromycin+estolate+on+rat+liver+cytochrome+P-450"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAmacher%26aufirst%3DD.%2BE.%26aulast%3DSchomaker%26aufirst%3DS.%2BJ.%26aulast%3DRetsema%26aufirst%3DJ.%2BA.%26atitle%3DComparison%2520of%2520the%2520effects%2520of%2520the%2520new%2520azalide%2520antibiotic%252C%2520azithromycin%252C%2520and%2520erythromycin%2520estolate%2520on%2520rat%2520liver%2520cytochrome%2520P-450%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1991%26volume%3D35%26spage%3D1186%26epage%3D1190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Sartori, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaforge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuy, D.</span><span> </span><span class="NLM_article-title">In vivo interaction of rat liver cytochrome P-450 with erythromycin, oleandomycin and erythralosamine derivatives. Importance of structural factor</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">2061</span><span class="NLM_x">–</span> <span class="NLM_lpage">2068</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1989&pages=2061-2068&author=E.+Sartoriauthor=M.+Delaforgeauthor=D.+Mansuy&title=In+vivo+interaction+of+rat+liver+cytochrome+P-450+with+erythromycin%2C+oleandomycin+and+erythralosamine+derivatives.+Importance+of+structural+factor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSartori%26aufirst%3DE.%26aulast%3DDelaforge%26aufirst%3DM.%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DIn%2520vivo%2520interaction%2520of%2520rat%2520liver%2520cytochrome%2520P-450%2520with%2520erythromycin%252C%2520oleandomycin%2520and%2520erythralosamine%2520derivatives.%2520Importance%2520of%2520structural%2520factor%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1989%26volume%3D38%26spage%3D2061%26epage%3D2068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Ekroos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjogren, T.</span><span> </span><span class="NLM_article-title">Structural basis for ligand promiscuity in cytochrome P450 3A4</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">13682</span><span class="NLM_x">–</span> <span class="NLM_lpage">13687</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1073%2Fpnas.0603236103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=16954191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFerurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=13682-13687&author=M.+Ekroosauthor=T.+Sjogren&title=Structural+basis+for+ligand+promiscuity+in+cytochrome+P450+3A4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for ligand promiscuity in cytochrome P 450 3A4</span></div><div class="casAuthors">Ekroos, Marika; Sjoegren, Tove</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">13682-13687</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Cytochrome P 450 (CYP) 3A4 is the most promiscuous of the human CYP isoforms and contributes to the metab. of ∼50% of marketed drugs.  It is also the isoform most often involved in unwanted drug-drug interactions.  A better understanding of the mol. mechanisms governing CYP3A4-ligand interactions therefore would be of great importance to any drug discovery effort.  Here, the authors present crystal structures of human CYP3A4 in complex with 2 well-characterized drugs, ketoconazole and erythromycin.  In contrast to previous reports, the protein undergoes dramatic conformational changes upon ligand binding with an increase in the active site vol. by >80%.  The structures represent 2 distinct open conformations of CYP3A4 because ketoconazole and erythromycin induce different types of coordinate shifts.  The binding of 2 mols. of ketoconazole to the CYP3A4 active site and the clear indication of multiple binding modes for erythromycin has implications for the interpretation of the atypical kinetic data often displayed by CYP3A4.  The extreme flexibility revealed by the present structures also challenges any attempt to apply computational design tools without the support of relevant exptl. data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnDKVSe72voLVg90H21EOLACvtfcHk0lh-DSYu-7OF-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFerurs%253D&md5=d343043ae054f93d9de31148c09bb987</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0603236103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0603236103%26sid%3Dliteratum%253Aachs%26aulast%3DEkroos%26aufirst%3DM.%26aulast%3DSjogren%26aufirst%3DT.%26atitle%3DStructural%2520basis%2520for%2520ligand%2520promiscuity%2520in%2520cytochrome%2520P450%25203A4%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D13682%26epage%3D13687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Paris, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheinkoenig, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ndikum-Moffor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, A.</span><span> </span><span class="NLM_article-title">In vitro inhibition and induction of human liver cytochrome P450 enzymes by milnacipran</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">2045</span><span class="NLM_x">–</span> <span class="NLM_lpage">2054</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=2045-2054&author=B.+L.+Parisauthor=B.+W.+Ogilvieauthor=J.+A.+Scheinkoenigauthor=F.+Ndikum-Mofforauthor=R.+Gibsonauthor=A.+Parkinson&title=In+vitro+inhibition+and+induction+of+human+liver+cytochrome+P450+enzymes+by+milnacipran"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParis%26aufirst%3DB.%2BL.%26aulast%3DOgilvie%26aufirst%3DB.%2BW.%26aulast%3DScheinkoenig%26aufirst%3DJ.%2BA.%26aulast%3DNdikum-Moffor%26aufirst%3DF.%26aulast%3DGibson%26aufirst%3DR.%26aulast%3DParkinson%26aufirst%3DA.%26atitle%3DIn%2520vitro%2520inhibition%2520and%2520induction%2520of%2520human%2520liver%2520cytochrome%2520P450%2520enzymes%2520by%2520milnacipran%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D2045%26epage%3D2054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Chan, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">New, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. C.</span><span> </span><span class="NLM_article-title">Reversible time-dependent inhibition of cytochrome P450 enzymes by duloxetine and inertness of its thiophene ring towards bioactivation</span> <span class="citation_source-journal">Toxicol. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">206</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.toxlet.2011.07.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=21839818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1agurfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=206&publication_year=2011&pages=314-324&author=C.+Y.+Chanauthor=L.+S.+Newauthor=H.+K.+Hoauthor=E.+C.+Chan&title=Reversible+time-dependent+inhibition+of+cytochrome+P450+enzymes+by+duloxetine+and+inertness+of+its+thiophene+ring+towards+bioactivation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible time-dependent inhibition of cytochrome P450 enzymes by duloxetine and inertness of its thiophene ring towards bioactivation</span></div><div class="casAuthors">Chan, Chun Yip; New, Lee Sun; Ho, Han Kiat; Chan, Eric Chun Yong</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">206</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">314-324</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Duloxetine is a selective serotonin-norepinephrine reuptake inhibitor (SNRI) approved to treat major depressive disorder and diabetic peripheral neuropathic pain.  It is known to cause hepatotoxicity, in some cases leading to death.  It has been reported that duloxetine causes time-dependent inhibition (TDI) of CYP1A2, CYP2B6, CYP2C19 and CYP3A4/5; but the nature of these TDI (whether reversible or irreversible) is not known.  Irreversible TDI can cause clin. significant drug-drug interactions and also immune-mediated hepatotoxicity.  Structurally, duloxetine possesses several toxicophores, i.e. the naphthyl and thiophene rings.  It has been reported that the naphthyl ring undergoes epoxidn. and was subsequently adducted to glutathione, but bioactivation related to the thiophene ring has not been completely elucidated.  In this paper, the potential of duloxetine in causing irreversible TDI and generating reactive metabolites was investigated.  Human liver microsomal assays demonstrated that duloxetine did not cause irreversible TDI of CYP1A2, CYP2B6, CYP2D6, CYP2C19 and CYP3A4/5.  Subsequently, reactive metabolite trapping assays using soft nucleophiles (glutathione and glutathione Et ester) revealed a previously reported adduct at the naphthyl ring of duloxetine but not at the thiophene ring.  Trapping assays utilizing a hard nucleophile (semicarbazide) did not demonstrate adducts with the thiophene ring, indicating an absence of thiophene ring opening.  The hepatotoxicity of duloxetine is possibly not related to the irreversible TDI of CYP450 or the bioactivation of its thiophene moiety, but might be due to the epoxidn. of its naphthyl ring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2Ze6sQYk6W7Vg90H21EOLACvtfcHk0livLcFefsTGcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1agurfL&md5=7e61dd91445d7427fe939e5cd0a2642b</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.toxlet.2011.07.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.toxlet.2011.07.019%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DC.%2BY.%26aulast%3DNew%26aufirst%3DL.%2BS.%26aulast%3DHo%26aufirst%3DH.%2BK.%26aulast%3DChan%26aufirst%3DE.%2BC.%26atitle%3DReversible%2520time-dependent%2520inhibition%2520of%2520cytochrome%2520P450%2520enzymes%2520by%2520duloxetine%2520and%2520inertness%2520of%2520its%2520thiophene%2520ring%2520towards%2520bioactivation%26jtitle%3DToxicol.%2520Lett.%26date%3D2011%26volume%3D206%26spage%3D314%26epage%3D324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Knadler, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chappell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, R.</span><span> </span><span class="NLM_article-title">Duloxetine: clinical pharmacokinetics and drug interactions</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">281</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2165%2F11539240-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=21366359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntlKlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=281-294&author=M.+P.+Knadlerauthor=E.+Loboauthor=J.+Chappellauthor=R.+Bergstrom&title=Duloxetine%3A+clinical+pharmacokinetics+and+drug+interactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Duloxetine: clinical pharmacokinetics and drug interactions</span></div><div class="casAuthors">Knadler, Mary Pat; Lobo, Evelyn; Chappell, Jill; Bergstrom, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">281-294</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  Duloxetine, a potent reuptake inhibitor of serotonin (5-HT) and norepinephrine, is effective for the treatment of major depressive disorder, diabetic neuropathic pain, stress urinary incontinence, generalized anxiety disorder and fibromyalgia.  Duloxetine achieves a max. plasma concn. (Cmax) of approx. 47 ng/mL (40 mg twice-daily dosing) to 110 ng/mL (80 mg twice-daily dosing) approx. 6 h after dosing.  The elimination half-life of duloxetine is approx. 10-12 h and the vol. of distribution is approx. 1640 L.  The goal of this paper is to provide a review of the literature on intrinsic and extrinsic factors that may impact the pharmacokinetics of duloxetine with a focus on concomitant medications and their clin. implications.  Patient demog. characteristics found to influence the pharmacokinetics of duloxetine include sex, smoking status, age, ethnicity, cytochrome P 450 (CYP) 2D6 genotype, hepatic function and renal function.  Of these, only impaired hepatic function or severely impaired renal function warrant specific warnings or dose recommendations.  Pharmacokinetic results from drug interaction studies show that activated charcoal decreases duloxetine exposure, and that CYP1A2 inhibition increases duloxetine exposure to a clin. significant degree.  Specifically, following oral administration in the presence of fluvoxamine, the area under the plasma concn.-time curve and Cmax of duloxetine significantly increased by 460% (90% CI 359, 584) and 141% (90% CI 93, 200), resp.  In addn., smoking is assocd. with a 30% decrease in duloxetine concn.  The exposure of duloxetine with CYP2D6 inhibitors or in CYP2D6 poor metabolizers is increased to a lesser extent than that obsd. with CYP1A2 inhibition and does not require a dose adjustment.  In addn., duloxetine increases the exposure of drugs that are metabolized by CYP2D6, but not CYP1A2.  Pharmacodynamic study results indicate that duloxetine may enhance the effects of benzodiazepines, but not alc. or warfarin.  An increase in gastric pH produced by histamine H2-receptor antagonists or antacids did not impact the absorption of duloxetine.  While duloxetine is generally well tolerated, it is important to be knowledgeable about the potential for pharmacokinetic interactions between duloxetine and drugs that inhibit CYP1A2 or drugs that are metabolized by CYP2D6 enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6yAIBWsbwCrVg90H21EOLACvtfcHk0lh53rARMDA_LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntlKlsbg%253D&md5=5e453b083889f9c03e87e4b3aa7ad19a</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.2165%2F11539240-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11539240-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DKnadler%26aufirst%3DM.%2BP.%26aulast%3DLobo%26aufirst%3DE.%26aulast%3DChappell%26aufirst%3DJ.%26aulast%3DBergstrom%26aufirst%3DR.%26atitle%3DDuloxetine%253A%2520clinical%2520pharmacokinetics%2520and%2520drug%2520interactions%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2011%26volume%3D50%26spage%3D281%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vashishtha, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erve, J. C.</span><span> </span><span class="NLM_article-title">Characterization of glutathione conjugates of duloxetine by mass spectrometry and evaluation of in silico approaches to rationalize the site of conjugation for thiophene containing rings</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1393</span><span class="NLM_x">–</span> <span class="NLM_lpage">1404</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx100141d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=1393-1404&author=G.+Wuauthor=S.+C.+Vashishthaauthor=J.+C.+Erve&title=Characterization+of+glutathione+conjugates+of+duloxetine+by+mass+spectrometry+and+evaluation+of+in+silico+approaches+to+rationalize+the+site+of+conjugation+for+thiophene+containing+rings"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Ftx100141d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx100141d%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DVashishtha%26aufirst%3DS.%2BC.%26aulast%3DErve%26aufirst%3DJ.%2BC.%26atitle%3DCharacterization%2520of%2520glutathione%2520conjugates%2520of%2520duloxetine%2520by%2520mass%2520spectrometry%2520and%2520evaluation%2520of%2520in%2520silico%2520approaches%2520to%2520rationalize%2520the%2520site%2520of%2520conjugation%2520for%2520thiophene%2520containing%2520rings%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2010%26volume%3D23%26spage%3D1393%26epage%3D1404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Winston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boffito, M.</span><span> </span><span class="NLM_article-title">The management of HIV-1 protease inhibitor pharmacokinetic interactions</span> <span class="citation_source-journal">J. Antimicrob. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1093%2Fjac%2Fdki184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15941777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmsV2iur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2005&pages=1-5&author=A.+Winstonauthor=M.+Boffito&title=The+management+of+HIV-1+protease+inhibitor+pharmacokinetic+interactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">The management of HIV-1 protease inhibitor pharmacokinetic interactions</span></div><div class="casAuthors">Winston, Alan; Boffito, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-5</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  The HIV-1 protease inhibitors (PIs) are widely used in combination antiretroviral therapy for the management of HIV-1 infection.  Certain characteristics of the PIs, in particular their metab. being mainly via the cytochrome P 450 isoenzyme group and their gastric absorption being pH dependent, make them prone to clin. significant drug interactions with other antiretrovirals, concomitant medication and complementary treatments.  Owing to the nature of the disease, individuals with HIV are frequently prescribed complex treatment regimens (both for the management of intolerance, toxicity and viral resistance to antiretroviral therapy, and in the management of co-morbid states) that may interact with PI therapy.  For many of these potential interactions, few data are available.  This review will focus on the current use of PIs, highlighting some important management issues encountered with common pharmacokinetic interactions seen in clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_nyqEZk_mlLVg90H21EOLACvtfcHk0lh53rARMDA_LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmsV2iur8%253D&md5=6364cefc26a387dd411167586a216d4d</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdki184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdki184%26sid%3Dliteratum%253Aachs%26aulast%3DWinston%26aufirst%3DA.%26aulast%3DBoffito%26aufirst%3DM.%26atitle%3DThe%2520management%2520of%2520HIV-1%2520protease%2520inhibitor%2520pharmacokinetic%2520interactions%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2005%26volume%3D56%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Ernest, C. S.,  2nd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. R.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of CYP3A by HIV protease inhibitors</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x">, </span> <span class="NLM_fpage">583</span><span class="NLM_x">–</span> <span class="NLM_lpage">591</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1124%2Fjpet.104.075416" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15523003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsVCnsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2005&pages=583-591&author=C.+S.+Ernestauthor=S.+D.+Hallauthor=D.+R.+Jones&title=Mechanism-based+inactivation+of+CYP3A+by+HIV+protease+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inactivation of CYP3A by HIV protease inhibitors</span></div><div class="casAuthors">Ernest, C. Steven, II; Hall, Stephen D.; Jones, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">583-591</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Human immunodeficiency virus (HIV) protease inhibitors (PIs) are inhibitors of CYP3A enzymes, but the mechanism is poorly defined.  In this study, time- and concn.-dependent decreases in activity as defined by max. rate of inactivation (kinact) and inhibitor concn. that gives 50% maximal inactivation (K1) of CYP3A by amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir were quantified using testosterone 6β-hydroxylation as a marker for CYP3A activity with recombinant CYP3A4(+b5), recombinant CYP3A5, and pooled human liver microsomes (HLMs).  All the PIs, except indinavir, displayed inactivation with CYP3A4(+b5) and HLMs.  Ritonavir was the most potent (K1 = 0.10 and 0.17 μM) and demonstrated high kinact values (0.32 and 0.40 min-1) with both CYP3A4(+b5) and HLMs.  Ritonavir was not significantly depleted by high-affinity binding with CYP3A4(+b5) and confirmed that estn. of reversible inhibition was confounded with irreversible inhibition.  For CYP3A5, nelfinavir exhibited the highest kinact (0.47 min-1), but ritonavir was the most potent (K1 = 0.12 μM).  Saquinavir and indinavir did not show time- and concn.-dependent decreases in activity with CYP3A5.  Spectrophotometrically detd. metabolic intermediate complex formation was obsd. for all of the PIs with CYP3A4(+b5), except for lopinavir and saquinavir.  The addn. of nucleophilic and free aldehyde trapping agents and free iron and reactive oxygen species scavengers did not prevent inactivation of CYP3A4(+b5) by ritonavir, amprenavir, or nelfinavir, but glutathione decreased the inactivation by saquinavir (17%) and catalase decreased the inactivation by lopinavir (39%).  In conclusion, all the PIs exhibited mechanism-based inactivation, and predictions of the extent and time course of drug interactions with PIs could be underestimated if based solely on reversible inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjaqMRAR0CXbVg90H21EOLACvtfcHk0lju_uN0YUZ0Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsVCnsb0%253D&md5=514ecebccd37156c9ef12621d7e98c82</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.075416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.075416%26sid%3Dliteratum%253Aachs%26aulast%3DErnest%26aufirst%3DC.%2BS.%26aulast%3DHall%26aufirst%3DS.%2BD.%26aulast%3DJones%26aufirst%3DD.%2BR.%26atitle%3DMechanism-based%2520inactivation%2520of%2520CYP3A%2520by%2520HIV%2520protease%2520inhibitors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D312%26spage%3D583%26epage%3D591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Lillibridge, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quart, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shetty, B. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. A.</span><span> </span><span class="NLM_article-title">Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus protease inhibitor nelfinavir mesylate</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">–</span> <span class="NLM_lpage">616</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1998&pages=609-616&author=J.+H.+Lillibridgeauthor=B.+H.+Liangauthor=B.+M.+Kerrauthor=S.+Webberauthor=B.+Quartauthor=B.+V.+Shettyauthor=C.+A.+Lee&title=Characterization+of+the+selectivity+and+mechanism+of+human+cytochrome+P450+inhibition+by+the+human+immunodeficiency+virus+protease+inhibitor+nelfinavir+mesylate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLillibridge%26aufirst%3DJ.%2BH.%26aulast%3DLiang%26aufirst%3DB.%2BH.%26aulast%3DKerr%26aufirst%3DB.%2BM.%26aulast%3DWebber%26aufirst%3DS.%26aulast%3DQuart%26aufirst%3DB.%26aulast%3DShetty%26aufirst%3DB.%2BV.%26aulast%3DLee%26aufirst%3DC.%2BA.%26atitle%3DCharacterization%2520of%2520the%2520selectivity%2520and%2520mechanism%2520of%2520human%2520cytochrome%2520P450%2520inhibition%2520by%2520the%2520human%2520immunodeficiency%2520virus%2520protease%2520inhibitor%2520nelfinavir%2520mesylate%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1998%26volume%3D26%26spage%3D609%26epage%3D616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Kempf, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denissen, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukulka, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granneman, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baroldi, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pizzuti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plattner, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norbeck, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, J. M.</span><span> </span><span class="NLM_article-title">Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">654</span><span class="NLM_x">–</span> <span class="NLM_lpage">660</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1997&pages=654-660&author=D.+J.+Kempfauthor=K.+C.+Marshauthor=G.+Kumarauthor=A.+D.+Rodriguesauthor=J.+F.+Denissenauthor=E.+McDonaldauthor=M.+J.+Kukulkaauthor=A.+Hsuauthor=G.+R.+Grannemanauthor=P.+A.+Baroldiauthor=E.+Sunauthor=D.+Pizzutiauthor=J.+J.+Plattnerauthor=D.+W.+Norbeckauthor=J.+M.+Leonard&title=Pharmacokinetic+enhancement+of+inhibitors+of+the+human+immunodeficiency+virus+protease+by+coadministration+with+ritonavir"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKempf%26aufirst%3DD.%2BJ.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DKumar%26aufirst%3DG.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26aulast%3DDenissen%26aufirst%3DJ.%2BF.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DKukulka%26aufirst%3DM.%2BJ.%26aulast%3DHsu%26aufirst%3DA.%26aulast%3DGranneman%26aufirst%3DG.%2BR.%26aulast%3DBaroldi%26aufirst%3DP.%2BA.%26aulast%3DSun%26aufirst%3DE.%26aulast%3DPizzuti%26aufirst%3DD.%26aulast%3DPlattner%26aufirst%3DJ.%2BJ.%26aulast%3DNorbeck%26aufirst%3DD.%2BW.%26aulast%3DLeonard%26aufirst%3DJ.%2BM.%26atitle%3DPharmacokinetic%2520enhancement%2520of%2520inhibitors%2520of%2520the%2520human%2520immunodeficiency%2520virus%2520protease%2520by%2520coadministration%2520with%2520ritonavir%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1997%26volume%3D41%26spage%3D654%26epage%3D660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J.</span><span> </span><span class="NLM_article-title">Metabolomic screening and identification of bioactivation pathways of ritonavir</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2109</span><span class="NLM_x">–</span> <span class="NLM_lpage">2114</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=2109-2114&author=X.+Maauthor=F.+Liauthor=J.+Lu&title=Metabolomic+screening+and+identification+of+bioactivation+pathways+of+ritonavir"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DJ.%26atitle%3DMetabolomic%2520screening%2520and%2520identification%2520of%2520bioactivation%2520pathways%2520of%2520ritonavir%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D2109%26epage%3D2114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Mathias, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">German, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kearney, B. P.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity</span> <span class="citation_source-journal">Clin. Pharmacol. Ther</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">322</span><span class="NLM_x">–</span> <span class="NLM_lpage">329</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1038%2Fclpt.2009.228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=20043009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitVSqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2010&pages=322-329&author=A.+A.+Mathiasauthor=P.+Germanauthor=B.+P.+Murrayauthor=L.+Weiauthor=A.+Jainauthor=S.+Westauthor=D.+Warrenauthor=J.+Huiauthor=B.+P.+Kearney&title=Pharmacokinetics+and+pharmacodynamics+of+GS-9350%3A+a+novel+pharmacokinetic+enhancer+without+anti-HIV+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer without Anti-HIV Activity</span></div><div class="casAuthors">Mathias, A. A.; German, P.; Murray, B. P.; Wei, L.; Jain, A.; West, S.; Warren, D.; Hui, J.; Kearney, B. P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">322-329</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">GS-9350 is a new chem. entity under development as a potent, mechanism-based inhibitor of human cytochrome P 450 3A (CYP3A) isoforms.  Its intended use is to increase the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes.  Unlike ritonavir, which is in current clin. use for this purpose, GS-9350 is devoid of anti-HIV activity.  The pharmacokinetics of GS-9350 and its efficacy in increasing systemic exposure of the probe CYP3A substrate midazolam were examd. in a study involving single- and multiple-dose escalations of GS-9350 from 50 to 400 mg.  Single-dose escalation from 50 to 400 mg resulted in a 164-fold increase in GS-9350 exposure, whereas multiple-dose escalation in the dosage range of 50-300 mg resulted in a 47-fold increase in exposure.  GS-9350 potently inhibited midazolam apparent clearance (95% redn.), similar in effect to ritonavir 100 mg.  GS-9350 was generally well tolerated at all doses, and there was no evidence of dose-limiting toxicity.  Establishing proof-of-concept, GS-9350 is currently under phase II development as a potential alternative to ritonavir for use with antiretroviral agents (including the HIV integrase inhibitor elvitegravir) that are often prescribed along with a "booster" drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIdpdocXWNQbVg90H21EOLACvtfcHk0lj9mD4D-yixCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitVSqtbw%253D&md5=1cc99e46f1178edb9507664fc19406b7</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2009.228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2009.228%26sid%3Dliteratum%253Aachs%26aulast%3DMathias%26aufirst%3DA.%2BA.%26aulast%3DGerman%26aufirst%3DP.%26aulast%3DMurray%26aufirst%3DB.%2BP.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DJain%26aufirst%3DA.%26aulast%3DWest%26aufirst%3DS.%26aulast%3DWarren%26aufirst%3DD.%26aulast%3DHui%26aufirst%3DJ.%26aulast%3DKearney%26aufirst%3DB.%2BP.%26atitle%3DPharmacokinetics%2520and%2520pharmacodynamics%2520of%2520GS-9350%253A%2520a%2520novel%2520pharmacokinetic%2520enhancer%2520without%2520anti-HIV%2520activity%26jtitle%3DClin.%2520Pharmacol.%2520Ther%26date%3D2010%26volume%3D87%26spage%3D322%26epage%3D329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaz, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lame, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soglia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abramov, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendsch, Z. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hop, C. E.</span><span> </span><span class="NLM_article-title">Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P4503A4</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=243-253&author=A.+S.+Kalgutkarauthor=A.+D.+Vazauthor=M.+E.+Lameauthor=K.+R.+Henneauthor=J.+Sogliaauthor=S.+X.+Zhaoauthor=Y.+A.+Abramovauthor=F.+Lombardoauthor=C.+Collinauthor=Z.+S.+Hendschauthor=C.+E.+Hop&title=Bioactivation+of+the+nontricyclic+antidepressant+nefazodone+to+a+reactive+quinone-imine+species+in+human+liver+microsomes+and+recombinant+cytochrome+P4503A4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DVaz%26aufirst%3DA.%2BD.%26aulast%3DLame%26aufirst%3DM.%2BE.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DSoglia%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DAbramov%26aufirst%3DY.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DCollin%26aufirst%3DC.%26aulast%3DHendsch%26aufirst%3DZ.%2BS.%26aulast%3DHop%26aufirst%3DC.%2BE.%26atitle%3DBioactivation%2520of%2520the%2520nontricyclic%2520antidepressant%2520nefazodone%2520to%2520a%2520reactive%2520quinone-imine%2520species%2520in%2520human%2520liver%2520microsomes%2520and%2520recombinant%2520cytochrome%2520P4503A4%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D243%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Bauman, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawant, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsky, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span> </span><span class="NLM_article-title">Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1016</span><span class="NLM_x">–</span> <span class="NLM_lpage">1029</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1124%2Fdmd.108.020545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=18332080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVOmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1016-1029&author=J.+N.+Baumanauthor=K.+S.+Frederickauthor=A.+Sawantauthor=R.+L.+Walskyauthor=L.+M.+Coxauthor=R.+S.+Obachauthor=A.+S.+Kalgutkar&title=Comparison+of+the+bioactivation+potential+of+the+antidepressant+and+hepatotoxin+nefazodone+with+aripiprazole%2C+a+structural+analog+and+marketed+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug</span></div><div class="casAuthors">Bauman, Jonathan N.; Frederick, Kosea S.; Sawant, Aarti; Walsky, Robert L.; Cox, Loretta M.; Obach, Ronald S.; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1016-1029</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In vitro metab./bioactivation of structurally related central nervous system agents nefazodone (hepatotoxin) and aripiprazole (nonhepatotoxin) were undertaken in human liver microsomes in an attempt to understand the differences in toxicol. profile.  NADPH-supplemented microsomal incubations of nefazodone and glutathione generated conjugates derived from addn. of thiol to quinonoid intermediates.  Inclusion of cyanide afforded cyano conjugates to iminium ions derived from α-carbon oxidn. of the piperazine ring in nefazodone and downstream metabolites.  Although the arylpiperazine motif in aripiprazole did not succumb to bioactivation, the dihydroquinolinone group was bioactivated via an intermediate monohydroxy metabolite to a reactive species, which was trapped by glutathione.  Studies with synthetic dehydroaripiprazole metabolite revealed an analogous glutathione conjugate with mol. wt. 2 Da lower.  Based on the proposed structure of the glutathione conjugate(s), a bioactivation sequence involving arom. ortho- or para-hydroxylation on the quinolinone followed by oxidn. to a quinone-imine was proposed.  P 4503A4 inactivation studies in microsomes indicated that, unlike nefazodone, aripiprazole was not a time- and concn.-dependent inactivator of the enzyme.  Overall, these studies reinforce the notion that not all drugs that are bioactivated in vitro elicit a toxicol. response in vivo.  A likely explanation for the markedly improved safety profile of aripiprazole (vs. nefazodone) despite the accompanying bioactivation liability is the vastly improved pharmacokinetics (enhanced oral bioavailability, longer elimination half-life) due to reduced P 4503A4-mediated metab./bioactivation, which result in a lower daily dose (5-20 mg/day) compared with nefazodone (200-400 mg/day).  This attribute probably reduces the total body burden to reactive metabolite exposure and may not exceed a threshold needed for toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVpVGcV7pKb7Vg90H21EOLACvtfcHk0lhFbldkgn7KWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVOmtbo%253D&md5=fbc3413e2855e61631687d253971a08c</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.020545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.020545%26sid%3Dliteratum%253Aachs%26aulast%3DBauman%26aufirst%3DJ.%2BN.%26aulast%3DFrederick%26aufirst%3DK.%2BS.%26aulast%3DSawant%26aufirst%3DA.%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DCox%26aufirst%3DL.%2BM.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DComparison%2520of%2520the%2520bioactivation%2520potential%2520of%2520the%2520antidepressant%2520and%2520hepatotoxin%2520nefazodone%2520with%2520aripiprazole%252C%2520a%2520structural%2520analog%2520and%2520marketed%2520drug%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D1016%26epage%3D1029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Greene, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbhaiya, R. H.</span><span> </span><span class="NLM_article-title">Clinical pharmacokinetics of nefazodone</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2165%2F00003088-199733040-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=9342502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK2sXntVGgtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1997&pages=260-275&author=D.+S.+Greeneauthor=R.+H.+Barbhaiya&title=Clinical+pharmacokinetics+of+nefazodone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of nefazodone</span></div><div class="casAuthors">Greene, Douglas S.; Barbhaiya, Rashmi H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">260-275</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">A review with 51 refs.  Nefazodone is a new antidepressant drug, chem. unrelated to the tricyclic, tetracyclic or selective serotonin uptake inhibitors.  Nefazodone blocks the serotonin 5-HT2 receptors and reversibly inhibits serotonin reuptake in vivo.  Nefazodone is completely and rapidly absorbed after oral administration with a peak plasma concn. obsd. within 2 h of administration.  Nefazodone undergoes significant first-pass metab. resulting in an oral bioavailability of approx. 20%.  Although there is an 18% increase in nefazodone bioavailability with food, this increase is not clin. significant and nefazodone can be administered without regard to meals.  Three pharmacol. active nefazodone metabolites have been identified: hydroxy-nefazodone, triazoledione and m-chlorophenylpiperazine (mCPP).  The pharmacokinetics of nefazodone are nonlinear.  The increase in plasma concns. of nefazodone are greater than would be expected if they were proportional to increases in dose.  Steady-state plasma concns. of nefazodone are attained within 4 days of the commencement of administration.  The pharmacokinetics of nefazodone are not appreciably altered in patients with renal or mild-to-moderate hepatic impairment.  However, nefazodone plasma concns. are increased in severe hepatic impairment and in the elderly, esp. in elderly females.  Lower doses of nefazodone may be necessary in these groups.  Nefazodone is a weak inhibitor of cytochrome P 450 (CYP) 2D6 and does not inhibit CYP1A2.  It is not anticipated that nefazodone will interact with drugs cleared by these isoenzymes.  Indeed, nefazodone did not affect the pharmacokinetics of theophylline, a compd. cleared by CYP1A2.  Nefazodone is metabolized by and inhibits CYP3A4.  Clin. significant interactions have been obsd. between nefazodone and the benzodiazepines triazolam and alprazolam, cyclosporin and carbamazepine.  The potential for a clin. significant interaction between nefazodone and other drugs cleared by CYP3A4 (e.g. terfenadine) should be considered before the coadministration of these compds.  There was an increase in haloperidol plasma concns. when coadministered with nefazodone; nefazodone pharmacokinetics were not affected after coadministration.  No clin. significant interaction was obsd. when nefazodone was administered with lorazepam, lithium, alc., cimetidine, warfarin, theophylline or propranolol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowyKhx9mQWVrVg90H21EOLACvtfcHk0lhFbldkgn7KWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXntVGgtrk%253D&md5=a5606549e2a64ad8d479197334bc3b65</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.2165%2F00003088-199733040-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199733040-00002%26sid%3Dliteratum%253Aachs%26aulast%3DGreene%26aufirst%3DD.%2BS.%26aulast%3DBarbhaiya%26aufirst%3DR.%2BH.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520nefazodone%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1997%26volume%3D33%26spage%3D260%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">DeVane, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donovan, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liston, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markowitz, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risch, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willard, L.</span><span> </span><span class="NLM_article-title">Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers</span> <span class="citation_source-journal">J. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1097%2F01.jcp.0000104908.75206.26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=14709940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtlCmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=4-10&author=C.+L.+DeVaneauthor=J.+L.+Donovanauthor=H.+L.+Listonauthor=J.+S.+Markowitzauthor=K.+T.+Chengauthor=S.+C.+Rischauthor=L.+Willard&title=Comparative+CYP3A4+inhibitory+effects+of+venlafaxine%2C+fluoxetine%2C+sertraline%2C+and+nefazodone+in+healthy+volunteers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative CYP3A4 Inhibitory Effects of Venlafaxine, Fluoxetine, Sertraline, and Nefazodone in Healthy Volunteers</span></div><div class="casAuthors">DeVane, C. Lindsay; Donovan, Jennifer L.; Liston, Heidi L.; Markowitz, John S.; Cheng, Kenneth T.; Risch, S. Craig; Willard, Lauren</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-10</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">An antidepressant for use in the patient receiving concomitant drug treatment, over-the-counter medications, or herbal products should lack cytochrome P 450 (CYP) 3A4 inductive or inhibitory activity to provide the least likelihood of a drug-drug interaction.  This study addresses the potential of 4 diverse antidepressants (venlafaxine, nefazodone, sertraline, and fluoxetine) to inhibit or induce CYP3A4.  In a 4-way crossover design, 16 subjects received clin. relevant doses of venlafaxine, nefazodone, or sertraline for 8 days or fluoxetine for 11 days.  Treatments were sepd. by a 7- to 14-day washout period and fluoxetine was always the last antidepressant taken.  CYP3A4 activity was evaluated for each subject at baseline and following each antidepressant using the erythromycin breath test (EBT) and by the pharmacokinetics of alprazolam (ALPZ) after 2-mg dose of oral ALPZ.  Compared to baseline, venlafaxine, sertraline, and fluoxetine caused no apparent inhibition or induction of erythromycin metab. (P > 0.05).  For nefazodone, a statistically significant inhibition was obsd. (P < 0.0005).  Nefazodone was also the only antidepressant that caused a significant change in ALPZ disposition, decreasing its area under the concn.-vs.-time curve (AUC; P < 0.01), and increasing its elimination half-life (16.4 vs. 12.3 h; P < 0.05) compared with values at baseline.  No significant differences were found in the pharmacokinetics of ALPZ with any of the other antidepressants tested.  These results demonstrate in vivo that, unlike nefazodone, venlafaxine, sertraline, and fluoxetine do not possess significant metabolic inductive or inhibitory effects on CYP3A4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQJt9i-5P-L7Vg90H21EOLACvtfcHk0lhFbldkgn7KWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtlCmsw%253D%253D&md5=a445f0a02a02c9e17710a691b5e1ffab</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1097%2F01.jcp.0000104908.75206.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.jcp.0000104908.75206.26%26sid%3Dliteratum%253Aachs%26aulast%3DDeVane%26aufirst%3DC.%2BL.%26aulast%3DDonovan%26aufirst%3DJ.%2BL.%26aulast%3DListon%26aufirst%3DH.%2BL.%26aulast%3DMarkowitz%26aufirst%3DJ.%2BS.%26aulast%3DCheng%26aufirst%3DK.%2BT.%26aulast%3DRisch%26aufirst%3DS.%2BC.%26aulast%3DWillard%26aufirst%3DL.%26atitle%3DComparative%2520CYP3A4%2520inhibitory%2520effects%2520of%2520venlafaxine%252C%2520fluoxetine%252C%2520sertraline%252C%2520and%2520nefazodone%2520in%2520healthy%2520volunteers%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2004%26volume%3D24%26spage%3D4%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Thompson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuels, S.</span><span> </span><span class="NLM_article-title">Rhabdomyolysis with simvastatin and nefazodone</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x">, </span> <span class="NLM_fpage">1607</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1176%2Fappi.ajp.159.9.1607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=12202291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A280%3ADC%252BD38vmtFSmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2002&pages=1607&author=M.+Thompsonauthor=S.+Samuels&title=Rhabdomyolysis+with+simvastatin+and+nefazodone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Rhabdomyolysis with simvastatin and nefazodone</span></div><div class="casAuthors">Thompson Matthew; Samuels Steven</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1607</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSy_jgJgoceo2gRQsDqrjW_fW6udTcc2eZKrvpNkxQld7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vmtFSmsQ%253D%253D&md5=c278a93efbdc46c4b662bab559713dc4</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.159.9.1607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.159.9.1607%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DM.%26aulast%3DSamuels%26aufirst%3DS.%26atitle%3DRhabdomyolysis%2520with%2520simvastatin%2520and%2520nefazodone%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2002%26volume%3D159%26spage%3D1607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Choi, S.</span><span> </span><span class="NLM_article-title">Nefazodone (Serzone) withdrawn because of hepatotoxicity</span> <span class="citation_source-journal">Can. Med. Assoc. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">169</span><span class="NLM_x">, </span> <span class="NLM_fpage">1187</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=14638657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A280%3ADC%252BD3srls1yqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2003&pages=1187&author=S.+Choi&title=Nefazodone+%28Serzone%29+withdrawn+because+of+hepatotoxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Nefazodone (Serzone) withdrawn because of hepatotoxicity</span></div><div class="casAuthors">Choi Stephen</div><div class="citationInfo"><span class="NLM_cas:title">CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1187</span>
        ISSN:<span class="NLM_cas:issn">0820-3946</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkxphSHq9grg5nADWVYHg1fW6udTcc2eZKrvpNkxQld7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3srls1yqtw%253D%253D&md5=5d755f54ddfc2569e2ce16aabd6e4371</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DS.%26atitle%3DNefazodone%2520%2528Serzone%2529%2520withdrawn%2520because%2520of%2520hepatotoxicity%26jtitle%3DCan.%2520Med.%2520Assoc.%2520J.%26date%3D2003%26volume%3D169%26spage%3D1187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soglia, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S. X.</span><span> </span><span class="NLM_article-title">Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1814</span><span class="NLM_x">–</span> <span class="NLM_lpage">1822</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx800161s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Knurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=1814-1822&author=R.+S.+Obachauthor=A.+S.+Kalgutkarauthor=J.+R.+Sogliaauthor=S.+X.+Zhao&title=Can+in+vitro+metabolism-dependent+covalent+binding+data+in+liver+microsomes+distinguish+hepatotoxic+from+nonhepatotoxic+drugs%3F+An+analysis+of+18+drugs+with+consideration+of+intrinsic+clearance+and+daily+dose"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Can In Vitro Metabolism-Dependent Covalent Binding Data in Liver Microsomes Distinguish Hepatotoxic from Nonhepatotoxic Drugs? An Analysis of 18 Drugs with Consideration of Intrinsic Clearance and Daily Dose</span></div><div class="casAuthors">Obach, R. Scott; Kalgutkar, Amit S.; Soglia, John R.; Zhao, Sabrina X.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1814-1822</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In vitro covalent binding assessments of drugs have been useful in providing retrospective insights into the assocn. between drug metab. and a resulting toxicol. response.  On the basis of these studies, it has been advocated that in vitro covalent binding to liver microsomal proteins in the presence and the absence of NADPH be used routinely to screen drug candidates.  However, the utility of this approach in predicting toxicities of drug candidates accurately remains an unanswered question.  Importantly, the years of research that have been invested in understanding metabolic bioactivation and covalent binding and its potential role in toxicity have focused only on those compds. that demonstrate toxicity.  Investigations have not frequently queried whether in vitro covalent binding could be obsd. with drugs with good safety records.  Eighteen drugs (nine hepatotoxins and nine nonhepatotoxins in humans) were assessed for in vitro covalent binding in NADPH-supplemented human liver microsomes.  Of the two sets of nine drugs, seven in each set were shown to undergo some degree of covalent binding.  Among hepatotoxic drugs, acetaminophen, carbamazepine, diclofenac, indomethacin, nefazodone, sudoxicam, and tienilic acid demonstrated covalent binding, while benoxaprofen and felbamate did not.  Of the nonhepatotoxic drugs evaluated, buspirone, diphenhydramine, meloxicam, paroxetine, propranolol, raloxifene, and simvastatin demonstrated covalent binding, while ibuprofen and theophylline did not.  A quant. comparison of covalent binding in vitro intrinsic clearance did not sep. the two groups of compds., and in fact, paroxetine, a nonhepatotoxin, showed the greatest amt. of covalent binding in microsomes.  Including factors such as the fraction of total metab. comprised by covalent binding and the total daily dose of each drug improved the discrimination between hepatotoxic and nontoxic drugs based on in vitro covalent binding data; however, the approach still would falsely identify some agents as potentially hepatotoxic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9_hVRAC3RD7Vg90H21EOLACvtfcHk0ljd5JsbdgQ6bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Knurw%253D&md5=67c82883825ef529c84d03f462b1f669</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Ftx800161s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx800161s%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26atitle%3DCan%2520in%2520vitro%2520metabolism-dependent%2520covalent%2520binding%2520data%2520in%2520liver%2520microsomes%2520distinguish%2520hepatotoxic%2520from%2520nonhepatotoxic%2520drugs%253F%2520An%2520analysis%2520of%252018%2520drugs%2520with%2520consideration%2520of%2520intrinsic%2520clearance%2520and%2520daily%2520dose%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D1814%26epage%3D1822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Zimmerlin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trunzer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faller, B.</span><span> </span><span class="NLM_article-title">CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1046</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1039-1046&author=A.+Zimmerlinauthor=M.+Trunzerauthor=B.+Faller&title=CYP3A+time-dependent+inhibition+risk+assessment+validated+with+400+reference+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DTrunzer%26aufirst%3DM.%26aulast%3DFaller%26aufirst%3DB.%26atitle%3DCYP3A%2520time-dependent%2520inhibition%2520risk%2520assessment%2520validated%2520with%2520400%2520reference%2520drugs%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1039%26epage%3D1046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lame, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaz, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soglia, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hop, C. E.</span><span> </span><span class="NLM_article-title">Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4</span> <span class="citation_source-journal">Chem.-Biol. Interact.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">155</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.cbi.2005.03.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15978881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFGisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2005&pages=10-20&author=A.+S.+Kalgutkarauthor=K.+R.+Henneauthor=M.+E.+Lameauthor=A.+D.+Vazauthor=C.+Collinauthor=J.+R.+Sogliaauthor=S.+X.+Zhaoauthor=C.+E.+Hop&title=Metabolic+activation+of+the+nontricyclic+antidepressant+trazodone+to+electrophilic+quinone-imine+and+epoxide+intermediates+in+human+liver+microsomes+and+recombinant+P4503A4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P450 3A4</span></div><div class="casAuthors">Kalgutkar, Amit S.; Henne, Kirk R.; Lame, Mary E.; Vaz, Alfin D. N.; Collin, Claire; Soglia, John R.; Zhao, Sabrina X.; Hop, Cornelis E. C. A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">10-20</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Therapy with the antidepressant trazodone has been assocd. with several cases of idiosyncratic hepatotoxicity.  While the mechanism of hepatotoxicity remains unknown, it is possible that reactive metabolites of trazodone play a causative role.  Studies were initiated to det. whether trazodone undergoes bioactivation in human liver microsomes to electrophilic intermediates.  LC/MS/MS anal. of incubations contg. trazodone and NADPH-supplemented microsomes or recombinant P 4503A4 in the presence of glutathione revealed the formation of conjugates derived from the addn. of the sulfydryl nucleophile to mono-hydroxylated- and hydrated-trazodone metabolites.  Product ion spectra suggested that mono-hydroxylation and sulfydryl conjugation occurred on the 3-chlorophenyl-ring, whereas hydration and subsequent sulfydryl conjugation had occurred on the triazolopyridinone ring system.  These findings are consistent with bioactivation sequences involving: (1) arom. hydroxylation of the 3-chlorophenyl-ring in trazodone followed by the two-electron oxidn. of this metabolite to a reactive quinone-imine intermediate, which reacts with glutathione in a 1,4-Michael fashion and (2) oxidn. of the pyridinone ring to an electrophilic epoxide, ring opening of which, by glutathione or water generates the corresponding hydrated-trazodone-thiol conjugate or the stable diol metabolite, resp.  The pathway involving trazodone bioactivation to the quinone-imine has also been obsd. with many para-hydroxyanilines including the structurally related antidepressant nefazodone.  It is proposed that the quinone-imine and/or the epoxide intermediate(s) may represent a rate-limiting step in the initiation of trazodone-mediated hepatotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolswLWloW_gbVg90H21EOLACvtfcHk0ljd5JsbdgQ6bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFGisLk%253D&md5=eac3b8b1c4e8710f6f4fc653a15e6e7d</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2005.03.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2005.03.036%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DLame%26aufirst%3DM.%2BE.%26aulast%3DVaz%26aufirst%3DA.%2BD.%26aulast%3DCollin%26aufirst%3DC.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DHop%26aufirst%3DC.%2BE.%26atitle%3DMetabolic%2520activation%2520of%2520the%2520nontricyclic%2520antidepressant%2520trazodone%2520to%2520electrophilic%2520quinone-imine%2520and%2520epoxide%2520intermediates%2520in%2520human%2520liver%2520microsomes%2520and%2520recombinant%2520P4503A4%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2005%26volume%3D155%26spage%3D10%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Di Gion, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanefendt, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheffler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshyenko, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuhr, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaehde, U.</span><span> </span><span class="NLM_article-title">Clinical pharmacokinetics of tyrosine kinase inhibitors</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">551</span><span class="NLM_x">–</span> <span class="NLM_lpage">603</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2165%2F11593320-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=21827214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1KrsLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=551-603&author=P.+Di+Gionauthor=F.+Kanefendtauthor=A.+Lindauerauthor=M.+Schefflerauthor=O.+Doroshyenkoauthor=U.+Fuhrauthor=J.+Wolfauthor=U.+Jaehde&title=Clinical+pharmacokinetics+of+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles</span></div><div class="casAuthors">Di Gion, Paola; Kanefendt, Friederike; Lindauer, Andreas; Scheffler, Matthias; Doroshyenko, Oxana; Fuhr, Uwe; Wolf, Juergen; Jaehde, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">551-603</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  Pyrimidine (imatinib, dasatinib, nilotinib and pazopanib), pyridine (sorafenib) and pyrrole (sunitinib) tyrosine kinase inhibitors (TKIs) are multi-targeted TKIs with high activity towards several families of receptor and non-receptor tyrosine kinases involved in angiogenesis, tumor growth and metastatic progression of cancer.  These orally administered TKIs have quite diverse characteristics with regard to absorption from the gastrointestinal tract.  Abs. bioavailability in humans has been investigated only for imatinib (almost 100%) and pazopanib (14-39%; n = 3).  On the basis of human radioactivity data, dasatinib is considered to be well absorbed after oral administration (19% and 0.1% of the total radioactivity were excreted as unchanged dasatinib in the faeces and urine, resp.).  Quite low abs. bioavailability under fasted conditions is assumed for nilotinib (31%), sorafenib (50%) and sunitinib (50%).  Imatinib, dasatinib and sunitinib exhibit dose-proportional increases in their area under the plasma concn.-time curve values over their therapeutic dose ranges.  Less than dose-proportional increases were obsd. for nilotinib at doses ≥400 mg/day and for sorafenib and pazopanib at doses ≥800 mg/day.  At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).  Concomitant intake of a high-fat meal does not alter exposure to imatinib, dasatinib and sunitinib but leads to considerably increased bioavailability of nilotinib and pazopanib and decreased bioavailability of sorafenib.  With the exception of pazopanib, the TKIs described here have large apparent vols. of distribution, exceeding the vol. of body water by at least 4-fold.  Very low penetration into the central nervous system in humans has been reported for imatinib and dasatinib, but there are currently no published human data for nilotinib, pazopanib, sorafenib or sunitinib.  All TKIs that have been described are more than 90% bound to the plasma proteins: α1-acid glycoprotein and/or albumin.  They are metabolized primarily via cytochrome P 450 (CYP) 3A4, the only exception being sorafenib, for which uridine diphosphate glucuronosyltransferase 1A9 is the other main enzyme involved.  Active metabolites of imatinib and sunitinib contribute to their antitumor activity.  Although some patient demographics have been identified as significant co-factors that partly explain interindividual variability in exposure to TKIs, these findings have not been regarded as sufficient to recommend age-, sex-, bodyweight- or ethnicity-specific dose adjustment.  Systemic exposure to imatinib, sorafenib and pazopanib increases in patients with hepatic impairment, and redn. of the initial therapeutic dose is recommended in this subpopulation.  The starting dose of imatinib should also be reduced in renally impaired subjects.  Because the soly. of dasatinib is pH dependent, co-administration of histamine H2-receptor antagonists and proton pump inhibitors with dasatinib should be avoided.  With the exception of sorafenib, systemic exposure to TKIs is significantly decreased/increased by co-administration of potent CYP3A4 inducers/inhibitors, and so it is strongly recommended that the TKI dose is adjusted or that such co-administration is avoided.  Caution is also recommended for co-administration of CYP3A4 substrates with TKIs, esp. for those with a narrow therapeutic index.  However, current recommendations with regard to dose adjustment of TKIs need to be validated in clin. studies.  Further investigations are needed to explain the large interindividual variability in the pharmacokinetics of these drugs and to assess the clin. relevance of their interaction potential and inhibitory effects on metabolizing enzymes and transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowEdzHq6mAsbVg90H21EOLACvtfcHk0lhXxogmmLEajQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1KrsLrF&md5=4a49fcb300a03c49a9ac58bc31d1edbe</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.2165%2F11593320-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11593320-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BGion%26aufirst%3DP.%26aulast%3DKanefendt%26aufirst%3DF.%26aulast%3DLindauer%26aufirst%3DA.%26aulast%3DScheffler%26aufirst%3DM.%26aulast%3DDoroshyenko%26aufirst%3DO.%26aulast%3DFuhr%26aufirst%3DU.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DJaehde%26aufirst%3DU.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2011%26volume%3D50%26spage%3D551%26epage%3D603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">O’Brien, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinhardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bond, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutreix, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehring, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milosavljev, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, T.</span><span> </span><span class="NLM_article-title">Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">1855</span><span class="NLM_x">–</span> <span class="NLM_lpage">1859</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1038%2Fsj.bjc.6601152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=14612892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVersrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2003&pages=1855-1859&author=S.+G.+O%E2%80%99Brienauthor=P.+Meinhardtauthor=E.+Bondauthor=J.+Beckauthor=B.+Pengauthor=C.+Dutreixauthor=G.+Mehringauthor=S.+Milosavljevauthor=C.+Huberauthor=R.+Capdevilleauthor=T.+Fischer&title=Effects+of+imatinib+mesylate+%28STI571%2C+Glivec%29+on+the+pharmacokinetics+of+simvastatin%2C+a+cytochrome+P450+3A4+substrate%2C+in+patients+with+chronic+myeloid+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia</span></div><div class="casAuthors">O'Brien, S. G.; Meinhardt, P.; Bond, E.; Beck, J.; Peng, B.; Dutreix, C.; Mehring, G.; Milosavljev, S.; Huber, C.; Capdeville, R.; Fischer, T.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1855-1859</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The inhibition by imatinib of the cytochrome P 450 3A4 isoenzyme may reduce the CYP3A4-mediated metabolic clearance of clin. important coadministered drugs.  The main purpose of this study was to evaluate the effect of the coadministration of imatinib on the pharmacokinetics of simvastatin, a probe CYP3A4 substrate.  In total, 20 patients with chronic myeloid leukemia received an oral dose of 40 mg of simvastatin on study day 1.  On study days 2-7, each patient received 400 mg of imatinib once daily orally and on study day 8, 400 mg imatinib together with 40 mg of simvastatin was given.  Blood levels of simvastatin were measured predose and for 24 h postdose on study days 1 and 8.  Two addnl. blood samples were taken for imatinib pharmacokinetic (PK) assessment on day 8 before, and 24 h after, imatinib administration.  Imatinib increased the mean max. concn. (Cmax) value of simvastatin two-fold and the area under concn.-time curve (AUC (0-inf)) value 3.5-fold (P<0.001) compared with simvastatin alone.  There was a statistically significant decrease in total-body clearance of drug from the plasma (CL/F) with a mean redn. of 70% for simvastatin (P<0.001): the mean half-life of simvastatin was prolonged from 1.4-2.7 h when given together with imatinib.  No changes in imatinib PK parameters were found when given concomitantly with simvastatin.  In conclusion, the coadministration of imatinib at steady state with 40 mg simvastatin increases the exposure (Cmax and AUCs) of simvastatin significantly (P<0.001) by two-three-fold.  Caution is therefore required when administering imatinib with CYP3A4 substrates with a narrow therapeutic window.  The coadministration of simvastatin with imatinib (400 mg) was well tolerated and no major safety findings were reported in this study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6n6TNNlDup7Vg90H21EOLACvtfcHk0lhXxogmmLEajQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVersrs%253D&md5=3d0fcc73b4d5609907bb22c8c3aab2c4</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6601152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6601152%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BG.%26aulast%3DMeinhardt%26aufirst%3DP.%26aulast%3DBond%26aufirst%3DE.%26aulast%3DBeck%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DDutreix%26aufirst%3DC.%26aulast%3DMehring%26aufirst%3DG.%26aulast%3DMilosavljev%26aufirst%3DS.%26aulast%3DHuber%26aufirst%3DC.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DFischer%26aufirst%3DT.%26atitle%3DEffects%2520of%2520imatinib%2520mesylate%2520%2528STI571%252C%2520Glivec%2529%2520on%2520the%2520pharmacokinetics%2520of%2520simvastatin%252C%2520a%2520cytochrome%2520P450%25203A4%2520substrate%252C%2520in%2520patients%2520with%2520chronic%2520myeloid%2520leukaemia%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2003%26volume%3D89%26spage%3D1855%26epage%3D1859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Connolly, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett-Mayer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeter, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donehower, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fetting, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emens, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stearns, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolff, A. C.</span><span> </span><span class="NLM_article-title">Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1007%2Fs10549-011-1413-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=21350820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksFegt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2011&pages=153-162&author=R.+M.+Connollyauthor=M.+A.+Rudekauthor=E.+Garrett-Mayerauthor=S.+C.+Jeterauthor=M.+G.+Donehowerauthor=L.+A.+Wrightauthor=M.+Zhaoauthor=J.+H.+Fettingauthor=L.+A.+Emensauthor=V.+Stearnsauthor=N.+E.+Davidsonauthor=S.+D.+Bakerauthor=A.+C.+Wolff&title=Docetaxel+metabolism+is+not+altered+by+imatinib%3A+findings+from+an+early+phase+study+in+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer</span></div><div class="casAuthors">Connolly, Roisin M.; Rudek, Michelle A.; Garrett-Mayer, Elizabeth; Jeter, Stacie C.; Donehower, Michele G.; Wright, Laurie A.; Zhao, Ming; Fetting, John H.; Emens, Leisha A.; Stearns, Vered; Davidson, Nancy E.; Baker, Sharyn D.; Wolff, Antonio C.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">153-162</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Docetaxel is primarily metabolized by CYP3A4 and susceptible to alterations in clearance by CYP3A4 inhibition and induction.  Imatinib is a CYP3A4 inhibitor.  A phase I study of docetaxel and imatinib in metastatic breast cancer (MBC) was conducted to test the hypothesis that imatinib decreased docetaxel clearance.  Docetaxel was administered weekly × 3 with daily imatinib, repeated every 28 days; during cycle 1, imatinib was started on day 8.  Docetaxel and imatinib pharmacokinetics, and hepatic CYP3A4 activity (erythromycin breath test) were evaluated during cycles 1 and 2.  Toxicity and efficacy were assessed.  Twelve patients were enrolled to three docetaxel/imatinib dose levels: 20 mg/m2/600 mg (DL1), 25 mg/m2/600 mg (DL2), and 25 mg/m2/400 mg (DL2a).  Median no. of prior chemotherapy regimens was 2 (range, 0-8).  Toxicities were primarily obsd. at DL2; dose-limiting toxicities were Grade 3 transaminase elevations and diarrhea, and 5 patients had grade 2 nausea.  Two patients had partial responses (7 mo); two stable disease (2 and 4 mo); five had progressive disease.  Despite a 42% decrease in CYP3A4 activity after 3 wk of imatinib co-administration, docetaxel clearance was unchanged.  Mean ± std. deviation steady-state imatinib trough concn. (2.6 ± 1.2 μg/mL) was approx. 2.6-fold higher than previously obsd. in other cancer populations, and likely contributed to the poor tolerability of the combination in MBC.  In conclusion, imatinib inhibited CYP3A4 but did not affect docetaxel clearance.  Clin., further investigation of this combination in MBC is not warranted due to excessive toxicities.  However, these unexpected pharmacokinetic findings support further investigation of mechanisms underlying docetaxel elimination pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTISM9lNnY77Vg90H21EOLACvtfcHk0likPVca_7enRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksFegt7o%253D&md5=3f2f258f49e34eaad76f54b024d84192</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1007%2Fs10549-011-1413-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-011-1413-6%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DR.%2BM.%26aulast%3DRudek%26aufirst%3DM.%2BA.%26aulast%3DGarrett-Mayer%26aufirst%3DE.%26aulast%3DJeter%26aufirst%3DS.%2BC.%26aulast%3DDonehower%26aufirst%3DM.%2BG.%26aulast%3DWright%26aufirst%3DL.%2BA.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DFetting%26aufirst%3DJ.%2BH.%26aulast%3DEmens%26aufirst%3DL.%2BA.%26aulast%3DStearns%26aufirst%3DV.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26aulast%3DBaker%26aufirst%3DS.%2BD.%26aulast%3DWolff%26aufirst%3DA.%2BC.%26atitle%3DDocetaxel%2520metabolism%2520is%2520not%2520altered%2520by%2520imatinib%253A%2520findings%2520from%2520an%2520early%2520phase%2520study%2520in%2520metastatic%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2011%26volume%3D127%26spage%3D153%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Filppula, A. M.; Laitila, J.; Neuvonen, P. J.; Backman, J. T.</span><span> </span><span class="NLM_article-title">Potent mechanism-based inhibition of CYP3A4 by imatinib explains its interaction liability with CYP3A4 substrates</span>.  <span class="citation_source-journal">Br. J. Pharmacol.</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01732.x</span> . Published Online: Oct 20,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1111%2Fj.1476-5381.2011.01732.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+M.+Filppula&author=J.+Laitila&author=P.+J.+Neuvonen&author=J.+T.+Backman&title=Potent+mechanism-based+inhibition+of+CYP3A4+by+imatinib+explains+its+interaction+liability+with+CYP3A4+substrates&doi=10.1111%2Fj.1476-5381.2011.01732.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01732.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01732.x%26sid%3Dliteratum%253Aachs%26aulast%3DFilppula%26aufirst%3DA.%2BM.%26atitle%3DPotent%2520mechanism-based%2520inhibition%2520of%2520CYP3A4%2520by%2520imatinib%2520explains%2520its%2520interaction%2520liability%2520with%2520CYP3A4%2520substrates%26jtitle%3DBr.%2520J.%2520Pharmacol.%26doi%3D10.1111%2Fj.1476-5381.2011.01732.x%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Haouala, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widmer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duchosal, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montemurro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buclin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decosterd, L A.</span><span> </span><span class="NLM_article-title">Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">e75</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=e75-87&author=A.+Haoualaauthor=N.+Widmerauthor=M.+A.+Duchosalauthor=M.+Montemurroauthor=T.+Buclinauthor=L+A.+Decosterd&title=Drug+interactions+with+the+tyrosine+kinase+inhibitors+imatinib%2C+dasatinib%2C+and+nilotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHaouala%26aufirst%3DA.%26aulast%3DWidmer%26aufirst%3DN.%26aulast%3DDuchosal%26aufirst%3DM.%2BA.%26aulast%3DMontemurro%26aufirst%3DM.%26aulast%3DBuclin%26aufirst%3DT.%26aulast%3DDecosterd%26aufirst%3DL%2BA.%26atitle%3DDrug%2520interactions%2520with%2520the%2520tyrosine%2520kinase%2520inhibitors%2520imatinib%252C%2520dasatinib%252C%2520and%2520nilotinib%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3De75%26epage%3D87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koenig, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, M. D.</span><span> </span><span class="NLM_article-title">Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1242</span><span class="NLM_x">–</span> <span class="NLM_lpage">1250</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1242-1250&author=X.+Liauthor=Y.+Heauthor=C.+H.+Ruizauthor=M.+Koenigauthor=M.+D.+Cameron&title=Characterization+of+dasatinib+and+its+structural+analogs+as+CYP3A4+mechanism-based+inactivators+and+the+proposed+bioactivation+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DRuiz%26aufirst%3DC.%2BH.%26aulast%3DKoenig%26aufirst%3DM.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26atitle%3DCharacterization%2520of%2520dasatinib%2520and%2520its%2520structural%2520analogs%2520as%2520CYP3A4%2520mechanism-based%2520inactivators%2520and%2520the%2520proposed%2520bioactivation%2520pathways%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1242%26epage%3D1250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Teng, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">New, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahlin, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. C.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of cytochrome P4503A4 by lapatinib</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">703</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2010&pages=693-703&author=W.+C.+Tengauthor=J.+W.+Ohauthor=L.+S.+Newauthor=M.+D.+Wahlinauthor=S.+D.+Nelsonauthor=H.+K.+Hoauthor=E.+C.+Chan&title=Mechanism-based+inactivation+of+cytochrome+P4503A4+by+lapatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTeng%26aufirst%3DW.%2BC.%26aulast%3DOh%26aufirst%3DJ.%2BW.%26aulast%3DNew%26aufirst%3DL.%2BS.%26aulast%3DWahlin%26aufirst%3DM.%2BD.%26aulast%3DNelson%26aufirst%3DS.%2BD.%26aulast%3DHo%26aufirst%3DH.%2BK.%26aulast%3DChan%26aufirst%3DE.%2BC.%26atitle%3DMechanism-based%2520inactivation%2520of%2520cytochrome%2520P4503A4%2520by%2520lapatinib%26jtitle%3DMol.%2520Pharmacol.%26date%3D2010%26volume%3D78%26spage%3D693%26epage%3D703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Takakusa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahlin, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">New, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S. D.</span><span> </span><span class="NLM_article-title">Metabolic intermediate complex formation of human cytochrome P4503A4 by lapatinib</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1022</span><span class="NLM_x">–</span> <span class="NLM_lpage">1030</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1022-1030&author=H.+Takakusaauthor=M.+D.+Wahlinauthor=C.+Zhaoauthor=K.+L.+Hansonauthor=L.+S.+Newauthor=E.+C.+Chanauthor=S.+D.+Nelson&title=Metabolic+intermediate+complex+formation+of+human+cytochrome+P4503A4+by+lapatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakakusa%26aufirst%3DH.%26aulast%3DWahlin%26aufirst%3DM.%2BD.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DHanson%26aufirst%3DK.%2BL.%26aulast%3DNew%26aufirst%3DL.%2BS.%26aulast%3DChan%26aufirst%3DE.%2BC.%26aulast%3DNelson%26aufirst%3DS.%2BD.%26atitle%3DMetabolic%2520intermediate%2520complex%2520formation%2520of%2520human%2520cytochrome%2520P4503A4%2520by%2520lapatinib%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1022%26epage%3D1030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamenecka, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, M. D.</span><span> </span><span class="NLM_article-title">Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1736</span><span class="NLM_x">–</span> <span class="NLM_lpage">1742</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx900256y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=1736-1742&author=X.+Liauthor=T.+M.+Kameneckaauthor=M.+D.+Cameron&title=Bioactivation+of+the+epidermal+growth+factor+receptor+inhibitor+gefitinib%3A+implications+for+pulmonary+and+hepatic+toxicities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Ftx900256y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx900256y%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DKamenecka%26aufirst%3DT.%2BM.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26atitle%3DBioactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%2520gefitinib%253A%2520implications%2520for%2520pulmonary%2520and%2520hepatic%2520toxicities%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D1736%26epage%3D1742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamenecka, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, M. D.</span><span> </span><span class="NLM_article-title">Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1238</span><span class="NLM_x">–</span> <span class="NLM_lpage">1245</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1238-1245&author=X.+Liauthor=T.+M.+Kameneckaauthor=M.+D.+Cameron&title=Cytochrome+P450-mediated+bioactivation+of+the+epidermal+growth+factor+receptor+inhibitor+erlotinib+to+a+reactive+electrophile"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DKamenecka%26aufirst%3DT.%2BM.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26atitle%3DCytochrome%2520P450-mediated%2520bioactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%2520erlotinib%2520to%2520a%2520reactive%2520electrophile%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1238%26epage%3D1245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Veeraputhiran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundermeyer, M.</span><span> </span><span class="NLM_article-title">Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin</span> <span class="citation_source-journal">Clin. Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">232</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.3816%2FCLC.2008.n.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=18650173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVWntb%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=232-234&author=M.+Veeraputhiranauthor=M.+Sundermeyer&title=Rhabdomyolysis+resulting+from+pharmacologic+interaction+between+erlotinib+and+simvastatin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin</span></div><div class="casAuthors">Veeraputhiran, Muthu; Sundermeyer, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lung Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">232-234</span>CODEN:
                <span class="NLM_cas:coden">CLCLCA</span>;
        ISSN:<span class="NLM_cas:issn">1525-7304</span>.
    
            (<span class="NLM_cas:orgname">CIG Media Group, LP</span>)
        </div><div class="casAbstract">Erlotinib is an epidermal growth factor receptor inhibitor indicated as a second line of therapy for locally advanced and metastatic non-small-cell lung cancer after the failure of 1 previous chemotherapy.  Simvastatin belongs to the statin family used to lower blood cholesterol.  Drug interaction between erlotinib and statin has not been reported before.  Both drugs are major substrates of the CYP3A4 enzyme in the liver.  Thus, co-administration of these drugs can increase their serum levels, potentially leading to adverse effects.  We report the interaction between erlotinib and simvastatin leading to rhabdomyolysis.  Thus, caution is required with increasing usage of both of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5pBd7vbbexbVg90H21EOLACvtfcHk0ljrlrddn6i2DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVWntb%252FF&md5=85f7cead100accac93464078c353d6fe</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.3816%2FCLC.2008.n.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3816%252FCLC.2008.n.036%26sid%3Dliteratum%253Aachs%26aulast%3DVeeraputhiran%26aufirst%3DM.%26aulast%3DSundermeyer%26aufirst%3DM.%26atitle%3DRhabdomyolysis%2520resulting%2520from%2520pharmacologic%2520interaction%2520between%2520erlotinib%2520and%2520simvastatin%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2008%26volume%3D9%26spage%3D232%26epage%3D234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lathia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchter, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redlinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span> </span><span class="NLM_article-title">Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advance melanoma: a phase I/II pharmacokinetic interaction study</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">1111</span><span class="NLM_x">–</span> <span class="NLM_lpage">1118</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1007%2Fs00280-011-1585-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=21350850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsV2iu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2011&pages=1111-1118&author=K.+T.+Flahertyauthor=C.+Lathiaauthor=R.+F.+Fryeauthor=L.+Schuchterauthor=M.+Redlingerauthor=M.+Rosenauthor=P.+J.+O%E2%80%99Dwyer&title=Interaction+of+sorafenib+and+cytochrome+P450+isoenzymes+in+patients+with+advance+melanoma%3A+a+phase+I%2FII+pharmacokinetic+interaction+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study</span></div><div class="casAuthors">Flaherty, Keith T.; Lathia, Chetan; Frye, Reginald F.; Schuchter, Lynn; Redlinger, Maryann; Rosen, Mark; O'Dwyer, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1111-1118</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background In vitro data indicate that the sorafenib is a moderate inhibitor of cytochrome P 450 (CYP) enzymes, including CYP3A4, CYP2C19, and CYP2D6.  This phase I/II study in patients with advanced melanoma evaluated the potential effect of sorafenib on the pharmacokinetics of midazolam, omeprazole, and dextromethorphan, specific substrates of CYP3A4, CYP2C19, and CYP2D6, resp.  Methods Twenty-one patients received sorafenib 400 mg twice daily for 28 consecutive days.  On days 1 and 28, a cocktail contg. midazolam 2 mg, omeprazole 20 mg, and dextromethorphan 30 mg was administered.  Pharmacokinetic analyses were performed on day 1 without sorafenib and day 28 after steady-state sorafenib exposure; sorafenib pharmacokinetics were evaluated on day 28.  We defined an interaction to be excluded if the 90% confidence interval of the ratio of all day 28:day 1 analyses fell within a range from 0.80 to 1.25.  Results In all, 18 patients were evaluable.  On day 28, area under the plasma concn.-time curve from time 0 to 12 h (AUC0-12) and max. plasma concn. (Cmax) for sorafenib were 38.1 mg h/l and 4.9 mg/l, resp.  Day 28:day 1 ratios for AUC from time 0 extrapolated to infinity (AUC0-inf) and Cmax for midazolam were 0.85 and 0.98, resp.  Day 28:day 1 ratio for 5-OH-omeprazole:omeprazole plasma concn. at 3 h postdose was 1.26, slightly outside of the 0.80-1.25 range.  Thus, an interaction could not be excluded, but is considered unlikely to be clin. significant.  Day 28:day 1 ratio for dextromethorphan:dextrorphan concn. in urine was 0.94.  Sorafenib had an acceptable safety profile.  The most frequently obsd. grade 3-4 toxicities in cycle 1 included elevated lipase (19%) and hypertension (10%).  Conclusions In this patient population, our results demonstrate that exposures of probes of CYP3A4, CYP2D6, or CYP2C19 activity are potentially altered by administration of sorafenib at 400 mg twice daily.  However, these differences are sufficiently small that a clin. significant inhibition or induction of these important drug metabolizing P 450 isoenzymes is unlikely.  Clin. and, where possible, drug level monitoring may still be appropriate for drugs of narrow therapeutic range co-administered with sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9HELt_N8Op7Vg90H21EOLACvtfcHk0lgI9Ufjs89yVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsV2iu7fN&md5=f181d46594e09645235d89e15c8d7b37</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1585-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1585-0%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DLathia%26aufirst%3DC.%26aulast%3DFrye%26aufirst%3DR.%2BF.%26aulast%3DSchuchter%26aufirst%3DL.%26aulast%3DRedlinger%26aufirst%3DM.%26aulast%3DRosen%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26atitle%3DInteraction%2520of%2520sorafenib%2520and%2520cytochrome%2520P450%2520isoenzymes%2520in%2520patients%2520with%2520advance%2520melanoma%253A%2520a%2520phase%2520I%252FII%2520pharmacokinetic%2520interaction%2520study%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2011%26volume%3D68%26spage%3D1111%26epage%3D1118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Lathia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lettieri, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cihon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallentine, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radtke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaresan, P.</span><span> </span><span class="NLM_article-title">Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">–</span> <span class="NLM_lpage">692</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1007%2Fs00280-005-0068-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=16133532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjs1KktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2006&pages=685-692&author=C.+Lathiaauthor=J.+Lettieriauthor=F.+Cihonauthor=M.+Gallentineauthor=M.+Radtkeauthor=P.+Sundaresan&title=Lack+of+effect+of+ketoconazole-mediated+CYP3A+inhibition+on+sorafenib+clinical+pharmacokinetics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics</span></div><div class="casAuthors">Lathia, Chetan; Lettieri, John; Cihon, Frank; Gallentine, Martha; Radtke, Martin; Sundaresan, Pavur</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">685-692</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Sorafenib is a novel, small-mol. anticancer compd. that inhibits tumor cell proliferation by targeting Raf in the Raf/MEK/ERK signaling pathway, and inhibits angiogenesis by targeting tyrosine kinases such as vascular-endothelial growth factor receptor (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor (PDGFR).  In vitro microsomal data indicate that sorafenib is metabolized by two pathways: phase I oxidn. mediated by cytochrome P 450 (CYP) 3A4; and phase II conjugation mediated by UGT1A9.  Approx. 50% of an orally administered dose is recovered as unchanged drug in the feces, due to either biliary excretion or lack of absorption.  The aim of this study was to evaluate the effect of CYP3A inhibition by ketoconazole on sorafenib pharmacokinetics.  This was an open-label, non-randomized, 2-period, one-way crossover study in sixteen healthy male subjects.  A single 50 mg dose of sorafenib was administered alone (period 1) and in combination with ketoconazole 400 mg once daily (period 2) (ketoconazole was given for 7 days, and a single 50 mg sorafenib dose was administered concomitantly on day 4).  No clin. relevant change in pharmacokinetics of sorafenib and no clin. relevant adverse events or lab. abnormalities were obsd. in this study upon co-administration of the two drugs.  Plasma concns. of the main CYP3A4 generated metabolite, sorafenib N-oxide, decreased considerably upon ketoconazole co-administration.  This effect is in accordance with the in vitro finding that CYP3A4 is the primary enzyme for sorafenib N-oxide formation.  Further, these data indicate that blocking sorafenib metab. by the CYP3A4 pathway will not lead to an increase in sorafenib exposure.  This is consistent with data from a clin. mass-balance study that showed 15% of the administered dose was eliminated by glucuronidation, compared to less than 5% eliminated as oxidative metabolites.  Since there was no increase in sorafenib exposure following concomitant administration of the highly potent CYP3A4 inhibitor ketoconazole with low dose sorafenib, it is postulated that higher therapeutic doses of sorafenib may be safely co-administered with ketoconazole, as well as with other inhibitors of CYP3A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV-01_MtXZH7Vg90H21EOLACvtfcHk0lgI9Ufjs89yVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjs1KktLk%253D&md5=7d13ee0c45f5280fcdaf9d6982339dec</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1007%2Fs00280-005-0068-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-005-0068-6%26sid%3Dliteratum%253Aachs%26aulast%3DLathia%26aufirst%3DC.%26aulast%3DLettieri%26aufirst%3DJ.%26aulast%3DCihon%26aufirst%3DF.%26aulast%3DGallentine%26aufirst%3DM.%26aulast%3DRadtke%26aufirst%3DM.%26aulast%3DSundaresan%26aufirst%3DP.%26atitle%3DLack%2520of%2520effect%2520of%2520ketoconazole-mediated%2520CYP3A%2520inhibition%2520on%2520sorafenib%2520clinical%2520pharmacokinetics%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2006%26volume%3D57%26spage%3D685%26epage%3D692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navid, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. D.</span><span> </span><span class="NLM_article-title">Quantitation of sorafenib and its active metabolite sorafenib <i>N</i>-oxide in human plasma by liquid chromatography–tandem mass spectrometry</span> <span class="citation_source-journal">J. Chromatogr., B: Anal. Technol. Biomed. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">878</span><span class="NLM_x">, </span> <span class="NLM_fpage">3033</span><span class="NLM_x">–</span> <span class="NLM_lpage">3038</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.jchromb.2010.08.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=20870468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlSnu7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=878&publication_year=2010&pages=3033-3038&author=L.+Liauthor=M.+Zhaoauthor=F.+Navidauthor=K.+Pratzauthor=B.+D.+Smithauthor=M.+A.+Rudekauthor=S.+D.+Baker&title=Quantitation+of+sorafenib+and+its+active+metabolite+sorafenib+N-oxide+in+human+plasma+by+liquid+chromatography%E2%80%93tandem+mass+spectrometry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry</span></div><div class="casAuthors">Li, Lie; Zhao, Ming; Navid, Fariba; Pratz, Keith; Smith, B. Doug; Rudek, Michelle A.; Baker, Sharyn D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">878</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3033-3038</span>CODEN:
                <span class="NLM_cas:coden">JCBAAI</span>;
        ISSN:<span class="NLM_cas:issn">1570-0232</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A simple and rapid method with high performance liq. chromatog./tandem mass spectrometry is described for the quantitation of the kinase inhibitor sorafenib and its active metabolite sorafenib N-oxide in human plasma.  A protein pptn. extn. procedure was applied to 50 μL of plasma.  Chromatog. sepn. of the two analytes, and the internal std. [2H3 13C]-sorafenib, was achieved on a C18 anal. column and isocratic flow at 0.3 mL/min for 4 min.  Mean within-run and between-run precision for all analytes were <6.9% and accuracy was <5.3%.  Calibration curves were linear over the concn. range of 50-10,000 ng/mL for sorafenib and 10-2500 ng/mL for sorafenib N-oxide.  This method allows a specific, sensitive, and reliable detn. of the kinase inhibitor sorafenib and its active metabolite sorafenib N-oxide in human plasma in a single anal. run.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJxMkbb0kf67Vg90H21EOLACvtfcHk0ljOBwnxxk9_EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlSnu7zI&md5=724e2c8ebd5cd7b9470157961fbea54c</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.jchromb.2010.08.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jchromb.2010.08.049%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DNavid%26aufirst%3DF.%26aulast%3DPratz%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DRudek%26aufirst%3DM.%2BA.%26aulast%3DBaker%26aufirst%3DS.%2BD.%26atitle%3DQuantitation%2520of%2520sorafenib%2520and%2520its%2520active%2520metabolite%2520sorafenib%2520N-oxide%2520in%2520human%2520plasma%2520by%2520liquid%2520chromatography%25E2%2580%2593tandem%2520mass%2520spectrometry%26jtitle%3DJ.%2520Chromatogr.%252C%2520B%253A%2520Anal.%2520Technol.%2520Biomed.%2520Life%2520Sci.%26date%3D2010%26volume%3D878%26spage%3D3033%26epage%3D3038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Pereillo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maftouh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrieu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uzabiaga, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedili, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maffrand, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picard, C.</span><span> </span><span class="NLM_article-title">Structure and stereochemistry of the active metabolite of clopidogrel</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1288</span><span class="NLM_x">–</span> <span class="NLM_lpage">1295</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=1288-1295&author=J.+M.+Pereilloauthor=M.+Maftouhauthor=A.+Andrieuauthor=M.+F.+Uzabiagaauthor=O.+Fediliauthor=P.+Saviauthor=M.+Pascalauthor=J.+M.+Herbertauthor=J.+P.+Maffrandauthor=C.+Picard&title=Structure+and+stereochemistry+of+the+active+metabolite+of+clopidogrel"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPereillo%26aufirst%3DJ.%2BM.%26aulast%3DMaftouh%26aufirst%3DM.%26aulast%3DAndrieu%26aufirst%3DA.%26aulast%3DUzabiaga%26aufirst%3DM.%2BF.%26aulast%3DFedili%26aufirst%3DO.%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DPascal%26aufirst%3DM.%26aulast%3DHerbert%26aufirst%3DJ.%2BM.%26aulast%3DMaffrand%26aufirst%3DJ.%2BP.%26aulast%3DPicard%26aufirst%3DC.%26atitle%3DStructure%2520and%2520stereochemistry%2520of%2520the%2520active%2520metabolite%2520of%2520clopidogrel%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D1288%26epage%3D1295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Dansette, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Libraire, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertho, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuy, D.</span><span> </span><span class="NLM_article-title">Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">373</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx8004828" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtV2ksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=369-373&author=P.+M.+Dansetteauthor=J.+Libraireauthor=G.+Berthoauthor=D.+Mansuy&title=Metabolic+oxidative+cleavage+of+thioesters%3A+evidence+for+the+formation+of+sulfenic+acid+intermediates+in+the+bioactivation+of+the+antithrombotic+prodrugs+ticlopidine+and+clopidogrel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic Oxidative Cleavage of Thioesters: Evidence for the Formation of Sulfenic Acid Intermediates in the Bioactivation of the Antithrombotic Prodrugs Ticlopidine and Clopidogrel</span></div><div class="casAuthors">Dansette, Patrick M.; Libraire, Julie; Bertho, Gildas; Mansuy, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">369-373</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Metabolic cleavage of the CO-S bond of some thioesters RCOSR' with the formation of RCOOH requires a monooxygenase-dependent oxidative activation of this bond.  The nature of the S-contg. product(s) resulting from this cleavage remains unclear in most cases.  This communication provides the first evidence for the formation of sulfenic acid intermediates 4a and 4b during the oxidative cleavage of the CO-S bond of thiolactone metabolites 2a and 2b of antithrombotic prodrugs, ticlopidine and clopidogrel, by rat and human liver microsomes.  These intermediates have been trapped by dimedone, and the corresponding adducts 5a and 5b have been characterized by mass spectrometry (MS) and 1H and 13C NMR spectroscopy.  Their formation is monooxygenase-dependent and almost completely inhibited by microsomal cytochrome P 450 inhibitors.  Moreover, they were also formed upon incubation with microsomes contg. recombinant human P 450 3A4, 3A5, 2C8, 2C9, 2C19, 2D6, or 1A2.  In the presence of thiols such as mercaptoethanol, N-acetylcysteine, or glutathione, microsomal incubations of 2a led to mixed disulfides that have been characterized by MS and should result from reaction of 4a with these thiols.  At high thiol concns., one obsd. in HPLC-MS the formation of a product exhibiting the MS expected for the previously described thiol metabolite 3a, a redn. product of 4a that has been reported as the pharmacol. active metabolite of ticlopidine.  These data provide the first evidence for the formation of sulfenic acid reactive metabolites upon P 450-catalyzed oxidative cleavage of thioesters.  They also provide a first detailed mechanism for the previously described formation of pharmacol. active thiols such as 3a upon oxidative metab. of ticlopidine and clopidogrel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT08wJDRg6g7Vg90H21EOLACvtfcHk0ljqEM19HlbCfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtV2ksrc%253D&md5=5b7783f3cfabd4dff3de96558bf9a63a</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Ftx8004828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx8004828%26sid%3Dliteratum%253Aachs%26aulast%3DDansette%26aufirst%3DP.%2BM.%26aulast%3DLibraire%26aufirst%3DJ.%26aulast%3DBertho%26aufirst%3DG.%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DMetabolic%2520oxidative%2520cleavage%2520of%2520thioesters%253A%2520evidence%2520for%2520the%2520formation%2520of%2520sulfenic%2520acid%2520intermediates%2520in%2520the%2520bioactivation%2520of%2520the%2520antithrombotic%2520prodrugs%2520ticlopidine%2520and%2520clopidogrel%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D369%26epage%3D373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Ha-Duong, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dijols, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macherey, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansette, P. M</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuy, D.</span><span> </span><span class="NLM_article-title">Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P4502C19</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">12112</span><span class="NLM_x">–</span> <span class="NLM_lpage">12122</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi010254c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=12112-12122&author=N.+T.+Ha-Duongauthor=S.+Dijolsauthor=A.+C.+Machereyauthor=J.+A.+Goldsteinauthor=P.+M+Dansetteauthor=D.+Mansuy&title=Ticlopidine+as+a+selective+mechanism-based+inhibitor+of+human+cytochrome+P4502C19"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Fbi010254c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi010254c%26sid%3Dliteratum%253Aachs%26aulast%3DHa-Duong%26aufirst%3DN.%2BT.%26aulast%3DDijols%26aufirst%3DS.%26aulast%3DMacherey%26aufirst%3DA.%2BC.%26aulast%3DGoldstein%26aufirst%3DJ.%2BA.%26aulast%3DDansette%26aufirst%3DP.%2BM%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DTiclopidine%2520as%2520a%2520selective%2520mechanism-based%2520inhibitor%2520of%2520human%2520cytochrome%2520P4502C19%26jtitle%3DBiochemistry%26date%3D2001%26volume%3D40%26spage%3D12112%26epage%3D12122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Nishiya, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okudaira, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okazaki, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, T.</span><span> </span><span class="NLM_article-title">Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">836</span><span class="NLM_x">–</span> <span class="NLM_lpage">843</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=836-843&author=Y.+Nishiyaauthor=K.+Hagiharaauthor=A.+Kuriharaauthor=N.+Okudairaauthor=N.+A.+Faridauthor=O.+Okazakiauthor=T.+Ikeda&title=Comparison+of+mechanism-based+inhibition+of+human+cytochrome+P450+2C19+by+ticlopidine%2C+clopidogrel%2C+and+prasugrel"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNishiya%26aufirst%3DY.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DOkudaira%26aufirst%3DN.%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DOkazaki%26aufirst%3DO.%26aulast%3DIkeda%26aufirst%3DT.%26atitle%3DComparison%2520of%2520mechanism-based%2520inhibition%2520of%2520human%2520cytochrome%2520P450%25202C19%2520by%2520ticlopidine%252C%2520clopidogrel%252C%2520and%2520prasugrel%26jtitle%3DXenobiotica%26date%3D2009%26volume%3D39%26spage%3D836%26epage%3D843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Mega, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Close, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiviott, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hockett, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antman, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macias, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braunwald, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatine, M. S.</span><span> </span><span class="NLM_article-title">Cytochrome P-450 polymorphisms and response to clopidogrel</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">360</span><span class="NLM_x">, </span> <span class="NLM_fpage">354</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1056%2FNEJMoa0809171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=19106084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVSlsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=354-362&author=J.+L.+Megaauthor=S.+L.+Closeauthor=S.+D.+Wiviottauthor=L.+Shenauthor=R.+D.+Hockettauthor=J.+T.+Brandtauthor=J.+R.+Walkerauthor=E.+M.+Antmanauthor=W.+Maciasauthor=E.+Braunwaldauthor=M.+S.+Sabatine&title=Cytochrome+P-450+polymorphisms+and+response+to+clopidogrel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P-450 polymorphisms and response to clopidogrel</span></div><div class="casAuthors">Mega, Jessica L.; Close, Sandra L.; Wiviott, Stephen D.; Shen, Lei; Hockett, Richard D.; Brandt, John T.; Walker, Joseph R.; Antman, Elliott M.; Macias, William; Braunwald, Eugene; Sabatine, Marc S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">354-362</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Clopidogrel requires transformation into an active metabolite by cytochrome P 450 (CYP) enzymes for its antiplatelet effect.  The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function.  METHODS: We tested the assocn. between functional genetic variants in CYP genes, plasma concns. of active drug metabolite, and platelet inhibition in response to clopidogrel in 162 healthy subjects.  We then examd. the assocn. between these genetic variants and cardiovascular outcomes in a sep. cohort of 1477 subjects with acute coronary syndromes who were treated with clopidogrel in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38.  RESULTS: In healthy subjects who were treated with clopidogrel, carriers of at least one CYP2C19 reduced-function allele (approx. 30% of the study population) had a relative redn. of 32.4% in plasma exposure to the active metabolite of clopidogrel, as compared with noncarriers (P < 0.001).  Carriers also had an abs. redn. in maximal platelet aggregation in response to clopidogrel that was 9 percentage points less than that seen in noncarriers (P < 0.001).  Among clopidogrel-treated subjects in TRITON-TIMI 38, carriers had a relative increase of 53% in the composite primary efficacy outcome of the risk of death from cardiovascular causes, myocardial infarction, or stroke, as compared with noncarriers (12.1% vs. 8.0%; hazard ratio for carriers, 1.53; 95% confidence interval [CI], 1.07 to 2.19; P = 0.01) and an increase by a factor of 3 in the risk of stent thrombosis (2.60/% vs. 0.8%; hazard ratio, 3.09; 95% CI, 1.19 to 8.00; P = 0.02).  CONCLUSIONS: Among persons treated with clopidogrel, carriers of a reduced-function CYP2C19 allele had significantly lower levels of the active metabolite of clopidogrel, diminished platelet inhibition, and a higher rate of major adverse cardiovascular events, including stent thrombosis, than did noncarriers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPuhhoYObiQrVg90H21EOLACvtfcHk0ljqEM19HlbCfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVSlsbs%253D&md5=3afb94927199d94890771d7e2ce26253</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0809171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0809171%26sid%3Dliteratum%253Aachs%26aulast%3DMega%26aufirst%3DJ.%2BL.%26aulast%3DClose%26aufirst%3DS.%2BL.%26aulast%3DWiviott%26aufirst%3DS.%2BD.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DHockett%26aufirst%3DR.%2BD.%26aulast%3DBrandt%26aufirst%3DJ.%2BT.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DAntman%26aufirst%3DE.%2BM.%26aulast%3DMacias%26aufirst%3DW.%26aulast%3DBraunwald%26aufirst%3DE.%26aulast%3DSabatine%26aufirst%3DM.%2BS.%26atitle%3DCytochrome%2520P-450%2520polymorphisms%2520and%2520response%2520to%2520clopidogrel%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D354%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Kurihara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazui, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozeki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, T.</span><span> </span><span class="NLM_article-title">In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in the active metabolite formation</span> <span class="citation_source-journal">Drug Metab. Rev., Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=99&author=A.+Kuriharaauthor=K.+Hagiharaauthor=M.+Kazuiauthor=T.+Ozekiauthor=N.+A.+Faridauthor=T.+Ikeda&title=In+vitro+metabolism+of+antiplatelet+agent+clopidogrel%3A+cytochrome+P450+isoforms+responsible+for+two+oxidation+steps+involved+in+the+active+metabolite+formation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DKazui%26aufirst%3DM.%26aulast%3DOzeki%26aufirst%3DT.%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DIkeda%26aufirst%3DT.%26atitle%3DIn%2520vitro%2520metabolism%2520of%2520antiplatelet%2520agent%2520clopidogrel%253A%2520cytochrome%2520P450%2520isoforms%2520responsible%2520for%2520two%2520oxidation%2520steps%2520involved%2520in%2520the%2520active%2520metabolite%2520formation%26jtitle%3DDrug%2520Metab.%2520Rev.%252C%2520Suppl.%26date%3D2005%26volume%3D2%26spage%3D99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Hagihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiya, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazui, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, T.</span><span> </span><span class="NLM_article-title">Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel and ticlopidine</span> <span class="citation_source-journal">Drug Metab. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">412</span><span class="NLM_x">–</span> <span class="NLM_lpage">420</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2133%2Fdmpk.23.412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=19122335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1ags7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2008&pages=412-420&author=K.+Hagiharaauthor=Y.+Nishiyaauthor=A.+Kuriharaauthor=M.+Kazuiauthor=N.+A.+Faridauthor=T.+Ikeda&title=Comparison+of+human+cytochrome+P450+inhibition+by+the+thienopyridines+prasugrel%2C+clopidogrel+and+ticlopidine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine</span></div><div class="casAuthors">Hagihara, Katsunobu; Nishiya, Yumi; Kurihara, Atsushi; Kazui, Miho; Farid, Nagy A.; Ikeda, Toshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">412-420</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society for the Study of Xenobiotics</span>)
        </div><div class="casAbstract">Differences in the inhibition of cytochrome P 450 activities among thienopyridine antiplatelet agents, ticlopidine, clopidogrel, prasugrel, and the metabolites, 2-oxo-clopidogrel, clopidogrel acid metabolite, deacetylated metabolite of prasugrel (R-95913) and the pharmacol. active metabolites of clopidogrel and prasugrel, were examd. using recombinant cytochromes P 450 and fluorescent probe substrates.  Ticlopidine and clopidogrel inhibited CYP2B6 with IC50 values of 0.0517 ± 0.0323 μM and 0.0182 ± 0.0069 μM, resp., and inhibited CYP2C19 with IC50 values of 0.203 ± 0.124 μM and 0.524 ± 0.160 μM, resp.  Ticlopidine also inhibited CYP2D6 (IC50 of 0.354 ± 0.158 μM).  In contrast, 2-oxo-clopidogrel, prasugrel and R-95913 were much weaker inhibitors of CYP2B6, CYP2C19 and CYP2D6.  The inhibitory effects of all the compds. tested were much weaker on the isoforms other than those indicated above.  The active metabolites of clopidogrel and prasugrel and clopidogrel acid metabolite also did not affect the activities of the P450s examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxq55ig_qqtbVg90H21EOLACvtfcHk0lgoXS2Dok3kjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1ags7o%253D&md5=e8c0d0d2edfe2c4ebd12d21aab12de05</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.2133%2Fdmpk.23.412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2133%252Fdmpk.23.412%26sid%3Dliteratum%253Aachs%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DNishiya%26aufirst%3DY.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DKazui%26aufirst%3DM.%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DIkeda%26aufirst%3DT.%26atitle%3DComparison%2520of%2520human%2520cytochrome%2520P450%2520inhibition%2520by%2520the%2520thienopyridines%2520prasugrel%252C%2520clopidogrel%2520and%2520ticlopidine%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2008%26volume%3D23%26spage%3D412%26epage%3D420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Rehmel, J. L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckstein, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasper, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrighton, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ring, B. J.</span><span> </span><span class="NLM_article-title">Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">600</span><span class="NLM_x">–</span> <span class="NLM_lpage">607</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=600-607&author=J.+L.+F.+Rehmelauthor=J.+A.+Ecksteinauthor=N.+A.+Faridauthor=J.+B.+Heimauthor=S.+C.+Kasperauthor=A.+Kuriharaauthor=S.+A.+Wrightonauthor=B.+J.+Ring&title=Interactions+of+two+major+metabolites+of+prasugrel%2C+a+thienopyridine+antiplatelet+agent%2C+with+the+cytochromes+P450"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRehmel%26aufirst%3DJ.%2BL.%2BF.%26aulast%3DEckstein%26aufirst%3DJ.%2BA.%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DHeim%26aufirst%3DJ.%2BB.%26aulast%3DKasper%26aufirst%3DS.%2BC.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DWrighton%26aufirst%3DS.%2BA.%26aulast%3DRing%26aufirst%3DB.%2BJ.%26atitle%3DInteractions%2520of%2520two%2520major%2520metabolites%2520of%2520prasugrel%252C%2520a%2520thienopyridine%2520antiplatelet%2520agent%252C%2520with%2520the%2520cytochromes%2520P450%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D600%26epage%3D607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Nishiya, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tajima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, T.</span><span> </span><span class="NLM_article-title">Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">589</span><span class="NLM_x">–</span> <span class="NLM_lpage">593</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=589-593&author=Y.+Nishiyaauthor=K.+Hagiharaauthor=T.+Itoauthor=M.+Tajimaauthor=S.+Miuraauthor=A.+Kuriharaauthor=N.+A.+Faridauthor=T.+Ikeda&title=Mechanism-based+inhibition+of+human+cytochrome+P450+2B6+by+ticlopidine%2C+clopidogrel%2C+and+the+thiolactone+metabolite+of+prasugrel"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNishiya%26aufirst%3DY.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DTajima%26aufirst%3DM.%26aulast%3DMiura%26aufirst%3DS.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DIkeda%26aufirst%3DT.%26atitle%3DMechanism-based%2520inhibition%2520of%2520human%2520cytochrome%2520P450%25202B6%2520by%2520ticlopidine%252C%2520clopidogrel%252C%2520and%2520the%2520thiolactone%2520metabolite%2520of%2520prasugrel%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D589%26epage%3D593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Richter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murdter, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinkele, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pleiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatzel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwab, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichelbaum, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanger, U. M.</span><span> </span><span class="NLM_article-title">Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1124%2Fjpet.103.056127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=14563790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsFegsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2004&pages=189-197&author=T.+Richterauthor=T.+E.+Murdterauthor=G.+Heinkeleauthor=J.+Pleissauthor=S.+Tatzelauthor=M.+Schwabauthor=M.+Eichelbaumauthor=U.+M.+Zanger&title=Potent+mechanism-based+inhibition+of+human+CYP2B6+by+clopidogrel+and+ticlopidine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine</span></div><div class="casAuthors">Richter, Tanja; Muerdter, Thomas E.; Heinkele, Georg; Pleiss, Juergen; Tatzel, Stephan; Schwab, Matthias; Eichelbaum, Michel; Zanger, Ulrich M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">189-197</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The thienopyridine derivs. ticlopidine and clopidogrel are inhibitors of ADP-induced platelet aggregation.  Pharmacol. activity of these prodrugs depends on cytochrome P 450 (P 450)-dependent oxidn. to the active antithrombotic agent.  In this study, we investigated the interaction potential of clopidogrel and ticlopidine by using human liver microsomes and recombinantly expressed P 450 isoforms.  Both clopidogrel and ticlopidine inhibited CYP2B6 with highest potency and CYP2C19 with lower potency.  Clopidogrel also inhibited CYP2C9, and ticlopidine also inhibited CYP1A2, with lower potency.  Inhibition of CYP2B6 was time- and concn.-dependent, and as shown by dialysis expts., it was irreversible and dependent on NADPH, suggesting a mechanism-based mode of action.  Inactivation was of nonpseudo-first-order type with maximal rates of inactivation (Kinact) for clopidogrel and ticlopidine in microsomes (recombinant CYP2B6) of 0.35 (1.5 min-1) and 0.5 min-1 (0.8 min-1), resp., and half-maximal inactivator concns. (KI) were 0.5 μM (1.1 μM) for clopidogrel and 0.2 μM (0.8 μM) for ticlopidine.  Inhibition was attenuated by the presence of alternative active site ligands but not by nucleophilic trapping agents or reactive oxygen scavengers, further supporting mechanism-based action.  A chem. mechanism is discussed based on the known metabolic activation of clopidogrel and on the finding that hemoprotein integrity of recombinant CYP2B6 was not affected by irreversible inhibition.  These results suggest the possibility of drug interactions between thienopyridine derivs. and drug substrates of CYP2B6 and CYP2C19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriG4-lqQezJLVg90H21EOLACvtfcHk0lgbsOvbWudU4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsFegsg%253D%253D&md5=aa9debeee9b3eac31888f6a843de6518</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.056127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.056127%26sid%3Dliteratum%253Aachs%26aulast%3DRichter%26aufirst%3DT.%26aulast%3DMurdter%26aufirst%3DT.%2BE.%26aulast%3DHeinkele%26aufirst%3DG.%26aulast%3DPleiss%26aufirst%3DJ.%26aulast%3DTatzel%26aufirst%3DS.%26aulast%3DSchwab%26aufirst%3DM.%26aulast%3DEichelbaum%26aufirst%3DM.%26aulast%3DZanger%26aufirst%3DU.%2BM.%26atitle%3DPotent%2520mechanism-based%2520inhibition%2520of%2520human%2520CYP2B6%2520by%2520clopidogrel%2520and%2520ticlopidine%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D308%26spage%3D189%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amunugama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ney, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenberg, P. F.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">839</span><span class="NLM_x">–</span> <span class="NLM_lpage">847</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=839-847&author=H.+Zhangauthor=H.+Amunugamaauthor=S.+Neyauthor=N.+Cooperauthor=P.+F.+Hollenberg&title=Mechanism-based+inactivation+of+human+cytochrome+P450+2B6+by+clopidogrel%3A+involvement+of+both+covalent+modification+of+cysteinyl+residue+475+and+loss+of+heme"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DAmunugama%26aufirst%3DH.%26aulast%3DNey%26aufirst%3DS.%26aulast%3DCooper%26aufirst%3DN.%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26atitle%3DMechanism-based%2520inactivation%2520of%2520human%2520cytochrome%2520P450%25202B6%2520by%2520clopidogrel%253A%2520involvement%2520of%2520both%2520covalent%2520modification%2520of%2520cysteinyl%2520residue%2520475%2520and%2520loss%2520of%2520heme%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26spage%3D839%26epage%3D847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Turpeinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolonen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uusitalo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalonen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelkonen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laine, K.</span><span> </span><span class="NLM_article-title">Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">553</span><span class="NLM_x">–</span> <span class="NLM_lpage">559</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.clpt.2005.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15961986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt1Gqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2005&pages=553-559&author=M.+Turpeinenauthor=A.+Tolonenauthor=J.+Uusitaloauthor=J.+Jalonenauthor=O.+Pelkonenauthor=K.+Laine&title=Effect+of+clopidogrel+and+ticlopidine+on+cytochrome+P450+2B6+activity+as+measured+by+bupropion+hydroxylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation</span></div><div class="casAuthors">Turpeinen, Miia; Tolonen, Ari; Uusitalo, Jouko; Jalonen, Jorma; Pelkonen, Olavi; Laine, Kari</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">553-559</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Our objective was to study the effect of the antiplatelet agents clopidogrel and ticlopidine on bupropion (INN, amfebutamone) hydroxylation, a probe reaction for cytochrome P 450 (CYP) 2B6 activity.  Twelve healthy male volunteers took a single 150-mg oral dose of bupropion either alone or after pretreatment with 75 mg clopidogrel once daily or 250 mg ticlopidine twice daily for 4 days.  On day 4, a single 150-mg oral dose of bupropion was administered.  Plasma concns. of bupropion and its CYP2B6-catalyzed metabolite, hydroxybupropion, were measured for up to 72 h.  The mean area under the plasma concn.-time curve (AUC) of hydroxybupropion calcd. from time 0 to infinity was reduced by 52% (P = .001; 95% confidence interval [CI], 39% to 66%) by clopidogrel and by 84% (P < .0001; 95% CI, 73% to 94%) by ticlopidine.  Clopidogrel reduced the AUC ratio of hydroxybupropion over bupropion by 68% (P = .002; 95% CI, 58% to 77%) and ticlopidine by 90% (P = .001; 95% CI, 85% to 96%).  The AUC of bupropion was increased by 60% (P = .02; 95% CI, 21% to 98%) and by 85% (P < .0001; 95% CI, 48% to 85%) with clopidogrel and ticlopidine, resp.  Both clopidogrel and ticlopidine significantly inhibited the CYP2B6-catalyzed bupropion hydroxylation.  Patients receiving either clopidogrel or ticlopidine are likely to require dose adjustments when treated with drugs primarily metabolized by CYP2B6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY2fUuI14JnLVg90H21EOLACvtfcHk0lhU3TmMWRQtYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt1Gqt7k%253D&md5=0c2c6314543eb7cee27c29b7dbe6ff40</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2005.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2005.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DTurpeinen%26aufirst%3DM.%26aulast%3DTolonen%26aufirst%3DA.%26aulast%3DUusitalo%26aufirst%3DJ.%26aulast%3DJalonen%26aufirst%3DJ.%26aulast%3DPelkonen%26aufirst%3DO.%26aulast%3DLaine%26aufirst%3DK.%26atitle%3DEffect%2520of%2520clopidogrel%2520and%2520ticlopidine%2520on%2520cytochrome%2520P450%25202B6%2520activity%2520as%2520measured%2520by%2520bupropion%2520hydroxylation%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2005%26volume%3D77%26spage%3D553%26epage%3D559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Farid, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernest, C. S.,  2nd.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salazar, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D. S.</span><span> </span><span class="NLM_article-title">Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1177%2F0091270007309709" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=18094219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVGqt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=53-59&author=N.+A.+Faridauthor=C.+D.+Payneauthor=C.+S.+Ernestauthor=Y.+G.+Liauthor=K.+J.+Wintersauthor=D.+E.+Salazarauthor=D.+S.+Small&title=Prasugrel%2C+a+new+thienopyridine+antiplatelet+drug%2C+weakly+inhibits+cytochrome+P450+2B6+in+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans</span></div><div class="casAuthors">Farid, Nagy A.; Payne, Christopher D.; Ernest, C. Steven, II; Li, Y. Grace; Winters, Kenneth J.; Salazar, Daniel E.; Small, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-59</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Prasugrel, a thienopyridine prodrug, is hydrolyzed in vivo by esterases to a thiolactone followed by a single cytochrome P 450 (CYP)-dependent step to an active metabolite that is a potent inhibitor of ADP-induced platelet aggregation.  This open-label, multiple-dose, 2-period, fixed-sequence study assessed CYP2B6 inhibition by prasugrel using bupropion as a probe substrate, where its active metabolite, hydroxybupropion, is almost exclusively formed by CYP2B6.  Thirty healthy subjects received a single 150-mg oral dose of sustained-release bupropion.  After a 7-day washout, a 60-mg prasugrel loading dose, followed by a 10-mg daily maintenance dose for 10 days, was administered.  Bupropion (150 mg) was given with prasugrel on day 7 of this phase.  Prasugrel weakly inhibited CYP2B6 activity as it increased bupropion Cmax and AUC0-∞ by 14% and 18%, resp., and decreased hydroxybupropion Cmax and AUC0-∞ by 32% and 23%.  These results are consistent with patients receiving prasugrel not requiring dose adjustments when treated with drugs primarily metabolized by CYP2B6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3NGiEGDmKJbVg90H21EOLACvtfcHk0lhU3TmMWRQtYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVGqt78%253D&md5=940e4dd7b49069ab2747f83c8ac371a4</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1177%2F0091270007309709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270007309709%26sid%3Dliteratum%253Aachs%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DPayne%26aufirst%3DC.%2BD.%26aulast%3DErnest%26aufirst%3DC.%2BS.%26aulast%3DLi%26aufirst%3DY.%2BG.%26aulast%3DWinters%26aufirst%3DK.%2BJ.%26aulast%3DSalazar%26aufirst%3DD.%2BE.%26aulast%3DSmall%26aufirst%3DD.%2BS.%26atitle%3DPrasugrel%252C%2520a%2520new%2520thienopyridine%2520antiplatelet%2520drug%252C%2520weakly%2520inhibits%2520cytochrome%2520P450%25202B6%2520in%2520humans%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D48%26spage%3D53%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kivisto, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Gemfibrozil is a potent inhibitor of human cytochrome P4502C9</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1359</span><span class="NLM_x">–</span> <span class="NLM_lpage">1361</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2001&pages=1359-1361&author=X.+Wenauthor=J.+S.+Wangauthor=J.+T.+Backmanauthor=K.+T.+Kivistoauthor=P.+J.+Neuvonen&title=Gemfibrozil+is+a+potent+inhibitor+of+human+cytochrome+P4502C9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%2BS.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DKivisto%26aufirst%3DK.%2BT.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DGemfibrozil%2520is%2520a%2520potent%2520inhibitor%2520of%2520human%2520cytochrome%2520P4502C9%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2001%26volume%3D29%26spage%3D1359%26epage%3D1361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Wang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1352</span><span class="NLM_x">–</span> <span class="NLM_lpage">1356</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=1352-1356&author=J.+S.+Wangauthor=M.+Neuvonenauthor=X.+Wenauthor=J.+T.+Backmanauthor=P.+J.+Neuvonen&title=Gemfibrozil+inhibits+CYP2C8-mediated+cerivastatin+metabolism+in+human+liver+microsomes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BS.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DGemfibrozil%2520inhibits%2520CYP2C8-mediated%2520cerivastatin%2520metabolism%2520in%2520human%2520liver%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D1352%26epage%3D1356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyrklund, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Gemfibrozil greatly increases plasma concentrations of cerivastatin</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">–</span> <span class="NLM_lpage">691</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1067%2Fmcp.2002.128469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=12496749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlt1SjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2002&pages=685-691&author=J.+T.+Backmanauthor=C.+Kyrklundauthor=M.+Neuvonenauthor=P.+J.+Neuvonen&title=Gemfibrozil+greatly+increases+plasma+concentrations+of+cerivastatin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Gemfibrozil greatly increases plasma concentrations of cerivastatin</span></div><div class="casAuthors">Backman, Janne T.; Kyrklund, Carl; Neuvonen, Mikko; Neuvonen, Pertti J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">685-691</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Concomitant use of gemfibrozil with statins, particularly with cerivastatin, increases the risk of rhabdomyolysis, but the mechanism of this potentially fatal drug interaction remains unclear.  Our aim was to study the effect of gemfibrozil on cerivastatin pharmacokinetics.  In a randomized, double-blind crossover study, 10 healthy volunteers took 600 mg gemfibrozil or placebo twice daily for 3 days.  On day 3, each subject ingested a single 0.3-mg dose of cerivastatin.  Plasma concns. of cerivastatin, its metabolites, and gemfibrozil were measured up to 24 h.  During gemfibrozil treatment, the area under the plasma concn.-time curve [AUC(0-∞)] of parent cerivastatin was on av. 559% (range, 138% to 995%; P =.0002) and the peak concn. in plasma was 307% (138% to 809%; P =.0019) of the corresponding values in the placebo phase.  Gemfibrozil increased the AUC(0-∞) of cerivastatin lactone, on av., to 440% (94% to 594%; P =.0024) and that of metabolite M-1 to 435% (216% to 802%; P =.0002) of the control (placebo) values, whereas the AUC(0-24) of metabolite M-23 was decreased to 22% (11% to 74%; P=.0017).  Gemfibrozil greatly increases plasma concns. of cerivastatin, cerivastatin lactone, and metabolite M-1, whereas the level of metabolite M-23 is markedly reduced by gemfibrozil.  Gemfibrozil therefore inhibits the formation of M-23, which is thought to be dependent on CYP2C8.  The increased exposure to cerivastatin in the presence of gemfibrozil may explain the high incidence of myopathy obsd. with this combination, although the role of pharmacodynamic interactions between these 2 agents cannot be excluded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyOpdQOdq0kLVg90H21EOLACvtfcHk0lgDexugj-eSIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlt1SjsQ%253D%253D&md5=2dce3480b6cea92874faf468c81b834c</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2002.128469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2002.128469%26sid%3Dliteratum%253Aachs%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DKyrklund%26aufirst%3DC.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DGemfibrozil%2520greatly%2520increases%2520plasma%2520concentrations%2520of%2520cerivastatin%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2002%26volume%3D72%26spage%3D685%26epage%3D691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Jaakkola, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">404</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.clpt.2004.12.266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15900286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFCrtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2005&pages=404-414&author=T.+Jaakkolaauthor=J.+T.+Backmanauthor=M.+Neuvonenauthor=P.+J.+Neuvonen&title=Effects+of+gemfibrozil%2C+itraconazole%2C+and+their+combination+on+the+pharmacokinetics+of+pioglitazone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone</span></div><div class="casAuthors">Jaakkola, Tiina; Backman, Janne T.; Neuvonen, Mikko; Neuvonen, Pertti J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">404-414</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background and objective: The thiazolidinedione antidiabetic drug pioglitazone is metabolized mainly by cytochrome P 450 (CYP) 2C8 and CYP3A4 in vitro.  Our objective was to study the effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone to det. the role of these enzymes in the fate of pioglitazone in humans.  Methods: In a randomized, double-blind, 4-phase crossover study, 12 healthy volunteers took either 600 mg gemfibrozil or 100 mg itraconazole (first dose, 200 mg), both gemfibrozil and itraconazole, or placebo twice daily for 4 days.  On day 3, they received a single dose of 15 mg pioglitazone.  Plasma drug concns. and the cumulative excretion of pioglitazone and its metabolites into urine were measured for up to 48 h.  Results: Gemfibrozil alone raised the mean total area under the plasma concn.-time curve from time 0 to infinity [AUC(0-∞)] of pioglitazone 3.2-fold (range, 2.3-fold to 6.5-fold; P <.001) and prolonged its elimination half-life (t1/2) from 8.3 to 22.7 h (P <.001) but had no significant effect on its peak concn. (Cmax) compared with placebo (control).  Gemfibrozil increased the 48-h excretion of pioglitazone into urine by 2.5-fold (P <.001) and reduced the ratios of the active metabolites M-III and M-IV to pioglitazone in plasma and urine.  Gemfibrozil decreased the area under the plasma concn.-time curve from time 0 to 48 h [AUC(0-48)] of the metabolites M-III and M-IV by 42% (P <.05) and 45% (P <.001), resp., but their total AUC(0-∞) values were reduced by less or not at all.  Itraconazole had no significant effect on the pharmacokinetics of pioglitazone and did not alter the effect of gemfibrozil on pioglitazone pharmacokinetics.  The mean area under the concn. vs. time curve to 49 h [AUC(0-49)] of itraconazole was 46% lower (P <.001) during the gemfibrozil-itraconazole phase than during the itraconazole phase.  Conclusions: Gemfibrozil elevates the plasma concns. of pioglitazone, probably by inhibition of its CYP2C8-mediated metab.  CYP2C8 appears to be of major importance and CYP3A4 of minor importance in pioglitazone metab. in vivo in humans.  Concomitant use of gemfibrozil with pioglitazone may increase the effects and risk of dose-related adverse effects of pioglitazone.  However, studies in diabetic patients are needed to det. the clin. significance of the gemfibrozil-pioglitazone interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjiP-NzZlXnrVg90H21EOLACvtfcHk0lgDexugj-eSIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFCrtLg%253D&md5=44f68ebede1b1bf43cd353ac13007899</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2004.12.266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2004.12.266%26sid%3Dliteratum%253Aachs%26aulast%3DJaakkola%26aufirst%3DT.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DEffects%2520of%2520gemfibrozil%252C%2520itraconazole%252C%2520and%2520their%2520combination%2520on%2520the%2520pharmacokinetics%2520of%2520pioglitazone%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2005%26volume%3D77%26spage%3D404%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Lilja, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1111%2Fj.1365-2125.2004.02323.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15801938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFals7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2005&pages=433-439&author=J.+J.+Liljaauthor=J.+T.+Backmanauthor=P.+J.+Neuvonen&title=Effect+of+gemfibrozil+on+the+pharmacokinetics+and+pharmacodynamics+of+racemic+warfarin+in+healthy+subjects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects</span></div><div class="casAuthors">Lilja, Jari J.; Backman, Janne T.; Neuvonen, Pertti J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">433-439</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Case reports suggest that gemfobrozil can increase the anticoagulant effect of warfarin.  Because gemfibrozil inhibits CYP2C9 in vitro, we studied its effects on the pharmacokinetics and pharmacodynamics of racemic warfarin.  In a randomized cross-over study, 10 healthy subjects ingested 600 mg gemfibrozil or placebo twice daily for 8 days.  On day 3, they were administered a single dose of 10 mg racemic R-S-warfarin orally.  The concns. of R- and S-warfarin in plasma and thromboplastin time were monitored up to 168 h.  Gemfibrozil decreased the mean (±SD) area under the plasma concn.-time curve [AUC(0-∞)] of S-warfarin by 11%, from 19.9 ± 5.2 mg l-1 h to 17.6 ± 4.7 mg l-1 h (95% Cl on the difference -3.7, -0.78; P < 0.01) and that of R-warfarin by 6% from 31.3 ± 7.5 mg l-1 h during the gemfibrozil phase to 29.5 ± 6.9 mg l-1 h during the placebo phase (95% Cl -3.3, -0.33; P < 0.05).  There were no significant differences in the elimination half-lives of S- or R-warfarin between the phases.  Gemfibrozil did not alter the anticoagulant effect of warfarin.  Unexpectedly, gemfibrozil slightly decreased the plasma concns. of R- and S-warfarin.  Displacement of warfarin from plasma albumin by gemfibrozil or its interference with the absorption of warfarin could explain the present findings.  Usual therapeutic doses of gemfibrozil seem to have limited effects on the pharmacokinetics and pharmacodynamics of single dose warfarin in healthy subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI1IjWgq_Ub7Vg90H21EOLACvtfcHk0lirKmOQcZKEsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFals7o%253D&md5=930bbdaf7f9814d486875d423b7981e5</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2004.02323.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2004.02323.x%26sid%3Dliteratum%253Aachs%26aulast%3DLilja%26aufirst%3DJ.%2BJ.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DEffect%2520of%2520gemfibrozil%2520on%2520the%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520racemic%2520warfarin%2520in%2520healthy%2520subjects%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D59%26spage%3D433%26epage%3D439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Shitara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span> </span><span class="NLM_article-title">Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug–drug interaction between cerivastatin and gemfibrozil</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">311</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">–</span> <span class="NLM_lpage">236</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1124%2Fjpet.104.068536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=15194707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXosVKrt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2004&pages=228-236&author=Y.+Shitaraauthor=M.+Hiranoauthor=H.+Satoauthor=Y.+Sugiyama&title=Gemfibrozil+and+its+glucuronide+inhibit+the+organic+anion+transporting+polypeptide+2+%28OATP2%2FOATP1B1%3ASLC21A6%29-mediated+hepatic+uptake+and+CYP2C8-mediated+metabolism+of+cerivastatin%3A+analysis+of+the+mechanism+of+the+clinically+relevant+drug%E2%80%93drug+interaction+between+cerivastatin+and+gemfibrozil"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil</span></div><div class="casAuthors">Shitara, Yoshihisa; Hirano, Masaru; Sato, Hitoshi; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">228-236</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A serious pharmacokinetic interaction between cerivastatin (CER) and gemfibrozil (GEM) has been reported.  In the present study, we examd. the inhibitory effects of GEM and its metabolites, M3 and gemfibrozil 1-O-β-glucuronide (GEM-1-O-glu), on the uptake of CER by human org. anion transporting polypeptide 2 (OATP2)-expressing cells and its metab. in cytochrome P 450 expression systems.  Uptake studies showed that GEM and GEM-1-O-glu significantly inhibited the OATP2-mediated uptake of CER with IC50 values of 72 and 24 μM, resp.  They also inhibited the CYP2C8-mediated metab. of CER with IC50 values of 28 and 4 μM, resp., whereas M3 had no effects.  GEM and GEM-1-O-glu minimally inhibited the CYP3A4-mediated metab. of CER.  The IC50 values of GEM and GEM-1-O-glu for the uptake and the metab. of CER obtained in the present study were lower than their total, and not unbound, plasma concns.  However, considering the possibly concd. high unbound concns. of GEM-1-O-glu in the liver and its relatively larger plasma unbound fraction compared with GEM itself, the glucuronide inhibition of the CYP2C8-mediated metab. of CER appears to be the main mechanism for the clin. relevant drug-drug interaction.  Previously reported clin. drug interaction studies showing that coadministration of GEM with pravastatin or pitavastatin, both of which are known to be cleared from the plasma by the uptake transporters in the liver, only minimally (less than 2-fold) increased the area under the plasma concn.-time curve of these statins, also supported our present conclusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplgMf8fP3WyrVg90H21EOLACvtfcHk0lirKmOQcZKEsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXosVKrt7g%253D&md5=47713127a0aa0747c2e9520811193a22</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.068536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.068536%26sid%3Dliteratum%253Aachs%26aulast%3DShitara%26aufirst%3DY.%26aulast%3DHirano%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DGemfibrozil%2520and%2520its%2520glucuronide%2520inhibit%2520the%2520organic%2520anion%2520transporting%2520polypeptide%25202%2520%2528OATP2%252FOATP1B1%253ASLC21A6%2529-mediated%2520hepatic%2520uptake%2520and%2520CYP2C8-mediated%2520metabolism%2520of%2520cerivastatin%253A%2520analysis%2520of%2520the%2520mechanism%2520of%2520the%2520clinically%2520relevant%2520drug%25E2%2580%2593drug%2520interaction%2520between%2520cerivastatin%2520and%2520gemfibrozil%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D311%26spage%3D228%26epage%3D236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Ogilvie, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gipson, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holsapple, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, A.</span><span> </span><span class="NLM_article-title">Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug–drug interactions</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=191-197&author=B.+W.+Ogilvieauthor=D.+Zhangauthor=W.+Liauthor=A.+D.+Rodriguesauthor=A.+E.+Gipsonauthor=J.+Holsappleauthor=P.+Torenauthor=A.+Parkinson&title=Glucuronidation+converts+gemfibrozil+to+a+potent%2C+metabolism-dependent+inhibitor+of+CYP2C8%3A+implications+for+drug%E2%80%93drug+interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOgilvie%26aufirst%3DB.%2BW.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26aulast%3DGipson%26aufirst%3DA.%2BE.%26aulast%3DHolsapple%26aufirst%3DJ.%26aulast%3DToren%26aufirst%3DP.%26aulast%3DParkinson%26aufirst%3DA.%26atitle%3DGlucuronidation%2520converts%2520gemfibrozil%2520to%2520a%2520potent%252C%2520metabolism-dependent%2520inhibitor%2520of%2520CYP2C8%253A%2520implications%2520for%2520drug%25E2%2580%2593drug%2520interactions%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D191%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Tornio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laitila, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalliokoski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span> </span><span class="NLM_article-title">The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">403</span><span class="NLM_x">–</span> <span class="NLM_lpage">411</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1038%2Fclpt.2008.34" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=18388877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVShtr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2008&pages=403-411&author=A.+Tornioauthor=M.+Niemiauthor=M.+Neuvonenauthor=J.+Laitilaauthor=A.+Kalliokoskiauthor=P.+J.+Neuvonenauthor=J.+T.+Backman&title=The+effect+of+gemfibrozil+on+repaglinide+pharmacokinetics+persists+for+at+least+12+h+after+the+dose%3A+evidence+for+mechanism-based+inhibition+of+CYP2C8+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo</span></div><div class="casAuthors">Tornio, A.; Niemi, M.; Neuvonen, M.; Laitila, J.; Kalliokoski, A.; Neuvonen, P. J.; Backman, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">403-411</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Repaglinide is metabolized by cytochrome P 450 (CYP) 2C8 and 3A4.  Gemfibrozil has the effect of increasing the area under the concn.-time curve (AUC) of repaglinide eightfold.  We studied the effect of dosing interval on the extent of the gemfibrozil-repaglinide interaction.  In a randomized five-phase crossover study, 10 healthy volunteers ingested 0.25 mg repaglinide, with or without gemfibrozil pretreatment.  Plasma repaglinide, gemfibrozil, their metabolites, and blood glucose were measured.  When the last dose of 600 mg gemfibrozil was ingested simultaneously with repaglinide, or 3, 6, or 12 h before, it increased the AUC0-∞ of repaglinide 7.0-, 6.5-, 6.2- and 5.0-fold, resp. (P < 0.001).  The peak repaglinide concn. increased approx. twofold (P < 0.001), and the half-life was prolonged from 1.2 h to 2-3 h (P < 0.001) during all the gemfibrozil phases.  The drug interaction effects persisted at least 12 h after gemfibrozil was administered, although plasma gemfibrozil and gemfibrozil 1-O-β-glucuronide concns. were only 5 and 10% of their peak values, resp.  The long-lasting interaction is likely caused by mechanism-based inhibition of CYP2C8 by gemfibrozil glucuronide.  Clin. Pharmacol. & Therapeutics (2008); 84, 3, 403-411 doi:10.1038/clpt.2008.34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrcii5pN3YQLVg90H21EOLACvtfcHk0liK8wOBpCoVUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVShtr7K&md5=bb45f6f89c9f504af39116de52b5b825</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2008.34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2008.34%26sid%3Dliteratum%253Aachs%26aulast%3DTornio%26aufirst%3DA.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DLaitila%26aufirst%3DJ.%26aulast%3DKalliokoski%26aufirst%3DA.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520effect%2520of%2520gemfibrozil%2520on%2520repaglinide%2520pharmacokinetics%2520persists%2520for%2520at%2520least%252012%2520h%2520after%2520the%2520dose%253A%2520evidence%2520for%2520mechanism-based%2520inhibition%2520of%2520CYP2C8%2520in%2520vivo%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2008%26volume%3D84%26spage%3D403%26epage%3D411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Honkalammi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1038%2Fclpt.2010.358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=21368757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjs1Cls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=579-586&author=J.+Honkalammiauthor=M.+Niemiauthor=P.+J.+Neuvonenauthor=J.+T.+Backman&title=Mechanism-based+inactivation+of+CYP2C8+by+gemfibrozil+occurs+rapidly+in+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans</span></div><div class="casAuthors">Honkalammi, J.; Niemi, M.; Neuvonen, P. J.; Backman, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">579-586</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To study the time to onset of mechanism-based inactivation of cytochrome P 450 (CYP) 2C8 by gemfibrozil in vivo, we conducted a randomized five-phase crossover study in 10 healthy volunteers.  In one phase the volunteers ingested 0.25 mg of repaglinide alone (control), and in the other phases they received 600 mg of gemfibrozil 0-6 h prior to the repaglinide dose.  When gemfibrozil was taken 0, 1, 3, or 6 h before repaglinide, the geometric mean ratio relative to control (90% confidence interval (CI)) of repaglinide area under the plasma concn.-time curve (AUC0-∞) was 5.0-fold (4.3-5.7-fold), 6.3-fold (5.4-7.5-fold), 6.6-fold (5.6-7.7-fold), and 5.4-fold (4.8-6.1-fold), resp. (P < 0.001 vs. control).  The geometric mean ratio relative to control (90% CI) of the max. plasma concn. (Cmax) of the CYP2C8-mediated metabolite M4 was 1.0-fold (0.8-1.3-fold), 0.10-fold (0.06-0.17-fold, P < 0.001), 0.06-fold (0.04-0.10-fold, P < 0.001), and 0.09-fold (0.05-0.14-fold, P < 0.001), resp.  The strong inactivation of CYP2C8, evident as soon as 1 h after gemfibrozil dosing, has implications in clin. practice and in studies with gemfibrozil as a CYP2C8 model inhibitor.  Clin. Pharmacol. & Therapeutics (2011) 89 4, 579-586. doi:10.1038/clpt.2010.358.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0t7uqdCQkRLVg90H21EOLACvtfcHk0lgQEH-GAfxdAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjs1Cls70%253D&md5=6aaf0c8576c45142bb428bad130cae77</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2010.358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2010.358%26sid%3Dliteratum%253Aachs%26aulast%3DHonkalammi%26aufirst%3DJ.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26atitle%3DMechanism-based%2520inactivation%2520of%2520CYP2C8%2520by%2520gemfibrozil%2520occurs%2520rapidly%2520in%2520humans%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D89%26spage%3D579%26epage%3D586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Baer, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeLisle, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Benzylic oxidation of gemfibrozil-1-<i>O</i>-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1298</span><span class="NLM_x">–</span> <span class="NLM_lpage">1309</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx900105n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=1298-1309&author=B.+R.+Baerauthor=R.+K.+DeLisleauthor=A.+Allen&title=Benzylic+oxidation+of+gemfibrozil-1-O-beta-glucuronide+by+P450+2C8+leads+to+heme+alkylation+and+irreversible+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Ftx900105n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx900105n%26sid%3Dliteratum%253Aachs%26aulast%3DBaer%26aufirst%3DB.%2BR.%26aulast%3DDeLisle%26aufirst%3DR.%2BK.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DBenzylic%2520oxidation%2520of%2520gemfibrozil-1-O-beta-glucuronide%2520by%2520P450%25202C8%2520leads%2520to%2520heme%2520alkylation%2520and%2520irreversible%2520inhibition%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D1298%26epage%3D1309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Jenkins, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, A. D.</span><span> </span><span class="NLM_article-title">Studies to further investigate the inhibition of human liver microsomal cytochrome P4502C8 (CYP2C8) by the acyl-β-glucuronide of gemfibrozil</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">2421</span><span class="NLM_x">–</span> <span class="NLM_lpage">2430</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=2421-2430&author=S.+M.+Jenkinsauthor=T.+Zvyagaauthor=S.+R.+Johnsonauthor=J.+Hurleyauthor=A.+Wagnerauthor=R.+Burrellauthor=W.+Turleyauthor=J.+E.+Leetauthor=T.+Philipauthor=A.+D.+Rodrigues&title=Studies+to+further+investigate+the+inhibition+of+human+liver+microsomal+cytochrome+P4502C8+%28CYP2C8%29+by+the+acyl-%CE%B2-glucuronide+of+gemfibrozil"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJenkins%26aufirst%3DS.%2BM.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DHurley%26aufirst%3DJ.%26aulast%3DWagner%26aufirst%3DA.%26aulast%3DBurrell%26aufirst%3DR.%26aulast%3DTurley%26aufirst%3DW.%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DPhilip%26aufirst%3DT.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26atitle%3DStudies%2520to%2520further%2520investigate%2520the%2520inhibition%2520of%2520human%2520liver%2520microsomal%2520cytochrome%2520P4502C8%2520%2528CYP2C8%2529%2520by%2520the%2520acyl-%25CE%25B2-glucuronide%2520of%2520gemfibrozil%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D2421%26epage%3D2430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roadcap, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Mechanistic studies on metabolic interactions between gemfibrozil and statins</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">301</span><span class="NLM_x">, </span> <span class="NLM_fpage">1042</span><span class="NLM_x">–</span> <span class="NLM_lpage">1051</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1124%2Fjpet.301.3.1042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=12023536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlGjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=2002&pages=1042-1051&author=T.+Prueksaritanontauthor=J.+J.+Zhaoauthor=B.+Maauthor=B.+A.+Roadcapauthor=C.+Tangauthor=Y.+Qiuauthor=L.+Liuauthor=J.+H.+Linauthor=P.+G.+Pearsonauthor=T.+A.+Baillie&title=Mechanistic+studies+on+metabolic+interactions+between+gemfibrozil+and+statins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic studies on metabolic interactions between gemfibrozil and statins</span></div><div class="casAuthors">Prueksaritanont, Thomayant; Zhao, Jamie J.; Ma, Bennett; Roadcap, Brad A.; Tang, Cuyue; Qiu, Yue; Liu, Lida; Lin, Jiunn H.; Pearson, Paul G.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1042-1051</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A series of studies were conducted to explore the mechanism of the pharmacokinetic interaction between simvastatin (SV) and gemfibrozil (GFZ) reported recently in human subjects.  After administration of a single dose of SV (4 mg/kg p.o.) to dogs pretreated with GFZ (75 mg/kg p.o., twice daily for 5 days), there was an increase (∼4-fold) in systemic exposure to simvastatin hydroxy acid (SVA), but not to SV, similar to the observation in humans.  GFZ pretreatment did not increase the ex vivo hydrolysis of SV to SVA in dog plasma.  In dog and human liver microsomes, GFZ exerted a minimal inhibitory effect on CYP3A-mediated SVA oxidn., but did inhibit SVA glucuronidation.  After i.v. administration of [14C]SVA to dogs, GFZ treatment significantly reduced (2-3-fold) the plasma clearance of SVA and the biliary excretion of SVA glucuronide (together with its cyclization product SV), but not the excretion of a major oxidative metabolite of SVA, consistent with the in vitro findings in dogs.  Among six human UGT isoenzymes tested, UGT1A1 and 1A3 were capable of catalyzing the glucuronidation of both GFZ and SVA.  Further studies conducted in human liver microsomes with atorvastatin (AVA) showed that, as with SVA, GFZ was a less potent inhibitor of the CYP3A4-mediated oxidn. of this drug than its glucuronidation.  However, with cerivastatin (CVA), the glucuronidation as well as the CYP2C8- and CYP3A4-mediated oxidn. pathways were much more susceptible to inhibition by GFZ than was obsd. with SVA or AVA.  Collectively, the results of these studies provide metabolic insight into the nature of drug-drug interaction between GFZ and statins, and a possible explanation for the enhanced susceptibility of CVA to interactions with GFZ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqflGfEYfS4MbVg90H21EOLACvtfcHk0lhcOGlAu3eGjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlGjsbw%253D&md5=f265ac0589d946766de5206f4fb41de7</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1124%2Fjpet.301.3.1042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.301.3.1042%26sid%3Dliteratum%253Aachs%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DRoadcap%26aufirst%3DB.%2BA.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DMechanistic%2520studies%2520on%2520metabolic%2520interactions%2520between%2520gemfibrozil%2520and%2520statins%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D301%26spage%3D1042%26epage%3D1051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strong-Basalyga, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenhandler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlini, E. J.</span><span> </span><span class="NLM_article-title">Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">71</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2005&pages=71-78&author=T.+Prueksaritanontauthor=K.+M.+Richardsauthor=Y.+Qiuauthor=K.+Strong-Basalygaauthor=A.+Millerauthor=C.+Liauthor=R.+Eisenhandlerauthor=E.+J.+Carlini&title=Comparative+effects+of+fibrates+on+drug+metabolizing+enzymes+in+human+hepatocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DRichards%26aufirst%3DK.%2BM.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DStrong-Basalyga%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DEisenhandler%26aufirst%3DR.%26aulast%3DCarlini%26aufirst%3DE.%2BJ.%26atitle%3DComparative%2520effects%2520of%2520fibrates%2520on%2520drug%2520metabolizing%2520enzymes%2520in%2520human%2520hepatocytes%26jtitle%3DPharm.%2520Res.%26date%3D2005%26volume%3D22%26spage%3D71%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngui, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doss, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNinno, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blizzard, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stearns, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">907</span><span class="NLM_x">–</span> <span class="NLM_lpage">914</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx0200109" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD38Xkt1KrurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2002&pages=907-914&author=Q.+Chenauthor=J.+S.+Nguiauthor=G.+A.+Dossauthor=R.+W.+Wangauthor=X.+Caiauthor=F.+P.+DiNinnoauthor=T.+A.+Blizzardauthor=M.+L.+Hammondauthor=R.+A.+Stearnsauthor=D.+C.+Evansauthor=T.+A.+Baillie&title=Cytochrome+P450+3A4-mediated+bioactivation+of+raloxifene%3A+irreversible+enzyme+inhibition+and+thiol+adduct+formation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation</span></div><div class="casAuthors">Chen, Qing; Ngui, Jason S.; Doss, George A.; Wang, Regina W.; Cai, Xiaoxin; DiNinno, Frank P.; Blizzard, Timothy A.; Hammond, Milton L.; Stearns, Ralph A.; Evans, David C.; Baillie, Thomas A.; Tang, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">907-914</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Raloxifene is a selective estrogen receptor modulator which is effective in the treatment of osteoporosis in postmenopausal women.  We report herein that cytochrome P 450 3A4 is inhibited by raloxifene in human liver microsomal incubations.  The nature of the inhibition was irreversible and was NADPH- and preincubation time-dependent, with KI and kinact values estd. at 9.9 μM and 0.16 min-1, resp.  The obsd. loss of P 450 3A4 activity was attenuated partially by glutathione (GSH), implying the involvement of a reactive metabolite(s) in the inactivation process.  Subsequently, GSH adducts of raloxifene were identified in incubations with human liver microsomes; substitution with GSH occurred at the 5- or 7-position of the benzothiophene moiety or at the 3'-position of the phenol ring, with the 7-glutathionyl deriv. being most abundant based on LC/MS and NMR analyses.  These adducts are postulated to derive from addn. of GSH to raloxifene arene oxides followed by dehydration and aromatization.  Alternatively, raloxifene may be oxidized to an extended quinone intermediate, which then is trapped by GSH conjugation.  The bioactivation of raloxifene most likely is catalyzed by P 450 3A4, since the formation of GSH adducts was almost abolished when liver microsomes were pretreated with ketoconazole or with an inhibitory anti-P 450 3A4 IgG.  The GSH adducts also were detected in incubations of raloxifene with rat or human hepatocytes, while the corresponding N-acetylcysteine adducts were identified in the bile and urine from rats treated orally with the drug at 5 mg/kg.  Taken together, these data indicate that P 450 3A4-mediated bioactivation of raloxifene in vitro is accompanied by loss of enzyme activity.  The significance of these findings with respect to the clin. use of raloxifene remains to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvQ7INUtJwIbVg90H21EOLACvtfcHk0lhcOGlAu3eGjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xkt1KrurY%253D&md5=cec21bf3d8ce150474291a5e48206744</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Ftx0200109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx0200109%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DNgui%26aufirst%3DJ.%2BS.%26aulast%3DDoss%26aufirst%3DG.%2BA.%26aulast%3DWang%26aufirst%3DR.%2BW.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DDiNinno%26aufirst%3DF.%2BP.%26aulast%3DBlizzard%26aufirst%3DT.%2BA.%26aulast%3DHammond%26aufirst%3DM.%2BL.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DCytochrome%2520P450%25203A4-mediated%2520bioactivation%2520of%2520raloxifene%253A%2520irreversible%2520enzyme%2520inhibition%2520and%2520thiol%2520adduct%2520formation%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2002%26volume%3D15%26spage%3D907%26epage%3D914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Baer, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wienkers, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rock, D. A.</span><span> </span><span class="NLM_article-title">Time-dependent inactivation of P4503A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">954</span><span class="NLM_x">–</span> <span class="NLM_lpage">964</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx700037e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=954-964&author=B.+R.+Baerauthor=L.+C.+Wienkersauthor=D.+A.+Rock&title=Time-dependent+inactivation+of+P4503A4+by+raloxifene%3A+identification+of+Cys239+as+the+site+of+apoprotein+alkylation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Ftx700037e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx700037e%26sid%3Dliteratum%253Aachs%26aulast%3DBaer%26aufirst%3DB.%2BR.%26aulast%3DWienkers%26aufirst%3DL.%2BC.%26aulast%3DRock%26aufirst%3DD.%2BA.%26atitle%3DTime-dependent%2520inactivation%2520of%2520P4503A4%2520by%2520raloxifene%253A%2520identification%2520of%2520Cys239%2520as%2520the%2520site%2520of%2520apoprotein%2520alkylation%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D954%26epage%3D964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Pearson, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahlstrom, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickman, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halpert, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wienkers, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foti, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rock, D. A.</span><span> </span><span class="NLM_article-title">Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1778</span><span class="NLM_x">–</span> <span class="NLM_lpage">1786</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx700207u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=1778-1786&author=J.+T.+Pearsonauthor=J.+L.+Wahlstromauthor=L.+J.+Dickmanauthor=S.+Kumarauthor=J.+R.+Halpertauthor=L.+C.+Wienkersauthor=R.+S.+Fotiauthor=D.+A.+Rock&title=Differential+time-dependent+inactivation+of+P450+3A4+and+P450+3A5+by+raloxifene%3A+a+key+role+for+C239+in+quenching+reactive+intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Ftx700207u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx700207u%26sid%3Dliteratum%253Aachs%26aulast%3DPearson%26aufirst%3DJ.%2BT.%26aulast%3DWahlstrom%26aufirst%3DJ.%2BL.%26aulast%3DDickman%26aufirst%3DL.%2BJ.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DHalpert%26aufirst%3DJ.%2BR.%26aulast%3DWienkers%26aufirst%3DL.%2BC.%26aulast%3DFoti%26aufirst%3DR.%2BS.%26aulast%3DRock%26aufirst%3DD.%2BA.%26atitle%3DDifferential%2520time-dependent%2520inactivation%2520of%2520P450%25203A4%2520and%2520P450%25203A5%2520by%2520raloxifene%253A%2520a%2520key%2520role%2520for%2520C239%2520in%2520quenching%2520reactive%2520intermediates%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D1778%26epage%3D1786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Yukinaga, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takami, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shioyama, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozuka, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masumoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okazaki, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudo, K.</span><span> </span><span class="NLM_article-title">Identification of cytochrome P450 3A4 modification site with reactive metabolite using linear ion trap-Fourier transform mass spectrometry</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1373</span><span class="NLM_x">–</span> <span class="NLM_lpage">1378</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx700165q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=1373-1378&author=H.+Yukinagaauthor=T.+Takamiauthor=S.+H.+Shioyamaauthor=Z.+Tozukaauthor=H.+Masumotoauthor=O.+Okazakiauthor=K.+Sudo&title=Identification+of+cytochrome+P450+3A4+modification+site+with+reactive+metabolite+using+linear+ion+trap-Fourier+transform+mass+spectrometry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Ftx700165q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx700165q%26sid%3Dliteratum%253Aachs%26aulast%3DYukinaga%26aufirst%3DH.%26aulast%3DTakami%26aufirst%3DT.%26aulast%3DShioyama%26aufirst%3DS.%2BH.%26aulast%3DTozuka%26aufirst%3DZ.%26aulast%3DMasumoto%26aufirst%3DH.%26aulast%3DOkazaki%26aufirst%3DO.%26aulast%3DSudo%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520cytochrome%2520P450%25203A4%2520modification%2520site%2520with%2520reactive%2520metabolite%2520using%2520linear%2520ion%2520trap-Fourier%2520transform%2520mass%2520spectrometry%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D1373%26epage%3D1378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">Mizuma, T.</span><span> </span><span class="NLM_article-title">Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10</span> <span class="citation_source-journal">Int. J. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">378</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.ijpharm.2009.05.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=19486934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovFKqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2009&pages=140-141&author=T.+Mizuma&title=Intestinal+glucuronidation+metabolism+may+have+a+greater+impact+on+oral+bioavailability+than+hepatic+glucuronidation+metabolism+in+humans%3A+a+study+with+raloxifene%2C+substrate+for+UGT1A1%2C+1A8%2C+1A9%2C+and+1A10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10</span></div><div class="casAuthors">Mizuma, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">140-141</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The kinetic impact of intestinal glucuronidation metab. on oral bioavailability (F) was assessed using reported human data of raloxifene, of which oral bioavailability was only 2%.  Kinetic anal. showed that presystemic intestinal availability (Fpg) was 5.4%, whereas fraction absorbed (Ff) and hepatic availability (Fh) were 63% and 59.3%, resp.  Thus, Fpg was the lowest among factors, which affect oral bioavailability.  In addn., Fpg was much lower than Fh, suggesting that intestinal glucuronidation metab. has a greater impact on oral bioavailability than hepatic glucuronidation metab.  It has been reported that UDP-glucuronosyltransferase (UGT) 1A1, UGT1A8, UGT1A9, and UGT1A10 are enzymes for raloxifene glucuronidation, and UGT1A8 and UGT1A10 are absent in the human liver, whereas UGT1A1, UGT1A8, UGT1A9, and UGT1A10 are present in the human intestine.  Therefore, it is also suggested that intestinal glucuronidation catalyzed by UGTs, particularly UGT1A8 and UGT1A10, may play important roles in the first-pass metab., causing low oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFWR7hNsC17rVg90H21EOLACvtfcHk0liLtLAn0Bubug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovFKqtbs%253D&md5=293c4c269d54a0e92e32c9aa473d50d6</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2009.05.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2009.05.044%26sid%3Dliteratum%253Aachs%26aulast%3DMizuma%26aufirst%3DT.%26atitle%3DIntestinal%2520glucuronidation%2520metabolism%2520may%2520have%2520a%2520greater%2520impact%2520on%2520oral%2520bioavailability%2520than%2520hepatic%2520glucuronidation%2520metabolism%2520in%2520humans%253A%2520a%2520study%2520with%2520raloxifene%252C%2520substrate%2520for%2520UGT1A1%252C%25201A8%252C%25201A9%252C%2520and%25201A10%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2009%26volume%3D378%26spage%3D140%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Mullins, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horowitz, B. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linden, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stump, J.</span><span> </span><span class="NLM_article-title">Life-threatening interaction between mibefradil and beta-blockers with dihydropyridine calcium channel blockers</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">158</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=1998&pages=157-158&author=M.+E.+Mullinsauthor=B.+Z.+Horowitzauthor=D.+H.+Lindenauthor=G.+W.+Smithauthor=R.+L.+Nortonauthor=J.+Stump&title=Life-threatening+interaction+between+mibefradil+and+beta-blockers+with+dihydropyridine+calcium+channel+blockers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMullins%26aufirst%3DM.%2BE.%26aulast%3DHorowitz%26aufirst%3DB.%2BZ.%26aulast%3DLinden%26aufirst%3DD.%2BH.%26aulast%3DSmith%26aufirst%3DG.%2BW.%26aulast%3DNorton%26aufirst%3DR.%2BL.%26aulast%3DStump%26aufirst%3DJ.%26atitle%3DLife-threatening%2520interaction%2520between%2520mibefradil%2520and%2520beta-blockers%2520with%2520dihydropyridine%2520calcium%2520channel%2520blockers%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D1998%26volume%3D280%26spage%3D157%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Schmassmann-Suhijar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullingham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmutz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haefeli, W. E.</span><span> </span><span class="NLM_article-title">Rhabdomyolysis due to interaction of simvastatin with mibefradil</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">351</span><span class="NLM_x">, </span> <span class="NLM_fpage">1929</span><span class="NLM_x">–</span> <span class="NLM_lpage">1930</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=1998&pages=1929-1930&author=D.+Schmassmann-Suhijarauthor=R.+Bullinghamauthor=R.+Gasserauthor=J.+Schmutzauthor=W.+E.+Haefeli&title=Rhabdomyolysis+due+to+interaction+of+simvastatin+with+mibefradil"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchmassmann-Suhijar%26aufirst%3DD.%26aulast%3DBullingham%26aufirst%3DR.%26aulast%3DGasser%26aufirst%3DR.%26aulast%3DSchmutz%26aufirst%3DJ.%26aulast%3DHaefeli%26aufirst%3DW.%2BE.%26atitle%3DRhabdomyolysis%2520due%2520to%2520interaction%2520of%2520simvastatin%2520with%2520mibefradil%26jtitle%3DLancet%26date%3D1998%26volume%3D351%26spage%3D1929%26epage%3D1930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Billups, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, B. L.</span><span> </span><span class="NLM_article-title">Mibefradil withdrawn from the market</span> <span class="citation_source-journal">Ann. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">841</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1998&pages=841&author=S.+J.+Billupsauthor=B.+L.+Carter&title=Mibefradil+withdrawn+from+the+market"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBillups%26aufirst%3DS.%2BJ.%26aulast%3DCarter%26aufirst%3DB.%2BL.%26atitle%3DMibefradil%2520withdrawn%2520from%2520the%2520market%26jtitle%3DAnn.%2520Pharmacother.%26date%3D1998%26volume%3D32%26spage%3D841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reider, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver microsomes</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1046%2Fj.1365-2125.1999.00903.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=10215754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK1MXisVKiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1999&pages=291-298&author=T.+Prueksaritanontauthor=B.+Maauthor=C.+Tangauthor=Y.+Mengauthor=C.+Assangauthor=P.+Luauthor=P.+J.+Reiderauthor=J.+H.+Linauthor=T.+A.+Baillie&title=Metabolic+interactions+between+mibefradil+and+HMG-CoA+reductase+inhibitors%3A+an+in+vitro+investigation+with+human+liver+microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations</span></div><div class="casAuthors">Prueksaritanont, Thomayant; Ma, Bennett; Tang, Cuyue; Meng, Yuan; Assang, Carol; Lu, Ping; Reider, Paul J.; Lin, Jiunn H.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-298</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Aims: To det. the effects of mibefradil on the metab. in human liver microsomal prepns. of the HMG-CoA reductase inhibitors simvastatin, lovastatin, atorvastatin, cerivastatin and fluvastatin.  Metab. of the above five statins (0.5, 5 or 10 μM), as well as of specific CYP3A4/5 and CYP2C8/9 marker substrates, was examd. in human liver microsomal prepns. in the presence and absence of mibefradil (0.1-50 μM).  Mibefradil inhibited, in a concn.-dependent fashion, the metab. of the four statins (simvastatin, lovastatin, atorvastatin and cerivastatin) known to be substrates for CYP3A.  The potency of inhibition was such that the IC50 values (< 1μM) for inhibition of all of the CYP3A substrates fell within the therapeutic plasma concns. of mibefradil, and was comparable with that of ketoconazole.  However, the inhibition by mibefradil, unlike that of ketoconazole, was at least in part mechanism-based.  Based on the kinetics of its inhibition of hepatic testosterone 6β-hydroxylase activity, mibefradil was judged to be a powerful mechanism-based inhibitor of CYP3A4/5, with values for Kinactivation, Ki and partition ratio (moles of mibefradil metabolized per mol. of enzyme inactivated) of 0.4 min-1, 2.3 μM and 1.7, resp.  In contrast to the results with substrates of CYP3A, metab. of fluvastatin, a substrate of CYP2C8/9, and the hydroxylation of tolbutamide, a functional probe for CYP2C8/9, were not inhibited by mibefradil.  Mibefradil, at therapeutically relevant concns., strongly suppressed the metab. in human liver microsomes of simvastatin, lovastatin, atorvastatin and cerivastatin through its inhibitory effects on CYP3A4/5, while the effects of mibefradil on fluvastatin, a substrate for CYP2C8/9, were minimal in this system.  Since mibefradil is a potent mechanism-based inhibitor of CYP3A4/5, it is anticipated that clin. significant drug-drug interactions will likely ensue when mibefradil is coadministered with agents which are cleared primarily by CYP3A-mediated pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2qEUHS8dzULVg90H21EOLACvtfcHk0lhfAjKTaffn7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXisVKiu7c%253D&md5=b919d4f3a0312ad030c4b9b80c9ef4f9</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2125.1999.00903.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2125.1999.00903.x%26sid%3Dliteratum%253Aachs%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DMeng%26aufirst%3DY.%26aulast%3DAssang%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DReider%26aufirst%3DP.%2BJ.%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DMetabolic%2520interactions%2520between%2520mibefradil%2520and%2520HMG-CoA%2520reductase%2520inhibitors%253A%2520an%2520in%2520vitro%2520investigation%2520with%2520human%2520liver%2520microsomes%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1999%26volume%3D47%26spage%3D291%26epage%3D298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Wiltshire, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heeps, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betty, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angus, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madigan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, S. R.</span><span> </span><span class="NLM_article-title">Metabolism of the calcium antagonist, mibefradil (POSICOR, Ro 40-5967). Part II. Metabolism in hepatic microsomes from rat, marmoset, cynomolgus monkey, rabbit and man</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">556</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1997&pages=539-556&author=H.+R.+Wiltshireauthor=B.+M.+Suttonauthor=G.+Heepsauthor=A.+M.+Bettyauthor=D.+W.+Angusauthor=M.+J.+Madiganauthor=S.+R.+Sharp&title=Metabolism+of+the+calcium+antagonist%2C+mibefradil+%28POSICOR%2C+Ro+40-5967%29.+Part+II.+Metabolism+in+hepatic+microsomes+from+rat%2C+marmoset%2C+cynomolgus+monkey%2C+rabbit+and+man"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWiltshire%26aufirst%3DH.%2BR.%26aulast%3DSutton%26aufirst%3DB.%2BM.%26aulast%3DHeeps%26aufirst%3DG.%26aulast%3DBetty%26aufirst%3DA.%2BM.%26aulast%3DAngus%26aufirst%3DD.%2BW.%26aulast%3DMadigan%26aufirst%3DM.%2BJ.%26aulast%3DSharp%26aufirst%3DS.%2BR.%26atitle%3DMetabolism%2520of%2520the%2520calcium%2520antagonist%252C%2520mibefradil%2520%2528POSICOR%252C%2520Ro%252040-5967%2529.%2520Part%2520II.%2520Metabolism%2520in%2520hepatic%2520microsomes%2520from%2520rat%252C%2520marmoset%252C%2520cynomolgus%2520monkey%252C%2520rabbit%2520and%2520man%26jtitle%3DXenobiotica%26date%3D1997%26volume%3D27%26spage%3D539%26epage%3D556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">Foti, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rock, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahlstrom, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wienkers, L. C.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of cytochrome P4503A4 by mibefradil through heme destruction</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1188</span><span class="NLM_x">–</span> <span class="NLM_lpage">1195</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1188-1195&author=R.+S.+Fotiauthor=D.+A.+Rockauthor=J.+T.+Pearsonauthor=J.+L.+Wahlstromauthor=L.+C.+Wienkers&title=Mechanism-based+inactivation+of+cytochrome+P4503A4+by+mibefradil+through+heme+destruction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFoti%26aufirst%3DR.%2BS.%26aulast%3DRock%26aufirst%3DD.%2BA.%26aulast%3DPearson%26aufirst%3DJ.%2BT.%26aulast%3DWahlstrom%26aufirst%3DJ.%2BL.%26aulast%3DWienkers%26aufirst%3DL.%2BC.%26atitle%3DMechanism-based%2520inactivation%2520of%2520cytochrome%2520P4503A4%2520by%2520mibefradil%2520through%2520heme%2520destruction%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1188%26epage%3D1195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Magee, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripp, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buzon, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chupak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougherty, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finegan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagen, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcone, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granskog, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardnik, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huband, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamicker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knickerbocker, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noe, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penzien, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, U. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schafer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tait-Kamradt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaz, A. D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widlicka, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishka, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolkowski, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span> </span><span class="NLM_article-title">Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7446</span><span class="NLM_x">–</span> <span class="NLM_lpage">7457</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900729s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7446-7457&author=T.+V.+Mageeauthor=S.+L.+Rippauthor=B.+Liauthor=R.+A.+Buzonauthor=L.+Chupakauthor=T.+J.+Doughertyauthor=S.+M.+Fineganauthor=D.+Girardauthor=A.+E.+Hagenauthor=M.+J.+Falconeauthor=K.+A.+Farleyauthor=K.+Granskogauthor=J.+R.+Hardnikauthor=M.+D.+Hubandauthor=B.+J.+Kamickerauthor=T.+Kanekoauthor=M.+J.+Knickerbockerauthor=J.+L.+Lirasauthor=A.+Marraauthor=I.+Medinaauthor=T.-T.+Nguyenauthor=M.+C.+Noeauthor=R.+S.+Obachauthor=J.+P.+O%E2%80%99Donnellauthor=J.+B.+Penzienauthor=U.+D.+Reillyauthor=J.+R.+Schaferauthor=Y.+Shenauthor=G.+G.+Stoneauthor=T.+J.+Strelevitzauthor=J.+Sunauthor=A.+Tait-Kamradtauthor=A.+D.+N.+Vazauthor=D.+A.+Whippleauthor=D.+W.+Widlickaauthor=D.+G.+Wishkaauthor=J.+P.+Wolkowskiauthor=M.+E.+Flanagan&title=Discovery+of+azetidinyl+ketolides+for+the+treatment+of+susceptible+and+multidrug+resistant+community-acquired+respiratory+tract+infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Fjm900729s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900729s%26sid%3Dliteratum%253Aachs%26aulast%3DMagee%26aufirst%3DT.%2BV.%26aulast%3DRipp%26aufirst%3DS.%2BL.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DBuzon%26aufirst%3DR.%2BA.%26aulast%3DChupak%26aufirst%3DL.%26aulast%3DDougherty%26aufirst%3DT.%2BJ.%26aulast%3DFinegan%26aufirst%3DS.%2BM.%26aulast%3DGirard%26aufirst%3DD.%26aulast%3DHagen%26aufirst%3DA.%2BE.%26aulast%3DFalcone%26aufirst%3DM.%2BJ.%26aulast%3DFarley%26aufirst%3DK.%2BA.%26aulast%3DGranskog%26aufirst%3DK.%26aulast%3DHardnik%26aufirst%3DJ.%2BR.%26aulast%3DHuband%26aufirst%3DM.%2BD.%26aulast%3DKamicker%26aufirst%3DB.%2BJ.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DKnickerbocker%26aufirst%3DM.%2BJ.%26aulast%3DLiras%26aufirst%3DJ.%2BL.%26aulast%3DMarra%26aufirst%3DA.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DNguyen%26aufirst%3DT.-T.%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BP.%26aulast%3DPenzien%26aufirst%3DJ.%2BB.%26aulast%3DReilly%26aufirst%3DU.%2BD.%26aulast%3DSchafer%26aufirst%3DJ.%2BR.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DStone%26aufirst%3DG.%2BG.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DTait-Kamradt%26aufirst%3DA.%26aulast%3DVaz%26aufirst%3DA.%2BD.%2BN.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DWidlicka%26aufirst%3DD.%2BW.%26aulast%3DWishka%26aufirst%3DD.%2BG.%26aulast%3DWolkowski%26aufirst%3DJ.%2BP.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26atitle%3DDiscovery%2520of%2520azetidinyl%2520ketolides%2520for%2520the%2520treatment%2520of%2520susceptible%2520and%2520multidrug%2520resistant%2520community-acquired%2520respiratory%2520tract%2520infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7446%26epage%3D7457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Linus, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanza, T.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieczykowski, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treonze, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Si, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manior, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuelke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pivnichny, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacCoss, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mumford, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagmann, W. K.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-{<i>N</i>-[(3-cyanophenyl)sulfonyl]-4(<i>R</i>)-cyclobutylamino-(<span class="smallcaps smallerCapital">l</span>)-prolyl}-4-[(3′,5′-dichloroisonicotinoyl)amino]-(<span class="smallcaps smallerCapital">l</span>)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3449</span><span class="NLM_x">–</span> <span class="NLM_lpage">3452</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3449-3452&author=L.+S.+Linusauthor=T.+Lanzaauthor=J.+P.+Jewellauthor=P.+Liuauthor=C.+Jonesauthor=G.+R.+Kieczykowskiauthor=K.+Treonzeauthor=Q.+Siauthor=S.+Maniorauthor=G.+Kooauthor=X.+Tongauthor=J.+Wangauthor=A.+Schuelkeauthor=J.+Pivnichnyauthor=R.+Wangauthor=C.+Raabauthor=S.+Vincentauthor=P.+Daviesauthor=M.+MacCossauthor=R.+A.+Mumfordauthor=W.+K.+Hagmann&title=Discovery+of+N-%7BN-%5B%283-cyanophenyl%29sulfonyl%5D-4%28R%29-cyclobutylamino-%28l%29-prolyl%7D-4-%5B%283%E2%80%B2%2C5%E2%80%B2-dichloroisonicotinoyl%29amino%5D-%28l%29-phenylalanine+%28MK-0668%29%2C+an+extremely+potent+and+orally+active+antagonist+of+very+late+antigen-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLinus%26aufirst%3DL.%2BS.%26aulast%3DLanza%26aufirst%3DT.%26aulast%3DJewell%26aufirst%3DJ.%2BP.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DKieczykowski%26aufirst%3DG.%2BR.%26aulast%3DTreonze%26aufirst%3DK.%26aulast%3DSi%26aufirst%3DQ.%26aulast%3DManior%26aufirst%3DS.%26aulast%3DKoo%26aufirst%3DG.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSchuelke%26aufirst%3DA.%26aulast%3DPivnichny%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DRaab%26aufirst%3DC.%26aulast%3DVincent%26aufirst%3DS.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DMacCoss%26aufirst%3DM.%26aulast%3DMumford%26aufirst%3DR.%2BA.%26aulast%3DHagmann%26aufirst%3DW.%2BK.%26atitle%3DDiscovery%2520of%2520N-%257BN-%255B%25283-cyanophenyl%2529sulfonyl%255D-4%2528R%2529-cyclobutylamino-%2528l%2529-prolyl%257D-4-%255B%25283%25E2%2580%25B2%252C5%25E2%2580%25B2-dichloroisonicotinoyl%2529amino%255D-%2528l%2529-phenylalanine%2520%2528MK-0668%2529%252C%2520an%2520extremely%2520potent%2520and%2520orally%2520active%2520antagonist%2520of%2520very%2520late%2520antigen-4%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3449%26epage%3D3452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Westaway, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fell, S. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacPherson, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myatt, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanway, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seal, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stemp, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawless, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKay, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cluff, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahmood, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohamed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolton, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvie, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanger, G. J.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(3-fluorophenyl)-1-[(4-([(3<i>S</i>)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1180</span><span class="NLM_x">–</span> <span class="NLM_lpage">1189</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801332q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1180-1189&author=S.+M.+Westawayauthor=S.+L.+Brownauthor=S.+C.+M.+Fellauthor=C.+N.+Johnsonauthor=D.+T.+MacPhersonauthor=D.+J.+Mitchellauthor=J.+W.+Myattauthor=S.+J.+Stanwayauthor=J.+T.+Sealauthor=G.+Stempauthor=M.+Thompsonauthor=K.+Lawlessauthor=F.+McKayauthor=A.+I.+Muirauthor=J.+M.+Barfordauthor=C.+Cluffauthor=S.+R.+Mahmoodauthor=K.+L.+Matthewsauthor=S.+Mohamedauthor=B.+Smithauthor=A.+J.+Stevensauthor=V.+J.+Boltonauthor=E.+M.+Jarvieauthor=G.+J.+Sanger&title=Discovery+of+N-%283-fluorophenyl%29-1-%5B%284-%28%5B%283S%29-3-methyl-1-piperazinyl%5Dmethyl%29phenyl%29acetyl%5D-4-piperidinamine+%28GSK962040%29%2C+the+first+small+molecule+motilin+receptor+agonist+clinical+candidate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(3-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the First Small Molecule Motilin Receptor Agonist Clinical Candidate</span></div><div class="casAuthors">Westaway, Susan M.; Brown, Samantha L.; Fell, Stephen C. M.; Johnson, Christopher N.; MacPherson, David T.; Mitchell, Darren J.; Myatt, James W.; Stanway, Steven J.; Seal, Jon T.; Stemp, Geoffrey; Thompson, Mervyn; Lawless, Kirk; McKay, Fiona; Muir, Alison I.; Barford, Jonathan M.; Cluff, Chermaine; Mahmood, Sadhia R.; Matthews, Kim L.; Mohamed, Shiyam; Smith, Beverley; Stevens, Alexander J.; Bolton, Victoria J.; Jarvie, Emma M.; Sanger, Gareth J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1180-1189</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-(3-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine 12 (GSK962040) is a novel small mol. motilin receptor agonist.  It possesses excellent activity at the recombinant human motilin receptor and also at the native rabbit motilin receptor where its agonist activity results in potentiation of the amplitude of neuronal-mediated contractions of isolated gastric antrum tissue.  Compd. 12 also possesses highly promising pharmacokinetic profiles in both rat and dog, and these results, in combination with further profiling in human native tissue and an in vivo model of gastrointestinal transit in the rabbit, have led to its selection as a candidate for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQHUqCK5ybBrVg90H21EOLACvtfcHk0lh2PZog9FKb6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSltbg%253D&md5=908680cc14aa8542d05cb128a2cea49b</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Fjm801332q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801332q%26sid%3Dliteratum%253Aachs%26aulast%3DWestaway%26aufirst%3DS.%2BM.%26aulast%3DBrown%26aufirst%3DS.%2BL.%26aulast%3DFell%26aufirst%3DS.%2BC.%2BM.%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26aulast%3DMacPherson%26aufirst%3DD.%2BT.%26aulast%3DMitchell%26aufirst%3DD.%2BJ.%26aulast%3DMyatt%26aufirst%3DJ.%2BW.%26aulast%3DStanway%26aufirst%3DS.%2BJ.%26aulast%3DSeal%26aufirst%3DJ.%2BT.%26aulast%3DStemp%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DM.%26aulast%3DLawless%26aufirst%3DK.%26aulast%3DMcKay%26aufirst%3DF.%26aulast%3DMuir%26aufirst%3DA.%2BI.%26aulast%3DBarford%26aufirst%3DJ.%2BM.%26aulast%3DCluff%26aufirst%3DC.%26aulast%3DMahmood%26aufirst%3DS.%2BR.%26aulast%3DMatthews%26aufirst%3DK.%2BL.%26aulast%3DMohamed%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DStevens%26aufirst%3DA.%2BJ.%26aulast%3DBolton%26aufirst%3DV.%2BJ.%26aulast%3DJarvie%26aufirst%3DE.%2BM.%26aulast%3DSanger%26aufirst%3DG.%2BJ.%26atitle%3DDiscovery%2520of%2520N-%25283-fluorophenyl%2529-1-%255B%25284-%2528%255B%25283S%2529-3-methyl-1-piperazinyl%255Dmethyl%2529phenyl%2529acetyl%255D-4-piperidinamine%2520%2528GSK962040%2529%252C%2520the%2520first%2520small%2520molecule%2520motilin%2520receptor%2520agonist%2520clinical%2520candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1180%26epage%3D1189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leister, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. L.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinney, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiller, P.; R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolkenberg, S. C.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamides as novel, selective and potent GlyT1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1488</span><span class="NLM_x">–</span> <span class="NLM_lpage">1491</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1488-1491&author=Z.+Zhaoauthor=W.+H.+Leisterauthor=J.+A.+O%E2%80%99Brienauthor=W.+Lemaireauthor=D.+L.+Williamsauthor=M.+A.+Jacobsonauthor=C.+Surauthor=G.+G.+Kinneyauthor=D.+J.+Pettiboneauthor=P.%3B+R.+Tillerauthor=S.+Smithauthor=G.+D.+Hartmanauthor=C.+W.+Lindsleyauthor=S.+C.+Wolkenberg&title=Discovery+of+N-%7B%5B1-%28propylsulfonyl%29-4-pyridin-2-ylpiperidin-4-yl%5Dmethyl%7Dbenzamides+as+novel%2C+selective+and+potent+GlyT1+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLeister%26aufirst%3DW.%2BH.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%2BA.%26aulast%3DLemaire%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DD.%2BL.%26aulast%3DJacobson%26aufirst%3DM.%2BA.%26aulast%3DSur%26aufirst%3DC.%26aulast%3DKinney%26aufirst%3DG.%2BG.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DTiller%26aufirst%3DP.%253B%2BR.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DWolkenberg%26aufirst%3DS.%2BC.%26atitle%3DDiscovery%2520of%2520N-%257B%255B1-%2528propylsulfonyl%2529-4-pyridin-2-ylpiperidin-4-yl%255Dmethyl%257Dbenzamides%2520as%2520novel%252C%2520selective%2520and%2520potent%2520GlyT1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1488%26epage%3D1491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Wu, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dworetzky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzpatrick, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harden, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knox, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sivarao, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tertyshnikova, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeola, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoeckler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span> </span><span class="NLM_article-title">Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (<i>S</i>)-<i>N</i>-[1-(4-fluoro-3-morpholin-4-ylphenyl)ethyl]-3-(4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3778</span><span class="NLM_x">–</span> <span class="NLM_lpage">3781</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm034111v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3778-3781&author=Y.-J.+Wuauthor=C.+D.+Davisauthor=S.+Dworetzkyauthor=W.+C.+Fitzpatrickauthor=D.+Hardenauthor=H.+Heauthor=R.+J.+Knoxauthor=A.+E.+Newtonauthor=T.+Philipauthor=C.+Polsonauthor=D.+V.+Sivaraoauthor=L.-Q.+Sunauthor=S.+Tertyshnikovaauthor=D.+Weaverauthor=S.+Yeolaauthor=M.+Zoecklerauthor=M.+W.+Sinz&title=Fluorine+substitution+can+block+CYP3A4+metabolism-dependent+inhibition%3A+identification+of+%28S%29-N-%5B1-%284-fluoro-3-morpholin-4-ylphenyl%29ethyl%5D-3-%284-fluorophenyl%29acrylamide+as+an+orally+bioavailable+KCNQ2+opener+devoid+of+CYP3A4+metabolism-dependent+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Fjm034111v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034111v%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-J.%26aulast%3DDavis%26aufirst%3DC.%2BD.%26aulast%3DDworetzky%26aufirst%3DS.%26aulast%3DFitzpatrick%26aufirst%3DW.%2BC.%26aulast%3DHarden%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DKnox%26aufirst%3DR.%2BJ.%26aulast%3DNewton%26aufirst%3DA.%2BE.%26aulast%3DPhilip%26aufirst%3DT.%26aulast%3DPolson%26aufirst%3DC.%26aulast%3DSivarao%26aufirst%3DD.%2BV.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DTertyshnikova%26aufirst%3DS.%26aulast%3DWeaver%26aufirst%3DD.%26aulast%3DYeola%26aufirst%3DS.%26aulast%3DZoeckler%26aufirst%3DM.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26atitle%3DFluorine%2520substitution%2520can%2520block%2520CYP3A4%2520metabolism-dependent%2520inhibition%253A%2520identification%2520of%2520%2528S%2529-N-%255B1-%25284-fluoro-3-morpholin-4-ylphenyl%2529ethyl%255D-3-%25284-fluorophenyl%2529acrylamide%2520as%2520an%2520orally%2520bioavailable%2520KCNQ2%2520opener%2520devoid%2520of%2520CYP3A4%2520metabolism-dependent%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D3778%26epage%3D3781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Velaparthi, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carboni, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balimane, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurlburt, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discenza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saulnier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D.</span><span> </span><span class="NLM_article-title">Discovery and evaluation of 4-(2-(4-chloro-1<i>H</i>-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)pyridin-2(1<i>H</i>)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5897</span><span class="NLM_x">–</span> <span class="NLM_lpage">5900</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800832q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5897-5900&author=U.+Velaparthiauthor=M.+Wittmanauthor=P.+Liuauthor=J.+M.+Carboniauthor=F.+Y.+Leeauthor=R.+Attarauthor=P.+Balimaneauthor=W.+Clarkeauthor=M.+W.+Sinzauthor=W.+Hurlburtauthor=K.+Patelauthor=L.+Discenzaauthor=S.+Kimauthor=M.+Gottardisauthor=A.+Greerauthor=A.+Liauthor=M.+Saulnierauthor=Z.+Yangauthor=K.+Zimmermannauthor=G.+Trainorauthor=D.+Vyas&title=Discovery+and+evaluation+of+4-%282-%284-chloro-1H-pyrazol-1-yl%29ethylamino%29-3-%286-%281-%283-fluoropropyl%29piperidin-4-yl%29-4-methyl-1H-benzo%5Bd%5Dimidazol-2-yl%29pyridin-2%281H%29-one+%28BMS-695735%29%2C+an+orally+efficacious+inhibitor+of+insulin-like+growth+factor-1+receptor+kinase+with+broad+spectrum+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Fjm800832q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800832q%26sid%3Dliteratum%253Aachs%26aulast%3DVelaparthi%26aufirst%3DU.%26aulast%3DWittman%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCarboni%26aufirst%3DJ.%2BM.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DAttar%26aufirst%3DR.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DW.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DHurlburt%26aufirst%3DW.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DGreer%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DSaulnier%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZimmermann%26aufirst%3DK.%26aulast%3DTrainor%26aufirst%3DG.%26aulast%3DVyas%26aufirst%3DD.%26atitle%3DDiscovery%2520and%2520evaluation%2520of%25204-%25282-%25284-chloro-1H-pyrazol-1-yl%2529ethylamino%2529-3-%25286-%25281-%25283-fluoropropyl%2529piperidin-4-yl%2529-4-methyl-1H-benzo%255Bd%255Dimidazol-2-yl%2529pyridin-2%25281H%2529-one%2520%2528BMS-695735%2529%252C%2520an%2520orally%2520efficacious%2520inhibitor%2520of%2520insulin-like%2520growth%2520factor-1%2520receptor%2520kinase%2520with%2520broad%2520spectrum%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5897%26epage%3D5900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stearns, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakshi, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nargund, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: a case study with melanocortin-4 receptor agonists</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1437</span><span class="NLM_x">–</span> <span class="NLM_lpage">1451</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2008&pages=1437-1451&author=W.+Tangauthor=R.+A.+Stearnsauthor=R.+W.+Wangauthor=R.+R.+Millerauthor=Q.+Chenauthor=J.+Nguiauthor=R.+K.+Bakshiauthor=R.+P.+Nargundauthor=D.+C.+Deanauthor=T.+A.+Baillie&title=Assessing+and+minimizing+time-dependent+inhibition+of+cytochrome+P450+3A+in+drug+discovery%3A+a+case+study+with+melanocortin-4+receptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DW.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DWang%26aufirst%3DR.%2BW.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DNgui%26aufirst%3DJ.%26aulast%3DBakshi%26aufirst%3DR.%2BK.%26aulast%3DNargund%26aufirst%3DR.%2BP.%26aulast%3DDean%26aufirst%3DD.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DAssessing%2520and%2520minimizing%2520time-dependent%2520inhibition%2520of%2520cytochrome%2520P450%25203A%2520in%2520drug%2520discovery%253A%2520a%2520case%2520study%2520with%2520melanocortin-4%2520receptor%2520agonists%26jtitle%3DXenobiotica%26date%3D2008%26volume%3D38%26spage%3D1437%26epage%3D1451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Roberts, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whalen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulford, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Autry, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emerson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Alsina, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorenzen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berliner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luzzio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaGreca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jani, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wessel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marr, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vajdos, F.</span><span> </span><span class="NLM_article-title">Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">1935</span><span class="NLM_x">–</span> <span class="NLM_lpage">1944</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=1935-1944&author=W.+G.+Robertsauthor=E.+Ungauthor=P.+Whalenauthor=B.+Cooperauthor=C.+Hulfordauthor=C.+Autryauthor=D.+Richterauthor=E.+Emersonauthor=J.+Linauthor=J.+Kathauthor=K.+Colemanauthor=L.+Yaoauthor=L.+Martinez-Alsinaauthor=M.+Lorenzenauthor=M.+Berlinerauthor=M.+Luzzioauthor=N.+Patelauthor=E.+Schmittauthor=S.+LaGrecaauthor=J.+Janiauthor=M.+Wesselauthor=E.+Marrauthor=M.+Grifforauthor=F.+Vajdos&title=Antitumor+activity+and+pharmacology+of+a+selective+focal+adhesion+kinase+inhibitor%2C+PF-562%2C271"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26aulast%3DUng%26aufirst%3DE.%26aulast%3DWhalen%26aufirst%3DP.%26aulast%3DCooper%26aufirst%3DB.%26aulast%3DHulford%26aufirst%3DC.%26aulast%3DAutry%26aufirst%3DC.%26aulast%3DRichter%26aufirst%3DD.%26aulast%3DEmerson%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DKath%26aufirst%3DJ.%26aulast%3DColeman%26aufirst%3DK.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMartinez-Alsina%26aufirst%3DL.%26aulast%3DLorenzen%26aufirst%3DM.%26aulast%3DBerliner%26aufirst%3DM.%26aulast%3DLuzzio%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DSchmitt%26aufirst%3DE.%26aulast%3DLaGreca%26aufirst%3DS.%26aulast%3DJani%26aufirst%3DJ.%26aulast%3DWessel%26aufirst%3DM.%26aulast%3DMarr%26aufirst%3DE.%26aulast%3DGriffor%26aufirst%3DM.%26aulast%3DVajdos%26aufirst%3DF.%26atitle%3DAntitumor%2520activity%2520and%2520pharmacology%2520of%2520a%2520selective%2520focal%2520adhesion%2520kinase%2520inhibitor%252C%2520PF-562%252C271%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D1935%26epage%3D1944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Walker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bi, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soglia, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aspnes, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klug-McLeod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawistoski, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGlynn, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulford, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Autry, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luzzio, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ung, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnette, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckbinder, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffor, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman-Perez, A.</span><span> </span><span class="NLM_article-title">Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure–activity relationships and strategies for the elimination of reactive metabolite formation</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">6071</span><span class="NLM_x">–</span> <span class="NLM_lpage">6077</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6071-6077&author=D.+P.+Walkerauthor=F.+C.+Biauthor=A.+S.+Kalgutkarauthor=J.+N.+Baumanauthor=S.+X.+Zhaoauthor=J.+R.+Sogliaauthor=G.+E.+Aspnesauthor=D.+W.+Kungauthor=J.+Klug-McLeodauthor=M.+P.+Zawistoskiauthor=M.+A.+McGlynnauthor=R.+Oliverauthor=M.+Dunnauthor=J.+C.+Liauthor=D.+T.+Richterauthor=B.+A.+Cooperauthor=J.+C.+Kathauthor=C.+A.+Hulfordauthor=C.+L.+Autryauthor=M.+J.+Luzzioauthor=E.+J.+Ungauthor=W.+G.+Robertsauthor=P.+C.+Bonnetteauthor=L.+Buckbinderauthor=A.+Mistryauthor=M.+C.+Grifforauthor=S.+Hanauthor=A.+Guzman-Perez&title=Trifluoromethylpyrimidine-based+inhibitors+of+proline-rich+tyrosine+kinase+2+%28PYK2%29%3A+structure%E2%80%93activity+relationships+and+strategies+for+the+elimination+of+reactive+metabolite+formation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBi%26aufirst%3DF.%2BC.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DBauman%26aufirst%3DJ.%2BN.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DAspnes%26aufirst%3DG.%2BE.%26aulast%3DKung%26aufirst%3DD.%2BW.%26aulast%3DKlug-McLeod%26aufirst%3DJ.%26aulast%3DZawistoski%26aufirst%3DM.%2BP.%26aulast%3DMcGlynn%26aufirst%3DM.%2BA.%26aulast%3DOliver%26aufirst%3DR.%26aulast%3DDunn%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%2BC.%26aulast%3DRichter%26aufirst%3DD.%2BT.%26aulast%3DCooper%26aufirst%3DB.%2BA.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DHulford%26aufirst%3DC.%2BA.%26aulast%3DAutry%26aufirst%3DC.%2BL.%26aulast%3DLuzzio%26aufirst%3DM.%2BJ.%26aulast%3DUng%26aufirst%3DE.%2BJ.%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26aulast%3DBonnette%26aufirst%3DP.%2BC.%26aulast%3DBuckbinder%26aufirst%3DL.%26aulast%3DMistry%26aufirst%3DA.%26aulast%3DGriffor%26aufirst%3DM.%2BC.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26atitle%3DTrifluoromethylpyrimidine-based%2520inhibitors%2520of%2520proline-rich%2520tyrosine%2520kinase%25202%2520%2528PYK2%2529%253A%2520structure%25E2%2580%2593activity%2520relationships%2520and%2520strategies%2520for%2520the%2520elimination%2520of%2520reactive%2520metabolite%2520formation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D6071%26epage%3D6077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Wong, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonn, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadano Lohr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B. K.</span><span> </span><span class="NLM_article-title">Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug–drug interaction</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">841</span><span class="NLM_x">–</span> <span class="NLM_lpage">850</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=841-850&author=S.+G.+Wongauthor=P.+W.+Fanauthor=R.+Subramanianauthor=G.+R.+Tonnauthor=K.+R.+Henneauthor=M.+G.+Johnsonauthor=M.+Tadano+Lohrauthor=B.+K.+Wong&title=Bioactivation+of+a+novel+2-methylindole-containing+dual+chemoattractant+receptor-homologous+molecule+expressed+on+T-helper+type-2+cells%2FD-prostanoid+receptor+antagonist+leads+to+mechanism-based+CYP3A+inactivation%3A+glutathione+adduct+characterization+and+prediction+of+in+vivo+drug%E2%80%93drug+interaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DS.%2BG.%26aulast%3DFan%26aufirst%3DP.%2BW.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DTonn%26aufirst%3DG.%2BR.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DTadano%2BLohr%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DB.%2BK.%26atitle%3DBioactivation%2520of%2520a%2520novel%25202-methylindole-containing%2520dual%2520chemoattractant%2520receptor-homologous%2520molecule%2520expressed%2520on%2520T-helper%2520type-2%2520cells%252FD-prostanoid%2520receptor%2520antagonist%2520leads%2520to%2520mechanism-based%2520CYP3A%2520inactivation%253A%2520glutathione%2520adduct%2520characterization%2520and%2520prediction%2520of%2520in%2520vivo%2520drug%25E2%2580%2593drug%2520interaction%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D841%26epage%3D850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dube, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dube, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagne, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">gallant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudreault, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimm, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacombe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laliberte, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, J.-F.</span><span> </span><span class="NLM_article-title">Addressing time-dependent CYP3A4 inhibition in a novel series substituted amino propanamide renin inhibitors, a case study</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5074</span><span class="NLM_x">–</span> <span class="NLM_lpage">5079</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5074-5079&author=A.+Chenauthor=D.+Dubeauthor=L.+Dubeauthor=S.+Gagneauthor=M.+gallantauthor=M.+Gaudreaultauthor=E.+Grimmauthor=R.+Houleauthor=P.+Lacombeauthor=S.+Laliberteauthor=S.+Liuauthor=D.+MacDonaldauthor=B.+Mackayauthor=D.+Martinauthor=D.+McKayauthor=D.+Powellauthor=J.-F.+Levesque&title=Addressing+time-dependent+CYP3A4+inhibition+in+a+novel+series+substituted+amino+propanamide+renin+inhibitors%2C+a+case+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DA.%26aulast%3DDube%26aufirst%3DD.%26aulast%3DDube%26aufirst%3DL.%26aulast%3DGagne%26aufirst%3DS.%26aulast%3Dgallant%26aufirst%3DM.%26aulast%3DGaudreault%26aufirst%3DM.%26aulast%3DGrimm%26aufirst%3DE.%26aulast%3DHoule%26aufirst%3DR.%26aulast%3DLacombe%26aufirst%3DP.%26aulast%3DLaliberte%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMacDonald%26aufirst%3DD.%26aulast%3DMackay%26aufirst%3DB.%26aulast%3DMartin%26aufirst%3DD.%26aulast%3DMcKay%26aufirst%3DD.%26aulast%3DPowell%26aufirst%3DD.%26aulast%3DLevesque%26aufirst%3DJ.-F.%26atitle%3DAddressing%2520time-dependent%2520CYP3A4%2520inhibition%2520in%2520a%2520novel%2520series%2520substituted%2520amino%2520propanamide%2520renin%2520inhibitors%252C%2520a%2520case%2520study%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5074%26epage%3D5079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aspiotis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campeau, L.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cauchon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chefson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ducharme, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falgueyret, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagné, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laliberté, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larouche, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lévesque, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Percival, D.</span><span> </span><span class="NLM_article-title">Renin inhibitors for treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">7399</span><span class="NLM_x">–</span> <span class="NLM_lpage">7404</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=7399-7404&author=A.+Chenauthor=R.+Aspiotisauthor=L.-C.+Campeauauthor=E.+Cauchonauthor=A.+Chefsonauthor=Y.+Ducharmeauthor=J.-P.+Falgueyretauthor=S.+Gagn%C3%A9author=Y.+Hanauthor=R.+Houleauthor=S.+Lalibert%C3%A9author=G.+Laroucheauthor=J.-F.+L%C3%A9vesqueauthor=D.+McKayauthor=D.+Percival&title=Renin+inhibitors+for+treatment+of+hypertension%3A+design+and+optimization+of+a+novel+series+of+spirocyclic+piperidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DA.%26aulast%3DAspiotis%26aufirst%3DR.%26aulast%3DCampeau%26aufirst%3DL.-C.%26aulast%3DCauchon%26aufirst%3DE.%26aulast%3DChefson%26aufirst%3DA.%26aulast%3DDucharme%26aufirst%3DY.%26aulast%3DFalgueyret%26aufirst%3DJ.-P.%26aulast%3DGagn%25C3%25A9%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DHoule%26aufirst%3DR.%26aulast%3DLalibert%25C3%25A9%26aufirst%3DS.%26aulast%3DLarouche%26aufirst%3DG.%26aulast%3DL%25C3%25A9vesque%26aufirst%3DJ.-F.%26aulast%3DMcKay%26aufirst%3DD.%26aulast%3DPercival%26aufirst%3DD.%26atitle%3DRenin%2520inhibitors%2520for%2520treatment%2520of%2520hypertension%253A%2520design%2520and%2520optimization%2520of%2520a%2520novel%2520series%2520of%2520spirocyclic%2520piperidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D7399%26epage%3D7404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">Yarnell, A. T.</span><span> </span><span class="NLM_article-title">Heavy-hydrogen drugs turn heads, again</span> <span class="citation_source-journal">Chem. Eng. News</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">36</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><div class="note"><p class="first last">; <a href="http://pubs.acs.org/cen/science/87/8725sci1.html" class="extLink">http://pubs.acs.org/cen/science/87/8725sci1.html</a></p></div></span><div class="citationLinks">[<a href="/doi/10.1021/cen-v087n025.p036" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2009&pages=36-39&author=A.+T.+Yarnell&title=Heavy-hydrogen+drugs+turn+heads%2C+again"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Fcen-v087n025.p036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcen-v087n025.p036%26sid%3Dliteratum%253Aachs%26aulast%3DYarnell%26aufirst%3DA.%2BT.%26atitle%3DHeavy-hydrogen%2520drugs%2520turn%2520heads%252C%2520again%26jtitle%3DChem.%2520Eng.%2520News%26date%3D2009%26volume%3D87%26spage%3D36%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marfat, A.</span><span> </span><span class="NLM_article-title">Disposition of CP-671,305, a selective phosphodiesterase 4 inhibitor in preclinical species</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">755</span><span class="NLM_x">–</span> <span class="NLM_lpage">770</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2004&pages=755-770&author=A.+S.+Kalgutkarauthor=E.+Chooauthor=T.+J.+Taylorauthor=A.+Marfat&title=Disposition+of+CP-671%2C305%2C+a+selective+phosphodiesterase+4+inhibitor+in+preclinical+species"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DChoo%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DT.%2BJ.%26aulast%3DMarfat%26aufirst%3DA.%26atitle%3DDisposition%2520of%2520CP-671%252C305%252C%2520a%2520selective%2520phosphodiesterase%25204%2520inhibitor%2520in%2520preclinical%2520species%26jtitle%3DXenobiotica%26date%3D2004%26volume%3D34%26spage%3D755%26epage%3D770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group">Ishiguro, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igarashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamai, I.</span><span> </span><span class="NLM_article-title">Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">499</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=495-499&author=N.+Ishiguroauthor=A.+Saitoauthor=K.+Yokoyamaauthor=M.+Morikawaauthor=T.+Igarashiauthor=I.+Tamai&title=Transport+of+the+dopamine+D2+agonist+pramipexole+by+rat+organic+cation+transporters+OCT1+and+OCT2+in+kidney"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIshiguro%26aufirst%3DN.%26aulast%3DSaito%26aufirst%3DA.%26aulast%3DYokoyama%26aufirst%3DK.%26aulast%3DMorikawa%26aufirst%3DM.%26aulast%3DIgarashi%26aufirst%3DT.%26aulast%3DTamai%26aufirst%3DI.%26atitle%3DTransport%2520of%2520the%2520dopamine%2520D2%2520agonist%2520pramipexole%2520by%2520rat%2520organic%2520cation%2520transporters%2520OCT1%2520and%2520OCT2%2520in%2520kidney%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D495%26epage%3D499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">James, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayeux, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinson, J. A.</span><span> </span><span class="NLM_article-title">Acetaminophen-induced hepatotoxicity</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1499</span><span class="NLM_x">–</span> <span class="NLM_lpage">1506</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=1499-1506&author=L.+P.+Jamesauthor=P.+R.+Mayeuxauthor=J.+A.+Hinson&title=Acetaminophen-induced+hepatotoxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DL.%2BP.%26aulast%3DMayeux%26aufirst%3DP.%2BR.%26aulast%3DHinson%26aufirst%3DJ.%2BA.%26atitle%3DAcetaminophen-induced%2520hepatotoxicity%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2003%26volume%3D31%26spage%3D1499%26epage%3D1506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Halmes, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samokyszyn, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinton, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pumford, N. R.</span><span> </span><span class="NLM_article-title">The acetaminophen regioisomer 3′-hydroxyacetanilide inhibits and covalently binds to cytochrome P4502E1</span> <span class="citation_source-journal">Toxicol. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2FS0378-4274%2897%2900100-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=9544700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaK1cXhtVWkt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1998&pages=65-71&author=N.+C.+Halmesauthor=V.+M.+Samokyszynauthor=T.+W.+Hintonauthor=J.+A.+Hinsonauthor=N.+R.+Pumford&title=The+acetaminophen+regioisomer+3%E2%80%B2-hydroxyacetanilide+inhibits+and+covalently+binds+to+cytochrome+P4502E1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">The acetaminophen regioisomer 3'-hydroxyacetanilide inhibits and covalently binds to cytochrome P450 2E1</span></div><div class="casAuthors">Halmes, N. Christine; Samokyszyn, Victor M.; Hinton, Thomas W.; Hinson, Jack A.; Pumford, Neil R.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-71</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">3'-Hydroxyacetanilide has been previously studied as a nontoxic regioisomer of the analgesic acetaminophen (4'-hydroxyacetanilide).  The radiolabeled deriv. has been shown to covalently bind to liver proteins at levels similar to that obsd. with hepatotoxic doses of radiolabeled acetaminophen with no evidence of hepatic damage.  Using an anti-arylacetamide antiserum the primary protein adduct detected following administration of 3'-hydroxyacetanilide (300 and 600 mg/kg) to mice was a 50 kDa microsomal protein that co-migrated with cytochrome P 450 2E1.  Cytochrome P 450 2E1 enzyme activity (p-nitrophenol hydroxylase) was decreased by 79 in the mice treated with 3'-hydroxyacetanilide (600 mg/kg).  Incubation of 3'-hydroxyacetanilide with hepatic microsomes resulted in a time dependent 47 decrease in cytochrome P 450 2E1 activity.  Pre-incubation of acetaminophen with microsomes did not result in covalent binding to the cytochrome P 450 nor was there a decrease in p-nitrophenol hydroxylase activity.  These data suggest that 3'-hydroxyacetanilide covalently binds to cytochrome P 450 2E1 with preferential loss of activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmncuZqNcypbVg90H21EOLACvtfcHk0lgtVN7sq6FNWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtVWkt7s%253D&md5=102c168d3d3827021f55791cd658dcab</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2FS0378-4274%2897%2900100-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-4274%252897%252900100-8%26sid%3Dliteratum%253Aachs%26aulast%3DHalmes%26aufirst%3DN.%2BC.%26aulast%3DSamokyszyn%26aufirst%3DV.%2BM.%26aulast%3DHinton%26aufirst%3DT.%2BW.%26aulast%3DHinson%26aufirst%3DJ.%2BA.%26aulast%3DPumford%26aufirst%3DN.%2BR.%26atitle%3DThe%2520acetaminophen%2520regioisomer%25203%25E2%2580%25B2-hydroxyacetanilide%2520inhibits%2520and%2520covalently%2520binds%2520to%2520cytochrome%2520P4502E1%26jtitle%3DToxicol.%2520Lett.%26date%3D1998%26volume%3D94%26spage%3D65%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group">Zientek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayscue, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klug-McLeod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekins, S.</span><span> </span><span class="NLM_article-title">Integrated in silico–in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">664</span><span class="NLM_x">–</span> <span class="NLM_lpage">676</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx900417f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=664-676&author=M.+Zientekauthor=C.+Stonerauthor=R.+Ayscueauthor=J.+Klug-McLeodauthor=Y.+Jiangauthor=M.+Westauthor=C.+Collinsauthor=S.+Ekins&title=Integrated+in+silico%E2%80%93in+vitro+strategy+for+addressing+cytochrome+P450+3A4+time-dependent+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Ftx900417f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx900417f%26sid%3Dliteratum%253Aachs%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DStoner%26aufirst%3DC.%26aulast%3DAyscue%26aufirst%3DR.%26aulast%3DKlug-McLeod%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DIntegrated%2520in%2520silico%25E2%2580%2593in%2520vitro%2520strategy%2520for%2520addressing%2520cytochrome%2520P450%25203A4%2520time-dependent%2520inhibition%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2010%26volume%3D23%26spage%3D664%26epage%3D676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Kassahun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skordos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntosh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slaughter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doss, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yost, G. S.</span><span> </span><span class="NLM_article-title">Zafirlukast metabolism by cytochrome P450 3A4 produces an electrophilic alpha,beta-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1427</span><span class="NLM_x">–</span> <span class="NLM_lpage">1437</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx050092b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=1427-1437&author=K.+Kassahunauthor=K.+Skordosauthor=I.+McIntoshauthor=D.+Slaughterauthor=G.+A.+Dossauthor=T.+A.+Baillieauthor=G.+S.+Yost&title=Zafirlukast+metabolism+by+cytochrome+P450+3A4+produces+an+electrophilic+alpha%2Cbeta-unsaturated+iminium+species+that+results+in+the+selective+mechanism-based+inactivation+of+the+enzyme"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Ftx050092b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx050092b%26sid%3Dliteratum%253Aachs%26aulast%3DKassahun%26aufirst%3DK.%26aulast%3DSkordos%26aufirst%3DK.%26aulast%3DMcIntosh%26aufirst%3DI.%26aulast%3DSlaughter%26aufirst%3DD.%26aulast%3DDoss%26aufirst%3DG.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DYost%26aufirst%3DG.%2BS.%26atitle%3DZafirlukast%2520metabolism%2520by%2520cytochrome%2520P450%25203A4%2520produces%2520an%2520electrophilic%2520alpha%252Cbeta-unsaturated%2520iminium%2520species%2520that%2520results%2520in%2520the%2520selective%2520mechanism-based%2520inactivation%2520of%2520the%2520enzyme%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2005%26volume%3D18%26spage%3D1427%26epage%3D1437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yost, G. S.</span><span> </span><span class="NLM_article-title">Metabolic activation of a novel 3-substituted indole-containing TNF-alpha inhibitor: dehydrogenation and inactivation of CYP3A4</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">374</span><span class="NLM_x">–</span> <span class="NLM_lpage">385</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx700294g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=374-385&author=H.+Sunauthor=G.+S.+Yost&title=Metabolic+activation+of+a+novel+3-substituted+indole-containing+TNF-alpha+inhibitor%3A+dehydrogenation+and+inactivation+of+CYP3A4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Ftx700294g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx700294g%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DYost%26aufirst%3DG.%2BS.%26atitle%3DMetabolic%2520activation%2520of%2520a%2520novel%25203-substituted%2520indole-containing%2520TNF-alpha%2520inhibitor%253A%2520dehydrogenation%2520and%2520inactivation%2520of%2520CYP3A4%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D374%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">Gay, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilderman, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, V. L.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenberg, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halpert, J. R.</span><span> </span><span class="NLM_article-title">Structural analysis of mammalian cytochrome P450 2B4 covalently bound to the mechanism-based inactivator <i>tert</i>-butylphenylacetylene: insight into partial enzymatic activity</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">4903</span><span class="NLM_x">–</span> <span class="NLM_lpage">4911</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi200482g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVCntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=4903-4911&author=S.+C.+Gayauthor=H.+Zhangauthor=P.+R.+Wildermanauthor=A.+G.+Robertsauthor=T.+Liuauthor=S.+Liauthor=H.+L.+Linauthor=Q.+Zhangauthor=V.+L.+Woodsauthor=C.+D.+Stoutauthor=P.+F.+Hollenbergauthor=J.+R.+Halpert&title=Structural+analysis+of+mammalian+cytochrome+P450+2B4+covalently+bound+to+the+mechanism-based+inactivator+tert-butylphenylacetylene%3A+insight+into+partial+enzymatic+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Structural analysis of mammalian cytochrome P 450 2B4 covalently bound to the mechanism-based inactivator tert-butylphenylacetylene: Insight into partial enzymatic activity</span></div><div class="casAuthors">Gay, Sean C.; Zhang, Haoming; Wilderman, P. Ross; Roberts, Arthur G.; Liu, Tong; Li, Sheng; Lin, Hsia-lien; Zhang, Qinghai; Woods, Virgil L.; Stout, C. David; Hollenberg, Paul F.; Halpert, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4903-4911</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A combined crystal structure and computational anal. of rabbit cytochrome P 450 2B4 (CYP2B4)covalently bound to the mechanism-based inactivator, tert-butylphenylacetylene (tBPA), yielded insight into how the enzyme retains partial activity.  Since conjugation to tBPA modified a highly conserved active site residue, the residual activity of tBPA-labeled CYP2B4 obsd. in previous studies was puzzling.  Here, the authors describe the 1st crystal structures of a modified mammalian P 450, which show an oxygenated metabolite of tBPA conjugated to Thr-302 of helix I.  These results were consistent with previous studies that identified Thr-302 as the site of conjugation.  In each structure, the core of CYP2B4 remained unchanged, but the arrangement of plastic regions differs.  This resulted in one structure that was compact and closed.  In this conformation, tBPA pointed toward helix B', making a 31° angle with the heme plane.  This conformation was in agreement with previously performed in silico expts.  However, dimerization of CYP2B4 in the other structure, which was caused by movement of the B/C loop and helixes F through G, altered the position of tBPA.  In this case, tBPA was found to lie almost parallel to the heme plane due to the presence of helix F' of the opposite monomer entering the active site to stabilize the dimer.  However, docking expts. using this open form showed that tBPA was able to rotate upward to give testosterone and 7-ethoxy-4-trifluoromethylcoumarin access to the heme, which could explain the previously obsd. partial activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojn823UJa1s7Vg90H21EOLACvtfcHk0lhvwdkCw1v1GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVCntbw%253D&md5=93172e85e5683fa426975dbd221ffcc4</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Fbi200482g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi200482g%26sid%3Dliteratum%253Aachs%26aulast%3DGay%26aufirst%3DS.%2BC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWilderman%26aufirst%3DP.%2BR.%26aulast%3DRoberts%26aufirst%3DA.%2BG.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DH.%2BL.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DWoods%26aufirst%3DV.%2BL.%26aulast%3DStout%26aufirst%3DC.%2BD.%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26aulast%3DHalpert%26aufirst%3DJ.%2BR.%26atitle%3DStructural%2520analysis%2520of%2520mammalian%2520cytochrome%2520P450%25202B4%2520covalently%2520bound%2520to%2520the%2520mechanism-based%2520inactivator%2520tert-butylphenylacetylene%253A%2520insight%2520into%2520partial%2520enzymatic%2520activity%26jtitle%3DBiochemistry%26date%3D2011%26volume%3D50%26spage%3D4903%26epage%3D4911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">Lin, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratt-Hyatt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenberg, P. F.</span><span> </span><span class="NLM_article-title">Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by <i>tert</i>-butylphenylacetylene</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">2431</span><span class="NLM_x">–</span> <span class="NLM_lpage">2439</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=2431-2439&author=H.+L.+Linauthor=H.+Zhangauthor=M.+Pratt-Hyattauthor=P.+F.+Hollenberg&title=Thr302+is+the+site+for+the+covalent+modification+of+human+cytochrome+P450+2B6+leading+to+mechanism-based+inactivation+by+tert-butylphenylacetylene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%2BL.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPratt-Hyatt%26aufirst%3DM.%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26atitle%3DThr302%2520is%2520the%2520site%2520for%2520the%2520covalent%2520modification%2520of%2520human%2520cytochrome%2520P450%25202B6%2520leading%2520to%2520mechanism-based%2520inactivation%2520by%2520tert-butylphenylacetylene%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D2431%26epage%3D2439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">Lightning, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rushmore, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trager, W. F.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">4276</span><span class="NLM_x">–</span> <span class="NLM_lpage">4287</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi992412u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=4276-4287&author=L.+K.+Lightningauthor=J.+P.+Jonesauthor=T.+Friedbergauthor=M.+P.+Pritchardauthor=M.+Shouauthor=T.+H.+Rushmoreauthor=W.+F.+Trager&title=Mechanism-based+inactivation+of+cytochrome+P450+3A4+by+L-754%2C394"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Fbi992412u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi992412u%26sid%3Dliteratum%253Aachs%26aulast%3DLightning%26aufirst%3DL.%2BK.%26aulast%3DJones%26aufirst%3DJ.%2BP.%26aulast%3DFriedberg%26aufirst%3DT.%26aulast%3DPritchard%26aufirst%3DM.%2BP.%26aulast%3DShou%26aufirst%3DM.%26aulast%3DRushmore%26aufirst%3DT.%2BH.%26aulast%3DTrager%26aufirst%3DW.%2BF.%26atitle%3DMechanism-based%2520inactivation%2520of%2520cytochrome%2520P450%25203A4%2520by%2520L-754%252C394%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D4276%26epage%3D4287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">He, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolf, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenberg, P. F.</span><span> </span><span class="NLM_article-title">Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">252</span><span class="NLM_x">–</span> <span class="NLM_lpage">259</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx970192k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1998&pages=252-259&author=K.+Heauthor=K.+R.+Iyerauthor=R.+N.+Hayesauthor=M.+W.+Sinzauthor=T.+F.+Woolfauthor=P.+F.+Hollenberg&title=Inactivation+of+cytochrome+P450+3A4+by+bergamottin%2C+a+component+of+grapefruit+juice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Ftx970192k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx970192k%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DK.%26aulast%3DIyer%26aufirst%3DK.%2BR.%26aulast%3DHayes%26aufirst%3DR.%2BN.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DWoolf%26aufirst%3DT.%2BF.%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26atitle%3DInactivation%2520of%2520cytochrome%2520P450%25203A4%2520by%2520bergamottin%252C%2520a%2520component%2520of%2520grapefruit%2520juice%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1998%26volume%3D11%26spage%3D252%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group">Chang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fancher, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, J.</span><span> </span><span class="NLM_article-title">Mechanism-based inhibition of human cytochrome P4503A4 by domperidone</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">138</span><span class="NLM_x">–</span> <span class="NLM_lpage">145</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2010&pages=138-145&author=S.+Y.+Changauthor=R.+M.+Fancherauthor=H.+Zhangauthor=J.+Gan&title=Mechanism-based+inhibition+of+human+cytochrome+P4503A4+by+domperidone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%2BY.%26aulast%3DFancher%26aufirst%3DR.%2BM.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGan%26aufirst%3DJ.%26atitle%3DMechanism-based%2520inhibition%2520of%2520human%2520cytochrome%2520P4503A4%2520by%2520domperidone%26jtitle%3DXenobiotica%26date%3D2010%26volume%3D40%26spage%3D138%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group">Kajbaf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longhi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, S.</span><span> </span><span class="NLM_article-title">Evaluation of different approaches to identifying a higher throughput assay for time-dependent inhibition (TDI)</span> <span class="citation_source-journal">Drug Metab. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">113</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.2174%2F187231211795305230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=21457139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltF2mt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=104-113&author=M.+Kajbafauthor=R.+Longhiauthor=S.+Fontana&title=Evaluation+of+different+approaches+to+identifying+a+higher+throughput+assay+for+time-dependent+inhibition+%28TDI%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of different approaches to identifying a higher throughput assay for time-dependent inhibition (TDI)</span></div><div class="casAuthors">Kajbaf, M.; Longhi, R.; Fontana, S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">104-113</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The availability of a reliable in vitro assay to evaluate time-dependent inhibition (TDI) of cytochrome P 450 enzymes by novel compds. is essential for the identification of candidate medicines.  We have evaluated three assay methods, making use of 59 marketed compds. and 28 novel GSK compds.  Recombinant bactosomes expressing the CYP3A4 isoenzyme were used with two fluorescence-based methods: a "Re-addn." assay and a "30 min" assay.  The third method evaluated used pooled human liver microsomes (PHLM) with LC-MS/MS detection (the data for GSK compds. were evaluated in this study, whereas data for marketed drugs were reported recently).  Our evaluation showed that the Re-addn. method is comparable to the LC-MS/MS method in terms of predictivity and reproducibility.  In conclusion, Re-addn. method is inexpensive, and provides a simple assessment of the risk of TDI for novel compds.  This assay is particularly appropriate for use during the early stages of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmyXN8bHdYPLVg90H21EOLACvtfcHk0lgGP-HE60ZXYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltF2mt7o%253D&md5=1a863e49da22633485ef524ad8ddfbf1</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.2174%2F187231211795305230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231211795305230%26sid%3Dliteratum%253Aachs%26aulast%3DKajbaf%26aufirst%3DM.%26aulast%3DLonghi%26aufirst%3DR.%26aulast%3DFontana%26aufirst%3DS.%26atitle%3DEvaluation%2520of%2520different%2520approaches%2520to%2520identifying%2520a%2520higher%2520throughput%2520assay%2520for%2520time-dependent%2520inhibition%2520%2528TDI%2529%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2011%26volume%3D5%26spage%3D104%26epage%3D113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group">Ortiz de Montellano, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunze, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yost, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mico, B. A.</span><span> </span><span class="NLM_article-title">Self-catalyzed destruction of cytochrome P450: covalent binding of ethynyl sterols to prosthetic heme</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">746</span><span class="NLM_x">–</span> <span class="NLM_lpage">749</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1979&pages=746-749&author=P.+R.+Ortiz+de+Montellanoauthor=K.+L.+Kunzeauthor=G.+S.+Yostauthor=B.+A.+Mico&title=Self-catalyzed+destruction+of+cytochrome+P450%3A+covalent+binding+of+ethynyl+sterols+to+prosthetic+heme"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrtiz%2Bde%2BMontellano%26aufirst%3DP.%2BR.%26aulast%3DKunze%26aufirst%3DK.%2BL.%26aulast%3DYost%26aufirst%3DG.%2BS.%26aulast%3DMico%26aufirst%3DB.%2BA.%26atitle%3DSelf-catalyzed%2520destruction%2520of%2520cytochrome%2520P450%253A%2520covalent%2520binding%2520of%2520ethynyl%2520sterols%2520to%2520prosthetic%2520heme%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1979%26volume%3D76%26spage%3D746%26epage%3D749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group">Guengerich, F. P.</span><span> </span><span class="NLM_article-title">Metabolism of 17a-ethynylestradiol in humans</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1981</span><span class="NLM_x">–</span> <span class="NLM_lpage">1988</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1990&pages=1981-1988&author=F.+P.+Guengerich&title=Metabolism+of+17a-ethynylestradiol+in+humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuengerich%26aufirst%3DF.%2BP.%26atitle%3DMetabolism%2520of%252017a-ethynylestradiol%2520in%2520humans%26jtitle%3DLife%2520Sci.%26date%3D1990%26volume%3D47%26spage%3D1981%26epage%3D1988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group">Lin, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, U. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenberg, P. F.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of cytochrome P4503A4 by 17α-ethynylestradiol: evidence for heme destruction and covalent binding to protein</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">301</span><span class="NLM_x">, </span> <span class="NLM_fpage">160</span><span class="NLM_x">–</span> <span class="NLM_lpage">167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1124%2Fjpet.301.1.160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=11907170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=2002&pages=160-167&author=H.-L.+Linauthor=U.+M.+Kentauthor=P.+F.+Hollenberg&title=Mechanism-based+inactivation+of+cytochrome+P4503A4+by+17%CE%B1-ethynylestradiol%3A+evidence+for+heme+destruction+and+covalent+binding+to+protein"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inactivation of cytochrome P450 3A4 by 17α-ethynylestradiol: Evidence for heme destruction and covalent binding to protein</span></div><div class="casAuthors">Lin, Hsia-Lien; Kent, Ute M.; Hollenberg, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">160-167</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">17α-Ethynylestradiol (EE), a major constituent of many oral contraceptives, inactivated the testosterone 6β-hydroxylation activity of purified P 450 3A4 reconstituted with phospholipid and NADPH-cytochrome P 450 reductase in a mechanism-based manner.  The inactivation of P 450 3A4 followed pseudo first order kinetics and was dependent on NADPH.  The values for the K1 and kinact were 18 μM and 0.04 min-1, resp., and the t1/2 was 16 min.  Incubation of 50 μM EE with P 450 3A4 at 37° for 30 min resulted in a 67% loss of testosterone 6β-hydroxylation activity accompanied by a 35% loss of the spectral absorbance of the native protein at 415 nm and a 70% loss of the spectrally detectable P 450-CO complex.  The inactivation of P 450 3A4 by EE was irreversible.  Testosterone, an alternate substrate, was able to protect P 450 3A4 from EE-dependent inactivation.  The partition ratio was ∼50.  The stoichiometry of binding was approx. 1.3 nmol of an EE metabolite bound per nmol of P 450 3A4 inactivated.  SDS-polyacrylamide gel electrophoresis anal. demonstrated that [3H]EE was irreversibly bound to the P 450 3A4 apoprotein.  After extensive dialysis of the [3H]EE inactivated samples, high-pressure liq. chromatog. (HPLC) anal. demonstrated that the inactivation resulting from EE metab. led to the destruction of approx. half the heme with the concomitant generation of modified heme and EE-labeled heme fragments and produced covalently radiolabeled P 450 3A4 apoprotein.  Electrospray mass spectrometry demonstrated that the fraction corresponding to the major radiolabeled product of EE metab. has a mass (M - H)- of 479 Da.  HPLC and gas chromatog.-mass spectrometry analyses revealed that EE metab. by P 450 3A4 generated one major metabolite, 2-hydroxyethynylestradiol, and at least three addnl. metabolites.  In conclusion, our results demonstrate that EE is an effective mechanism-based inactivator of P 450 3A4 and that the mechanism of inactivation involves not only heme destruction, but also the irreversible modification of the apoprotein at the active site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7_op9UJz9HrVg90H21EOLACvtfcHk0lgGP-HE60ZXYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kru7Y%253D&md5=0e1f037095f387682c995f4c8ca85038</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1124%2Fjpet.301.1.160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.301.1.160%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.-L.%26aulast%3DKent%26aufirst%3DU.%2BM.%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26atitle%3DMechanism-based%2520inactivation%2520of%2520cytochrome%2520P4503A4%2520by%252017%25CE%25B1-ethynylestradiol%253A%2520evidence%2520for%2520heme%2520destruction%2520and%2520covalent%2520binding%2520to%2520protein%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D301%26spage%3D160%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group">Purba, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggs, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Back, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, B. K.</span><span> </span><span class="NLM_article-title">The metabolism of 17α-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">447</span><span class="NLM_x">–</span> <span class="NLM_lpage">453</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1111%2Fj.1365-2125.1987.tb03074.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=3555579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADyaL2sXktVWjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1987&pages=447-453&author=H.+S.+Purbaauthor=J.+L.+Maggsauthor=M.+L.+Ormeauthor=D.+J.+Backauthor=B.+K.+Park&title=The+metabolism+of+17%CE%B1-ethinyloestradiol+by+human+liver+microsomes%3A+formation+of+catechol+and+chemically+reactive+metabolites"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolism of 17α-ethinylestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites</span></div><div class="casAuthors">Purba, H. S.; Maggs, J. L.; Orme, M. L. E.; Back, D. J.; Park, B. K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">447-53</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    </div><div class="casAbstract">The metab. of 17α-ethynylestradiol (EE2) to catechol and reactive metabolites by human liver microsomes was investigated.  2-Hydroxyethynylestradiol (2-OHEE2) was either the sole or principal metabolite and small amts. of 6-hydroxyethynylestradiol and 16-hydroxyethynylestradiol were produced by some of the livers.  EE2 (10 μm) underwent substantial (5-20% of incubated drug), though highly variable, NADPH-dependent metab. to material irreversibly bound to microsomal protein.  2-OHEE2 appeared to be the proreactive metabolite.  The max. EE2 2-hydroxylase activity was 0.67 nmol/min/mg microsomal protein, with a Km value of 8.6 mM.  Estradiol, which is mainly hydroxylated to 2-hydroxyestradiol, was the most potent inhibitor of hydroxylase activity and exhibited competitive inhibition.  Progesterone, which undergoes 2-hydroxylation to a minor extent was also a competitive inhibitor, whereas cholesterol and cortisol did not have any appreciable inhibitory effect.  Primaquine was the most potent nonsteroidal inhibitor but was noncompetitive.  Other nonsteroidal compds. investigated, e.g., antipyrine, had no effect on EE2 2-hydroxylation.  Evidently, EE2 2-hydroxylation is metabolized by a form(s) of cytochrome P 450 which has affinity for endogenous steroids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKoA2Y7m5eObVg90H21EOLACvtfcHk0lhVzn0JjzYpBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXktVWjsr8%253D&md5=2661a4e945f907a58ca94acfa4031f4d</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.1987.tb03074.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.1987.tb03074.x%26sid%3Dliteratum%253Aachs%26aulast%3DPurba%26aufirst%3DH.%2BS.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DOrme%26aufirst%3DM.%2BL.%26aulast%3DBack%26aufirst%3DD.%2BJ.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DThe%2520metabolism%2520of%252017%25CE%25B1-ethinyloestradiol%2520by%2520human%2520liver%2520microsomes%253A%2520formation%2520of%2520catechol%2520and%2520chemically%2520reactive%2520metabolites%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1987%26volume%3D23%26spage%3D447%26epage%3D453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group">Nakayama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atsumi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takakusa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okazaki, O.</span><span> </span><span class="NLM_article-title">A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1970</span><span class="NLM_x">–</span> <span class="NLM_lpage">1977</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1124%2Fdmd.109.027797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=19487250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1970-1977&author=S.+Nakayamaauthor=R.+Atsumiauthor=H.+Takakusaauthor=Y.+Kobayashiauthor=A.+Kuriharaauthor=Y.+Nagaiauthor=D.+Nakaiauthor=O.+Okazaki&title=A+zone+classification+system+for+risk+assessment+of+idiosyncratic+drug+toxicity+using+daily+dose+and+covalent+binding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding</span></div><div class="casAuthors">Nakayama, Shintaro; Atsumi, Ryo; Takakusa, Hideo; Kobayashi, Yoshimasa; Kurihara, Atsushi; Nagai, Yoko; Nakai, Daisuke; Okazaki, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1970-1977</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The risk of idiosyncratic drug toxicity (IDT) is of great concern to the pharmaceutical industry.  Current hypotheses based on retrospective studies suggest that the occurrence of IDT is related to covalent binding and daily dose.  The authors detd. the covalent binding of 42 radiolabeled drugs in three test systems (human liver microsomes and hepatocytes in vitro and rat liver in vivo) to assess the risk of IDT.  On the basis of safety profiles given in official documentation, tested drugs were classified into the safety categories of safe, warning, black box warning, and withdrawn.  The covalent binding in each of the three test systems did not distinguish the safety categories clearly.  However, when the log-normalized covalent binding was plotted against the log-normalized daily dose, the distribution of the plot in the safety categories became clear.  An ordinal logistic regression anal. indicated that both covalent binding and daily dose were significantly correlated with safety category and that covalent binding in hepatocytes was the best predictor among the three systems.  When two sepn. lines were drawn on the correlation graph between covalent binding in human hepatocytes and daily dose by a regression anal. to create three zones, 30 of 37 tested drugs were located in zones corresponding to their resp. classified safety categories.  In conclusion, the authors established a zone classification system using covalent binding in human hepatocytes and daily dose for the risk assessment of IDTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtahZPkNJ3JbVg90H21EOLACvtfcHk0lhVzn0JjzYpBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO&md5=425119e0451fc50ec6ca95d5e3fe5fd3</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.027797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.027797%26sid%3Dliteratum%253Aachs%26aulast%3DNakayama%26aufirst%3DS.%26aulast%3DAtsumi%26aufirst%3DR.%26aulast%3DTakakusa%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DNakai%26aufirst%3DD.%26aulast%3DOkazaki%26aufirst%3DO.%26atitle%3DA%2520zone%2520classification%2520system%2520for%2520risk%2520assessment%2520of%2520idiosyncratic%2520drug%2520toxicity%2520using%2520daily%2520dose%2520and%2520covalent%2520binding%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1970%26epage%3D1977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group">Park, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boobis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldring, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenna, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laverty, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naisbitt, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll-Griffith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Routledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tweedie, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeulen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Managing the challenge of chemically reactive metabolites in drug development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">292</span><span class="NLM_x">–</span> <span class="NLM_lpage">306</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1038%2Fnrd3408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=21455238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=292-306&author=B.+K.+Parkauthor=A.+Boobisauthor=S.+Clarkeauthor=C.+E.+Goldringauthor=D.+Jonesauthor=J.+G.+Kennaauthor=C.+Lambertauthor=H.+G.+Lavertyauthor=D.+J.+Naisbittauthor=S.+Nelsonauthor=D.+A.+Nicoll-Griffithauthor=R.+S.+Obachauthor=P.+Routledgeauthor=D.+A.+Smithauthor=D.+J.+Tweedieauthor=N.+Vermeulenauthor=D.+P.+Williamsauthor=I.+D.+Wilsonauthor=T.+A.+Baillie&title=Managing+the+challenge+of+chemically+reactive+metabolites+in+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Managing the challenge of chemically reactive metabolites in drug development</span></div><div class="casAuthors">Park, B. Kevin; Boobis, Alan; Clarke, Stephen; Goldring, Chris E. P.; Jones, David; Kenna, J. Gerry; Lambert, Craig; Laverty, Hugh G.; Naisbitt, Dean J.; Nelson, Sidney; Nicoll-Griffith, Deborah A.; Obach, R. Scott; Routledge, Philip; Smith, Dennis A.; Tweedie, Donald J.; Vermeulen, Nico; Williams, Dominic P.; Wilson, Ian D.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">292-306</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The normal metab. of drugs can generate metabolites that have intrinsic chem. reactivity towards cellular mols., and therefore have the potential to alter biol. function and initiate serious adverse drug reactions.  Here, we present an assessment of the current approaches used for the evaluation of chem. reactive metabolites.  We also describe how these approaches are being used within the pharmaceutical industry to assess and minimize the potential of drug candidates to cause toxicity.  At early stages of drug discovery, iteration between medicinal chem. and drug metab. can eliminate perceived reactive metabolite-mediated chem. liabilities without compromising pharmacol. activity or the need for extensive safety evaluation beyond std. practices.  In the future, reactive metabolite evaluation may also be useful during clin. development for improving clin. risk assessment and risk management.  Currently, there remains a huge gap in our understanding of the basic mechanisms that underlie chem. stress-mediated adverse reactions in humans.  This Review summarizes our views on this complex topic, and includes insights into practices considered by the pharmaceutical industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBv41vr7ZlNLVg90H21EOLACvtfcHk0lgUuA-3yvFfgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGnu78%253D&md5=8f6865f17bbe50b51aa4282379e82a08</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1038%2Fnrd3408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3408%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DBoobis%26aufirst%3DA.%26aulast%3DClarke%26aufirst%3DS.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DLambert%26aufirst%3DC.%26aulast%3DLaverty%26aufirst%3DH.%2BG.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DS.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DRoutledge%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DTweedie%26aufirst%3DD.%2BJ.%26aulast%3DVermeulen%26aufirst%3DN.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3DWilson%26aufirst%3DI.%2BD.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DManaging%2520the%2520challenge%2520of%2520chemically%2520reactive%2520metabolites%2520in%2520drug%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D292%26epage%3D306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group">Stepan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aleo, M. D.</span><span> </span><span class="NLM_article-title">Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1345</span><span class="NLM_x">–</span> <span class="NLM_lpage">1410</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx200168d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1345-1410&author=A.+F.+Stepanauthor=D.+P.+Walkerauthor=J.+Baumanauthor=D.+A.+Priceauthor=T.+A.+Baillieauthor=A.+S.+Kalgutkarauthor=M.+D.+Aleo&title=Structural+alert%2Freactive+metabolite+concept+as+applied+in+medicinal+chemistry+to+mitigate+the+risk+of+idiosyncratic+drug+toxicity%3A+a+perspective+based+on+the+critical+examination+of+trends+in+the+top+200+drugs+marketed+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States</span></div><div class="casAuthors">Stepan, Antonia F.; Walker, Daniel P.; Bauman, Jonathan; Price, David A.; Baillie, Thomas A.; Kalgutkar, Amit S.; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1345-1410</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Because of a preconceived notion that eliminating reactive metabolite (RM) formation with new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM formation is routinely examd. as part of lead optimization efforts in drug discovery.  Likewise, avoidance of "structural alerts" is almost a norm in drug design.  However, there is a growing concern that the perceived safety hazards assocd. with structural alerts and/or RM screening tools as standalone predictors of toxicity risks may be over exaggerated.  In addn., the multifactorial nature of idiosyncratic toxicity is now well recognized based upon observations that mechanisms other than RM formation (e.g., mitochondrial toxicity and inhibition of bile salt export pump (BSEP)) also can account for certain target organ toxicities.  Hence, fundamental questions arise such as: When is a mol. that contains a structural alert (RM pos. or neg.) a cause for concern.  Could the mol. in its parent form exert toxicity.  Can a low dose drug candidate truly mitigate metab.-dependent and -independent idiosyncratic toxicity risks.  In an effort to address these questions, we have retrospectively examd. 68 drugs (recalled or assocd. with a black box warning due to idiosyncratic toxicity) and the top 200 drugs (prescription and sales) in the United States in 2009 for trends in physiochem. characteristics, daily doses, presence of structural alerts, evidence for RM formation as well as toxicity mechanism(s) potentially mediated by parent drugs.  Collectively, our anal. revealed that a significant proportion (∼78-86%) of drugs assocd. with toxicity contained structural alerts and evidence indicating that RM formation as a causative factor for toxicity has been presented in 62-69% of these mols.  In several cases, mitochondrial toxicity and BSEP inhibition mediated by parent drugs were also noted as potential causative factors.  Most drugs were administered at daily doses exceeding several hundred milligrams.  There was no obvious link between idiosyncratic toxicity and physicochem. properties such as mol. wt., lipophilicity, etc.  Approx. half of the top 200 drugs for 2009 (prescription and sales) also contained one or more alerts in their chem. architecture, and many were found to be RM-pos.  Several instances of BSEP and mitochondrial liabilities were also noted with agents in the top 200 category.  However, with relatively few exceptions, the vast majority of these drugs are rarely assocd. with idiosyncratic toxicity, despite years of patient use.  The major differentiating factor appeared to be the daily dose; most of the drugs in the top 200 list are administered at low daily doses.  In addn., competing detoxication pathways and/or alternate nonmetabolic clearance routes provided suitable justifications for the safety records of RM-pos. drugs in the top 200 category.  Thus, while RM elimination may be a useful and pragmatic starting point in mitigating idiosyncratic toxicity risks, our anal. suggests a need for a more integrated screening paradigm for chem. hazard identification in drug discovery.  Thus, in addn. to a detailed assessment of RM formation potential (in relationship to the overall elimination mechanisms of the compd.(s)) for lead compds., effects on cellular health (e.g., cytotoxicity assays), BSEP inhibition, and mitochondrial toxicity are the recommended suite of assays to characterize compd. liabilities.  However, the prospective use of such data in compd. selection will require further validation of the cellular assays using marketed agents.  Until we gain a better understanding of the pathophysiol. mechanisms assocd. with idiosyncratic toxicities, improving pharmacokinetics and intrinsic potency as means of decreasing the dose size and the assocd. "body burden" of the parent drug and its metabolites will remain an overarching goal in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IhczIcvVDLVg90H21EOLACvtfcHk0lgvSeC_6eovbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D&md5=632b73f755738e49eb233bc8dca1fbcc</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Ftx200168d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200168d%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DStructural%2520alert%252Freactive%2520metabolite%2520concept%2520as%2520applied%2520in%2520medicinal%2520chemistry%2520to%2520mitigate%2520the%2520risk%2520of%2520idiosyncratic%2520drug%2520toxicity%253A%2520a%2520perspective%2520based%2520on%2520the%2520critical%2520examination%2520of%2520trends%2520in%2520the%2520top%2520200%2520drugs%2520marketed%2520in%2520the%2520United%2520States%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1345%26epage%3D1410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group">Brown, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galetin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houston, J. B.</span><span> </span><span class="NLM_article-title">Prediction of in vivo drug–drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">508</span><span class="NLM_x">–</span> <span class="NLM_lpage">518</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1111%2Fj.1365-2125.2005.02483.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=16236041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Ojt7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2005&pages=508-518&author=H.+S.+Brownauthor=K.+Itoauthor=A.+Galetinauthor=J.+B.+Houston&title=Prediction+of+in+vivo+drug%E2%80%93drug+interactions+from+in+vitro+data%3A+impact+of+incorporating+parallel+pathways+of+drug+elimination+and+inhibitor+absorption+rate+constant"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant</span></div><div class="casAuthors">Brown, Hayley S.; Ito, Kiyomi; Galetin, Aleksandra; Houston, J. Brian</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">508-518</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Aims: Success of the quant. prediction of drug-drug interactions via inhibition of CYP-mediated metab. from the inhibitor concn. at the enzyme active site ([I]) and the in vitro inhibition const. (Ki) is variable.  The aim of this study was to examine the impact of the fraction of victim drug metabolized by a particular CYP (fmCYP) and the inhibitor absorption rate const. (ka) on prediction accuracy.  Methods: Drug-drug interaction studies involving inhibition of CYP2C9, CYP2D6 and CYP3A4 (n = 115) were investigated.  Data on fmCYP for the probe substrates of each enzyme and ka values for the inhibitors were incorporated into in vivo predictions, alone or in combination, using either the max. hepatic input or the av. systemic plasma concn. as a surrogate for [I].  The success of prediction (AUC ratio predicted within twofold of in vivo value) was compared using nominal values of fmCYP = 1 and ka = 0.1 min-1.  Results: The incorporation of fmCYP values into in vivo predictions using the hepatic input plasma concn. resulted in 84% of studies within twofold of in vivo value.  The effect of ka values alone significantly reduced the no. of over-predictions for CYP2D6 and CYP3A4; however, less precision was obsd. compared with the fmCYP.  The incorporation of both fmCYP and ka values resulted in 81% of studies within twofold of in vivo value.  Conclusions: The incorporation of substrate and inhibitor-related information, namely fmCYP and ka, markedly improved prediction of 115 interaction studies with CYP2C9, CYP2D6 and CYP3A4 in comparison with [I]/Ki ratio alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovEiyVGwCJZ7Vg90H21EOLACvtfcHk0lgvSeC_6eovbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Ojt7bJ&md5=57ba994039c26e7d21d0ee0e159aa4ac</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2005.02483.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2005.02483.x%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DH.%2BS.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DGaletin%26aufirst%3DA.%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26atitle%3DPrediction%2520of%2520in%2520vivo%2520drug%25E2%2580%2593drug%2520interactions%2520from%2520in%2520vitro%2520data%253A%2520impact%2520of%2520incorporating%2520parallel%2520pathways%2520of%2520drug%2520elimination%2520and%2520inhibitor%2520absorption%2520rate%2520constant%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D60%26spage%3D508%26epage%3D518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maclin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span> </span><span class="NLM_article-title">Mechanism-based inhibition of human liver microsomal cytochrome P450 3A by a focal adhesion kinase (FAK) inhibitor PF-562,271</span> <span class="citation_source-journal">Drug Metab. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">86</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=86&issue=Suppl.+2&author=H.+Rongauthor=D.+Maclinauthor=L.+Yaoauthor=J.+Linauthor=D.+Yinauthor=H.+Xu&title=Mechanism-based+inhibition+of+human+liver+microsomal+cytochrome+P450+3A+by+a+focal+adhesion+kinase+%28FAK%29+inhibitor+PF-562%2C271"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRong%26aufirst%3DH.%26aulast%3DMaclin%26aufirst%3DD.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DH.%26atitle%3DMechanism-based%2520inhibition%2520of%2520human%2520liver%2520microsomal%2520cytochrome%2520P450%25203A%2520by%2520a%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%2520inhibitor%2520PF-562%252C271%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2008%26volume%3D40%26issue%3DSuppl.%25202%26spage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group">Tucker, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houston, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. M.</span><span> </span><span class="NLM_article-title">Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential—towards a consensus</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">117</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1046%2Fj.0306-5251.2001.temp.1441.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=11453898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A280%3ADC%252BD3Mvhs1WqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2001&pages=107-117&author=G.+T.+Tuckerauthor=J.+B.+Houstonauthor=S.+M.+Huang&title=Optimizing+drug+development%3A+strategies+to+assess+drug+metabolism%2Ftransporter+interaction+potential%E2%80%94towards+a+consensus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus</span></div><div class="casAuthors">Tucker G T; Houston J B; Huang S M</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-17</span>
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8P0AfNxMICYIRAdBLKY41fW6udTcc2eZQt2cxfucOOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3Mvhs1WqsQ%253D%253D&md5=a6edcbdd0b2ba6f88784f2b30673c808</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1046%2Fj.0306-5251.2001.temp.1441.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.0306-5251.2001.temp.1441.x%26sid%3Dliteratum%253Aachs%26aulast%3DTucker%26aufirst%3DG.%2BT.%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26aulast%3DHuang%26aufirst%3DS.%2BM.%26atitle%3DOptimizing%2520drug%2520development%253A%2520strategies%2520to%2520assess%2520drug%2520metabolism%252Ftransporter%2520interaction%2520potential%25E2%2580%2594towards%2520a%2520consensus%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2001%26volume%3D52%26spage%3D107%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group">Fahmi, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripp, S. L.</span><span> </span><span class="NLM_article-title">Evaluation of models for predicting drug–drug interactions due to induction</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1399</span><span class="NLM_x">–</span> <span class="NLM_lpage">1416</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1517%2F17425255.2010.516251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=20955108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=1399-1416&author=O.+A.+Fahmiauthor=S.+L.+Ripp&title=Evaluation+of+models+for+predicting+drug%E2%80%93drug+interactions+due+to+induction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of models for predicting drug-drug interactions due to induction</span></div><div class="casAuthors">Fahmi, Odette A.; Ripp, Sharon L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1399-1416</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Drug-drug interactions caused by induction of metabolizing enzymes, particularly CYP3A, can impact the efficacy and safety of co-administered drugs.  It is, therefore, important to understand a new compd.'s potential for enzyme induction and to understand how to use the induction data generated in vitro to predict potential for drug-drug interactions in vivo.  Areas covered in this review: Recent advances in methods for using in vitro data to predict potential for CYP3A induction in vivo are reviewed.  What the reader will gain: The reader will gain a comprehensive understanding of the advantages and disadvantages of various prediction methods for induction and be able to directly compare different methods using a common in vitro data set.  Take home message: The various methods for predicting clin. CYP3A induction from in vitro induction data all have demonstrated utility; it is the authors' opinion that the correlation-based approaches offer as good or better predictivity and have simpler input requirements than more complex approaches.  Of the different correlation approaches, the relatively simple unbound Cmax/EC50 or AUC/EC50 approaches are the simplest and yet show the best correlation to the obsd. clin. data.  While the approaches discussed herein represent an improvement in our understanding of the predictive value of in vitro induction data, it is important to recognize that there is still room for improvement in quant. prediction of magnitude of drug interactions due to induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBLyowSf3OMrVg90H21EOLACvtfcHk0lhmBK-7L_LI_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtbzN&md5=1b95f24bb423f019f8d2b349cc4af592</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1517%2F17425255.2010.516251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2010.516251%26sid%3Dliteratum%253Aachs%26aulast%3DFahmi%26aufirst%3DO.%2BA.%26aulast%3DRipp%26aufirst%3DS.%2BL.%26atitle%3DEvaluation%2520of%2520models%2520for%2520predicting%2520drug%25E2%2580%2593drug%2520interactions%2520due%2520to%2520induction%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2010%26volume%3D6%26spage%3D1399%26epage%3D1416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group">Fahmi, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardenas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boldt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettleton, D.</span><span> </span><span class="NLM_article-title">A combined model for predicting CYP3A4 clinical net drug–drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1698</span><span class="NLM_x">–</span> <span class="NLM_lpage">1708</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1698-1708&author=O.+A.+Fahmiauthor=T.+S.+Maurerauthor=M.+Kishauthor=E.+Cardenasauthor=S.+Boldtauthor=D.+Nettleton&title=A+combined+model+for+predicting+CYP3A4+clinical+net+drug%E2%80%93drug+interaction+based+on+CYP3A4+inhibition%2C+inactivation%2C+and+induction+determined+in+vitro"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFahmi%26aufirst%3DO.%2BA.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DKish%26aufirst%3DM.%26aulast%3DCardenas%26aufirst%3DE.%26aulast%3DBoldt%26aufirst%3DS.%26aulast%3DNettleton%26aufirst%3DD.%26atitle%3DA%2520combined%2520model%2520for%2520predicting%2520CYP3A4%2520clinical%2520net%2520drug%25E2%2580%2593drug%2520interaction%2520based%2520on%2520CYP3A4%2520inhibition%252C%2520inactivation%252C%2520and%2520induction%2520determined%2520in%2520vitro%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D1698%26epage%3D1708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group">Jones, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youdim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosset, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attkins, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurrell, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bungay, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, I. B.</span><span> </span><span class="NLM_article-title">Application of PBPK modelling in drug discovery and development at Pfizer</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2011&pages=94-106&author=H.+M.+Jonesauthor=M.+Dickinsauthor=K.+Youdimauthor=J.+R.+Gossetauthor=N.+J.+Attkinsauthor=T.+L.+Hayauthor=I.+K.+Gurrellauthor=Y.+R.+Loganauthor=P.+J.+Bungayauthor=B.+C.+Jonesauthor=I.+B.+Gardner&title=Application+of+PBPK+modelling+in+drug+discovery+and+development+at+Pfizer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DH.%2BM.%26aulast%3DDickins%26aufirst%3DM.%26aulast%3DYoudim%26aufirst%3DK.%26aulast%3DGosset%26aufirst%3DJ.%2BR.%26aulast%3DAttkins%26aufirst%3DN.%2BJ.%26aulast%3DHay%26aufirst%3DT.%2BL.%26aulast%3DGurrell%26aufirst%3DI.%2BK.%26aulast%3DLogan%26aufirst%3DY.%2BR.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DGardner%26aufirst%3DI.%2BB.%26atitle%3DApplication%2520of%2520PBPK%2520modelling%2520in%2520drug%2520discovery%2520and%2520development%2520at%2520Pfizer%26jtitle%3DXenobiotica%26date%3D2011%26volume%3D42%26spage%3D94%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group">de LT Vieira, M.; Zhao, P.; Huang, S.-M.</span><span> </span><span class="NLM_article-title">Predicting Drug Interaction Potential of Telithromycin Using a Physiologically-Based Pharmacokinetic (PBPK) Model That Incorporates Time-Dependent Enzyme Inhibition Mechanism Derived from Nonlinear Pharmacokinetics</span>. Presented at the AAPS Annual Meeting, Washington, DC, October 23–27,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>Poster.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+de+LT+Vieira&author=P.+Zhao&author=S.-M.+Huang&title=Predicting+Drug+Interaction+Potential+of+Telithromycin+Using+a+Physiologically-Based+Pharmacokinetic+%28PBPK%29+Model+That+Incorporates+Time-Dependent+Enzyme+Inhibition+Mechanism+Derived+from+Nonlinear+Pharmacokinetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLT%2BVieira%26aufirst%3DM.%26atitle%3DPredicting%2520Drug%2520Interaction%2520Potential%2520of%2520Telithromycin%2520Using%2520a%2520Physiologically-Based%2520Pharmacokinetic%2520%2528PBPK%2529%2520Model%2520That%2520Incorporates%2520Time-Dependent%2520Enzyme%2520Inhibition%2520Mechanism%2520Derived%2520from%2520Nonlinear%2520Pharmacokinetics%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group">Rowland Yeo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsky, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rostami-Hodjegan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, G. T.</span><span> </span><span class="NLM_article-title">Prediction of time-dependent CYP3A4 drug–drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover</span> <span class="citation_source-journal">Eur. J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">160</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Fjm300065h&amp;key=10.1016%2Fj.ejps.2011.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Fjm300065h&amp;key=21540107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Fjm300065h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFSkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2011&pages=160-173&author=K.+Rowland+Yeoauthor=R.+L.+Walskyauthor=M.+Jameiauthor=A.+Rostami-Hodjeganauthor=G.+T.+Tucker&title=Prediction+of+time-dependent+CYP3A4+drug%E2%80%93drug+interactions+by+physiologically+based+pharmacokinetic+modelling%3A+impact+of+inactivation+parameters+and+enzyme+turnover"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: Impact of inactivation parameters and enzyme turnover</span></div><div class="casAuthors">Rowland Yeo, K.; Walsky, R. L.; Jamei, M.; Rostami-Hodjegan, A.; Tucker, G. T.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">160-173</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Predicting the magnitude of time-dependent metabolic drug-drug (mDDIs) interactions involving cytochrome P 450 3A4 (CYP3A4) from in vitro data requires accurate knowledge of the inactivation parameters of the inhibitor (K I, k inact) and of the turnover of the enzyme (k deg) in both the gut and the liver.  We have predicted the magnitude of mDDIs obsd. in 29 in vivo studies involving six CYP3A4 probe substrates and five mechanism based inhibitors of CYP3A4 of variable potency (azithromycin, clarithromycin, diltiazem, erythromycin and verapamil).  Inactivation parameters detd. anew in a single lab. under standardised conditions together with data from substrate and inhibitor files within the Simcyp Simulator (Version 9.3) were used to det. a value of the hepatic k deg (0.0193 or 0.0077 h-1) most appropriate for the prediction of mDDIs involving time-dependent inhibition of CYP3A4.  The higher value resulted in decreased bias (geometric mean fold error - 1.05 vs. 1.30) and increased precision (root mean squared error - 1.29 vs. 2.30) of predictions of mean ratios of AUC in the absence and presence of inhibitor.  Depending on the k deg value used (0.0193 vs. 0.0077 h-1), predicted mean ratios of AUC were within 2-fold of the obsd. values for all (100%) and 27 (93%) of the 29 studies, resp. and within 1.5-fold for 24 (83%) and 17 (59%) of the 29 studies, resp.  Comprehensive PBPK models were applied for accurate assessment of the potential for mDDIs involving time-dependent inhibition of CYP3A4 using a hepatic k deg value of 0.0193 h-1 in conjunction with inactivation parameters detd. by the conventional exptl. approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3Smu_gOTvVbVg90H21EOLACvtfcHk0ljW4sZplErimA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFSkt7Y%253D&md5=ab242e3e6c530c220ca3d73340d6ac00</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2011.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2011.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DRowland%2BYeo%26aufirst%3DK.%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DJamei%26aufirst%3DM.%26aulast%3DRostami-Hodjegan%26aufirst%3DA.%26aulast%3DTucker%26aufirst%3DG.%2BT.%26atitle%3DPrediction%2520of%2520time-dependent%2520CYP3A4%2520drug%25E2%2580%2593drug%2520interactions%2520by%2520physiologically%2520based%2520pharmacokinetic%2520modelling%253A%2520impact%2520of%2520inactivation%2520parameters%2520and%2520enzyme%2520turnover%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D43%26spage%3D160%26epage%3D173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group">Zientek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span> </span><span class="NLM_article-title">Utilization of a multi-staged time-dependent inhibition assay to assess the impact of intestinal metabolism on drug–drug interaction potential</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">467</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=467-473&author=M.+Zientekauthor=D.+Dalvie&title=Utilization+of+a+multi-staged+time-dependent+inhibition+assay+to+assess+the+impact+of+intestinal+metabolism+on+drug%E2%80%93drug+interaction+potential"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DDalvie%26aufirst%3DD.%26atitle%3DUtilization%2520of%2520a%2520multi-staged%2520time-dependent%2520inhibition%2520assay%2520to%2520assess%2520the%2520impact%2520of%2520intestinal%2520metabolism%2520on%2520drug%25E2%2580%2593drug%2520interaction%2520potential%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D467%26epage%3D473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group">Fahmi, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plowchalk, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youdim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phipps, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darekar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Comparison of different algorithms for predicting clinical drug–drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1658</span><span class="NLM_x">–</span> <span class="NLM_lpage">1666</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1658-1666&author=O.+A.+Fahmiauthor=S.+Hurstauthor=D.+Plowchalkauthor=J.+Cookauthor=F.+Guoauthor=K.+Youdimauthor=M.+Dickinsauthor=A.+Phippsauthor=A.+Darekarauthor=R.+Hylandauthor=R.+S.+Obach&title=Comparison+of+different+algorithms+for+predicting+clinical+drug%E2%80%93drug+interactions%2C+based+on+the+use+of+CYP3A4+in+vitro+data%3A+predictions+of+compounds+as+precipitants+of+interaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFahmi%26aufirst%3DO.%2BA.%26aulast%3DHurst%26aufirst%3DS.%26aulast%3DPlowchalk%26aufirst%3DD.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DF.%26aulast%3DYoudim%26aufirst%3DK.%26aulast%3DDickins%26aufirst%3DM.%26aulast%3DPhipps%26aufirst%3DA.%26aulast%3DDarekar%26aufirst%3DA.%26aulast%3DHyland%26aufirst%3DR.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DComparison%2520of%2520different%2520algorithms%2520for%2520predicting%2520clinical%2520drug%25E2%2580%2593drug%2520interactions%252C%2520based%2520on%2520the%2520use%2520of%2520CYP3A4%2520in%2520vitro%2520data%253A%2520predictions%2520of%2520compounds%2520as%2520precipitants%2520of%2520interaction%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1658%26epage%3D1666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm300065h&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-11%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Fjm300065h%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm300065h" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a9cb4de303c4c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
